PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Darmon, AJ; Ley, TJ; Nicholson, DW; Bleackley, RC				Darmon, AJ; Ley, TJ; Nicholson, DW; Bleackley, RC			Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; DEATH GENE CED-3; INTERLEUKIN-1-BETA CONVERTING-ENZYME; IL-1-BETA-CONVERTING ENZYME; SERINE PROTEASES; CYSTEINE PROTEASES; MOLECULAR-CLONING; MAMMALIAN HOMOLOG; RAPID INDUCTION; NATURAL-KILLER	Cytotoxic T lymphocytes (CTLs) are able to recognize and destroy target cells bearing foreign antigen using one of two distinct mechanisms: granule- or Fas-mediated cytotoxicity. The exact mechanisms involved in the induction of apoptotic cell death remain elusive; however, it seems likely that a family of cysteine proteases related to interleukin-1 beta converting enzyme are involved. One family member, CPP32, has been identified as an intracellular substrate for granzyme B, a CTL-specific serine protease responsible for the early induction of target cell DNA fragmentation. Here we use cytolytic cells from granzyme B-deficient mice to confirm that cleavage and activation of CPP32 represents a nonredundant role for granzyme B and that this activation plays a rob in the induction of DNA fragmentation in target cells, a signature event for apoptotic cell death. A peptide inhibitor of CPP32-like proteases confirmed the function of these enzymes in fragmentation. Cr-51 release was not suppressed under these conditions, suggesting that granzyme B cleavage of CPP32 is primarily involved in the induction of DNA fragmentation and not membrane damage during CTL-induced apoptosis.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL, ST LOUIS, MO 63110 USA; MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM & MOL BIOL, POINTE CLAIRE, PQ H9R 4P8, CANADA	University of Alberta; Washington University (WUSTL); Washington University (WUSTL); Merck & Company					NIDDK NIH HHS [DK 49786] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GARNER R, 1994, J IMMUNOL, V153, P5413; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NettFiordalisi M, 1995, J LEUKOCYTE BIOL, V58, P717, DOI 10.1002/jlb.58.6.717; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PODACK ER, 1995, CURR TOP MICROBIOL, V178, P175; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	42	131	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21709	21712		10.1074/jbc.271.36.21709	http://dx.doi.org/10.1074/jbc.271.36.21709			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702964	hybrid			2022-12-27	WOS:A1996VF61200006
J	Vasconcelos, EG; Ferreira, ST; deCarvalho, TMU; deSouza, W; Kettlun, AM; Mancilla, M; Valenzuela, MA; VerjovskiAlmeida, S				Vasconcelos, EG; Ferreira, ST; deCarvalho, TMU; deSouza, W; Kettlun, AM; Mancilla, M; Valenzuela, MA; VerjovskiAlmeida, S			Partial purification and immunohistochemical localization of ATP diphosphohydrolase from Schistosoma mansoni - Immunological cross-reactivities with potato apyrase and Toxoplasma gondii nucleoside triphosphate hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANUM-TUBEROSUM; PROTEIN	ATP diphosphohydrolase from tegumental membranes of Schistosoma mansoni was solubilized with Triton X-100 plus deoxycholate and separated by preparative nondenaturing polyacrylamide gel electrophoresis. Two isoforms with ATP-hydrolytic activity were identified and excised from nondenaturing gels. For each of the active bands, two protein bands (63 and 55 kDa) were detected with Coomassie Blue staining, following sodium dodecyl sulfate polyacrylamide gel electrophoresis. Western blots developed with polyclonal antipotato apyrase antibody revealed a single protein of 63 kDa, either with samples excised from active bands or with total S. mansoni tegument. Anti-potato apyrase antibody immobilized on Sepharose-Protein A depleted over 95% of ATPase and ADPase activities from detergent-solubilized tegument. Confocal laser scanning microscopy showed anti-potato apyrase antibody on the outer surface of S. mansoni tegument. A different antibody against a fusion protein derived from recently cloned Toxoplasma gondii nucleoside triphosphate hydrolase (Bermudes, D., Peck, K. R., Afifi, M. A. Peckers, C. J. M., and Joiner, K. A. (1994) J. Biol. Chem. 269, 29252-29260) revealed the same 63-kDa band in Western blots of S. mansoni tegument. Since anti-potato apyrase antibodies exhibited cross-reactivity with S. mansoni ATP diphosphohydrolase, we decided to gain further information on the primary structure of potato apyrase by sequencing the protein. Three novel peptides were obtained: amino-terminal sequence and two internal sequences from tryptic fragments. Eight sequences recently deposited in the data bank, including that of T. gondii nucleoside triphosphate hydrolase, have considerable homologies to potato apyrase suggesting a new family of nucleoside triphosphatases which contains a conserved motif (I/V)(V/M/I)(I/L/F/C)DAGS(S/T) near the amino-terminal. Antibody cross-reactivities in the present work suggest that conserved epitopes from S. mansoni ATP diphosphohydrolase are present in this family of nucleotide-splitting enzymes.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-05599970 SAO PAULO,BRAZIL; UNIV FED RIO DE JANEIRO,DEPT BIOQUIM MED,BR-21941590 RIO JANEIRO,BRAZIL; UNIV ESTADUAL NORTE FLUMINENSE,LAB BIOL CELULAR & TECIDUAL,BR-28015620 RIO JANEIRO,BRAZIL; UNIV CHILE,DEPT BIOQUIM & BIOL MOL,SANTIAGO,CHILE	Universidade de Sao Paulo; Universidade Federal do Rio de Janeiro; Universidade Estadual do Norte Fluminense; Universidad de Chile			Verjovski-Almeida, Sergio/E-4082-2012; Ferreira, Sergio/AAZ-1576-2020	Verjovski-Almeida, Sergio/0000-0002-6356-2401; Ferreira, Sergio/0000-0001-7160-9866				ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BOUT D, 1986, SCIENCE, V231, P153, DOI 10.1126/science.3079916; CAPRON A, 1982, IMMUNOL REV, V61, P41, DOI 10.1111/j.1600-065X.1982.tb00373.x; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Ferreira Sergio T., 1995, Ciencia e Cultura (Sao Paulo), V47, P151; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; Harlow E., 1988, ANTIBODIES LAB MANUA; KETTLUN AM, 1992, PHYTOCHEMISTRY, V31, P1889, DOI 10.1016/0031-9422(92)80328-C; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; PLESNER L, 1995, INT REV CYTOL, V158, P141; SIBLEY LD, 1993, MOL PAR C SEPT 26 29; SIMPSON AJG, 1981, PARASITOLOGY, V83, P163, DOI 10.1017/S0031182000050137; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TRAN A, 1992, AGENTS ACTIONS, V36, P39, DOI 10.1007/BF01991226; TRAVERSOCORI A, 1995, ARCH BIOCHEM BIOPHYS, V109, P173; VASCONCELOS EG, 1993, MOL BIOCHEM PARASIT, V58, P205, DOI 10.1016/0166-6851(93)90042-V; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2940; VERMUND SH, 1983, AM J TROP MED HYG, V32, P1040, DOI 10.4269/ajtmh.1983.32.1040	27	119	123	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22139	22145		10.1074/jbc.271.36.22139	http://dx.doi.org/10.1074/jbc.271.36.22139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703025	hybrid			2022-12-27	WOS:A1996VF61200067
J	Creasy, CL; Ambrose, DM; Chernoff, J				Creasy, CL; Ambrose, DM; Chernoff, J			The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; AUTOPHOSPHORYLATION; LOCALIZATION; ACTIVATION; SUBUNITS; ENCODES	The human serine/threonine protein kinases, Mst1 and Mst2, share considerable homology to Ste20 and p21-activated kinase (Pak) throughout their catalytic domains. However, outside the catalytic domains there are no significant homologies to previously described Ste20-like kinases or other proteins. To understand the role of the nonhomologous regions, we performed a structure/function analysis of Mst1. A series of COOH-terminal and internal deletions indicates that there is an element within a central 63-amino acid region of the molecule that inhibits kinase activity. Removal of this domain increases kinase activity approximately 9-fold. Coimmunoprecipitation assays, the yeast two-hybrid procedure, and in vitro cross-linking analysis indicate that Mst1 homodimerizes and that the extreme COOH-terminal 57 amino acids are required for self-association. Size exclusion chromatography indicates that Mst1 is associated with a high molecular weight complex in cells, suggesting that other proteins may also oligomerize with this kinase. While loss of dimerization alone does not affect kinase activity, a molecule lacking both the dimerization and inhibitory domains is not as active as one which lacks only the inhibitory domain. Comparison of Mst1 and Mst2 indicates that both functional domains lie in regions conserved between the two molecules.	FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center			Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA058836] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58836, CA-09035, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BARTEL PL, 1994, CELLULAR INTERACTION, P153; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DATTA K, 1995, MOL CELL BIOL, V15, P2304; EVAN GL, 1985, MOL CELL BIOL, V8, P551; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HATZ P, 1994, J BIOL CHEM, V269, P16802; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543	25	173	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21049	21053		10.1074/jbc.271.35.21049	http://dx.doi.org/10.1074/jbc.271.35.21049			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702870	hybrid			2022-12-27	WOS:A1996VE47700016
J	Downey, GP; Butler, JR; Brumell, J; Borregaard, N; Kjeldsen, L; SueAQuan, AK; Grinstein, S				Downey, GP; Butler, JR; Brumell, J; Borregaard, N; Kjeldsen, L; SueAQuan, AK; Grinstein, S			Chemotactic peptide-induced activation of MEK-2, the predominant isoform in human neutrophils - Inhibition by wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; MAP KINASE; SUBSTRATE RECOGNITION; RESPIRATORY BURST; TYROSINE KINASE; GENE-PRODUCT; PHOSPHORYLATION; RECEPTOR	Exposure of neutrophils to a variety of agonists including chemoattractant peptides and cytokines induces degranulation and activation of the oxidative burst which are required for bacterial killing, The signaling pathways regulating these important functions are incompletely characterized, Mitogen-activated protein (MAP) kinases, which include the extracellular signal-regulated kinases (ERKs), are activated rapidly in neutrophils, suggesting that they may regulate cell activation, We found that neutrophils express two isoforms of MAP/ERK kinase (MEK), mixed-function kinases that are responsible for phosphorylation and activation of ERK. Like MEK-1, MEK-2 was found to reside in the cytosol both before and after stimulation, Studies were undertaken to define the relative abundance and functional contribution of MEK-1 and MEK-2 in neutrophils and to characterize the signaling pathways leading to their activation, Although the abundance of the two isoforms was similar, the activity of MEK-2 was at least 3-fold greater than that of MEK-1, A rise in cytosolic [Ca2+] was insufficient for MEK stimulation, and blunting the [Ca2+] change with intracellular chelators failed to prevent receptor-mediated activation of either isoform, implying that cytosolic Ca2+ transients are not necessary. In contrast, both MEK-1 and MEK-2 were activated by exposure of cells to protein kinase C (PKC) agonists. Conversely, PKC antagonists inhibited the chemotactic stimulation of both isoforms, suggesting that PKC was required for their activation, Despite these similarities, clear differences were also found in the pathways leading to activation of the MEK isoforms, In particular, MEK-2 was considerably more sensitive than MEK-1 to the phosphatidylinositol 3-kinase inhibitor wortmannin, Phosphorylation and activation of ERK-1 and ERK-2 were also reduced by this inhibitor, In summary, MEK-2 is stimulated in formyl-methionyl-leucyl-phenylalanine-treated neutrophils, where it appears to be functionally the predominant isoform, The time course and inhibitor sensitivity of MEK-2 activation parallel those of several components of the microbicidal response, suggesting a signaling role of the MEK-ERK pathway.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; RIGSHOSP,GRANULOCYTE RES LAB,DK-2100 COPENHAGEN,DENMARK; HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; Rigshospitalet; University of Copenhagen; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Downey, GP (corresponding author), UNIV TORONTO,DEPT MED,INST MED SCI,RM 6264,MED SCI BLDG,1 KINGS COLL CIRCLE,TORONTO,ON M5S 1A8,CANADA.		Kjeldsen, Lars/AAF-2096-2019	Downey, Gregory P/0000-0003-3253-5862				ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P335; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SMITH RM, 1991, BLOOD, V77, P673; TAUBER AI, 1987, BLOOD, V69, P711; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WOLFF SM, 1972, ANN INTERN MED, V76, P293, DOI 10.7326/0003-4819-76-2-293; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	42	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21005	21011		10.1074/jbc.271.35.21005	http://dx.doi.org/10.1074/jbc.271.35.21005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702863	hybrid			2022-12-27	WOS:A1996VE47700009
J	Fung, KL; Hilgenberg, L; Wang, NM; Chirico, WJ				Fung, KL; Hilgenberg, L; Wang, NM; Chirico, WJ			Conformations of the nucleotide and polypeptide binding domains of a cytosolic Hsp70 molecular chaperone are coupled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ATP HYDROLYSIS; PEPTIDE-BINDING; DNAK CHAPERONE; UNCOATING PROTEIN; SUBSTRATE-BINDING; POTASSIUM AFFECTS; REACTION CYCLE; ACTIVE-SITE; HSC70	70-kDa heat shock protein (Hsp70) molecular chaperones are ATPases that participate in protein folding by regulating protein-protein interactions. ATP binds to the highly conserved amino-terminal domain, whereas polypeptides bind to the less conserved carboxyl-terminal domain. These domains are functionally coupled. Polypeptides were previously shown to dissociate from Hsp70s upon ATP binding and to stimulate ATPase activity. We probed the structure of the yeast cytosolic Hsp70 Ssa1p using limited proteolysis to determine whether the conformations of its nucleotide and polypeptide binding domains are also coupled. Ssa1p adopted three distinct conformations, nucleotide-free, ADP-dependent, and ATP-dependent. Complete conformational changes required K+ and Mg2+. Using amino-terminal sequencing, ATP-agarose chromatography, and a carboxyl-terminal-specific antibody, we mapped the locations of the major proteolytic fragments. Nucleotides altered the conformations of both the nucleotide and polypeptide binding domains. Similarly, a polypeptide altered the conformations of both domains. These results indicate that the conformations of the nucleotide and polypeptide binding domains are coupled.	SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Endo T, 1996, J BIOL CHEM, V271, P4161; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, BIOL HEAT SHOCK PROT, P251; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HOHFELD J, 1995, CELL, V83, P589; Horst M, 1996, PROTEIN SCI, V5, P759; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAIN B, 1994, J BIOL CHEM, V269, P15588; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PARK K, 1993, PROTEIN SCI, V2, P325; Penefsky H S, 1979, Methods Enzymol, V56, P527; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WANG TF, 1993, J BIOL CHEM, V268, P26049; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	47	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21559	21565		10.1074/jbc.271.35.21559	http://dx.doi.org/10.1074/jbc.271.35.21559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702942	hybrid			2022-12-27	WOS:A1996VE47700088
J	Maeda, N; Nishiwaki, T; Shintani, T; Hamanaka, H; Noda, M				Maeda, N; Nishiwaki, T; Shintani, T; Hamanaka, H; Noda, M			6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTP beta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; NERVOUS-SYSTEM; ADULT-RAT; BRAIN; EXPRESSION; NEURONS; CLONING; MIDKINE	A major chondroitin sulfate proteoglycan in the brain, 6B4 proteoglycan/phosphacan, corresponds to the extracellular region of a receptor-like protein-tyrosine phosphatase, PTP zeta/RPTP beta. Here, we purified and characterized 6B4 proteoglycan-binding proteins from rat brain. From the CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid) extract of brain microsomal fractions, 18- 28-, and 40-kDa proteins were specifically isolated using 6B4 proteoglycan-Sepharose. N-terminal amino acid sequencing identified the 18-kDa protein as pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). Scatchard analysis of 6B4 proteoglycan-pleiotrophin binding revealed low (K-d = 3 nM) and high (K-d = 0.25 nM) affinity binding sites. Chondroitinase ABC digestion of the proteoglycan decreased the binding affinities to a single value (K-d = 13 nM) without changing the number of binding sites. This suggested the presence of two subpopulations of the proteoglycan with different chondroitin sulfate structures. Heparin potently inhibited binding of 6B4 proteoglycan to pleiotrophin (IC50 = 3.5 ng/ml). Heparan sulfate and chondroitin sulfate C inhibited moderately (IC50 = 150 and 400 ng/ml, respectively), but, in contrast, chondroitin sulfate A and keratan sulfate were poor inhibitors (IC50 > 100 mu g/ml). Immunofluorescence and immunoblotting analyses indicated that both 6B4 proteoglycan and PTP zeta are located on cortical neurons. Anti-6B4 proteoglycan antibody added to the culture medium suppressed pleiotrophin-induced neurite outgrowth of cortical neurons. These results suggested that interaction between 6B4 proteoglycan and pleiotrophin is required for the action of pleiotrophin, and chondroitin sulfate chains on 6B4 proteoglycan play regulatory roles in its binding.	NATL INST BASIC BIOL,DIV MOL NEUROBIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOL BIOMECH,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X; Shintani, Takafumi/0000-0002-6165-2307				BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; CANNOLL P, 1993, DEV BRAIN RES, V75, P293; GRUMET M, 1994, J BIOL CHEM, V269, P14142; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1996, DEVELOPMENT, V122, P647; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; MATSUMOTO K, 1994, NEUROSCI LETT, V178, P216, DOI 10.1016/0304-3940(94)90762-5; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; NISBIZUKA M, 1996, NEUROSCI RES, V24, P345; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RANVALA H, 1994, DEV BRAIN RES, V79, P157; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANAKA A, 1993, DEV BRAIN RES, V72, P133, DOI 10.1016/0165-3806(93)90166-8; WEWETZER K, 1995, BRAIN RES, V693, P31, DOI 10.1016/0006-8993(95)00683-H; WTANABE E, 1996, J NEUROSCI RES, V44, P84	31	254	265	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21446	21452		10.1074/jbc.271.35.21446	http://dx.doi.org/10.1074/jbc.271.35.21446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702927	hybrid			2022-12-27	WOS:A1996VE47700073
J	Beggah, A; Mathews, P; Beguin, P; Geering, K				Beggah, A; Mathews, P; Beguin, P; Geering, K			Degradation and endoplasmic reticulum retention of unassembled alpha- and beta-subunits of Na,K-ATPase correlate with interaction of BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; NA+-K+-ATPASE; INTRACELLULAR-TRANSPORT; BINDING-PROTEIN; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; EXTRACELLULAR DOMAIN; MOLECULAR CHAPERONE; SECRETORY PROTEINS; AMINO-ACIDS	Assembly of alpha- and beta-subunits in the endoplasmic reticulum is a prerequisite for the structural and functional maturation of oligomeric P-type ATPases. In Xenopus oocytes, overexpressed, unassembled alpha- and beta-subunits of Xenopus Na,K-ATPase are retained in the endoplasmic reticulum (ER) and are degraded with different kinetics, while unassembled beta-subunits of gastric H,K-ATPase leave the ER. In this study, we have investigated the role of the immunoglobulin-binding protein, BiP, in the folding, assembly, and ER retention of ATPase subunits. We determined the primary sequence of Xenopus BiP and used polyclonal antibodies to examine the interaction with BiP of various wild type and mutant alpha- and beta-subunits overexpressed in Xenopus oocytes, Our results show that ER-retained, unassembled Na,K-ATPase beta-subunits, but not transport-competent H,K-ATPase beta-subunits, efficiently associate with BiP until assembly with alpha-subunits occurs. Furthermore, the kinetics of BiP interaction with unassembled wildtype and with mutant Na,K-ATPase beta-subunits parallels their respective stability against cellular degradation. Finally, alpha-subunits that are overexpressed in oocytes and are rapidly degraded and endogenous oocyte alpha-subunits that are stably expressed as individual assembly-competent proteins also interact with oocyte or exogenous BiP, and the interaction time correlates with the protein's stability. These data demonstrate for the first time that BiP might be involved in a long term maturation arrest and/or in the ER quality control of a multimembrane-spanning protein and lend support for a universal chaperone function of BiP.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Lausanne					FIC NIH HHS [1 F20 TWO1917-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ACKERMANN U, 1992, J BIOL CHEM, V267, P12911; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; CHANG A, 1993, P NATL ACAD SCI USA, V90, P5808, DOI 10.1073/pnas.90.12.5808; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FEIGE U, 1994, EXPERIENTIA, V50, P979, DOI 10.1007/BF01923452; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; HORISBERGER JD, 1994, NA K ATPASE STRUCTUR; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCIER F, 1989, BIOL CELL, V65, P7; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHMITZ A, 1995, EMBO J, V14, P1091, DOI 10.1002/j.1460-2075.1995.tb07092.x; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; VITALE A, 1993, J EXP BOT, V44, P1417, DOI 10.1093/jxb/44.9.1417; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WINNING RS, 1991, DIFFERENTIATION, V46, P167, DOI 10.1111/j.1432-0436.1991.tb00878.x; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	54	64	65	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20895	20902		10.1074/jbc.271.34.20895	http://dx.doi.org/10.1074/jbc.271.34.20895			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702846	hybrid			2022-12-27	WOS:A1996VD33700098
J	Francis, SH; Smith, JA; Colbran, JL; Grimes, K; Walsh, KA; Kumar, S; Corbin, JD				Francis, SH; Smith, JA; Colbran, JL; Grimes, K; Walsh, KA; Kumar, S; Corbin, JD			Arginine 75 in the pseudosubstrate sequence of type I beta cGMP-dependent protein kinase is critical for autoinhibition, although autophosphorylated serine 63 is outside this sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE CARDIAC-MUSCLE; LIGHT-CHAIN KINASE; REGULATORY SUBUNIT; MOLECULAR-CLONING; CYCLIC-GMP; INTRASTERIC REGULATION; CDNA STRUCTURE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY	Autoinhibitory domains in many protein kinases include either a phosphorylatable substrate-like sequence or a pseudosubstrate sequence, This study shows that I beta cGMP-dependent protein kinase (cGK) autophosphorylates Ser-63, which is in an atypical cGK substrate sequence (-(59)AQKQSAS-) that is amino-terminal to the pseudosubstrate motif (-(74)KRQAI-), cGMP increases the rate of autophosphorylation (similar to 0,8 phosphate/cGK monomer) similar to 3-fold, Autophosphorylation is an intramolecular process since it is independent of cGK concentration, cGMP activation of cGK enhances proteolysis within and near the pseudosubstrate site; treatment of dimeric cGK with three proteases produces three cGK monomers (similar to 67-70 kDa each), Their amino-terminal sequences are (75)RQAISAEPT-, (76)QAlSAEPTAF-, and (86)DIQDLSXV-, respectively, cGMP stimulates these kinases by 10-, 2.5-, and 1,4-fold, respectively, compared with a 10-fold effect on intact cGK, Increased basaI activity accounts for the diminished stimulation, Thus, the primary autophosphorylation site of I beta cGK is well outside the pseudosubstrate site, but Arg-75 in the pseudosubstrate site is critical for autoinhibition, Autoinhibition also involves elements that are carboxyl-terminal to Arg-75.	UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	Francis, SH (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MOL PHYSIOL & BIOPHYS, 702 LIGHT HALL, NASHVILLE, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BOYER PD, 1986, ENZYMES, V17, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DEJONGE HR, 1977, J BIOL CHEM, V252, P2780; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; GAO ZH, 1995, J BIOL CHEM, V270, P10125, DOI 10.1074/jbc.270.17.10125; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1979, J BIOL CHEM, V254, P9728; GLASS DB, 1983, J BIOL CHEM, V258, P4797; GLASS DB, 1990, PEPTIDES PROTEIN PHO, P210; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HEMMINGS BA, 1986, FEBS LETT, V209, P219, DOI 10.1016/0014-5793(86)81114-0; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1989, CELL SIGNAL, V1, P303, DOI 10.1016/0898-6568(89)90049-1; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; LU XY, 1990, J BIOL CHEM, V265, P3293; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; PATTON BL, 1990, J BIOL CHEM, V265, P11204; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SMITH J, 1993, FASEB J, V7, pA1123; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SMITH JA, 1992, FASEB J, V6, pA315; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAKIO K, 1983, J BIOL CHEM, V258, P5531; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; UHLER MD, 1993, J BIOL CHEM, V268, P13586; VINTERMYR OK, 1993, J CELL PHYSIOL, V156, P160, DOI 10.1002/jcp.1041560122; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157	70	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20748	20755		10.1074/jbc.271.34.20748	http://dx.doi.org/10.1074/jbc.271.34.20748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702827	hybrid			2022-12-27	WOS:A1996VD33700079
J	Park, JC; Takeuchi, A; Sharma, S				Park, JC; Takeuchi, A; Sharma, S			Characterization of a new isoform of the NFAT (nuclear factor of activated T cells) gene family member NFATc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; TRANSCRIPTION FACTOR NFATP; HUMAN B-CELL; CYCLOSPORINE-A; IMMUNOSUPPRESSIVE DRUGS; REGULATORY ELEMENTS; EXPRESSION; PROMOTER; INDUCTION; BINDING	The cyclosporin A (CsA)/FK506-sensitive nuclear factor of activated T cells (NFAT) plays a key role in the inducible expression of cytokine genes in T cells. Although NFAT has been recently shown to be inducible in several non-T immune cells, the NFAT gene family members characterized to date have been isolated only from T cells. To further characterize NFAT function in human B cells and to demonstrate cytokine gene specificity of NFAT proteins, we report here the isolation and characterization of a cDNA clone from the Rail B cell line. The cDNA clone encodes a new isoform, NFATc.beta, of the NFAT gene family member NFATc (designated here NFATc.alpha). The amino acid sequence of NFATc.beta differs from that of NFATc.alpha in the first NR(2)-terminal 29 residues and contains an additional region of 142 residues at the COOH terminus. Northern analysis using a probe encompassing a common region of both isoforms showed two mRNA species of 2.7 and 4.5 kilobase pairs, while an NFATc.beta-specific probe detected only the 4.5-kilobase pair mRNA which was preferentially expressed in the spleen. Transient expression of NFATc.beta was capable of activating an interleukin-2 NFAT-driven reporter gene in stimulated Jurkat cells in a CsA-sensitive manner. However, NFATc.beta neither bound to the kappa 3 element (an NFAT-binding site) in the tumor necrosis factor-alpha promoter nor activated the tumor necrosis factor-alpha promoter in cotransfection assays. These data suggest that different members or isoforms of NFAT gene family may regulate inducible expression of different cytokine genes.	BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,EXPT PATHOL SECT,PROVIDENCE,RI 02908	Brown University; Roger Williams Medical Center					NATIONAL CANCER INSTITUTE [R01CA055910] Funding Source: NIH RePORTER; NCI NIH HHS [CA55910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1992, P NATL ACAD SCI USA, V89, P12198, DOI 10.1073/pnas.89.24.12198; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P804; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; KLAUS GGB, 1988, TRANSPLANTATION, V46, pS11; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; Weiss DL, 1996, MOL CELL BIOL, V16, P228; YASEEN NR, 1993, J BIOL CHEM, V268, P14285; YASEEN NR, 1994, MOL CELL BIOL, V14, P6886, DOI 10.1128/MCB.14.10.6886	44	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20914	20921		10.1074/jbc.271.34.20914	http://dx.doi.org/10.1074/jbc.271.34.20914			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702849	hybrid			2022-12-27	WOS:A1996VD33700101
J	PuzonMcLaughlin, W; Takada, Y				PuzonMcLaughlin, W; Takada, Y			Critical residues for ligand binding in an I domain-like structure of the integrin beta 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTEIN SECONDARY STRUCTURE; PLATELET GLYCOPROTEIN-IIIA; INTERCELLULAR-ADHESION MOLECULE-1; COMPLEMENT RECEPTOR TYPE-3; VONWILLEBRAND-FACTOR; ALPHA-SUBUNIT; FIBRONECTIN RECEPTOR; STRUCTURE PREDICTION; CR3 CD11B/CD18	Several integrin alpha subunits have an inserted sequence of about 200 residues (the I or A domain) that is critical for ligand interactions. The presence of an I domain-like structure within the integrin beta subunit has been proposed based on the similarity of the hydropathy profiles and the homology of sequences between the alpha and beta subunits. This study was designed to determine whether the region of the beta 1 subunit that includes residues 101-335 has the characteristics of an I domain. We found novel critical residues for ligand binding (Ser-132, Asn-224, Asp-226, Glu-229, Asp-233, Asp-267, and Asp-295, in addition to the previously reported Asp-130) using site-directed mutagenesis, The critical residues for ligand binding are located in several of loop structures of the region (or in a potential loop between an alpha helix and a beta strand), which have been predicted using multiple secondary structure prediction methods. The data suggest that the beta subunit has multiple disrupted critical oxygenated residues for ligand binding similar to those found in the alpha I domain.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157, GM49899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BRACIALE TJ, 1986, J IMMUNOL, V137, P995; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; BROWN PJ, 1986, J CELL BIOL, V103, P1595, DOI 10.1083/jcb.103.4.1595; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GEOURJOU C, 1995, IN PRESS COMPUT APPL; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LANZA F, 1990, J BIOL CHEM, V265, P18098; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2623; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MOYLE M, 1991, J BIOL CHEM, V266, P19650; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEINER B, 1993, J BIOL CHEM, V268, P6870; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; THE TH, 1970, IMMUNOLOGY, V18, P865; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; ZHOU LB, 1994, J BIOL CHEM, V269, P17075; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	80	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20438	20443		10.1074/jbc.271.34.20438	http://dx.doi.org/10.1074/jbc.271.34.20438			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702782	hybrid			2022-12-27	WOS:A1996VD33700034
J	Wang, SY; Miura, M; Jung, YK; Zhu, H; Gagliardini, V; Shi, LF; Greenberg, AH; Yuan, JY				Wang, SY; Miura, M; Jung, YK; Zhu, H; Gagliardini, V; Shi, LF; Greenberg, AH; Yuan, JY			Identification and characterization of Ich-3, a member of the interleukin-1 beta converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; IL-1-BETA-CONVERTING ENZYME; GRANZYME-B; MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; CYSTEINE PROTEASES; MAMMALIAN HOMOLOG; DNA FRAGMENTATION; MICE DEFICIENT; CRMA	We report here the isolation and characterization of a new member of the ice/ced-3 family of cell death genes, named ich-3. The predicted amino acid sequence of Ich-3 protein shares 54% identity with murine interleukin-1 beta converting enzyme (ICE). Overexpression of ich-3 in Rat-1 and HeLa cells induces apoptosis, which can be inhibited by CrmA and Bcl-2. The mRNA and proteins of ich-3 are dramatically induced in vivo upon stimulation with lipopolysaccharide, an inducer of septic shock. The ich-3 gene product can be cleaved by cytotoxic T cells granule serine protease granzyme B, suggesting that Ich-3 may mediate apoptosis induced by granzyme B. Ich-3 does not process proIL-1 beta directly but does promote proIL-1 beta processing by ICE. These results suggest that Ich-3 may play a very important role in apoptosis and inflammatory responses and may be an upstream regulator of ICE.	MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV TSUKUBA,DEPT MOL NEUROBIOL,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV MANITOBA,MANITOBA INST CELL BIOL,MANITOBA CANC TREATMENT & RES FDN,WINNIPEG,MB R3E 0V9,CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Tsukuba; University of Tsukuba; University of Manitoba				Zhu, Hong/0000-0002-2575-4031; Jung, Yong-Keun/0000-0002-9686-3120; Gagliardini, Valeria/0000-0001-9471-0764				DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENKART PA, 1994, CURR OPIN IMMUNOL, V5, P404; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LI W, 1995, CELL DEATH DIFFER, V3, P105; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	31	186	196	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20580	20587		10.1074/jbc.271.34.20580	http://dx.doi.org/10.1074/jbc.271.34.20580			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702803	Green Published, hybrid			2022-12-27	WOS:A1996VD33700055
J	Jacob, JS; Cistola, DP; Hsu, FF; Muzaffar, S; Mueller, DM; Hazen, SL; Heinecke, JW				Jacob, JS; Cistola, DP; Hsu, FF; Muzaffar, S; Mueller, DM; Hazen, SL; Heinecke, JW			Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LINKING AMINO-ACID; ATHEROSCLEROTIC LESIONS; HYPOCHLOROUS ACID; CROSS-LINKING; FERTILIZATION MEMBRANE; LIPID-PEROXIDATION; HUMAN-NEUTROPHILS; OXIDATION; SUPEROXIDE	Myeloperoxidase, a heme protein secreted by activated phagocytes, may be a catalyst for lipoprotein oxidation in vivo. Active myeloperoxidase is a component of human atherosclerotic lesions, and atherosclerotic tissue exhibits selective enrichment of protein dityrosine cross-links, a well characterized product of myeloperoxidase, Tyrosylation of lipoproteins with peroxidase-generated tyrosyl radical generates multiple protein-bound tyrosine oxidation products in addition to dityrosine. The structural characterization of these products would thus serve as an important step in determining the role of myeloperoxidase in lipoprotein oxidation in the artery wall. We now report the identification and characterization of four distinct tyrosyl radical addition products generated by human phagocytes. Activated neutrophils synthesized three major fluorescent products from L-tyrosine; on reverse phase HPLC, each compound coeluted with fluorescent oxidation products formed by myeloperoxidase. We purified the oxidation products to apparent homogeneity by cation and anion exchange chromatographies and identified the compounds as dityrosine (3,3'-dityrosine), trityrosine (3,3',5',3 ''-trityrosine) and pulcherosine (5-[4 ''-(2-carboxy-2-aminoethyl)phenoxy]3,3'-dityrosine) by high resolution NMR spectroscopy and mass spectrometry. Additionally, we have found that dityrosine is a precursor to trityrosine, but not pulcherosine. In a search for a precursor to pulcherosine, we identified isodityrosine (3-[4'-(2-carboxy-2-aminoethyl)phenoxy] tyrosine), a non-fluorescent product of L-tyrosine oxidation by human phagocytes. Our results represent the first identification of this family of tyrosyl radical addition products in a mammalian system. Moreover, these compounds may serve as markers specific for tyrosyl radical-mediated oxidative damage in atherosclerosis and other inflammatory conditions.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Hazen, Stanley L/ABD-5845-2021	Cistola, David/0000-0002-9586-8720; Hsu, Fong-Fu/0000-0001-5368-0183	NIA NIH HHS [R01 AG12293] Funding Source: Medline; NICHD NIH HHS [R01 HD29920] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; AMADO R, 1984, METHOD ENZYMOL, V107, P377; Andersen S.O, 1966, ACTA PHYSIOL SC S263, V66, P1; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DEITS T, 1984, J BIOL CHEM, V259, P3525; ESTERBAUER H, 1993, BRIT MED BULL, V49, P566, DOI 10.1093/oxfordjournals.bmb.a072631; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; HOFF HF, 1992, J BIOL CHEM, V267, P602; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; Musso H., 1963, ANGEW CHEM INT EDIT, V2, P723, DOI DOI 10.1002/ANIE.196307231; NOMURA K, 1990, BIOCHEMISTRY-US, V29, P4525, DOI 10.1021/bi00471a004; PANDEY NK, 1979, J BACTERIOL, V137, P1208, DOI 10.1128/JB.137.3.1208-1218.1979; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RAVEN DJ, 1971, BIOCHIM BIOPHYS ACTA, V251, P96, DOI 10.1016/0005-2795(71)90065-1; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SCOTT AI, 1965, Q REV CHEM SOC, V19, P1, DOI 10.1039/qr9651900001; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	53	141	151	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19950	19956		10.1074/jbc.271.33.19950	http://dx.doi.org/10.1074/jbc.271.33.19950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702710	hybrid			2022-12-27	WOS:A1996VC66900051
J	Kim, JM; DasSarma, S				Kim, JM; DasSarma, S			Isolation and chromosomal distribution of natural Z-DNA-forming sequences in Halobacterium halobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; PLASMIDS; NUCLEI	Conditions favoring left-handed Z-DNA such as high salinity (> 4 M), high negative DNA supercoiling, and GC-rich DNA [statistically favoring d(CG)(n) repeat sequences], are all found in the extremely halophilic archaeum (archaebaeterium) Halobacterium halobium. In order to identify and study Z-DNA regions of the H. halobium genome, an affinity chromatography method with high Z-DNA selection efficiency was developed. Supercoiled plasmids were incubated with a Z-DNA-specific antibody (Z22) and passed over a protein A-agarose column, and the bound plasmids were eluted using an ethidium bromide gradient. In control experiments using mixtures of pUC12 (Z-negative) and a d(CG)(5)-containing (Z-positive) pUC12 derivative, up to 4,000-fold enrichment of the Z-DNA-containing plasmid was demonstrated per cycle of the Z-DNA selection procedure. The selection efficiency was determined by transformation of Escherichia coli DH5 alpha with eluted plasmids and blue-white screening on X-gal plates. Twenty recombinant plasmids containing Z-DNA-forming sequences of H. halobium were isolated from a genomic library using affinity chromatography, Z-DNA-forming sequences in selected plasmids were identified by bandshift and antibody footprinting assays using Z22 monoclonal antibody. Alternating purine-pyrimidine sequences ranging from 8 base pairs (bp) to 13 bp with at least a 6-bp alternating d(GC) stretch were found in the Z22 antibody binding regions of isolated plasmids. The distribution of Z-DNA-forming sequences in the Halobacterium salinarum GRB chromosome was analyzed by dot-blot hybridization of an ordered cosmid library using the cloned H. halobium, Z-DNA segments as probe. Among the 11 Z-DNA segments tested, five were found to be clustered in a 100-kilobase pair region of the genome, whereas six others were distributed throughout the rest of the genome.	UNIV MASSACHUSETTS,DEPT MICROBIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst				DasSarma, Shiladitya/0000-0003-4162-2810	NIGMS NIH HHS [GM41980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDTJOVIN DJ, 1993, BIOCHEMISTRY-US, V32, P4862, DOI 10.1021/bi00069a023; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BLAHO JA, 1987, J BIOL CHEM, V262, P6082; CHRISTIAN JHB, 1962, BIOCHIM BIOPHYS ACTA, V65, P506, DOI 10.1016/0006-3002(62)90453-5; DASSARMA S, 1987, MOL MICROBIOL, V1, P365, DOI 10.1111/j.1365-2958.1987.tb01943.x; FERL RJ, 1992, PLANT MOL BIOL, V18, P1181, DOI 10.1007/BF00047722; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GARNER MM, 1987, J MOL BIOL, V196, P581, DOI 10.1016/0022-2836(87)90034-9; HACKETT NR, 1994, J BACTERIOL, V176, P7711, DOI 10.1128/JB.176.24.7711-7718.1994; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HOHEISEL JD, 1987, J MOL BIOL, V193, P447, DOI 10.1016/0022-2836(87)90259-2; JOHNSTON BH, 1992, METHOD ENZYMOL, V211, P127; KILPATRICK MW, 1984, J BIOL CHEM, V259, P7268; Kim J, 1996, J BIOL CHEM, V271, P9340, DOI 10.1074/jbc.271.16.9340; KIM JM, 1995, THESIS U MASSACHUSET; LAFER EM, 1981, P NATL ACAD SCI-BIOL, V78, P3546, DOI 10.1073/pnas.78.6.3546; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOORE RL, 1969, J BACTERIOL, V99, P248, DOI 10.1128/JB.99.1.248-254.1969; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PECK LJ, 1985, CELL, V40, P129, DOI 10.1016/0092-8674(85)90316-2; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSARMA S, 1995, ARCHAEA LAB MANUAL H; SEHROTH GP, 1992, J BIOL CHEM, V267, P11846; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; STIRDIVANT SM, 1982, J BIOL CHEM, V257, P159; STJEAN A, 1994, NUCLEIC ACIDS RES, V22, P1476; THOMAE R, 1983, P NATL ACAD SCI-BIOL, V80, P5550, DOI 10.1073/pnas.80.18.5550; THOMAS MJ, 1990, MOL CELL BIOL, V53, P78; VLACH J, 1989, BIOCHEM BIOPH RES CO, V158, P737, DOI 10.1016/0006-291X(89)92783-6; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; Yang CF, 1996, J BACTERIOL, V178, P840, DOI 10.1128/jb.178.3.840-845.1996; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x	40	6	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19724	19731		10.1074/jbc.271.33.19724	http://dx.doi.org/10.1074/jbc.271.33.19724			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702677	hybrid			2022-12-27	WOS:A1996VC66900018
J	Milstien, S; Jaffe, H; Kowlessur, D; Bonner, TI				Milstien, S; Jaffe, H; Kowlessur, D; Bonner, TI			Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MESSENGER-RNA EXPRESSION; TETRAHYDROBIOPTERIN LEVELS; COFACTOR BIOSYNTHESIS; INTERFERON-GAMMA; SMOOTH-MUSCLE; RAT; TRIPHOSPHATE; ENZYME; CELLS	The activity of GTP cyclohydrolase I, the initial enzyme of the de novo pathway for biosynthesis of tetrahydrobiopterin, the cofactor required for aromatic amino acid hydroxylations and nitric oxide synthesis, is sensitive to end-product feedback inhibition by tetrahydrobiopterin. This inhibition by tetrahydrobiopterin is mediated by the GTP cyclohydrolase I feedback regulatory protein GFRP, previously named p35 (Harada, T., Kagamiyama, H., and Hatakeyama, K. (1993) Science 260, 1507-1510), and L-phenylalanine specifically reverses the tetrahydrobiopterin dependent inhibition. As a first step in the investigation of the physiological role of this unique mechanism of regulation, a convenient procedure has been developed to co purify to homogeneity both GTP cyclohydrolase I and GFRP from rat liver, GTP cyclohydrolase I and GFRP exist in a complex which can be bound to a GTP-affinity column from which GTP cyclohydrolase I and GFRP are separately and selectively eluted. GFRP is dissociated from the GTP agarose-bound complex with 0.2 M NaCl, a concentration of salt which also effectively blocks the tetrahydrobiopterin-dependent inhibitory activity of GFRP. GTP cyclohydrolase I is then eluted from the GTP-agarose column with GTP, Both GFRP and GTP cyclohydrolase I were then purified separately to near homogeneity by sequential high performance anion exchange and gel filtration chromatography, GFRP was found to have a native molecular mass of 20 kDa and consist of a homodimer of 9.5-kDa subunits. Based on peptide sequences obtained from purified GFRP, oligonucleotides were synthesized and used to clone a cDNA from a rat liver cDNA library by polymerase chain reaction-based methods. The cDNA contained an open reading frame that encoded a novel protein of 84 amino acids (calculated molecular mass 9665 daltons). This protein when expressed in Escherichia coli as a thioredoxin fusion protein had tetrahydrobiopterin-dependent GTP cyclohydrolase I inhibitory activity. Northern blot analysis indicated the presence of an 0.8-kilobase GFRP mRNA in most rat tissues, the amounts generally correlating with levels of GTP cyclohydrolase I and tetrahydrobiopterin. Thus, mRNA levels were relatively high in liver and kidney and somewhat lower in testis, heart, brain, and lung. These results suggest that GFRP is widely expressed and may play a role in regulating not only phenylalanine metabolism in the liver, but also the production of biogenic amine neurotransmitters as well as nitric oxide synthesis.	NINCDS,LNC NINDS PROT PEPTIDE SEQUENCING FACIL,NIH,BETHESDA,MD 20892; NIMH,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Milstien, S (corresponding author), NIMH,CELL BIOL LAB,36 CONVENT DR,BLDG 36,RM 3A-17,BETHESDA,MD 20892, USA.							ABOUDONIA MM, 1983, ENDOCRINOLOGY, V112, P2088, DOI 10.1210/endo-112-6-2088; ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; BELLAHSENE Z, 1984, BIOCHEM J, V217, P59, DOI 10.1042/bj2170059; BLAU N, 1986, BIOCHIM BIOPHYS ACTA, V880, P26, DOI 10.1016/0304-4165(86)90115-7; BLAU N, 1985, J CLIN CHEM CLIN BIO, V23, P169; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; DUCH DS, 1991, J NUTR BIOCHEM, V2, P411, DOI 10.1016/0955-2863(91)90110-Q; DUCH DS, 1986, MOL CELL ENDOCRINOL, V47, P209, DOI 10.1016/0303-7207(86)90114-0; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GUTLICH M, 1994, BIOCHEM J, V302, P215, DOI 10.1042/bj3020215; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HIRAYAMA K, 1993, J NEUROCHEM, V61, P1006, DOI 10.1111/j.1471-4159.1993.tb03614.x; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MILSTIEN S, 1991, PTERINS BIOGENIC AMI, P89; MILSTIEN S, 1983, CHEM BIOL PTERIDINES, P753; MONCADA S, 1991, PHARMACOL REV, V43, P109; NIEDERWIESER A, 1984, EUR J PEDIATR, V141, P208, DOI 10.1007/BF00572762; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; STONE KL, 1990, LABORATORY METHODOLO, P181; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1993, FEBS LETT, V322, P223, DOI 10.1016/0014-5793(93)81574-J; ZAGALAK B, 1988, BIOCHEM BIOPH RES CO, V152, P1193, DOI 10.1016/S0006-291X(88)80411-X	30	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19743	19751		10.1074/jbc.271.33.19743	http://dx.doi.org/10.1074/jbc.271.33.19743			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702680	hybrid			2022-12-27	WOS:A1996VC66900021
J	Rajagopalan, LE; Malter, JS				Rajagopalan, LE; Malter, JS			Turnover and translation of in vitro synthesized messenger RNAs in transfected, normal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; URIDINE BINDING-FACTOR; 3'-UNTRANSLATED REGION; TRANSFERRIN RECEPTOR; C-FOS; AUUUA MOTIFS; DEGRADATION; PROTEIN; STABILITY	We have developed a novel system to examine intracellular mRNA decay pathways in the absence of transcriptional blockade. In vitro transcribed, capped, and adenylated granulocyte macrophage colony stimulating factor (GM-CSF) or globin mRNAs were introduced by particle-mediated gene transfer into primary cultures of normal peripheral blood mononuclear cells. Transfected wild type, human GM-CSF (GM-AUUUA) mRNA decayed rapidly (t(1/2) = 9 min), while a mutated version lacking AUUUA repeats (hGM-AUGUA) was significantly more stable (t(1/2) = 30 min). A truncated GM-CSF mRNA lacking the entire 3'-UTR (hGM-Delta 3' UTR) was still more stable (t(1/2) = 80 min) demonstrating the existence of non-AUUUA, 3'-UTR destabilizing domains. Transfected beta-globin mRNA was very stable, decaying with a half-life of >360 min. Transfected mRNAs were >90% polysome associated with transgenic protein detectable within 15 min of transfection. The most stable GM-CSF mRNAs were not associated with maximal GM-CSF protein production. Agents known or hypothesized to interfere with mRNA decay, including cycloheximide, phorbol ester, or actinomycin D, stabilized both hGM-AUUUA and hGM-AUGUA mRNAs. These data demonstrate the presence of 3'-UTR, destabilizing, and translational regulatory elements outside of the AUUUA repeats and unambiguously show that actinomycin D at concentrations commonly used to inhibit transcription stabilizes cytokine mRNAs.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53792; UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10675] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AKASHI M, 1994, BLOOD, V83, P3182; BICKEL M, 1990, J IMMUNOL, V145, P840; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURKHOLDER JK, 1993, J IMMUNOL METHODS, V165, P149, DOI 10.1016/0022-1759(93)90340-D; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; ELDREDGE ER, 1995, METHOD ENZYMOL, V254, P481; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOLDBERG MA, 1991, BLOOD, V77, P271; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; IWAI Y, 1993, J IMMUNOL, V150, P4386; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Qiu P, 1996, GENE THER, V3, P262; RAJAGOPALAN LE, 1995, BLOOD, V86, P2551; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SONG HJ, 1995, EUR J BIOCHEM, V232, P778, DOI 10.1111/j.1432-1033.1995.778zz.x; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWIC.A, 1990, P NATL ACAD SCI USA, V290, P777; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	52	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19871	19876		10.1074/jbc.271.33.19871	http://dx.doi.org/10.1074/jbc.271.33.19871			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702698	hybrid			2022-12-27	WOS:A1996VC66900039
J	Sobel, JH; Gawinowicz, MA				Sobel, JH; Gawinowicz, MA			Identification of the alpha chain lysine donor sites involved in factor XIII(a) fibrin cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ALPHA-2-PLASMIN INHIBITOR; ELECTROPHORETIC TRANSFER; MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; TRANSGLUTAMINASE; CROSSLINKING; PROTEINS; HETEROGENEITIES; NITROCELLULOSE	Biochemical studies of fibrin cross-linking were conducted to identify the specific A alpha chain lysine residues that potentially serve as Factor XIII(a) amine donor substrates during alpha polymer formation. A previously characterized Factor XIII(a) fibrin lysine labeling system was employed to localize sites of donor activity based on their covalent incorporation of a synthetic peptide acceptor substrate analog modelled after the NH2-terminal cross-linking domain of alpha(2) antiplasmin, Peptide-decorated fibrin was prepared using purified fibrinogen as the starting material, Cyanogen bromide digestion, immunoaffinity chromatography, high pressure liquid chromatography (HPLC), and enzyme-linked immunosorbent assay (anti-peptide) methodologies were employed to isolate purified CNBr fibrin fragments whose structures included the acceptor probe in cross-linked form and, therefore, represented regions of (amine) donor activity, Five alpha chain CNBr fragments (within A alpha 208-610) and one gamma chain CNBr fragment (gamma 385-411) were the only portions of fibrin found associated with the acceptor peptide, based on collective sequencing, mass, and compositional data, Trypsin digestion, HPLC, and enzyme-linked immunosorbent assay (anti-peptide) methodologies were used to isolate smaller derivatives whose structures included an or chain tryptic cleavage product (the donor arm) cross-linked to the trypsin-resistant synthetic peptide (the acceptor arm). Biochemical characterization and quantitative peptide recovery data revealed that 12 of the 23 potential lysine donor residues within alpha 208-610 had incorporated the peptide probe, whereas gamma chain donor activity was due solely to peptide cross-linking at, (gamma) Lys(406); the alpha chain lysines, Lys(556) and Lys(580), accounted for 50% of the total alpha chain donor cross-linking activity observed, with Lys(539), Lys(508), Lys(418), and Lys(448) contributing an additional 25% and Lys(601), Lys(606), Lys(427), Lys(429), Lys(208), Lys(224), and/or Lys(219) responsible for the remaining proportion (25%, each), The collective findings extend current models proposed for the mechanism of alpha polymer formation, raise questions concerning the physiological role of multiple cu chain donor sites, and, most importantly, provide specific information that should facilitate future efforts to identify the respective lysine and glutamine partners involved in native fibrin alpha chain cross-linking.			Sobel, JH (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,IRVING CTR CLIN RES,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045936] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45936] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CORCORAN DH, 1980, THROMB RES, V19, P883, DOI 10.1016/0049-3848(80)90016-X; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1715, DOI 10.1021/bi00627a030; DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006-291X(71)80163-8; EHRLICH PH, 1983, BIOCHEMISTRY-US, V22, P4184, DOI 10.1021/bi00287a004; FATH MJ, 1994, BIOCHEMISTRY-US, V33, P6911, DOI 10.1021/bi00188a021; FINLAYSON J S, 1973, Thrombosis Research, V2, P467, DOI 10.1016/0049-3848(73)90001-7; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FRETTO LJ, 1978, J BIOL CHEM, V253, P6614; GALANAKIS DK, 1983, THROMB RES, V31, P403, DOI 10.1016/0049-3848(83)90405-X; GARDLUND B, 1977, EUR J BIOCHEM, V77, P595, DOI 10.1111/j.1432-1033.1977.tb11704.x; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HIROSAWA S, 1988, P NATL ACAD SCI USA, V85, P6836, DOI 10.1073/pnas.85.18.6836; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; KIMURA S, 1986, J BIOL CHEM, V261, P5591; KOEHN JA, 1981, ANAL BIOCHEM, V116, P349, DOI 10.1016/0003-2697(81)90370-5; KOOPMAN J, 1992, BLOOD, V80, P1972; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LORAND L, 1992, BIOCONJUGATE CHEM, V3, P37, DOI 10.1021/bc00013a006; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; Lorand L., 1970, METHOD ENZYMOL, V19, P770; LOTTSPEICH F, 1978, H-S Z PHYSIOL CHEM, V359, P1611; LOTTSPEICH F, 1978, H-S Z PHYSIOL CHEM, V359, P1451; MATACIC S, 1968, BIOCHEM BIOPH RES CO, V30, P356, DOI 10.1016/0006-291X(68)90750-X; MCDONAGH RP, 1971, FEBS LETT, V14, P33, DOI 10.1016/0014-5793(71)80268-5; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; Mitkevich OV, 1996, BLOOD COAGUL FIBRIN, V7, P85, DOI 10.1097/00001721-199601000-00011; MOSESSON MW, 1990, J LAB CLIN MED, V116, P8; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; SOBEL JH, 1983, BIOCHEMISTRY-US, V22, P4175, DOI 10.1021/bi00287a003; SOBEL JH, 1995, BLOOD, V86, P989, DOI 10.1182/blood.V86.3.989.bloodjournal863989; SOBEL JH, 1988, THROMB HAEMOSTASIS, V60, P160; SOBEL JH, 1994, BLOOD, V84, P535; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P68, DOI 10.1021/bi00568a011; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	46	64	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19288	19297		10.1074/jbc.271.32.19288	http://dx.doi.org/10.1074/jbc.271.32.19288			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702612	hybrid			2022-12-27	WOS:A1996VB68400046
J	Bohm, SK; Khitin, LM; Grady, EF; Aponte, G; Payan, DG; Bunnett, NW				Bohm, SK; Khitin, LM; Grady, EF; Aponte, G; Payan, DG; Bunnett, NW			Mechanisms of desensitization and resensitization of proteinase-activated receptor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL THROMBIN RECEPTOR; SUBSTANCE-P RECEPTOR; KINASE-C; MOLECULAR-CLONING; INDUCED INTERNALIZATION; SELECTIVE INHIBITOR; FEEDBACK-REGULATION; ENDOCYTIC PATHWAY; COUPLED RECEPTOR; NK1 RECEPTOR	Proteinase activated receptor-2 (PAR-2) is a G-protein-coupled receptor that is expressed by intestinal epithelial cells, which are episodically exposed to pancreatic trypsin in the intestinal lumen. Trypsin cleaves PAR-2 to expose a tethered ligand, which irreversibly activates the receptor. Thus, PAR-2 may desensitize and resensitize by novel mechanisms. We examined these mechanisms in kidney epithelial cells, stably expressing human PAR-2, and intestinal epithelial cells, which naturally express PAR-2. Trypsin stimulated a prompt increase in [Ca2+](i), due to mobilization of intracellular Ca2+, followed by a sustained plateau, due to influx of extracellular Ca2+. Repeated application of trypsin caused marked desensitization of this response, which is due in part to (a) irreversible cleavage of the receptor by trypsin and (b) protein kinase C-mediated termination of signaling. Trypsin exposure resulted in internalization of PAR-2 into early endosomes and then lysosomes; but endocytosis was not the mechanism of rapid desensitization. Thus, activated PAR-2 is endocytosed and degraded. The Ca2+ response to trypsin resensitized by 60-90 min. Brefeldin A, which disrupted Golgi stores of PAR-2, and cycloheximide, which inhibited protein synthesis, markedly attenuated resensitization. Thus, PAR-2-mediated Ca2+ mobilization desensitizes by irreversible receptor cleavage, protein kinase C-mediated termination of signaling, and PAR-2 targeting to lysosomes. It resensitizes by mobilization of large Golgi stores and synthesis of new receptors.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT NUTR SCI,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley				Bunnett, Nigel W./0000-0003-3367-0644	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R56DK043207, R01DK039957, R01DK046285, R37DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46285, DK43207, DK39957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALANI B, 1995, CAN J PHYSIOL PHARM, V73, P1203, DOI 10.1139/y95-172; ALI H, 1993, J BIOL CHEM, V268, P24247; APONTE GW, 1991, P NATL ACAD SCI USA, V88, P5282, DOI 10.1073/pnas.88.12.5282; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bohm SK, 1996, BIOCHEM J, V314, P1009; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FUSHIKI T, 1989, FASEB J, V3, P121, DOI 10.1096/fasebj.3.2.2644146; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GODFRAIND T, 1986, PHARMACOL REV, V38, P321; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEVINE L, 1994, PROSTAGLANDINS, V47, P437, DOI 10.1016/0090-6980(94)90044-2; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MACFIE HL, 1981, DRUG INTEL CLIN PHAR, V15, P94, DOI 10.1177/106002808101500202; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MUNSHI R, 1993, MOL PHARMACOL, V44, P1185; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RYU SH, 1990, J BIOL CHEM, V265, P17941; SAKAI T, 1992, CELL CALCIUM, V13, P329, DOI 10.1016/0143-4160(92)90068-4; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SOLOMON TE, 1994, PHYSL GASTROINTESTIN, V2, P1499; TANG H, 1995, CIRC RES, V77, P239, DOI 10.1161/01.RES.77.2.239; TEPPERMAN BL, 1994, PHYSL GASTROINTESTIN, V2, P1331; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALSH JH, 1993, J CELL PHYSIOL, V156, P333, DOI 10.1002/jcp.1041560216; XU YP, 1995, J BIOL CHEM, V270, P23887, DOI 10.1074/jbc.270.41.23887; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; YU SS, 1993, J BIOL CHEM, V268, P337; ZACHARIAS U, 1995, EXP CELL RES, V216, P371, DOI 10.1006/excr.1995.1047; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	54	210	213	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22003	22016						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703006				2022-12-27	WOS:A1996VF61200048
J	Dai, K; Kobayashi, R; Beach, D				Dai, K; Kobayashi, R; Beach, D			Physical interaction of mammalian CDC37 with CDK4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEIN HSP90; D-TYPE CYCLINS; CELL-DIVISION; KINASE; CEREVISIAE; CDC28; CAK	CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins. The exact functional mechanism by which CDC37 promotes this association, however, remains unknown. CDK4 is a cyclin D-dependent kinase that controls progression through G(1) of the mammalian cell cycle. We have detected a specific association of CDK4 with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian CDC37. A physical interaction between CDC37 and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4. Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute								Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOSCHELLI F, 1993, J CELL SCI, V105, P519; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; REED SI, 1980, GENETICS, V95, P561; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	31	128	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22030	22034		10.1074/jbc.271.36.22030	http://dx.doi.org/10.1074/jbc.271.36.22030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703009	hybrid			2022-12-27	WOS:A1996VF61200051
J	Goswitz, VC; Matzke, EA; Taylor, MR; JessenMarshall, AE; Brooker, RJ				Goswitz, VC; Matzke, EA; Taylor, MR; JessenMarshall, AE; Brooker, RJ			Structural topology of transmembrane helix 10 in the lactose permease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; CARRIER PROTEIN; DIRECTED MUTAGENESIS; ENHANCED RECOGNITION; ACTIVE-TRANSPORT; PROTON; MEMBRANE; SYMPORT; MUTANTS; MALTOSE	In the lactose permease of Escherichia coli, transmembrane helix 10 has been shown to be functionally important, The structure of this helix has been examined in greater detail in this study, A total of 46 substitution and 8 insertional mutants were constructed and analyzed along the entire length of transmembrane helix 10, The results identified amino acids that are tolerant of substitutions by a variety of amino acids, Since a number of these amino acids (Thr-320, Val-331, Phe-325, and Ile-317) are clustered in one region in a helical wheel projection of transmembrane helix 10, it seems likely that this face of helix 10 is interacting with the membrane, The channel lining domain is thought to consist of the helical face containing Glu-325, Leu-318, Leu-329, His-322, Val-315, Cys-333, Val-326, and Lys-319 based on the results here and from earlier findings, Deleterious mutations along this face tended to greatly increase the K-m value for lactose transport with only minor effects on the V-max. Analysis of insertional mutants revealed that perturbation of the spatial relationship between amino acids at the periplasmic edge is less deleterious than perturbation in the center of the helix or the cytoplasmic edge. Using all of the above information, a detailed structural topology of transmembrane helix 10 is proposed.	UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; CRANE RK, 1962, FED PROC, V21, P891; CRANE RK, 1960, PHYSIOL REV, V40, P784; EDDY AA, 1971, BIOCHEM J, V122, P701, DOI 10.1042/bj1220701; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HOFER M, 1978, BIOCHEM J, V172, P15; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KOMOR E, 1973, FEBS LETT, V38, P16, DOI 10.1016/0014-5793(73)80501-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MALAMY MH, 1966, COLD SPRING HARB SYM, V31, P189, DOI 10.1101/SQB.1966.031.01.027; Mandel M, 1970, J MOL BIOL, V53, P154; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL IH, 1975, ENZYME KINETICS; SLAYMAN CL, 1974, P NATL ACAD SCI USA, V71, P1935, DOI 10.1073/pnas.71.5.1935; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON TH, 1983, CELL MEMBR METH REV, V1, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21927	21932		10.1074/jbc.271.36.21927	http://dx.doi.org/10.1074/jbc.271.36.21927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702996	hybrid			2022-12-27	WOS:A1996VF61200038
J	Huang, RP; Reusch, RN				Huang, RP; Reusch, RN			Poly(3-hydroxybutyrate) is associated with specific proteins in the cytoplasm and membranes of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-BETA-HYDROXYBUTYRATE; PLASMA-MEMBRANES; COMPLEXES; COMPETENCE; ACID	Poly(3-hydroxybutyrate) (PHB) is well-known as a high molecular weight homopolymer of R-3-hydroxybutyrate which accumulates in storage granules within the cytosols of certain bacteria. Escherichia coli does not amass these granules; however, small amounts of low molecular weight PHB (<0.02% of dry weight) have been found in the plasma membranes in complexes with calcium polyphosphate; the complexes serve as voltage-activated calcium channels. Here we report that polyphosphate-complexed PHB is only a minor fraction of the polyester in E. coli. PRE comprises 0.36 to 0.55% of the dry weight of log-phase cells, depending on culture medium, and this amount increases by 15 to 20% when the cells are made genetically competent. The PHB is widely distributed throughout the cell, wherein it is primarily associated with proteins. The identity of protein-associated PHB was established by antibody reaction, chemical assay, and H-1 NMR spectroscopy. As expected, the physical and chemical properties of protein-associated PHB were found to be considerably different from those of the bulk polymer or granule PHB, e.g. protein-PHB complexes are normally insoluble in chloroform, soluble in water and alkaline hypochlorite, and are converted to crotonic acid more slowly on heating in concentrated sulfuric acid. Our studies indicate that the majority of cellular PHB (over 80%) is located in cytoplasmic proteins, especially proteins of the ribosomal fraction. Western immunoblots, probed with polyclonal anti-PHB IgG, revealed a number of PHB-polypeptides having a wide range of molecular weights in all cell fractions. These results suggest that PHB is a fundamental constituent of cells that may have physiological functions in addition to facilitating ion transmembrane transport or serving as a carbon reserve.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM 33375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BRANDL H, 1992, FEMS MICROBIOL REV, V103, P441; BRAUNEGG G, 1978, EUR J APPL MICROBIOL, V6, P29, DOI 10.1007/BF00500854; CASTUMA CE, 1995, J BIOL CHEM, V270, P12980, DOI 10.1074/jbc.270.22.12980; Dawes E A, 1973, Adv Microb Physiol, V10, P135, DOI 10.1016/S0065-2911(08)60088-0; HANAHAN D, 1987, ESCHERICHIA COLI SAL, V2, P1177; HOLMES PA, 1987, DEV CRYSTALLINE POLY, V2, P10; HUANG RP, 1995, J BACTERIOL, V177, P486, DOI 10.1128/jb.177.2.486-490.1995; KARR DB, 1983, APPL ENVIRON MICROB, V46, P1339, DOI 10.1128/AEM.46.6.1339-1344.1983; LAW JH, 1961, J BACTERIOL, V82, P33, DOI 10.1128/JB.82.1.33-36.1961; LAW JH, 1961, J BACTERIOL, V82, P37; REUSCH RN, 1992, BIOCHIM BIOPHYS ACTA, V1123, P33, DOI 10.1016/0005-2760(92)90168-U; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; REUSCH RN, 1995, BIOPHYS J, V69, P754, DOI 10.1016/S0006-3495(95)79958-1; REUSCH RN, 1983, J BACTERIOL, V156, P778, DOI 10.1128/JB.156.2.778-788.1983; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; REUSCH RN, 1986, J BACTERIOL, V168, P553, DOI 10.1128/jb.168.2.553-562.1986; REUSCH RN, 1992, FEMS MICROBIOL LETT, V103, P119, DOI 10.1016/0378-1097(92)90301-4; SEEBACH D, 1994, EUR J BIOCHEM, V224, P317, DOI 10.1111/j.1432-1033.1994.00317.x; SYKES J, 1971, METHODS MICROBIOLO B, V5, P55	20	71	74	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22196	22202		10.1074/jbc.271.36.22196	http://dx.doi.org/10.1074/jbc.271.36.22196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703033	hybrid			2022-12-27	WOS:A1996VF61200075
J	Jakobsson, PJ; Mancini, JA; FordHutchinson, AW				Jakobsson, PJ; Mancini, JA; FordHutchinson, AW			Identification and characterization of a novel human microsomal glutathione S-transferase with leukotriene C-4 synthase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LUNG; ARACHIDONIC-ACID; BIOSYNTHESIS INHIBITORS; SUBSTRATE-SPECIFICITY; PARTIAL-PURIFICATION; MOLECULAR-CLONING; MEMBRANE-PROTEIN; HUMAN-PLATELETS; EXPRESSION; CELLS	5-Lipoxygenase-activating protein (FLAP) and leukotriene C-4 (LTC(4)) synthase, two proteins involved in leukotriene biosynthesis, have been demonstrated to be 31% identical at the amino acid level. We have recently identified and characterized a novel member of the FLAP/LTC(4) synthase gene family termed microsomal glutathione S-transferase II (microsomal GST-II). The open reading frame encodes a 16.6-kDa protein with a calculated pi of 10.4, Microsomal GST-II has 33% amino acid identity to FLAP, 44% amino acid identity to LTC(4) synthase, and 11% amino acid identity to the previously characterized human microsomal GST (microsomal GST-I). Microsomal GST-II also has a similar hydrophobicity pattern to FLAP, LTC(4) synthase, and microsomal GST-I. Fluorescent in situ hybridization mapped microsomal GST-II to chromosomal localization 4q28-31. Microsomal GST-II has a wide tissue distribution (at the mRNA level) and was specifically expressed in human liver, spleen, skeletal muscle, heart, adrenals, pancreas, prostate, testis, fetal liver, and fetal spleen. In contrast, microsomal GST-II mRNA expression was very low (when present) in lung, brain, placenta, and bone marrow. This differs from FLAP mRNA, which was detected in lung, various organs of the immune system, and peripheral blood leukocytes, and LTC(4) synthase mRNA, which could not be detected in any tissues by Northern blot analysis. Microsomal GST-II and LTC(4) synthase were expressed in a baculovirus insect cell system, and microsomes from Sf9 cells containing microsomal GST-II or LTC(4) synthase were both found to catalyze the production of LTC(4) from LTA(4) and reduced glutathione. Microsomal GST-II also catalyzed the formation of another product, displaying a conjugated triene UV absorption spectra with a maximum at 283 nm, suggesting less catalytic stereospecificity compared with LTC(4) synthase. Also, the apparent K-m for LTA(4) was higher for microsomal GST-II (41 mu M) than LTC(4) synthase (7 mu M). In addition, unlike LTC(4) synthase, microsomal GST-II was able to catalyze the conjugation of 1-chloro-2,4-dinitrobenzene with reduced glutathione. Therefore, it is proposed that this novel membrane protein is a member of the microsomal glutathione S-transferase family, also including LTC(4) synthase, with significant sequence identities to both LTC(4) synthase and FLAP.	MERCK FROSST CTR THERAPEUT RES,KIRKLAND,PQ H9H 3L1,CANADA	Merck & Company			Jakobsson, Per-Johan/ABC-5594-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; ALI A, 1994, J IMMUNOL, V153, P776; ANDERSON PM, 1994, CLIN PHARMACOKINET, V27, P19, DOI 10.2165/00003088-199427010-00003; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; BOYUM A, 1974, TISSUE ANTIGENS, V4, P269; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; DEJONG JL, 1990, GENOMICS, V6, P379, DOI 10.1016/0888-7543(90)90580-N; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DU JT, 1983, BIOCHIM BIOPHYS ACTA, V753, P159, DOI 10.1016/0005-2760(83)90003-6; EDENIUS C, 1988, EUR J BIOCHEM, V178, P81, DOI 10.1111/j.1432-1033.1988.tb14431.x; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HABIG WH, 1974, J BIOL CHEM, V249, P7130; IZUMI T, 1988, BIOCHIM BIOPHYS ACTA, V959, P305; JAKOBSSON PJ, 1991, BIOCHEM BIOPH RES CO, V178, P302, DOI 10.1016/0006-291X(91)91814-S; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MANCINI JA, 1993, J LIPID MEDIATOR, V8, P145; MANCINI JA, 1994, LIFE SCI, V54, pPL137, DOI 10.1016/0024-3205(94)00872-8; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MANNERVIK B, 1984, FEBS LETT, V175, P289, DOI 10.1016/0014-5793(84)80753-X; MANTLE TJ, 1995, BIOCHEM SOC T, V23, P423, DOI 10.1042/bst0230423; MAYER RJ, 1993, FASEB J, V7, P389; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; METTERS KM, 1994, J BIOL CHEM, V269, P12816; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MORGENSTERN R, 1979, BIOCHEM BIOPH RES CO, V87, P657, DOI 10.1016/0006-291X(79)92009-6; MORGENSTERN R, 1984, BIOCHEM PHARMACOL, V33, P3609, DOI 10.1016/0006-2952(84)90145-X; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; MOSIALOU E, 1995, ARCH BIOCHEM BIOPHYS, V320, P210, DOI 10.1016/0003-9861(95)90002-0; MOSIALOU E, 1993, FEBS LETT, V315, P77, DOI 10.1016/0014-5793(93)81137-O; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; Nugteren D H, 1980, Adv Prostaglandin Thromboxane Res, V6, P129; PACEASCIAK CR, 1986, BIOCHIM BIOPHYS ACTA, V877, P68, DOI 10.1016/0005-2760(86)90119-0; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; PETRIC R, 1995, BBA-LIPID LIPID MET, V1254, P207, DOI 10.1016/0005-2760(94)00185-2; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SODERSTROM M, 1988, BIOCHEM J, V250, P713, DOI 10.1042/bj2500713; SODERSTROM M, 1985, BIOCHEM BIOPH RES CO, V128, P265, DOI 10.1016/0006-291X(85)91673-0; STENKE L, 1987, ACTA ONCOL, V27, P803; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; TSUCHIDA S, 1987, EUR J BIOCHEM, V170, P159, DOI 10.1111/j.1432-1033.1987.tb13681.x; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	61	120	154	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22203	22210		10.1074/jbc.271.36.22203	http://dx.doi.org/10.1074/jbc.271.36.22203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703034	hybrid			2022-12-27	WOS:A1996VF61200076
J	Kimura, Y; Kurzydlowski, K; Tada, M; MacLennan, DH				Kimura, Y; Kurzydlowski, K; Tada, M; MacLennan, DH			Phospholamban regulates the Ca2+-ATPase through intramembrane interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CA-2+ PUMP; FUNCTIONAL ASSOCIATION; CYTOPLASMIC DOMAIN; ATPASE; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; SEQUENCE; ASSAY	There is clear evidence for direct regulatory protein-protein interactions between phospholamban (PLN) and the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) in cytoplasmic domains, but there is less clear evidence for regulatory interactions in the transmembrane domains of the two proteins. We have now coexpressed SERCA isoforms with the transmembrane sequence of PLN and with epitope-tagged transmembrane sequences of PLN to study intramembrane interactions in the absence of cytoplasmic interactions. Coexpression of the transmembrane sequence of phospholamban (Met-PLN(28-52)) with SERCA1a, SERCA2a, and SERCA3 inhibited Ca2+ transport by lowering apparent Ca2+ affinity. Addition of the hemagglutinin (IIA) epitope to the transmembrane sequence of PLN (HA-PLN(28-52)) or deletion of PLN residues 21-29 (PLN(1-20)-PLN(30-52)) ''supershifted'' apparent Ca2+ affinity to values lower than those observed with native PLN without uncoupling Ca2+ transport from ATP hydrolysis. Inhibition by PLN(1-20)-PLN(30-52) or by Flag-PLN(28-52) was reversed by PLN antibody or by Flag antibody, demonstrating that inhibition by these constructs is reversible and that the inhibitory constructs are properly oriented in the membrane. These results suggest that PLN modulates the apparent Ca2+ affinity of SERCA2a through intramembrane interactions, which are disrupted at long range and in concert with disruption of the well characterized cytoplasmic interactions.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; OSAKA UNIV,SCH MED,DEPT MED & PATHOPHYSIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; Osaka University								BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1993, J BIOL CHEM, V268, P11486; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490	25	122	129	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21726	21731		10.1074/jbc.271.36.21726	http://dx.doi.org/10.1074/jbc.271.36.21726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702967	hybrid			2022-12-27	WOS:A1996VF61200009
J	Larcher, JC; Boucher, D; Lazereg, S; Gros, F; Denoulet, P				Larcher, JC; Boucher, D; Lazereg, S; Gros, F; Denoulet, P			Interaction of kinesin motor domains with alpha- and beta-tubulin subunits at a tau-independent binding site - Regulation by polyglutamylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MOUSE-BRAIN NEURONS; CYTOPLASMIC DYNEIN; 3-DIMENSIONAL STRUCTURE; AXONAL-TRANSPORT; HEAVY-CHAIN; IN-VITRO; CENP-E; MAP2; PHOSPHORYLATION	interaction of rat kinesin and Drosophila nonclaret disjunctional motor domains with tubulin was studied by a blot overlay assay. Either plus-end or minus-end-directed motor domain binds at the same extent to both alpha- and beta-tubulin subunits, suggesting that kinesin binding is an intrinsic property of each tubulin subunit and that motor directionality cannot be related to a preferential interaction with a given tubulin subunit. Binding features of dimeric versus monomeric rat kinesin heads suggest that dimerization could drive conformational changes to enhance binding to tubulin. Competition experiments have indicated that kinesin interacts with tubulin at a Tau-independent binding site. Complementary experiments have shown that kinesin does not interact with the same efficiency with the different tubulin isoforms. Masking the polyglutamyl chains with a specific monoclonal antibody leads to a complete inhibition of kinesin binding. These results are consistent with a model in which polyglutamylation of tubulin regulates kinesin binding through progressive conformational changes of the whole carboxyl-terminal domain of tubulin as a function of the polyglutamyl chain length, thus modulating the affinity of tubulin for kinesin and Tau as well. These results indicate that microtubules, through tubulin polymorphism, do have the ability to control microtubule-associated protein binding.	UNIV PARIS 06, COLL FRANCE, F-75005 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Sorbonne Universite	Larcher, JC (corresponding author), CNRS, UPR 9065, 11 PL MARCELIN BERTHELOT, F-75005 PARIS, FRANCE.							ALLAN V, 1995, J CELL BIOL, V127, P1671; ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; AUDEBERT S, 1993, MOL BIOL CELL, V4, P615, DOI 10.1091/mbc.4.6.615; AUDEBERT S, 1994, J CELL SCI, V107, P2313; BERNSTEIN M, 1994, J CELL BIOL, V125, P1313, DOI 10.1083/jcb.125.6.1313; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; BREITLING F, 1986, J MOL BIOL, V189, P367, DOI 10.1016/0022-2836(86)90517-6; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; GAGNON C, 1996, IN PRESS J CELL SCI; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GOLDSMITH M, 1991, CELL MOTIL CYTOSKEL, V20, P249, DOI 10.1002/cm.970200308; HAGIWARA H, 1994, J BIOL CHEM, V269, P3581; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HEINS S, 1991, J CELL SCI, P121; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOPEZ LA, 1993, CELL MOTIL CYTOSKEL, V24, P1, DOI 10.1002/cm.970240102; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MARYA PK, 1994, J CELL SCI, V107, P339; MASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MILLER RH, 1987, SCIENCE, V235, P220, DOI 10.1126/science.2432661; Murphy DB, 1991, CURR OPIN CELL BIOL, V3, P43, DOI 10.1016/0955-0674(91)90164-T; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; OKADA Y, 1995, J NEUROSCI, V15, P3053; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PONSTINGL H, 1979, NATURE, V282, P423, DOI 10.1038/282423a0; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SAWIN KE, 1992, J CELL SCI, V101, P303; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WOLFF A, 1994, BIOL CELL, V81, P11, DOI 10.1016/0248-4900(94)90049-3; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	58	143	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22117	22124		10.1074/jbc.271.36.22117	http://dx.doi.org/10.1074/jbc.271.36.22117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703022	hybrid			2022-12-27	WOS:A1996VF61200064
J	Okadome, T; Oeda, E; Saitoh, M; Ichijo, H; Moses, HL; Miyazono, K; Kawabata, M				Okadome, T; Oeda, E; Saitoh, M; Ichijo, H; Moses, HL; Miyazono, K; Kawabata, M			Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; PROTEIN; TRANSCRIPTION; CLONING; FAMILY; INHIBITION; SCHNURRI; DOMAINS; ENCODES	The type I transforming growth factor-beta receptor (T beta R-I) is the efferent component of the receptor complex, which presumably phosphorylates intracellular targets. FKBP12, a binding protein for FK506 and rapamycin, is shown to associate with the cytoplasmic region of T beta R-I in vitro. In this report, we investigated the interaction of FKBP12 with T beta R-I in vivo. FKBP12 interacts with T beta R-I in mammalian cells as well as in yeast. Ligand addition does not affect the interaction, and both constitutively active and kinase-negative mutants of T beta R-I bind FKBP12. FKBP12 dissociates from T beta PR-I in the presence of a high concentration of FK506. The juxtamembrane region of T beta R-I, containing the major phosphorylation sites by the type II receptor, is required for the interaction. One of the deletion mutants in this region, which was shown to mediate transcriptional response, does not bind FKBP12, suggesting that FKBP12 is not directly involved in TGF-beta signaling. Furthermore T beta R-I does not phosphorylate FKBP12 in vitro, FKBP12 may not be a direct substrate of T beta R-I but possibly modulates the T beta R-I function through its interaction with the regulatory domain of the kinase.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; VANDERBILT UNIV,CTR CANC,NASHVILLE,TN 37232	Japanese Foundation for Cancer Research; Vanderbilt University				Ichijo, Hidenori/0000-0002-5005-6438				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SEKELSKY JJ, 1995, GENETICS, V139, P1347; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	32	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21687	21690		10.1074/jbc.271.36.21687	http://dx.doi.org/10.1074/jbc.271.36.21687			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702959				2022-12-27	WOS:A1996VF61200001
J	Ritchie, HH; Wang, LH				Ritchie, HH; Wang, LH			Sequence determination of an extremely acidic rat dentin phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; HYDROXYAPATITE FORMATION; SUBSTRATE DETERMINANTS; SYNTHETIC PEPTIDES; COLLAGEN FIBRILS; MATRIX PROTEINS; PHOSPHOPHORYN; INCISOR; INVITRO; BINDING	The mineralization process associated with the conversion of predentin to dentin is believed to be initiated and controlled by a set of acidic regulatory noncollagenous proteins (NCPs) which include phosphophoryn, the major NCP in dentin. Phosphophoryn binds tightly to collagen and is believed to initiate the formation of apatite crystals which play a central role in the mineralization process. During the process of analyzing the 3' end of an odontoblast-specific cDNA which codes for dentin sialoprotein (Ritchie, H. H., Hou, H., Veis, A., and Butler, W. T. (1994) J. Biol. Chem. 269, 3698-3702), we discovered a 801-base pair open reading frame. This downstream open reading frame encodes a putative leader sequence and a very acidic mature protein sequence having a deduced amino acid composition containing high percentages of both Ser (43%) and Asp (31%) residues which closely coincides with the amino acid composition of phosphophoryns from human, bovine, rat, and rabbit (i.e. Asp (30-40%) and Ser (38-50%)). This newly identified cDNA therefore encodes a protein with characteristics similar to phosphophoryn. Here we present the cDNA sequence, the deduced amino acid sequence, and the prospective Ser residue-specific casein kinase I and II phosphorylation sites for this putative phosphophoryn.	UNIV TEXAS, SCH MED, DEPT INTERNAL MED, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DIV HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas System	Ritchie, HH (corresponding author), UNIV IOWA, DEPT PEDIAT, BB135, IOWA CITY, IA 52242 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011442] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11442-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BOSKEY AL, 1990, BONE MINER, V11, P55, DOI 10.1016/0169-6009(90)90015-8; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; CROSSLEY MA, 1996, J DENT RES, V75, P154; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; DIMUZIO MT, 1978, J BIOL CHEM, V253, P6845; EVANS JS, 1994, BIOPOLYMERS, V34, P1359, DOI 10.1002/bip.360341008; EVANS JS, 1994, BIOPOLYMERS, V34, P507, DOI 10.1002/bip.360340407; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LINDE A, 1989, CALCIFIED TISSUE INT, V44, P286, DOI 10.1007/BF02553763; Linde A., 1985, CHEM BIOL MINERALIZE, P344; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; LUSSI A, 1988, ARCH ORAL BIOL, V33, P685, DOI 10.1016/0003-9969(88)90124-0; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P346, DOI 10.1021/bi00427a047; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1989, EUR J BIOCHEM, V186, P459, DOI 10.1111/j.1432-1033.1989.tb15229.x; MUNKSGAARD EC, 1978, ARCH ORAL BIOL, V23, P583, DOI 10.1016/0003-9969(78)90275-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAHIMA M, 1988, J HISTOCHEM CYTOCHEM, V36, P153, DOI 10.1177/36.2.3335773; RICHARDSON WS, 1977, J DENT RES, V56, P233, DOI 10.1177/00220345770560030701; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STETLERSTEVENSON WG, 1986, CALCIFIED TISSUE INT, V38, P135, DOI 10.1007/BF02556873; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; TAKAGI Y, 1984, CALCIFIED TISSUE INT, V36, P259, DOI 10.1007/BF02405327; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; TRAUB W, 1992, MATRIX, V12, P197, DOI 10.1016/S0934-8832(11)80062-4; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; Veis A, 1985, CHEM BIOL MINERALIZE, P170; VEIS A, 1978, IONS MACROMOLECULAR, P259; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; WU CB, 1992, J BIOL CHEM, V267, P16588	41	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21695	21698		10.1074/jbc.271.36.21695	http://dx.doi.org/10.1074/jbc.271.36.21695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702961	hybrid			2022-12-27	WOS:A1996VF61200003
J	Zhao, ZZ; Tan, ZJ; Diltz, CD; You, M; Fischer, EH				Zhao, ZZ; Tan, ZJ; Diltz, CD; You, M; Fischer, EH			Activation of mitogen-activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; T-CELL ACTIVATION; RAT ADIPOCYTES; INTACT-CELLS; VANADATE; PHOSPHORYLATION; PHOSPHOTYROSINE; TRANSFORMATION; STIMULATION; 2A	Rapid tyrosine phosphorylation of key cellular pro teins is a crucial event in signal transduction. The regulatory role of protein-tyrosine phosphatases (PTPs) in this process was explored by studying the effects of a powerful PTP inhibitor, pervanadate, on the activation of the mitogen-activated protein (MAP) kinase cascade. Treatment of HeLa cells with pervanadate resulted in a marked inhibition of PTP activity, accompanied by a drastic increase in tyrosine phosphorylation of cellular proteins. The increased tyrosine phosphorylation coincided with the activation of the MAP kinase cascade as indicated by enzymatic activity assays of MEK (MAP kinase/ERK-kinase) and MAP kinase and gel mobility shift analyses of Raf-1 and MAP kinase. The activation was sustained but reversible. Upon removal of pervanadate, both tyrosine phosphorylation and MAP kinase activation declined to basal levels. Therefore, inhibition of PTP activity is sufficient per se to initiate a complete MAP kinase activation program.	VANDERBILT UNIV, DEPT MED, DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; University of Washington; University of Washington Seattle	Zhao, ZZ (corresponding author), VANDERBILT UNIV, DEPT MED, DIV HEMATOL, NASHVILLE, TN 37232 USA.		You, Min/I-4973-2012	You, Min/0000-0003-1977-3479	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007902] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHEN J, 1994, J BIOL CHEM, V269, P7957; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FANTUS IG, 1994, DIABETES, V43, P375, DOI 10.2337/diabetes.43.3.375; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RIJKSEN G, 1993, J CELL PHYSIOL, V154, P393, DOI 10.1002/jcp.1041540223; ROGERS MV, 1994, NEUROSCIENCE, V60, P479, DOI 10.1016/0306-4522(94)90259-3; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; SHISHEVA A, 1993, ENDOCRINOLOGY, V133, P1562, DOI 10.1210/en.133.4.1562; SWEITZER SM, 1995, J BIOL CHEM, V270, P16510, DOI 10.1074/jbc.270.28.16510; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	30	118	122	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22251	22255		10.1074/jbc.271.36.22251	http://dx.doi.org/10.1074/jbc.271.36.22251			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703041	hybrid			2022-12-27	WOS:A1996VF61200083
J	Braun, JR; Willnow, TE; Ishibashi, S; Ashwell, G; Herz, J				Braun, JR; Willnow, TE; Ishibashi, S; Ashwell, G; Herz, J			The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; MEDIATED ENDOCYTOSIS; LIGAND-BINDING; PROTEIN LRP; LIVER; CELLS; LECTIN; OLIGOSACCHARIDES; SEQUENCE	The mammalian asialoglycoprotein receptor (ASGPR) is located on the sinusoidal membrane of hepatocytes where it binds and endocytoses galactose-terminated glycoproteins (asialoglycoproteins). ASGPR is composed of two highly homologous subunits, termed hepatic lectin 1 and 2. Despite numerous studies the contribution of both subunits to biosynthesis and functional activity of ASGPR in vivo has remained controversial. Mice lacking the murine hepatic lectin (MHL)-2 subunit are viable and fertile without obvious phenotypic abnormalities. In the absence of MHL-2, knockout mice express MHL-1 protein at reduced levels. Here, we examine the intracellular fate and function of this remaining subunit. The results show that MHL-1 reaches the hepatocellular surface in knockout mice but is unable to effectively remove any one of three different radiolabeled ligands within 30 min. A small but detectable residual ligand clearance in knockout mice at 4 h is apparently not mediated by remaining MHL-1. Serum concentrations of galactose-terminating glycoproteins are not elevated in these ASGPR-deficient mice. However, competitive in vitro degradation experiments suggest that other endogenous ASGPR ligands, the nature of which remain to be determined, accumulate in serum of knockout animals.	UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; NIDDKD, NIH, BETHESDA, MD 20892 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Willnow, Thomas/0000-0001-9515-7921	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH M, 1989, J CELL BIOL, V108, P367, DOI 10.1083/jcb.108.2.367; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BIDER MD, 1995, EUR J BIOCHEM, V230, P207, DOI 10.1111/j.1432-1033.1995.0207i.x; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CHIU MH, 1994, J BIOL CHEM, V269, P16195; CLARENBURG R, 1983, AM J PHYSIOL, V244, pG247, DOI 10.1152/ajpgi.1983.244.3.G247; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HARLOW E, 1988, ANTIBODIES LABORATOR, P354; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KOLBBACHOFEN V, 1982, CELL, V29, P859, DOI 10.1016/0092-8674(82)90447-0; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KURANDA MJ, 1983, ARCH BIOCHEM BIOPHYS, V224, P526, DOI 10.1016/0003-9861(83)90240-0; LEE YC, 1983, J BIOL CHEM, V258, P199; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MONROE RS, 1994, GENE, V148, P237, DOI 10.1016/0378-1119(94)90694-7; MORELL AG, 1968, J BIOL CHEM, V243, P155; OZAKI K, 1992, J BIOL CHEM, V267, P9229; RICE KG, 1990, J BIOL CHEM, V265, P18429; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; SCHAUER R, 1985, CLIN CHIM ACTA, V146, P119, DOI 10.1016/0009-8981(85)90050-6; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713; WEIGEL PH, 1980, J BIOL CHEM, V255, P6111; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P491; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; WONG KL, 1974, CLIN SCI MOL MED, V46, P763, DOI 10.1042/cs0460763	44	62	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21160	21166		10.1074/jbc.271.35.21160	http://dx.doi.org/10.1074/jbc.271.35.21160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702886	hybrid			2022-12-27	WOS:A1996VE47700032
J	Cotten, JF; Ostedgaard, LS; Carson, MR; Welsh, MJ				Cotten, JF; Ostedgaard, LS; Carson, MR; Welsh, MJ			Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CFTR CHLORIDE CHANNELS; P-GLYCOPROTEIN; MULTIDRUG RESISTANCE; SEQUENCE VARIATIONS; MOLECULAR-BASIS; CL CHANNELS; MEMBRANE; IDENTIFICATION; GENE	The cystic fibrosis transmembrane conductance regulator (CFTR) contains multiple membrane spanning sequences that form a Cl- channel pore and cytosolic domains that control the opening and closing of the channel. The fourth intracellular loop (ICL4), which connects the tenth and eleventh transmembrane spans, has a primary sequence that is highly conserved across species, is the site of a preserved sequence motif in the ABC transporter family, and contains a relatively large number of missense mutations associated with cystic fibrosis (CF). To investigate the role of ICL4 in CFTR function and to learn how CF mutations in this region disrupt function, we studied several CF-associated ICL4 mutants. We found that most ICL4 mutants disrupted the biosynthetic processing of CFTR, although not as severely as the most common Delta F508 mutation. The mutations had no discernible effect on the channel's pore properties; but some altered gating behavior, the response to increasing concentrations of ATP, and stimulation in response to pyrophosphate. These effects on activity were similar to those observed with mutations in the nucleotide-binding domains, suggesting that ICL4 might help couple activity of the nucleotide-binding domains to gating of the Cl- channel pore. The data also explain how these mutations cause a loss of CFTR function and suggest that some patients with mutations in ICL4 may have a milder clinical phenotype because they retain partial activity of CFTR at the cell membrane.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL029851, P50HL042385, R01HL029851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385, HL29851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BOZON D, 1994, HUM MUTAT, V3, P330, DOI 10.1002/humu.1380030329; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; CHAMPIGNY G, 1995, EMBO J, V14, P2417, DOI 10.1002/j.1460-2075.1995.tb07239.x; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DASSA E, 1993, MOL MICROBIOL, V7, P39, DOI 10.1111/j.1365-2958.1993.tb01095.x; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; FEREC C, 1992, NAT GENET, V1, P188, DOI 10.1038/ng0692-188; FEREC C, 1993, HUM MOL GENET, V2, P1557, DOI 10.1093/hmg/2.10.1557; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MERCIER B, 1993, GENOMICS, V16, P296, DOI 10.1006/geno.1993.1183; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SAVOV A, 1994, HUM MOL GENET, V3, P57; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; XIE JX, 1995, J BIOL CHEM, V270, P28084; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253	46	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21279	21284		10.1074/jbc.271.35.21279	http://dx.doi.org/10.1074/jbc.271.35.21279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702904	hybrid			2022-12-27	WOS:A1996VE47700050
J	Sapirstein, A; Spech, RA; Witzgall, R; Bonventre, JV				Sapirstein, A; Spech, RA; Witzgall, R; Bonventre, JV			Cytosolic phospholipase A(2), (PLA(2)), but not secretory PLA(2), potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INDUCED DNA-DAMAGE; SUPEROXIDE-DISMUTASE; ARACHIDONIC-ACID; LIPID-PEROXIDATION; LLC-PK1 CELLS; ENZYMATIC-ACTIVITY; CALCIUM IONOPHORE; PROXIMAL TUBULES; OXIDATIVE STRESS	Phospholipase A(2) (PLA(2)) and reactive oxygen species have been implicated both individually and synergistically in various forms of cellular injury. The form(s) of PLA(2) important for cell injury and the implications of enhanced activity of the enzyme, however, have not been discerned. Previous studies reveal an increase in PLA(2) activity associated with cell injury, but this association does not establish a causal relationship between the increase in activity and the injury. LLC-PK1 cell lines were created that express either the cytosolic PLA(2) or a group II PLA(2). The susceptibility of these cells to hydrogen peroxide toxicity was determined in order to evaluate the relative importance of these two forms of PLA(2) in oxidant injury. Expression of cytosolic PLA(2) in the LLC-cPLA(2) cell line was associated with a 50-fold increase in PLA(2) activity in the cytosolic fraction, an increase in agonist-stimulated arachidonate release, and immunodetection of the cytosolic PLA(2) protein that was undetectable in control cells. Exposure to hydrogen peroxide or menadione, but not mercuric chloride, resulted in significantly greater lactate dehydrogenase release in LLC-cPLA(2) cells when compared with control cells. Exogenous arachidonic acid (150 mu M) did not enhance hydrogen peroxide-induced injury. The intracellular calcium chelator, 1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/tetra(acetoxymethyl) ester, protected the cells against injury, but the calcium ionophore, A23187, did not increase injury. Glycine conferred no protective effect against hydrogen peroxide toxicity. By contrast to these results with cytosolic PLA(2)-expressing cells, secretory PLA(2) expression to very high levels did not increase susceptibility to hydrogen peroxide. Thus, cytosolic PLA(2) may an be an important mediator of oxidant damage to renal epithelial cells.	MASSACHUSETTS GEN HOSP EAST, MED SERV, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP EAST, ANESTHESIA SERV, CHARLESTOWN, MA 02129 USA; DEPT MED, CHARLESTOWN, MA 02129 USA; DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Witzgall, Ralph/0000-0002-5283-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R01DK039773, R37DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aebi H., 1974, METHOD ENZYMAT AN, P273; BALLMAIER D, 1995, CARCINOGENESIS, V16, P335, DOI 10.1093/carcin/16.2.335; Beutler E., 1975, RED CELL METABOLISM, V2nd, P71; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BONVENTRE JV, 1995, CONTEMP ISS NEPHROL, P23; BONVENTRE JV, 1996, IN PRESS J LIPID MED; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHIARIELLO M, 1987, J PHARMACOL EXP THER, V241, P560; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Crapo J D, 1978, Methods Enzymol, V53, P382; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOLE VP, 1960, J BIOL CHEM, V235, P2595; ELLIGET KA, 1994, PATHOBIOLOGY, V62, P298, DOI 10.1159/000163923; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOLCONDA MS, 1993, KIDNEY INT, V44, P1228, DOI 10.1038/ki.1993.373; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Griffith O.W., 1985, METHODS ENZYMATIC AN, V7, P521; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LIFSCHITZ MD, 1982, J BIOL CHEM, V257, P2611; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; Malis C D, 1988, Prog Clin Biol Res, V282, P235; MALIS CD, 1990, P NATL ACAD SCI USA, V87, P8845, DOI 10.1073/pnas.87.22.8845; MALIS CD, 1986, J BIOL CHEM, V261, P14201; MATTHYS E, 1984, KIDNEY INT, V26, P153, DOI 10.1038/ki.1984.149; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NAKAMURA H, 1991, J CLIN INVEST, V87, P1810, DOI 10.1172/JCI115202; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; OHNO K, 1990, BIOCHEM BIOPH RES CO, V168, P551, DOI 10.1016/0006-291X(90)92356-5; OTAMIRI T, 1987, GUT, V28, P1445, DOI 10.1136/gut.28.11.1445; PORTILLA D, 1994, J CLIN INVEST, V93, P1609, DOI 10.1172/JCI117141; PROZIALECK WC, 1995, TOXICOL APPL PHARM, V134, P285, DOI 10.1006/taap.1995.1194; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RORDORF G, 1991, J NEUROSCI, V11, P1829; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALGO MG, 1992, BIOCHIM BIOPHYS ACTA, V1127, P131, DOI 10.1016/0005-2760(92)90268-Z; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; SANTOS AA, 1994, ANN SURG, V219, P183, DOI 10.1097/00000658-199402000-00010; SCHNELLMANN RG, 1994, J BIOCHEM TOXICOL, V9, P211, DOI 10.1002/jbt.2570090406; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SHI MM, 1994, J BIOL CHEM, V269, P26512; SierraHonigmann R, 1996, LAB INVEST, V74, P684; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; THOMAS JP, 1990, J BIOL CHEM, V265, P454; THOR H, 1982, J BIOL CHEM, V257, P2419; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; TROYER DA, 1986, KIDNEY INT, V29, P530, DOI 10.1038/ki.1986.31; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; VANDENBERG JJM, 1993, BIOCHEMISTRY-US, V32, P4962, DOI 10.1021/bi00069a035; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; VENKATACHALAM MA, 1995, KIDNEY INT, V48, P118, DOI 10.1038/ki.1995.275; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58; WEINBERG JM, 1991, LAB INVEST, V65, P671; WEINBERG JM, 1987, J CLIN INVEST, V80, P1446, DOI 10.1172/JCI113224; WETZELS JFM, 1993, AM J PHYSIOL, V264, pF94, DOI 10.1152/ajprenal.1993.264.1.F94; Zager RA, 1996, J AM SOC NEPHROL, V7, P64; ZAGER RA, 1993, P NATL ACAD SCI USA, V90, P8297, DOI 10.1073/pnas.90.17.8297	77	125	126	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21505	21513		10.1074/jbc.271.35.21505	http://dx.doi.org/10.1074/jbc.271.35.21505			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702935	hybrid			2022-12-27	WOS:A1996VE47700081
J	Beamish, H; Williams, R; Chen, P; Lavin, MF				Beamish, H; Williams, R; Chen, P; Lavin, MF			Defect in multiple cell cycle checkpoints in ataxia-telangiectasia postirradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPAMYCIN-INDUCED INHIBITION; IONIZING-RADIATION; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT KINASES; DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; MAMMALIAN PROTEIN; CATALYTIC SUBUNIT; X-IRRADIATION; P53 PROTEIN	The recent description of a novel gene (ATM) mutated in ataxia-telangiectasia (A-T), with homologies to genes encoding proteins involved in both G(1)/S and G(2)/M checkpoint control, points to a common defect in cell cycle control in A-T operating through the cyclin-dependent kinases. In this report we demonstrate that cyclin-dependent kinases are resistant to inhibition by ionizing radiation exposure in A-T cells, and this appears to be due to insufficient induction of WAF1. Exposure of control lymphoblastoid cells to radiation during S phase and in G(2) phase causes a rapid inhibition of cyclin A-Cdk2 and cyclin B-Cdc2 activities, respectively, Irradiation led to a 5-20-fold increase in Cdk-associated WAF1 in these cells, which accounts at least in part for the decrease in cyclin-dependent kinase activity. In contrast, radiation did not inhibit any of the cyclin-dependent kinase activities in S phase or G(2) phase in A-T cells at short times after irradiation nor was there any significant change in the level of Cdk-associated WAF1 compared to unirradiated cells. These results are similar to those reported previously for the G(1) checkpoint and provide additional evidence for the involvement of ATM at multiple points in cell cycle regulation.	QUEENSLAND INST MED RES,BANCROFT CTR,QUEENSLAND CANC FUND RES UNIT,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT SURG,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8492; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BODEY B, 1994, MODERN PATHOL, V7, P846; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN P, 1983, THESIS U QUEENSLAND; DEWEY WC, 1976, RADIAT RES, V65, P511, DOI 10.2307/3574383; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARL KL, 1996, CELL, V82, P815; HARPER JW, 1993, CELL, V75, P805; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LAVIN MF, 1994, INT J RADIAT BIOL, V66, P5151; LEEPER DB, 1972, RADIAT RES, V50, P410; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI Y, 1994, ONCOGENE, V9, P2261; LINDMO T, 1979, CELL TISSUE KINET, V12, P43, DOI 10.1111/j.1365-2184.1979.tb00112.x; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEYN MS, 1994, INT J RADIAT BIOL, V66, P5141; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NAGASAWA H, 1983, MUTAT RES, V109, P2987; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PRICE BD, 1994, CANCER RES, V54, P896; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHNEIDERMAN MH, 1977, RADIAT RES, V70, P130, DOI 10.2307/3574737; SCHREIBER SL, 1991, TRANSPLANT P, V23, P2839; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	59	126	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20486	20493		10.1074/jbc.271.34.20486	http://dx.doi.org/10.1074/jbc.271.34.20486			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702789	hybrid			2022-12-27	WOS:A1996VD33700041
J	Szabo, I; Gulbins, E; Apfel, H; Zhang, XF; Barth, P; Busch, AE; Schlottmann, K; Pongs, O; Lang, F				Szabo, I; Gulbins, E; Apfel, H; Zhang, XF; Barth, P; Busch, AE; Schlottmann, K; Pongs, O; Lang, F			Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; VOLUME REGULATION; PATCH-CLAMP; KINASE; CHARYBDOTOXIN; PURIFICATION; TEMPERATURE; ACTIVATION; MARGATOXIN; APOPTOSIS	Selective cell death plays a critical role in the development of the immune system and in the elimination of target cells expressing foreign antigens. Most of programmed cell death occurs by apoptosis, Apoptotic cell death of lymphocytes can be triggered by ligation of APO-1/Fas (CD95) antigen (Suda, T., and Nagata, S. (1994) J. Exp. Med. 179, 873-879; Nagata, S., and Golstein, P. (1995) Science 267, 1449-1456). We find that activation of Fas leads to the inhibition of the voltage-dependent n-type K+ channels (Kv1.3) studied by patch clamp technique in Jurkat T lymphocytes, Tyrosine kinases have been shown to be crucial in Fas-induced cell death (Eischen, C. M., Dick, C. J,, and Leibson, P. J. (1994) J. Immunol. 153, 1947-1954), The inhibition of the current is correlated with the tyrosine phosphorylation of immunoprecipitated and blotted K+ channel protein. We show, that the Src-like protein-tyrosine kinase inhibitor herbimycin A and the deficiency of the p56(lck) tyrosine kinase in mutant Jurkat cells abolished the channel inhibition and phosphorylation by anti-Fas antibody, while reconstitution of the p56(lck) kinase partly restored these effects of Fas receptor triggering. These results suggest a regulation of n-type K+ channels by tyrosine kinases upon Fas receptor triggering, which might be important for apoptosis.	OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; UNIV HAMBURG, CTR MOL NEUROBIOL, D-20246 HAMBURG, GERMANY	University System of Ohio; Ohio State University; University of Hamburg	Szabo, I (corresponding author), UNIV TUBINGEN, INST PHYSIOL 1, D-72076 TUBINGEN, GERMANY.		Szabo, Ildiko/AAW-5972-2021; Gulbins, Erich/L-6989-2014; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; Gulbins, Erich/0000-0002-3117-1342; 				BEDNAREK MA, 1994, BIOCHEM BIOPH RES CO, V198, P619, DOI 10.1006/bbrc.1994.1090; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1985, J NEUROIMMUNOL, V10, P71, DOI 10.1016/0165-5728(85)90035-9; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; LEE SC, 1990, BIOPHYS J, V57, P49, DOI 10.1016/S0006-3495(90)82506-6; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PAHAPILL PA, 1990, J PHYSIOL-LONDON, V422, P103, DOI 10.1113/jphysiol.1990.sp017975; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VEH RW, 1995, IN PRESS EUR J NEURO, V7	25	192	197	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20465	20469		10.1074/jbc.271.34.20465	http://dx.doi.org/10.1074/jbc.271.34.20465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702786	hybrid			2022-12-27	WOS:A1996VD33700038
J	Wiborg, O; Andersen, C; Knudsen, CR; Clark, BFC; Nyborg, J				Wiborg, O; Andersen, C; Knudsen, CR; Clark, BFC; Nyborg, J			Mapping Escherichia coli elongation factor Tu residues involved in binding of aminoacyl-tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; CRYSTAL-STRUCTURE; TRANSFER-RNA; NUCLEOTIDE-SEQUENCE; HISTIDINE-RESIDUES; STEP PURIFICATION; TERNARY COMPLEX; GTP HYDROLYSIS; MECHANISM; CONFORMATION	Two residues of Escherichia coli elongation factor Tu involved in binding of aminoacyl-tRNA were identified and subjected to mutational analysis, Lys-89 and Asn-90 were each replaced by either Ala or Glu. The four single mutants were denoted K89A, K89E, N90A, and N90E, respectively. The mutants were characterized with respect to thermal and chemical stability, GTPase activity, tRNA affinity, and activity in an in vitro translation assay, Most conspicuously tRNA affinities were reduced for all mutants. The results verify our structural analysis of elongation factor Tu in complex with aminoacyl-tRNA, which suggested an important role of Lys-89 and Asn-90 in tRNA binding, Furthermore, our results indicate helix B to be an important target site for nucleotide exchange factor EF-Ts. Also the mutants His-66 to Ala and His-118 to either Ala or Glu were characterized in an in vitro translation assay. Their functional roles are discusses in relation to the structure of elongation factor Tu in complex with aminoacyl-tRNA.	AARHUS UNIV, DEPT CHEM, DK-8000 AARHUS C, DENMARK	Aarhus University	Wiborg, O (corresponding author), HOSP PSYCHIAT, CYTOGENET LAB, SKOVAGERVEJ 2, DK-8240 RISSKOV, DENMARK.			Knudsen, Charlotte/0000-0003-2356-4821				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AN G, 1980, GENE, V12, P33, DOI 10.1016/0378-1119(80)90013-X; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Bodley J W, 1974, Methods Enzymol, V30, P235; BOGESTRAND S, 1995, FEBS LETT, V368, P49, DOI 10.1016/0014-5793(95)00597-3; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Clark Brian F. C., 1995, P423; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DUFFY LK, 1981, BIOCHEMISTRY-US, V20, P4663, DOI 10.1021/bi00519a022; EHRENBERG M, 1988, RIBOSOMES PROTEIN SY, P101; GUMUSEL F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P215, DOI 10.1016/0167-4781(90)90169-3; HARMARK K, 1990, EUR J BIOCHEM, V194, P731, DOI 10.1111/j.1432-1033.1990.tb19463.x; JONAK J, 1987, BIOCHIM BIOPHYS ACTA, V908, P97, DOI 10.1016/0167-4781(87)90026-1; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; KJAERSGARD IVH, 1995, EUR J BIOCHEM, V228, P184; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEDER P, 1971, METHOD ENZYMOL, V20, P302; LOUIE A, 1985, BIOCHEMISTRY-US, V24, P6433, DOI 10.1021/bi00344a019; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; Miller D L, 1974, Methods Enzymol, V30, P219; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PINGOUD A, 1979, ANAL BIOCHEM, V92, P123, DOI 10.1016/0003-2697(79)90632-8; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; von der Haar F, 1979, Methods Enzymol, V59, P257; WIBORG O, 1994, BIOTECHNOL APPL BIOC, V19, P3; WOOLLEY P, 1989, BIO-TECHNOL, V7, P913, DOI 10.1038/nbt0989-913; YOKOTA T, 1980, GENE, V12, P25	48	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20406	20411		10.1074/jbc.271.34.20406	http://dx.doi.org/10.1074/jbc.271.34.20406			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702777	hybrid			2022-12-27	WOS:A1996VD33700029
J	Yu, Q; Toole, BP				Yu, Q; Toole, BP			A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONATE RECEPTOR; ADHESION MOLECULE; HOMING RECEPTOR; MONOCLONAL-ANTIBODY; PERICELLULAR MATRIX; LUNG DEVELOPMENT; SERUM CD44; EXPRESSION; DIFFERENTIATION; VARIANTS	The numerous isoforms of murine CD44 contain a common peptide region that is encoded by exons 1-5, 16-18, and 20 and variant regions derived from exons 6-15, usually referred to as v1-v10, We have obtained evidence for expression of an additional exon between v9 (or exon 14) and the exon previously termed v10 (or exon 15), Thus, we now number the variant exons as follows: v1-v9 (exons 6-14), v10 (exon 15), and v11 (exon 16); the remaining 3'-exons become exons 17-21 (newly numbered exons are underlined), The new exon, now termed exon v10, contains 93 base pairs and can be internally spliced; the 5'-region is termed v10a, and the 3'-region, v10b, Stop codons are positioned in v10a such that translated protein would be truncated prior to the transmembrane domain and secreted as a soluble protein, We have also found that the previously described v9 exon (now termed v9a), which is 90 base pairs in length, is actually the 5'-region of a longer exon of 142 base pairs (the 3'-region is termed v9b) and thus arises by internal splicing of the longer exon, Using reverse transcription-polymerase chain reaction, four different cDNAs for CD44 isoforms that use different combinations of the new exonic sequences have been found, The mRNAs containing the new exonic sequences are restricted in their expression; to date, we have demonstrated their presence in murine G8 myoblasts in culture and in embryonic muscle and cartilage tissues in vivo, Of these new isoforms, the predominant, full-length amplified product is encoded by exons 1-5, exon 13 (v8), the 5'-part of exon 14 (v9a), exon 15 (v10), exon 16 (v11), exons 17-19, and exon 21, When COS-7 cells were transfected with v10-containing cDNA constructs, the cells secreted low molecular weight soluble CD44 into their medium, Thus, the stop codons within the new exon v10 provide a molecular basis for de novo synthesis of soluble CD44 isoforms.	TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University					NICHD NIH HHS [HD23681] Funding Source: Medline; NIDCR NIH HHS [DE05838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005838] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1992, J IMMUNOL, V149, P747; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P422; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HUA Q, 1993, J CELL SCI, V106, P365; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; KAINZ C, 1995, CANCER LETT, V90, P231, DOI 10.1016/0304-3835(95)03708-5; KASPER M, 1995, AM J RESP CELL MOL, V13, P648, DOI 10.1165/ajrcmb.13.6.7576702; KATOH S, 1994, J IMMUNOL, V153, P3440; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUCAS MG, 1989, BLOOD, V73, P596; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; ORKIN RW, 1985, DEV BIOL, V107, P527, DOI 10.1016/0012-1606(85)90333-1; RISTAMAKI R, 1994, BLOOD, V84, P238; RUDY W, 1993, CANCER RES, V53, P1262; RUIZ P, 1995, BIOESSAYS, V17, P17, DOI 10.1002/bies.950170106; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; YANG H, 1993, IMMUNOLOGY, V78, P547	34	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20603	20607		10.1074/jbc.271.34.20603	http://dx.doi.org/10.1074/jbc.271.34.20603			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702806	hybrid			2022-12-27	WOS:A1996VD33700058
J	Takeuchi, M; Rothe, M; Goeddel, DV				Takeuchi, M; Rothe, M; Goeddel, DV			Anatomy of TRAF2 - Distinct domains for nuclear factor-kappa B activation and association with tumor necrosis factor signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; DEATH DOMAIN; TNF RECEPTOR; FACTOR-ALPHA; CELL-DEATH; CD40; INTERACTS; FAMILY	The tumor necrosis factor (TNF) receptor-associated factor (TRAF) family of proteins interact with and transduce signals for members of the TNF receptor superfamily. TRAF1, TRAF2, and TRAF3 share a conserved C-terminal TRAF domain. TRAF2 plays a key role in transducing signals for activation of the transcription factor nuclear factor-kappa B (NF-kappa B). We have performed extensive mutational analysis on TRAF2, examining the requirements for NF-kappa B activation, self-association, and interaction with other molecules involved in TNF signaling. Examination of point mutants and TRAF2-TRAF3 chimeric proteins indicates that the N-terminal RING finger and two adjacent zinc fingers of TRAF2 are required for NF-kappa B activation. The two distinct TRAF-N and TRAF-C subdomains of the TRAF domain appear to independently mediate self-association and interaction with TRAF1. Interaction of TRAF2 with TNF-R2 and TRADD requires sequences at the C terminus of the TRAF-C domain, whereas interaction with the protein kinase receptor-interacting protein V(RIP) occurs via sequences at the N terminus of the TRAF-C domain. Thus, distinct domains of TRAF2 are involved in recruitment and signaling functions.	TULARIK INC, San Francisco, CA 94080 USA; YAMANOUCHI PHARMACEUT CO LTD, TSUKUBA, IBARAKI 305, JAPAN	Astellas Pharmaceuticals								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRUPPA G, 1992, J IMMUNOL, V148, P3152; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1	30	274	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19935	19942		10.1074/jbc.271.33.19935	http://dx.doi.org/10.1074/jbc.271.33.19935			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702708	hybrid			2022-12-27	WOS:A1996VC66900049
J	Wardenburg, JB; Fu, C; Jackman, JK; Flotow, H; Wilkinson, SE; Williams, DH; Johnson, R; Kong, GH; Chan, AC; Findell, PR				Wardenburg, JB; Fu, C; Jackman, JK; Flotow, H; Wilkinson, SE; Williams, DH; Johnson, R; Kong, GH; Chan, AC; Findell, PR			Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; ANTIGEN-RECEPTOR; MAJOR SUBSTRATE; MICE LACKING; HS1 PROTEIN; ACTIVATION; GRB2; SYK; PHOSPHOPROTEIN; IDENTIFICATION	Two families of tyrosine kinases, the Src and Syk families, are required for T-cell receptor activation. While the Src kinases are responsible for phosphorylation of receptor-encoded signaling motifs and for up-regulation of ZAP-70 activity, the downstream substrates of ZAP-70 are unknown. Evidence is presented herein that the Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa (SLP-76) is a substrate of ZAP-70. Phosphorylation of SLP-76 is diminished in T cells that express a catalytically inactive ZAP-70. Moreover, SLP-76 is preferentially phosphorylated by ZAP-70 in vitro and in heterologous cellular systems. In T cells, overexpression of wild-type SLP-76 results in a hyperactive receptor, while expression of a SLP-76 molecule that is unable to be tyrosine-phosphorylated attenuates receptor function. In addition, the SH2 domain of SLP-76 is required for T-cell receptor function, although its role is independent of the ability of SLP-76 to undergo tyrosine phosphorylation. As SLP-76 interacts with both Grb2 and phospholipase C-gamma 1, these data indicate that phosphorylation of SLP-76 by ZAP-70 provides an important functional link between the T-cell receptor and activation of ras and calcium pathways.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; ROCHE BIOSCI,PALO ALTO,CA 94304; ROCHE RES CTR,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Roche Holding			Orchard, Sandra/ABC-1609-2020	Orchard, Sandra/0000-0002-8878-3972	NIGMS NIH HHS [5T32GM07200] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN A, 1994, ANNU REV IMMUNOL, V14, P555; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1996, IN PRESS CURR OPINIO; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; COLIGAN JE, 1995, CURRENT PROTOCOLS IM, V2; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; IWASHIMA M, 1994, SCIENCE, V263, P1163; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; LAHESMAA R, 1995, J IMMUNOL, V155, P3815; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REIF K, 1994, J BIOL CHEM, V269, P14081; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; RUBY RDJ, 1995, J BIOL CHEM, V270, P30241; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629	38	265	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19641	19644		10.1074/jbc.271.33.19641	http://dx.doi.org/10.1074/jbc.271.33.19641			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702662	hybrid			2022-12-27	WOS:A1996VC66900003
J	Auge, N; Andrieu, N; NegreSalvayre, A; Thiers, JC; Levade, T; Salvayre, R				Auge, N; Andrieu, N; NegreSalvayre, A; Thiers, JC; Levade, T; Salvayre, R			The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; ACIDIC SPHINGOMYELINASE; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; LIPID PEROXIDES; HL-60 CELLS; FREE SYSTEM; ACTIVATION	Development of atherosclerosis is believed to involve proliferation of smooth muscle cells (SMC). Our laboratory previously demonstrated that the growth of bovine aortic SMC was stimulated by mildly oxidized low density lipoproteins (oxLDL) and that the mitogenic effect of oxLDL was greater than that induced by native LDL (AugB, N., Pieraggi, M. T., Thiers, J. C., Negre-Salvayre, A., and Salvayre R. (1995) Biochem. J. 309, 1015-1020). Since the lipid mediator ceramide has been described to be proliferative, the present work aimed at studying the potential involvement of the so-called sphingomyelin ceramide pathway in the Signal transduction cascade induced by oxLDL. Incubation of SMC with UV-oxidized LDL induced sphingomyelin hydrolysis (32%), which peaked at 60 min and was accompanied by a concomitant increase of intracellular ceramide level. The effect of oxidized LDL on sphingomyelin turnover exhibited the same LDL dose dependence as their mitogenic effect, Exogenous bacterial sphingomyelinase induced sphingomyelin hydrolysis and ceramide generation and also stimulated cell growth, in contrast to exogenous phospholipases A2, C, or D. This mitogenic effect was reproduced by incubating the cells with the cell-permeant ceramides, N-acetyl- and N-hexanoylsphingosines. Altogether, these data strongly suggest for the first time that activation of the sphingomyelin-ceramide pathway may play a pivotal role in the oxLDL-induced SMC proliferation and atherogenesis.	UNIV TOULOUSE 3,RANGUEIL FAC MED,INSERM CJF9206,METAB DIS SECT,LAB BIOCHEM,F-31054 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOLCH J, 1957, J BIOL CHEM, V226, P497; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HAVEL RI, 1955, J CLIN INVEST, V39, P1345; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NATARAJAN V, 1995, J LIPID RES, V36, P2005; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PRICE P, 1990, CANCER RES, V50, P1392; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; SCHUTTE B, 1987, J HISTOCHEM CYTOCHEM, V35, P1343, DOI 10.1177/35.11.3116075; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	49	112	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19251	19255		10.1074/jbc.271.32.19251	http://dx.doi.org/10.1074/jbc.271.32.19251			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702606	hybrid			2022-12-27	WOS:A1996VB68400040
J	Kim, S; Kim, HD; Park, IW; Lee, YH				Kim, S; Kim, HD; Park, IW; Lee, YH			Mutational analysis of RNA structures and sequences postulated to affect 3' processing of M1 RNA, the RNA component of Escherichia coli RNase P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; SECONDARY STRUCTURE; MESSENGER-RNA; E-CLEAVAGE; SUBUNIT; ENZYME; GENE; PRECURSOR; TRANSCRIPTION; SPECIFICITY	When the rnpB gene encoding M1 RNA, the RNA component of Escherichia coli RNase P, is transcribed, the primary M1 RNA transcript (pM1 RNA) is produced and subsequently processed at the 3' end to generate the mature M1 RNA, To study features of pM1 RNA thought to be involved in RNA processing, systematic mutations were introduced, in sequence elements and secondary structures surrounding the processing site using p23 RNA, a truncated pM1 RNA transcribed from the internally deleted, rnpB gene, as a model substrate and the processing of its mutant derivatives was analyzed in vivo and in vitro. Neither the alteration of two bases forming the processing site nor the disruption of secondary structures surrounding the site significantly affected the processing efficiency although the secondary structures were required for maintaining RNA stability. In contrast, mutations at the rne-dependent site, GAUUU, immediately 3' to the processing site inhibited the processing and the extent of the inhibition varied with the altered sequences. Furthermore, the processing of the mutants of the rne-dependent site as well as wild-type p23 RNA was inhibited in an E. coli rne(ts) strain at the nonpermissive temperature.	KOREA ADV INST SCI & TECHNOL, DEPT CHEM, TAEJON 305701, SOUTH KOREA; SEOUL NATL UNIV, DEPT CHEM, SEOUL 151742, SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU)			Lee, Younghoon/C-1991-2011	Lee, Younghoon/0000-0002-3841-719X; Kim, Semi/0000-0001-8043-1465				ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; Bechhofer D., 1993, CONTROL MESSENGER RN, P31; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; Higgins C.F., 1993, CONTROL MESSENGER RN, P13; JAIN SK, 1982, J MOL BIOL, V162, P515, DOI 10.1016/0022-2836(82)90386-2; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KOLE R, 1981, BIOCHEMISTRY-US, V20, P1902, DOI 10.1021/bi00510a028; LAWRENCE NP, 1987, P NATL ACAD SCI USA, V84, P6825, DOI 10.1073/pnas.84.19.6825; LEE SJ, 1991, MOL CELLS, V1, P415; LEE Y, 1989, J BIOL CHEM, V264, P5098; LEE Y M, 1989, Korean Biochemical Journal, V22, P276; LEE YH, 1985, J BACTERIOL, V164, P556, DOI 10.1128/JB.164.2.556-562.1985; LUNDBERG U, 1995, RNA, V1, P327; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MOTAMEDI H, 1984, P NATL ACAD SCI-BIOL, V81, P3959, DOI 10.1073/pnas.81.13.3959; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; REED RE, 1983, P NATL ACAD SCI-BIOL, V80, P5359, DOI 10.1073/pnas.80.17.5359; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SAKAMOTO H, 1983, P NATL ACAD SCI-BIOL, V80, P6187, DOI 10.1073/pnas.80.20.6187; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	33	51	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19330	19337		10.1074/jbc.271.32.19330	http://dx.doi.org/10.1074/jbc.271.32.19330			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702618	hybrid			2022-12-27	WOS:A1996VB68400052
J	Reinhardt, DP; Sasaki, T; Dzamba, BJ; Keene, DR; Chu, ML; Gohring, W; Timpl, R; Sakai, LY				Reinhardt, DP; Sasaki, T; Dzamba, BJ; Keene, DR; Chu, ML; Gohring, W; Timpl, R; Sakai, LY			Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; BETA-BINDING-PROTEIN; EGF-LIKE REPEATS; MARFAN-SYNDROME; ELASTIC FIBERS; STRUCTURAL CHARACTERIZATION; NIDOGEN AFFINITY; CALCIUM-BINDING; GENE-PRODUCT; MICROFIBRILS	Microfibrils 10-12 nm in diameter are found in elastic and non-elastic tissues with fibrillin as a major component. Little is known about the supramolecular structure of these microfibrils and the protein interactions it is based on. To identify protein binding ligands of fibrillin-1, we tested binding of recombinant fibrillin-1 peptides to different extracellular matrix proteins in solid phase assays. Among the proteins tested, only fibulin-2 showed significant binding to rF11, the N-terminal half of fibrillin-1, in a calcium-dependent manner. Surface plasmon resonance demonstrated high affinity binding with a K-d=56 nM. With overlapping recombinant fibrillin-1 peptides, the binding site for fibulin-2 was narrowed down to the N terminus of fibrillin-1 (amino acid positions 45-450). Immunofluorescence in tissues demonstrated colocalization of fibrillin and fibulin-2 in skin, perichondrium, elastic intima of blood vessels, and kidney glomerulus. Fibulin-2 was not present in ocular ciliary zonules, tendon, and the connective tissue around kidney tubules and lung alveoli, which all contain fibrillin. Immunogold labeling of fibulin-2 on microfibrils in skin was found preferentially at the interface between microfibrils and the amorphous elastin core, suggesting that in vivo the interaction between fibrillin-1 and fibulin-2 is regulated by cellular expression and deposition as well as by protein-protein interactions.	SHRINERS HOSP CRIPPLED CHILDREN,PORTLAND,OR 97201; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Max Planck Society; Jefferson University; Jefferson University; Oregon Health & Science University			Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872	NIAMS NIH HHS [AR38923] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALBONA K, 1992, J BIOL CHEM, V267, P20120; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BROWN JC, 1994, J CELL SCI, V107, P329; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DIETZ HC, 1994, ADV HUM GENET, V22, P153; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FARQUHAR MG, 1961, J EXP MED, V113, P47, DOI 10.1084/jem.113.1.47; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HURLE JM, 1994, DEV DYNAM, V200, P321, DOI 10.1002/aja.1002000407; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LITTLE CD, 1995, EXPERIENTIA, V51, P873, DOI 10.1007/BF01921738; LOW FN, 1962, ANAT REC, V142, P131, DOI 10.1002/ar.1091420205; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOREN A, 1994, J BIOL CHEM, V269, P32469; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; RAVIOLA G, 1971, INVEST OPHTH VISUAL, V10, P851; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; TSUJI T, 1980, BRIT J DERMATOL, V102, P413, DOI 10.1111/j.1365-2133.1980.tb06554.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YIN WS, 1995, J BIOL CHEM, V270, P1798, DOI 10.1074/jbc.270.4.1798; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	46	170	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19489	19496		10.1074/jbc.271.32.19489	http://dx.doi.org/10.1074/jbc.271.32.19489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702639	Green Published, hybrid			2022-12-27	WOS:A1996VB68400073
J	Sekiguchi, J; Shuman, S				Sekiguchi, J; Shuman, S			Covalent DNA binding by vaccinia topoisomerase results in unpairing of the thymine base 5' of the scissile bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; DUPLEX DNA; ESCHERICHIA-COLI; STRAND CLEAVAGE; MUTANT ALLELES; I CLEAVAGE; SV40 DNA; SEQUENCE; RECOMBINATION; CATALYSIS	We have used potassium permanganate to probe contacts between vaccinia DNA topoisomerase and thymine residues in its 5'-CCCTT down arrow DNA target site. Two major conclusions emerge from the experiments presented: (i) permanganate oxidation of the +2T base of the scissile strand interferes with topoisomerase binding to DNA, and (ii) the +1T base of the scissile strand becomes unpaired upon formation of the covalent topoisomerase-DNA intermediate. Disruption of T:A base pairing is confined to the +1-position. Covalently bound DNAs that have experienced this structural distortion (such DNAs being marked by oxidation at +1T) are fully capable of being religated. We suggest that a protein-induced DNA conformational change is a component of the strand passage step of the topoisomerase reaction.			Sekiguchi, J (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.			Sekiguchi, JoAnn/0000-0002-7178-4258	NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; ENG WK, 1989, J BIOL CHEM, V264, P13373; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KLEMPERER N, 1993, J BIOL CHEM, V268, P15887; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5827; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SEKIGUCHI J, 1996, IN PRESS EMBO J; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978	36	21	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19436	19442		10.1074/jbc.271.32.19436	http://dx.doi.org/10.1074/jbc.271.32.19436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702632	hybrid			2022-12-27	WOS:A1996VB68400066
J	Chou, SJ; Lai, KN; Chung, BC				Chou, SJ; Lai, KN; Chung, BC			Characterization of the upstream sequence of the human CYP11A1 gene for cell type-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; BOX-BINDING-PROTEINS; SIDE-CHAIN CLEAVAGE; STEROID HYDROXYLASE GENES; TRANSCRIPTIONAL ACTIVATION; DNA-REPLICATION; ADRENAL-CORTEX; P450SCC GENE; DEVELOPMENTAL EXPRESSION; SYNERGISTIC ACTIVATION	The CYP11A1 gene encodes the cholesterol side-chain cleavage enzyme P450scc, which catalyzes the synthesis of steroids from cholesterol. This gene is expressed only in steroidogenic organs such as the adrenal, gonad, placenta, and brain. We have characterized an upstream regulatory element of the human CYP11A1 gene, termed AdE, which contributed to its cell type-specific expression. The AdE sequence contains two protein binding regions, AdE1 and AdE2, which bind many proteins including NF1- and Sp1-like proteins as shown by electrophoretic mobility shift assay, footprinting, competition, antibody supershift, and mutagenesis of the binding sites. When cloned in front of the CYP11A1 promoter or the heterologous thymidine kinase promoter, AdE sequences enhanced expression of the reporter gene in steroidogenic cell lines of the adrenal, gonad, and placental origin but not in nonsteroidogenic cell lines such as COS-1 and Rat-1. The function of AdE1 and AdE2 was lower when present individually than together. The combined action of multiple transcription factors binding to the AdE sequence brings about the final activation of the CYP11A1 gene in a tissue-specific manner.	ACAD SINICA,INST MOL BIOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,GRAD SCH ZOOL,TAIPEI,TAIWAN	Academia Sinica - Taiwan; National Taiwan University				Chung, Bon-chu/0000-0002-8612-0219				ALLAN GF, 1991, J BIOL CHEM, V266, P5905; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHEN CT, 1995, DNA CELL BIOL, V9, P803; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; ESKILD W, 1994, MOL ENDOCRINOL, V8, P732, DOI 10.1210/me.8.6.732; FISHER RJ, 1991, ONCOGENE, V6, P2449; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAESSMANN A, 1979, J VIROL, V32, P989, DOI 10.1128/JVI.32.3.989-994.1979; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; GUO IC, 1993, DNA CELL BIOL, V12, P849, DOI 10.1089/dna.1993.12.849; GUO IC, 1994, J BIOL CHEM, V269, P6362; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HENNIGHAUSEN L, 1989, NUCLEIC ACIDS RES, V17, P8197, DOI 10.1093/nar/17.20.8197; HONDA S, 1993, J BIOL CHEM, V268, P7494; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KEENEY DS, 1995, MOL ENDOCRINOL, V9, P1091, DOI 10.1210/me.9.8.1091; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V94, P235, DOI 10.1016/0303-7207(93)90172-G; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MUKAI K, 1995, MOL CELL BIOL, V15, P6003; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; ROGLER LE, 1993, MOL ENDOCRINOL, V7, P453, DOI 10.1210/me.7.3.453; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHIMMER BP, 1989, METHOD ENZYMOL, V58, P570; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; ZHANG PL, 1995, MOL ENDOCRINOL, V9, P1571, DOI 10.1210/me.9.11.1571; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340	67	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22125	22129		10.1074/jbc.271.36.22125	http://dx.doi.org/10.1074/jbc.271.36.22125			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703023	hybrid			2022-12-27	WOS:A1996VF61200065
J	Okazaki, IJ; Kim, HJ; Moss, J				Okazaki, IJ; Kim, HJ; Moss, J			Cloning and characterization of a novel membrane-associated lymphocyte NAD:arginine ADP-ribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; DIPHTHERIA-TOXIN; CELLS; RIBOSYLATION; RAT; EXPRESSION; CONSERVATION; TRANSFUSION; PREVENTION; PROTEINS	Mono-ADP-ribosylation is a post-translational modification of proteins in which the ADP-ribose moiety of NAD is transferred to proteins and is responsible for the toxicity of some bacterial toxins (e.g. cholera toxin and pertussis toxin). NAD:arginine ADP-ribosyltransferases cloned from human and rabbit skeletal muscle and from mouse lymphoma (Yac-1) cells are glycosylphosphatidylinositol-anchored and have similar enzymatic and physical properties; transferases cloned from chicken heterophils and red cells have signal peptides and may be secreted. We report here the cloning and characterization of an ADP-ribosyltransferase (Yac-2), also from Yac-1 lymphoma cells, that differs in properties from the previously identified eukaryotic transferases. The nucleotide and deduced amino acid sequences of the Yac-1 and Yac-2 transferases are 58 and 33% identical, respectively. The Yac-2 protein is membrane-bound but, unlike the Yac-1 enzyme, appears not to be glycosylphosphatidylinositol-anchored. The Yac-1 and Yac-2 enzymes, expressed as glutathione S-transferase fusion proteins in Escherichia coli, were used to compare their ADP-ribosyltransferase and NAD glycohydrolase activities. Using agmatine as the ADP-ribose acceptor, the Yac-1 enzyme was predominantly an ADP-ribosyltransferase, whereas the transferase and NAD glycohydrolase activities of the recombinant Yac-a protein were equivalent. The deduced amino acid sequence of the Yac-2 transferase contained consensus regions common to several bacterial toxin and mammalian transferases and NAD glycohydrolases, consistent with the hypothesis that there is a common mechanism of NAD binding and catalysis among ADP-ribosyltransferases.			Okazaki, IJ (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,10 CTR DR,MSC 1434,BLDG 10,RM 5N-307,BETHESDA,MD 20892, USA.							BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BURSTEIN D, 1989, DIABETES, V38, P24, DOI 10.2337/diabetes.38.1.24; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1985, P NATL ACAD SCI USA, V82, P7237, DOI 10.1073/pnas.82.21.7237; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; DOUKAS J, 1993, J IMMUNOL, V150, P1036; GREINER DL, 1986, J IMMUNOL, V136, P148; GRIMALDI JC, 1995, J IMMUNOL, V155, P811; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; LEE HC, 1989, J BIOL CHEM, V264, P1608; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MISHIMA K, 1991, J BIOCHEM-TOKYO, V110, P388, DOI 10.1093/oxfordjournals.jbchem.a123591; MISHIMA K, 1992, J BIOL CHEM, V267, P24109; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; OKAZAKI IJ, 1996, IN PRESS BLOOD; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; Rigby MR, 1996, J IMMUNOL, V156, P4259; ROSSINI AA, 1986, J CLIN INVEST, V77, P1399, DOI 10.1172/JCI112448; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1995, J BIOL CHEM, V270, P51; TERASHIMA M, 1992, EUR J BIOCHEM, V204, P305, DOI 10.1111/j.1432-1033.1992.tb16638.x; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; UI M, 1990, ADP RIBOSYLATING TOX, P45; WANG J, 1994, J IMMUNOL, V153, P4048; WICK MJ, 1990, ADP RIBOSYLATING TOX, P31; YAMADA K, 1992, FEBS LETT, V311, P203, DOI 10.1016/0014-5793(92)81102-R; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352; [No title captured]	35	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22052	22057		10.1074/jbc.271.36.22052	http://dx.doi.org/10.1074/jbc.271.36.22052			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703012	hybrid			2022-12-27	WOS:A1996VF61200054
J	LiaudetCoopman, EDE; Wellstein, A				LiaudetCoopman, EDE; Wellstein, A			Regulation of gene expression of a binding protein for fibroblast growth factors by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPEUTIC ANTICANCER AGENTS; SQUAMOUS-CELL DIFFERENTIATION; MESSENGER-RNA EXPRESSION; RESPONSE ELEMENT; HUMAN HEAD; RECEPTOR; STABILITY; ESTROGEN; INHIBITION; CARCINOMA	Retinoids are potent regulators of growth and differentiation and have shown promise as chemotherapeutic agents against selected cancers in particular squamous cell carcinoma (SCC), Earlier studies from our laboratory showed that a secreted binding protein for fibroblast growth factors (BP) is expressed at high levels in SCC cell lines and tissue samples. Here we investigate whether retinoids affect BP gene expression in SCC. In six different human SCC cell lines, we found that all-trans-retinoic acid (tRA) down-regulated BP mRNA by 39-89% within 24 h, From this group of cell lines, we selected the ME-180 cell line for more detailed studies of the mechanisms of this regulation, tRA down-regulated BP mRNA in a time- and dose-dependent manner. The effect of tRA was reversible, and BP mRNA returned to control levels within 24 h after removal of tRA. We also measured BP mRNA half-life and performed nuclear run-on experiments to study if tRA down-regulates BP by destabilizing the mRNA and/or by decreasing the rate of transcription. BP mRNA in ME-180 cells is very stable with a half-life of >16 h, and tRA decreased BP mRNA with a half-time of 5 h, Actinomycin D and cycloheximide blocked the tRA effect, suggesting that transcriptional regulation as well as de novo protein synthesis contribute to this post-transcriptional regulation of BP mRNA levels, In addition, tRA decreased the rate of BP gene transcription by 2- to 3-fold within 1 h, We conclude that retinoids down-regulate BP gene expression by post-transcriptional as well as by transcriptional mechanisms.	GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA	Georgetown University			Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEMAYOR E, 1992, LARYNGOSCOPE, V102, P1133, DOI 10.1288/00005537-199210000-00008; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BERTRAM JS, 1987, CANCER RES, V47, P3012; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BUSAM KJ, 1993, ONCOGENE, V8, P2267; COCHRANE AW, 1988, J MOL BIOL, V203, P555, DOI 10.1016/0022-2836(88)90192-1; CROWE DL, 1993, J CELL SCI, V106, P183; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FROST GH, 1993, J BIOL CHEM, V268, P6748; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; JETTEN AM, 1990, INT J CANCER, V45, P195, DOI 10.1002/ijc.2910450135; LABBAYE C, 1993, BLOOD, V81, P475; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LIPPMAN SM, 1993, J NATL CANCER I, V85, P499, DOI 10.1093/jnci/85.6.499; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; LOPEZBARAHONA M, 1989, MOL ENDOCRINOL, V3, P805; LOTAN R, 1993, J CELL BIOCHEM, P167; LOTNA R, 1994, CANC RES S7, V54, pS1987; MARODER M, 1990, NUCLEIC ACIDS RES, V18, P1153, DOI 10.1093/nar/18.5.1153; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MOON RC, 1990, CHEM BIOL SYNTHETIC; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PAN CJ, 1992, MOL ENDOCRINOL, V6, P572, DOI 10.1210/me.6.4.572; POLLARD M, 1991, CANCER RES, V51, P3610; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; SCHOENBERG DR, 1989, MOL ENDOCRINOL, V3, P805, DOI 10.1210/mend-3-5-805; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHKLAR G, 1980, ORAL SURG ORAL MED O, V50, P45, DOI 10.1016/0030-4220(80)90330-8; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; WU DQ, 1991, J BIOL CHEM, V266, P16778; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZOU CP, 1994, CANCER RES, V54, P5479	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21303	21308		10.1074/jbc.271.35.21303	http://dx.doi.org/10.1074/jbc.271.35.21303			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702908	hybrid			2022-12-27	WOS:A1996VE47700054
J	Zhu, AH; Kuziora, MA				Zhu, AH; Kuziora, MA			Homeodomain interaction with the beta subunit of the general transcription factor TFIIE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; C-TERMINAL DOMAIN; DNA COMPLEX; HOMEO DOMAIN; DROSOPHILA; SEQUENCE; ACTIVATION; ULTRABITHORAX; EXTRADENTICLE	Homeodomain-containing proteins play a crucial role as transcriptional regulators in the process of cell differentiation, The homeodomain performs a dual function in this regard, acting as a DNA binding domain and participating in protein-protein interactions that enhance DNA binding specificity or regulatory activity, Here we describe a homeodomain class-specific interaction with the beta subunit of the general transcription factor TFIIE. We show that the Antennapedia and Abdominal-B homeodomains bind to TFIIE beta, but the even-skipped homeodomain does not, Using a two-hybrid assay performed in cultured cells, we demonstrate that the homeodomain-TFIIE beta interaction occurs in vivo, The Abdominal-B homeodomain is shown to activate transcription in vitro, and this activation can be blocked with anti-TFIIE beta antibody without affecting basal transcription levels, Together with published data demonstrating an interaction between proteins containing even-skipped class homeodomains and the TATA-binding protein (Um, M., Li, C., and Manley, J. L. (1995) Mol. Cell. Biol. 15, 5007-5016; Zhang, H., Catron, K. M., and Abate-Shen, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1764-1769), these results suggest various homeodomain containing proteins interact with different general transcription factors, an observation that may have important implications for transcriptional regulation.			Zhu, AH (corresponding author), UNIV PITTSBURGH,DEPT BIOL SCI,A234 LANGLEY HALL,PITTSBURGH,PA 15260, USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lutz B, 1996, GENE DEV, V10, P176, DOI 10.1101/gad.10.2.176; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TONG X, 1995, MOL CELL BIOL, V15, P4735; UM M, 1995, MOL CELL BIOL, V15, P5007; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; Zhu AH, 1996, DEVELOPMENT, V122, P1577	44	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20993	20996		10.1074/jbc.271.35.20993	http://dx.doi.org/10.1074/jbc.271.35.20993			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702862	hybrid			2022-12-27	WOS:A1996VE47700006
J	Damaj, BB; McColl, SR; Neote, K; Hebert, CA; Naccache, PH				Damaj, BB; McColl, SR; Neote, K; Hebert, CA; Naccache, PH			Diverging signal transduction pathways activated by interleukin 8 (IL-8) and related chemokines in human neutrophils - IL-8 and Gro-alpha differentially stimulate calcium influx through IL-8 receptors A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC CYTOKINES; A RECEPTOR; BINDING; LEUKOCYTES; EXPRESSION; MEMBRANES; RESIDUES; DOMAIN; NAP-2; CELLS	Interleukin 8 (IL-8) and Gro-alpha are members of the CXC branch of a family of cytokines recently designated the ''chemokine'' superfamily. Recent evidence indicates that, contrary to previously held beliefs, IL-8 and Gro-alpha may not be perceived equivalently by neutrophils. In this study, we have evaluated the effects of IL-8 and Gro-alpha on the rate of calcium influx in human neutrophils and in 293 cells transfected with type A or type B IL-8 receptors, Of these two chemokines, only Gro-alpha induced an influx of calcium in neutrophils as judged by the sensitivity of the mobilization of calcium to the extracellular calcium chelator EGTA and to the nonselective divalent cation channel inhibitor SK&F 96365, as well as by manganese quenching experiments, IL-8 was similarly without effect on the rate of Mn2+ influx in 293 cells transfected with IL-8 receptor A (IL-8RA) or IL-8RB. On the other hand, Gro-alpha induced an SK&F 96365-sensitive increase of the rate of Mn+2 influx in IL-8RB-, but not in IL-8RA-transfected 293 cells. These results indicate not only that neutrophils respond differently to IL-8 than they do to Gro-alpha but, furthermore, that the consequences of the binding of IL-8 and Gro-alpha to IL-8RB are distinct.	CHUL,CTR RECH RHUMATOL & IMMUNOL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA; PFIZER INC,DIV CENT RES,GROTON,CT 06340; GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080	Laval University; Laval University; University of Adelaide; Pfizer; Roche Holding; Genentech								Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1993, CLIN INVESTIGATOR, V71, P812; BARNETT ML, 1993, BIOCHIM BIOPHYS ACTA, V1177, P275, DOI 10.1016/0167-4889(93)90123-7; BIGNOLD LP, 1992, INT ARCH ALLERGY IMM, V97, P350, DOI 10.1159/000236144; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; GEISER T, 1993, J BIOL CHEM, V268, P15419; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1993, CANCER INVEST, V11, P743, DOI 10.3109/07357909309046949; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LHEUREUX G, 1994, BLOOD, V85, P522; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MOLSKI TFP, 1983, CELL CALCIUM, V4, P57, DOI 10.1016/0143-4160(83)90049-0; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PETERSEN F, 1994, J IMMUNOL, V152, P2467; PIEPER SC, 1996, CHEMOATTRACTANT LIGA; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; STRIETER RM, 1994, J LAB CLIN MED, V123, P183; TSIEN RY, 1982, J CELL BIOL, V94, P3325; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	30	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20540	20544		10.1074/jbc.271.34.20540	http://dx.doi.org/10.1074/jbc.271.34.20540			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702797	hybrid			2022-12-27	WOS:A1996VD33700049
J	Hisano, T; Hata, Y; Fujii, T; Liu, JQ; Kurihara, T; Esaki, N; Soda, K				Hisano, T; Hata, Y; Fujii, T; Liu, JQ; Kurihara, T; Esaki, N; Soda, K			Crystal structure of L-2-haloacid dehalogenase from Pseudomonas sp YL - An alpha/beta hydrolase structure that is different from the alpha/beta hydrolase fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN-YL; ACID DEHALOGENASE; HALOALKANE DEHALOGENASE; REACTION-MECHANISM; SERINE CARBOXYPEPTIDASE; TRIACYLGLYCEROL LIPASE; TRIAD FORMS; PURIFICATION; PROTEINS; RESOLUTION	L-2-Haloacid dehalogenase catalyzes the hydrolytic dehalogenation of L-2-haloalkanoic acids to yield the corresponding D-2-hydroxyalkanoic acids. The crystal structure of the homodimeric enzyme from Pseudomonas sp. YL has been determined by a multiple isomorphous replacement method and refined at 2.5 Angstrom resolution to a crystallographic R-factor of 19.5%. The subunit consists of two structurally distinct domains: the core domain and the subdomain. The core domain has an alpha/beta structure formed by a six-stranded parallel beta-sheet flanked by five alpha-helices. The subdomain inserted into the core domain has a four helix bundle structure providing the greater part of the interface for dimer formation. There is an active site cavity between the domains. An experimentally identified nucleophilic residue, Asp-10, is located on a loop following the amino-terminal beta-strand in the core domain, and other functional residues, Thr-14, Arg-41, Ser-118, Lys-151, Tyr-157, Ser-175, Asn-177, and Asp-180, detected by a site-directed mutagenesis experiment, are arranged around the nucleophile in the active site. Although the enzyme is an alpha/beta-type hydrolase, it does not belong to the alpha/beta hydrolase fold family, from the viewpoint of the topological feature and the position of the nucleophile.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN	Kyoto University								BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA U, 1994, NAT STRUCT BIOL, V1, P36, DOI 10.1038/nsb0194-36; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; Hisano T, 1996, PROTEINS, V24, P520, DOI 10.1002/(SICI)1097-0134(199604)24:4<520::AID-PROT12>3.0.CO;2-N; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAWASAKI H, 1981, AGR BIOL CHEM TOKYO, V45, P35, DOI 10.1080/00021369.1981.10864494; KLAGES U, 1983, H-S Z PHYSIOL CHEM, V364, P529, DOI 10.1515/bchm2.1983.364.1.529; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; LIU JQ, 1995, BIODEGRADATION, V6, P223, DOI 10.1007/BF00700461; LIU JQ, 1994, J BIOCHEM-TOKYO, V116, P248, DOI 10.1093/oxfordjournals.jbchem.a124514; LUZZATI V, 1953, ACTA CRYSTALLOGR, V6, P142, DOI 10.1107/S0365110X53000508; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MOTOSUGI K, 1982, J BACTERIOL, V150, P522, DOI 10.1128/JB.150.2.522-527.1982; MOTOSUGI K, 1982, AGR BIOL CHEM TOKYO, V46, P837, DOI 10.1080/00021369.1982.10865158; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NARDIDEI V, 1994, APPL ENVIRON MICROB, V60, P3375, DOI 10.1128/AEM.60.9.3375-3380.1994; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; ROMAO MJ, 1992, J MOL BIOL, V226, P1111, DOI 10.1016/0022-2836(92)91056-U; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SMITH JM, 1990, J GEN MICROBIOL, V136, P881, DOI 10.1099/00221287-136-5-881; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WEIGHTMAN AJ, 1982, J GEN MICROBIOL, V128, P1755; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	48	129	132	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20322	20330		10.1074/jbc.271.34.20322	http://dx.doi.org/10.1074/jbc.271.34.20322			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702766	hybrid			2022-12-27	WOS:A1996VD33700018
J	Johnson, NP; Mazarguil, H; Lopez, A				Johnson, NP; Mazarguil, H; Lopez, A			Strandedness discrimination in peptide-polynucleotide complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; DNA-BINDING; NUCLEIC-ACIDS; RECOMBINATION; TRYPTOPHAN; OLIGOLYSINES; BACTERIOPHAGE-T4; THERMODYNAMICS; DOMAIN; YEAST	Preferential binding to single- or double-stranded nucleic acids is important for the activity of many proteins that process RNA and DNA. We have investigated the mechanism of strandedness discrimination with peptides derived from the putative DNA-binding domain of the RecA protein, a bacterial recombinase that modulates its affinity for single-stranded DNA by means of ATP binding and hydrolysis. Contributions of electrostatic and non-electrostatic interactions to binding of these peptides with polynucleotides were evaluated by fluorescence spectroscopy as a function of salt concentration and peptide charge. Binding of these peptides to single- and double-stranded nucleic acids was dominated by non-electrostatic interactions. Small electrostatic contributions selectively enhanced peptide complexation with single-stranded nucleic acids. Similar results were observed in control experiments carried out with tripeptides containing charged and aromatic amino acid residues, It was possible to modify the strandedness preference of peptide-polynucleotide complexes by changing electrostatic contributions to the binding free energy. These observations suggest a mechanism whereby some proteins that interact with DNA or RNA might determine and regulate their relative affinity for single- and double-stranded nucleic acids.			Johnson, NP (corresponding author), CNRS,INST PHARMACOL & BIOL STRUCT,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE.							BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CAZAUX C, 1992, J MOL BIOL, V223, P823, DOI 10.1016/0022-2836(92)90243-D; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LATT SA, 1967, BIOCHEMISTRY-US, V6, P3293, DOI 10.1021/bi00862a040; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MASCOTTI DP, 1993, BIOCHEMISTRY-US, V32, P10568, DOI 10.1021/bi00091a006; MASCOTTI DP, 1992, BIOCHEMISTRY-US, V31, P8932, DOI 10.1021/bi00152a033; MCGEE JD, 1974, J MOL BIOL, V86, P469; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MORAND P, 1977, J BACTERIOL, V131, P572, DOI 10.1128/JB.131.2.572-582.1977; RAJESWARI MR, 1987, BIOCHEMISTRY-US, V26, P6825, DOI 10.1021/bi00395a036; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TOULME JJ, 1974, P NATL ACAD SCI USA, V71, P3185, DOI 10.1073/pnas.71.8.3185; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	30	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19675	19679		10.1074/jbc.271.33.19675	http://dx.doi.org/10.1074/jbc.271.33.19675			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702670	hybrid			2022-12-27	WOS:A1996VC66900011
J	Keck, JL; Marqusee, S				Keck, JL; Marqusee, S			The putative substrate recognition loop of Escherichia coli ribonuclease H is not essential for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; AMINO-ACID-RESIDUES; DOMAIN; MUTAGENESIS; SITE	The RNase H family of enzymes catalyzes the hydrolysis of RNA from RNA . DNA hybrids in a divalent metal-dependent fashion. To date, structure/function studies have focused on two members of this family: Escherichia coli RNase HI, a small monomeric protein; and human immunodeficiency virus, type I (HIV) RNase H, a domain of HIV reverse transcriptase. The isolated RNase H domain from HIV reverse transcriptase can be expressed independently and shares significant structural homology with its E. coli homologue; however, unlike the bacterial protein, it is inactive. The most notable difference between the inactive domain from HIV and the active E. coli protein is a basic helix/loop sequence, present in E. coli but absent from the HIV homologue. Substitution of this basic region into the HIV domain partially restores its activity and increases its thermodynamic stability, By deleting the basic helix/loop region, we have modeled the structural difference between these two polypeptides onto the E. coli homologue. Surprisingly, the resulting mutant protein is active in Mn2+-dependent fashion. Therefore, the basic helix/loop is not required for RNase H activity.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Keck, James/0000-0002-5961-0220				BERKOWER I, 1973, J BIOL CHEM, V248, P5914; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; Cantor C.R., 1980, BIOPHYS CHEM; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DABORA JM, 1994, PROTEIN SCI, V3, P1401, DOI 10.1002/pro.5560030906; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; EVANS DB, 1991, J BIOL CHEM, V266, P20583; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HARUKI M, 1994, J BIOL CHEM, V269, P26904; Hostomsky Z., 1993, NUCLEASES, V2nd, P341; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA E, 1995, J BIOL CHEM, V270, P19853, DOI 10.1074/jbc.270.34.19853; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KANE CM, 1988, BIOCHEMISTRY-US, V27, P3187, DOI 10.1021/bi00409a010; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KECH JL, 1995, P NATL ACAD SCI USA, V29, P2740; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; ODA Y, 1993, J BIOL CHEM, V268, P88; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	29	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19883	19887		10.1074/jbc.271.33.19883	http://dx.doi.org/10.1074/jbc.271.33.19883			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702700	hybrid			2022-12-27	WOS:A1996VC66900041
J	Martinez, A; Haavik, J; Flatmark, T; Arrondo, JLR; Muga, A				Martinez, A; Haavik, J; Flatmark, T; Arrondo, JLR; Muga, A			Conformational properties and stability of tyrosine hydroxylase studied by infrared spectroscopy - Effect of iron/catecholamine binding and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMAL-DENATURATION; PROTEIN-KINASE; CLONED ENZYME; CHOLERA-TOXIN; METAL-IONS; PURIFICATION; 3-MONOOXYGENASE; EXPRESSION; ISOZYMES; RECEPTOR	The conformation and stability of recombinant tetrameric human tyrosine hydroxylase isoenzyme 1 (hTH1) was studied by infrared spectroscopy and by limited tryptic proteolysis, Its secondary structure was estimated to be 42% alpha-helix, 35% beta-extended structures (including beta-sheet), 14% beta-turns, and 10% nonstructured conformations. Addition of Fe(II) or Fe(II) plus dopamine to the apoenzyme did not significantly modify its secondary structure. However, an increased thermal stability and resistance to proteolysis, as well as a decreased cooperativity in the thermal denaturation transition, was observed for the ligand-bound forms. Thus, as compared with the apoenzyme, the ligand-bound subunits of hTH1 showed a more compact tertiary structure but weaker intersubunit contacts within the protein tetramer. Phosphorylation of the apoenzyme by cyclic AMP-dependent protein kinase did not change its overall conformation but allowed on iron binding a conformational change characterized by an increase (about 10%) in alpha-helix and protein stability. Our results suggest that the conformational events involved in TH inhibition by catecholamines are mainly related to modifications of tertiary and quaternary structural features. However, the combined effect of iron binding and phosphorylation. which activates the enzyme, also involves modifications of the protein secondary structure.	UNIV BASQUE COUNTRY, FAC SCI, DEPT BIOCHEM & MOL BIOL, E-48080 BILBAO, SPAIN; UNIV BERGEN, DEPT BIOCHEM & MOL BIOL, N-5009 BERGEN, NORWAY	University of Basque Country; University of Bergen			Haavik, Jan/AAI-3974-2020; Muga, Arturo/N-1174-2014; Haavik, Jan/ABE-1535-2020; Martinez, Aurora/M-3088-2019	Haavik, Jan/0000-0001-7865-2808; Muga, Arturo/0000-0003-0345-6882; Martinez, Aurora/0000-0003-1643-6506				ABATE C, 1988, BIOCHEM BIOPH RES CO, V151, P1446, DOI 10.1016/S0006-291X(88)80524-2; ALMAS B, 1992, EUR J BIOCHEM, V209, P249, DOI 10.1111/j.1432-1033.1992.tb17283.x; ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; ECHABE I, 1995, BIOCHEMISTRY-US, V34, P13565, DOI 10.1021/bi00041a036; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FUJISAWA H, 1987, AMINO ACIDS HLTH DIS, P245; GAHN LG, 1995, BIOCHEMISTRY-US, V34, P252, DOI 10.1021/bi00001a030; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1990, FEBS LETT, V262, P363, DOI 10.1016/0014-5793(90)80230-G; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; HADDEN JM, 1994, BBA-PROTEIN STRUCT M, V1205, P59, DOI 10.1016/0167-4838(94)90092-2; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1981, J NEUROCHEM, V36, P677, DOI 10.1111/j.1471-4159.1981.tb01641.x; LEBOURDELLES B, 1988, J NEUROCHEM, V50, P988; LEBOURDELLES B, 1991, J BIOL CHEM, V266, P17124; MANN SP, 1979, J NEUROCHEM, V33, P133, DOI 10.1111/j.1471-4159.1979.tb11715.x; MUGA A, 1993, ARCH BIOCHEM BIOPHYS, V300, P451, DOI 10.1006/abbi.1993.1061; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779	35	72	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19737	19742		10.1074/jbc.271.33.19737	http://dx.doi.org/10.1074/jbc.271.33.19737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702679	hybrid			2022-12-27	WOS:A1996VC66900020
J	Beck, CA; Zhang, YX; Altmann, M; Weigel, NL; Edwards, DP				Beck, CA; Zhang, YX; Altmann, M; Weigel, NL; Edwards, DP			Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; ACTIVATED PROTEIN-KINASE; HUMAN ANDROGEN RECEPTOR; DNA-BINDING; GLUCOCORTICOID RECEPTOR; BREAST-CANCER; A-FORM; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT PHOSPHORYLATION	Human progesterone receptor (PR) in T47D breast cancer cells is phosphorylated on nine different serine residues; three are hormone-inducible (Ser(102), Ser(294), and Ser(345)), while others are basal but hormone-stimulated. In the present, study, we have compared the phosphorylation state of native and recombinant PR expressed in a baculovirus insect cell system, Stoichiometric measurements showed that unliganded native PR in T47D cells was approximately 50% phosphorylated (approximate to 4 phosphates/PR) and became essentially 100% phosphorylated (approximate to 9 phosphates/PR) when bound to hormone. Unliganded PR expressed in Sf9 insect cells was phosphorylated with a similar stoichiometry (approximate to 3 phosphates/PR), but the phosphate content did not change with hormone addition. Site-specific phosphorylation analyzed by tryptic phosphopeptide mapping and manual peptide sequencing revealed that expressed PR bound to hormone in the Sf9 insect cells was phosphorylated on all the same sites as hormone-treated PR in T47D cells. Only minor differences were detected in the relative proportion of three sites (two basal sites and Ser(345)) and phosphorylation did not occur on alternate sites, Interestingly unliganded baculovirus-expressed PR was constitutively phosphorylated on hormone inducible sites and was phosphorylated on basal sites to the same extent as hormone treated PR. Thus, in the absence of hormone, the phosphorylation state of baculovirus-expressed PR resembled that of the hyperphosphorylated native PR, In contrast to native PR, the expressed receptor in cytosols of Sf9 cells did not form a large oligomeric complex suggesting that hyperphosphorylation may be due to dissociation of the complex in the absence of hormone. This study demonstrating phosphorylation on correct sites with a stoichiometry similar to that of native PR indicates that overexpressed PR in the baculovirus system is suitable for in vitro structure/function studies.	UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM MOL BIOL, DENVER, CO 80262 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Baylor College of Medicine				Zhang, Yixian/0000-0002-6429-3127	NATIONAL CANCER INSTITUTE [R01CA057539, P30CA046934, R55CA057539] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA46934, CA57539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BECK CA, 1993, ENDOCRINOLOGY, V133, P728, DOI 10.1210/en.133.2.728; Beck CA, 1996, J BIOL CHEM, V271, P1209, DOI 10.1074/jbc.271.2.1209; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BROWN M, 1990, J BIOL CHEM, V265, P11238; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; EDWARDS DP, 1992, BIOCHEMISTRY-US, V31, P2482, DOI 10.1021/bi00124a007; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6462; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; JURUTKA PW, 1993, BIOCHEM BIOPH RES CO, V191, P1089, DOI 10.1006/bbrc.1993.1328; KALLIO PJ, 1993, ANN NY ACAD SCI, V684, P233, DOI 10.1111/j.1749-6632.1993.tb32295.x; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; OFIATE SA, 1994, MOL CELL BIOL, V14, P3376; ONATE SA, 1991, MOL ENDOCRINOL, V5, P1993, DOI 10.1210/mend-5-12-1993; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; ROSS TK, 1991, P NATL ACAD SCI USA, V88, P6555, DOI 10.1073/pnas.88.15.6555; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; XIE YB, 1992, J BIOL CHEM, V267, P4939; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	52	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19546	19555		10.1074/jbc.271.32.19546	http://dx.doi.org/10.1074/jbc.271.32.19546			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702648	hybrid			2022-12-27	WOS:A1996VB68400082
J	Rahfeld, JU; Rucknagel, KP; Stoller, G; Horne, SM; Schierhorn, A; Young, KD; Fischer, G				Rahfeld, JU; Rucknagel, KP; Stoller, G; Horne, SM; Schierhorn, A; Young, KD; Fischer, G			Isolation and amino acid sequence of a new 22-kDa FKBP-like peptidyl-prolyl cis/trans-isomerase of Escherichia coli - Similarity to Mip-like proteins of pathogenic bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASES; LEGIONELLA-PNEUMOPHILA; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEINS; NUCLEOTIDE-SEQUENCE; IMMUNOPHILIN; FAMILY; CYCLOPHILIN; INFECTION; RAPAMYCIN	We identified a periplasmic peptidyl-prolyl cis/trans-isomerase (PPIase) of the (FK506-binding protein (FKBP) type in Escherichia coli (FK506 represents a natural peptidomacrolide containing an acylated pipecolic acid residue). After purification to homogeneity, its complete amino acid sequence was determined by a combination of Edman degradation and electrospray mass spectrometry of the authentic protein and peptides generated by proteolysis. The molecular mass calculated from the amino acid sequence of the protein was 22,085.53 Da, which corresponded perfectly with the value of 22,084 +/- 1.47 Da as determined by mass spectrometry. The corresponding gene was cloned and analyzed, and Southern blot experiments revealed the existence of similar genes in various Gram-negative bacteria. The amino acid sequence of the novel FKBP22 shows similarity to Mip (macrophage infectivity potentiator)-like proteins produced by a number of pathogenic bacteria. However, FKBP22 is inhibited more strongly by FK506 than are other Mip-homologues, as indicated by the K-i value of 25 nM. The subsite specificity regarding the P-1 position of the substrate resembles that for Mip-FKBP25 from Legionella pneumophila. The mature FKBP22 enzyme of 205 amino acids exists as a dimer in solution.	MAX PLANCK GESELL,ARBEITSGRP ENZYMOL PEPTIDBINDUNG,D-06120 HALLE,GERMANY; UNIV HALLE WITTENBERG,LEHRSTUHL MOL BIOCHEM,D-06120 HALLE,GERMANY; UNIV N DAKOTA,SCH MED,DEPT MICROBIOL & IMMUNOL,GRAND FORKS,ND 58202	Max Planck Society; Martin Luther University Halle Wittenberg; University of North Dakota Grand Forks			Young, Kevin/A-7954-2013	Young, Kevin/0000-0003-1760-281X				BANGSBORG JM, 1991, INFECT IMMUN, V59, P3836, DOI 10.1128/IAI.59.10.3836-3840.1991; BOUVIER J, 1991, NUCLEIC ACIDS RES, V19, P180, DOI 10.1093/nar/19.1.180; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU PY, 1978, ADV ENZYMOLOGY RELAT, V0047, P00145; CIANCIOTTO NP, 1990, INFECT IMMUN, V58, P2912, DOI 10.1128/IAI.58.9.2912-2918.1990; CIANCIOTTO NP, 1989, INFECT IMMUN, V57, P1255, DOI 10.1128/IAI.57.4.1255-1262.1989; CIANCIOTTO NP, 1995, CURR MICROBIOL, V30, P1149; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P330; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1992, MOL MICROBIOL, V6, P1375, DOI 10.1111/j.1365-2958.1992.tb00858.x; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Fischer G, 1994, ANGEW CHEM, V106, P1479; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HACKER J, 1993, ZBL BAKT-INT J MED M, V278, P348, DOI 10.1016/S0934-8840(11)80851-0; HACKER J, 1993, MOL MICROBIOL, V10, P445, DOI 10.1111/j.1365-2958.1993.tb00917.x; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG B, 1994, FEMS MICROBIOL LETT, V118, P23, DOI 10.1016/0378-1097(94)90591-6; LUNDEMOSE AG, 1992, MOL MICROBIOL, V6, P2539; LUNDEMOSE AG, 1993, MOL MICROBIOL, V7, P777, DOI 10.1111/j.1365-2958.1993.tb01168.x; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MORO A, 1995, EMBO J, V14, P2483, DOI 10.1002/j.1460-2075.1995.tb07245.x; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; ROOF WD, 1994, J BIOL CHEM, V269, P2902; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHECHTER L, 1966, BIOCHEMISTRY-US, V5, P3362; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMIDT B, 1994, FEBS LETT, V352, P185, DOI 10.1016/0014-5793(94)00970-8; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SELANDER RK, 1987, ESCHERICHIA COLI SAL, V2, P1625; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WINN W C JR, 1988, Clinical Microbiology Reviews, V1, P60; WULFING C, 1994, J BIOL CHEM, V269, P2895	49	50	51	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22130	22138		10.1074/jbc.271.36.22130	http://dx.doi.org/10.1074/jbc.271.36.22130			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703024	hybrid			2022-12-27	WOS:A1996VF61200066
J	Renshaw, MW; Toksoz, D; Schwartz, MA				Renshaw, MW; Toksoz, D; Schwartz, MA			Involvement of the small GTPase Rho in integrin-mediated activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; CELL-ADHESION; CDC42 GTPASES; MAP KINASE; BINDING; GROWTH; RAC; PATHWAY	Engagement and clustering of integrins triggers a number of intracellular signaling events, including activation of the mitogen-activated protein (MAP) kinases Erk1 and Erk2. To investigate the mechanism by which integrins mediate the activation of MAP kinases upon binding of NIH 3T3 cells to fibronectin, we assessed the effects of both inhibiting and activating the small GTPase Rho. We observed that inhibition of Rho by the Rho-specific inhibitor C3 exoenzyme or by a dominant negative Rho A (RhoN19) inhibited MAP kinase activation. Conversely, activation of Rho by expression of an activated Rho A mutant (RhoQ63L), or the Rho-specific guanine nucleotide exchange factor Ibc, enhanced and partially mimicked activation of Erk2 by plating on fibronectin. These results therefore show that Rho is involved in the integrin-dependent activation of MAP kinase.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02115 USA	Scripps Research Institute; Tufts University				schwartz, martin/0000-0002-2071-1243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07695] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	32	128	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21691	21694		10.1074/jbc.271.36.21691	http://dx.doi.org/10.1074/jbc.271.36.21691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702960	hybrid			2022-12-27	WOS:A1996VF61200002
J	Clarke, K; Kashiwaya, Y; King, MT; Gates, D; Keon, CA; Cross, HR; Radda, GK; Veech, RL				Clarke, K; Kashiwaya, Y; King, MT; Gates, D; Keon, CA; Cross, HR; Radda, GK; Veech, RL			The beta/alpha peak height ratio of ATP - A measure of free [Mg2+] using P-31 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE EQUILIBRIUM; INTRAVENOUS LOADING TEST; MAGNETIC-RESONANCE; INTRACELLULAR PH; MAGNESIUM-DEFICIENCY; HEART-DISEASE; FREE MG-2+; SPECTROSCOPY; LIVER; MGATP	From P-31 NMR measurements made in vitro at 38 degrees C, I = 0.25, pH 5.75-8.5, and calculated free [Mg2+] from 0 to 5 mm, we show that, within the physiological range of cytosolic free [Mg-2+] from 0.25 to 1.5 mM, the chemical shift difference between the alpha- and beta-ATP resonances, delta(alpha beta), changes by only 0.6 ppm. Consequently, we developed new formalisms from known acid and Mg2+ dissociation constants by which the observed chemical shift of P-i, delta(Pi), and the peak height ratio of the beta- and alpha-ATP resonances, (h) over bar(beta/alpha), could be related to free [Mg2+] by simultaneous solution of: [GRAPHICS] We found that (H) over bar(beta/alpha) changed 2.5-fold as free [Mg2+] varied from 0.25 to 1.5 mM, providing a more sensitive and accurate measure of free cytosolic [Mg2+]. In working rat heart perfused with glucose, free [Mg2+] was 1.0 +/- 0.1 from (h) over bar(beta/alpha) and 1.2 +/- 0.03 from measured [citrate]/ [isocitrate] but 0.51 +/- 0.1 from delta(alpha beta). Addition of ketone bodies to the perfusate decreased free [Mg2+] estimated from (h) over bar(beta/alpha) to 0.61 +/- 0.02 and 0.74 +/- 0.11 by [citrate]/ [isocitrate] but the estimate from delta(alpha beta) was unchanged at 0.46 +/- 0.04 mM. Such differences in estimated free [Mg2+] alter the apparent K-eq of the creatine kinase reaction and hence the estimated cytosolic free [Sigma ADP].	NIAAA, DEPT MEMBRANE BIOCHEM & BIOPHYS, ROCKVILLE, MD 20852 USA; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Oxford								ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; BAILEY IA, 1981, BIOCHEM J, V196, P171, DOI 10.1042/bj1960171; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BOCK JL, 1980, J INORG BIOCHEM, V12, P119, DOI 10.1016/S0162-0134(00)80123-3; BUNN HF, 1971, J BIOL CHEM, V246, P5273; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHEN SM, 1983, J BIOL CHEM, V258, P4294; COHN M, 1962, J BIOL CHEM, V237, P176; CORNELL NW, 1979, J BIOL CHEM, V254, P6522; DOBSON GP, 1992, NMR BIOMED, V5, P20, DOI 10.1002/nbm.1940050105; DOWD TL, 1993, J BIOL CHEM, V268, P991; GOLDBERG RN, 1991, BIOPHYS CHEM, V40, P241, DOI 10.1016/0301-4622(91)80024-L; GULLESTAD L, 1992, SCAND J CLIN LAB INV, V52, P245, DOI 10.3109/00365519209088355; GUPTA RK, 1983, BIOCHEM BIOPH RES CO, V117, P210, DOI 10.1016/0006-291X(83)91562-0; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1980, J BIOL CHEM, V255, P3987; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hille B., IONIC CHANNELS EXCIT; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P1215, DOI 10.1073/pnas.93.3.1215; JONES JE, 1969, ANN NY ACAD SCI, V162, P934, DOI 10.1111/j.1749-6632.1969.tb13022.x; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KOST GJ, 1990, MAGN RESON MED, V14, P496, DOI 10.1002/mrm.1910140307; KWACK H, 1992, METABOLITE METABOLIS, P185; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LAWSON JWR, 1976, GLUCONEOGENESIS ITS, P481; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; LOPRESTI P, 1989, BIOCHIM BIOPHYS ACTA, V998, P317, DOI 10.1016/0167-4838(89)90291-4; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MCLEAN RM, 1994, AM J MED, V96, P63, DOI 10.1016/0002-9343(94)90117-1; MEEMA HE, 1987, KIDNEY INT, V32, P388, DOI 10.1038/ki.1987.222; MOON RB, 1973, J BIOL CHEM, V248, P7276; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; MURPHY E, 1993, MINER ELECTROL METAB, V19, P250; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P128; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; RASMUSSEN HS, 1988, ARCH INTERN MED, V148, P329, DOI 10.1001/archinte.148.2.329; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSE IA, 1968, P NATL ACAD SCI USA, V61, P1079, DOI 10.1073/pnas.61.3.1079; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; SMITH RM, 1956, J AM CHEM SOC, V78, P2376, DOI 10.1021/ja01592a009; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; VEECH RL, 1994, ALCOHOL CLIN EXP RES, V18, P1040, DOI 10.1111/j.1530-0277.1994.tb00081.x; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WAGMAN DD, 1982, J PHSY CHEM REF D S2, V11, P73; Walser M, 1967, Ergeb Physiol, V59, P185; Weiss Matthias, 1994, Magnesium Research, V7, P135	51	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21142	21150		10.1074/jbc.271.35.21142	http://dx.doi.org/10.1074/jbc.271.35.21142			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702884	hybrid			2022-12-27	WOS:A1996VE47700030
J	Kutty, RK; Kutty, G; Kambadur, R; Duncan, T; Koonin, EV; Rodriguez, IR; Odenwald, WF; Wiggert, B				Kutty, RK; Kutty, G; Kambadur, R; Duncan, T; Koonin, EV; Rodriguez, IR; Odenwald, WF; Wiggert, B			Molecular characterization and developmental expression of a retinoid- and fatty acid-binding glycoprotein from Drosophila - A putative lipophorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; PROTEIN SECONDARY STRUCTURE; LIPID TRANSPORT; GENE; LIPOPROTEIN; ENCODES; DNA; NITROCELLULOSE; BIOSYNTHESIS; LIPOVITELLIN	A detailed understanding of the mechanism of Lipid transport in insects has been hampered by the inability to identify the proapolipophorin gene that encodes apolipophorins I and II, the principal protein components of lipophorin, the lipid transport vehicle, Here we provide the first molecular description of the Drosophila gene encoding a retinoid- and fatty acid-binding glycoprotein (RFABG) and present evidence that it is a member of the proapolipophorin gene family, The gene, localized to the chromosome 4 (102 F region), encodes a 3351-amino acid protein that could serve as the precursor for the similar to 70-kDa and > 200-kDa polypeptides associated with RFABG, The N-terminal sequence of the similar to 70-kDa polypeptide and that predicted for the > 200-kDa polypeptide showed high sequence similarity to blowfly apolipophorin II and apolipophorin I, respectively. The RFABG precursor contains a signal peptide and exhibits a multidomain mosaic protein structure, which is typical of extracellular proteins. It has structural domains similar to lipid-binding proteins, namely vitellogenins and apolipoprotein B. The protein also contains a domain similar to the D domain of von Willebrand factor and mucin, The gene is expressed in the Drosophila embryo during development in cells that make up the amnioserosa and fat bodies. Immunolocalizations using specific antibodies against RFABG reveal that the protein is initially dispersed through the embryonic amnioserosa sac and latter concentrated at skeletal muscle-epidermis apodemeal contact junctions during larval development, This novel gene may play an important role in the transport of lipids, including retinoids and fatty acids, in insects.	NINCDS,NEUROGENET UNIT,NEUROCHEM LAB,BETHESDA,MD 20892; NIH,NATL CTR BIOTECHNOL INFORMAT,NATL LIB MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Kutty, RK (corresponding author), NEI,RETINAL CELL & MOL BIOL LAB,BETHESDA,MD 20892, USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANASZAK L, 1991, ANNU REV BIOPHYS BIO, V20, P221, DOI 10.1146/annurev.biophys.20.1.221; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BARWIG B, 1985, J COMP PHYSIOL B, V155, P135, DOI 10.1007/BF00685206; BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; Bork P, 1992, CURR OPIN STRUC BIOL, V2, P413; BORST DE, 1989, J BIOL CHEM, V264, P1115; CHEN JS, 1994, J MOL BIOL, V237, P641, DOI 10.1006/jmbi.1994.1261; CHINO H, 1985, COMPREHENSIVE INSECT, V10, P115; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DUNCAN T, 1994, ARCH BIOCHEM BIOPHYS, V312, P158, DOI 10.1006/abbi.1994.1294; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERNANDOWARNAKULASURIYA GJP, 1988, ARCH INSECT BIOCHEM, V8, P243, DOI 10.1002/arch.940080405; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; GELLISSEN G, 1983, NATURWISSENSCHAFTEN, V70, P45, DOI 10.1007/BF00365962; GUM JR, 1994, J BIOL CHEM, V269, P2440; HEILMANN LJ, 1993, ARCH INSECT BIOCHEM, V23, P125, DOI 10.1002/arch.940230304; JOURNET AM, 1993, THROMB HAEMOSTASIS, V70, P1053; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KING LE, 1992, INSECT BIOCHEM MOLEC, V22, P817, DOI 10.1016/0965-1748(92)90108-Q; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MELLERICK DM, 1992, NEURON, V9, P789, DOI 10.1016/0896-6273(92)90234-5; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; Pho DB, 1996, ARCH INSECT BIOCHEM, V31, P289, DOI 10.1002/(SICI)1520-6327(1996)31:3&lt;289::AID-ARCH4&gt;3.0.CO;2-T; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1995, PROTEIN SCI, V4, P521; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; SHAPIRO JP, 1988, ANNU REV ENTOMOL, V33, P297, DOI 10.1146/annurev.en.33.010188.001501; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWELL SC, 1994, COMP BIOCHEM PHYS B, V109, P339, DOI 10.1016/0305-0491(94)90018-3; VANDERHORST DJ, 1993, INSECT LIPIDS: CHEMISTRY, BIOCHEMISTRY AND BIOLOGY, P1; WEERS PMM, 1993, J BIOL CHEM, V268, P4300; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X	49	72	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20641	20649		10.1074/jbc.271.34.20641	http://dx.doi.org/10.1074/jbc.271.34.20641			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702812	hybrid			2022-12-27	WOS:A1996VD33700064
J	Lander, HM; Jacovina, AT; Davis, RJ; Tauras, JM				Lander, HM; Jacovina, AT; Davis, RJ; Tauras, JM			Differential activation of mitogen-activated protein kinases by nitric oxide-related species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; STRESS; RAS; PHOSPHORYLATION; CASCADE; PATHWAY; GTPASES; CDC42	Many studies have identified nitric oxide (NO) and related chemical species (NOx) as having critical roles in neurotransmission, vasoregulation, and cellular signaling, Previous work in this laboratory has focused on elucidating the mechanism of NOx signaling in cells. We have demonstrated that NOx-induced activation of the guanine nucleotide-binding protein p21(ras) leads to nuclear translocation of the transcription factor NF kappa B. Here, we investigated whether intermediary signaling elements, namely the mitogen-activated protein (MAP) kinases, are involved in mediating NOx signaling. We found that NOx activates the extracellular signal regulated kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK) subgroups of MAP kinases in human Jurkat T cells. JNK was found to be 100-fold more sensitive to NOx stimulation than p38 and ERK. In addition, the activation of JNK and p38 by NOx was more rapid than ERK activation. Depletion of intracellular glutathione augmented the NOx-induced increase in kinase activity. Furthermore, endogenous NOx generated from NO synthase, activated ERK, and NOx-induced MAP kinase activation was effectively blocked by the farnesyl transferase inhibitor alpha-hydroxyfarnesylphosphonic acid. These data support the hypothesis that critical signaling kinases, such as ERK, p38, and JNK, are activated by NO-related species and thus participate in NO signal. transduction. These findings establish a role for multi pie MAP kinase signaling pathways in the cellular response to NOx.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOL MED,DEPT BIOCHEM & MOL BIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Lander, HM (corresponding author), CORNELL UNIV,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA58396] Funding Source: Medline; NHLBI NIH HHS [HL46403] Funding Source: Medline; NIAID NIH HHS [AI37637] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	281	290	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19705	19709		10.1074/jbc.271.33.19705	http://dx.doi.org/10.1074/jbc.271.33.19705			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702674	hybrid			2022-12-27	WOS:A1996VC66900015
J	Ward, LD; Hammacher, A; Howlett, GJ; Matthews, JM; Fabri, L; Moritz, RL; Nice, EC; Weinstock, J; Simpson, RJ				Ward, LD; Hammacher, A; Howlett, GJ; Matthews, JM; Fabri, L; Moritz, RL; Nice, EC; Weinstock, J; Simpson, RJ			Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6 receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; SIGNAL TRANSDUCER; MOLECULAR-CLONING; BINDING CONSTANTS; TYROSINE KINASE; 2 DISTINCT; GP130; ASSOCIATION; ACTIVATION; EXPRESSION	The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130. Monomeric (IL-6(M)) and dimeric (IL-6(D)) forms of Escherichia coli-derived human IL-6 and the extracellular (''soluble'') portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex. Although IL-6(D) has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6(M) is more potent than IL-6(D) in a STAT3 phosphorylation assay. The difference in potency is significantly less pronounced when measured in the murine 7TD1 hybridoma growth factor assay and the human hepatoma HepG2 bioassay due to time-dependent dissociation of 37 degrees C of IL-6 dimers into active monomers. The increased binding affinity of IL-6(D) appears to be due to its ability to cross-link two sIL-6R molecules on the biosensor surface. Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6(D) resulted from a decreased ability of the IL-6(D) .(sIL-6R)(2) complex to couple with the soluble portion of gp130. These data imply that the IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 . IL-6R . gp130)(2) complex. A model is presented whereby the trimeric complex of IL-6R, pg130, and IL-6(M) forms before the functional hexamer. Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.	UNIV MELBOURNE,LUDWIG INST CANC RES,WALTER & ELIZA HALL INST MED RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT BIOCHEM,PARKVILLE,VIC 3050,AUSTRALIA; LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne; Ludwig Institute for Cancer Research			Nice, Edouard C/B-1026-2011; Matthews, Jacqueline/A-7322-2013; Moritz, Robert L/B-9222-2011	Matthews, Jacqueline/0000-0001-8518-3472; Simpson, Richard/0000-0002-9834-0796; fabri, louis/0000-0003-4033-3304				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Hammacher A, 1996, J BIOL CHEM, V271, P5464, DOI 10.1074/jbc.271.10.5464; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1994, CYTOKINE HDB, P145; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAY LT, 1991, J BIOL CHEM, V266, P9950; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Narazaki M., 1994, GUIDEBOOK CYTOKINES, P56; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WARD LD, 1995, TECH PROT CHEM, V6, P417, DOI 10.1016/S1080-8914(06)80051-7; WARD LD, 1994, J BIOL CHEM, V269, P23286; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2931; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1992, IMMUNOL LETT, V31, P123, DOI 10.1016/0165-2478(92)90138-E; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	46	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20138	20144		10.1074/jbc.271.33.20138	http://dx.doi.org/10.1074/jbc.271.33.20138			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702737	hybrid			2022-12-27	WOS:A1996VC66900078
J	Hocking, AM; Strugnell, RA; Ramamurthy, P; McQuillan, DJ				Hocking, AM; Strugnell, RA; Ramamurthy, P; McQuillan, DJ			Eukaryotic expression of recombinant biglycan - Post-translational processing and the importance of secondary structure for biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; GROWTH-FACTOR-BETA; LINE UMR 106-01; ARTICULAR-CARTILAGE; SMALL PROTEOGLYCAN; VACCINIA VIRUS; CORE PROTEIN; I COLLAGEN; DECORIN; BINDING	Biglycan is a small chondroitin sulfate proteoglycan found in many tissues and is structurally related to decorin, fibromodulin, and lumican. The biological function of biglycan is poorly understood, although several studies have indicated interaction with other extracellular matrix components, We have initiated studies of structural and functional domains of biglycan by transient eukaryotic expression using the vaccinia virus/T7 bacteriophage expression system, A recombinant vaccinia virus, vBGN4 encoding the mature biglycan core protein as a polyhistidine fusion protein under control of the T7 phage promoter was expressed in HT-1080 cells and UMR106 cells, The structure of the recombinant biglycan secreted by these cells was defined by analyzing molecules labeled in the presence of [S-35]sulfate, [H-3]glucosamine, and [S-35]methionine. Glycoforms of biglycan were separated by imidazole gradient elution, under non-denaturing conditions, and comprised: a large proteoglycan form substituted with two chondroitin sulfate chains of molecular mass similar to 34 kDa (HT-1080 cells) or similar to 40 kDa (UMR106 cells); a small proteoglycan form substituted with two chondroitin sulfate chains with a median molecular mass similar to 28 kDa; and a core protein form secreted devoid of glycosaminoglycan chains, All the glycoforms were substituted with two N-linked oligosaccharides, and the disaccharide composition of the two glycosaminoglycan populations were identical, Approximately 70% of the recombinant biglycan secreted by HT-1080 cells was substituted with chondroitin sulfate chains, whereas about 50% of the biglycan expressed by UMR106 cells was substituted with chondroitin sulfate chains, Infection with vBGN4 in both HT-1080 and UMR106 cells resulted in the production of approximately 10 mg of biglycan/10(9) cells per 24 h, The native recombinant biglycan was shown to bind to collagen type V and the complement protein, Clq, However, when the secondary structure of recombinant biglycan was disrupted by exposure to 4 hi guanidine hydrochloride, the affinity for collagen type V was dramatically reduced. These data demonstrate the importance of secondary structure to the function of this small proteoglycan.	TEXAS A&M UNIV,INST BIOSCI & TECHNOL,CTR EXTRACELLULAR MATRIX BIOL,HOUSTON,TX 77030	Texas A&M University System				Hocking, Anne/0000-0003-2130-3732; Strugnell, Richard/0000-0003-0614-5641	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 42826] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; CARLSON DM, 1968, J BIOL CHEM, V243, P616; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FONT B, 1993, J BIOL CHEM, V268, P25015; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JOHNSTONE B, 1993, BIOCHEM J, V292, P661, DOI 10.1042/bj2920661; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUMDIECK R, 1992, J IMMUNOL, V149, P3965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1994, J BIOL CHEM, V269, P28366; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; POGANY G, 1994, ARCH BIOCHEM BIOPHYS, V313, P102, DOI 10.1006/abbi.1994.1365; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	33	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19571	19577		10.1074/jbc.271.32.19571	http://dx.doi.org/10.1074/jbc.271.32.19571			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702651	hybrid			2022-12-27	WOS:A1996VB68400085
J	Kalchman, MA; Graham, RK; Xia, G; Koide, HB; Hodgson, JG; Graham, KC; Goldberg, YP; Gietz, RD; Pickart, CM; Hayden, MR				Kalchman, MA; Graham, RK; Xia, G; Koide, HB; Hodgson, JG; Graham, KC; Goldberg, YP; Gietz, RD; Pickart, CM; Hayden, MR			Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; PALLIDOLUYSIAN ATROPHY DRPLA; PROTEIN-PROTEIN INTERACTIONS; FAMILIAL ALZHEIMERS-DISEASE; CAG REPEAT; INSITU HYBRIDIZATION; ERYTHROID-DIFFERENTIATION; PROTEOLYTIC PATHWAY; PROTEASOME PATHWAY; MISSENSE MUTATIONS	Using the yeast two-hybrid system, we have identified a human ubiquitin-conjugating enzyme (hE2-25K) as a protein that interacts with the gene product for Huntington disease (HD) (Huntingtin). This protein has complete amino acid identity with the bovine E2-25K protein and has striking similarity to the UBC-1, -4 and -5 enzymes of Saccharomyces cerevisiae. This protein is highly expressed in brain and a slightly larger protein recognized by an anti-E2-25K polyclonal antibody is selectively expressed in brain regions affected in HD. The huntingtin-E2-25K interaction is not obviously modulated by CAG length. We also demonstrate that huntingtin is ubiquitinated. These findings have implications for the regulated catabolism of the gene product for HD.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z4,CANADA; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205; UNIV MANITOBA,DEPT HUMAN GENET,WINNIPEG,MB R3E 0W3,CANADA	University of British Columbia; Johns Hopkins University; University of Manitoba			Graham, Rona K/R-7358-2018; Hayden, Michael R/D-8581-2011	Graham, Rona K/0000-0003-3722-6241; Hayden, Michael R/0000-0001-5159-1419				ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; CAMMARATA S, 1993, NEUROSCI LETT, V156, P96, DOI 10.1016/0304-3940(93)90448-T; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; GUSELLA JF, 1994, NEW ENGL J MED, V330, P1400; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HARPER JW, 1993, CELL, V75, P805; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KOEMER TJ, 1990, METHOD ENZYMOL, V194, P477; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Miller J.H., 1972, EXPT MOL GENETICS; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P621, DOI 10.1177/36.6.2835410; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHIFFER D, 1994, NEUROSCI LETT, V180, P21, DOI 10.1016/0304-3940(94)90904-0; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUGIYAMA H, 1994, CLIN NEUROPATHOL, V13, P55; TADDEI N, 1993, NEUROSCI LETT, V151, P158, DOI 10.1016/0304-3940(93)90010-I; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; UENO S, 1995, HUM MOL GENET, V4, P663, DOI 10.1093/hmg/4.4.663; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEFES I, 1995, P NATL ACAD SCI USA, V92, P4982, DOI 10.1073/pnas.92.11.4982; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; 1993, CELL, V72, P971	62	285	305	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19385	19394		10.1074/jbc.271.32.19385	http://dx.doi.org/10.1074/jbc.271.32.19385			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702625	hybrid			2022-12-27	WOS:A1996VB68400059
J	Oelmuller, R; Herrmann, RG; Pakrasi, HB				Oelmuller, R; Herrmann, RG; Pakrasi, HB			Molecular studies of CtpA, the carboxyl-terminal processing protease for the D1 protein of the photosystem II reaction center in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-CENTER COMPLEX; PRECURSOR PROTEIN; SCENEDESMUS-OBLIQUUS; PARTIAL-PURIFICATION; SPINACH; GENE; IDENTIFICATION; CHLOROPLASTS; POLYPEPTIDE; EXPRESSION	The D1 reaction center protein of the Photosystem II complex in green plants is synthesized with a short carboxyl-terminal extension, Proteolytic cleavage and removal of this extension peptide in the thylakoid lumen are necessary for the assembly of a manganese cluster that is essential for the oxygen evolution activity of Photosystem II. We have isolated cDNAs encoding CtpA, the carboxyl-terminal processing protease for the D1 protein, from two higher plants, spinach and barley, In each of these organisms, CtpA is encoded by a single copy nuclear gene, and its steady-state mRNA levels are light-regulated. The CtpA protein is detectable in etiolated material, and its level increases similar to 5-fold upon illumination. Moreover, the CtpA gene is expressed in shoot tissues and not in roots. In its precursor form, the CtpA protein harbors a bipartite transit sequence characteristic for thylakoid lumenal proteins. Cell fractionation studies demonstrated that CtpA is associated with thylakoid membranes and is resistant to treatments with thermolysin, consistent with its localization in the lumen of thylakoids. Comparisons of the sequence of the higher plant CtpA enzyme with those of other related carboxyl-terminal processing proteases suggest that these proteins constitute a new family of proteases.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	Washington University (WUSTL); University of Munich								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; BRAND SN, 1992, PLANT MOL BIOL, V20, P481, DOI 10.1007/BF00040607; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINER BA, 1988, J BIOL CHEM, V263, P8972; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FERNANDEZGONZAL.F, 1993, J CELL SCI, V105, P7; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLIEGER K, 1993, PLANT J, V4, P9, DOI 10.1046/j.1365-313X.1993.04010009.x; FUJITA S, 1995, PLANT CELL PHYSIOL, V36, P1169; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; Harlow E., 1988, ANTIBODIES LAB MANUA; Herrmann R. G., 1991, Plant molecular biology 2. Proceedings of a NATO Advanced Study Institute, 14-23 May 1990, Elmau, Germany., P411; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; INAGAKI N, 1989, FEBS LETT, V246, P218, DOI 10.1016/0014-5793(89)80286-8; ISLAM MR, 1993, J BIOL CHEM, V268, P22627; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MARKGRAF T, 1991, PLANTA, V185, P97, DOI 10.1007/BF00194520; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MENON NK, 1993, FEBS LETT, V331, P91, DOI 10.1016/0014-5793(93)80303-C; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; MINAMI E, 1985, PLANT CELL PHYSIOL, V26, P839; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; ROBINSON C, 1994, PLANT MOL BIOL, V26, P14; ROSSMANN R, 1995, EUR J BIOCHEM, V227, P545, DOI 10.1111/j.1432-1033.1995.tb20422.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; Stavenga D.G., 1991, P261; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGUCHI F, 1993, FEBS LETT, V326, P227, DOI 10.1016/0014-5793(93)81796-3; TAGUCHI F, 1995, J BIOL CHEM, V270, P10711, DOI 10.1074/jbc.270.18.10711; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WESTHOFF P, 1985, MOL GEN GENET, V199, P290, DOI 10.1007/BF00330271	45	58	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21848	21852		10.1074/jbc.271.36.21848	http://dx.doi.org/10.1074/jbc.271.36.21848			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702985	hybrid			2022-12-27	WOS:A1996VF61200027
J	Benito, A; Feliu, JX; Villaverde, A				Benito, A; Feliu, JX; Villaverde, A			beta-galactosidase enzymatic activity as a molecular probe to detect specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE VIRUS; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ALKALINE-PHOSPHATASE; MALATE-DEHYDROGENASE; FUSION PROTEINS; ANTIGENIC SITE; VIRAL PEPTIDE; LACZ-GENE	The main antigenic region of foot-and-mouth disease virus serotype C-1, also called site A, has been inserted in zones of the beta-galactosidase important for the stabilization of the active site, causing important changes in the K-m and the specific activity of the resulting enzymes. The peptide is displayed at the surface of the recombinant proteins and, in all the cases, presents a good antigenicity. Among the recombinant proteins constructed, in proteins M278VP1 and M275SVP1 the peptide is inserted in a large loop of the beta-galactosidase (amino acids 272-288) involved in the formation of the activating interface. In these constructs, the binding of the specific antibodies directed to the foreign peptide causes an increase of the beta-galactosidase activity up to about 200%. This phenomenon has been proved using monoclonal antibodies and also using polyclonal sera generated against the peptide. Different hypothesis of the mechanism of modulation upon antibody binding are discussed. This insertion site seems to be sensitive enough to enzymatic modulation mediated by antibody binding. We propose further exploring this insertion site as a tool for a rapid detection of specific antibodies in a quick and simple homogeneous assay based on the colorimetric determination of beta-galactosidase activity.	UNIV AUTONOMA BARCELONA,INST BIOL FONAMENTAL,BELLATERRA 08193,BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,DEPT GENET & MICROBIOL,BELLATERRA 08193,BARCELONA,SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona			Villaverde, Antonio/N-3986-2018; Benito, Antoni/D-8537-2011; Wood, David W/B-2992-2012	Villaverde, Antonio/0000-0002-2615-4521; Benito, Antoni/0000-0002-9776-1003; 				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BENITO A, 1993, J BIOTECHNOL, V29, P299, DOI 10.1016/0168-1656(93)90061-Q; BENITO A, 1994, FEMS MICROBIOL LETT, V123, P107, DOI 10.1016/0378-1097(94)90281-X; BENITO A, 1993, ENZYME MICROB TECH, V15, P66, DOI 10.1016/0141-0229(93)90118-L; BENITO A, 1995, BIO-TECHNOL, V13, P801, DOI 10.1038/nbt0895-801; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; BRENNAN C, 1994, PROTEIN ENG, V7, P509, DOI 10.1093/protein/7.4.509; BRENNAN CA, 1995, P NATL ACAD SCI USA, V92, P5783, DOI 10.1073/pnas.92.13.5783; BREUL A, 1991, EUR J BIOCHEM, V195, P191, DOI 10.1111/j.1432-1033.1991.tb15694.x; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CELADA F, 1972, Q REV BIOPHYS, V5, P395, DOI 10.1017/S0033583500000998; FELIU JX, 1994, BIOTECHNOL TECH, V8, P509, DOI 10.1007/BF00222845; HENDERSON DR, 1986, CLIN CHEM, V32, P1637; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KHANA P, 1991, PRINCIPLES PRACTICE, P326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; MATEU MG, 1992, EUR J IMMUNOL, V22, P1385, DOI 10.1002/eji.1830220609; MATEU MG, 1990, J GEN VIROL, V71, P629, DOI 10.1099/0022-1317-71-3-629; MATEU MG, 1989, P NATL ACAD SCI USA, V86, P5883, DOI 10.1073/pnas.86.15.5883; Miller J. H, 1972, EXPT MOL GENETICS; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; ROWLEY GL, 1975, J BIOL CHEM, V250, P3759; ROWLEY GL, 1976, 172 AM CHEM SOC M; RUBENSTEIN KE, 1972, BIOCHEM BIOPH RES CO, V47, P846, DOI 10.1016/0006-291X(72)90570-0; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ULLMAN EF, 1979, BIOCHIM BIOPHYS ACTA, V567, P66, DOI 10.1016/0005-2744(79)90173-6; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; VILLANUEVA N, 1983, GENE, V23, P185, DOI 10.1016/0378-1119(83)90050-1; Wallenfels K., 1972, ENZYMES, V7, P617; ZABALLOS A, 1987, GENE, V58, P67, DOI 10.1016/0378-1119(87)90030-8	38	46	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21251	21256		10.1074/jbc.271.35.21251	http://dx.doi.org/10.1074/jbc.271.35.21251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702899	hybrid			2022-12-27	WOS:A1996VE47700045
J	Hajjar, KA; Guevara, CA; Lev, E; Dowling, K; Chacko, J				Hajjar, KA; Guevara, CA; Lev, E; Dowling, K; Chacko, J			Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface - Essential role of endonexin repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; DEPENDENT CA-2+ BINDING; ANTICOAGULANT PROTEIN-I; GROWTH-FACTOR-I; SECRETORY PATHWAY; GLYCOSYL-PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE EXPOSURE; PHOSPHOLIPID BINDING; MEMBRANE-BINDING; SIGNAL SEQUENCE	Endothelial cells express a cell surface co-receptor for plasminogen and tissue plasminogen activator (t-PA) which we recently identified as annexin II (Hajjar, K. A., Jacovina, A. T., and Chacko, J. (1994) J. Biol. Chem., 269, 21191-21197). This protein enhances the catalytic efficiency of t-PA-dependent plasmin generation by 60-fold (Cesarman, G. M., Guevara, C. A., and Hajjar, K. A, (1994) J. Biol. Chem. 269, 21198-21203). Here, we demonstrate that annexin II is constitutively translocated to the endothelial cell surface within 16 h of biosynthesis, and that cell surface annexin II comprises 4.3 +/- 1.0% of the total cellular pool. Exogenous I-125-annexin II bound to EGTA-washed endothelial cells with high affinity (K-d 49 nM) and in a calcium-dependent (I-50 = 3 mu M), phospholipid-sensitive manner. Peptides KASMKGLGTDED and YDSMKGKGTRDK, mimicking the calcium-binding ''endonexin'' motif (KGXGT) of annexin II, blocked its interaction with endothelial cells. Recombinant annexin II, bearing the calcium-binding site substitution D161A of core repeat 2, failed to compete with binding of the wild type protein to the cell surface, while E246A and D321A mutants, corresponding to core repeats 3 and 4, behaved as effective competitors. These data suggest that translocated annexin II interacts with cell surface phospholipid via a high affinity calcium-dependent binding site that includes residues 118-122 (KGLGT) and the coordinating Asp(161) of core repeat 2. Thus, calcium-regulated expression of annexin II on the endothelial cell surface may play a central role in control of plasmin-mediated processes.	CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021	Cornell University	Hajjar, KA (corresponding author), CORNELL UNIV,COLL MED,DEPT PEDIAT,DIV HEMATOL ONCOL,1300 YORK AVE,BOX 45,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL 46403, HL 42493] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042493, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GERKE V, 1992, ANNEXINS, P47; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GOULET F, 1992, BIOCHEM BIOPH RES CO, V188, P554, DOI 10.1016/0006-291X(92)91091-4; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HAJJAR KA, 1995, THROMB HAEMOSTASIS, V74, P294; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUNTER KW, 1986, METHOD ENZYMOL, V121, P541; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOST M, 1992, EUR J BIOCHEM, V207, P923, DOI 10.1111/j.1432-1033.1992.tb17125.x; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAND A, 1991, AM J PATHOL, V139, P629; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MA ASP, 1994, J CELL SCI, V107, P1973; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; SORIC J, 1985, SCIENCE, V230, P563, DOI 10.1126/science.2996139; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; VANHEERDE WL, 1994, BIOCHEM J, V302, P305, DOI 10.1042/bj3020305; WENG XW, 1993, PROTEIN SCI, V2, P448; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	54	105	109	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21652	21659		10.1074/jbc.271.35.21652	http://dx.doi.org/10.1074/jbc.271.35.21652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702954	hybrid			2022-12-27	WOS:A1996VE47700100
J	Voorberg, J; vanStempvoort, G; Bos, JMK; Mertens, K; vanMourik, JA; Donath, MJSH				Voorberg, J; vanStempvoort, G; Bos, JMK; Mertens, K; vanMourik, JA; Donath, MJSH			Enhanced thrombin sensitivity of a factor VIII heparin cofactor II hybrid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; SUBUNIT STRUCTURE; ALPHA-THROMBIN; PROTEIN-C; FACTOR XA; INHIBITION; RECEPTOR; HIRUDIN; ACTIVATION; BINDING	Generation of thrombin at a site of vascular injury is a key event in the arrest of bleeding, In addition to the conversion of fibrinogen into the insoluble fibrin, thrombin can initiate a number of positive and negative feedback mechanisms that either sustain or down-regulate clot formation. We have modulated the thrombin sensitivity of human blood coagulation factor VIII, an essential cofactor in the intrinsic pathway of blood coagulation, We have substituted an acidic region of factor VIII corresponding to amino acid sequence Asp(712)-Ala(736) by amino acid sequence Ile(51)-Leu(80) of the thrombin inhibitor heparin cofactor II. Functional analysis of the resulting factor VIII-heparin cofactor II hybrid, termed des-(868-1562)-factor VIII-HCII, revealed an increase in procoagulant activity as measured in a one-stage clotting assay. Incubation of purified des-(868-1562)-factor VIII-HCII with different amounts of thrombin showed that this protein was more readily activated by thrombin when compared with des-(868-1562)-factor VIII, a control protein lacking amino acid sequence Ile(51)-Leu(80) of heparin cofactor II. This was manifested by an increase in the second order rate constant of activation by thrombin for des-(868-1562) factor VIII-HCII (12.0 +/- 0.48 x 10(6) M(-1) s(-1)) compared with des-(868-1562)-factor VIII (1.77 +/- 0.21 x 10(6) M(-1) s(-1)). Our data suggest that amino acid sequence Ile(51)-Leu(80) of heparin cofactor II endows factor VIII with increased sensitivity towards thrombin which results in accelerated clot formation.			Voorberg, J (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,PLESMANLAAN 125,NL-1066 CX AMSTERDAM,NETHERLANDS.			Voorberg, Jan/0000-0003-4585-2621				BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Davie EW, 1991, BIOCHEMISTRY-US, V30, P10364; DONATH MJS, 1995, THESIS U AMSTERDAM; DONATH MJSH, 1995, BIOCHEM J, V312, P49, DOI 10.1042/bj3120049; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FAY PJ, 1991, J BIOL CHEM, V266, P8957; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HORTIN GL, 1990, BIOCHEM BIOPH RES CO, V169, P437, DOI 10.1016/0006-291X(90)90350-V; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KANE WH, 1988, BLOOD, V71, P539; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LIU LW, 1991, J BIOL CHEM, V266, P16977; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; NEUENSCHWANDER P, 1990, ANAL BIOCHEM, V184, P347, DOI 10.1016/0003-2697(90)90692-3; PITMANN DD, 1988, P NATL ACAD SCI USA, V85, P2429; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SKRZYPCZAKJANKUN E, 1989, J MOL BIOL, V206, P755, DOI 10.1016/0022-2836(89)90582-2; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	30	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20985	20988		10.1074/jbc.271.35.20985	http://dx.doi.org/10.1074/jbc.271.35.20985			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702860	hybrid			2022-12-27	WOS:A1996VE47700004
J	Wolf, A; Lee, KC; Kirsch, JF; Ames, GFL				Wolf, A; Lee, KC; Kirsch, JF; Ames, GFL			Ligand-dependent conformational plasticity of the periplasmic histidine-binding protein HisJ - Involvement in transport specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MALTOSE-BINDING; RHODOBACTER-CAPSULATUS; MEMBRANE-COMPONENTS; GLUTAMATE RECEPTORS; CRYSTAL-STRUCTURE; ARGININE-BINDING	The periplasmic histidine permease of Salmonella typhimurium is composed of a membrane-bound complex and a soluble histidine-binding protein (the periplasmic receptor), HisJ. Liganded receptor interacts with the membrane-bound complex, inducing ATP hydrolysis and substrate translocation. Preliminary evidence had shown a lack of direct correlation between the affinity of HisJ for a ligand and translocation efficiency, suggesting that the precise form of the receptor is important in determining its interaction with the membrane-bound complex. We have investigated the nature of the conformations assumed by HisJ upon binding a variety of ligands by tryptophan fluorescence enhancement, reaction with a closed form-specific monoclonal antibody, and changes in UV absorption spectra. It is demonstrated that although HisJ binds all the ligands and undergoes a conformational change, it assumes measurably different conformations. We also show that the interaction between HisJ and the membrane-bound complex depends on the nature of the ligand. Transport specificity appears to be defined, at least in part, by the conformation of the bound receptor, manifested either by the effect of a given ligand on the closed structure per se, or by the effect of ligand association on the equilibrium constant relating the open and the closed liganded forms.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NIGMS NIH HHS [GM35393] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035393] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES GFL, 1972, J BIOL CHEM, V247, P4309; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1977, J BACTERIOL, V129, P1289, DOI 10.1128/JB.129.3.1289-1297.1977; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DUNTEN P, 1995, PROTEIN SCI, V4, P2327, DOI 10.1002/pro.5560041110; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FLOCCO MM, 1995, PROTEIN SCI, V4, P2118, DOI 10.1002/pro.5560041017; FRIGUET B, 1990, IMMUNOCHEMICAL ANAL, P287; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; KANG CH, 1991, J BIOL CHEM, V266, P23893; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LEVER JE, 1972, J BIOL CHEM, V247, P4317; LEVER JE, 1972, ANAL BIOCHEM, V50, P73, DOI 10.1016/0003-2697(72)90487-3; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MARTINEAU P, 1990, J MOL BIOL, V214, P337, DOI 10.1016/0022-2836(90)90165-I; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OH BH, 1994, J BIOL CHEM, V269, P26323; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PAYNE GM, 1985, MOL GEN GENET, V200, P493, DOI 10.1007/BF00425737; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHIFRIN S, 1966, J BIOL CHEM, V241, P3424; SHUMAN HA, 1993, J BIOENERG BIOMEMBR, V25, P613; SPEISER DM, 1989, THESIS U CALIFORNIA; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; TRAKHANOV SD, 1989, J MOL BIOL, V207, P847, DOI 10.1016/0022-2836(89)90253-2; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TWYMAN RE, 1995, NEURON, V14, P755, DOI 10.1016/0896-6273(95)90219-8; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549; ZUKIN RS, 1986, BIOPHYS J, V49, P1229, DOI 10.1016/S0006-3495(86)83752-3	65	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21243	21250		10.1074/jbc.271.35.21243	http://dx.doi.org/10.1074/jbc.271.35.21243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702898	hybrid			2022-12-27	WOS:A1996VE47700044
J	Jackowski, S				Jackowski, S			Cell cycle regulation of membrane phospholipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE-C; SWISS 3T3 CELLS; MITOGENIC SIGNAL-TRANSDUCTION; STIMULATING FACTOR-I; HAMSTER OVARY CELLS; GROWTH-FACTOR; NUCLEAR-ENVELOPE; TERMINAL DOMAIN; DNA-SYNTHESIS		UNIV TENNESSEE, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO M, 1994, J BIOL CHEM, V269, P12360; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BERGERON JJ, 1970, BIOCHEM J, V119, P489, DOI 10.1042/bj1190489; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; CONNER GE, 1980, BIOCHEMISTRY-US, V19, P277, DOI 10.1021/bi00543a005; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; CORNELL RB, 1980, J CELL BIOL, V86, P810, DOI 10.1083/jcb.86.3.810; COTTRELL SF, 1981, J BIOL CHEM, V256, P973; CUNNINGHAM DD, 1972, J BIOL CHEM, V247, P2464; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DUBOIS C, 1978, BIOCHIMIE, V60, P1307; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FIELDS AP, 1990, J CELL SCI, V96, P107; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GROSS G, 1988, BIOCHIM BIOPHYS ACTA, V962, P220, DOI 10.1016/0005-2760(88)90163-4; HABENICHT AJR, 1985, J BIOL CHEM, V260, P1370; HATTEN ME, 1977, EXP CELL RES, V107, P31, DOI 10.1016/0014-4827(77)90382-2; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Houweling M, 1996, EUR J CELL BIOL, V69, P55; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KONDO T, 1992, J BIOL CHEM, V267, P23609; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MARALDI NM, 1993, J CELL SCI, V104, P853; MARALDI NM, 1992, ADV ENZYME REGUL, V32, P73; Martelli AM, 1996, BIOCHEM BIOPH RES CO, V218, P182, DOI 10.1006/bbrc.1996.0032; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MARUTA H, 1975, J CELL BIOL, V65, P631, DOI 10.1083/jcb.65.3.631; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; ONEILL EA, 1987, J BACTERIOL, V169, P2618, DOI 10.1128/jb.169.6.2618-2623.1987; PASTERNA.CA, 1972, J CELL BIOL, V53, P231, DOI 10.1083/jcb.53.1.231; PASTERNAK CA, 1970, BIOCHEM J, V119, P473, DOI 10.1042/bj1190473; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RISTOW HJ, 1973, Z NATURFORSCH C, VC 28, P188; ROBBINS E, 1966, CELL SYNCHRONY, P353; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHIAO YJ, 1995, BIOCHEM J, V310, P673, DOI 10.1042/bj3100673; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; TERCE F, 1994, J LIPID RES, V35, P2130; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WARDEN CH, 1980, BIOCHEM BIOPH RES CO, V94, P690, DOI 10.1016/0006-291X(80)91287-5; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; Wieprecht M, 1996, J BIOL CHEM, V271, P9955, DOI 10.1074/jbc.271.17.9955; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; YORK JD, 1994, J BIOL CHEM, V269, P19992; YORK JD, 1994, J BIOL CHEM, V269, P7847	67	188	194	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20219	20222		10.1074/jbc.271.34.20219	http://dx.doi.org/10.1074/jbc.271.34.20219			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702749	hybrid			2022-12-27	WOS:A1996VD33700001
J	Pellizzari, R; Rossetto, O; Lozzi, L; Giovedi, S; Johnson, E; Shone, CC; Montecucco, C				Pellizzari, R; Rossetto, O; Lozzi, L; Giovedi, S; Johnson, E; Shone, CC; Montecucco, C			Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS; PROTEOLYTIC CLEAVAGE; SEROTYPE-A; IN-VITRO; PROTEIN; TOXIN; TRANSPORT; FUSION; VAMP/SYNAPTOBREVIN	Tetanus and botulinum neurotoxins type B and G are zinc-endopeptidases of remarkable specificity. They recognize and cleave a synaptic vesicle-associated membrane protein (VAMP)/synaptobrevin, an essential protein component of the vesicle docking and fusion apparatus. VAMP contains two copies of a nine-residue motif, also present in SNAP-25 (synaptosomal-associated protein of 25 kDa) and syntaxin, the two other substrates of clostridial neurotoxins. This motif was suggested to be a determinant of the target specificity of neurotoxins. Antibodies raised against this motif cross-react among VAMP, SNAP-25, and syntaxin and inhibit the proteolytic activity of the neurotoxins. Moreover; the various neurotoxins cross-inhibit each other's proteolytic action. The role of the three negatively charged residues of the motif in neurotoxin recognition was probed by site-directed mutagenesis. Substitution of acidic residues in both copies of the VAMP motif indicate that the first one is involved in tetanus neurotoxin recognition, whereas the second one is implicated in binding botulinum B and G neurotoxins. These results suggest that the two copies of the motif have a tandem association in the VAMP molecule.	UNIV PADUA,CTR CONSIGLIO NAZL RIC BIOMEMBRANE,I-35100 PADUA,ITALY; UNIV SIENA,DIPARTIMENTO BIOL MOL,SIENA,ITALY; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,SALISBURY SP4 0JG,WILTS,ENGLAND	University of Padua; University of Siena; University of Wisconsin System; University of Wisconsin Madison	Pellizzari, R (corresponding author), UNIV PADUA,DIPARTIMENTO SCI BIOMED,VIA TRIESTE 75,I-35100 PADUA,ITALY.		Lozzi, Luisa/Q-8542-2018; rossetto, ornella/AAC-3866-2022; Giovedì, Silvia/AAB-7614-2019	Lozzi, Luisa/0000-0002-1603-8770; rossetto, ornella/0000-0002-6113-3857; GIOVEDI', SILVIA/0000-0001-7949-4274	Telethon [763] Funding Source: Medline	Telethon(Fondazione Telethon)		BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CORNILLE F, 1994, EUR J BIOCHEM, V222, P173, DOI 10.1111/j.1432-1033.1994.tb18855.x; DasGupta B. R., 1994, THERAPY BOTULINUM TO, P15; DENTE L, 1987, METHOD ENZYMOL, V155, P111; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; EFFERINK LA, 1989, J BIOL CHEM, V264, P11061; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; FORAN P, 1994, BIOCHEMISTRY-US, V33, P15365, DOI 10.1021/bi00255a017; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBEDA FJ, 1994, PROTEINS, V20, P293, DOI 10.1002/prot.340200402; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROSSETTO O, 1992, BIOCHEM J, V285, P9, DOI 10.1042/bj2850009; ROSSETTO O, 1995, J PHYSIOLOGY-PARIS, V89, P43, DOI 10.1016/0928-4257(96)80550-X; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1995, METHOD ENZYMOL, V248, P643; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SCHIAVO G, 1991, EUR J BIOCHEM, V199, P705, DOI 10.1111/j.1432-1033.1991.tb16174.x; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; SHONE CC, 1994, EUR J BIOCHEM, V225, P263, DOI 10.1111/j.1432-1033.1994.00263.x; SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x; Shone CC, 1995, CURR TOP MICROBIOL, V195, P143; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; [No title captured]	44	92	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20353	20358		10.1074/jbc.271.34.20353	http://dx.doi.org/10.1074/jbc.271.34.20353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702770	hybrid, Green Published			2022-12-27	WOS:A1996VD33700022
J	Saint, N; Lou, KL; Widmer, C; Luckey, M; Schirmer, T; Rosenbusch, JP				Saint, N; Lou, KL; Widmer, C; Luckey, M; Schirmer, T; Rosenbusch, JP			Structural and functional characterization of OmpF porin mutants selected for larger pore size .2. Functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI OUTER-MEMBRANE; ESCHERICHIA-COLI; CHANNELS; PROTEIN; SELECTIVITY; DIFFUSION; BACTERIA	The effects on the channel characteristics of four single amino acid substitutions in OmpF porin and of a deletion mutant in the constriction loop L3 have been studied. These mutations are all located in the narrow section of the channel of the protein that forms pores across the outer membrane of Escherichia coli, The single channel conductance of the deletion mutant (Delta 109-114) is decreased by one third, whereas the point mutations do not exhibit significant deviations from that of the wild-type protein. The mutants exhibit drastic changes in ion selectivities. In the wild-type protein, the critical threshold potential (V-c), above which channels close reversibly, exhibits a strong pH dependence, with a titration point of similar to pH 7.7, which is abolished in all mutants studied here. Diffusion of six monosaccharides is little affected in the point mutants, while four disaccharides are taken up at highly increased rates by the deletion mutant. The functional results, presented here, are correlated to the x-ray structures of the mutants (Leu, K.-L., Saint, N., Prilipov, A, Rummel, G., Benson, S.A., Rosenbusch, J.P., and Schirmer, T. (1998) J. Biol. Chem. 271, 20669-20675). in most, but not all, cases, the structural changes explain the functional alterations observed.	UNIV BASEL, BIOZENTRUM, DEPT MICROBIOL, CH-4056 BASEL, SWITZERLAND; UNIV BASEL, BIOZENTRUM, DEPT BIOL STRUCT, CH-4056 BASEL, SWITZERLAND; SAN FRANCISCO STATE UNIV, DEPT CHEM & BIOCHEM, SAN FRANCISCO, CA 94132 USA	University of Basel; University of Basel; California State University System; San Francisco State University			Saint, Nathalie/S-5286-2016	Saint, Nathalie/0000-0001-5219-9486				BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BUEHLER LK, 1991, J BIOL CHEM, V266, P24446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1987, FEBS LETT, V220, P136, DOI 10.1016/0014-5793(87)80891-8; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; EISENBERG RS, 1995, J CHEM PHYS, V102, P1767, DOI 10.1063/1.468704; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; KARSHIKOFF A, 1994, J MOL BIOL, V240, P372, DOI 10.1006/jmbi.1994.1451; Lou KL, 1996, J BIOL CHEM, V271, P20669, DOI 10.1074/jbc.271.34.20669; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; Saint N, 1996, BIOCHEM BIOPH RES CO, V223, P118, DOI 10.1006/bbrc.1996.0855; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SCHINDLER H, 1981, P NATL ACAD SCI-BIOL, V78, P2302, DOI 10.1073/pnas.78.4.2302; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SCHIRMER T, 1995, SCIENCE, V264, P914; STEIERT M, 1993, THESIS U BASEL BASEL; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10479, DOI 10.1021/bi00158a010	25	169	175	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20676	20680		10.1074/jbc.271.34.20676	http://dx.doi.org/10.1074/jbc.271.34.20676			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702817	hybrid			2022-12-27	WOS:A1996VD33700069
J	Murthy, YVSN; Massey, V				Murthy, YVSN; Massey, V			F-19 NMR studies with 2'-F-2'-deoxyarabinoflavoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; NUCLEAR MAGNETIC-RESONANCE; FLAVIN MONONUCLEOTIDES; FLAVOPROTEINS; RESOLUTION; BINDING; LIGAND; SITE; FORM	Apoproteins of several flavoproteins were reconstituted with 2'-F-2'-deoxyarabinoflavins and studied by F-19 NMR and absorption spectroscopy. Extensive protein-fluorine interactions were observed by large chemical shift changes on binding to the apoprotein of Old Yellow Enzyme (apoOYE) and apoflavodoxin, whereas binding to apoglucose oxidase and apo D-amino acid oxidase (apoDAAO) resulted in minimal interactions. Modification at the flavin 2'-position in OYE resulted in a substantial decrease in the binding affinity of the flavin, possibly from the disruption of two important hydrogen bonds to Pro-35 and Arg-243. F-19 NMR studies of complexes of OYE with testosterone, cyclohexenone, and beta-estradiol suggest that phenols and alpha,beta-unsaturated ketones orient differently at the active site on binding. The two separate one-electron potentials for the EFl(ox)/EFl(sq) and EFl(sq)/EFl(red) couples were different for the reconstituted OYE. With native enzyme, there is 15-20% thermodynamic stabilization of the anionic flavin semiquinone, while no detectable amount of semiquinone was observed with modified OYE. This change in potential was further substantiated by blue shifts for the maxima of the modified protein-phenol charge transfer complexes. In accordance with the crystal structure of the OYE-p-OH-benzaldehyde complex (Fox, K.M. & Karplus, P.A. (1994) Structure 2, 1089-1105), F-19 NMR studies with the modified OYE-2,4-F-2-phenol suggest strong interaction between the para-fluorine of the phenol and Tyr-375.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; BEINERT WD, 1985, EUR J BIOCHEM, V152, P573, DOI 10.1111/j.1432-1033.1985.tb09234.x; BEINERT WD, 1985, EUR J BIOCHEM, V152, P581, DOI 10.1111/j.1432-1033.1985.tb09235.x; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Fox KM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P381; GHISLA S, 1986, BIOCHEM J, V239, P1; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GREIG JP, 1978, BIOL MAGN RESON, V1, P139; JARDETZKY O, 1981, NMR MOL BIOL, P52; LINDON JC, 1980, PROG NUCL MAG RES SP, V14, P27, DOI 10.1016/0079-6565(80)80002-1; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Massey V, 1994, FLAVINS AND FLAVOPROTEINS 1993, P371; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MATTHEWS RG, 1975, J BIOL CHEM, V250, P9294; MAYER EJ, 1981, ANAL BIOCHEM, V116, P227, DOI 10.1016/0003-2697(81)90348-1; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; MAYHEW SG, 1969, J BIOL CHEM, V244, P794; MILLER SM, 1995, BIOCHEMISTRY-US, V34, P13066, DOI 10.1021/bi00040a018; MURTHY YVSN, 1995, J BIOL CHEM, V270, P28586, DOI 10.1074/jbc.270.48.28586; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; SCHOPFER LM, 1990, STUDY ENZYMES, P247; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; Sykes B D, 1978, Methods Enzymol, V49, P270; SYKES BD, 1980, MAGNETIC RESONANCE B, V1, P171; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; YAGI K, 1992, BIOCHIM BIOPHYS ACTA, V56, P413; [No title captured]	34	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19915	19921		10.1074/jbc.271.33.19915	http://dx.doi.org/10.1074/jbc.271.33.19915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702705	hybrid			2022-12-27	WOS:A1996VC66900046
J	Walker, WH; Girardet, C; Habener, JF				Walker, WH; Girardet, C; Habener, JF			Alternative exon splicing controls a translational switch from activator to repressor isoforms of transcription factor CREB during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN CREB; MESSENGER-RNAS; GENE; ADENOSINE-3',5'-MONOPHOSPHATE; EXPRESSION; CELLS; INITIATION; CONTAINS; ELEMENTS; ENHANCER	The cAMP/protein kinase A signaling pathway activates the cAMP-responsive transcription factor CREB. Here we describe a unique alternative RNA splicing event that occurs during the development of germ cells in the testis, resulting in a translational switch from an mRNA encoding activator CREB to an mRNA encoding novel inhibitor CREB isoforms (I-CREBs). Alternative splicing of an additional exon into the CREB mRNA in mid to late pachytene spermatocytes results in the premature termination of translation and consequent downstream reinitiation of translation producing I-CREBs, The I-CREBs down-regulate cAMP activated gene expression by inhibiting activator CREB from binding to cAMP response elements. Further, the developmental stage-specific expression of I-CREBs in germ cells of the seminiferous tubules correlates with the cyclical down-regulation of activator CREB, suggesting that I-CREBs repress expression of the cAMP-inducible CREB gene as well as other genes transiently induced by cAMP during the 12-day cycle of spermatogenesis.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,LAB MOL ENDOCRINOL,BOSTON,MA 02114; CTR MED UNIV GENEVA,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; University of Geneva					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025532] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; Girardet C, 1996, MOL ENDOCRINOL, V10, P879, DOI 10.1210/me.10.7.879; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONOCO L, 1995, P NATL ACAD SCI USA, V92, P10673; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; WAEBER G, 1992, ENDOCRINOLOGY, V131, P2010, DOI 10.1210/en.131.4.2010; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALKER WH, 1995, ENDOCRINOLOGY, V136, P3534, DOI 10.1210/en.136.8.3534; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423	24	67	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20145	20150						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702738	hybrid			2022-12-27	WOS:A1996VC66900079
J	Sechi, S; Roller, PP; WilletteBrown, J; Kinet, JP				Sechi, S; Roller, PP; WilletteBrown, J; Kinet, JP			A conformational rearrangement upon binding of IgE to its high affinity receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BOUND IMMUNOGLOBULIN-E; ALPHA-CHAIN; MAST-CELLS; CIRCULAR-DICHROISM; MEMBRANE-SURFACE; SITE; PROTEIN; COMPLEX; DOMAIN	One of the critical steps in the allergic reaction is the binding of immunoglobulin E (IgE) to its high affinity receptor (Fc epsilon RI), Fc epsilon RI is a tetrameric complex composed of an a chain, a beta-chain, and a dimeric gamma-chain. The extracellular paction of the alpha-chain (alpha-t) is sufficient for the binding of IgE. The Fe portion of IgE contains two copies of the Fc epsilon RI binding sites, In contrast, the binding stoichiometry is 1:1, Previously, it was hypothesized that the binding of Fc epsilon EI to IgE results in a conformational change ill IgE that precludes the binding of a second molecule (Presta, L., Shields, R., O'Connel, L., Lahr, S., Porter, J., German, C., and Jardieu, P. (1994) J. Biol. Chem. 269, 26568-26313), Here we characterize the secondary structure of IgE and alpha-t and analyze their interaction by circular dichroism spectroscopy, Binding experiments show that when IgE interacts with alpha-t there is a 15-26% decrease of the negative ellipticity at 217 nm, Together, the absence of all alpha-helix element in alpha-t and the small contribution of alpha-t to the spectra of the complex indicate that upon binding, a major conformational rearrangement must occur oil IgE, In addition, we analyze the thermal unfolding of alpha-t, IgE, and their complex. Despite the several domains that constitute IgE and alpha-t. these molecules unfold cooperatively with two-state kinetics.	NIAID,MOL ALLERGY & IMMUNOL SECT,NIH,ROCKVILLE,MD 20852; NCI,DIV BASIC SCI,MED CHEM LAB,NIH,BETHESDA,MD 20892; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School								ARGOS P, 1989, PROTEIN STRUCTURE PR, P169; ATTANASIO R, 1994, J BIOL CHEM, V269, P1834; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BASU M, 1993, J BIOL CHEM, V268, P13118; BLANK U, 1991, J BIOL CHEM, V266, P2639; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CASSIM JY, 1969, BIOCHEMISTRY-US, V8, P1947, DOI 10.1021/bi00833a026; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORRINGTON KJ, 1978, IMMUNOL REV, V41, P3, DOI 10.1111/j.1600-065X.1978.tb01458.x; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HOLOWKA D, 1985, BIOCHEMISTRY-US, V24, P6260, DOI 10.1021/bi00343a033; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3475, DOI 10.1021/bi00283a026; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; HULLET MD, 1994, ADV IMMUNOLOGY; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; KEOWN MB, 1995, P NATL ACAD SCI USA, V92, P1841, DOI 10.1073/pnas.92.6.1841; KOCHWA S, 1971, ANN NY ACAD SCI, V190, P49, DOI 10.1111/j.1749-6632.1971.tb13523.x; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; OGRADY JH, 1986, J IMMUNOL, V137, P2307; ORTEGA E, 1991, BIOCHEMISTRY-US, V30, P3473, DOI 10.1021/bi00228a018; PADLAN EA, 1986, MOL IMMUNOL, V23, P1063, DOI 10.1016/0161-5890(86)90005-2; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; WOODY WR, 1995, METHOD ENZYMOL, V260, P34; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	43	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19256	19263		10.1074/jbc.271.32.19256	http://dx.doi.org/10.1074/jbc.271.32.19256			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702607	hybrid			2022-12-27	WOS:A1996VB68400041
J	Cavenagh, MM; Whitney, JA; Carroll, K; Zhang, CJ; Boman, AL; Rosenwald, AG; Mellman, I; Kahn, RA				Cavenagh, MM; Whitney, JA; Carroll, K; Zhang, CJ; Boman, AL; Rosenwald, AG; Mellman, I; Kahn, RA			Intracellular distribution of Arf proteins in mammalian cells - Arf6 is uniquely localized to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; GOLGI MEMBRANES; BREFELDIN-A; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; SACCHAROMYCES-CEREVISIAE; COAT PROTEINS; CHOLERA-TOXIN; BETA-COP	Subcellular distributions of the five human Arf proteins were examined, using a set of isoform-specific polyclonal and a pan-Arf monoclonal antibodies. Subcellular fractionation of cultured mammalian cells allowed the demonstration that Arf6 is uniquely localized to the plasma membranes of Chinese hamster ovary cells, The plasma membrane distrubution was unaffected by either GTP gamma S (guanosine 5'-O-(3-thio)triphosphate) or brefeldin A, an activator and inhibitor of Arf activities, respectively. In contrast, Arf proteins 1, 3, 4, and 5 were predominantly cytosolic but could be recruited to a variety of intracellular membranes, but not plasma membranes, upon incubation in the presence of GTP gamma S. The GTP gamma S-promoted binding of the cytosolic Arf proteins to membranes was blocked by brefeldin A. The stable association of Arf6 with plasma membranes and the insensitivity of its localization to either GTP gamma S or brefeldin A revealed a clear distinction between Arf6 and the other Arf isoforms. Localization of Arf6 to the plasma membrane suggests a unique cellular role for this isoform at the plasma membrane, but failure to find endogenous Arf6 on endocytic structures, including clathrin-coated vesicles, appears inconsistent with the proposed role of Arf6 in assembly of coat structures or endosomes in transfected fibroblasts (1, 2).	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Emory University; Yale University			Kahn, Richard/ABD-2666-2020; Mellman, Ira/ABG-5896-2020	Kahn, Richard/0000-0002-0259-0601; 				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; Harlow E., 1988, ANTIBODIES LAB MANUA; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9556; RANDAZZO PA, 1994, METHOD ENZYMOL, V250, P394; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1993, J BIOL CHEM, V268, P10820; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITNEY JA, 1995, CELL, V83, P703; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	57	200	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21767	21774		10.1074/jbc.271.36.21767	http://dx.doi.org/10.1074/jbc.271.36.21767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702973	hybrid			2022-12-27	WOS:A1996VF61200015
J	Izard, JW; Rusch, SL; Kendall, DA				Izard, JW; Rusch, SL; Kendall, DA			The amino-terminal charge and core region hydrophobicity interdependently contribute to the function of signal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PEPTIDE HYDROPHOBICITY; POSITIVE CHARGE; SECA; TRANSPORT; RESIDUES; CLEAVAGE; EXPORT	We have constructed a series of signal sequence mutants that contain negatively charged amino termini and simplified core regions of varying hydrophobicity levels. This series provides a means of exploring the relative roles of the amino terminus and the hydrophobic core region during transport. The signal peptides with highly hydrophobic core regions support a rapid rate of transport in the presence of a negatively charged amino terminus. We have found that these negatively charged mutants are secreted in a manner similar to the wild-type signal sequence; sodium azide and carbonyl cyanide 3-chlorophenylhydrazone treatments indicate that the negatively charged mutants depend on SecA and the protonmotive force, respectively. These same mutants also demonstrate reduced competition with co-expressed beta-lactamase, reflecting the lower overall affinity for the transport pathway due to the net negative charge at the amino terminus. In addition, the pronounced effects of introducing three negative charges support the conclusion that the two regions function in a concerted manner.	UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06269	University of Connecticut					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; AUSTEN BM, 1979, FEBS LETT, V103, P308, DOI 10.1016/0014-5793(79)81351-4; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHEN M, 1994, J BACTERIOL, V176, P5796, DOI 10.1128/JB.176.18.5796-5801.1994; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; ERNST F, 1994, J BIOL CHEM, V269, P12840; GELLER BL, 1991, MOL MICROBIOL, V5, P2093, DOI 10.1111/j.1365-2958.1991.tb02138.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HIKITA C, 1992, J BIOL CHEM, V267, P12375; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; IZARD JW, 1995, BIOCHEMISTRY-US, V34, P9904, DOI 10.1021/bi00031a012; Keller RCA, 1996, BIOCHEMISTRY-US, V35, P3063, DOI 10.1021/bi951870+; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; Miller J.H., 1972, EXPT MOL GENETICS; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7	29	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21579	21582		10.1074/jbc.271.35.21579	http://dx.doi.org/10.1074/jbc.271.35.21579			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702945	hybrid			2022-12-27	WOS:A1996VE47700091
J	Sukhan, A; Hancock, REW				Sukhan, A; Hancock, REW			The role of specific lysine residues in the passage of anions through the Pseudomonas aeruginosa porin OprP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-12 OUTER-MEMBRANE; ESCHERICHIA-COLI; PROTEIN-P; MUTAGENESIS; MALTOPORIN; CHANNELS; PHOE; RESOLUTION; DOMAINS; SITE	When grown under phosphate-limiting conditions Pseudomonas aeruginosa expresses the phosphate-specific porin OprP. In order to determine whether any of the lysine residues located in the amino-terminal half of the protein play a role in the transport of anions through the channels, the first nine amino-terminal lysine residues of OprP were substituted with glutamates. The mutant proteins were purified and the channels they formed were characterized by reconstituting the purified porins in planar lipid membranes. In comparison to the wild-type protein, the Lys(74), Lys(121), and Lys(126) mutants all displayed reduced levels of conductance at KCl concentrations below 1 M, and the Lys(74) and Lys(121) mutants no longer exhibited a saturation of conductance at high anion concentrations. In addition, the ability of phosphate ions to inhibit the conductance of Cl- ions through the channels formed by the Lys(121) mutant was greatly reduced, while their ability to inhibit the Cl- conductance of the Lys(74) mutant was reduced by approximately a fold. To clarify the roles that Lys(74), Lys(121), and Lys(126) play in regulating the channel characteristics of OprP, these amino acids were replaced with either glycine or glutamine residues. Analysis of these mutants suggested that both Lys(74) and Lys(126) may serve to funnel anions toward the binding site, but only the presence of Lys(121) is required for the formation of the inorganic phosphate-specific binding site of OprP.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia			Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENZ R, 1983, BIOCHIM BIOPHYS ACTA, V730, P387, DOI 10.1016/0005-2736(83)90356-5; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1988, J MOL BIOL, V201, P497, DOI 10.1016/0022-2836(88)90632-8; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; HANCOCK REW, 1982, J BACTERIOL, V150, P730, DOI 10.1128/JB.150.2.730-738.1982; HANCOCK REW, 1986, BIOCHIM BIOPHYS ACTA, V860, P699, DOI 10.1016/0005-2736(86)90569-9; HANCOCK REW, 1983, BIOCHIM BIOPHYS ACTA, V735, P137, DOI 10.1016/0005-2736(83)90269-9; HEINE HG, 1988, J BACTERIOL, V170, P1730, DOI 10.1128/jb.170.4.1730-1738.1988; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SUKHAN A, 1995, J BACTERIOL, V177, P4914, DOI 10.1128/jb.177.17.4914-4920.1995; TOMMASSEN J, 1985, EMBO J, V4, P1583, DOI 10.1002/j.1460-2075.1985.tb03820.x; TOMMASSEN J, 1984, MOL GEN GENET, V197, P503, DOI 10.1007/BF00329950; VANDERLEY P, 1985, EUR J BIOCHEM, V147, P401; WANNER BL, 1980, GENETICS, V96, P353; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; YOUNG M, 1992, ANTIMICROB AGENTS CH, V36, P2365, DOI 10.1128/AAC.36.11.2365	21	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21239	21242		10.1074/jbc.271.35.21239	http://dx.doi.org/10.1074/jbc.271.35.21239			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702897	hybrid			2022-12-27	WOS:A1996VE47700043
J	Xu, M; Chakraborti, PK; Garabedian, MJ; Yamamoto, KR; Simons, SS				Xu, M; Chakraborti, PK; Garabedian, MJ; Yamamoto, KR; Simons, SS			Modular structure of glucocorticoid receptor domains is not equivalent to functional independence - Stability and activity of the steroid binding domain are controlled by sequences in separate domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HEAT-SHOCK PROTEIN-90; DNA-BINDING; NUCLEAR RECEPTOR; TRANSCRIPTIONAL REGULATION; TYROSINE AMINOTRANSFERASE; CRYSTAL-STRUCTURE; FUSION PROTEINS; GENE-REGULATION; HSP90 BINDING	A long-standing conundrum of glucocorticoid receptors has been why the steroid binding domain is active in hybrid proteins but not in isolation, For this reason, the precise boundaries of the steroid binding domain have not been de fined. These questions have How been systematically examined with a variety of receptor deletion constructs, Plasmids encoding amino acids 537-673 and 537-795 of the rat receptor did not yield stable proteins, while the fusion of receptor or non-receptor sequences upstream of 537-673 afforded stable proteins that did not bind steroid, Wild type steroid binding affinity could be obtained, however, when proteins such as beta-galactosidase or dihydrofolate reductase were fused upstream of receptor amino acids 531-795, Studies of a series of dhfr/receptor constructs with deletions at the amino- and carboxyl-terminal ends of the receptor sequence localized the boundaries of the steroid binding domain to 550-795, The absence of steroid binding upon deletion of sequences in the carboxyl-terminal half of this domain was consistent with improperly folded receptor sequences. This conclusion was supported by analyses of the proteolysis and thermal stability of the mutant receptors, Thus, three independent regions appear to be required for the generation of the steroid binding form of receptors: 1) a protein sequence upstream of the steroid binding domain, which conveys stability to the steroid binding domain, 2) sequences of the carboxyl-terminal amino acids (674-795), which are required far the correct folding of the steroid binding domain, and 3) amino-terminal sequences (550-673), which may be sufficient for steroid binding after the entire steroid binding domain is properly folded. These results establish that the steroid binding domain of glucocorticoid receptors is not independently functional and illustrate the importance of both protein stability and protein folding when constructing mutant proteins.	NIDDK,STEROID HORMONES SECT,LMCB,NATL INST HLTH,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco				xu, ming/0000-0002-3920-8947				ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BANIAHMAD C, 1991, J MOL BIOL, V222, P155, DOI 10.1016/0022-2836(91)90202-H; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EYLES SJ, 1994, BIOCHEMISTRY-US, V33, P13038, DOI 10.1021/bi00248a013; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; ISRAEL DI, 1993, P NATL ACAD SCI USA, V90, P4290, DOI 10.1073/pnas.90.9.4290; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KIPPEN AD, 1995, BIOCHEMISTRY-US, V34, P1464, DOI 10.1021/bi00004a042; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIYASHITA Y, 1993, J STEROID BIOCHEM, V46, P309, DOI 10.1016/0960-0760(93)90220-Q; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; OPOKU J, 1994, J BIOL CHEM, V269, P503; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1994, VITAM HORM, V49, P49; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; STELLWAGEN RH, 1992, J BIOL CHEM, V267, P23713; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; THOLE HH, 1994, BIOCHEM BIOPH RES CO, V199, P826, DOI 10.1006/bbrc.1994.1303; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WRANGE O, 1978, J BIOL CHEM, V253, P856; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	79	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21430	21438		10.1074/jbc.271.35.21430	http://dx.doi.org/10.1074/jbc.271.35.21430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702925	hybrid			2022-12-27	WOS:A1996VE47700071
J	Ames, RS; Li, Y; Sarau, HM; Nuthulaganti, P; Foley, JJ; Ellis, C; Zeng, ZZ; Su, K; Jurewicz, AJ; Hertzberg, RP; Bergsma, DJ; Kumar, C				Ames, RS; Li, Y; Sarau, HM; Nuthulaganti, P; Foley, JJ; Ellis, C; Zeng, ZZ; Su, K; Jurewicz, AJ; Hertzberg, RP; Bergsma, DJ; Kumar, C			Molecular cloning and characterization of the human anaphylatoxin C3a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; C5A ANAPHYLATOXIN; CELL-LINE; SEQUENCE; RESPONSES; BINDING	In a human neutrophil cDNA library, an orphan G-protein-coupled receptor, HNFAG09, with 37% nucleotide identity to the C5a receptor (C5a-R, CD88) was identified. A novel feature of this gene, unlike C5a-R and other G-protein-coupled receptors, is the presence of an extraordinarily large predicted extracellular loop comprised of in excess of 160 amino acid residues between transmembrane domains 4 and 5. Northern blot analysis revealed that expression of mRNA for this receptor in human tissues, while similar, was distinct from C5a-R expression. Although there were differences in expression, transcripts for both receptors were detected in tissues throughout the body and the central nervous system. Mammalian cells stably expressing HNFAG09 specifically bound I-125-C3a and responded to a C3a carboxyl-terminal analogue synthetic peptide and to human C3a but not to rC5a with a robust calcium mobilization response. HNFAG09 encodes the human anaphylatoxin C3a receptor.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOL DISCOVERY,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PULMONOL PHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Ames, RS (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL UE0548,709 SWEDELAND RD,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KLOS A, 1992, BIOCHEMISTRY-US, V31, P11274, DOI 10.1021/bi00161a003; MORGAN BP, 1994, EUR J CLIN INVEST, V24, P219, DOI 10.1111/j.1365-2362.1994.tb01078.x; MURAKAMI Y, 1993, IMMUNOL LETT, V36, P301, DOI 10.1016/0165-2478(93)90104-A; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; RITTERSUERMANN D, 1988, COMPLEMENT SYSTEM, P367; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; SAUSSY DL, 1989, J BIOL CHEM, V264, P19845; SIRAGANIAN RP, 1982, FED PROC, V41, P30; VOGT W, 1986, Complement, V3, P177; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	21	201	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20231	20234		10.1074/jbc.271.34.20231	http://dx.doi.org/10.1074/jbc.271.34.20231			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702752	hybrid			2022-12-27	WOS:A1996VD33700004
J	Caplan, S; Baniyash, M				Caplan, S; Baniyash, M			Normal T cells express two T cell antigen receptor populations, one of which is linked to the cytoskeleton via zeta chain and displays a unique activation-dependent phosphorylation pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE MEMBRANE-PROTEINS; LIGAND-INDUCED ASSOCIATION; TYROSINE KINASE-ACTIVITY; CROSS-LINKING; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; CD3-ZETA CHAIN; ZAP-70; TCR; ANTIBODY	The TCR couples antigen recognition and the transmission of activation signals, We report the expression of two TCR populations on the surface of T lymphocytes, one of which is linked to the cytoskeleton via the zeta chain, We also demonstrate that assembly of the CD3 subunits with cytoskeleton associated zeta is necessary for their maximal localization to the cytoskeleton, The potential significance of these two receptor forms is underscored by differences observed in non-activated T cells; while detergent-soluble phosphorylated zeta appears as a 21-kDa protein, phosphorylated cytoskeleton-associated zeta appears as a 16-kDa form, This dichotomous phosphorylation pattern is rigidly maintained following activation, although each of the receptor populations undergoes different activation-dependent modifications: 1) levels of soluble phosphorylated 21-kDa zeta are enhanced, while phosphorylated 16-kDa cytoskeleton-associated zeta exhibits little change; 2) soluble non-phosphorylated 16-kDa zeta translocates to the cytoskeleton; 3) activation dependent ubiquitinated zeta forms localize to both fractions, albeit with different kinetics, We also show that the protein tyrosine kinase Lck undergoes activation-dependent modifications and translocates to the cytoskeleton, The phosphorylation profiles of the dichotomous TCR populations in both non-activated and activated lymphocytes suggest that each population could regulate distinct cellular functions, possibly by select intermolecular associations.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,LAUTENBERG CTR GEN & TUMOR IMMUNOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ALBRECHT DL, 1988, J IMMUNOL, V141, P3915; APGAR JR, 1990, J IMMUNOL, V145, P3814; AVNUR Z, 1983, J CELL BIOL, V96, P1622, DOI 10.1083/jcb.96.6.1622; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BRAUN J, 1982, J IMMUNOL, V128, P1198; CAPLAN S, 1995, IMMUNOL RES, V14, P98, DOI 10.1007/BF02918171; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; DEBELL KE, 1992, J IMMUNOL, V149, P2271; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GEPPERT TD, 1991, J IMMUNOL, V146, P3298; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2838, DOI 10.1210/en.133.6.2838; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOU D, 1994, J BIOL CHEM, V269, P14244; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MARANO N, 1989, J IMMUNOL, V143, P931; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; OFFRINGA R, 1993, J BIOL CHEM, V268, P4979; ONO S, 1995, IMMUNITY, V2, P639, DOI 10.1016/1074-7613(95)90008-X; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PARSEY MV, 1993, J IMMUNOL, V151, P1881; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; ROZDZIAL MM, 1995, IMMUNITY, V3, P323; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SALMERON A, 1995, J IMMUNOL, V154, P1675; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WODA BA, 1983, J IMMUNOL, V131, P1917; WODA BA, 1984, J IMMUNOL, V133, P2767	55	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20705	20712		10.1074/jbc.271.34.20705	http://dx.doi.org/10.1074/jbc.271.34.20705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702821	hybrid			2022-12-27	WOS:A1996VD33700073
J	Chandran, UR; Attardi, B; Friedman, R; Zheng, ZW; Roberts, JL; DeFranco, DB				Chandran, UR; Attardi, B; Friedman, R; Zheng, ZW; Roberts, JL; DeFranco, DB			Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL HYPOTHALAMIC-AMENORRHEA; PROTEIN-PROTEIN-INTERACTION; OCTAMER-BINDING PROTEINS; NEURON-SPECIFIC ENHANCER; TRANSCRIPTION FACTOR; CELL-LINES; POU DOMAIN; KINASE-C; LUTEINIZING-HORMONE; NEGATIVE REGULATION	We have identified two regions of the mouse gonadotropin-releasing hormone (GnRH) promoter, one between -237 and -201 (distal element) and the other between -184 and -150 (proximal element), which are required for glucocorticoid repression in transiently transfected GT1-7 cells. These sequences show no similarity to known positive or negative glucocorticoid response elements (nGREs) and do not function when placed upstream of heterologous viral promoters. The glucocorticoid receptor (GR) does not bind directly to the distal or proximal promoter elements but may participate in glucocorticoid repression of GdRH gene transcription by virtue of its association within multiprotein complexes at these nGREs. Electrophoretic mobility shift assays with GT1-7 nuclear extract demonstrate the presence of GR-containing protein complexes on GnRH nGREs. One protein that co-occupies the distal nGRE fn vitro along with GR is the POU domain transcription factor Oct-1. Thus, the tethering of Oh to the GnRH distal nGRE, by virtue of a direct or indirect association with DNA-bound Oct-1, could play a role in hormone-dependent transcriptional repression of the GnRH gene. In contrast, Oct-1 does not appear to be a component of the GR-containing protein complex that is bound to the proximal nGRE.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15261 USA; MT SINAI SCH MED, ARTHUR M FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047938] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK47938] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHIMA RS, 1992, NEUROENDOCRINOLOGY, V56, P845, DOI 10.1159/000126315; ATTARDI B, 1991, FOCUS, V13, P84; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BERGA SL, 1989, J CLIN ENDOCR METAB, V68, P301, DOI 10.1210/jcem-68-2-301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANN DW, 1991, BIOL REPROD, V44, P1005, DOI 10.1095/biolreprod44.6.1005; BRUDER JM, 1992, ENDOCRINOLOGY, V131, P2552, DOI 10.1210/en.131.6.2552; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHANDRAN UR, 1994, ENDOCRINOLOGY, V134, P1467, DOI 10.1210/en.134.3.1467; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; DELAESCALERA G, 1995, NEUROENDOCRINOLOGY, V61, P310, DOI 10.1159/000126853; DELAESCALERA GM, 1994, NEUROENDOCRINOLOGY, V59, P420, DOI 10.1159/000126687; DELAESCALERA GM, 1992, ENDOCRINOLOGY, V131, P1397; DELAESCALERA GM, 1992, ENDOCRINOLOGY, V131, P2965; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DUBEY AK, 1985, BIOL REPROD, V33, P423, DOI 10.1095/biolreprod33.2.423; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; KEPA JK, 1994, ENDOCRINE, V2, P947; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MORETTO M, 1993, ENDOCRINOLOGY, V133, P2399, DOI 10.1210/en.133.5.2399; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; PADMANABHAN V, 1983, ENDOCRINOLOGY, V112, P1782, DOI 10.1210/endo-112-5-1782; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; POMERANTZ JL, 1995, P NATL ACAD SCI USA, V92, P9752, DOI 10.1073/pnas.92.21.9752; REAME NE, 1985, J CLIN ENDOCR METAB, V61, P851, DOI 10.1210/jcem-61-5-851; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMBROOK J, 1982, MOL CLONING LAB MANU, P1; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; SUH BY, 1988, J CLIN ENDOCR METAB, V66, P733, DOI 10.1210/jcem-66-4-733; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WETSEL WC, 1993, ENDOCRINOLOGY, V132, P2360, DOI 10.1210/en.132.6.2360; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU KL, 1994, MOL CELL ENDOCRINOL, V102, P85, DOI 10.1016/0303-7207(94)90101-5	62	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20412	20420		10.1074/jbc.271.34.20412	http://dx.doi.org/10.1074/jbc.271.34.20412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702778	hybrid			2022-12-27	WOS:A1996VD33700030
J	Liapakis, G; Fitzpatrick, D; Hoeger, C; Rivier, J; Vandlen, R; Reisine, T				Liapakis, G; Fitzpatrick, D; Hoeger, C; Rivier, J; Vandlen, R; Reisine, T			Identification of ligand binding determinants in the somatostatin receptor subtypes 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-OPIOID RECEPTOR; TYROSINE PHOSPHATASE; CELL-PROLIFERATION; MOLECULAR-BIOLOGY; GASTRIC-ACID; ANALOGS; INHIBITION; CLONING; SSTR2; AFFINITY	The somatostatin (SRIF) receptors (SSTRs) 1 and 2 bind SRIF and SRIF 28 with high affinity, although a number of synthetic hexapeptide and octapeptide analogs of SRIF bind selectively to SSTR2. Extracellular loop three and its adjoining trans-membrane-spanning regions contain elements essential for the binding of such analogs to murine SSTR2. In particular, a stretch of amino acids from residues 294-297 (FDFV) in murine SSTR2 in trans membrane domain seven can determine affinity for the SSTR2-selective analogs. Within this region, Phe(294) has previously been predicted to be essential for the binding of octapeptides (Kaupmann, K., Bruns, C., Raulf, F., Weber, H., Mattes, H., and Lubbert, H. (1995) EMBO J. 14, 727-735) based on the observation that SSTR1 can bind the octapeptide SMS-201-995 with reasonable affinity after a Ser to-Phe conversion in the analogous region of this receptor (SSTR(1S305F)). We find that SSTR1(S305F) has low affinity for a number of SSTR2-selective hexapeptides, suggesting that these analogs have different binding requirements than SMS-201-995. A correlation is seen between the ability of SSTR1(S305F) to bind hexapeptide analogs and the presence of a phenylalanine, but not tyrosine, at position two in these small cyclic molecules. Thus, a single hydroxyl group in hexapeptides can play a critical role in determining re ceptor binding to these receptor mutants. We also find that the second extracellular loop of SSTR1 is important for the selectivity of certain SRIF agonists for binding to SSTR1. Taken together, our data indicate that there are multiple elements in the somatostatin receptors that can determine the binding affinity and selectivity of peptide analogs.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; GENENTECH INC,DEPT PROT CHEM,SAN FRANCISCO,CA 94080; SALK INST BIOL STUDIES,PEPTIDE BIOL LAB,LA JOLLA,CA 92037	University of Pennsylvania; Roche Holding; Genentech; Salk Institute					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048518] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45533, MH48518] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BLOOM SR, 1975, GUT, V16, P834; BRAZEAU P, 1972, SCIENCE, V129, P77; BROWN M, 1977, SCIENCE, V196, P1467, DOI 10.1126/science.867045; BROWN NJ, 1990, AM J MED SCI, V300, P267, DOI 10.1097/00000441-199010000-00011; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FONG TM, 1992, MOL PHARMACOL, V41, P24; GOMEZPAN A, 1975, LANCET, V1, P888; HELLMAN B, 1969, ENDOCRINOLOGY, V84, P1484, DOI 10.1210/endo-84-6-1484; HUANG ZW, 1992, J AM CHEM SOC, V114, P9390, DOI 10.1021/ja00050a019; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KUBOTA A, 1994, J CLIN INVEST, V93, P1321, DOI 10.1172/JCI117090; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MANDARINO L, 1981, NATURE, V291, P76, DOI 10.1038/291076a0; OCARROLL AM, 1994, MOL PHARMACOL, V46, P291; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; RAYNOR K, 1992, CRIT REV NEUROBIOL, V16, P273; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROSSOWSKI WJ, 1994, BIOCHEM BIOPH RES CO, V205, P341, DOI 10.1006/bbrc.1994.2670; ROSSOWSKI WJ, 1994, PEPTIDES, V15, P1421, DOI 10.1016/0196-9781(94)90118-X; TAYLOR JE, 1994, PEPTIDES, V15, P1229, DOI 10.1016/0196-9781(94)90146-5; WANG JB, 1994, J BIOL CHEM, V269, P25966; XUE JC, 1994, J BIOL CHEM, V269, P30195; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422	38	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20331	20339		10.1074/jbc.271.34.20331	http://dx.doi.org/10.1074/jbc.271.34.20331			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702767	hybrid			2022-12-27	WOS:A1996VD33700019
J	Sugahara, T; Pixley, MR; Fares, F; Boime, I				Sugahara, T; Pixley, MR; Fares, F; Boime, I			Characterization of the O-glycosylation sites in the chorionic gonadotropin beta subunit in vivo using site-directed mutagenesis and gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; LINKED GLYCOSYLATION; UDP-GALNAC; PEPTIDE; CARBOHYDRATE; SEQUENCES; SECRETION; INVITRO; OLIGOSACCHARIDE	Human chorionic gonadotropin (CG) is a member of a family of glycoprotein hormones which are heterodimers containing two nonidentical subunits: a common alpha and a hormone-specific beta subunit, One of the distinguishing features of the CG beta subunit is the presence of four serine accepters clustered within the last 25 amino acids. We previously demonstrated that this carboxyl terminal region is important for maintaining its biologic half-life, and when the sequence was genetically fused to either the common alpha or follitropin beta subunits, O-glycosylation was observed, Because this carboxyl-terminal sequence is located at the end of the subunit, we considered this region a convenient in vivo model for studying O-linked glycosylation in domains containing multiple serine recognition sites. A CG beta gene was engineered in which the N-linked sites were inactivated to eliminate background from those carbohydrate groups, Using this construct, we made a series of truncation and amino acid substitutions of acceptor serines, and these mutants were transfected into Chinese hamster ovary cells, O-Glycosylation was determined by [H-3]glucosamine incorporation and glycanase sensitivity of the products on SDS-polyacrylamide gels, We show that the O-linked sites comprise independent repetitive regions in which each acceptor serine has a recognition signal bounded by the next carboxy acceptor serine within four to five amino acids, It is also apparent that recognition of one site is not dependent on the glycosylation of another acceptor, Amino acid mutations in the acceptor regions demonstrated the importance of proline as a necessary feature for O-linked recognition in the CG beta sequence.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092922] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD92922] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BIRKEN S, 1977, J BIOL CHEM, V252, P5386; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; COLE LA, 1985, BIOCHEM BIOPH RES CO, V126, P333, DOI 10.1016/0006-291X(85)90610-2; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; GREEN ED, 1985, J BIOL CHEM, V260, P5623; HILL HD, 1977, J BIOL CHEM, V252, P3799; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; KALYAN NK, 1983, J BIOL CHEM, V258, P67; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KEUTMANN HT, 1977, J BIOL CHEM, V252, P5393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG Y, 1992, J BIOL CHEM, V267, P17209; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	33	15	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20797	20804		10.1074/jbc.271.34.20797	http://dx.doi.org/10.1074/jbc.271.34.20797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702834	hybrid			2022-12-27	WOS:A1996VD33700086
J	Li, QS; DasGupta, J; Hunt, AG				Li, QS; DasGupta, J; Hunt, AG			A plant poly(A) polymerase requires a novel RNA-binding protein for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLYADENYLATION SIGNAL; GENE; PURIFICATION; EXPRESSION; ELEMENT	We have purified a novel factor (PAP-III) that is a component of a multisubunit poly(A) polymerase from pea seedlings. This factor consists of one or more polypeptides with molecular masses of about 105 kDa and of a population of associated RNAs that can serve as substrates for polyadenylation. When these RNAs are separated from the 105-kDa polypeptides, polyadenylation becomes dependent upon exogenously added RNA. This RNA-dependent activity does not require the presence of a polyadenylation signal in the substrate, indicating that the activity under study is a nonspecific polyadenylation activity. One or more of the 108-kDa polypeptides could be cross-linked to the products of polyadenylation labeled with [alpha-P-32]ATP and to exogenously added labeled RNAs. Cross-linking of the 105-kDa polypeptides to the products of polyadenylation was not affected by the presence of exogenously added competitors, whereas cross-linking to exogenous RNAs was diminished by excesses of RNA homopolymers. Exogenous RNAs could be polyadenylated by the combination of PAP-I + PAP-III, and this activity was diminished if the binding of the exogenous RNAs to PAP-III was prevented. We conclude from these studies that PAP-III is an RNA binding protein, that polyadenylation by the poly(A) polymerase occurs while the substrate RNAs are associated with this protein, and that the pea poly(A) polymerase can only polyadenylate those RNAs that are associated with PAP-III.	UNIV KENTUCKY,DEPT AGRON,PLANT PHYSIOL BIOCHEM MOLEC BIOL PROGRAM,LEXINGTON,KY 40546	University of Kentucky			Li, Qingshun/C-5603-2009; Hunt, Arthur/A-8040-2009	Li, Qingshun/0000-0003-4105-1480; Hunt, Arthur/0000-0002-0008-4158				ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CORRUZZI G, 1994, EMBO J, V3, P1671; DASGUPTA J, 1995, PLANT SCI, V110, P215; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; LI QS, 1995, PLANT MOL BIOL, V28, P927, DOI 10.1007/BF00042076; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MANLEY JL, 1995, P NATL ACAD SCI USA, V92, P1800, DOI 10.1073/pnas.92.6.1800; MOGEN BD, 1992, MOL CELL BIOL, V12, P5406, DOI 10.1128/MCB.12.12.5406; PULLMAN JM, 1983, J CELL BIOL, V97, P99, DOI 10.1083/jcb.97.1.99; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397	22	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19831	19835		10.1074/jbc.271.33.19831	http://dx.doi.org/10.1074/jbc.271.33.19831			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702692	hybrid			2022-12-27	WOS:A1996VC66900033
J	Messmer, UK; Reed, JC; Brune, B				Messmer, UK; Reed, JC; Brune, B			Bcl-2 protects macrophages from nitric oxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR LYMPHOMA; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; MAMMALIAN-CELLS; BAX GENE; IN-VIVO; THYMOCYTES; EXPRESSION	Endogenously generated or exogenously supplied nitric oxide (NO)-induced apoptotic cell death in the mouse macrophage cell line RAW 264.7. Apoptotic signaling caused an early accumulation of the tumor suppressor p53 prior to DNA fragmentation. Contrary to the notion of specific activating signals, inhibitory transduction mechanisms largely remain unknown. Therefore, RAW 264.7 macrophages were stably transfected with human Bcl-2, an anti-apoptotic protein. Bcl-2 transfectants showed substantial protection from cell death induced following the exposure to NO donors such as S-nitrosoglutathione (GSNO) and spermine-NO. In contrast, RAW 264.7 parent or in neomycin control-transformed cells, these NO donors induced internucleosomal DNA cleavage in a dose-dependent manner. Similarly, expression of the inducible NO synthase in response to lipopolysaccharide and interferon-gamma also caused apoptosis in RAW macrophages and neo controls within 24 h. In contrast, Bcl-2 transfectants appeared highly resistant, although inducible NO synthase levels increased along with concomitant and Bcl-2 transfectants after GSNO addition. GSNO induced p53 expression in Bcl-2 transfectants at levels comparable with nontransfected RAW macrophages. Moreover, GSNO induced increases in the steady-state levels of Bax protein in parental and Bcl-2-transfected cells. We conclude therefore, that Bcl-2 acts downstream of p53, presumably nullifying the NO-mediated increased in Bax protein in RAW 264.7 cells.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT MED 4,EXPT DIV,D-91054 ERLANGEN,GERMANY; BURNHAM INST,CTR CANC RES,LA JOLLA,CA 92037	University of Erlangen Nuremberg; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER; NCI NIH HHS [CA60181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIOU CK, 1994, MOL CELL BIOL, V14, P2558; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; MESSMER UK, 1994, FEBS LETT, V355, P23; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muhl H, 1996, FEBS LETT, V382, P271, DOI 10.1016/0014-5793(96)00179-2; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Smith ML, 1996, AM J PATHOL, V148, P1019; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	35	199	203	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20192	20197		10.1074/jbc.271.33.20192	http://dx.doi.org/10.1074/jbc.271.33.20192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702745	hybrid			2022-12-27	WOS:A1996VC66900087
J	Fu, GK; Markovitz, DM				Fu, GK; Markovitz, DM			Purification of the pets factor - A nuclear protein that binds to the inducible TG-rich element of the human immunodeficiency virus type 2 enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; NF-KAPPA-B; DIFFERENTIAL REGULATION; POLYACRYLAMIDE GELS; RNA-POLYMERASE; ACTIVATION; TRANSCRIPTION; RECEPTOR; ELF-1; SPECIFICITY	The peri-ets (pets) site is a TG-rich element found immediately adjacent to two binding sites for the ets family member Elf-1 in the human immunodeficiency virus type 2 (HIV-2) enhancer, Enhancer activation in response to T cell stimulation by phorbol myristate acetate, phytohemagglutinin, soluble or cross-linked anti bodies to the T cell receptor, or antigen is mediated through this site in conjunction with its two adjacent Elf-1 binding sites, PuB1 and PuB2, and a KB site, Site-specific mutation of the pets element significantly reduces inducible activation of this enhancer but does not affect its transactivation by HIV-2 tat or other viral transactivators, Similar TG-rich sequences adjacent to ets-binding sites have also been found to be functionally important in the human T-cell leukemia virus type I and murine Moloney leukemia virus enhancers, As the cellular factor binding to the pets site plays a significant role in regulating the HIV-2 enhancer in both T cells and monocytes, we have purified this protein from bovine spleens and demonstrate that it is 43 kDa in size, In addition, using glycerol gradient centrifugation, Southwestern blotting, electrophoretic mobility shift assays employing purified protein eluted from a gel, and a new in solution UV cross-linking competitive assay, we show that the dominant protein binding to the pets site is 43 kDa in size, These results indicate that a nuclear protein of 43 kDa binds specifically to the pets site of the HIV-2 enhancer and may mediate transcriptional activation of this important human pathogen in response to T cell stimulation, As retroviruses generally expropriate important human regulatory proteins for their own use, the 43-kDa pets factor is also likely to play a significant role in signal transduction in T cells and in other cellular processes.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030924, R01AI036685] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09676] Funding Source: Medline; NIAID NIH HHS [AI36685, AI30924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYAN WS, 1983, CELL, V35, P79; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HANNIBAL MC, 1993, J VIROL, V67, P5035, DOI 10.1128/JVI.67.8.5035-5040.1993; HANNIBAL MC, 1994, BLOOD, V83, P1839; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; MARKOVITZ DM, 1993, ANN INTERN MED, V118, P211, DOI 10.7326/0003-4819-118-3-199302010-00010; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MARKOVITZ DM, 1992, J VIROL, V66, P3961, DOI 10.1128/JVI.66.6.3961-3965.1992; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19599	19605		10.1074/jbc.271.32.19599	http://dx.doi.org/10.1074/jbc.271.32.19599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702655	hybrid			2022-12-27	WOS:A1996VB68400089
J	Ramamurthy, P; Hocking, AM; McQuillan, DJ				Ramamurthy, P; Hocking, AM; McQuillan, DJ			Recombinant decorin glycoforms - Purification and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; PROTEODERMATAN SULFATE; HUMAN-FIBROBLASTS; PROTEIN; BINDING; CDNA; BIGLYCAN; SEQUENCE	The vaccinia virus/T7 bacteriophage expression system was used to express human decorin in HT-1080 cells by co-infection with vTF7-3, encoding T7 RNA polymerase, and vDCN1, encoding the decorin core protein fused to a polyhistidine-insulin signal sequence fusion-protein cassette. Overexpression using the vaccinia virus/T7 phage system resulted in secretion of approximately 30 mg of decorin/10(9) cells per 24 h which enabled purification and separation of multiple glycoforms under native conditions. Cells were cultured in the presence of [S-35]methionine or a mixture of [H-3]glucosamine and [S-35]sulfate, and recombinant glycoprotein purified by metal affinity chromatography which resolved the secreted decorin into two classes, a proteoglycan form and a core protein form, About 25% of the recombinant protein was secreted into the culture medium as core protein devoid of glycosaminoglycan chains. The decorin core protein was resolved into two forms (similar to 49 and similar to 53 kDa) that differed in the extent of N-linked oligosaccharide substitution (2 and 3 N-linked oligosaccharides, respectively), Deglycosylation of the recombinant proteoglycans and core proteins resulted in a single band migrating with an apparent molecular mass similar to 43 kDa when analyzed by SDS-polyacrylamide gel electrophoresis. Far-UV circular dichroism spectra of native decorin proteoglycan showed a minima at 218 nm, consistent with a secondary structure that is predominantly beta-sheet. Circular dichroism spectra of bovine decorin extracted from articular cartilage and recombinant decorin similarly treated revealed a minima of 205 nm indicating a loss of secondary structure, The affinity of decorin proteoglycan and core protein for collagen-like molecules was demonstrated, with the complement component C1q exhibiting the most striking affinity for decorin, although adherence to collagen types I and V was also observed, The extensive secondary structure maintained in the purified recombinant protein is likely to be important for the biological function of decorin.	TEXAS A&M UNIV, INST BIOSCI & TECHNOL, CTR EXTRACELLULAR MATRIX BIOL, HOUSTON, TX 77030 USA	Texas A&M University System				Hocking, Anne/0000-0003-2130-3732	NIAMS NIH HHS [R01 AR42826] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLOSSL J, 1983, BIOCHEM J, V215, P295; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HEINEGARD D, 1981, BIOCHEM J, V197, P355, DOI 10.1042/bj1970355; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HUNTER B, 1978, HDB EXPT IMMUNOLOGY; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Mackett M., 1985, DNA CLONING PRACTICA, P191; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	34	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19578	19584		10.1074/jbc.271.32.19578	http://dx.doi.org/10.1074/jbc.271.32.19578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702652	hybrid			2022-12-27	WOS:A1996VB68400086
J	Smart, CC; Fleming, AJ				Smart, CC; Fleming, AJ			Hormonal and environmental regulation of a plant PDR5-like ABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; CYSTIC-FIBROSIS MUTATIONS; ATP-DEPENDENT PERMEASES; BREFELDIN-A RESISTANCE; SPIRODELA-POLYRRHIZA L; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; ABSCISIC-ACID; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE	The PDR5 gene from yeast encodes an ABC (ATP-binding cassette) transporter involved in the ATP-dependent efflux of a variety of structurally unrelated cytotoxic compounds. We report here on the cDNA cloning and characterization of a PDR5 homolog (TUR2) from a higher eukaryote, the aquatic plant Spirodela polyrrhiza. We show that TUR2 transcripts accumulate throughout the plant following treatment with the steroid-like hormone, abscisic acid, and that this induction can be repressed by the adenine-derived hormone, kinetin. Furthermore, TUR2 gene expression is induced by environmental stress treatments such as low temperature and high salt. These data indicate that PDR5 homologs are present in plants, that they may function during stress conditions in an analogous fashion to that described in yeast, and that the expression of such ABC transporters is subject to a complex hormonal and environmental regulation.	UNIV BERN,INST PLANT PHYSIOL,CH-3013 BERN,SWITZERLAND	University of Bern	Smart, CC (corresponding author), ETH ZURICH,INST PLANT SCI PLANT BIOCHEM & PHYSIOL,UNIV STR 2,CH-8092 ZURICH,SWITZERLAND.							AHMED M, 1994, J BIOL CHEM, V269, P28506; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHALOUPKOVA K, 1994, PLANT PHYSIOL, V105, P497, DOI 10.1104/pp.105.2.497; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; DUDLER R, 1992, J BIOL CHEM, V267, P5882; EGNER R, 1995, MOL CELL BIOL, V15, P5879; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EWART GD, 1994, J BIOL CHEM, V269, P10370; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Fleming A. J., 1995, P273; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HOOF T, 1994, J BIOL CHEM, V269, P20575; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1993, EMBO J, V13, P3973; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; NAGAO K, 1995, J BACTERIOL, V177, P1536, DOI 10.1128/jb.177.6.1536-1543.1995; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROGERS SO, 1988, PLANT MOL BIOL MANUA, P1; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMART C, 1987, MOL BIOL PLANT GROWT, P345; SMART CC, 1983, PLANT CELL ENVIRON, V6, P507, DOI 10.1111/1365-3040.ep11588135; SMART CC, 1993, PLANT J, V4, P279, DOI 10.1046/j.1365-313X.1993.04020279.x; SMART CC, 1995, PLANT PHYSIOL, V108, P623, DOI 10.1104/pp.108.2.623; TURI TG, 1995, BIOCHEM BIOPH RES CO, V213, P410, DOI 10.1006/bbrc.1995.2147; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	44	89	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19351	19357		10.1074/jbc.271.32.19351	http://dx.doi.org/10.1074/jbc.271.32.19351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702621	hybrid			2022-12-27	WOS:A1996VB68400055
J	Parkin, DW				Parkin, DW			Purine-specific nucleoside N-ribohydrolase from Trypanosoma brucei brucei purification, specificity, and kinetic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALYSIS; CRITHIDIA-FASCICULATA; INHIBITOR DESIGN; HYDROLASE; METABOLISM; ENZYMES; CRUZI; CHEMOTHERAPY; SALVAGE; ACID	Trypanosomes have no de novo purine biosynthesis and thus depend upon salvage pathways to obtain purines for their metabolic pathways and for the biosynthesis of nucleic acids. An inosine-adenosine-guanosine preferring nucleoside hydrolase (IAG-nucleoside hydrolase) from the African trypanosome Trypanosoma brucei brucei represents similar to 0.2% of the soluble protein in this organism. The enzyme has been purified over 400-fold to >95% homogeneity from the bloodstream form of this parasite. IAG-nucleoside hydrolase is a dimer of M(r) 36,000 subunits. The k(cat)/K-m for inosine, adenosine, and guanosine are 1.9 x 10(6), 1.2 x 10(6), and 0.83 x 10(6) M(-1) s(-1), respectively. The kinetic mechanism with inosine as substrate is rapid equilibrium with random product release. The turnover rate for inosine at 30 degrees C is 34 s(-1). Pyrimidine nucleosides are poor substrates with k(cat)/K-m values of approximately 10(3) M(-1) s(-1). Deoxynucleosides are also poor substrates with k(cat)/K-m values near 10(2) M(-1) s(-1). AMP is not a detectable substrate and there is no measurable purine nucleoside phosphorylase activity, 3-Deazaadenosine, 7-deazaadenosine (tubercidin), and formycin B are competitive inhibitors with K-is of 1.8, 59, and 13 mu M, respectively. The K-m shows a slight dependence on pH with a pH optimum around 7. The V-max/K-m data indicate there are two ionizable enzymatic groups, pK(a) 8.6, required for the formation of the Michaelis complex. The V-max data indicate three ionizable groups involved in catalysis. Two essential groups exhibit pK(a) values of 8.8, and a third group with a pK(a) of 6.5 increases the V-max an additional 10-fold. All three groups must be protonated for optimum catalytic activity.			Parkin, DW (corresponding author), INT LIVESTOCK RES INST,POB 30709,NAIROBI,KENYA.							ALDHOUS P, 1994, SCIENCE, V264, P1857, DOI 10.1126/science.8009209; BOUTELLIER M, 1994, BIOCHEMISTRY-US, V33, P3994, DOI 10.1021/bi00179a028; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVIES MJ, 1983, PARASITOLOGY, V87, P211, DOI 10.1017/S0031182000052574; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; Fersht A., 1985, ENZYME STRUCTURE MEC; FISH WR, 1982, BIOCHIM BIOPHYS ACTA, V719, P223, DOI 10.1016/0304-4165(82)90092-7; GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040; GUTTERIDGE WE, 1981, FEBS LETT, V127, P211, DOI 10.1016/0014-5793(81)80207-4; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HOUBA V, 1982, ANIMAL HLTH YB; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MARR JJ, 1986, REV INFECT DIS, V8, P884; MAZZELLA LJ, 1996, IN PRESS J AM CHEM S, V6; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MILLER EN, 1981, PARASITOLOGY, V82, P63, DOI 10.1017/S0031182000041871; MILLER RL, 1984, J BIOL CHEM, V259, P5073; MILLER RL, 1986, BIOCHEM PHARMACOL, V36, P553; OGBUNUDE POJ, 1983, MOL BIOCHEM PARASIT, V9, P279, DOI 10.1016/0166-6851(83)90084-1; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; STEENKAMP DJ, 1991, EUR J BIOCHEM, V197, P431, DOI 10.1111/j.1432-1033.1991.tb15929.x; Tipton K F, 1979, Methods Enzymol, V63, P183; Vickerman K., 1993, Immunology and molecular biology of parasitic infections., P170; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001	28	83	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21713	21719		10.1074/jbc.271.36.21713	http://dx.doi.org/10.1074/jbc.271.36.21713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702965	hybrid			2022-12-27	WOS:A1996VF61200007
J	Salinelli, S; Lo, JY; Mims, MP; Zsigmond, E; Smith, LC; Chan, L				Salinelli, S; Lo, JY; Mims, MP; Zsigmond, E; Smith, LC; Chan, L			Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor - Functional importance of a properly folded surface loop covering the catalytic center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ALPHA(2)-MACROGLOBULIN RECEPTOR; PANCREATIC LIPASE; NONSENSE MUTATION; COMPLEMENTARY-DNA; ENZYME CATALYSIS; APOLIPOPROTEIN-E; TERMINAL DOMAIN; HEPARAN-SULFATE; GENE	We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce I-125-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of I-125-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/G239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	Salinelli, S (corresponding author), BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030, USA.				NHLBI NIH HHS [HL46860, HL27341, HL16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027341, R01HL046860, R01HL016512, R37HL016512, P60HL027341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; Cryer A., 1987, LIPOPROTEIN LIPASE, P277; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HENDERSON HE, 1993, J LIPID RES, V34, P1593; HIDE WA, 1992, J LIPID RES, V33, P167; KOBAYASHI J, 1992, BIOCHEM BIOPH RES CO, V182, P70, DOI 10.1016/S0006-291X(05)80113-5; KOZAKI K, 1993, J LIPID RES, V34, P1765; KWAMURA M, 1994, ARTERIOSCLER THROMB, V16, P235; LO JY, 1995, BIOCHEM BIOPH RES CO, V206, P266, DOI 10.1006/bbrc.1995.1037; MATTU RK, 1994, ARTERIOSCLER THROMB, V14, P1090, DOI 10.1161/01.ATV.14.7.1090; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; ROTH RI, 1983, J LIPID RES, V24, P1; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SKARLATOS SI, 1993, J CLIN ENDOCR METAB, V76, P793, DOI 10.1210/jc.76.3.793; Smith L. C., 1992, CURR OPIN STRUC BIOL, V2, P490, DOI DOI 10.1016/0959-440X(92)90076-J; STOCKS J, 1992, J LIPID RES, V33, P853; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WONG H, 1994, J BIOL CHEM, V269, P10319; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757; Zsigmond E, 1996, METHOD ENZYMOL, V263, P327	47	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21906	21913		10.1074/jbc.271.36.21906	http://dx.doi.org/10.1074/jbc.271.36.21906			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702993	hybrid			2022-12-27	WOS:A1996VF61200035
J	Benov, L; Kredich, NM; Fridovich, I				Benov, L; Kredich, NM; Fridovich, I			The mechanism of the auxotrophy for sulfur-containing amino acids imposed upon Escherichia coli by superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; DISMUTASE; DEHYDRATASE; INACTIVATION; CYSTEINE; ENZYME; MUTAGENESIS; CLUSTER; STRESS; GROWTH	Defects in both of the genes coding for the cytosolic superoxide dismutases (SODs) of Escherichia coli impose an oxygen-dependent nutritional requirement for cysteine. This is now seen to be a bradytrophy, rather than an absolute auxotrophy, since lack of Cys merely imposed a growth lag and escape from this growth lag did not involve genetic reversion. This Cys bradytrophy was not seen in the SOD-competent parental strain, and it was relieved by a cell-permeant mimic of SOD activity; hence, it was due to O-2(radical anion). It was also relieved by an osmolyte, such as sucrose; hence, it appears due to leakage from the cell of some component needed for Cys biosynthesis. Medium conditioned by the aerobic growth of the SOD-defective strain relieved the growth lag. Bioassays with Cys mutants suggested that the conditioned medium contained SO33- or its equivalent, and sulfite per se was able to eliminate the growth lag. However, some component of the conditioned medium reacted with added sulfite and interfered with attempts to assay for it colorimetrically. These results suggest that the cell envelope of the SOD-defective strain was weakened, directly or indirectly, by O-2(radical anion) and then leaked sulfite. This prevents cysteine biosynthesis until sulfite accumulates in the medium.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University			Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				BARRETT EL, 1979, J GEN MICROBIOL, V115, P513, DOI 10.1099/00221287-115-2-513; BECKER MA, 1969, J BIOL CHEM, V244, P2418; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BROWN OR, 1995, ARCH BIOCHEM BIOPHYS, V319, P10, DOI 10.1006/abbi.1995.1262; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CONWAY EJ, 1939, QUANTITATIVE ANAL MI; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FLINT DH, 1993, J BIOL CHEM, V268, P25547; GRANT WM, 1947, ANAL CHEM, V19, P345, DOI 10.1021/ac60005a023; HRYNIEWICZ MM, 1995, J BACTERIOL, V177, P2343, DOI 10.1128/jb.177.9.2343-2353.1995; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1991, MOL GEN GENET, V228, P410, DOI 10.1007/BF00260634; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; KUO CF, 1987, J BIOL CHEM, V262, P4724; LEINWEBER FJ, 1965, J BIOL CHEM, V240, P2699; LEINWEBER FJ, 1962, ANAL BIOCHEM, V4, P252, DOI 10.1016/0003-2697(62)90008-8; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H	24	47	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21037	21040		10.1074/jbc.271.35.21037	http://dx.doi.org/10.1074/jbc.271.35.21037			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702868	hybrid			2022-12-27	WOS:A1996VE47700014
J	Matsubara, M; Kusubata, M; Ishiguro, K; Uchida, T; Titani, K; Taniguchi, H				Matsubara, M; Kusubata, M; Ishiguro, K; Uchida, T; Titani, K; Taniguchi, H			Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; TAU-PROTEIN; BOVINE BRAIN; SUBSTRATE MARCKS; MAJOR SUBSTRATE; C SUBSTRATE; PURIFICATION; MICROTUBULE; PHOSPHOPROTEIN	Posttranslational modifications of synapsin I, a major phosphoprotein in synaptic terminals, were studied by mass spectrometry. In addition to a well known phosphorylation site by calmodulin-dependent protein kinase II (CaM kinase II), a hitherto unrecognized site (Ser(553)) was found phosphorylated in vivo. The phosphorylation site is immediately followed by a proline, suggesting that the protein is an in vivo substrate of so-called proline-directed protein kinase(s). To identify the kinase involved, three proline-directed protein kinases expressed highly in the brain, i.e. mitogen-activated protein (MAP) kinase, Cdk5-p23, and glycogen synthase kinase 3 beta, were tested for the in vitro phosphorylation of synapsin I, Only MAP kinase and Cdk5-p23 phosphorylated synapsin I stoichiometrically. The phosphorylation sites were determined to be Ser(551) and Ser(553) with Cdk5-p23, and Ser(62), Ser(67), and Ser(551) with MAP kinase, Upon phosphorylation with MAP kinase, synapsin I showed reduced F-actin bundling activity, while no significant effect on the interaction was observed with the protein phosphorylated with Cdk5-p23. These results raise the possibility that the so-called proline-directed protein kinases together with CaM kinase II and cAMP-dependent protein kinase play an important role in the regulation of synapsin I function.	FUJITA HLTH UNIV, INST COMPREHENS MED SCI, DIV BIOMED POLYMER SCI, TOYOAKE, AICHI 47011, JAPAN; MITSUBISHI KAGAKU INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN	Fujita Health University; Mitsubishi Kagaku Institute of Life Sciences (MITILS)			Taniguchi, Hisaaki/I-9171-2012; Matsubara, Mamoru/AAP-4016-2021	Matsubara, Mamoru/0000-0002-8893-0485				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; HUANG CK, 1982, J BIOL CHEM, V257, P6524; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; PETRUCCI TC, 1991, BIOCHEMISTRY-US, V30, P413, DOI 10.1021/bi00216a016; ROMANO C, 1987, J NEUROSCI, V7, P1300; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUDHOF TC, 1986, SCIENCE, V326, P704; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; UEDA T, 1977, J BIOL CHEM, V252, P5155; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	34	203	211	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21108	21113		10.1074/jbc.271.35.21108	http://dx.doi.org/10.1074/jbc.271.35.21108			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702879	hybrid			2022-12-27	WOS:A1996VE47700025
J	Royo, J; Vancanneyt, G; Perez, AG; Sanz, C; Stormann, K; Rosahl, S; SanchezSerrano, JJ				Royo, J; Vancanneyt, G; Perez, AG; Sanz, C; Stormann, K; Rosahl, S; SanchezSerrano, JJ			Characterization of three potato lipoxygenases with distinct enzymatic activities and different organ-specific and wound-regulated expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLANUM-TUBEROSUM-L; JASMONIC ACID; ARACHIDONATE 5-LIPOXYGENASE; METHYL JASMONATE; ESCHERICHIA-COLI; GENE-EXPRESSION; ACTIVE ENZYME; HIGH-LEVEL; PURIFICATION; ARABIDOPSIS	Lipoxygenases are ubiquitous enzymes in eukaryotes. In plants, lipoxygenases are involved in the synthesis of the hormone jasmonic acid that regulates plant responses to wounding and, in addition, is an inducer of tuberization in potato. We have isolated potato lipoxygenase cDNA clones, From their deduced amino acid sequences, three distinct classes are defined (Lox1, Lox2, and Lox3), They are encoded in gene families that display organ-specific expression, lox1 being expressed mostly in tubers and roots, lox2 in leaves, and lox3 in leaves and roots. Consistent with their organ-specific expression pattern, Lox1 expressed in bacteria preferentially uses as substrate linoleic acid, abundant in membrane lipids of tubers, whereas linolenic acid, prevalent in leaves, is the preferred substrate for the other two classes of lipoxygenase. Analyses on reaction products of the enzymes expressed in bacteria reveal that Lox1 primarily produces 9-hydroperoxides. In contrast, the jasmonic acid precursor, 13-hydroperoxylinolenic acid, is the major product, of the action of Lox2 and Lox3 on linolenic acid. Upon wounding, the levels of Lox2 and Lox3 transcripts rise markedly in leaves. While Lox3 mRNA accumulation peaks as early as 30 min after wounding, Lox2 shows a steady increase over a 24-h time course, suggesting different roles for these Lipoxygenase isoforms in the synthesis of the plant hormone jasmonic acid.	UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; CSIC, INST GRASA, E-41012 SEVILLE, SPAIN; MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG); Max Planck Society			Serrano, Jose J Sanchez/H-6955-2015; Pérez, Ana/GQA-6861-2022; Pérez, Ana G./AAB-4513-2021; Vancanneyt, Guy/P-3809-2015; Sanz, Carlos/K-1743-2014; Pérez, Ana G. G/K-1221-2014; Royo, Joaquin/L-4855-2015	Serrano, Jose J Sanchez/0000-0002-4489-4785; Pérez, Ana G./0000-0002-8096-9190; Vancanneyt, Guy/0000-0003-2557-0723; Sanz, Carlos/0000-0002-7387-3393; Pérez, Ana G. G/0000-0002-8096-9190; Royo, Joaquin/0000-0002-8245-5791				BELL E, 1993, PLANT PHYSIOL, V103, P1133, DOI 10.1104/pp.103.4.1133; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; BOSTOCK RM, 1992, PLANT PHYSIOL, V100, P1448, DOI 10.1104/pp.100.3.1448; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; CASEY R, 1995, PLANT PHYSIOL, V107, P265, DOI 10.1104/pp.107.1.265; CHAPMAN HW, 1958, PHYSIOL PLANTARUM, V11, P215, DOI 10.1111/j.1399-3054.1958.tb08460.x; COHEN JD, 1984, J CHROMATOGR, V303, P193, DOI 10.1016/S0021-9673(01)96061-3; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; DELIEU T, 1972, NEW PHYTOL, V71, P201, DOI 10.1111/j.1469-8137.1972.tb04068.x; Doyle JJ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; GALLIARD T, 1971, BIOCHEM J, V124, P431, DOI 10.1042/bj1240431; GALLIARD T, 1980, BIOCH PLANTS COMPREH, V4, P131; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; GREGORY LE, 1956, AM J BOT, V43, P281, DOI 10.2307/2438945; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; JACKSON SD, 1994, PLANTA, V194, P155, DOI 10.1007/BF01101673; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KODA Y, 1991, PHYTOCHEMISTRY, V30, P1435, DOI 10.1016/0031-9422(91)84180-Z; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MELAN MA, 1993, PLANT PHYSIOL, V101, P441, DOI 10.1104/pp.101.2.441; MULLIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V916, P13, DOI 10.1016/0167-4838(87)90205-6; NELSON MJ, 1994, CURR OPIN STRUC BIOL, V4, P878, DOI 10.1016/0959-440X(94)90270-4; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; PELACHO AM, 1991, PLANT PHYSIOL, V97, P1253, DOI 10.1104/pp.97.3.1253; PENACORTES H, 1995, P NATL ACAD SCI USA, V92, P4106, DOI 10.1073/pnas.92.10.4106; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; PENG YL, 1994, J BIOL CHEM, V269, P3755; REDDANNA P, 1990, METHOD ENZYMOL, V187, P268; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; Sambrook J., 1989, IMMUNOLOGY, V2nd; Saravitz DM, 1996, PLANT PHYSIOL, V110, P287, DOI 10.1104/pp.110.1.287; SHIMIZU T, 1990, METHOD ENZYMOL, V187, P296; SHIRANO Y, 1990, FEBS LETT, V271, P128, DOI 10.1016/0014-5793(90)80388-Y; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHASHI K, 1995, PLANT SCI, V111, P11, DOI 10.1016/0168-9452(95)04222-G; VICK BA, 1980, LIPIDS, V15, P468, DOI 10.1007/BF02534074; Vick Brady A., 1993, P167; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; YOSHIHARA T, 1989, AGR BIOL CHEM TOKYO, V53, P2835, DOI 10.1080/00021369.1989.10869712	43	178	211	0	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21012	21019		10.1074/jbc.271.35.21012	http://dx.doi.org/10.1074/jbc.271.35.21012			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702864	hybrid			2022-12-27	WOS:A1996VE47700010
J	Banerjee, A; Kowalchyk, JA; DasGupta, BR; Martin, TFJ				Banerjee, A; Kowalchyk, JA; DasGupta, BR; Martin, TFJ			SNAP-25 is required for a late postdocking step in Ca2+-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE FUSION; BOTULINUM NEUROTOXIN-A; AMINO-ACID-COMPOSITION; CLOSTRIDIAL NEUROTOXINS; CA2+-ACTIVATED SECRETION; PC12 CELLS; SEROTYPE-A; COMPLEX; PURIFICATION; DOCKING	The Ca2+-activated fusion of large dense core vesicles (LDCVs) with the plasma membrane is reconstituted in mechanically permeabilized PC12 cells by provision of millimolar MgATP and cytosolic proteins, Ca2+-activated LDCV exocytosis was inhibited completely by the type E but not the type A botulinum neurotoxin (BoNT) even though both BoNTs were equally effective in proteolytically cleaving the synaptosome-associated protein of 25 kDa (SNAP-25). The greater inhibition of exocytosis by BoNT E correlated with a greater destabilization of detergent-extracted complexes consisting of SNAP-25, synaptobrevin, and syntaxin. LDCVs in permeable PC12 cells can be poised at a late postdocking, prefusion state by MgATP dependent priming processes catalyzed by N-ethylmaleimide sensitive factor and priming in exocytosis proteins. BoNT E completely blocked Ca2+-activated LDCV exocytosis in ATP-primed cells, whereas BoNT A was only slightly inhibitory, implying that the C-terminal region of SNAP-25 (Ile(181)-Gln(197)) between the cleavage sites for BoNT E and BoNT A is essential for late postdocking steps. A required role for SNAP-25 at this stage was also indicated by inhibition of Ca2+-activated LDCV fusion in ATP-primed cells by a C-terminal peptide antibody. We conclude that plasma membrane SNAP-25, particularly residues 181-197, is required for Ca2+-regulated membrane fusion at a step beyond LDCV docking and ATP utilization.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT FOOD MICROBIOL & TOXICOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025861, R01DK040428, R01DK025861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40428, DK25861] Funding Source: Medline; NINDS NIH HHS [NS17742] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CARROLL AG, 1990, J NEUROCHEM, V55, P930, DOI 10.1111/j.1471-4159.1990.tb04580.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	28	133	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20227	20230		10.1074/jbc.271.34.20227	http://dx.doi.org/10.1074/jbc.271.34.20227			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702751	hybrid			2022-12-27	WOS:A1996VD33700003
J	Furukawa, K; Soejima, H; Niikawa, N; Shiku, H; Furukawa, K				Furukawa, K; Soejima, H; Niikawa, N; Shiku, H; Furukawa, K			Genomic organization and chromosomal assignment of the human beta 1,4-N-acetylgalactosaminyltransferase gene - Identification of multiple transcription units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; TISSUE-SPECIFIC EXPRESSION; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; EUKARYOTIC RIBOSOMES; GD2 GANGLIOSIDE; MESSENGER-RNA; DNA-BINDING; FACTOR AP-2; CELLS; GROWTH	The beta 1,4-N-acetylgalactosaminyltransferase (beta 1,4GalNAc-T) (EC 2.4.1.92) gene is expressed in normal brain tissues and in various malignant transformed cells, such as malignant melanoma, neuroblastoma, and adult T cell leukemia. To analyze the regulatory mechanisms of gene expression, we determined the genomic organization of the beta 1,4GalNAc-T gene. The gene consists of at least 11 exons and spans >8 kilobase pairs, The coding region is located in exons 2-11. To determine the transcription initiation sites, 5'-rapid amplification of cDNA ends analysis and ribonuclease protection assays were performed using RNA obtained from the human melanoma cell line SK-MEL-31. Consequently, we defined three transcription initiation sites and the alternative usage of three exons. Exons 1a and 1b partially overlap; the latter is part (3'-side) of the former and corresponds to the 5'-noncoding region of the cDNA clone previously isolated. The third transcript, exon 1c, corresponds to nucleotides -520 to -412 (position +1 = A of ATG of beta 1,4GalNAc-T cDNA), which are considered to be in intron 1 based on the cloned cDNA sequence. Ribonuclease protection assays revealed the corresponding protection bands in samples of the gene-expressing cell Lines. 5'-Flanking regions of individual initiation sites showed promoter activity when analyzed by chloramphenicol acetyltransferase assay in SK-MEL-31 cells. The multiple transcription initiation sites and their promoters/enhancers identified here might be differentially involved in the cell type-specific expression of the beta 1,4GalNAc-T gene. This gene was assigned to human chromosome 12q13.3 by means of fluorescence in situ hybridization.	NAGASAKI UNIV,SCH MED,DEPT HUMAN GENET,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 2,TSU,MIE 514,JAPAN	Nagasaki University; Mie University	Furukawa, K (corresponding author), NAGASAKI UNIV,SCH MED,DEPT ONCOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN.			Soejima, Hidenobu/0000-0001-5076-6563				Battey, 1986, BASIC METHODS MOL BI; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEUNG NKV, 1985, CANCER RES, V45, P2642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAZUKA S, 1994, CURR OPIN STRUT BIOL, V4, P683; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RUAN S, 1992, CANCER RES, V52, P5725; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; YAMASHIRO S, 1993, CANCER RES, V53, P5395; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	49	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20836	20844		10.1074/jbc.271.34.20836	http://dx.doi.org/10.1074/jbc.271.34.20836			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702839	hybrid			2022-12-27	WOS:A1996VD33700091
J	Gaidarov, I; Chen, Q; Falck, JR; Reddy, KK; Keen, JH				Gaidarov, I; Chen, Q; Falck, JR; Reddy, KK; Keen, JH			A functional phosphatidylinositol 3,4,5-trisphosphate/phosphoinositide binding domain in the clathrin adaptor AP-2 alpha subunit - Implications for the endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY PROTEIN AP-2; INOSITOL POLYPHOSPHATE RECEPTOR; GROWTH-FACTOR RECEPTOR; PLANAR LIPID BILAYERS; HIGH-AFFINITY BINDING; PLASMA-MEMBRANE; PHOSPHOINOSITIDE-3 KINASE; COATED VESICLES; 3-KINASE; INTERNALIZATION	Clathrin-coated pits are sites of concentration of ligand-bound signaling receptors. Several such receptors are known to recruit, bind, and activate the heterodimeric phosphatidylinositol-3-kinase, resulting in the generation of phosphatidylinositol 3,4,5-trisphosphate. We report here that dioctanoyl-phosphatidylinositol-3,4,5-P-3 binds specifically and saturably to soluble AP-2 and with greater affinity to AP-2 within assembled coat structures. Soluble D-myo-inositol hexakisphosphate shows converse behavior. Binding to bovine brain clathrin-coated vesicles is evident, only after detergent extraction. These observations and evidence for recognition of the diacylglyceryl backbone as well as the inositol phosphate headgroup are consistent with AP-2 interaction with membrane phosphoinositides in coated vesicles and with soluble inositol phosphates in cytoplasm. A discrete binding domain is identified near the N terminus of the AP-2 alpha subunit, and an expressed fusion protein containing this sequence exhibits specific, high affinity binding that is virtually identical to the parent protein. This region of the AP-2 alpha sequence also shows the greatest conservation between a Caenorhabditis elegans homolog and mammalian alpha, consistent with a function in recognition of an evolutionarily unchanging low molecular weight ligand. Binding of phosphatidylinositol 3,4,5-trisphosphate to AP-2 inhibits the protein's clathrin binding and assembly activities. These findings are discussed in the context of the potential roles of phosphoinositides and AP-2 in the internalization and trafficking of cell surface receptors.	THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	Jefferson University; Jefferson University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845	NIGMS NIH HHS [GM-49217] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049217] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BECK KA, 1992, J CELL BIOL, V119, P787, DOI 10.1083/jcb.119.4.787; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUCKCHONG CG, 1979, LIPIDS, V14, P492, DOI 10.1007/BF02533467; FLEISCHER B, 1994, J BIOL CHEM, V269, P71826; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JAUREGUIADELL J, 1975, ANAL BIOCHEM, V69, P468, DOI 10.1016/0003-2697(75)90148-7; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KIJIMA Y, 1993, J BIOL CHEM, V268, P16253; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KISHTA K, 1995, J ORG CHEM, V60, P3385; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Merisko E M, 1986, Pancreas, V1, P95, DOI 10.1097/00006676-198603000-00001; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	71	142	143	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20922	20929		10.1074/jbc.271.34.20922	http://dx.doi.org/10.1074/jbc.271.34.20922			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702850	hybrid			2022-12-27	WOS:A1996VD33700102
J	Koman, A; Cazaubon, S; Couraud, PO; Ullrich, A; Strosberg, AD				Koman, A; Cazaubon, S; Couraud, PO; Ullrich, A; Strosberg, AD			Molecular characterization and in vitro biological activity of placentin, a new member of the insulin gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-I; RECEPTOR; EXPRESSION; CELLS; DIFFERENTIATION; TROPHOBLAST; BINDING; INVITRO; SYSTEM	Insulin and insulin-like growth th factors belong to a family of polypeptides involved in essential physiological processes. Placentin, a new member of the insulin family, was recently identified as a 139-amino acid open reading frame from a cDNA clone isolated from a subtracted library of first trimester human placenta. Tris/Tricine/SDS-polyacrylamide gel electrophoresis and immunoblot analyses of histidine-tagged recombinant placentin indicate that it is composed of two peptide chains of apparent molecular masses of 4 and 13 kDa. Conditioned media produced by recombinant expression of placentin cDNA in the placental 3AsubE cell line were assayed for biological activity and found to stimulate tyrosine phosphorylation and DNA synthesis. While these effects closely mimicked those of insulin, they were not mediated by the insulin receptor as shown by the lack of tyrosine phosphorylation of this receptor upon placentin treatment. Moreover, in cytotrophoblast primary culture, production of chorionic gonadotropin, a marker of trophoblast differentiation, was increased upon treatment with placentin-conditioned media, while unaffected by insulin. These results suggest that placentin might participate in the cellular proliferation and/or differentiation processes during placental development.	MAX PLANCK INST BIOCHEM,DEPT MOL BIOL,D-82512 MARTINSRIED,GERMANY	Max Planck Society	Koman, A (corresponding author), UNIV PARIS 07,LAB IMMUNOPHARMACOL MOL,INST COCHIN GENET MOL,CNRS UPR 0415,22 RUE MECHAIN,F-75014 PARIS,FRANCE.							ALSAT E, 1993, J CELL PHYSIOL, V154, P122, DOI 10.1002/jcp.1041540115; BAYNE ML, 1987, P NATL ACAD SCI USA, V84, P2638, DOI 10.1073/pnas.84.9.2638; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BRYANTGREENWOOD GD, 1994, ENDOCR REV, V15, P5, DOI 10.1210/er.15.1.5; BURKHARDT E, 1994, GENOMICS, V20, P13, DOI 10.1006/geno.1994.1121; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHASSIN D, 1994, CANCER RES, V54, P5217; CHASSIN D, 1995, GENOMICS, V29, P465, DOI 10.1006/geno.1995.9980; CHOU JY, 1978, P NATL ACAD SCI USA, V75, P1409, DOI 10.1073/pnas.75.3.1409; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GROSKREUTZ DJ, 1994, J BIOL CHEM, V269, P6241; HOFMANN GE, 1992, J CLIN ENDOCR METAB, V74, P981, DOI 10.1210/jc.74.5.981; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; JONAS HA, 1986, P NATL ACAD SCI USA, V83, P4124, DOI 10.1073/pnas.83.12.4124; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; LEROITH D, 1993, ANN NY ACAD SCI, V692, P11; OHLSSON R, 1993, HUMAN PLACENTA, V1, P33; REN SG, 1991, ENDOCRINOLOGY, V128, P1623, DOI 10.1210/endo-128-3-1623; RITVOS O, 1988, ENDOCRINOLOGY, V122, P395, DOI 10.1210/endo-122-2-395; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHANG B, 1992, J BIOL CHEM, V267, P18320	26	34	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20238	20241		10.1074/jbc.271.34.20238	http://dx.doi.org/10.1074/jbc.271.34.20238			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702754	hybrid			2022-12-27	WOS:A1996VD33700006
J	Zheng, JA; Mitchell, AE; Jones, AD; Hammock, BD				Zheng, JA; Mitchell, AE; Jones, AD; Hammock, BD			Haloenol lactone is a new isozyme-selective and active site-directed inactivator of glutathione S-transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-PI; CYSTEINE RESIDUES; IDENTIFICATION; INHIBITION; MECHANISM; PURIFICATION; RAT	A haloenol lactone derivative has been synthesized and found to be an isozyme-selective and active site directed inactivator of glutathione S-transferase (GST). Preincubation of the haloenol lactone (100 mu M) With murine Alpha, Mu, or Pi GST isozyme (1.0 mu M) at pH 6.5, 37 degrees C resulted in time-dependent loss of enzyme activity with highly selective inhibition of the Pi isozyme (t(1/2), similar to 2 min), In a separate experiment, a 10-fold excess of the lactone was incubated with GST-Pi isozyme at 37 degrees C for 3 h, followed by dialysis against Nanopure water. GST activity lost upon incubation with the lactone could not be restored by exhaustive dialysis, and only 8% of enzyme activity for the modified GST remained relative to the control that was treated identically except the lactone was omitted from the incubation, Both control and modified GST were characterized using electrospray ionization mass spectrometry. No native GST (23,478 Da) was observed in the spectrum of modified GST. Instead, protein incubated with the lactone exhibited an increase in molecular mass of 230 Da relative to control GST. The lactone (100 mu M) was incubated with GST Pi isozyme (1.0 mu M) in the presence of the competitive inhibitor S-hexylglutathione (10 mu M), which suppressed time-dependent inhibition of GST by the lactone, The results suggest that this haloenol lactone is an irreversible and active site-directed inhibitor of GST that appears to inhibit the enzyme through two consecutive steps of nucleophilic attack.	UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; UNIV CALIF DAVIS,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Jones, Arthur D/C-2670-2013	Mitchell, Alyson/0000-0003-0286-5238; Jones, A. Daniel/0000-0002-7408-6690	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, P30ES005707] Funding Source: NIH RePORTER; NIEHS NIH HHS [1P30 ES05707, 2P42 ES04699-08] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CARMICHAEL J, 1985, CANCER RES, V45, P1169; CHEN WL, 1992, BIOCHEM J, V286, P205, DOI 10.1042/bj2860205; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1989, GLUTATHIONE S TRANSF, P3; JACOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KARSHIKOFF A, 1993, EUR J BIOCHEM, V215, P663, DOI 10.1111/j.1432-1033.1993.tb18077.x; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; KRAFFT GA, 1981, J AM CHEM SOC, V103, P5459, DOI 10.1021/ja00408a030; LIU S, 1992, J MED CHEM, V35, P1067, DOI 10.1021/jm00084a012; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MITCHELL AE, 1995, CHEM RES TOXICOL, V8, P1054, DOI 10.1021/tx00050a009; PLOEMEN JHTM, 1994, J BIOL CHEM, V269, P26890; PLOEMEN JHTM, 1993, BIOCHEM PHARMACOL, V45, P633, DOI 10.1016/0006-2952(93)90137-L; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; WINTERSTEN M, 1991, FEBS LETT, V293, P156	26	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20421	20425		10.1074/jbc.271.34.20421	http://dx.doi.org/10.1074/jbc.271.34.20421			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702779	hybrid			2022-12-27	WOS:A1996VD33700031
J	Lavigne, AC; Mengus, G; May, M; Dubrovskaya, V; Tora, L; Chambon, P; Davidson, I				Lavigne, AC; Mengus, G; May, M; Dubrovskaya, V; Tora, L; Chambon, P; Davidson, I			Multiple interactions between hTAF(II)55 and other TFIID subunits - Requirements for the formation of stable ternary complexes between hTAF(II)55 and the TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MEDIATE TRANSCRIPTIONAL ACTIVATION; HUMAN ESTROGEN-RECEPTOR; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; LESS PROMOTER; IN-VITRO; COACTIVATORS; TBP	We have cloned and characterized the human TATA-binding protein (TBP)-associated factor hTAF(II)55. hTAF(II)55, which has no known Drosophila counterpart, is present in both of the previously described TFIID alpha and TFIID beta subpopulations. We describe the interactions of hTAF(II)55 with other subunits of the transcription factor TFIID. By cotransfection in COS cells, we show that hTAF(II)55 interacts with hTAF(II)250, hTAF(II)100, hTAF(II)28, hTAF(II)20, and hTAF(II)18, but not with hTAF(II)30 or TBP. Analysis of the binding of hTAF(II)55 and TBP to hTAF(II)28 deletion mutants indicates that distinct regions of hTAF(II)28 are required for these interactions. Although hTAF(II)55 does not interact by itself with TBP, stable ternary complexes containing hTAF(II)55 and TBP can be formed in the presence of hTAF(II)250, hTAF(II)100, or hTAF(II)28. These results not only show that hTAF(II)100 and hTAF(II)28 interact with TBP, but also that they can nucleate the formation of partial TFIID complexes.	COLL FRANCE, INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,ULP, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Tora, Laszlo/E-9999-2018; Lavigne, Anne-Claire/O-8805-2015	Tora, Laszlo/0000-0001-7398-2250; MENGUS, Gabrielle/0000-0002-2844-1778; Davidson, Irwin/0000-0001-5533-1171				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1993, TRANSCRIPTIONAL REGU, V1, P227; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; DUBROVSKAYA V, 1996, IN PRESS EMBO J; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	60	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19774	19780		10.1074/jbc.271.33.19774	http://dx.doi.org/10.1074/jbc.271.33.19774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702684	Green Published, hybrid			2022-12-27	WOS:A1996VC66900025
J	Zhang, JD; Walker, GC				Zhang, JD; Walker, GC			Identification of elements of the peptide binding site of DnaK by peptide cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; LAMBDA-P-PROTEIN; ESCHERICHIA-COLI; ATPASE ACTIVITY; CLASS-I; MOLECULAR CHAPERONES; COGNATE PROTEIN; REPLICATION; GRPE; HSC70	We used photocross-linking of peptides to DnaK to identify elements of the peptide binding site of DnaK. We attached a photoactivatable group (N-hydroxysuccinimidyl-4-azido-salicylic acid (NHS-ASA) or N-iodoacetamidobutyl-4-azido-salicylic acid (I-ABASA)) to different positions on peptide C of the vesicular stomatitis virus glycoprotein, I-125-radiolabeled the cross-linker, cross-linked the peptide to DnaK by UV irradiation, and then determined the amino acid residues of DnaK that were cross-linked to the peptide. Limited trypsin digestion of the DnaK-peptide complex revealed that the derivatives modified with photoactivatable cross-linker peptide C cross-linked to a C-terminal fragment of DnaK and that the N-terminal 45-kDa fragment of DnaK was not cross-linked by these modified peptides. The attachment points of the three peptide C derivatives carrying photoactivatable cross-linkers at different locations on the peptide, PepC-ASA, PepC-S7C-ABASA, and PepC-S8C-ABASA, have been identified as Arg-536, Arg-527, and His-541 of DnaK, respectively. Thus all three peptides cross-linked to amino acids located close together in a sequence that includes one end of the long alpha-helix in the NMR-based secondary structure model of the peptide binding domain of Hsp70 family (Morshauser, R., Wang, H., Flynn, G., and Zuiderweg, E. (1995) Biochemistry 34, 6261-6266).	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				/0000-0001-7243-8261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028988] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28988, GM17100-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANECKI B, 1992, J BIOL CHEM, V267, P25051; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BAYLEY H, 1983, PHOTOGENERATED REAGE, P34; BAYLEY H, 1983, PHOTOGENERATED REAGE, P8; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BURKHOLDER WF, 1994, J MOL BIOL, V242, P364, DOI 10.1006/jmbi.1994.1587; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; HUANG SP, 1993, J BIOL CHEM, V268, P2063; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LI YZ, 1988, J AM CHEM SOC, V110, P8092, DOI 10.1021/ja00232a022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARCINEK A, 1993, J AM CHEM SOC, V115, P8609, DOI 10.1021/ja00072a013; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; Schuster G.B., 1992, ADV PHOTOCHEM, P69, DOI DOI 10.1002/9780470133484.CH2; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; WANG TF, 1993, J BIOL CHEM, V268, P26049; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	52	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19668	19674		10.1074/jbc.271.33.19668	http://dx.doi.org/10.1074/jbc.271.33.19668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702669	hybrid			2022-12-27	WOS:A1996VC66900010
J	AnandSrivastava, MB; Sehl, PD; Lowe, DG				AnandSrivastava, MB; Sehl, PD; Lowe, DG			Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase - Involvement of a pertussis toxin-sensitive G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; SIGNAL-TRANSDUCTION SYSTEM; GTP-BINDING PROTEIN; GROWTH-FACTOR; GUANYLATE-CYCLASE; PORCINE BRAIN; 2ND MESSENGER; ATRIAL; CELLS; MECHANISMS	Natriuretic peptide receptor C (NPR-C) is a disulfide-linked homodimer with an approximately 440-amino acid extracellular domain and a 37-amino acid cytoplasmic domain; it functions in the internalization and degradation of bound ligand. The use of NPR-C-specific natriuretic peptide analogs has implicated this receptor in mediating the inhibition of adenylyl cyclase or activation of phospholipase C, In the present studies we have investigated the role of the cytoplasmic domain of NPR-C in signaling the inhibition of adenylyl cyclase. Polyclonal rabbit antisera were raised against a 37-amino acid synthetic peptide (R37A) corresponding to the cytoplasmic domain of NPR-C. Incubation of anti-R37A with rat heart particulate fractions blocked atrial natriuretic peptide-dependent inhibition of adenylyl cyclase. The cytoplasmic domain peptides R37A and TMC (10 residues of transmembrane domain appended on R37A) were equipotent in inhibiting adenylyl cyclase (K-i similar to 1 nan) in a GTP-dependent manner, whereas K37E (a scrambled peptide control for R37A) did not inhibit adenylyl cyclase activity, Prior incubation of membranes with pertussis toxin blocked R37A or TMC inhibition of cAMP production. Detergent solubilization of the rat heart particulate fraction destroyed natriuretic peptide inhibition of adenylyl cyclase, but TMC was able to inhibit cAMP production in a dose-dependent manner. Our results provide evidence that the 37-amino acid cytoplasmic domain of NPR-C is sufficient for signaling inhibition of adenylyl cyclase through. a pertussis toxin-sensitive G protein.	GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	AnandSrivastava, MB (corresponding author), UNIV MONTREAL,FAC MED,DEPT PHYSIOL,CP 6128,SUCCURSALE CENTREVILLE,MONTREAL,PQ H3C 3J7,CANADA.							ANANDSRIVASTAVA MB, 1980, J NEUROCHEM, V35, P905, DOI 10.1111/j.1471-4159.1980.tb07089.x; ANANDSRIVASTAVA MB, 1986, AM J PHYSIOL, V251, pF417, DOI 10.1152/ajprenal.1986.251.3.F417; ANANDSRIVASTAVA MB, 1991, BIOCHEM J, V278, P211, DOI 10.1042/bj2780211; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; ANANDSRIVASTAVA MB, 1992, BIOCHEM J, V288, P79, DOI 10.1042/bj2880079; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BERL T, 1991, AM J PHYSIOL, V260, pF590, DOI 10.1152/ajprenal.1991.260.4.F590; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLAVELL AL, 1993, AM J PHYSIOL, V264, pR290, DOI 10.1152/ajpregu.1993.264.2.R290; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; FULLER F, 1988, J BIOL CHEM, V263, P9395; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; HUANG CL, 1986, P NATL ACAD SCI USA, V83, P8015, DOI 10.1073/pnas.83.20.8015; ITAKURA M, 1994, J BIOL CHEM, V269, P8314; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATADA T, 1982, J BIOL CHEM, V257, P3739; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEVIN ER, 1993, ENDOCRINOL METAB, V27, pE483; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; RESINK TJ, 1988, EUR J BIOCHEM, V174, P531, DOI 10.1111/j.1432-1033.1988.tb14131.x; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; STANTON BA, 1991, CAN J PHYSIOL PHARM, V69, P1546, DOI 10.1139/y91-230; STINGO AJ, 1992, AM J PHYSIOL, V262, pH308, DOI 10.1152/ajpheart.1992.262.1.H308; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STULTS JT, 1994, BIOCHEMISTRY-US, V33, P11372, DOI 10.1021/bi00203a036; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WALDMAN SA, 1987, PHARMACOL REV, V39, P163	53	143	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19324	19329		10.1074/jbc.271.32.19324	http://dx.doi.org/10.1074/jbc.271.32.19324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702617	hybrid			2022-12-27	WOS:A1996VB68400051
J	Brostjan, C; Anrather, J; Csizmadia, V; Stroka, D; Soares, M; Bach, FH; Winkler, H				Brostjan, C; Anrather, J; Csizmadia, V; Stroka, D; Soares, M; Bach, FH; Winkler, H			Glucocorticoid-mediated repression of NF kappa B activity in endothelial cells does not involve induction of I kappa B alpha synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL ANTAGONISM; DNA-BINDING; C-JUN; RECEPTOR; EXPRESSION; INHIBITION; HORMONE	Repression of NF kappa B-dependent gene expression is one of the major elements of immunosuppression by glucocorticoids. Protein-protein interactions between the glucocorticoid receptor and NF kappa B have been characterized and shown to be a possible mechanism of mutual inhibition of transactivation properties, More recently, glucocorticoid-mediated induction of I kappa B alpha, an inhibitor of NF kappa B, has been described in monocytes and lymphocytes; an increase in I kappa B alpha mRNA and protein resulted in inactivation and cytosolic retention of NF kappa B, Thus, rather than the physical interaction between the glucocorticoid receptor and NF kappa B, the up-regulation of I kappa B alpha was presented as the key element in immunosuppression by glucocorticoids. in contrast, we show that the I kappa B alpha pathway is not involved in glucocorticoid-mediated inhibition of NF kappa B activity in endothelial cells, Although transcriptional activation by NF kappa B was significantly reduced in the presence of glucocorticoids, we did not detect induction of I kappa B alpha protein that could prevent nuclear translocation of NF kappa B upon stimulation with lipopolysaccharide or tumor necrosis factor alpha, Furthermore, treatment with glucocorticoids did not seem to affect the transcription rate or mRNA stability of I kappa B alpha. Ne therefore conclude that, although induction of I kappa B alpha expression by glucocorticoids seems to be of importance in monocytes and lymphocytes, it cannot explain inhibition of NF kappa B-dependent gene expression in endothelial cells. Our results emphasize the relevance of physical interaction between the glucocorticoid receptor and NF kappa B in endothelial cells and thus in suppression of inflammation by glucocorticoids.			Brostjan, C (corresponding author), HARVARD UNIV,SCH MED,DEACONESS HOSP,SANDOZ CTR IMMUNOBIOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.		Stroka, Deborah M/F-1806-2013	Stroka, Deborah/0000-0002-3517-3871; Brostjan, Christine/0000-0003-1462-5397; Soares, Miguel/0000-0002-9314-4833				ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWAAL RMW, 1994, MOL BIOL REP, V19, P81, DOI 10.1007/BF00997151; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEW W, 1988, J IMMUNOL, V140, P1895; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1992, IMMUNOLOGY, V75, P674; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SUBRAMANIAM M, 1992, J CELL BIOCHEM, V50, P411, DOI 10.1002/jcb.240500410; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TOBLER A, 1992, BLOOD, V79, P45; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; WAAGE A, 1988, IMMUNOLOGY, V63, P299; WINKLER H, 1996, IN PRESS GENE; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	36	185	186	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19612	19616		10.1074/jbc.271.32.19612	http://dx.doi.org/10.1074/jbc.271.32.19612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702657	hybrid			2022-12-27	WOS:A1996VB68400091
J	Mitchell, AH; West, SC				Mitchell, AH; West, SC			Role of RuvA in branch migration reactions catalyzed by the RuvA and RuvB proteins of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HOLLIDAY JUNCTIONS; COMPLEX IN-VITRO; DNA-REPAIR; RECOMBINATION REPAIR; HEXAMERIC RINGS; ATPASE ACTIVITY; PURIFICATION; HYDROLYSIS	The RuvA and RuvB proteins of Escherichia coli promote ATP-dependent branch migration of Holliday junctions during homologous genetic recombination and DNA repair, In this process, RuvA acts as a specificity factor that targets RuvB, a hexameric ring motor protein, to the junction, Because elevated concentrations of RuvB can promote branch migration in the absence of RuvA, it has been suggested that RuvA acts as a molecular matchmaker, In the studies presented here, we compared the requirements for RuvAB- and RuvB-mediated branch migration reactions and found that reactions catalyzed by RuvB alone were highly sensitive to inhibition by NaCl, temperature, ADP, and ATP gamma S. Our observations indicate that the two reactions occur by distinct mechanisms and support the notion that RuvAB-mediated branch migration is physiologically more relevant than that catalyzed by RuvB, We also show that ongoing RuvAB-mediated branch migration reactions were blocked by the addition of polyclonal antibodies raised against RuvA, The role of RuvA is therefore unlikely to be restricted to RuvB targeting; instead, it is required continually during branch migration, Competition with excess synthetic Holliday junctions, sufficient to sequester released RuvA, failed to cause an immediate block and leads us to suggest that RuvAB promote branch migration by a processive mechanism.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					West, Stephen/0000-0001-8848-9418				ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HIOM K, 1995, NUCLEIC ACIDS RES, V23, P3621, DOI 10.1093/nar/23.18.3621; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KODADEK T, 1988, J BIOL CHEM, V263, P9427; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PARSONS CA, 1995, EMBO J, V14, P5736, DOI 10.1002/j.1460-2075.1995.tb00260.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; Whitby M. C., 1995, NUCLEIC ACIDS MOL BI, V9, P66	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19497	19502		10.1074/jbc.271.32.19497	http://dx.doi.org/10.1074/jbc.271.32.19497			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702640	hybrid			2022-12-27	WOS:A1996VB68400074
J	Fisher, AJ; Thompson, TB; Thoden, JB; Baldwin, TO; Rayment, I				Fisher, AJ; Thompson, TB; Thoden, JB; Baldwin, TO; Rayment, I			The 1.5-angstrom resolution crystal structure of bacterial luciferase in low salt conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; PHOTOBACTERIUM-LEIOGNATHI; NUCLEOTIDE-SEQUENCE; PROTEIN STRUCTURES; VIBRIO-HARVEYI; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; REACTIVE SULFHYDRYL; BARREL ENZYMES; ALPHA-SUBUNIT	Bacterial luciferase is a flavin monooxygenase that catalyzes the oxidation of a long-chain aldehyde and releases energy in the form of visible light. A new crystal form of luciferase cloned from Vibrio harveyi has been grown under low-salt concentrations, which diffract x-rays beyond 1.5-Angstrom resolution. The x-ray structure of bacterial. luciferase has been refined to a conventional R-factor of 18.2% for all recorded synchrotron data between 30.0 and 1.50-Angstrom resolution, Bacterial luciferase is an alpha-beta heterodimer, and the individual subunits fold into a single domain (beta/alpha)(8) barrel. The high resolution structure reveals a non-prolyl cis peptide bond that forms between Ala(74) and Ala(75) in the alpha subunit near the putative active site. This cis peptide bond may have functional significance for creating a cavity at the active site. Bacterial luciferase employs reduced flavin as a substrate rather than a cofactor. The structure presented was determined in the absence of substrates. A comparison of the structural similarities between luciferase and a nonfluorescent flavoprotein, which is expressed in the lux operon of one genus of bioluminescent bacteria, suggests that the two proteins originated from a common ancestor. However, the flavin binding sites of the nonfluorescent protein are likely not representative of the flavin binding site on luciferase. The structure presented here will furnish a detailed molecular model for all bacterial luciferases.	UNIV WISCONSIN, INST ENZYME RES, MADISON, WI 53705 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53705 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station			rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Fisher, Andrew/0000-0003-3488-6594; Thompson, Thomas/0000-0002-7041-5047	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008304, R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35186, AR08304] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; BALDWIN TO, 1978, J BIOL CHEM, V253, P5551; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P326, DOI 10.1002/bio.1170040145; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1979, P NATL ACAD SCI USA, V76, P4887, DOI 10.1073/pnas.76.10.4887; BALDWIN TO, 1980, FLAVINS FLAVOPROTEIN, P139; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BECVAR JE, 1975, P NATL ACAD SCI USA, V72, P3374, DOI 10.1073/pnas.72.9.3374; Boyle R., 1668, PHILOS T R SOC LOND, V2, P581; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Campbell A.K., 1989, Essays in Biochemistry, V24, P41; CLARK AC, 1993, J BIOL CHEM, V268, P10773; CLINE TW, 1972, BIOCHEMISTRY-US, V11, P3359, DOI 10.1021/bi00768a008; COHN DH, 1985, J BIOL CHEM, V260, P6139; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P6581, DOI 10.1021/bi00020a002; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Harvey E.N., 1952, BIOLUMINESCENCE; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HODEL A, 1995, PROTEIN SCI, V4, P636; HOLZMAN TF, 1980, P NATL ACAD SCI-BIOL, V77, P6363, DOI 10.1073/pnas.77.11.6363; HOLZMAN TF, 1980, BIOCHEM BIOPH RES CO, V94, P1199, DOI 10.1016/0006-291X(80)90546-X; ILLARIONOV BA, 1988, NUCLEIC ACIDS RES, V16, P9855, DOI 10.1093/nar/16.20.9855; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASAI S, 1982, FLAVINS FLAVOPROTEIN, P459; KISHAN KVR, 1994, PROTEIN SCI, V3, P779; KOIDE S, 1993, BIOCHEMISTRY-US, V32, P12299, DOI 10.1021/bi00097a005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIM LW, 1986, J BIOL CHEM, V261, P5140; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MAYR LM, 1993, J MOL BIOL, V231, P897, DOI 10.1006/jmbi.1993.1336; MAYR LM, 1994, J MOL BIOL, V240, P288, DOI 10.1006/jmbi.1994.1446; MEIGHEN EA, 1971, J BIOL CHEM, V246, P7666; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MINOR W, 1993, PURDUE U; MOORE SA, 1994, PROTEIN SCI, V3, P1914, DOI 10.1002/pro.5560031103; MOORE SA, 1995, J MOL BIOL, V249, P195, DOI 10.1006/jmbi.1995.0289; MOORE SA, 1993, EMBO J, V12, P1767, DOI 10.1002/j.1460-2075.1993.tb05824.x; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICOLI MZ, 1974, J BIOL CHEM, V249, P2393; NICOLI MZ, 1974, J BIOL CHEM, V249, P2385; NICOLI MZ, 1976, FLAVINS FLAVOPROTEIN, P87; OKANE DJ, 1987, FLAVINS FLAVOPROTEIN, P641; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossmann M. G., 1972, MOL REPLACEMENT METH; SCHULTZ DA, 1992, PROTEIN SCI, V1, P910, DOI 10.1002/pro.5560010709; SINCLAIR JF, 1993, BIOCHEMISTRY-US, V32, P5036, DOI 10.1021/bi00070a010; SINCLAIR JF, 1994, NAT STRUCT BIOL, V1, P320, DOI 10.1038/nsb0594-320; SMITH TJ, 1995, J MOL GRAPHICS, V13, P122, DOI 10.1016/0263-7855(94)00019-O; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; SWANSON R, 1985, J BIOL CHEM, V260, P1287; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIN X, 1991, BIOCHEMISTRY-US, V30, P11255, DOI 10.1021/bi00111a010; ZHANG XJ, 1995, J MOL BIOL, V250, P527, DOI 10.1006/jmbi.1995.0396; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760; ZIEGLER MM, 1987, ANAL APPL BIOLUMINES, P377; ZIEGLER MM, 1981, BIOLUMINESCENCE CHEM, P155; 1994, ACTA CRYSTALLOGR B, V50, P760	74	128	135	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21956	21968		10.1074/jbc.271.36.21956	http://dx.doi.org/10.1074/jbc.271.36.21956			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703001	hybrid			2022-12-27	WOS:A1996VF61200043
J	Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ			tau couples the leading- and lagging-strand polymerases at the Escherichia coli DNA replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE HOLOENZYME PARTICLE; OKAZAKI FRAGMENT SIZE; III HOLOENZYME; SLIDING CLAMPS; INITIATION COMPLEX; PRIMER SYNTHESIS; BETA-SUBUNIT; BACTERIOPHAGE-T4; PURIFICATION; PROTEINS	Synthesis of an Okazaki fragment occurs once every 1 or 2 s at the Escherichia coli replication fork. To account for the rapid recycling required of the lagging-strand polymerase, it has been proposed that it is held at the replication fork by protein-protein interactions with the leading-strand polymerase as part of a dimeric polymerase assembly, Solution studies showed that the replicative polymerase, the DNA polymerase III holoenzyme, was indeed a dimer with two catalytic cores held together by the tau subunit. However, the functionality of this arrangement at the replication fork has never been demonstrated, We showed previously that the lagging-strand polymerase acted processively during multiple rounds of Okazaki fragment synthesis, i.e. the same polymerase core assembly synthesized each and every fragment made by the fork. Using extreme dilution of active replication forks and the isolation of protein-DNA complexes capable of supporting coupled leading- and lagging-strand synthesis, we demonstrate here that this coupling of leading- and lagging-strand synthesis is, in fact, mediated by the tau subunit of the holoenzyme acting as a physical bridge between the core assemblies synthesizing the leading and lagging strands.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, S (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036255, R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36255, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1989, J BIOL CHEM, V264, P12220; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LEE MS, 1989, J BIOL CHEM, V264, P14531; MAKI H, 1988, J BIOL CHEM, V263, P6570; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SELICK HE, 1987, UCLA S MOL CELLULAR, P183; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; WU YH, 1984, J BIOL CHEM, V259, P2117; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	43	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21406	21412		10.1074/jbc.271.35.21406	http://dx.doi.org/10.1074/jbc.271.35.21406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702922	hybrid			2022-12-27	WOS:A1996VE47700068
J	Terry, MJ; Kendrick, RE				Terry, MJ; Kendrick, RE			The aurea and yellow-green-2 mutants of tomato are deficient in phytochrome chromophore synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG HYPOCOTYL MUTANTS; IMMUNOCHEMICALLY DETECTABLE PHYTOCHROME; SHADE-AVOIDANCE RESPONSES; FAR-RED LIGHT; SIGNAL-TRANSDUCTION; BLUE-LIGHT; BIOSYNTHESIS; ARABIDOPSIS; EXPRESSION; PLANTS	The phytochrome-deficient aurea mutant of tomato has been widely used for the study of both phytochrome function and the role of other photoreceptors in the control of development in higher plants. To date the exact nature of the aurea mutation has remained unknown, though this information is clearly important for the interpretation of these studies. It has been proposed that aurea and yellow-green-2, another mutant of tomato that has a similar phenotype to aurea, could be deficient in phytochrome chromophore synthesis. We have examined this hypothesis by measuring the activity of the enzymes committed to phytochrome chromophore synthesis in these mutants. The approach takes advantage of a recently developed high pressure liquid chromatography-based assay for the synthesis of the free phytochrome chromophore, phytochromobilin from its immediate precursors biliverdin IX alpha and heme. Isolated etioplasts from aurea and yellow-green-2 seedlings were specifically unable to convert biliverdin IX alpha to 3Z-phytochromobilin and heme to biliverdin IX alpha, respectively. In addition, the level of total noncovalently bound heme in the mutants was the same as in wild type seedlings. Together, these results identify both aurea and yellow-green-2 as mutants that are deficient in phytochrome chromophore synthesis.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,LAB PHOTOPERCEPT & SIGNAL TRANSDUCT,WAKO,SAITAMA 35101,JAPAN	RIKEN	Terry, MJ (corresponding author), UNIV SOUTHAMPTON,DEPT BIOL,BASSETT CRESCENT E,BIOMED SCI BLDG,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND.		Terry, Matthew/B-3000-2012; Terry, Matthew/ABE-6419-2020	Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708				ADAMSE P, 1988, J PLANT PHYSIOL, V133, P436, DOI 10.1016/S0176-1617(88)80032-4; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BECKER TW, 1992, PLANTA, V188, P39, DOI 10.1007/BF00198937; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burdick A.B., 1958, TOMATO GENET COOP RE, V8, P9; BUURMEIJER WF, 1987, PROGR PHOTOSYNTHESIS, V2, P383; CASAL JJ, 1993, PLANT CELL ENVIRON, V16, P703, DOI 10.1111/j.1365-3040.1993.tb00489.x; CHERESKIN BM, 1982, PLANT PHYSIOL, V68, P112; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; Darby L. A., 1978, UK, Glasshouse Crops Research Institute: Annual report 1977., P168; ELICH TD, 1989, J BIOL CHEM, V264, P183; ELICH TD, 1987, PLANT PHYSIOL, V84, P304, DOI 10.1104/pp.84.2.304; GEORGHIOU K, 1991, PHYSIOL PLANTARUM, V82, P127, DOI 10.1111/j.1399-3054.1991.tb02912.x; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KENDROR S, 1990, PLANT PHYSIOL, V9, P1004; KERCKHOFFS LHJ, 1992, PHOTOCHEM PHOTOBIOL, V56, P611, DOI 10.1111/j.1751-1097.1992.tb02210.x; KERR EA, 1979, TOMATO GENET COOP RE, V29, P27; KHUSH GS, 1968, CHROMOSOMA, V23, P452, DOI 10.1007/BF00625288; Koornneef M., 1981, Induced mutations -- a tool in plant research. Proceedings of an international symposium. Vienna, 9-13 March 1981, P227; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; KOORNNEEF M, 1985, J PLANT PHYSIOL, V120, P153, DOI 10.1016/S0176-1617(85)80019-5; KRAEPIEL Y, 1994, MOL GEN GENET, V242, P559, DOI 10.1007/BF00285279; LEE HJ, 1991, PLANT PHYSIOL, V96, P910, DOI 10.1104/pp.96.3.910; LESLEY JW, 1956, GENETICS, V41, P575; LOPEZJUEZ E, 1990, J PHOTOCH PHOTOBIO B, V4, P391, DOI 10.1016/1011-1344(90)85018-R; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OELMULLER R, 1989, PLANT MOL BIOL, V13, P223, DOI 10.1007/BF00016140; OELMULLER R, 1991, PLANT MOL BIOL, V16, P293, DOI 10.1007/BF00020560; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PARKS BM, 1987, PLANT MOL BIOL, V9, P97, DOI 10.1007/BF00015642; PARKS BM, 1989, PLANT MOL BIOL, V12, P425, DOI 10.1007/BF00017582; PETERS JL, 1992, PHOTOCHEM PHOTOBIOL, V56, P75, DOI 10.1111/j.1751-1097.1992.tb09605.x; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; SHARMA R, 1993, PLANT J, V4, P1035, DOI 10.1046/j.1365-313X.1993.04061035.x; SHARROCK RA, 1988, MOL GEN GENET, V213, P9, DOI 10.1007/BF00333391; SMITH H, 1993, PLANT CELL ENVIRON, V16, P929, DOI 10.1111/j.1365-3040.1993.tb00516.x; SMITH KM, 1975, PORPHYRINS METALLOPO, P872; TERRY MJ, 1995, J BIOL CHEM, V270, P11111, DOI 10.1074/jbc.270.19.11111; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; TERRY MJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P1, DOI 10.1006/abbi.1993.1473; VANTUINEN A, 1995, PLANT PHYSIOL, V108, P939, DOI 10.1104/pp.108.3.939; VANTUINEN A, 1995, MOL GEN GENET, V246, P133, DOI 10.1007/BF00294675; vanTuinen A, 1996, PLANT J, V9, P173, DOI 10.1046/j.1365-313X.1996.09020173.x; Weller JL, 1996, PLANT CELL, V8, P55; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439; WHITELAM GC, 1994, PLANT CELL ENVIRON, V17, P615, DOI 10.1111/j.1365-3040.1994.tb00153.x; WHITELAM GC, 1991, J PLANT PHYSIOL, V139, P119, DOI 10.1016/S0176-1617(11)80176-8	52	81	86	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21681	21686		10.1074/jbc.271.35.21681	http://dx.doi.org/10.1074/jbc.271.35.21681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702958	hybrid			2022-12-27	WOS:A1996VE47700104
J	Glerum, DM; Shtanko, A; Tzagoloff, A				Glerum, DM; Shtanko, A; Tzagoloff, A			SCO1 and SCO2 act as high copy suppressors of a mitochondrial copper recruitment defect Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; MEMBRANE SYSTEM; PROTEIN; GENE; CLONING; EXPRESSION; SITES; DNA; ENCODES	C129/U1 is a respiratory defective mutant of Saccharomyces cerevisiae arrested in cytochrome oxidase assembly due to a mutation in COX17, a nuclear gene encoding a low molecular weight cytoplasmic protein proposed to function in mitochondrial copper recruitment. In the present study we show that the respiratory defect of C129/U1 is rescuable by two multicopy suppressors, SCO1 and SCO2. SCO1 was earlier reported to code for a mitochondrial inner membrane protein with an essential function in cytochrome oxidase assembly (Buchwald, P., Krummeck, G., and Rodel, G. (1991) Mol. Gen, Genet, 229, 413-420). SCO2 is a homologue of SCO1, whose product is also localized in the mitochondrial membrane but is not required for respiration. SCO1 also suppresses a cox17 null mutant, indicating that overexpression of Sco1p can compensate for the absence of Cox17p, In contrast, neither copper, COX17 on a multicopy plasmid, or a combination of the two is able to restore respiration in sco1 mutants, Rescue of cox17 mutants by Sco1p suggests that this mitochondrial protein plays a role either in mitochondrial copper transport or insertion of copper into the active site of cytochrome oxidase, Although SCO2 can also partially restore respiratory growth in the cox17 null mutant, rescue in this case requires addition of copper to the growth medium, SCO2 does not suppress a sco1 null mutant, although it is able to partially rescue a sco1 point mutant, We interpret the ability of SCO2 to restore respiration in cox17, but not in sco1 mutants, to indicate that Sco1p and Sco2p have overlapping but not identical functions.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; BUGGY J, 1995, J BACTERIOL, V177, P6958, DOI 10.1128/jb.177.23.6958-6965.1995; CORUZZI G, 1979, J BIOL CHEM, V254, P9324; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CUYPERS H, 1993, J BACTERIOL, V175, P7236, DOI 10.1128/JB.175.22.7236-7246.1993; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHAN SM, 1994, MICROBIOL-SGM, V140, P2135, DOI 10.1099/13500872-140-8-2135; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VISSER ES, 1992, INFECT IMMUN, V60, P5139, DOI 10.1128/IAI.60.12.5139-5144.1992; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	30	270	274	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20531	20535		10.1074/jbc.271.34.20531	http://dx.doi.org/10.1074/jbc.271.34.20531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702795	hybrid			2022-12-27	WOS:A1996VD33700047
J	Pei, L				Pei, L			Identification of a negative glucocorticoid response element in the rat type 1 vasoactive intestinal polypeptide receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ENHANCER; DNA ELEMENT; HORMONE; LUNG; EXPRESSION; BINDING; INHIBITION; PROMOTER; PEPTIDE; MODULATION	Glucocorticoids play important roles in lung development and function by modulating the expression of a variety of genes. The type 1 vasoactive intestinal polypeptide (VIP) receptor gene is highly expressed in the lung where it mediates VIP physiological functions. In this study, the effect of glucocorticoid on VIP receptor gene expression was examined. Dexamethasone (100 nM) suppresses endogenous VIP receptor mRNA expression in cultured lung cells. Transient transfection of lung cells with fusion constructs containing various portions of the VIP receptor 5'-flanking sequences linked to the luciferase reporter gene shows that 126 base pairs (bp) of the VIP receptor upstream sequences are sufficient to mediate transcriptional repression by glucocorticoid. DNase I footprinting demonstrates that purified glucocorticoid receptor (Gat) binds to the VIP receptor promoter between -21 and -36 bp relative to the transcription start site. Point mutations within this binding site not only abolish GR binding and GR-mediated transcriptional repression of the VIP receptor gene, but basal transcription is also reduced to background levels, Co-transfection of GR expression vector and the VIP receptor GR binding site linked to the thymidine kinase promoter and luciferase shows that this sequence is sufficient to confer glucocorticoid-mediated transcriptional repression to a heterologous promoter. These results indicate that the VIP receptor gene contains a negative glucocorticoid response element between -21 and -36 bp that may act to regulate both basal and glucocorticoid-mediated expressions of the VIP receptor gene in lung cells.	UNIV CALIF LOS ANGELES, CEDARS SINAI RES INST, SCH MED, DIV ENDOCRINOL, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRODY JS, 1992, ANNU REV PHYSIOL, V54, P351, DOI 10.1146/annurev.physiol.54.1.351; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P1409; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LITWIN D K, 1989, American Review of Respiratory Disease, V139, pA158; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MARIENCHECK W, 1994, AM J RESP CELL MOL, V10, P419, DOI 10.1165/ajrcmb.10.4.8136157; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; OTTAWAY CA, 1987, IMMUNOLOGY, V62, P291; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PEI L, 1995, BIOCHEM J, V308, P719, DOI 10.1042/bj3080719; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SAID SI, 1988, ANN NY ACAD SCI, V527, P450; SAID SI, 1987, AM REV RESPIR DIS S, V136, P525; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SARANTOS P, 1993, METABOLISM, V42, P795, DOI 10.1016/0026-0495(93)90252-J; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P934; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCREEDHARAN SP, 1993, BIOCH BOPHYS RES COM, V193, P546; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; WASCHEK JA, 1995, CANCER LETT, V92, P143, DOI 10.1016/0304-3835(95)03768-R; WRANGE O, 1989, J BIOL CHEM, V264, P5253; WRANGE O, 1986, J BIOL CHEM, V261, P1770; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZITNIK RJ, 1994, AM J RESP CELL MOL, V10, P643, DOI 10.1165/ajrcmb.10.6.7516173	42	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20879	20884						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702844				2022-12-27	WOS:A1996VD33700096
J	Young, P; Andersson, J; Sahlin, M; Sjoberg, BM				Young, P; Andersson, J; Sahlin, M; Sjoberg, BM			Bacteriophage T4 anaerobic ribonucleotide reductase contains a stable glycyl radical at position 580	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; TYROSYL RADICAL-DIIRON(III) COFACTOR; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; MOSSBAUER SPECTROSCOPIES; DIPHOSPHATE REDUCTASE; PHENOTYPIC SELECTION; FE2+ REACTION; PROTEIN; IRON	It has been recently recognized that the class III anaerobic ribonucleotide reductase requires the presence of a second activating gene product, NrdG, me have proposed that the rob for NrdG involves the generation of an oxygen sensitive glycyl free radical within the NrdD enzyme, In this article we present the generation of such a glycyl free radical within the T4 NrdD subunit and its dependence upon the phage NrdG subunit, Initially, an overexpression system was created that allowed the joint production of T4 NrdD and T4 NrdG, With this system and in the presence of T4 NrdG, an oxygen-sensitive cleavage of NrdD was observed that mimicked the cleavage observed in phage infected Escherichia coli extracts, Under anaerobic conditions the presence of T4 NrdD with NrdG revealed a strong doublet EPR signal (g = 2.0039), Isotope labeling of the NrdD with [H-2]glycine and [C-13]glycine, respectively, confirmed the presence of a stabilized glycine radical, The unpaired electron is strongly coupled to C-2 in glycine and the doublet splitting originates from one of the alpha-protons, The glycine residue at position 580 was determined to be the radical containing residue through site-directed mutagenesis studies involving a G580A NrdD mutant, The glycyl radical generation was specific for the T4 NrdG, and the host E. coli NrdG was found to be unable to activate the phage reductase, Finally, anaerobic purification revealed the holoenzyme complex to contain iron, whereas the NrdD polypeptide was found to lack the metal, Our results suggest a tetrameric structure for the T4 anaerobic ribonucleotide reductase containing one homodimer each of NrdD and NrdG, with a single glycyl radical present.	UNIV STOCKHOLM, DEPT MOL BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ALBERTS BM, 1986, AM ZOOL, V26, P781; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BERGLUND O, 1972, J BIOL CHEM, V247, P7270; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; ELGREN TE, 1991, J BIOL CHEM, V266, P19265; ELIASSON R, 1994, J BIOL CHEM, V269, P26116; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ERIKSSON S, 1977, J BIOL CHEM, V252, P6132; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FREY M, 1994, J BIOL CHEM, V269, P12432; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARDER J, 1992, J BIOL CHEM, V267, P25548; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LING JS, 1994, J BIOL CHEM, V269, P5595; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P5712, DOI 10.1021/bi00017a002; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAWERS G, 1989, J BACTERIOL, V171, P2485, DOI 10.1128/jb.171.5.2485-2498.1989; SAWERS G, 1988, J BACTERIOL, V170, P5330, DOI 10.1128/jb.170.11.5330-5336.1988; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; STUBBE J, 1994, NATURE, V370, P502, DOI 10.1038/370502a0; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WATSON JD, 1987, MOL BIOL GENE, P1098; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005; YOUNG P, 1994, J BIOL CHEM, V269, P27815; YOUNG P, 1994, J BIOL CHEM, V269, P20229; ZEEH A, 1991, J BACTERIOL, V173, P6980, DOI 10.1128/jb.173.21.6980-6985.1991	44	46	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20770	20775		10.1074/jbc.271.34.20770	http://dx.doi.org/10.1074/jbc.271.34.20770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702830	hybrid			2022-12-27	WOS:A1996VD33700082
J	Hinoi, T; Kishida, S; Koyama, S; Ikeda, M; Matsuura, Y; Kikuchi, A				Hinoi, T; Kishida, S; Koyama, S; Ikeda, M; Matsuura, Y; Kikuchi, A			Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; C-TERMINAL REGION; GUANINE-NUCLEOTIDE EXCHANGE; PLASMA-MEMBRANE; ACTIVATING PROTEIN; P21; IDENTIFICATION; EFFECTOR; RAC1; GTPASES	Ral GDP dissociation stimulator (RalGDS) is a GDP/GTP exchange protein of Ral and a new effector protein of Ras. Therefore, there may be a new signaling pathway from Ras to Ral. In this paper, we examined the roles of the post-translational modifications of Ras and Ral on this new signal transduction pathway. The post-translationally modified form of Ras bound to RalGDS more effectively than the unmodified form. The modification of Ras was required to regulate the distribution of RalGDS between the cytosol and membrane fractions in COS cells. The post-translational modification of Ral enhanced the activities of RalGDS to stimulate the dissociation of GDP from and the binding of GTP to Ral. Furthermore, the modified form of Ral bound to Ral-binding protein 1 (RalBP1), a putative effector protein of Ral, more effectively than the unmodified form. Taken together with the observations that Ras and Ral are localized to the membranes, these results suggest that the post-translational modifications of Ras and Ral play a role for transmitting the signal effectively on the membranes in the signal transduction pathway of Ras/RalGDS/Ral/RalBP1.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST HLTH,DEPT VIROL 2,SHINJUKU KU,TOKYO 162,JAPAN	Hiroshima University			Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; FRECH M, 1990, J BIOL CHEM, V265, P6353; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HORI Y, 1991, ONCOGENE, V6, P515; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; ITOH T, 1993, J BIOL CHEM, V268, P3025; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLOFSSON B, 1988, ONCOGENE, V3, P231; ORITA S, 1993, J BIOL CHEM, V268, P25542; Park SH, 1995, ONCOGENE, V11, P2349; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	65	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19710	19716		10.1074/jbc.271.33.19710	http://dx.doi.org/10.1074/jbc.271.33.19710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702675	hybrid			2022-12-27	WOS:A1996VC66900016
J	Natochin, M; Artemyev, NO				Natochin, M; Artemyev, NO			An interface of interaction between photoreceptor cGMP phosphodiesterase catalytic subunits and inhibitory gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; AMINO-ACID-SEQUENCE; ALPHA-SUBUNIT; BETA-SUBUNIT; NUCLEOTIDE PHOSPHODIESTERASE; ACTIVATION MECHANISM; INTERACTION SITES; HIGH-AFFINITY; RETINAL RODS	Cyclic guanosine 5'-monophosphate (cGMP) phosphodiesterase (PDE) regulates the level of cGMP on transduction of a visual signal in vertebrate photoreceptor cells. Two identical inhibitory PDE gamma subunits (P gamma s) block catalytic activity of PDE-alpha and -beta subunits (P alpha beta) in the dark. The primary regions of P gamma involved in the interaction with P alpha beta are a central polycationic region, P gamma-24-45, and a C-terminal region of P gamma. Recently, we have shown that the C-terminal region of P gamma, which is the major P gamma inhibitory domain, blocks PDE activity by binding to the catalytic site of PDE (Artemyev, N. O Natochin, M., Busman, M., Schey, K. L., and Hamm, H. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5407-5412). Here, we localize the site on the rod cGMP PDE alpha subunit that binds to the central polycationic domain of P gamma. This site is located within a region that links a second noncatalytic cGMP binding site with the catalytic domain of PDE. A polypeptide coresponding to this region, P alpha-461-553, expressed as a glutathione S-transferase fusion protein in Escherichia coli and isolated after cleavage of the fusion protein with thrombin, blocks inhibition of PDE activity by P gamma. In addition, P alpha-461-553 binds to the P gamma-24-45 region (K-d, 7 mu M), as measured by a fluorescent increase in a P gamma-24-45Cys peptide labeled with 3-(bromoacetyl)-7-diethylaminocoumarin. The P alpha-461-553 region was further characterized by using a set of synthetic peptides. A peptide corresponding to residues 517-541 of P alpha (P alpha-517-541) effectively suppressed inhibition of PDE activity by P gamma and bound to P gamma-24-45Cys labeled with 3-(bromoacetyl) -7-diethylaminocoumarin (K-d, 22 mu M). P alpha-517-541 also competes with the activated rod G-protein alpha-subunit for binding to P gamma labeled with lucifer yellow vinyl sulfone. This suggests that light activation of rod PDE by the G-protein transducin involves competition between transducin alpha-guanosine 5'-triphosphate and P alpha-517-541 for binding: to the P gamma-24-45 region. Based on the results, we propose a linear model of interactions between catalytic and inhibitory PDE subunits.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa				Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; Maniatis T, 1989, MOL CLONING; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MIKI N, 1975, J BIOL CHEM, V250, P6320; OPPERT B, 1991, J BIOL CHEM, V266, P16607; OPPERT B, 1991, BIOCHEM BIOPH RES CO, V178, P474, DOI 10.1016/0006-291X(91)90131-P; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	40	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19964	19969		10.1074/jbc.271.33.19964	http://dx.doi.org/10.1074/jbc.271.33.19964			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702712	hybrid			2022-12-27	WOS:A1996VC66900053
J	Takeshima, H; Ikemoto, T; Nishi, M; Nishiyama, N; Shimuta, M; Sugitani, Y; Kuno, J; Saito, I; Saito, H; Endo, M; Iino, M; Noda, T				Takeshima, H; Ikemoto, T; Nishi, M; Nishiyama, N; Shimuta, M; Sugitani, Y; Kuno, J; Saito, I; Saito, H; Endo, M; Iino, M; Noda, T			Generation and characterization of mutant mice lacking ryanodine receptor type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; BINDING-PROTEIN ISOFORMS; BULLFROG SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; RABBIT BRAIN; CA2+ RELEASE; DNA; EXPRESSION; GENE	The ryanodine receptor type 3 (RyR-3) functions as a Ca2+-induced Ca2+ release (CICR) channel and is distributed in a wide variety of cell types including skeletal muscle and smooth muscle cells, neurons, and certain non-excitable cells. However, the physiological roles of RyR-3 are totally unclear. To gain an insight into the function of RyR-3 in vivo, we have generated mice lacking RyR-3 by means of the gene targeting technique. The mutant mice thus obtained showed apparently normal growth and reproduction. Although Ca2+-induced Ca2+ release from intracellular Ca2+ stores of the mutant skeletal muscle differed in Ca2+ sensitivity from that of wild-type muscle, excitation-contraction coupling of the mutant muscle seemed to be normal. Moreover, we could not find any significant disturbance in the smooth muscle and lymphocytes from the mutant mice. On the other hand, the mutant mice showed increased locomotor activity, which was about a-fold greater than that of the control mice. These results indicate that the loss of RyR-3 causes no gross abnormalities and suggest that the lack of RyR-3-mediated Ca2+ signaling results in abnormalities of certain neurons in the central nervous system.	SAITAMA MED SCH, DEPT PHARMACOL, MOROYAMA, SAITAMA 35001, JAPAN; TOKYO INST PSYCHIAT, DEPT NEUROCHEM, SETAGAYA KU, TOKYO 156, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT CHEM PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, MED RES INST, DIV IMMUNOL DIS, BUNKYO KU, TOKYO 113, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN	Saitama Medical University; Tokyo Institute of Psychiatry; University of Tokyo; Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Takeshima, H (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, HONGO 7-3-1, TOKYO 113, JAPAN.		Noda, Tetsuo/B-1667-2016; Tuluc, Petronel/C-2527-2011	Takeshima, Hiroshi/0000-0003-4525-3725				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHRIST M, 1994, J IMMUNOL, V153, P1936; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; RIOS E, 1994, PHYSIOL REV, V71, P840; Southern E, 1979, Methods Enzymol, V68, P152; SUTKO JL, 1991, J CELL BIOL, V113, P793, DOI 10.1083/jcb.113.4.793; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; ZHANG YX, 1994, BRAIN RES, V658, P127, DOI 10.1016/S0006-8993(09)90018-X	26	147	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19649	19652		10.1074/jbc.271.33.19649	http://dx.doi.org/10.1074/jbc.271.33.19649			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702664	hybrid			2022-12-27	WOS:A1996VC66900005
J	Wolfe, AM; Wray, S; Westphal, H; Radovick, S				Wolfe, AM; Wray, S; Westphal, H; Radovick, S			Cell-specific expression of the human gonadotropin-releasing hormone gene in transgenic animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTALIZED HYPOTHALAMIC NEURONS; GNRH MESSENGER-RNA; POU-DOMAIN; FEMALE RAT; TRANSCRIPTION FACTORS; INSITU HYBRIDIZATION; KALLMANN SYNDROME; ESTROGEN; LHRH; MOLECULES	We have previously demonstrated that 1131 base pairs (bp) of the human gonadotropin-releasing hormone (hGnRN) gene promoter can target simian virus 40 T antigen expression to GnRH neurons in transgenic mice. In these animals, GnRH neurons were transformed before they migrated to their final location in the rostral hypothalamus, complicating an analysis of cell-specific expression. To localize regions of the hGnRB promoter that are important for cell-specific expression, we created transgenic mice with various 5'-flanking regions of the hGnRH gene fused to the luciferase reporter gene, When 3828 or 1131 bp of the hGnRH promoter 5'-flanking DNA were used (-3828/+5LUC and -1131/+5LUC, respectively), luciferase expression in adult transgenic mice was observed in the rostral hypothalamus and olfactory tissues, regions which have been shown to be loci of GnRH-expressing neurons, Luciferase expression was not observed in other brain or peripheral tissues. Double-labeled in situ hybridization further demonstrated that luciferase expression was invariably colocalized with GnRH expression. When transgenic animals were created with a construct consisting of 484 bp of the hGnRH 5'-flanking DNA fused to the luciferase gene (-484/+5LUC), luciferase expression was not observed in the hypothalamus or in olfactory tissues. This is the first report localizing DNA sequences responsible for cell-specific expression of the GnRH gene in vivo.	CHILDRENS HOSP,DIV ENDOCRINOL,BOSTON,MA 02115; NINCDS,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892	Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Wray, Susan/AAT-2088-2021	wray, susan/0000-0001-7670-3915	NICHD NIH HHS [HD30040-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030040] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; Barry J., 1985, Handbook of Chemical Neuroanatomy, V4, P166; BESECKE LM, 1994, ENDOCRINOLOGY, V135, P1621, DOI 10.1210/en.135.4.1621; BOND CT, 1989, MOL ENDOCRINOL, V3, P1257, DOI 10.1210/mend-3-8-1257; BOSMA MM, 1993, J MEMBRANE BIOL, V136, P85; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONG KW, 1993, MOL ENDOCRINOL, V7, P1654, DOI 10.1210/me.7.12.1654; DUTLOW CM, 1992, J CLIN INVEST, V90, P2496, DOI 10.1172/JCI116142; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GORE AC, 1995, ENDOCRINOLOGY, V136, P879; HAYFLICK JS, 1989, NUCLEIC ACIDS RES, V17, P6403, DOI 10.1093/nar/17.15.6403; INGRAHAM HA, 1990, ANNU REV PHYSIOL, V52, P773; KELLY MJ, 1989, NEUROENDOCRINOLOGY, V49, P88, DOI 10.1159/000125095; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; KRSMANOVIC LZ, 1993, P NATL ACAD SCI USA, V90, P3908, DOI 10.1073/pnas.90.9.3908; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; MALIK KF, 1991, ANAT REC, V231, P457, DOI 10.1002/ar.1092310408; MARKS DL, 1994, ENDOCRINOLOGY, V134, P1991, DOI 10.1210/en.134.5.1991; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PARK O, 1990, ENDOCRINOLOGY, V127, P275; PETERSEN SL, 1995, ENDOCRINOLOGY, V136, P3604, DOI 10.1210/en.136.8.3604; RADOVICK S, 1991, J CLIN INVEST, V88, P1649, DOI 10.1172/JCI115479; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; ROBERTS JL, 1989, MOL BRAIN RES, V6, P127, DOI 10.1016/0169-328X(89)90046-6; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSIE R, 1990, J ENDOCRINOL, V124, P285, DOI 10.1677/joe.0.1240285; ROTHFELD J, 1989, MOL BRAIN RES, V6, P121, DOI 10.1016/0169-328X(89)90045-4; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SEEBURG PH, 1987, RECENT PROG HORM RES, V43, P69; Silverman Ann-Judith, 1994, P1683; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TORANZO D, 1989, MOL ENDOCRINOL, V3, P1748, DOI 10.1210/mend-3-11-1748; WEINER RI, 1993, HUM REPROD, V8, P13, DOI 10.1093/humrep/8.suppl_2.13; WETSEL WC, 1991, ENDOCRINOLOGY, V129, P1584, DOI 10.1210/endo-129-3-1584; WETSEL WC, 1993, ENDOCRINOLOGY, V132, P2360, DOI 10.1210/en.132.6.2360; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; WILSON TM, 1995, MOL ENDOCRINOL, V9, P44, DOI 10.1210/me.9.1.44; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; ZOELLER RT, 1988, ENDOCRINOLOGY, V122, P2570, DOI 10.1210/endo-122-6-2570	44	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20018	20023		10.1074/jbc.271.33.20018	http://dx.doi.org/10.1074/jbc.271.33.20018			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702719	hybrid			2022-12-27	WOS:A1996VC66900060
J	Xu, BXC; Wang, XZ; Darns, CJ; Kopchick, JJ				Xu, BXC; Wang, XZ; Darns, CJ; Kopchick, JJ			Growth hormone promotes the association of transcription factor STAT5 with the growth hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; TYROSINE-PHOSPHORYLATED PROTEINS; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; INTERFERON-GAMMA; GH RECEPTORS; DNA-BINDING; BETA-CHAIN; ACTIVATION; PROLACTIN	Members of the cytokine/growth hormone (GH)/prolactin receptor superfamily transduce signals by association and activation of JAK tyrosine kinases. For GH receptor (GHR), both JAK2 and the GHR undergo tyrosine phosphorylation upon GH stimulation. Also, GH has recently been shown to activate the transcription factor STAT5 by tyrosine phosphorylation. In the present study, we demonstrate that GH induces rapid tyrosine phosphorylation of different isoforms of STAT5 in mouse L cells stably transfected with a cDNA encoding porcine GHR (pGHR). In this cell system, STAT5 directly interacts with the GHR in a GH-dependent manner. Additionally, GH-induced tyrosine phosphorylation of STAT5 and the interaction of STATE with GHR can be observed in mouse 3T3-F442A cells which express endogenous mouse GHR. Interestingly; when cDNAs encoding the two mouse STAT5 homologs (STAT5A and STAT5B) were individually transfected into mouse L cells expressing pGHR, only STAT5A demonstrated the ability to interact with the pGHR and subsequently underwent GH-dependent tyrosine phosphorylation. STAT5B did not. Therefore, the GH-dependent interaction of a particular STATE with tyrosine-phosphorylated GHR may play an important role in GH-mediated signal transduction.	OHIO UNIV,EDISON BIOTECHNOL INST,KONNEKER RES LABS THE RIDGES,MOL & CELLULAR BIOL PROGRAM,ATHENS,OH 45701; OHIO UNIV,DEPT SCI BIOL,ATHENS,OH 45701; MASSACHUSETTS GEN HOSP,GENE THERAPY CTR,BOSTON,MA 02114	University System of Ohio; Ohio University; University System of Ohio; Ohio University; Harvard University; Massachusetts General Hospital								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHOW JC, 1996, IN PRESS ENDOCRINOLO; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAHARAJAN P, 1993, EXPERIENTIA, V49, P980, DOI 10.1007/BF02125645; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVA CM, 1994, J BIOL CHEM, V269, P27532; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1350; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG XZ, 1993, MOL CELL ENDOCRINOL, V94, P89, DOI 10.1016/0303-7207(93)90055-O; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU BC, 1995, RECEPTOR, V5, P105; ZHOU YH, 1994, RECEPTOR, V4, P143	43	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19768	19773		10.1074/jbc.271.33.19768	http://dx.doi.org/10.1074/jbc.271.33.19768			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702683	hybrid			2022-12-27	WOS:A1996VC66900024
J	Deleersnijder, W; Hong, GZ; Cortvrindt, R; Poirier, C; Tylzanowski, P; Pittois, K; VanMarck, E; Merregaert, J				Deleersnijder, W; Hong, GZ; Cortvrindt, R; Poirier, C; Tylzanowski, P; Pittois, K; VanMarck, E; Merregaert, J			Isolation of markers for chondro-osteogenic differentiation using cDNA library subtraction - Molecular cloning and characterization of a gene belonging to a novel multigene family of integral membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; MESENCHYMAL STEM-CELLS; MANDIBULAR CONDYLES; SECONDARY CARTILAGE; HUMAN BONE; HYBRIDIZATION; OSTEOBLASTS; CLONES; EXPRESSION; MOUSE	To identify novel marker molecules associated with chondro-osteogenic differentiation, we have set up a differential screening system based on a cDNA library subtraction in organ cultures of prenatal mouse mandibular condyles, Differential screening of a cDNA library constructed from in vitro cultured condyles allowed the isolation of a novel gene, named E25, Full-length E25 cDNA is predicted to encode a type II integral membrane protein of 263 amino acid residues, In situ hybridization experiments show that E25 is expressed in the outer perichondrial rim of the postnatal mandibular condyle, which contains the proliferating progenitor cells, but not in the deeper layers of the condyle containing the more differentiated chondroblasts and chondrocytes, Other cartilagenous tissues and their perichondrium were negative, Strong in situ hybridization signals were also detected on bone trabeculae of mature bone in tooth germs and in hair follicles, Northern blot analysis showed strong expression in osteogenic tissues, such as neonatal mouse calvaria, paws, tail, and in skin, This expression profile suggests that E25 could be a useful marker for chondro-osteogenic differentiation. Homology searches of DNA databanks showed that E25 belongs to a novel multigene family, containing three members both in man and mouse. The mouse E25 gene locus (Itm2) was mapped to the X chromosome.	UNIV ANTWERP,DEPT BIOCHEM,LAB MOL BIOTECHNOL,B-2610 WILRIJK,BELGIUM; UNIV ANTWERP,DEPT PATHOL,B-2610 WILRIJK,BELGIUM; NV INNOGENET,GHENT,BELGIUM; INST PASTEUR,UNITE GENET MAMMIFERES,F-75724 PARIS,FRANCE	University of Antwerp; University of Antwerp; Innogenetics NV; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Tylzanowski, Przemko/G-8881-2013	Tylzanowski, Przemko/0000-0003-0769-559X				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENAMI Y, 1993, CELL TISSUE RES, V271, P317, DOI 10.1007/BF00318618; BENNETT JH, 1991, J CELL SCI, V99, P131; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; BRUDER SP, 1990, BONE, V11, P189, DOI 10.1016/8756-3282(90)90213-I; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DENIS MG, 1992, INT J CANCER, V50, P930, DOI 10.1002/ijc.2910500619; FRIEMERT C, 1991, GENE, V103, P259, DOI 10.1016/0378-1119(91)90283-H; GLASSTONE S, 1968, NATURE, V220, P705, DOI 10.1038/220705a0; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HALL BK, 1987, CLIN ORTHOP RELAT R, V225, P255; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hong GZ, 1996, GENOMICS, V31, P295, DOI 10.1006/geno.1996.0051; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LANSKE B, 1992, VERH DTSCH GES PATHO, V76, P377; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MONTAGUTELLI X, 1990, J HERED, V81, P490, DOI 10.1093/oxfordjournals.jhered.a111033; Murray P. D. F., 1965, Australian Journal of Zoology, V13, P351, DOI 10.1071/ZO9650351; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; PALAZZOLO MJ, 1989, NEURON, V3, P527, DOI 10.1016/0896-6273(89)90211-0; ROSEN V, 1994, J BONE MINER RES, V9, P1759; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINFEST CW, 1992, INT J ONCOL, V1, P499; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILBERMANN M, 1987, J CRAN GENET DEV BIO, V7, P59; SILBERMANN M, 1983, ANAT REC, V206, P373, DOI 10.1002/ar.1092060404; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STRAUSS PG, 1990, J CELL BIOL, V110, P1369, DOI 10.1083/jcb.110.4.1369; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VINKKAPUHAKKA H, 1993, ARCH ORAL BIOL, V38, P49, DOI 10.1016/0003-9969(93)90154-E; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WALSH S, 1994, J BONE MINER RES, V9, P1687; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WAYE MMY, 1994, J CELL BIOCHEM, V54, P273, DOI 10.1002/jcb.240540303; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	51	91	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19475	19482		10.1074/jbc.271.32.19475	http://dx.doi.org/10.1074/jbc.271.32.19475			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702637	hybrid			2022-12-27	WOS:A1996VB68400071
J	Faber, C; Lindemann, A; Sticht, H; Ejchart, A; Kungl, A; Susani, M; Frank, RW; Kraft, D; Breitenbach, M; Rosch, P				Faber, C; Lindemann, A; Sticht, H; Ejchart, A; Kungl, A; Susani, M; Frank, RW; Kraft, D; Breitenbach, M; Rosch, P			Secondary structure and tertiary fold of the birch pollen allergen Bet v 1 in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; 3-DIMENSIONAL NMR-SPECTROSCOPY; MULTIPLE QUANTUM COHERENCE; COMMON AMINO-ACIDS; STRUCTURE PREDICTION; DISTANCE GEOMETRY; CHEMICAL-SHIFTS; MAJOR ALLERGEN; PROTEIN STRUCTURES; HETERONUCLEAR NMR	Bet v 1 is the major birch pollen allergen and therefore the main cause of type I allergies observed in early spring. It is composed of 159 amino acid residues adding up to a molecular mass of 17 kDa. We determined the secondary structure and tertiary fold of full-length Bet v 1 by NMR spectroscopy. Two- and three-dimensional NMR measurements suggest that Bet v 1 is a globular monomer in solution with a high content of well defined secondary structure. Of the total of 159 residues, 135 could be sequentially assigned, using an improved assignment strategy based mainly on heteronuclear experiments. An improved strategy for structure calculation revealed three helices and two beta-sheets as major elements of secondary structure. The globular tertiary structure is mainly stabilized by two antiparallel beta-sheets, The two helices at the C terminus are in accordance with the results from the solution structure of the chemically synthesized peptide Bet v 1-(125-154). This peptide is composed of two helices connected by a hinge. The structural features of Bet v 1 are highly similar to those found in the Ambrosia allergen Amb t V.	UNIV BAYREUTH,LEHRSTUHL BIOPOLYMERE,D-95447 BAYREUTH,GERMANY; SALZBURG UNIV,INST BIOL ALLGEMEINE GENET,A-5020 SALZBURG,AUSTRIA; ZENTRUM MOL BIOL,ZMBH,D-69120 HEIDELBERG,GERMANY; ADV BIOL SYST,A-5020 SALZBURG,AUSTRIA; SANDOZ INST MED RES,A-1235 VIENNA,AUSTRIA; INST ALLGEMEINE & EXPT PATHOL,A-1090 VIENNA,AUSTRIA	University of Bayreuth; Salzburg University; Ruprecht Karls University Heidelberg; Novartis; Sandoz			Faber, Cornelius/Q-2689-2016; Rösch, Paul/I-5445-2014	Faber, Cornelius/0000-0001-7683-7710; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X; Kungl, Andreas/0000-0003-3362-797X				BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BRUNGER AT, 1993, XPLOR 3 1 MANUAL; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; EBNER C, 1993, J IMMUNOL, V150, P1047; Ernst R.R., 1992, ANGEW CHEM, V104, P817; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FESIK SW, 1989, BIOCHEM BIOPH RES CO, V159, P842, DOI 10.1016/0006-291X(89)90071-5; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Frank R., 1988, MODERN METHODS PROTE, V3, P41; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRONENBORN AM, 1989, FEBS LETT, V243, P93, DOI 10.1016/0014-5793(89)81224-4; GRONENBORN AM, 1989, BIOCHEMISTRY-US, V28, P5081, DOI 10.1021/bi00438a027; GUNTERT P, 1992, J MAGN RESON, V96, P403, DOI 10.1016/0022-2364(92)90095-O; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LINDEMANN A, 1995, THESIS U BAYREUTH GE; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5177; MULLER L, 1979, J AM CHEM SOC, V101, P4481; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; QI PX, 1994, BIOCHEMISTRY-US, V33, P6408, DOI 10.1021/bi00187a004; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROST B, 1995, 3 INT C INT SYST MOL, P314; SCHMIDT JM, 1991, EUR J BIOCHEM, V197, P643, DOI 10.1111/j.1432-1033.1991.tb15954.x; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	44	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19243	19250		10.1074/jbc.271.32.19243	http://dx.doi.org/10.1074/jbc.271.32.19243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702605	hybrid			2022-12-27	WOS:A1996VB68400039
J	Falla, TJ; Karunaratne, DN; Hancock, REW				Falla, TJ; Karunaratne, DN; Hancock, REW			Mode of action of the antimicrobial peptide indolicidin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYER-MEMBRANES; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; ANTIBACTERIAL PEPTIDES; ESCHERICHIA-COLI; BACTERICIDAL ACTIVITY; SECONDARY STRUCTURE; BOVINE NEUTROPHILS; MAGAININ-2 AMIDE; PIG INTESTINE	Indolicidin is a cationic antimicrobial peptide isolated from bovine neutrophils. It consists of only 13 amino acids, has the highest tryptophan content of any known protein, and is amidated at the carboxyl terminus in nature. By circular dichroism spectroscopy a weak poly-L-proline II extended helix structure was observed that became substantially more pronounced upon interaction with liposomes, Indolicidin bound purified surface lipopolysaccharide with high affinity and permeabilized the outer membrane of Escherichia coli to the small hydrophobic molecule 1-N-phenylnapthylamine (M(x) 200), results consistent with indolicidin crossing the outer membrane via the self-promoted uptake pathway. The methyl esterification of indolicidin's carboxyl terminus increased its activity for Gram-negative and Gram-positive bacteria, In Gram-negative bacteria this was associated with an increased binding to lipopolysaccharide and increased permeabilization of the outer membrane, The cytoplasmic membrane was the site of action of indolicidin as assayed in E. coli by the unmasking of cytoplasmic beta-galactosidase due to membrane permeabilization, The mechanism for this activity was shown to be the ability of the peptide to cause an increase in the transmembrane current of planar lipid bilayers, This current increase was activated by transmembrane potentials in excess of -70 to -80 mV. Consistent with this, there was a substantial decrease in indolicidin-mediated bacterial killing and permeabilization of the cytoplasmic membrane of E. coli that had been pretreated with the uncoupler carbonyl cyanide-m-chlorophenyl hydrazone, In planar bilayers, indolicidin induced the formation of discrete channels, which ranged in conductance from 0.05-0.15 nS. Thus despite the small size and unique composition of indolicidin, it was capable of killing Gram-negative bacteria by crossing the outer membrane and causing disruption of the cytoplasmic membrane by channel formation.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia			Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; Amsterdam D., 1991, ANTIBIOTICS LAB MED, P72; ANGUS BL, 1982, ANTIMICROB AGENTS CH, V21, P299, DOI 10.1128/AAC.21.2.299; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V646, P298, DOI 10.1016/0005-2736(81)90336-9; BOHEIM G, 1974, J MEMBRANE BIOL, V19, P277, DOI 10.1007/BF01869983; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; CABIAUX V, 1994, EUR J BIOCHEM, V224, P1019, DOI 10.1111/j.1432-1033.1994.01019.x; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DAVID SA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P269, DOI 10.1016/0005-2760(92)90006-H; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; HANCOCK REW, 1981, ANTIMICROB AGENTS CH, V19, P777, DOI 10.1128/AAC.19.5.777; HANCOCK REW, 1979, J BACTERIOL, V140, P902, DOI 10.1128/JB.140.3.902-910.1979; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; JURETIC D, 1989, FEBS LETT, V249, P219, DOI 10.1016/0014-5793(89)80627-1; KADABA PK, 1972, SYNTH-INT J METHODS, P628; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KORDEL M, 1988, J BACTERIOL, V170, P84, DOI 10.1128/jb.170.1.84-88.1988; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; PIERS KL, 1994, MOL MICROBIOL, V12, P951, DOI 10.1111/j.1365-2958.1994.tb01083.x; RAJ PA, 1995, FEBS LETT, V368, P526, DOI 10.1016/0014-5793(95)00712-I; RANA FR, 1990, FEBS LETT, V261, P464, DOI 10.1016/0014-5793(90)80616-Q; RICHMOND MH, 1976, ANTIMICROB AGENTS CH, V10, P215, DOI 10.1128/AAC.10.2.215; ROMEO D, 1988, J BIOL CHEM, V263, P9573; RONISH EW, 1974, BIOPOLYMERS, V13, P1635, DOI 10.1002/bip.1974.360130810; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; SCHINDLER PRG, 1975, ANTIMICROB AGENTS CH, V8, P95, DOI 10.1128/AAC.8.1.95; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STEINER H, 1982, FEBS LETT, V137, P283, DOI 10.1016/0014-5793(82)80368-2; WEINSTEIN S, 1980, J MOL BIOL, V143, P1, DOI 10.1016/0022-2836(80)90121-7; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	41	380	412	2	64	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19298	19303		10.1074/jbc.271.32.19298	http://dx.doi.org/10.1074/jbc.271.32.19298			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702613	hybrid			2022-12-27	WOS:A1996VB68400047
J	King, SM; Barbarese, E; Dillman, JF; PatelKing, RS; Carson, JH; Pfister, KK				King, SM; Barbarese, E; Dillman, JF; PatelKing, RS; Carson, JH; Pfister, KK			Brain cytoplasmic and flagellar outer arm dyneins share a highly conserved M(r) 8,000 light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE CHAIN; CHLAMYDOMONAS FLAGELLA; POLYPEPTIDE COMPOSITION; RETROGRADE TRANSPORT; MOLECULAR ANALYSIS; PROTEIN; LOCALIZATION; PURIFICATION; MOTOR; IDENTIFICATION	Sequence comparisons with the M(r) 8,000 light chain from Chlamydomonas outer arm dynein revealed the presence of highly conserved homologues (up to 90% identity) in the expressed sequence tag data base (King, S. M. & Patel-King, R. S. (1995a) J. Biol. Chem. 270, 11445-11452). Several of these homologous sequences were derived from organisms and/or tissues that lack motile cilia/flagella, suggesting that these proteins may function in the cytoplasm. In Drosophila, lack of the homologous protein results in embryonic lethality (Dick, T., Ray, K., Salz, H. K. & Chia, W. (1996) Mol. Cell. Biol., 16, 1966-1977). Fractionation of mammalian brain homogenates reveals three distinct cytosolic pools of the homologous protein, one of which specifically copurifies with cytoplasmic dynein following both ATP-sensitive microtubule affinity/sucrose density gradient centrifugation and immunoprecipitation with a monoclonal antibody specific for the 74-kDa intermediate chain (IC74). Quantitative densitometry indicates that there is one copy of the M(r) 8,000 polypeptide per IC74. Dual channel confocal immunofluorescent microscopy revealed that the M(r) 8,000 protein is significantly colocalized with cytoplasmic dynein but not with kinesin in punctate structures (many of which are associated with microtubules) within mammalian oligodendrocytes. Thus, it appears that flagellar outer arm and brain cytoplasmic dyneins share a highly conserved light chain polypeptide that, at least in Drosophila, is essential for viability.	UNIV CONNECTICUT, CTR HLTH, DEPT NEUROL, FARMINGTON, CT 06032 USA; UNIV CONNECTICUT, CTR HLTH, CTR BIOMED IMAGING TECHNOL, FARMINGTON, CT 06032 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT CELL BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Connecticut; University of Connecticut; University of Virginia	King, SM (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, 263 FARMINGTON AVE, FARMINGTON, CT 06032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015190, R01NS019943, R56NS015190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51293] Funding Source: Medline; NINDS NIH HHS [NS 19943, NS 15190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1995, NATURE, V377, P3; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BARBARESE E, 1995, J CELL SCI, V108, P2781; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Corthesy-Theulaz I, 1992, J CELL BIOL, V118, P1333, DOI [10.1083/jcb.118.6.1333, DOI 10.1083/JCB.118.6.1333]; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dick T, 1996, MOL CELL BIOL, V16, P1966; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; GATTI JL, 1989, J BIOL CHEM, V264, P11450; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HAYS TS, 1994, J CELL SCI, V107, P1557; Holzbaur Erika L. F., 1994, V13, P251; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; King SM, 1989, CELL MOVEMENT DYNEIN, V1, P61; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Luck D.J.L., 1989, CELL MOVEMENT, V1, P49; MATSUKI Y, 1995, J DENT RES, V74, P307, DOI 10.1177/00220345950740010401; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1994, INT REV CYTOL, V155, P141, DOI 10.1016/S0074-7696(08)62098-7; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; MITCHELL DR, 1993, J CELL SCI, V105, P1069; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OGAWA K, 1995, MOL BIOL CELL, V6, P685, DOI 10.1091/mbc.6.6.685; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; STEPHENS RE, 1992, J CELL SCI, V103, P999; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Warner F.D., 1989, CELL MOVEMENT, V1; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; WILKERSON CG, 1994, J CELL SCI, V107, P497; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1991, SERONO SYM, V75, P439; Witman George B., 1994, V13, P229; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	60	187	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19358	19366		10.1074/jbc.271.32.19358	http://dx.doi.org/10.1074/jbc.271.32.19358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702622	hybrid			2022-12-27	WOS:A1996VB68400056
J	Anders, RA; Leof, EB				Anders, RA; Leof, EB			Chimeric granulocyte/macrophage colony-stimulating factor transforming growth factor-beta (TGF-beta) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTORS; AKR-2B CELLS; MESSENGER-RNA; HETEROOLIGOMERIC COMPLEXES; SERINE/THREONINE KINASES; EXPRESSION CLONING; OVERLAP EXTENSION; GENE-EXPRESSION; CARCINOMA-CELLS; GS DOMAIN	Transforming growth factor-beta (TGF-beta) belongs to a family of ligands that regulate cell growth and differentiation. The most commonly observed receptors are referred to as the type I, type II, and type III (betaglycan) TGF-beta receptors. Two receptor models have been presented to account for the various cellular responses to TGF-beta. The first proposes that all TGF-beta signaling results from the formation of a heteromeric type I/type II complex, while the second suggests that distinct type I or type II TGF-beta receptor combinations mediate aspects of TGF-beta signaling. We have addressed this general question relating to TGF-beta signaling by constructing chimeric receptors consisting of the extracellular domain of the granulocyte/macrophage colony-stimulating factor (GM-CSF) alpha or beta receptor fused to the transmembrane and cytoplasmic domain of the type I or type II TGF-beta receptor. Since high affinity GM-CSF binding requires dimerization of the alpha and beta ligand binding subunits, the response elicited by defined type I and/or type II TGF-beta receptor cytoplasmic domain homomers or heteromers can be examined. We show in mesenchymal AKR-2B cells that while TGF-beta-dependent transient luciferase activity, endogenous gene activity, and longterm biological responses are similarly induced by activating the chimeric heteromeric receptors with GM-CSF as the endogenous TGF-beta receptor, chimeric homomeric type I/type I or type II/type II receptors are signaling-incompetent.	MAYO CLIN & MAYO FDN,THORAC RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054200] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54200] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIJKE PT, 1994, PROG GROWTH FACTOR R, V5, P55; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; EBLEN ST, 1995, CANCER RES, V55, P1994; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; GOUSTIN AS, 1987, EXP CELL RES, V172, P293, DOI 10.1016/0014-4827(87)90388-0; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HOWE PH, 1989, CANCER RES, V49, P6024; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; KINSLEY DM, 1994, GENE DEV, V8, P133; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEE F, 1985, P NATL ACAD SCI USA, V82, P4360, DOI 10.1073/pnas.82.13.4360; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINASK KK, 1991, EXP CELL RES, V192, P1, DOI 10.1016/0014-4827(91)90149-O; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUO KX, 1995, P NATL ACAD SCI USA, V92, P11761, DOI 10.1073/pnas.92.25.11761; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OKADOME T, 1994, J BIOL CHEM, V269, P30753; REISS M, 1990, CANCER COMMUN, V2, P363, DOI 10.3727/095535490820874029; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	62	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21758	21766		10.1074/jbc.271.36.21758	http://dx.doi.org/10.1074/jbc.271.36.21758			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702972	hybrid			2022-12-27	WOS:A1996VF61200014
J	Chiaramello, A; Neuman, T; Peavy, DR; Zuber, MX				Chiaramello, A; Neuman, T; Peavy, DR; Zuber, MX			The GAP-43 gene is a direct downstream target of the basic helix-loop-helix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED PROTEIN; C-MYC GENE; DNA-BINDING PROTEINS; NERVOUS-SYSTEM; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; NEGATIVE REGULATOR; HLH PROTEINS; EXPRESSION; PROMOTER	The GAP-43 promoter region contains seven E-boxes (E1 to E7) that are organized in two clusters, a distal cluster (E3 to E7) and a proximal cluster (E1 and E2), Deletion analysis and site-directed mutagenesis of the GAP-43 promoter region showed that only the most proximal E1 E-box significantly modulates GAP-43 promoter activity. This E-box is conserved between the rat and human GAP-43 promoter sequences in terms of flanking sequence, core sequence (CAGTTG), and position. We found that endogenous E-box-binding proteins present in neuronal N18 cells recognize the E1 E-box and activate the GAP-43 promoter. The transcriptional activity of the GAP-43 promoter was repressed not only by the negative regulator Id2 protein, but also by two class A basic helix-loop-helix proteins, E12 and ME1a. In vitro analyses showed that both ME1a and E12 bind to the E1 E-box as homodimers. By Northern analyses, we established an inverse correlation between the level of E12 and ME1a mRNAs and GAP-43 mRNA in various neuronal cell lines as well as in ME1a-overexpressing PC12 cells. Therefore, we have identified a cis-acting element, the E1 E-box, located in the GAP-43 promoter region that modulates either positively or negatively the expression of the GAP-43 gene depending on which E-box-binding proteins occupy this site. Together, these data indicate that basic helix-loop-helix transcription factors regulate the expression of the GAP-43 gene and that the class A ME1a and E12 proteins act as down-regulators of GAP-43 expression.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523; COLORADO STATE UNIV,PROGRAM NEURONAL GROWTH & DEV,FT COLLINS,CO 80523; COLORADO STATE UNIV,DEPT BIOCHEM & MOL BIOL,FT COLLINS,CO 80523	Colorado State University; Colorado State University; Colorado State University			Chiaramello, Anne/AAG-9825-2020	Chiaramello, Anne/0000-0001-8424-0826	NINDS NIH HHS [NS33804] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033804] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; CAMPOSORTEGA JA, 1995, MOL NEUROBIOL, V10, P75, DOI 10.1007/BF02740668; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIARAMELLO A, 1995, MOL BRAIN RES, V29, P107, DOI 10.1016/0169-328X(94)00236-8; CHIARAMELLO A, 1995, MOL CELL BIOL, V15, P6036; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG MS, 1992, EUR J NEUROSCI, V4, P883, DOI 10.1111/j.1460-9568.1992.tb00115.x; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HELMS JA, 1994, MECH DEVELOP, V48, P93, DOI 10.1016/0925-4773(94)90019-1; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V194, P495; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; ORTOFT E, 1993, MOL CELL NEUROSCI, V4, P549, DOI 10.1006/mcne.1993.1068; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SOMMERVAILLE T, 1991, NEUROSCIENCE, V45, P213, DOI 10.1016/0306-4522(91)90117-7; STARR RG, 1994, BRAIN RES, V638, P211, DOI 10.1016/0006-8993(94)90652-1; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	56	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22035	22043		10.1074/jbc.271.36.22035	http://dx.doi.org/10.1074/jbc.271.36.22035			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703010	hybrid			2022-12-27	WOS:A1996VF61200052
J	Hollnagel, A; Schroder, D; Gross, G				Hollnagel, A; Schroder, D; Gross, G			Domain-specific gene activation by parathyroid hormone in osteoblastic ROS17/2.8 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE RECEPTOR; ORNITHINE DECARBOXYLASE ACTIVITY; MESSENGER-RIBONUCLEIC-ACID; PROTEIN-KINASE-C; ROS 17/2.8; ALKALINE-PHOSPHATASE; TRABECULAR BONE; CYCLIC-AMP; DNA METHYLTRANSFERASE; MOLECULAR-CLONING	Parathyroid hormone (PTH)-mediated gene activation was assessed in the osteoblast-like rat cell line ROS17/2.8 with two PTH fragments harboring distinct activating domains: PTH-(1-34) and PTH-(28-48). The PTH response of genes expressed immediate early in the cell cycle or in the osteoblast developmental sequence was investigated, In addition, subtractive cloning was used to identify genes in ROS17/2.8 cells that are activated by the two PTH domains, PTH-(1-34) immediately increased the transcript levels of c-fos and C-jun at a considerably higher rate than PTH-(28-48), A significant immediate PTH effect on osteoblastic marker genes could not be detected, with the exception of elevated ornithine decarboxylase transcript levels. However, continuous application of PTH-(1-34) increased transcript levels of the osteoblast-specific osteocalcin gene and reduced those of other osteoblastic marker genes including alkaline phosphatase and the PTH/PTH-related peptide receptor, By subtractive cloning, nine cDNAs were isolated corresponding to mRNAs directly up-regulated by PTH-(1-34) or PTH-(28-48). Among these were a cyclic phosphodiesterase, a (cytosine 5)-methyltransferase, an 80-kDa protein kinase C substrate, junB, and a novel GC-binding protein, Three cDNAs are unknown at present, Interestingly, in all cases, the efficiency of gene activation by PTH-(28-48) was substantially lower in comparison with PTH-(1-34), PTH-mediated protein kinase C signaling in ROS17/2.8 cells may therefore constitute a minor pathway in comparison with the dominant cAMP/protein kinase A cascade.	GESELL BIOTECHNOL FORSCH MBH,GENE REGULAT & DIFFERENTIAT,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH								AHOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOONEKAMP PM, 1985, BONE, V6, P37, DOI 10.1016/8756-3282(85)90405-3; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; Collip JB, 1925, J BIOL CHEM, V64, P485; COSMAN F, 1989, J BONE MINER RES, V4, P413; DORSSERS L, 1987, NUCLEIC ACIDS RES, V15, P3629, DOI 10.1093/nar/15.8.3629; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221-8747(84)90026-2; HEFTI E, 1982, CLIN SCI, V62, P389, DOI 10.1042/cs0620389; HOCK JM, 1989, J BONE MINER RES, V4, P449; HORI M, 1988, BONE MINER, V3, P193; JOHNSTON CC, 1962, J BIOL CHEM, V237, P3560; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1989, PEPTIDE HORMONES PRO, P325; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LIU CC, 1990, J BONE MINER RES, V5, P973; LOWIK CWGM, 1986, CALCIFIED TISSUE INT, V38, P21, DOI 10.1007/BF02556590; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MAJESKA RJ, 1985, ENDOCRINOLOGY, V116, P170, DOI 10.1210/endo-116-1-170; MAJESKA RJ, 1981, CALCIFIED TISSUE INT, V33, P36; Mallette Lawrence E., 1994, P171; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MURRAY TM, 1989, ENDOCRINOLOGY, V124, P1097, DOI 10.1210/endo-124-2-1097; NAKAMURA T, 1990, J BIOL CHEM, V265, P22011; NODA M, 1988, J BIOL CHEM, V263, P18574; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo-112-3-1000; RAISZ LG, 1976, HDB PHYSL, V3, P117; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REID IR, 1987, AM J PHYSIOL, V252, pE45; RODAN SB, 1986, ENDOCRINOLOGY, V118, P2510, DOI 10.1210/endo-118-6-2510; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SOMJEN D, 1990, BIOCHEM J, V272, P781; SOMJEN D, 1991, BIOCHEM J, V277, P863; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; TAKIGAWA M, 1979, J BIOCHEM-TOKYO, V84, P311; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; URENA P, 1994, ENDOCRINOLOGY, V134, P451, DOI 10.1210/en.134.1.451; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	55	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21870	21877		10.1074/jbc.271.36.21870	http://dx.doi.org/10.1074/jbc.271.36.21870			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702988	hybrid			2022-12-27	WOS:A1996VF61200030
J	Chen, Y; Houghton, LA; Brenna, JT; Noy, N				Chen, Y; Houghton, LA; Brenna, JT; Noy, N			Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoid-binding protein with 11-cis-retinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT-EPITHELIUM; FATTY-ACIDS; LIPID BILAYERS; PHOTORECEPTORS; PURIFICATION; AFFINITIES; RHODOPSIN; MECHANISM; VESICLES; RELEASE	Rapid transport of retinoids across the interphotoreceptor matrix is a critical part of the visual cycle, since it serves to replenish bleached rhodopsin with its chromophore 11-cis-retinal. The transport of retinoids in the interphotoreceptor matrix is believed to be mediated by the interphotoreceptor retinoid-binding protein (IRBP), a protein that, in addition to possessing two retinoid-binding sites, associates in vivo with long chain fatty acids. Here, the interrelationships between binding of the two types of ligands to IRBP were studied, The composition of fatty acids associated with IRBP in bovine retina was determined, and it was found that polyunsaturated fatty acids constitute a significant fraction of those, It was further found that docosahexaenoic acid, but not palmitic acid, induced a rapid and specific release of 11-cis-retinal from one of the protein's retinoid-binding sites, Based on these results and on the additional observation that a steep concentration gradient of docosahexaenoic acid exists between photoreceptor and pigment epithelium cells, a model for the mechanism by which IRBP may target 11-cis-retinal to photoreceptor cells is proposed.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853	Cornell University			Brenna, James T/A-4167-2008	Brenna, James Thomas/0000-0001-9494-4245	NEI NIH HHS [F32 EY06575, EY09296] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006575, R01EY009296] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, INVEST OPHTH VIS SCI, V26, P273; ANDERSON RE, 1976, EXP EYE RES, V23, P9; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; CHEN HM, 1992, EXP EYE RES, V55, P93, DOI 10.1016/0014-4835(92)90097-C; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007; CHEN Y, 1994, BIOCHEMISTRY-US, V33, P10658, DOI 10.1021/bi00201a013; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CONNORS KA, 1987, BINDING CONSTANTS, P175; CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FLEISLER SJ, 1983, PROG LIPID RES, V22, P79; FONG SL, 1984, J BIOL CHEM, V259, P6534; HO MTP, 1989, J BIOL CHEM, V264, P928; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; LEE RH, 1982, METHOD ENZYMOL, V81, P496; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; NOY N, 1995, J LIPID RES, V36, P375; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983; Ong D, 1980, Methods Enzymol, V67, P288; OTTONELLO S, 1984, CURR EYE RES, V3, P1085, DOI 10.3109/02713688409000806; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; ROYER CA, 1992, METHOD ENZYMOL, V210, P481; SAARI JC, 1985, J BIOL CHEM, V260, P195; SAARI JC, 1988, EXP EYE RES, V44, P569; Saari John C., 1994, P351	35	62	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20507	20515		10.1074/jbc.271.34.20507	http://dx.doi.org/10.1074/jbc.271.34.20507			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702792	hybrid			2022-12-27	WOS:A1996VD33700044
J	Graf, R; Harvey, WR; Wieczorek, H				Graf, R; Harvey, WR; Wieczorek, H			Purification and properties of a cytosolic V-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TOBACCO HORNWORM MIDGUT; VESICLE PROTON PUMP; V-ATPASE; PLASMA-MEMBRANE; NEUROSPORA-CRASSA; 14-KDA SUBUNIT; 40-KDA SUBUNIT; MANDUCA-SEXTA; BOVINE KIDNEY	The native V-1 complex of the tobacco hornworm vacuolar type ATPase (V-ATPase) was purified from cytosolic extracts of molting larval midgut. It consisted of the established V-ATPase subunits A, B, and E along with the 14-kDa subunit F and the novel 13-kDa subunit G, The final amount of purified V-1 complex made up an unexpectedly high 2% of the total cytosolic protein, with a yield of similar to 0.4 mg/g of tissue. An equally high amount of cytosolic V-1 complex was obtained from starving intermolt larvae, By contrast, the cytosolic V-1 pool was reduced drastically in feeding intermolt larvae or in larvae that had been refed after starvation. The activity of the membrane-bound V-ATPase holoenzyme was inversely related to the size of the cytosolic V-1 pool, suggesting that the insect plasma membrane V-ATPase is regulated by reversible disassembly of the V-1 complex as a function of the feeding condition of the larvae. Like F-1-ATPases, the purified V-1 complex exhibited Ca2+-dependent ATPase activity and, in the presence of 25% methanol, exhibited Mg2+-dependent ATPase activity. Therefore, we designate the native V-1 complex, V-1-ATPase. Both enzyme activities were completely inhibited by micromolar-N-ethylmaleimide. In contrast to the Ca2+-dependent V-1-ATPase activity, the Mg2+/methanol-dependent V-1-ATPase activity did not decrease with the incubation time and thus was not inhibited by ADP. Methanol appears to induce a conformational change of the V-1 complex, leading to enzymatic properties of the V-1-ATPase that are similar to those of the membrane-bound V-ATPase holoenzyme. This is the first time that a native and enzymatically active V-1 complex has been purified from the cytosol.	UNIV MUNICH,INST ZOOL,D-80333 MUNICH,GERMANY; TEMPLE UNIV,DEPT BIOL,PHILADELPHIA,PA 19122	University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			/AAU-6215-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; BALDWIN KM, 1991, TISSUE CELL, V23, P411, DOI 10.1016/0040-8166(91)90058-2; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DOW JAT, 1984, AM J PHYSIOL, V246, pR633, DOI 10.1152/ajpregu.1984.246.4.R633; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; FLORES GO, 1982, BIOCHIM BIOPHYS ACTA, V679, P466, DOI 10.1016/0005-2728(82)90168-2; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GLUCK SL, 1992, J EXP BIOL, V172, P219; GOGARTEN JP, 1992, J EXP BIOL, V172, P137; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GRAF R, 1995, P GER ZOOL SOC, V88, P103; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HARVEY WR, 1992, J EXP BIOL, V172, P1; HARVEY WR, 1983, J EXP BIOL, V106, P91; HARVEY WR, 1992, J EXP BIOL, V172; HICKS DB, 1986, J BIOL CHEM, V261, P2896; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KANE PM, 1995, J BIOL CHEM, V270, P17025; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; MCCARTY RE, 1992, J EXP BIOL, V172, P431; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; PENG SB, 1994, J BIOL CHEM, V269, P27778; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PENG SB, 1995, J BIOL CHEM, V270, P16926; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SCHUSTER SM, 1979, BIOCHEMISTRY-US, V18, P1162, DOI 10.1021/bi00574a007; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WARD JM, 1992, PLANT PHYSIOL, V99, P170, DOI 10.1104/pp.99.1.170; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1986, BIOCHIM BIOPHYS ACTA, V857, P271, DOI 10.1016/0005-2736(86)90356-1; WIECZOREK H, 1995, PHYSIOL ZOOL, V68, P15, DOI 10.1086/physzool.68.4.30166357; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; XIE XS, 1988, J BIOL CHEM, V263, P9859	54	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20908	20913		10.1074/jbc.271.34.20908	http://dx.doi.org/10.1074/jbc.271.34.20908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702848	hybrid			2022-12-27	WOS:A1996VD33700100
J	Hamelryck, TW; DaoThi, MH; Poortmans, F; Chrispeels, MJ; Wyns, L; Loris, R				Hamelryck, TW; DaoThi, MH; Poortmans, F; Chrispeels, MJ; Wyns, L; Loris, R			The crystallographic structure of phytohemagglutinin-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE DETERMINATION; BEANS PHASEOLUS-LUNATUS; ADENINE BINDING-SITES; ARCELIN SEED PROTEIN; LEGUME LECTIN; 2.3-ANGSTROM RESOLUTION; MOLECULAR RECOGNITION; ESCHERICHIA-COLI; LENTIL LECTIN; VULGARIS	The structure of phytohemagglutinin-L (PHA-L), a leucoagglutinating seed lectin from Phaseolus vulgaris, has been solved with molecular replacement using the coordinates of lentil lectin as model, and refined at a resolution of 2.8 Angstrom. The final R-factor of the structure is 20.0%. The quaternary structure of the PHA-L tetramer differs from the structures of the concanavalin A and peanut lectin tetramers, but resembles the structure of the soybean agglutinin tetramer. PHA-L consists of two canonical legume lectin dimers that pack together through the formation of a close contact between two beta-strands. Of the two covalently bound oligosaccharides per monomer, only one GlcNAc residue per monomer is visible in the electron density. In this article we describe the structure of PHA-L, and we discuss the putative position of the high affinity adenine binding site present in a number of legume lectins. A comparison with transthyretin, a protein that shows a remarkable resemblance to PHA-L, gives further ground to our proposal.	VLAAMSE INSTELLING TECHNOL ONDERZOEK, B-2400 MOL, BELGIUM; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	VITO; University of California System; University of California San Diego	Hamelryck, TW (corresponding author), FREE UNIV BRUSSELS VIB, DIENST ULTRASTRUCT, PAARDENSTRAAT 65, B-1640 RHODE ST GENESE, BELGIUM.		Loris, Remy/GPG-0894-2022; Hamelryck, Thomas/A-3923-2012	Hamelryck, Thomas/0000-0003-2917-3602; Loris, Remy/0000-0002-8862-3338				ANDREAS JR, 1986, THEOR APPL GENET, V72, P123, DOI 10.1007/BF00261467; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; CHOTHIA C, 1981, P NATL ACAD SCI-BIOL, V78, P4146, DOI 10.1073/pnas.78.7.4146; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; DaoThi MH, 1996, PROTEINS, V24, P134, DOI 10.1002/(SICI)1097-0134(199601)24:1<134::AID-PROT9>3.0.CO;2-K; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FERGUSON RN, 1975, BIOCHEMISTRY-US, V14, P282, DOI 10.1021/bi00673a014; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; GEGG CV, 1992, BIOCHEMISTRY-US, V31, P6938, DOI 10.1021/bi00145a011; GOOSSENS A, 1994, EUR J BIOCHEM, V225, P787, DOI 10.1111/j.1432-1033.1994.0787b.x; HAMMARSTROM S, 1982, P NATL ACAD SCI-BIOL, V79, P1611, DOI 10.1073/pnas.79.5.1611; HARTWECK LM, 1991, PLANT PHYSIOL, V97, P204, DOI 10.1104/pp.97.1.204; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; JORDAN ET, 1994, J BIOL CHEM, V269, P7674; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORIS R, 1994, J BIOL CHEM, V269, P26722; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; MALIARIK MJ, 1988, J BIOL CHEM, V263, P11274; McDonald I, 1993, HBPLUS COMPUTER PROG; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; MORENO J, 1989, P NATL ACAD SCI USA, V86, P7885, DOI 10.1073/pnas.86.20.7885; MURZIN AG, 1994, CURR OPIN STRUC BIOL, V4, P441, DOI 10.1016/S0959-440X(94)90114-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN TC, 1988, SCIENCE, V240, P207, DOI 10.1126/science.240.4849.207; PFLUGRATH JW, 1989, MADNESS MANUAL FAST; ROBERTS DD, 1982, J BIOL CHEM, V257, P1274; ROBERTS DD, 1983, J BIOL CHEM, V258, P3820; ROBERTS DD, 1983, CHEM TAXONOMY MOL BI, P131; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHADE RE, 1994, BIO-TECHNOL, V12, P793, DOI 10.1038/nbt0894-793; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; STURM A, 1986, PLANT PHYSIOL, V81, P320, DOI 10.1104/pp.81.1.320; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; YOUNG NM, 1995, J BIOL CHEM, V270, P2563, DOI 10.1074/jbc.270.6.2563	48	110	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20479	20485		10.1074/jbc.271.34.20479	http://dx.doi.org/10.1074/jbc.271.34.20479			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702788	hybrid			2022-12-27	WOS:A1996VD33700040
J	Imbalzano, AN; Schnitzler, GR; Kingston, RE				Imbalzano, AN; Schnitzler, GR; Kingston, RE			Nucleosome disruption by human SWI/SNF is maintained in the absence of continued ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; TUMOR VIRUS PROMOTER; RNA-POLYMERASE-II; HEAT-SHOCK FACTOR; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; DNA-BINDING; POSITIONED NUCLEOSOMES; MULTISUBUNIT COMPLEX; FACILITATED BINDING	We have examined the requirement for ATP in human (h) SWI/SNF-mediated alteration of nucleosome structure and facilitation of transcription factor binding to nucleosomal DNA. hSWI-SNF-mediated nucleosome alteration requires hydrolysis of ATP or dATP. The alteration is stable upon removal of ATP from the reaction or upon inhibition of activity by excess ATP gamma S, indicating that continued ATP hydrolysis is not required to maintain the altered nucleosome structure, This stable alteration is sufficient to facilitate binding of a transcriptional activator protein; concurrent ATP hydrolysis was not required to facilitate binding. These data suggest sequential steps that can occur in the process by which transcription factors gain access to nucleosomal DNA.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GODDE JS, 1995, J BIOL CHEM, V270, P27399, DOI 10.1074/jbc.270.46.27399; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P43275; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PHAM TA, 1992, BIOCHEMISTRY-US, V31, P1570, DOI 10.1021/bi00120a039; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	54	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20726	20733		10.1074/jbc.271.34.20726	http://dx.doi.org/10.1074/jbc.271.34.20726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702824	hybrid			2022-12-27	WOS:A1996VD33700076
J	Ishiai, M; Sanchez, JP; Amin, AA; Murakami, Y; Hurwitz, J				Ishiai, M; Sanchez, JP; Amin, AA; Murakami, Y; Hurwitz, J			Purification, gene cloning, and reconstitution of the heterotrimeric single-stranded DNA-binding protein from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; NUCLEOTIDE EXCISION-REPAIR; REPLICATION FACTOR-A; POLYMERASE-ALPHA-PRIMASE; XENOPUS EGG EXTRACTS; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; T-ANTIGEN; FISSION YEAST; CRITHIDIA-FASCICULATA	We have purified a single-stranded DNA-binding protein (SSB) from Schizosaccharomyces pombe (Sp) and have shown that it is composed of three subunits of 68, 30, and 12 kDa, The SpSSB supports T antigen-dependent unwinding of SV40 ori containing DNA, but is not functional in the SV40 in vitro replication reaction. All three genes that encode the SpSSB subunit have been isolated. The cloned cDNA of the ssb1(+), encoding the p68 subunit, contains 609 amino acids (68.3 kDa), while that of the ssb2(+), encoding the p30 subunit, contains a 279 amino acids (30.3 kDa). The genomic DNA clone of the p12 subunit gene (ssb3(+)) has 2 introns and an open reading frame of 104 amino acids (11.8 kDa). Significant homology is observed among tbe largest and middle subunits of eukaryotic SSBs, but there is poor homology among the smallest subunits, In addition, we have reconstituted the SpSSB complex by coexpression of all three subunits in Escherichia coli, The reconstituted complex is active in single-stranded DNA binding and the T antigen-dependent unwinding of SV40 ori DNA. Finally, we observed a cell cycle-dependent phosphorylation pattern of the p30 subunit of SpSSB, which is similar to that observed for She human and Saccharomyces myces cerevisiae SSB.	MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KESHAV KF, 1995, MOL CELL BIOL, V15, P3119; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; LUCHE RM, 1993, MOL CELL BIOL, V13, P5749, DOI 10.1128/MCB.13.9.5749; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MERTINS P, 1987, EMBO J, V6, P1757, DOI 10.1002/j.1460-2075.1987.tb02428.x; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MULLER F, 1994, J BIOL CHEM, V269, P17086; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SINGH KK, 1995, P NATL ACAD SCI USA, V92, P4907, DOI 10.1073/pnas.92.11.4907; SMITH J, 1995, MOL CELL BIOL, V15, P1632; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; WAGA S, 1994, J BIOL CHEM, V269, P10923; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	77	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20868	20878		10.1074/jbc.271.34.20868	http://dx.doi.org/10.1074/jbc.271.34.20868			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702843	hybrid			2022-12-27	WOS:A1996VD33700095
J	Kim, DR; McHenry, CS				Kim, DR; McHenry, CS			Identification of the beta-binding domain of the alpha subunit of Escherichia coli polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; 2 DNA-POLYMERASES; GAMMA-SUBUNIT; SLIDING CLAMPS; PROTEIN; TAU; MECHANISM; TEMPLATE; PURIFICATION; PRODUCTS	Rapid and processive DNA synthesis by Escherichia coli DNA polymerase III holoenzyme is achieved by the direct interaction between the alpha subunit of DNA polymerase III core and the beta sliding clamp (LaDuca, R. J,, Crute, J. J,, McHenry, C, S,, and Bambara, R, A. (1986) J, Biol. Chen, 261, 7550-7557; Stukenberg, T. P., Studwell-Vaughan, P, S., and O'Donnell, M, (1991) J. Biol. Chem. 266, 11328-11334), In this study, we localized the beta-binding domain of alpha to a carboxyl-terminal region by quantifying the interaction of beta with a series of alpha deletion proteins. Purification and binding analysis was facilitated by insertion of hexahistidine and short biotinylation sequences on the deletion terminus of alpha. Interaction of beta with alpha deletion proteins was studied by gel filtration and surface plasmon resonance, alpha lacking 169 COOH-terminal residues still possessed beta-binding activity; whereas deletion of 342 amino acids from the COOH terminus abolished beta binding, Deletion of 542 amino acids from the NH2 terminus of the 1160 residue alpha subunit resulted in a protein that bound beta 10-20-fold more strongly than native alpha. Hence, portions of alpha between residues 542 and 991 are involved in beta binding, DNA binding to alpha apparently triggers an increased affinity for beta (Naktinis, V., Turner, J., and O'Donnell, M. (1996) Cell 84, 137-145), Our findings extend this observation by implicating the amino-terminal polymerase domain in inducing a low affinity taut conformation in the carboxyl-terminal beta-binding domain. Deletion of the polymerase domain (or, presumably, its occupancy by DNA) relaxes the COOH-terminal domain, permitting it to assume a conformation with high affinity for beta.			Kim, DR (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262, USA.							BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUWABARA N, 1981, P NATL ACAD SCI-BIOL, V78, P5764, DOI 10.1073/pnas.78.9.5764; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TONGU K, 1994, J BIOL CHEM, V269, P4675; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030	31	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20699	20704		10.1074/jbc.271.34.20699	http://dx.doi.org/10.1074/jbc.271.34.20699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702820	hybrid			2022-12-27	WOS:A1996VD33700072
J	Lavoie, JN; LAllemain, G; Brunet, A; Muller, R; Pouyssegur, J				Lavoie, JN; LAllemain, G; Brunet, A; Muller, R; Pouyssegur, J			Cyclin D1 expression is regulated positively by the p42/p44(MAPK) and negatively by the p38/HOG(MAPK) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; C-JUN; GROWTH-FACTORS; CELL-CYCLE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; MAP KINASES; RETINOBLASTOMA PROTEIN; TRANSLATION INITIATION	Ne have previously shown that the persistent activation of p42/p44(MAPK) is required to pass the G(1) restriction point in fibroblasts (Pages, G., Lenormand, P., L'Allemain, G., Chambard, J. C., Meloche, S., and Pouyssegur, J. (1993) Proc. Natl. Acad Sci. U.S. A. 90, 8319-8323) and postulated that MAPKs control the activation of G, cyclin-dependent complexes. Ne examined the mitogen dependent-induction of cyclin D1 expression, one of the earliest cell cycle-related events to occur during the G(0)/G(1) to S-phase transition, as a potential target of MAPK regulation, Effects exerted either by the p42/p44(MAPK) or the p38/HOG(MAPK) cascade on the regulation of cyclin D1 promoter activity or cyclin D1 expression were compared in CCL39 cells, using a co-transfection procedure. Ne found that inhibition of the p42/p44(MAPK) signaling by expression of dominant-negative forms of either mitogen-activated protein kinase kinase 1 (MKK1) or p44(MAPK), gp by expression of the MAP kinase phosphatase, MKP-1, strongly inhibited expression of a reporter gene driven by the human cyclin D1 promoter as well as the endogenous cyclin D1 protein. Conversely, activation of this signaling pathway by expression of a constitutively active MKK1 mutant dramatically increased cyclin D1 promoter activity and cyclin D1 protein expression, in a growth factor-independent manner. Moreover, the use of a CCL39-derived cell line that stably expresses an inducible chimera of the estrogen receptor fused to a constitutively active Raf-1 mutant (Delta Raf-1:ER) revealed that in absence of growth factors, activation of the Raf > MKK1 > p42/p44MAPK cascade is sufficient to fully induce cyclin D1, In marked contrast, the p38(MAPK) cascade showed an opposite effect on the regulation of cyclin D1 expression. In cells co-expressing high levels of the p38(MAPK) kinase (MKK3) together with the p38(MAPK), significant inhibition of mitogen-induced cyclin D1 expression was observed. Furthermore, inhibition of p38(MAPK) activity with the specific inhibitor, SB203580, enhanced cyclin D1 transcription and protein level. Altogether, these results support the notion that MAPK cascades drive specific cell cycle responses to extracellular stimuli, at least in part, through the modulation of cyclin D1 expression and associated cdk activities.	FAC SCI,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 02,FRANCE; UNIV MARBURG,INST MOL BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADLER V, 1994, J BIOL CHEM, V269, P11186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUNET A, 1994, ONCOGENE, V9, P3379; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECOFFER P, 1994, ONCOGENE, V9, P911; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GRANA X, 1995, ONCOGENE, V11, P211; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HERBER B, 1994, ONCOGENE, V9, P1295; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JIANG W, 1993, ONCOGENE, V8, P3447; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; Noel J, 1996, J CELL SCI, V109, P929; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN H, 1993, CELL, V75, P437; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; WASYLYK B, 1993, P NATL ACAD SCI USA, V90, P7739; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	70	1068	1092	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20608	20616		10.1074/jbc.271.34.20608	http://dx.doi.org/10.1074/jbc.271.34.20608			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702807	hybrid			2022-12-27	WOS:A1996VD33700059
J	Ollivier, V; Parry, GCN; Cobb, RR; deProst, D; Mackman, N				Ollivier, V; Parry, GCN; Cobb, RR; deProst, D; Mackman, N			Elevated cyclic AMP inhibits NF-kappa B-mediated transcription in human monocytic cells and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TISSUE FACTOR GENE; FACTOR MESSENGER-RNA; LEUKOCYTE ADHESION MOLECULE-1; FACTOR EXPRESSION; FACTOR-ALPHA; E-SELECTIN; LIPOPOLYSACCHARIDE INDUCTION; MONONUCLEAR PHAGOCYTES; C-REL/P65 HETERODIMERS	The NF-kappa B/Rel family of transcription factors regulates the inducible expression of many genes in activated human monocytes and endothelial cells. In this study, we examined the molecular mechanism by which agents that elevate intracellular cAMP inhibit the expression of the tumor necrosis factor alpha (TNF alpha), tissue factor, endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1 genes. Both forskolin and dibutyryl cAMP, which elevate intracellular cAMP by independent mechanisms, inhibited TNF alpha and tissue factor expression at the level of transcription. Induction of NF-kappa B-dependent gene expression in transiently transfected human monocytic THP-1 cells and human umbilical vein endothelial cells was inhibited by elevated cAMP and by overexpression of the catalytic subunit of protein kinase A (PKA). Elevated cAMP did not prevent nuclear translocation of p50/p65 and c-Rel/p65 heterodimers, decrease nuclear translocation of p65, or significantly modify TNF alpha-induced phosphorylation of p65. Functional studies demonstrated that transcriptional activation of a plasmid containing multimerized kappa B sites by p65 was inhibited by agents that elevate cAMP and by overexpression of the catalytic subunit of PKA. This study indicates that activation of PKA reduces the induction of a distinct set of genes in monocytes and endothelial cells by inhibiting NF-kappa B-mediated transcription.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; TANABE RES LABS, DEPT BIOL, SAN DIEGO, CA 92121 USA; CHU XAVIER BICHAT, INSERM, U294, F-75877 PARIS 18, FRANCE; CHU XAVIER BICHAT, SERV HEMATOL & IMMUNOL BIOL, F-75877 PARIS 18, FRANCE	Scripps Research Institute; Scripps Research Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite			Ollivier, Véronique/AAA-2241-2022	Ollivier, Veronique/0000-0003-1318-1712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16411, HL48872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BENZAKOUR O, 1995, BIOCHEM J, V309, P385, DOI 10.1042/bj3090385; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CRUTCHLEY DJ, 1991, BLOOD, V78, P382; CRUTCHLEY DJ, 1993, ARTERIOSCLER THROMB, V13, P1082, DOI 10.1161/01.ATV.13.7.1082; CRUTCHLEY DJ, 1992, ARTERIOSCLER THROMB, V12, P664, DOI 10.1161/01.ATV.12.6.664; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DEPROST D, 1990, MOL PHARMACOL, V38, P562; EOTH P, 1995, BLOOD, V86, P4144; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GHERSA P, 1994, J BIOL CHEM, V269, P29129; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Grilli Mariagrazia, 1993, V143, P1; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; HIROZANE T, 1995, CLIN EXP IMMUNOL, V102, P186; HOHMANN HP, 1991, MOL CELL BIOL, V11, P2315, DOI 10.1128/MCB.11.4.2315; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; LALLI E, 1994, J BIOL CHEM, V269, P17359; LYBERG T, 1983, THROMB HAEMOSTASIS, V50, P804; MACKMAN N, 1994, J BIOL CHEM, V269, P26363; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; Maniatis T., 1982, MOL CLONING; Min W, 1996, MOL CELL BIOL, V16, P359; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOSIALOS G, 1993, ONCOGENE, V8, P721; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OLLIVIER V, 1993, BLOOD, V81, P973; OLLIVIER V, 1993, FEBS LETT, V322, P231, DOI 10.1016/0014-5793(93)81576-L; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; POBER JS, 1993, J IMMUNOL, V150, P5114; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; SOMMER N, 1995, NAT MED, V1, P244, DOI 10.1038/nm0395-244; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; TAYLOR R, 1994, J NIH RES, V6, P57; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TREDE NS, 1995, J IMMUNOL, V155, P902; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	58	306	312	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20828	20835		10.1074/jbc.271.34.20828	http://dx.doi.org/10.1074/jbc.271.34.20828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702838	hybrid			2022-12-27	WOS:A1996VD33700090
J	Dewilde, S; Blaxter, M; VanHauwaert, ML; Vanfleteren, J; Esmans, EL; Marden, M; Griffon, N; Moens, L				Dewilde, S; Blaxter, M; VanHauwaert, ML; Vanfleteren, J; Esmans, EL; Marden, M; Griffon, N; Moens, L			Globin and globin gene structure of the nerve myoglobin of Aphrodite aculeata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLAM LUCINA-PECTINATA; AMINO-ACID-SEQUENCES; GLYCERA-DIBRANCHIATA; HEMOGLOBIN GENE; ORGANIZATION; SUBSTITUTION; RESOLUTION; KINETICS; INTRONS; BINDING	The globin of the nerve cord of the polychaete annelid Aphrodite aculeata was isolated and purified to homogeneity, The native molecule has a pi of 6.3 and acts as a dimer of two identical M(r) 15,644.5 polypeptide chains as determined by electrospray mass spectrometry. It has an average affinity for oxygen (P-50 = 1.24 torr) resulting from fast association (k(on) = 170 x 10(6) M(-1). s(-1)) and dissociation rates (k(off) = 360 s(-1)). The partial primary structure of this nerve globin was determined at the protein level and completed and confirmed by translation of the cDNA sequence. The globin chain has 150 amino acid residues and a calculated M(r) of 15,602.69 strongly suggesting that the amino terminus is acetylated. The absence of a leader sequence and the lack of Cys at the positions NA2 and H9 needed for the formation of the high M(r) complexes found in extracellular annelid globins classify the Aphrodite globin with the cellular globin species. The Aphrodite nerve globin is unlikely to represent a separate globin family, as cDNA derived primers detect globin messenger RNA in muscle, gut, and pharynx tissue as well. The gene encoding this globin species is interrupted by a single intron, inserted at position G7.0. Comparison to other globin gene structures strongly suggest that introns can be lost independently, rather than simultaneously as a result of a single conversion event as suggested previously (Lewin, R. (1984) Science 226, 328).	UNIV ANTWERP,DEPT BIOCHEM,B-2610 ANTWERP,BELGIUM; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,ASHWORTH LABS,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; STATE UNIV GHENT,DEPT MORPHOL SYSTEMAT & ECOL,B-9000 GHENT,BELGIUM; UNIV ANTWERP,RIJKSUNIV CTR ANTWERP,NUCLEOSIDE RES & MASS SPECTROMETRY UNIT,B-2020 ANTWERP,BELGIUM; HOP BICETRE,INSERM,U299,F-94275 LE KREMLIN BICETR,FRANCE	University of Antwerp; University of Edinburgh; Ghent University; University of Antwerp; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Blaxter, Mark/O-2535-2019; Blaxter, Mark L/B-4113-2010; Marden, Michael C/G-3139-2012; Marden, Michael/AAA-5923-2020	Blaxter, Mark L/0000-0003-2861-949X; Marden, Michael C/0000-0002-5254-6385; 				ALLEN G, 1989, LAB TECHNIQUES BIOCH, V9; APPLEBY CA, 1983, SCIENCE, V220, P951, DOI 10.1126/science.220.4600.951; ARENTS G, 1989, J MOL BIOL, V210, P149, DOI 10.1016/0022-2836(89)90297-0; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BLAXTER ML, 1994, J BIOL CHEM, V269, P30181; COLACINO JM, 1984, COMP BIOCHEM PHYS A, V79, P363, DOI 10.1016/0300-9629(84)90528-0; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DIXON B, 1992, TRENDS BIOCHEM SCI, V17, P486; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; HOCKENHULLJOHNSON JD, 1991, J PROTEIN CHEM, V10, P609, DOI 10.1007/BF01025713; HOCKENHULLJOHNSON JD, 1993, J PROTEIN CHEM, V12, P261, DOI 10.1007/BF01028189; JHIANG SM, 1988, SCIENCE, V240, P334, DOI 10.1126/science.2832953; KAO WY, 1994, J MOL EVOL, V38, P241; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; KRAUS DW, 1988, BIOL BULL, V174, P346, DOI 10.2307/1541960; KRAUS DW, 1988, BIOL BULL, V174, P54, DOI 10.2307/1541759; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LEWIN R, 1984, SCIENCE, V226, P328, DOI 10.1126/science.226.4672.328; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MOENS L, 1992, FEBS LETT, V312, P105, DOI 10.1016/0014-5793(92)80915-4; PARKHURST LJ, 1980, BIOCHEMISTRY-US, V19, P2688, DOI 10.1021/bi00553a023; RIZZI M, 1994, J MOL BIOL, V244, P86, DOI 10.1006/jmbi.1994.1706; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; STOLTZFUS A, 1993, CURR BIOL, V3, P215, DOI 10.1016/0960-9822(93)90336-M; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; WILLIAMS S A, 1986, Biotechniques, V4, P138; WITTENBERG BA, 1965, BIOCHEM J, V96, P363, DOI 10.1042/bj0960363; ZAFAR RS, 1990, J BIOL CHEM, V265, P21843; [No title captured]	39	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19865	19870		10.1074/jbc.271.33.19865	http://dx.doi.org/10.1074/jbc.271.33.19865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702697	Green Published, hybrid			2022-12-27	WOS:A1996VC66900038
J	Meier, UT				Meier, UT			Comparison of the rat nucleolar protein Nopp140 with its yeast homolog SRP40 - Differential phosphorylation in vertebrates and yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEAR-LOCALIZATION SEQUENCES; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; MAMMALIAN NUCLEOLIN; MOLECULAR-WEIGHT; BINDING-PROTEIN; CDNA CLONING; GENE-PRODUCT; IDENTIFICATION	Rat Nopp140, a nonribosomal protein of the nucleolus and coiled bodies, was characterized as one of the most highly phosphorylated proteins in the cell. Based on its subcellular location, its nuclear localization signal binding capacity, and its shuttling between the nucleolus and the cytoplasm, Nopp140 was proposed to function as a chaperone in ribosome biogenesis, This study shows that casein kinase II phosphorylates Nopp140 to its unusual high degree and identifies the yeast SRP40 gene product as immunologically and structurally related to rat Nopp140. SRP40 encodes an acidic (pI = 3.9), serine-rich (49%) protein of 41 kDa whose carboxyl terminus exhibits 59% sequence identity to that of Nopp140 SRP40 localizes to the yeast nucleolus and is required at a specific cellular concentration for optimal growth as indicated by the negative effect on cell growth of both overexpression and deletion of its gene. Like Nopp140, SRP40 is phosphosylated by casein kinase II, but to a much lesser extent, While the parallels between these two proteins suggest that SRP40 is the bona fide yeast Nopp140 homolog, their disparities reflect the differences in nucleolar dynamics and regulation of ribosome biogenesis between yeast and vertebrates.			Meier, UT (corresponding author), ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NIGMS NIH HHS [GM50725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; BOU G, 1993, YEAST, V9, P1349, DOI 10.1002/yea.320091209; CAIRNS C, 1995, J CELL SCI, V108, P3339; CAJAL SR, 1910, TRAB LAB INVEST BIOL, V8, P1; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; ESPINET C, 1995, YEAST, V11, P25, DOI 10.1002/yea.320110104; FASMAN GD, 1978, CRC HDB BIOCH MOL BI, V1; FREEMAN JW, 1988, CANCER RES, V48, P1244; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GODAY A, 1994, PLANT CELL, V6, P351, DOI 10.1105/tpc.6.3.351; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GULLI MP, 1995, NUCLEIC ACIDS RES, V23, P1912, DOI 10.1093/nar/23.11.1912; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; KONDO K, 1992, J BIOL CHEM, V267, P16252; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LAFARGA M, 1983, ANAT EMBRYOL, V166, P19, DOI 10.1007/BF00317942; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; Maniatis T, 1989, MOL CLONING; MARIN O, 1990, INT J PEPT PROT RES, V36, P374; Marston F. A. O., 1987, DNA CLONING, P59; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Nomura N, 1994, DNA Res, V1, P47, DOI 10.1093/dnares/1.1.47; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAI CY, 1995, J CELL SCI, V108, P1911; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PFEIFLE J, 1984, EUR J BIOCHEM, V139, P417, DOI 10.1111/j.1432-1033.1984.tb08021.x; PFEIFLE J, 1986, EXP CELL RES, V162, P11, DOI 10.1016/0014-4827(86)90422-2; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SATOH K, 1981, CELL BIOL INT REP, V5, P857, DOI 10.1016/0309-1651(81)90200-9; SCHMIDTZACHMANN MS, 1984, EXP CELL RES, V153, P327, DOI 10.1016/0014-4827(84)90604-9; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; SOEIRO R, 1973, J MOL BIOL, V79, P507, DOI 10.1016/0022-2836(73)90402-6; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; VILARDELL J, 1990, PLANT MOL BIOL, V14, P423, DOI 10.1007/BF00028778; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XUE ZX, 1993, EUR J CELL BIOL, V62, P13	68	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19376	19384						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702624				2022-12-27	WOS:A1996VB68400058
J	Persechini, A; Gansz, KJ; Paresi, RJ				Persechini, A; Gansz, KJ; Paresi, RJ			A role in enzyme activation for the N-terminal leader sequence in calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; PEPTIDE COMPLEX; BASIC RESIDUES; TROPONIN-C; BINDING; FRAGMENTS	We have found that deletion of residues 2-8 from the N-terminal leader sequence: Ala(1)-Asp(2)-Gln-Leu(4)-Thr-Glu(6)-Glu-Gln(8), in calmodulin abolishes calmodulin-dependent activation of skeletal muscle myosin light chain kinase activity and reduces calmodulin-dependent activation of smooth muscle myosin light chain kinase activity to similar to 50% of the maximum level measured at a saturating calmodulin concentration, Calmodulin dependent activation of cerebellar nitric oxide synthase activity is not affected by this deletion. Overlapping tripeptide deletions from the leader sequence indicate that the acidic cluster, Glu(6)-Glu-Gln(8), contains the determinants necessary for activation of myosin light chain kinase activity, Deletion of Asp(2)-Gln-Leu(4) has no effect on activation of enzyme activity, Based on enzyme kinetic analyses, deletions in the leader sequence have little or no effect on the apparent affinities of calmodulin for the synthase or the two kinases, Since the N-terminal leader does not appear to play a significant structural role in the complexes between calmodulin and peptides representing the calmodulin-binding domains in the two kinases, our results indicate that it participates in secondary interactions with these enzymes that are important to activation, but not to recognition or binding of calmodulin.			Persechini, A (corresponding author), UNIV ROCHESTER,MED CTR,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERRING BP, 1991, J BIOL CHEM, V266, P11838; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488	19	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19279	19282		10.1074/jbc.271.32.19279	http://dx.doi.org/10.1074/jbc.271.32.19279			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702610	hybrid			2022-12-27	WOS:A1996VB68400044
J	Chong, SR; Shao, Y; Paulus, H; Benner, J; Perler, FB; Xu, MQ				Chong, SR; Shao, Y; Paulus, H; Benner, J; Perler, FB; Xu, MQ			Protein splicing involving the Saccharomyces cerevisiae VMA intein - The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHED INTERMEDIATE; INTERVENING SEQUENCE; CHEMICAL LIGATION; GENE-PRODUCT; PEPTIDE-BOND; SUBUNIT; INTRONS; IDENTIFICATION; SELECTION; MECHANISM	Protein splicing involves the excision of an internal protein segment, the intein, from a precursor protein and the concomitant ligation of the flanking N- and C-terminal regions. It occurs in mesophilic bacteria, yeast, and thermophilic archaea. The ability to control protein splicing of a thermophilic intein by temperature and pH in a foreign protein context facilitated the study of the mechanism of protein splicing in thermophiles. On the other hand, no direct studies have been done on the mechanism of protein splicing in mesophiles. We examined the splicing of a chimeric protein containing the intein of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae that involves cysteines rather than serines at the reaction center. The steps in the splicing process were deduced by analyzing intermediates and side products that accumulated as a result of amino acid substitutions and were found to be analogous to those occurring in thermophiles. Moreover, appropriate amino acid replacements allowed us to develop the first mesophilic in vitro protein splicing system as well as strategies for modulating the rate of protein splicing and for converting the splicing reaction to an efficient protein cleavage reaction at either splice junction.	NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915; BOSTON BIOMED RES INST,BOSTON,MA 02114	Boston Biomedical Research Institute				Chong, shaorong/0000-0002-6525-3389				BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUICE TC, 1966, BIOORGANIC MECH, V1, P266; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Gros E., 1967, METHOD ENZYMOL, V11, P238; GU HH, 1993, J BIOL CHEM, V268, P7372; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6253; JENCKS WP, 1960, J BIOL CHEM, V235, P3608; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWONG MY, 1994, PROTEIN SCI, V3, P147; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; MUELLER JE, 1994, NUCLEASES, P111; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SEIFTER S, 1960, J BIOL CHEM, V235, P2613; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; TAM JP, 1995, P NATL ACAD SCI USA, V92, P21485; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; XU MQ, 1996, INPRESS EMBO J	39	212	234	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22159	22168		10.1074/jbc.271.36.22159	http://dx.doi.org/10.1074/jbc.271.36.22159			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703028	hybrid			2022-12-27	WOS:A1996VF61200070
J	Hartley, D; Corvera, S				Hartley, D; Corvera, S			Formation of c-Cbl center dot phosphatidylinositol 3-kinase complexes on lymphocyte membranes by a p56(lck)-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN PRODUCT; TYROSINE KINASE; JURKAT CELLS; P85 SUBUNIT; V-CBL; PROTOONCOGENE; ASSOCIATION; ACTIVATION; PHOSPHORYLATION	The proto-oncogene c-Cbl was originally identified as a cellular homologue of the transforming protein expressed by the murine Cas NS-1 retrovirus. The full-length c-Cbl protein is a predominantly cytoplasmic protein, abundant in lymphoid cells, and potentially involved in signal transduction in several cell types, The specific signal transduction pathways in which c-Cbl participates, and its precise role in these pathways, are unclear. Previous studies from our laboratory have shown that c-Cbl is the predominant tyrosine-phosphorylated protein bound to the p85 subunit of phosphatidylinositol (PI) 3-kinase on T lymphocyte and B lymphocyte activation, To further understand the properties of c-Cbl and the significance of its interactions with PI 3-kinase, we have further studied the cellular biological and biochemical responses of c-Cbl to stimulation in lymphoid cells, We show that stimulation induces the association of a highly tyrosine-phosphorylated pool of c-Cbl with lymphocyte membranes and with a detergent-insoluble particulate fraction, Immunoprecipitation of c-Cbl from subcellular fractions reveals that p85 is predominantly associated with the c-Cbl pool recovered from the membrane fraction, despite the fact that this pool represents a small amount of total cellular c-Cbl. The formation of c-Cbl . PI 3-kinase complexes on lymphocyte membranes did not depend on the catalytic activity of PI 3-kinase since it was unaltered by the treatment of cells with wortmannin prior to stimulation, Interestingly, c-Cbl tyrosine phosphorylation and the formation of c-Cbl PI 3-kinase complexes were also observed in a mutant Jurkat cell line, JCaM1.6, lacking p56(lck) expression. Because p56(lck) is critical for mitogenic signal transduction in response to T cell receptor activation, our results suggest that the activation of c-Cbl and the formation of c-Cbl . PI 3-kinase complexes occur upstream or independently of mitogenic signal transduction pathways in T cells.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOL MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK40330] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; COLIGAN E, 1991, CURRENT PROTOCOLS IM; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; JANEWAY CA, 1993, CURR OPIN IMMUNOL, V5, P313, DOI 10.1016/0952-7915(93)90048-W; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	18	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21939	21943		10.1074/jbc.271.36.21939	http://dx.doi.org/10.1074/jbc.271.36.21939			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702998	hybrid			2022-12-27	WOS:A1996VF61200040
J	Komalavilas, P; Lincoln, TM				Komalavilas, P; Lincoln, TM			Phosphorylation of the inositol 1,4,5-trisphosphate receptor - Cyclic GMP-dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the intact rat aorta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; TRISPHOSPHATE RECEPTOR; CA2+ MOBILIZATION; HUMAN PLATELETS; CA-2+ RELEASE; AMP; CELLS; CALCIUM; PURIFICATION; HEPATOCYTES	The effects of cyclic GMP (cGMP) and activation of cGMP-dependent protein kinase (PKG) on the phosphorylation of the inositol 1,4,5-trisphosphate (IP3) receptor were examined in intact rat aorta using the technique of back phosphorylation, Aorta treated with the nitric oxide donors, S-nitroso-N-acetylpenicillamine and sodium nitroprusside, or the selective PKG activator, 8-(4-para-chlorophenylthio)-cGMP (8-CPT-cGMP), demonstrated increased IP3 receptor phosphorylation in situ, which was both time- and concentration-dependent with a stoichiometry of 0.5 mol of phosphate/mol of receptor above control, Treatment of aorta with the adenyl cyclase activator, forskolin, also demonstrated increased phosphorylation of the IP3 receptor on the PKG site, although the selective cAMP-dependent protein kinase activator, 8-(4-para-chlorophenylthio)-cAMP (8-CPT-cAMP), did not increase the phosphorylation of the IP3 receptor, Moreover, the PKG selective inhibitor, KT 5823, inhibited both sodium nitroprusside and forskolin-induced IP3 receptor phosphorylation more potently than the selective cAMP-dependent protein kinase inhibitor, KT 5720, suggesting that PKG mediates the increase in IP3 receptor phosphorylation by both cyclic nucleotides in intact aorta, These results provide further support for the notion that PKG is activated by both cAMP and cGMP in intact vascular smooth muscle and that PKG performs a critical role in cyclic nucleotide-dependent relaxation of blood vessels.			Komalavilas, P (corresponding author), UNIV ALABAMA, DEPT PATHOL, DIV MOL & CELLULAR PATHOL, VOLKER HALL RM G038, 1670 UNIV BLVD, BIRMINGHAM, AL 35294 USA.				NHLBI NIH HHS [HL-34646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALIOUA A, 1995, AM J PHYSIOL-LUNG C, V268, pL1057, DOI 10.1152/ajplung.1995.268.6.L1057; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FORN J, 1978, P NATL ACAD SCI USA, V75, P5195, DOI 10.1073/pnas.75.10.5195; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GRIDER JR, 1993, AM J PHYSIOL, V264, pG334, DOI 10.1152/ajpgi.1993.264.2.G334; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; JIANG H, 1992, J BIOL CHEM, V267, P1015; JIN JG, 1993, AM J PHYSIOL, V264, pG470, DOI 10.1152/ajpgi.1993.264.3.G470; KARCZEWSKI P, 1992, LIFE SCI, V51, P1205, DOI 10.1016/0024-3205(92)90357-U; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; Lincoln T., 1996, BIOCH SMOOTH MUSCLE, P257; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; MARKS AR, 1990, J BIOL CHEM, V265, P20719; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	41	159	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21933	21938		10.1074/jbc.271.36.21933	http://dx.doi.org/10.1074/jbc.271.36.21933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702997				2022-12-27	WOS:A1996VF61200039
J	Leitman, DC; Costa, CHRM; Graf, H; Baxter, JD; Ribeiro, RCJ				Leitman, DC; Costa, CHRM; Graf, H; Baxter, JD; Ribeiro, RCJ			Thyroid hormone activation of transcription is potentiated by activators of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED TRANSCRIPTION; RETINOID-X RECEPTOR; VITAMIN-D RECEPTOR; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTOR; CO-REPRESSOR; SYNERGISTIC ACTIVATION; GENE-TRANSCRIPTION; ESTROGEN-RECEPTOR; PHOSPHORYLATION	We characterized the cross-talk between activators of protein kinase A (PKA) and thyroid hormone (T-3) in T-3 receptor (TR)-mediated transcription. U937 cells mere cotransfected with a plasmid expressing the TR and a reporter plasmid containing a T-3 response element (TRE) oriented either as a direct repeat or as a palindrome upstream of the thymidine kinase promoter linked to the chloramphenicol acetyltransferase gene. T-3 activated transcription by 10-fold. T-3 response was potentiated 2.5-3-fold by activators of PKA, but an activator of protein kinase C or of guanylate kinase was ineffective. In the absence of T-3, activators of PKA had no effect on transcription. TR heterodimerization with the retinoid X receptor may facilitate T-3/PKA cross-talk because coexpression of the retinoid X receptor potentiated cross-talk. Synergy was not observed in JEG-3, F9, CV-1, HeLa, L929, and HTC cells, indicating that it may require cell-specific factors. Synergy required the DNA- and ligand-binding domains, but not the amino-terminal domain, indicating that T-3- and TRE-induced conformational changes on the TR are essential for cross-talk. PKA phosphorylated the TR in vitro, suggesting that, like other nuclear receptors, the TR is a target for PKA. These results imply that PICA cross-talks with T-3 at the level of the TRE-bound TR, enhancing its transcriptional. activity in a cell-specific manner.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA; UNIV FED PARANA, DEPT ENDOCRINOL, BR-80060900 CURITIBA, PARANA, BRAZIL	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade Federal do Parana					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARWISH HM, 1993, BIOCHIM BIOPHYS ACTA, V1167, P29, DOI 10.1016/0005-2760(93)90213-S; DAY RN, 1989, J BIOL CHEM, V264, P431; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENSPAN FS, 1994, BASIC CLIN ENDOCRINO, V1, P160; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSIEH JC, 1993, J BIOL CHEM, V268, P15118; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; NORDEEN SK, 1994, BIOCHEM BIOPH RES CO, V198, P1183, DOI 10.1006/bbrc.1994.1167; ONATE SA, 1995, SCIENCE, V270, P1354; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; STAUBER C, 1992, NEW BIOL, V4, P527; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	51	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21950	21955		10.1074/jbc.271.36.21950	http://dx.doi.org/10.1074/jbc.271.36.21950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703000	hybrid			2022-12-27	WOS:A1996VF61200042
J	Yohda, M; Endo, I; Abe, Y; Ohta, T; Iida, T; Maruyama, T; Kagawa, Y				Yohda, M; Endo, I; Abe, Y; Ohta, T; Iida, T; Maruyama, T; Kagawa, Y			Gene for aspartate racemase from the sulfur-dependent hyperthermophilic archaeum, Desulfurococcus strain SY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; GLUTAMATE RACEMASE; ESCHERICHIA-COLI; REACTION-MECHANISM; MOLLUSK SHELLS; D-SERINE; PURIFICATION; CLONING; PEPTIDOGLYCAN; LACTOBACILLUS	Amino acid racemases are ubiquitous throughout eubacteria, However, no amino acid racemases have yet been found in eukaryotes and archaea. We cloned a gene highly homologous to that for the aspartate racemase from the sulfur-dependent hyperthermophilic archaeum, Desulfurococcus strain SY, The product of the gene showed 35.2% amino acid sequence identity with the aspartate racemase of Streptococcus thermophilus IAM10064, and was also homologous to glutamate racemases around the putative catalytic cysteine residues, The encoded protein was expressed in Escherichia coli, The recombinant protein had amino acid racemizing activity, which was highly specific for aspartate and increased with temperature from 37 degrees C to 90 degrees C. Therefore, this was identified as the first hyperthermophilic archaeal amino acid racemase. A little aspartate racemizing activity was also detected in the crude extract of Desulfurococcus strain SY. The function of this aspartate racemase might be the uptake of D-aspartate formed at high temperature or the production of D-aspartate as a cell component, The fact that the amino acid racemases are distributed among both eubacteria and archaea suggests that endogenous D-amino acids in mammals are also synthesized by amino acid racemases.	UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; MARYLAND BIOTECHNOL INST,SHIMIZU,SHIZUOKA 424,JAPAN; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	University of Tsukuba; Jichi Medical University	Yohda, M (corresponding author), INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN.		Yohda, Masafumi/A-5149-2013	Yohda, Masafumi/0000-0001-8307-9671				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ADAMUS E, 1972, ENZYMES, V6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3970, DOI 10.1021/bi00851a026; CHOI SY, 1992, J BIOCHEM-TOKYO, V112, P139, DOI 10.1093/oxfordjournals.jbchem.a123853; CORRIGAN JJ, 1969, SCIENCE, V164, P142, DOI 10.1126/science.164.3876.142; DOUBLET P, 1993, J BACTERIOL, V175, P2970, DOI 10.1128/JB.175.10.2970-2979.1993; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; FINLAY TH, 1970, J BIOL CHEM, V245, P5248; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GOODFRIEND GA, 1992, NATURE, V357, P399, DOI 10.1038/357399a0; GOODFRIEND GA, 1991, GEOCHIM COSMOCHIM AC, V55, P3355, DOI 10.1016/0016-7037(91)90493-O; Hanzawa Satoshi, 1996, Journal of Marine Biotechnology, V4, P121; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; HOAKI T, 1993, APPL ENVIRON MICROB, V59, P610, DOI 10.1128/AEM.59.2.610-613.1993; JANNASCH HW, 1988, APPL ENVIRON MICROB, V54, P1203, DOI 10.1128/AEM.54.5.1203-1209.1988; KAGAWA Y, 1995, BIOCHEM BIOPH RES CO, V214, P730, DOI 10.1006/bbrc.1995.2346; KANDLER O, 1994, J BIOL PHYS, V20, P165; KANDLER O, 1994, BIOCH ARCHAEA, P223; KANDLER O, 1994, NOBEL S, V84; KERA Y, 1995, BBA-GEN SUBJECTS, V1243, P282, DOI 10.1016/0304-4165(94)00152-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZCARRION M, 1965, J BIOL CHEM, V240, P3547; NAKAJIMA N, 1986, AGR BIOL CHEM TOKYO, V50, P2853; NAKAJIMA N, 1988, AGR BIOL CHEM TOKYO, V53, P3099; OKADA H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P377, DOI 10.1016/0167-4838(91)90159-W; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; Sambrook J., 2002, MOL CLONING LAB MANU; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; SNELL EE, 1970, ENZYMES, V2, P353; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5095; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIZAWA K, 1989, J BIOL CHEM, V264, P2450; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WISEMAN JS, 1984, J BIOL CHEM, V259, P8907; YAGASAKI M, 1995, BIOSCI BIOTECH BIOCH, V59, P610, DOI 10.1271/bbb.59.610; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOHDA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P234, DOI 10.1016/0167-4781(91)90013-C; YOSHIMURA T, 1993, J BIOL CHEM, V268, P24242	43	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22017	22021		10.1074/jbc.271.36.22017	http://dx.doi.org/10.1074/jbc.271.36.22017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703007	hybrid			2022-12-27	WOS:A1996VF61200049
J	Lalo, D; Steffan, JS; Dodd, JA; Nomura, M				Lalo, D; Steffan, JS; Dodd, JA; Nomura, M			RRN11 encodes the third subunit of the complex containing Rrn6p and Rrn7p that is essential for the initiation of rDNA transcription by yeast RNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; BINDING PROTEIN; GENE; DNA; SPECIFICITY; MUTANTS; SL1; TBP	A new gene, RRN11, has been defined by certain rrn mutants of Saccharomyces cerevisiae which are defective specifically in the transcription of 35 S rRNA gene by RNA polymerase I (pol I), We have cloned the gene and found that it encodes a protein of 507 amino acids. We have used a strain with the chromosomal RRN11 deleted and carrying HA1 epitope-tagged RRN11 on a plasmid to isolate a protein complex containing the protein encoded by RRN11, This protein complex complemented rrn6 mutant extracts, which were previously shown to be deficient in the essential pol I transcription factor called Rrn6/7 complex or core factor (CF), The CF complex was previously shown to consist of three proteins, the 102- and 60-kDa subunits encoded by RRN6 and RRN7, respectively, and the 66-kDa subunit. The results of the above complementation experiments combined with mobility of Rrn11p in SDS-polyacrylamide gel electrophoresis analysis relative to Rrn6p and Rrn7p led to the conclusion that RRN11 encodes the 66-kDa subunit of CF. Glutathione S-transferase-Rrn11p fusion protein was found to bind strongly to S-35-labeled Rrn6p and Rrn7p but only weakly to S-35-labeled TATA-binding protein, Similarly, glutathione S-transferase-Rrn7p fusion protein bound strongly to S-3S-labeled Rrn6p and Rrn11p but only weakly to S-35-labeled TATA-binding protein, These results are consistent with the fact that one can purify CF consisting of Rrn6p, Rrn7p, and Rrn11p from yeast: cell extracts, but the purified complex does not contain TATA-binding protein, RRN11 was shown to be an essential gene, and [H-3]uridine pulse experiments demonstrated directly that RRN11 is essential for rDNA transcription by pol I in vivo, Thus all three subunits of CF are essential for rDNA transcription, Because of the resemblance of CF to mammalian essential pol I transcription factor SL1, the amino acid sequences of Rrn11p and the other two subunits of CF were compared with those of the three TATA-binding protein-associated factors (TAFs) in the human SL1, TAF(I)48, TAF(I)63, and TAF(I)110. No significant similarity was detected between two sets of the proteins. Similarity as well as differences between CF and SL1 are discussed.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92697	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035949] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM35949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P362; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P225; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P7026, DOI 10.1073/pnas.88.16.7026; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; REEDER RH, 1992, TRANSCRIPTIONAL REGU, V2, P315; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	30	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21062	21067		10.1074/jbc.271.35.21062	http://dx.doi.org/10.1074/jbc.271.35.21062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702872	hybrid			2022-12-27	WOS:A1996VE47700018
J	Moffett, S; Adams, L; Bonin, H; Loisel, TP; Bouvier, M; Mouillac, B				Moffett, S; Adams, L; Bonin, H; Loisel, TP; Bouvier, M; Mouillac, B			Palmitoylated cysteine 341 modulates phosphorylation of the beta(2)-adrenergic receptor by the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; CHINESE-HAMSTER FIBROBLASTS; SF9 CELLS; DISTINCT PATHWAYS; ADENYLATE-CYCLASE; CARBOXYL-TERMINUS; BOVINE RHODOPSIN; 2 DOMAINS; DESENSITIZATION	We previously showed that substitution of a glycine residue for the palmitoylated cysteine 341 of the human beta(2)-adrenergic receptor (Gly(341)beta(2)AR), increases the basal level of the receptor phosphorylation and reduces its ability to functionally interact with G(s). In the present study, we show that additional mutation of serines 345 and 346 (Ala(345,346)Gly(341)beta(2)AR) restored normal phosphorylation and receptor-G(s) coupling, thus suggesting that the increased phosphorylation of this site, rather than the lack of palmitoylation per se, is responsible for the poor coupling of the unpalmitoylated receptor. This is supported by the observation that chemical depalmitoylation of purified beta(2)AR did not affect the ability of the receptor to stimulate adenylyl cyclase in reconstitution assays. Furthermore, mutation of Ser(345,346) in a wild type receptor background (Ala(345,346)beta(2)AR) significantly decreased the rate of agonist-promoted desensitization of the receptor-stimulated adenylyl cyclase activity, supporting a role for this phosphorylation site in regulating the functional coupling of the receptor. Since serines 345 and 346 are located in a putative cyclic AMP-dependent protein kinase (PKA) phosphorylation site immediately downstream of the palmitoylated cysteine 341, the hypothesis that the accessibility of this site may be regulated by the receptor palmitoylation state mas further assessed in vitro. In membrane phosphorylation assays, Gly(341)beta(2)AR was found to be a better substrate for PKA than the wild type receptor, thus supporting the notion that palmitoylation restrains access of the phosphorylation site to the enzyme. Taken together, the data demonstrate that palmitoylation of cysteine 341 controls the phosphorylation state of the PKA site located in the carboxyl tail of the beta(2)AR and by doing so modulates the responsiveness of the receptor.	UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, GRP RECH SYST NERVEUX AUTONOME, MONTREAL, PQ H3C 3J7, CANADA; CNRS, INSERM, CTR PHARMACOL ENDOCRINOL, UNITE 401, F-34094 MONTPELLIER 5, FRANCE	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			MOUILLAC, Bernard/M-3896-2014; Bouvier, Michel/H-2758-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Bouvier, Michel/0000-0003-1128-0100				ALALUF S, 1995, J NEUROCHEM, V64, P1548; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DELEAN A, 1982, MOL PHARMACOL, V21, P5; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Post SR, 1996, J BIOL CHEM, V271, P895, DOI 10.1074/jbc.271.2.895; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHORR RGL, 1981, J BIOL CHEM, V256, P5820; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YUAN NY, 1994, J BIOL CHEM, V269, P23032	48	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21490	21497		10.1074/jbc.271.35.21490	http://dx.doi.org/10.1074/jbc.271.35.21490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702933	hybrid			2022-12-27	WOS:A1996VE47700079
J	Santee, SM; OwenSchaub, LB				Santee, SM; OwenSchaub, LB			Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; T-CELL DEVELOPMENT; NF-KAPPA-B; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; FUNCTIONAL-CHARACTERIZATION; VIRAL-PROTEINS; DNA-SEQUENCES; MESSENGER-RNA; EXPRESSION	Tumor necrosis factor receptor p75 (TNF-R p75) is a 75-kDa type I transmembrane protein expressed predominantly on cells of hematopoietic lineage. TNF-R p75 belongs to the TNF receptor superfamily characterized by cysteine rich extracellular regions composed of three to six disulfide-linked domains. In the present report we have characterized, for the first time, the complete gene structure for human TNF-R p75, which spans approximately 43 kbp. The gene consists of 10 exons (ranging from 34 base pairs to 2.5 kilobase pairs) and nine introns (343 base pairs to 19 kilobase pairs). Consensus elements for transcription factors involved in T cell development and activation were noted in the 5'-flanking region including T cell factor-1, Ikaros, AP-1, CK-2, interleukin-6 receptor E (IL-6RE), ISRE, GAS, NF-kappa B, and Sp1. The unusual (GATA)(n) and (GAA)(GGA) repeats found within intron 1 may prove useful for further genome analysis within the 1p36 chromosomal locus. Characterization of the human TNF-R p75 gene structure will permit further assessment of its involvement in normal hematopoietic cell development and function, autoimmune disease, and nonrandom translocations in hematopoietic malignancies.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE Y, 1995, J LEUKOCYTE BIOL, V57, P462, DOI 10.1002/jlb.57.3.462; AGGARWAL BB, 1993, LYMPHOKINE CYTOK RES, V12, P149; Ausubel FM, 1988, MOL REPROD DEV; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAKER E, 1991, CYTOGENET CELL GENET, V57, P117, DOI 10.1159/000133127; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BEMELMANS MHA, 1993, J IMMUNOL, V150, P2007; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BIRKELAND ML, 1995, EUR J IMMUNOL, V25, P926, DOI 10.1002/eji.1830250410; BLOOMFIELD CD, 1985, BLOOD, V66, P1409; CAMBRIN GR, 1986, CANCER GENET CYTOGEN, V22, P75, DOI 10.1016/0165-4608(86)90140-8; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DRAKE CG, 1994, P NATL ACAD SCI USA, V91, P4062, DOI 10.1073/pnas.91.9.4062; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EPPLEN JT, 1988, J HERED, V79, P409, DOI 10.1093/oxfordjournals.jhered.a110544; EPPLEN JT, 1992, CLIN CHIM ACTA, V209, pS5, DOI 10.1016/0009-8981(92)90174-O; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1994, J IMMUNOL, V153, P1963; GRIMALDI JC, 1992, J IMMUNOL, V149, P3921; GROSEN EA, 1993, GYNECOL ONCOL, V50, P68, DOI 10.1006/gyno.1993.1166; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; JACOBSEN FW, 1995, J IMMUNOL, V154, P3732; KAUFMAN BA, 1994, HUM GENET, V94, P418; KEMPER O, 1991, HUM GENET, V87, P623; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRAFT R, 1992, GENOMICS, V12, P555, DOI 10.1016/0888-7543(92)90448-2; KUHNERT P, 1994, GENE, V150, P381, DOI 10.1016/0378-1119(94)90457-X; KWON BS, 1994, J IMMUNOL, V152, P2256; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LINDVALL L, 1993, LYMPHOKINE CYTOK RES, V12, P205; LOENEN WAM, 1992, J IMMUNOL, V149, P3937; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOIR DJ, 1984, BLOOD, V64, P553; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEUNER P, 1994, CANCER RES, V54, P6001; OWENSCHAUB LB, 1989, J IMMUNOL, V143, P2236; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PANYUTIN IG, 1992, J BIOL CHEM, V267, P5495; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; REEVES BR, 1980, HUM GENET, V53, P349, DOI 10.1007/BF00287055; RICHARDS ML, 1991, J IMMUNOL, V147, P1067; ROTHE J, 1993, MOL IMMUNOL, V30, P165, DOI 10.1016/0161-5890(93)90088-S; RUDERT F, 1995, DNA CELL BIOL, V14, P931, DOI 10.1089/dna.1995.14.931; Singer M., 1991, GENES GENOMES; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANNENBAUM CS, 1993, J IMMUNOL, V151, P6833; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRENTIN L, 1993, BLOOD, V81, P752; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WELBORN JL, 1987, CANCER GENET CYTOGEN, V28, P277, DOI 10.1016/0165-4608(87)90214-7; WINZEN R, 1993, J IMMUNOL, V150, P4346; YAMADA K, 1983, CANCER GENET CYTOGEN, V9, P93, DOI 10.1016/0165-4608(83)90029-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	71	128	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21151	21159		10.1074/jbc.271.35.21151	http://dx.doi.org/10.1074/jbc.271.35.21151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702885	hybrid			2022-12-27	WOS:A1996VE47700031
J	Tang, CM; Tomkinson, AE; Lane, WS; Wold, MS; Seto, E				Tang, CM; Tomkinson, AE; Lane, WS; Wold, MS; Seto, E			Replication protein A is a component of a complex that binds the human metallothionein IIA gene transcription start site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; LONG TERMINAL REPEAT; DNA-REPLICATION; T-ANTIGEN; INITIATOR ELEMENTS; MAMMALIAN-CELLS; CAP SITE; TATA-BOX; SACCHAROMYCES-CEREVISIAE	Previous studies revealed that sequences surrounding the initiation sites in many mammalian and viral gene promoters, called initiator (Inr) elements, may be essential for promoter strength and for determining the actual transcription start sites. DNA sequences in the vicinity of the human metallothionein IIA (hMTIIA) gene transcription start site share homology with some of the previously identified Inr elements. However, in the present study we have found by in vitro transcription assays that the hMTIIA promoter does not contain a typical Inr. Electrophoretic mobility shift assays identified several DNA-protein complexes at the hMTIIA gene transcription start site. A partially purified protein fraction containing replication protein A (RPA) binds to the hMTIIA gene transcription start site and represses transcription from the hMTIIA promoter in vitro. In addition, overexpression of the human 70-kDa RPA-1 protein represses transcription of a reporter gene controlled by the hMTIIA promoter in vivo. These findings suggest that hMTIIA transcription initiation is controlled by a mechanism different from most mammalian and viral promoters and that the previously identified RPA may also be involved in transcription regulation.	UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOL MED,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	State University System of Florida; University of South Florida; University of Texas System; University of Texas Health San Antonio; Harvard University; University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NATIONAL CANCER INSTITUTE [R01CA061257] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA61257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BEACH LR, 1981, P NATL ACAD SCI-BIOL, V78, P2110, DOI 10.1073/pnas.78.4.2110; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BOYER TG, 1990, J BIOL CHEM, V265, P20524; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CONCINO MF, 1984, NUCLEIC ACIDS RES, V12, P7423, DOI 10.1093/nar/12.19.7423; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAINA B, 1990, P NATL ACAD SCI USA, V87, P2710, DOI 10.1073/pnas.87.7.2710; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1980, EUR J BIOCHEM, V107, P395; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIEBERMAN MW, 1983, CELL, V35, P207, DOI 10.1016/0092-8674(83)90223-4; MATTHIJS G, 1994, BIOCHEM BIOPH RES CO, V202, P65, DOI 10.1006/bbrc.1994.1894; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MULLER T, 1991, ARCH TOXICOL, V65, P20; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUDD CJ, 1979, TOXICOL APPL PHARM, V47, P273, DOI 10.1016/0041-008X(79)90321-1; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH KK, 1995, P NATL ACAD SCI USA, V92, P4907, DOI 10.1073/pnas.92.11.4907; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TALKINGTON CA, 1982, NATURE, V298, P192, DOI 10.1038/298192a0; TEBB G, 1988, EMBO J, V7, P3785, DOI 10.1002/j.1460-2075.1988.tb03263.x; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; TJIAN R, 1981, CELL, V26, P1, DOI 10.1016/0092-8674(81)90026-X; TOKUNAGA K, 1984, NUCLEIC ACIDS RES, V12, P1543, DOI 10.1093/nar/12.3.1543; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823	88	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21637	21644		10.1074/jbc.271.35.21637	http://dx.doi.org/10.1074/jbc.271.35.21637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702952	hybrid			2022-12-27	WOS:A1996VE47700098
J	Tremblay, JM; Helmkamp, GM; Yarbrough, LR				Tremblay, JM; Helmkamp, GM; Yarbrough, LR			Limited proteolysis of rat phosphatidylinositol transfer protein by trypsin cleaves the C terminus, enhances binding to lipid vesicles, and reduces phospholipid transfer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE RECOMBINANT PROTEINS; ESCHERICHIA-COLI; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; CA2+-ACTIVATED SECRETION; RNA-POLYMERASE; CLONED GENES; GROWTH; SEC14; EXCHANGE	Rat phosphatidylinositol transfer protein (PITP) is a 32-kDa protein of 271 amino acids that transfers phosphatidylinositol and phosphatidylcholine between membranes. The alpha isoform of rat PITP was expressed in Escherichia coli and purified in high yields, The purified protein contained 1 mol of phosphatidylglycerol and had a transfer activity for phosphatidylinositol and phosphatidylcholine equal to or greater than that of PITP purified from mammalian brain, Limited protease digestion was used to further define structure, activity, and function relationships in PITP. PITP alone is relatively resistant to digestion by chymotrypsin, trypsin, and Staphylococcus V8 protease but is readily cleaved by subtilisin. Phospholipid vesicles containing phosphatidic acid enhance susceptibility to digestion by all four proteases, In the presence of vesicles, PITP, which migrates as a 36-kDa protein in SDS-polyacrylamide gel electrophoresis, is cleaved rapidly by trypsin to a form that appears to be 2-3 kDa smaller than the native form, The tryptic fragment retains partial phospholipid transfer activity and shows an enhanced affinity for phospholipid vesicles containing phosphatidic acid. Analysis of the tryptic digestion products by immunoblotting, N-terminal sequencing, and electrospray mass spectrometry showed that trypsin cleaves the C terminus of PITP at Arg(253) and Arg(259), Thus, removal of the C terminus enhances the affinity of PITP for vesicles and results in a dimunition of transfer activity, Overall, the data show that PITP undergoes conformation changes and that the C terminus becomes more accessible to trypsin when bound to vesicles. Hence, the C terminus is not an essential component of the membrane binding site and may be located distal to it.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NIGMS NIH HHS [GM-24035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVRIES KJ, 1995, BIOCHEM J, V310, P648; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; DICORLETO PE, 1979, J BIOL CHEM, V254, P7795; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Helmkamp G M Jr, 1990, Subcell Biochem, V16, P129; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; KASPER AM, 1981, BIOCHIM BIOPHYS ACTA, V664, P22, DOI 10.1016/0005-2760(81)90025-4; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; LEE SC, 1992, J BIOL CHEM, V267, P2849; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SOMERHARJU P, 1983, BIOCHIM BIOPHYS ACTA, V731, P186, DOI 10.1016/0005-2736(83)90008-1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WYNN RM, 1992, J BIOL CHEM, V267, P12400	37	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21075	21080		10.1074/jbc.271.35.21075	http://dx.doi.org/10.1074/jbc.271.35.21075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702874	hybrid			2022-12-27	WOS:A1996VE47700020
J	Brechler, V; Chu, WN; Baxter, JD; Thibault, G; Reudelhuber, TL				Brechler, V; Chu, WN; Baxter, JD; Thibault, G; Reudelhuber, TL			A protease processing site is essential for prorenin sorting to the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY ATT-20 CELLS; HUMAN RENIN; GRANULES; PROPEPTIDE; PROTEINS; SEQUENCE; STORAGE; FURIN; PROOPIOMELANOCORTIN; PROSOMATOSTATIN	Transfected mouse pituitary AtT-20 cells were used to examine the sorting of human prorenin to dense core secretory granules and the regulated secretory pathway, These cells secrete prorenin constitutively and sort a portion of the prorenin to secretory granules, where it is converted to active renin by proteolytic processing. Pulse chase labeling of transfected AtT-20 cells demonstrated that regulated secretion of prorenin was prevented by: 1) the mutagenic deletion of the prosegment, 2) the premature proteolytic removal of the prosegment by a Golgi-resident processing protease, or 3) the mutation of the native cleavage site so as to prevent removal of the prosegment. In addition, expression of fusion proteins containing portions of the prorenin prosegment demonstrated that exposure of potential proteolytic cleavage sites was sufficient to confer cleavage-dependent regulated secretion of the corresponding protein. These data implicate the protease cleavage event in the regulated secretion of prorenin and are consistent with the involvement of a subclass of processing proteases in the sorting of certain proteins to secretory granules in AtT-20 cells.	CLIN RES INST MONTREAL,LAB MOL BIOCHEM HYPERTENS,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,LAB CELL BIOL HYPERTENS,MONTREAL,PQ H2W 1R7,CANADA; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of California System; University of California San Francisco								ARRANDALE JM, 1994, MOL ENDOCRINOL, V8, P1083, DOI 10.1210/me.8.8.1083; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHEVRIER D, 1993, MOL CELL ENDOCRINOL, V94, P213, DOI 10.1016/0303-7207(93)90170-O; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; MAINS RE, 1978, J BIOL CHEM, V253, P651; MERCURE C, 1995, J BIOL CHEM, V270, P16355, DOI 10.1074/jbc.270.27.16355; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; NAGAHAMA M, 1990, FEBS LETT, V264, P67, DOI 10.1016/0014-5793(90)80766-C; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; Reudelhuber Timothy L., 1995, P1621; Sealey Jean E., 1995, P1763; Seidah N G, 1992, NIDA Res Monogr, V126, P132; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; THIBAULT G, 1987, BIOCHEM J, V241, P265, DOI 10.1042/bj2410265; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; TUCKER PW, 1979, SCIENCE, V206, P1299, DOI 10.1126/science.117548; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; Yoo SH, 1996, J BIOL CHEM, V271, P1558	37	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20636	20640		10.1074/jbc.271.34.20636	http://dx.doi.org/10.1074/jbc.271.34.20636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702811	hybrid			2022-12-27	WOS:A1996VD33700063
J	Canet, D; Forge, V; Guillain, F; Mintz, E				Canet, D; Forge, V; Guillain, F; Mintz, E			Ca2+ translocation across sarcoplasmic reticulum ATPase randomizes the two transported ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; HIGH-AFFINITY; REACTION-MECHANISM; SITES; CA2+-ATPASE; PUMP; DISSOCIATION; TEMPERATURE; SUBSTRATE	Cytoplasmic Ca2+ dissociation is sequential, and the Ca2+ ions bound to the nonphosphorylated ATPase are commonly represented as superimposed on each other, so that the superficial Ca2+ is freely exchangeable from the cytoplasm, whereas the deeper Ca2+ is not. Under conditions where ADP-sensitive phosphoenzyme accumulates (leaky vesicles, 5 degrees C, pH 8, 300 mM K+), luminal Ca2+ dissociation is sequential as well, so that the representation of two superimposed Ca2+ ions still holds on the phosphoenzyme, with the superficial Ca2+ facing the lumen freely exchangeable and the deeper Ca2+ blocked by the superficial Ca2(+). Under the same conditions, we have investigated whether a prebuilt Ca2+ order is maintained during membrane translocation, Starting from a prebuilt order on the cytoplasmic side, we showed that the Ca2+ ions cannot be identified after translocation to the luminal side, The same result was obtained starting from a prebuilt order on the luminal side and following the luminal to cytoplasmic translocation, We conclude that the two Ca2+ ions are mixed during ATP-induced phosphorylation as well as during ADP-induced dephosphorylation.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOL,SECT BIOPHYS PROT & MEMBRANES,CNRS,UNITE RECH 2096,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Canet, D (corresponding author), CEA,F-91191 GIF SUR YVETTE,FRANCE.							ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; FORGE V, 1993, J BIOL CHEM, V268, P10953; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; Martonosi AN, 1995, BIOSCIENCE REP, V15, P263, DOI 10.1007/BF01788359; MESZAROS LG, 1992, BIOCHEMISTRY-US, V31, P1195, DOI 10.1021/bi00119a032; MESZAROS LG, 1993, BIOCHEMISTRY-US, V32, P10085, DOI 10.1021/bi00089a025; MOUTIN MJ, 1991, J BIOL CHEM, V266, P5580; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1979, J BIOL CHEM, V254, P4726; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, J BIOL CHEM, V267, P25739	25	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20566	20572		10.1074/jbc.271.34.20566	http://dx.doi.org/10.1074/jbc.271.34.20566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702801	hybrid			2022-12-27	WOS:A1996VD33700053
J	ODoherty, RM; Lehman, DL; Seoane, J; GomezFoix, AM; Guinovart, JJ; Newgard, CB				ODoherty, RM; Lehman, DL; Seoane, J; GomezFoix, AM; Guinovart, JJ; Newgard, CB			Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; GLYCOGEN-SYNTHASE; GLUCOSE-METABOLISM; REGULATORY PROTEIN; TRANSLOCATION; CELLS; LIVER; GENE; GLUCOSE-6-PHOSPHATE; PHOSPHORYLASE	The first step of glucose metabolism is the phosphorylation of glucose, catalyzed by the hexokinase family of enzymes. To address the metabolic impact of increasing glucose phosphorylation capacity in liver, rat primary hepatocytes were treated with recombinant adenoviruses containing the cDNAs encoding either rat Liver glucokinase (AdCMV-GKL) or rat hexokinase I (Ad-CMV-HKI). Maximal glucose phosphorylation in Ad-CMV-GKL- and AdCMV-HKI-treated hepatocytes was increased 7.1 +/- 1.2- and 6.3 +/- 0.8-fold, respectively, over hepatocytes treated with an adenovirus expressing beta-galactosidase. Glucose usage (measured with 3 and 20 mM 2-[H-3]glucose and 5-[H-3]glucose) was significantly increased in AdCMV-GKL-treated cells preincubated in 1 or 25 mM glucose. Treatment of hepatocytes with Ad-CMV-HKI also caused enhanced glucose utilization, but the increases were smaller and were less apparent in cells preincubated in high (25 mM) glucose. AdCMV-GKL-treated hepatocytes incubated for 48 h in the presence of variable glucose concentrations had glycogen levels that were maximally 15.0 +/- 0.6-fold greater than levels in corresponding control cells. AdCMV-HKI-treated hepatocytes incubated under similar conditions had unchanged glycogen levels relative to controls. In AdCMV-GKL-treated cells, lactate output was increased to a maximum of 3.0 +/- 0.4-fold (at 25 mM glucose), glucose oxidation was increased 3.5 +/- 0.3-fold, and triglyceride production was unchanged relative to untreated cells. Among these three parameters, only lactate production was increased in AdCMV-HKI-treated cells, and then only at low glucose concentrations. We conclude that overexpression of glucokinase has potent effects on glucose storage and utilization in hepatocytes and that these effects are not matched by overexpression of hexokinase I.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV BARCELONA,FAC QUIM,DEPT BIOQUIM & BIOL MOL,E-08028 BARCELONA,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Barcelona			Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974	PHS HHS [1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CIUDAD CJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P30, DOI 10.1016/0003-9861(88)90566-8; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; TOYODA Y, 1995, BIOCHEM BIOPH RES CO, V215, P467, DOI 10.1006/bbrc.1995.2488; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WILSON JE, 1984, REGULATION CARBOHYDR, P45	28	66	67	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20524	20530		10.1074/jbc.271.34.20524	http://dx.doi.org/10.1074/jbc.271.34.20524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702794	hybrid			2022-12-27	WOS:A1996VD33700046
J	Saito, H; Masuda, S; Inui, K				Saito, H; Masuda, S; Inui, K			Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; EXPRESSION CLONING; MOLECULAR-CLONING; PROTEIN; LIVER; ACID; SPECIFICITY; INHIBITION; SEQUENCES; BINDING	We have cloned a cDNA coding for a novel member of organic anion transporter, designated OAT-K1, expressed specifically in the kidney of rats, The rat OAT-K1 cDNA (2788 base pairs) had an open reading frame encoding for a 669-amino acid protein (calculated molecular mass of 74 kDa) which shows 72% identity with the cloned rat liver organic anion transporter, oatp, Northern hybridization and reverse transcription coupled polymerase chain reaction revealed that the rat OAT-K1 messenger RNA transcript is expressed predominantly in the kidney. By use of stable LLC-PK1 cell monolayers transfected with the rat OAT-K1 cDNA, the transporter was suggested to mediate basolateral uptake of methotrexate, an anionic anticancer drug, but not taurocholate, p-aminohippurate, prostaglandin E(2), and leukotriene C-4, The methotrexate transport by rat OAT-K1 was unaffected by the presence of Na+ or Cl(-)gradient. The methotrexate accumulation by the OAT-K1-expressing cells showed saturability with the apparent K-m value of 1.0 mu m. Folate, sulfobromophthalein, and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) inhibited the methotrexate accumulation markedly, These findings suggest that the rat OAT-K1 is localized in the basolateral membranes of renal tubules, where it mediates renal clearance of methotrexate from the blood.	KYOTO UNIV HOSP,FAC MED,DEPT PHARM,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Inui, Ken-ichi/AAH-8748-2020; Masuda, Satohiro/E-6691-2010	Masuda, Satohiro/0000-0002-3589-5989				BOURKE RS, 1975, CANCER RES, V35, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; GU H, 1994, J BIOL CHEM, V269, P7124; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HE YL, 1991, DRUG METAB DISPOS, V19, P729; HORNE DW, 1992, ARCH BIOCHEM BIOPHYS, V298, P121, DOI 10.1016/0003-9861(92)90102-3; JACKSON RC, 1984, PHARMACOL THERAPEUT, V25, P61, DOI 10.1016/0163-7258(84)90024-X; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; NIERENBERG DW, 1987, J PHARMACOL EXP THER, V240, P712; SAID HM, 1987, BIOCHEM J, V247, P141, DOI 10.1042/bj2470141; SAITO H, 1992, AM J PHYSIOL, V262, pC59, DOI 10.1152/ajpcell.1992.262.1.C59; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879	28	185	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20719	20725		10.1074/jbc.271.34.20719	http://dx.doi.org/10.1074/jbc.271.34.20719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702823	hybrid			2022-12-27	WOS:A1996VD33700075
J	Vadlamudi, RK; Joung, I; Strominger, JL; Shin, J				Vadlamudi, RK; Joung, I; Strominger, JL; Shin, J			p62, a phosphotyrosine-independent ligand of the SH2 domain of p56(lck), belongs to a new class of ubiquitin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								p62 is a novel cellular protein which was initially identified as a phosphotyrosine-independent ligand of the SH2 domain of p56(lck). In the yeast two-hybrid system, p62 specifically interacted with ubiquitin in vivo. Furthermore, p62 bound to ubiquitin-conjugated Sepharose beads in vitro and was efficiently competed by soluble ubiquitin. The interaction was independent of ATP hydrolysis, and its dissociation did not require a reducing agent. Thus, p62 binds to ubiquitin noncovalently. Further analysis showed that the C-terminal 80 amino acids of p62 were indispensable for its interaction with ubiquitin. However, p62 has homology neither with ubiquitin C-terminal hydrolases nor with the S5a subunit of the 26 S proteasome complex, the only proteins known to bind to ubiquitin noncovalently. These results suggest that p62 belongs to a new class of ubiquitinbinding proteins and that p62 affects signal transduction at least partly through ubiquitination-mediated protein degradation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048961] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIGMS NIH HHS [GM48961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PREDERGAST JA, 1995, J BIOL CHEM, V270, P9347; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774	16	243	252	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20235	20237		10.1074/jbc.271.34.20235	http://dx.doi.org/10.1074/jbc.271.34.20235			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702753	hybrid			2022-12-27	WOS:A1996VD33700005
J	Priest, JW; Hajduk, SL				Priest, JW; Hajduk, SL			In vitro import of the Rieske iron-sulfur protein by trypanosome mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; PRECURSOR PROTEINS; INNER MEMBRANE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; DEVELOPMENTAL REGULATION; BLOOD-STREAM; MATRIX ATP; HEME LYASE; SACCHAROMYCES-CEREVISIAE	Most of the proteins present in the mitochondrion are imported to that location from the cytosol. While this process has been studied extensively in fungal and mammalian systems, little work has been done in other eukaryotic organisms. We are particularly interested in the Trypanosoma brucei system because this organism developmentally regulates mitochondrial function during its life cycle and because one of the imported proteins lacks a conventional targeting sequence. We report here the development of an in vitro import system using crude trypanosome mitochondria and a nuclear encoded, mitochondrial protein. Import of the Rieske iron-sulfur protein subunit of the cytochrome c reductase complex requires a membrane potential, ATP, and a protein component on the mitochondrial surface. The precursor protein is sequentially processed to the mature form in two steps by peptidases that require divalent metal ions far activity. As in other eukaryotic systems, the first processing event occurs inside the inner membrane and is probably catalyzed by a matrix-processing protease. Surprisingly, the second processing activity is located outside the inner membrane. Both processing steps require ATP but are independent of a membrane potential. We suggest that the trypanosome iron-sulfur protein is imported along a ''conservative sorting pathway'' but that the assembly mechanism of the reductase complex may be unique to trypanosomes.	UNIV ALABAMA,DEPT MOL GENET & BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED & DENT,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI021401, P01AI028780, R01AI021401, F32AI008259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28780, AI21401, AI08259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; CYR DM, 1993, J BIOL CHEM, V268, P23751; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; FU W, 1990, J BIOL CHEM, V265, P16541; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Hauser R, 1996, J CELL SCI, V109, P517; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HWANG ST, 1991, J BIOL CHEM, V266, P21083; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; ISAYA G, 1992, J BIOL CHEM, V267, P7904; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P51; JAPA S, 1994, ARCH BIOCHEM BIOPHYS, V312, P414, DOI 10.1006/abbi.1994.1327; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PETERSON GC, 1993, MOL BIOCHEM PARASIT, V58, P63, DOI 10.1016/0166-6851(93)90091-B; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; PRIEST JW, 1995, BBA-MOL CELL RES, V1269, P201, DOI 10.1016/0167-4889(95)00154-6; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; RAMABADRAN RS, 1992, ARCH BIOCHEM BIOPHYS, V296, P279, DOI 10.1016/0003-9861(92)90573-F; REID GA, 1982, J BIOL CHEM, V257, P3062; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; TORRI AF, 1988, MOL CELL BIOL, V8, P4625, DOI 10.1128/MCB.8.11.4625; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VERCESI AE, 1992, MOL BIOCHEM PARASIT, V56, P251, DOI 10.1016/0166-6851(92)90174-I; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WILLIAMS N, 1991, ARCH BIOCHEM BIOPHYS, V288, P509, DOI 10.1016/0003-9861(91)90228-B; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	71	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20060	20069		10.1074/jbc.271.33.20060	http://dx.doi.org/10.1074/jbc.271.33.20060			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702725	hybrid			2022-12-27	WOS:A1996VC66900066
J	Rooney, TA; Joseph, SK; Queen, C; Thomas, AP				Rooney, TA; Joseph, SK; Queen, C; Thomas, AP			Cyclic GMP induces oscillatory calcium signals in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHASE; CA2+ MOBILIZATION; PERMEABILIZED HEPATOCYTES; TRISPHOSPHATE RECEPTORS; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA2+; CA-2+ LEVELS	The ability of guanosine-3',5'-cyclic monophosphate (cGMP) to induce increases in the intracellular free calcium ion concentration ([Ca2+](i)) was studied at the single cell level in fura-a-loaded rat hepatocytes. Both 8-bromo-cGMP (Br-cGMP) and dibutyryl cGMP (db-cGMP) produced oscillatory [Ca2+](i) increases in hepato cytes. In addition, Br-cGMP increased the frequency of agonist-induced spiking or converted [Ca2+](i) oscillations into sustained nonoscillatory [Ca2+](i) responses, Addition of the nitric oxide donor sodium nitroprusside also produced oscillatory [Ca2+](i) increases similar to those generated by cGMP analogues. In the absence of extracellular Ca2+, cGMP-induced [Ca2+](i) responses were significantly reduced and mainly appeared as single transient [Ca2+](i) increases. The effects of cGMP analogues do not appear to be mediated by a secondary increase in cAMP or activation of cAMP-dependent protein kinase (PKA), since [Ca2+](i) responses to cGMP analogues were inhibited by the G-kinase inhibitor 8-bromoguanosine-3',5'-cyclic monophosphorothioate (RpBr-cGMP[S]). Both Br-cGMP and db-cGMP also increased [Ca2+](i) in the presence of the PKA inhibitor 8-bromoadenosine-3',5' cyclic monophosphorothioate (Rp-Br-cAMP[S]) and when the cGMP-inhibitable cAMP phosphodiesterase activity was inhibited by pretreatment with siguazodan. Br-cGMP stimulated the Mn2+ induced quench of compartmentalized fura-2 in intact hepatocytes, indicating a site of action at the level of the Ca2+ stores. This locus was further supported by the finding that pretreatment of hepatocytes with Br-cGMP potentiated submaximal inositol 1,4,5-trisphosphate (InsP(3))-induced Mn2+ quench in subsequently permeabilized hepatocytes, db-cGMP also decreased PKA-mediated back phosphorylation of the hepatic type-1 InsP(3) receptor, indicating that G-kinase phosphorylates the InsP(3) receptor at sites targeted by PKA. These data indicate that phosphorylation of the hepatic InsP(3) receptor by G-kinase increases the sensitivity to InsP(3) for [Ca2+](i) release and is associated with the production of [Ca2+](i) oscillations in single rat hepatocytes.	THOMAS JEFFERSON UNIV, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA10413] Funding Source: Medline; NIDDK NIH HHS [DK38422, DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK034804, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010413] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BURGSTAHLER AD, 1995, AM J PHYSIOL-GASTR L, V269, pG789, DOI 10.1152/ajpgi.1995.269.5.G789; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CHIAVAROLI C, 1994, J BIOL CHEM, V269, P25570; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; Clementi E, 1995, MOL PHARMACOL, V48, P1068; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DUFOUR JFJ, 1995, GASTROENTEROLOGY, V108, P841, DOI 10.1016/0016-5085(95)90459-X; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FORTE LR, 1989, MOL PHARMACOL, V34, P506; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MATTER N, 1993, J BIOL CHEM, V268, P732; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MILBOURNE EA, 1995, CELL CALCIUM, V18, P207, DOI 10.1016/0143-4160(95)90065-9; MILBOURNE EA, 1995, CELL SIGNAL, V7, P313, DOI 10.1016/0898-6568(95)00005-A; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MURTHY KS, 1993, AM J PHYSIOL, V264, pG967, DOI 10.1152/ajpgi.1993.264.5.G967; NAKADE S, 1994, J BIOL CHEM, V269, P6735; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V183, P238, DOI 10.1016/0006-291X(92)91634-3; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SARCEVIC B, 1989, J BIOL CHEM, V264, P20648; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THOMAS AP, 1995, CIBA F SYMP, V188, P18; THOMAS AP, 1983, J BIOL CHEM, V258, P5716; TOESCU EC, 1995, AM J PHYSIOL-GASTR L, V269, pG173, DOI 10.1152/ajpgi.1995.269.2.G173; XU X, 1994, J BIOL CHEM, V269, P12645; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	57	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19817	19825		10.1074/jbc.271.33.19817	http://dx.doi.org/10.1074/jbc.271.33.19817			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702690	hybrid			2022-12-27	WOS:A1996VC66900031
J	Sasaoka, T; Ishihara, H; Sawa, T; Ishiki, M; Morioka, H; Imamura, T; Usui, I; Takata, Y; Kobayashi, M				Sasaoka, T; Ishihara, H; Sawa, T; Ishiki, M; Morioka, H; Imamura, T; Usui, I; Takata, Y; Kobayashi, M			Functional importance of amino-terminal domain of Shc for interaction with insulin and epidermal growth factor receptors in phosphorylation-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; MITOGENIC SIGNAL-TRANSDUCTION; FACTOR-I; AUTOPHOSPHORYLATION SITES; BINDING-SITES; SUBSTRATE-1; GRB2; ACTIVATION; PROTEIN; MOTIF	Shc has two distinct domains, amino-terminal and SH2 domain, which cam interact with activated growth factor receptors. Shc interacts with insulin receptor via Shc-amino-terminal (N) domain, whereas Shc associates with epidermal growth factor (EGF) receptor through both Shc-N and -SH2 domains. In accordance with the different functional roles between insulin and EGF receptors, EGF stimulated tyrosine phosphorylation of Shc faster than insulin, To clarify the functional importance of three distinct Shc domains on insulin and EGF signaling, we microinjected glutathione S-transferase (GST) fusion proteins containing the amino terminus plus collagen homology domain (NCH), collagen homology domain (CM), and Src homology 2 domain (SH2) into Rat1 fibroblasts expressing insulin receptors (HIRc). Bromodeoxyuridine (BrdUrd) incorporation into newly synthesized DNA was subsequently studied to assess the importance of the three distinct domains of Shc, Microinjection of the NCH-GST fusion protein inhibited BrdUrd incorporation induced by both EGF and insulin, whereas microinjection of the SH2-GST fusion protein inhibited EGF, but not insulin stimulation of DNA syn thesis, Neither EGF- nos insulin-induced BrdUrd incorporation was inhibited by the CH-GST fusion protein, Following EGF or insulin stimulation, Shc is phosphorylated on single Tyr-317 residue serving as a docking site for Grb2. Microinjection of Shc-N+CH GST fusion protein with Tyr-317 --> Phe replacement (Y317F) also inhibited insulin stimulation of DNA synthesis, Next, we stably overexpressed wild-type Shc or Y317F mutant She into HIRc cells, Insulin-induced tyrosine phosphorylation of IRS-1 was compared among the transfected cell lines, since IRS-1 and Shc could competitively interact with insulin receptor, Insulin-stimulated tyrosine phosphorylation of IRS-1 was decreased in both WT-Shc and Y317F-Shc cells compared with that in HIRc cells, Furthermore, overexpression of the Shc-SH2 domain or Shc-N+CH domain with Y317F mutation interfered with EGF-stimulated endogenous She phosphorylation. These results suggest that the amino terminus domain of Shc is functionally important in insulin- and EGF-induced cell cycle progression and that the phosphorylation of Shc Tyr-317 residue is independent of Shc interaction with these receptors.			Sasaoka, T (corresponding author), TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN.							BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20082	20087		10.1074/jbc.271.33.20082	http://dx.doi.org/10.1074/jbc.271.33.20082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702728	hybrid			2022-12-27	WOS:A1996VC66900069
J	Schrader, M; Danielsson, C; Wiesenberg, I; Carlberg, C				Schrader, M; Danielsson, C; Wiesenberg, I; Carlberg, C			Identification of natural monomeric response elements of the nuclear receptor RZR/ROR - They also bind COUP-TF homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; HUMAN-BREAST-CANCER; GLAND HORMONE MELATONIN; BONE SIALOPROTEIN GENE; THYROID-HORMONE; MAMMALIAN-TISSUES; ROR-ALPHA; VITAMIN-D; ORPHAN; PROMOTER	The receptor RZR/ROR is an important member of the nuclear receptor superfamily and has recently been shown to be the nuclear receptor for the pineal gland hormone melatonin, RZR/ROR binds as a monomer to DNA, and the human 5-lipoxygenase gene has been identified as the first RZR/ROR/melatonin-responding gene. Another prominent nuclear receptor is COUP-TF, which binds as a dimer to DNA. In this study, the sequences of known promoter regions of genes that may be involved in the physiological action of melatonin have been screened for putative monomeric RZR/ROR response elements. The binding of RZR/ROR and COUP-TF was compared and quantified on a set of 12 putative response elements, Interestingly, COUP-TF homodimers were found to bind with high affinity to some of the monomeric RZR/ROR response elements, Four RZR/ROR response elements, found in the genes of the mouse bifunctional enzyme, the rat bone sialoprotein, mouse Purkinje cell protein 2, and human p21(WAF1/CIP1), were shown to be inducible by melatonin under conditions of low constitutive activity, Surprisingly, the constitutive activity of COUP-TF was also stimulated by an unknown serum compound. The novel Purkinje cell protein 2 and p21(WAF1/CIP1) RZR/ROR/melatonin-responding genes may be the key for understanding the role of RZR/ROR alpha in the mouse mutation staggerer and the antiproliferative action of melatonin, respectively.	HOP CANTONAL UNIV GENEVA, DERMATOL CLIN, CH-1211 GENEVA 14, SWITZERLAND; CIBA GEIGY AG, PHARMA FORSCH, CH-4002 BASEL, SWITZERLAND	University of Geneva; Novartis			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; ACUNACASTROVIEJO D, 1993, RES COMMUN CHEM PATH, V82, P253; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BELLAHCENE A, 1994, CANCER RES, V54, P2823; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BLASK DE, 1986, J NEURAL TRANSM, P433; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARPER JW, 1993, CELL, V75, P805; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HILL SM, 1988, CANCER RES, V48, P6121; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZOU LL, 1994, J BIOL CHEM, V269, P13346	54	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19732	19736		10.1074/jbc.271.33.19732	http://dx.doi.org/10.1074/jbc.271.33.19732			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702678	hybrid			2022-12-27	WOS:A1996VC66900019
J	Brouns, GS; deVries, E; Neefjes, JJ; Borst, J				Brouns, GS; deVries, E; Neefjes, JJ; Borst, J			Assembled pre-B cell receptor complexes are retained in the endoplasmic reticulum by a mechanism that is not selective for the pseudo-light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; HEAVY-CHAIN; IMMUNOGLOBULIN HEAVY; TARGETED DISRUPTION; ANTIGEN RECEPTORS; ALLELIC EXCLUSION; TYROSINE KINASE; MEMBRANE EXON; BONE-MARROW; SURFACE	The pre-B cell receptor (BCR) complex, consisting of mu heavy chain, a pseudo-light drain, and the Mb-1/B29 heterodimer, directs the transition to the mature B cell stage, Plasma membrane expression of the pre-BCR is extremely low, despite its presumed signaling function, We have compared assembly and intracellular transport of the pre-BCR complex with that of the BCR complex in mature B cells, Synthesis and assembly rate of pre-BCR and BCR components are comparable, However, the pre-BCR is subject to a highly efficient retention mechanism, which only allows exit of a few percent of the complexes from the endoplasmic reticulum (ER). This small transported pool of pre-BCR complexes is significantly enriched for protein-tyrosine kinase activity, as compared with the ER-localized receptor pool, Accordingly, the Src-related tyrosine kinase Lyn was found in the transported glycoprotein action but not in association with ER-localized glycoproteins. Upon introduction of a conventional light chain into pre-B cells, plasma membrane receptor levels increased, but the efficiency of intracellular transport of the receptor complex was not restored to that in mature B cells. This indicates that the ER retention mechanism is not selective for the pseudo-light chain and may be inherent to pre-B cells, We propose that this retention mechanism contributes to the regulation of pre-BCR-mediated signal transduction.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; Borst, Jannie/0000-0002-8043-5009				BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; BROUNS GS, 1995, INT IMMUNOL, V7, P359, DOI 10.1093/intimm/7.3.359; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CLARK MR, 1992, J IMMUNOL, V149, P2857; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GUELPAFONLUPT V, 1994, EUR J IMMUNOL, V24, P257, DOI 10.1002/eji.1830240140; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LEPRINCE C, 1992, EUR J IMMUNOL, V22, P2093, DOI 10.1002/eji.1830220820; MASON DY, 1991, J IMMUNOL, V147, P2474; MASON DY, 1995, BLOOD, V86, P1453, DOI 10.1182/blood.V86.4.1453.bloodjournal8641453; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SALAMERO J, 1995, EUR J IMMUNOL, V25, P2757, DOI 10.1002/eji.1830251007; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19272	19278		10.1074/jbc.271.32.19272	http://dx.doi.org/10.1074/jbc.271.32.19272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702609	hybrid			2022-12-27	WOS:A1996VB68400043
J	Deng, L; Hagler, J; Shuman, S				Deng, L; Hagler, J; Shuman, S			Factor-dependent release of nascent RNA by ternary complexes of vaccinia RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION FACTOR; VIRUS EARLY TRANSCRIPTION; MESSENGER-RNA; CAPPING ENZYME; EARLY GENES; ELONGATION; PROMOTER; CLEAVAGE; NUSG; SII	Factor-dependent transcription termination during synthesis of vaccinia early mRNAs occurs at heterogeneous sites downstream of a UUUUUNU signal in the nascent transcript. The choice of termination site is flexible and is determined by a kinetic balance between nascent chain elongation and the transmission of the RNA signal to the polymerase. To eliminate ongoing elongation as a variable, we have established a system to study transcript release by purified ternary complexes halted at st defined template position 50-nucleotides 3' of the first U residue of the termination signal. Release of the nascent RNA depends on the vaccinia termination factor (VTF) and an ATP cofactor. Transcript release is blocked by BrUMP substitution within the termination signal of the nascent RNA, in these respects, the release reaction faithfully mimics the properties of the termination event. We demonstrate that ternary complexes are refractory to VTF-mediated transcript release when the first U of the UUUUUNU signal is situated 20 nucleotides from the growing point of the nascent chain. Ribonuclease footprinting of the arrested ternary complexes defines a nascent RNA binding site oil the polymerase elongation complex that encompasses a 16-21 nucleotide RNA segment extending proximally from the 3' end of the chain. We surmise that access of VTF to the signal sequence is prevented when UUUUUNU is bound within the nascent RNA binding site. Hence, physical not kinetic constraints determine the minimal distance between the signal and potential sites of 3' end formation.	SLOAN KETTERING INST,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1994, J VIROL, V68, P6052, DOI 10.1128/JVI.68.9.6052-6056.1994; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; DENG L, 1994, J BIOL CHEM, V269, P14323; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10009; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LI J, 1993, J BIOL CHEM, V268, P2773; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1995, J VIROL, V69, P3852, DOI 10.1128/JVI.69.6.3852-3856.1995; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NEHRKE KW, 1994, J MOL BIOL, V243, P830, DOI 10.1006/jmbi.1994.1685; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; ZHANG YF, 1994, J VIROL, V68, P1360, DOI 10.1128/JVI.68.3.1360-1370.1994	31	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19556	19562		10.1074/jbc.271.32.19556	http://dx.doi.org/10.1074/jbc.271.32.19556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702649	hybrid			2022-12-27	WOS:A1996VB68400083
J	Lavrik, OI; Prasad, R; Beard, WA; Safronov, IV; Dobrikov, MI; Srivastava, DK; Shishkin, GV; Wood, TG; Wilson, SH				Lavrik, OI; Prasad, R; Beard, WA; Safronov, IV; Dobrikov, MI; Srivastava, DK; Shishkin, GV; Wood, TG; Wilson, SH			dNTP binding to HIV-1 reverse transcriptase and mammalian DNA polymerase beta as revealed by affinity labeling with a photoreactive dNTP analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; STEADY-STATE KINETICS; DOUBLE-STRANDED DNA; I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; CATALYTIC DOMAIN; RNA-POLYMERASES; PRIMER BINDING; MECHANISM	The dNTP binding pocket of human immunodeficiency virus type 1 reverse transcriptase (RT) and DNA polymerase beta (beta-pol) were labeled using a photoreactive analog of dCTP, exo-N-[beta-(p-azidotetrafluorobenzamido)ethyl]-deoxycytidine-5'-triphosphate (FABdCTP), Two approaches of photolabeling were utilized, In one approach, photoreactive FABdCTP and radiolabeled primer-template were UV-irradiated in the presence of each enzyme and resulted in polymerase radiolabeling. In an alternate approach, FABdCTP was first UV-cross linked to enzyme; subsequently, radiolabeled primer-template was added, and the enzyme-linked dCTP analog was incorporated onto the 3'-end of the radiolabeled primer. The results showed strong labeling of the p66 subunit of RT, with only minor labeling of p51. No difference in the intensity of cross linking was observed with either approach, FABdCTP crosslinking was increased in the presence of a dideoxyterminated primer-template with RT, but not with beta-pol, suggesting a significant influence of prior primer-template binding on dNTP binding for RT. Mutagenesis of beta-pol residues observed to interact with the incoming dNTP in the crystal structure of the ternary complex resulted in labeling consistent with kinetic characterization of these mutants and indicated specific labeling of the dNTP binding pocket.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; RUSSIAN ACAD SCI, INST BIOORGAN CHEM, SIBERIAN DIV, NOVOSIBIRSK 630090, RUSSIA	University of Texas System; University of Texas Medical Branch Galveston; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences			Lavrik, Olga I/G-4641-2013; Wilson, Samuel H/E-6644-2019; Wood, Thomas/B-6172-2012; Wood, Thomas/GWZ-2481-2022	Wilson, Samuel H/0000-0002-1702-5293; Wood, Thomas/0000-0001-8962-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06776, ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; CHENG N, 1993, BIOCHEMISTRY-US, V32, P7630, DOI 10.1021/bi00081a005; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DORONIN SV, 1994, FEBS LETT, V354, P200, DOI 10.1016/0014-5793(94)01110-9; DORONIN SV, 1992, FEBS LETT, V313, P31, DOI 10.1016/0014-5793(92)81177-N; DORONIN SV, 1989, FEBS LETT, V259, P83, DOI 10.1016/0014-5793(89)81500-5; GRACHEV MA, 1982, FEBS LETT, V137, P89, DOI 10.1016/0014-5793(82)80321-9; HUSAIN I, 1995, NUCLEIC ACIDS RES, V23, P1597, DOI 10.1093/nar/23.9.1597; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KNORRE DG, 1988, BIOCHIMIE, V70, P655, DOI 10.1016/0300-9084(88)90250-7; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1993, BIOCHEMISTRY-US, V32, P7466, DOI 10.1021/bi00080a018; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MITINA RL, 1990, FEBS LETT, V272, P181, DOI 10.1016/0014-5793(90)80478-2; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PELLETIER H, 1994, SCIENCE, V266, P2025, DOI 10.1126/science.7801132; PELLETIER H, 1996, IN PRESS BIOCHEMISTR; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sambrook J, 1989, MOL CLONING; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; Zakharova OD, 1995, BIOCHIMIE, V77, P699, DOI 10.1016/0300-9084(96)88184-3	44	34	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21891	21897		10.1074/jbc.271.36.21891	http://dx.doi.org/10.1074/jbc.271.36.21891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702991	hybrid			2022-12-27	WOS:A1996VF61200033
J	Galisteo, ML; Chernoff, J; Su, YC; Skolnik, EY; Schlessinger, J				Galisteo, ML; Chernoff, J; Su, YC; Skolnik, EY; Schlessinger, J			The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase pak1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; CDC42; SH3; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION; DOMAINS; PLASMID	Nck is an adaptor protein composed of a single SH2 domain and three SH3 domains. Upon growth factor stimulation, Nck is recruited to receptor tyrosine kinases via its SH2 domain, probably initiating one or more signaling cascades, In this report, we show that Nck is bound in living cells to the serine-threonine kinase Pak1. The association between Nck and Pak1 is mediated by the second SH3 domain of Nck and a proline-rich sequence in the amino terminus of Pak1. We also show that Pak1 is recruited by activated epidermal growth factor (EGF) and platelet-derived growth factor receptors, Moreover, Pak1 kinase activity is increased in response to EGF in HeLa cells transfected with human Pak1, and the kinase activity was enhanced when Nck was co-transfected. It is concluded that Nck links receptor tyrosine kinases with Pak1 and is probably involved in targeting and regulation of Pak1 activity.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	New York University; Fox Chase Cancer Center			Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [R01 CA58836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harlow E., 1988, ANTIBODIES LAB MANUA; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCCUNE K, 1993, YEAST, V9, P295; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARK D, 1992, MOL CELL BIOL, V12, P5834; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rose MD., 1990, METHODS YEAST GENETI; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1993, CURR BIOL, V3, P434; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	236	240	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20997	21000		10.1074/jbc.271.35.20997	http://dx.doi.org/10.1074/jbc.271.35.20997			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8798379	hybrid			2022-12-27	WOS:A1996VE47700007
J	Tomic, M; Jobin, RM; Vergara, LA; Stojilkovic, SS				Tomic, M; Jobin, RM; Vergara, LA; Stojilkovic, SS			Expression of purinergic receptor channels and their role in calcium signaling and hormone release in pituitary gonadotrophs - Integration of P-2 channels in plasma membrane- and endoplasmic reticulum-derived calcium oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; CHROMAFFIN CELLS; ATP RECEPTORS; CA2+ RELEASE; EXTRACELLULAR ATP; XENOPUS-OOCYTES; SENSORY NEURONS; ION CHANNELS; AR42J CELLS; ADENOSINE	The role of ATP as a positive feedback element in Ca2+ signaling and secretion was examined in female rat pituitary gonadotrophs. ATP and ADP, but not AMP or adenosine, induced a dose- and extracellular Ca2+-dependent rise in [Ca-2+](i) in identified gonadotrophs in a Mg2+- and suramin-sensitive manner. ATP, adenosine-5'-O-(3-thiotriphosphate), adenosine-5'-O-(1-thiotriphosphate), 2-methylthio-ATP, and 3'-O-(4-benzoyl)benzoyl-ATP. were roughly equipotent in rising [Ca2+](i) in gonadotrophs, while ADP was effective only at submillimolar concentration range, and none of these compounds permeabilized the cells. On the other hand, alpha,beta-methylene-ATP, beta,gamma-methylene-ATP, and UTP were unable to induce any rise in [Ca2+](i). This pharmacological profile is consistent with expression of P2X(2) and/or P2X(5) purinergic receptor channels. Patch-clamp experiments showed that ATP induced an inward depolarizing current in gonadotrophs clamped at -90 mV, associated with an increase in [Ca2+](i). The ATP-induced [Ca2+](i) response was partially inhibited by nifedipine, a blocker of voltage-sensitive Ca2+ channels (VSCC), but was not affected by tetrodotoxin, a blocker of voltage-sensitive Na+ channels. Thus, the P-2-depolarizing current itself drives Ca2+ into the cell, but also activates Ca2+ entry through VSCC. In accord with this, low [ATP] induced plasma membrane-dependent [Ca2+](i) oscillations in quiescent cells, and increased the frequency of spiking in spontaneously active cells. ATP-induced Ca2+ influx also affected agonist-induced and InsP(3)-dependent [Ca2+](i) oscillations by increasing the frequency, base line, and duration of Ca2+ spiking. In addition, ATP stimulated gonadotropin secretion and enhanced agonist-induced gonadotropin release. ATP was found to be secreted by pituitary cells during agonist stimulation and was promptly degraded by ectonucleotidase to adenosine. These observations indicate that ATP represents a paracrine/autocrine factor in the regulation of Ca2+ signaling and secretion in gonadotrophs, and that these actions are mediated by P-2 receptor channels.	NICHHD,ERRB,UCS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Tomic, Melanija/C-3371-2016					ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BENNETT MR, 1995, BIOPHYS J, V68, P925, DOI 10.1016/S0006-3495(95)80268-7; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BOSMA MM, 1992, ENDOCRINOLOGY, V130, P3411, DOI 10.1210/en.130.6.3411; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; CAREW MA, 1994, CELL CALCIUM, V16, P227, DOI 10.1016/0143-4160(94)90025-6; CASTRO E, 1995, J BIOL CHEM, V270, P5098, DOI 10.1074/jbc.270.10.5098; CENA V, 1990, BIOCHIM BIOPHYS ACTA, V1023, P213, DOI 10.1016/0005-2736(90)90416-L; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chen ZP, 1996, ENDOCRINOLOGY, V137, P248, DOI 10.1210/en.137.1.248; CHEN ZP, 1994, ENDOCRINOLOGY, V135, P1280, DOI 10.1210/en.135.3.1280; CHEN ZP, 1995, P NATL ACAD SCI USA, V92, P5219, DOI 10.1073/pnas.92.11.5219; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; Collo G, 1996, J NEUROSCI, V16, P2495; CUSACK NJ, 1993, DRUG DEVELOP RES, V28, P244, DOI 10.1002/ddr.430280310; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DEUSSEN A, 1993, AM J PHYSIOL, V264, pH692, DOI 10.1152/ajpheart.1993.264.3.H692; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; ILLES P, 1993, TRENDS PHARMACOL SCI, V14, P50, DOI 10.1016/0165-6147(93)90030-N; JOBIN RM, 1995, ENDOCRINOLOGY, V136, P3398, DOI 10.1210/en.136.8.3398; KEIZER J, 1995, MOL BIOL CELL, V6, P945, DOI 10.1091/mbc.6.8.945; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; KUKULJAN M, 1994, J BIOL CHEM, V269, P4860; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI YX, 1995, BIOPHYS J, V69, P785, DOI 10.1016/S0006-3495(95)79952-0; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MARCHETTI C, 1987, AM J PHYSIOL, V252, pE340, DOI 10.1152/ajpendo.1987.252.3.E340; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Pearson J.D., 1985, METHODS PHARM, V6, P83; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROZENGURT E, 1975, BIOCHEM BIOPH RES CO, V67, P1581, DOI 10.1016/0006-291X(75)90207-7; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1994, MOL PHARMACOL, V45, P1013; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; STOJILKOVIC SS, 1990, NEW BIOL, V3, P272; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TSCHOPL M, 1992, EUR J PHARMACOL, V213, P71, DOI 10.1016/0014-2999(92)90234-U; TSE A, 1993, ENDOCRINOLOGY, V132, P1475, DOI 10.1210/en.132.4.1475; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VANDERMERWE PA, 1989, FEBS LETT, V243, P333, DOI 10.1016/0014-5793(89)80156-5; VERGARA LA, 1995, BIOPHYS J, V69, P1606, DOI 10.1016/S0006-3495(95)80033-0; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHAO H, 1990, J BIOL CHEM, V265, P20856	58	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21200	21208		10.1074/jbc.271.35.21200	http://dx.doi.org/10.1074/jbc.271.35.21200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702891	hybrid			2022-12-27	WOS:A1996VE47700037
J	Amano, M; Ito, M; Kimura, K; Fukata, Y; Chihara, K; Nakano, T; Matsuura, Y; Kaibuchi, K				Amano, M; Ito, M; Kimura, K; Fukata, Y; Chihara, K; Nakano, T; Matsuura, Y; Kaibuchi, K			Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; GTP-BINDING-PROTEIN; LIGHT CHAIN KINASE; ADP-RIBOSYLATION; SIGNAL-TRANSDUCTION; INVOLVEMENT; INHIBITION; TYROSINE; CELLS; P21	The small GTPase Rho is implicated in physiological functions associated with actin-myosin filaments such as cytokinesis, cell motility, and smooth muscle contraction. We have recently identified and molecularly cloned Rho-associated serine/threonine kinase (Rho-kinase), which is activated by GTP-Rho (Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., Nakano, T., Okawa, H., Iwamatsu, A., and Kaibuchi, K. (1996) EMBO J. 15, 2208-2216). Here we found that Rho-kinase stoichiometrically phosphorylated myosin light chain (MLC). Peptide mapping and phosphoamino acid analyses revealed that the primary phosphorylation site of MLC by Rho-kinase was Ser-19, which is the site phosphorylated by MLC kinase. Rho-kinase phosphorylated recombinant MLC, whereas it failed to phosphorylate recombinant MLC, which contained Ala substituted for both Thr-18 and Ser-19. We also found that the phosphorylation of MLC by Rho-kinase resulted in the facilitation of the actin activation of myosin ATPase. Thus, it is likely that once Rho is activated, then it can interact with Rho-kinase and activate it. The activated Rho-kinase subsequently phosphorylates MLC. This may partly account for the mechanism by which Rho regulates cytokinesis, cell motility, or smooth muscle contraction.	NARA INST SCI & TECHNOL,PLANT MOL GENET LAB,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 1,TSU,MIE 514,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAT 2,KYOTO 606,JAPAN; NATL INST HLTH,DEPT VIROL 2,TOKYO 162,JAPAN	Nara Institute of Science & Technology; Mie University; Kyoto University			Kimura, Kazushi/ABB-4007-2020; Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Fukata, Yuko/0000-0001-7724-8643				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRESNICK AR, 1995, BIOCHEMISTRY-US, V34, P12576, DOI 10.1021/bi00039a012; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; IKEBE M, 1984, BIOCHEMISTRY-US, V23, P5062, DOI 10.1021/bi00316a036; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MORELAND S, 1992, AM J PHYSIOL, V263, pC540, DOI 10.1152/ajpcell.1992.263.2.C540; NAKA M, 1983, NATURE, V306, P490, DOI 10.1038/306490a0; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1993, J BIOL CHEM, V268, P22251	43	1594	1635	0	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20246	20249		10.1074/jbc.271.34.20246	http://dx.doi.org/10.1074/jbc.271.34.20246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702756	hybrid			2022-12-27	WOS:A1996VD33700008
J	Moffat, GJ; McLaren, AW; Wolf, CR				Moffat, GJ; McLaren, AW; Wolf, CR			Functional characterization of the transcription silencer element located within the human Pi class glutathione S-transferase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; ANTIOXIDANT RESPONSIVE ELEMENT; DNA-PROTEIN INTERACTION; ESCHERICHIA-COLI K-12; CRP ACTIVATOR COMPLEX; BINDING PROTEIN; CYTR REPRESSOR; RETINOBLASTOMA PROTEIN; REGULATORY ELEMENTS; CONFERS RESISTANCE	We have previously demonstrated enhanced transcriptional activity of the human Pi class glutathione S-transferase (GSTP1) promoter in a multidrug-resistant derivative (VCREMS) of the human mammary carcinoma cell line, MCF7 (Moffat, G, J,, McLaren, A. W., and Wolf, C. R (1994) J. Biol. Chem. 269, 16397-16402), Furthermore, we have identified an essential sequence (C1; -70 to -59) within the GSTP1 promoter that bound a Jun-Fos heterodimer in VCREMS but not in MCF7 cells, These present studies have examined the negative regulatory element (-105 to -86), which acted to suppress GSTP1 transcription in MCF7 cells. Mutational analysis of this silencer element further defined the repressor binding site to be located between nucleotides -97 and -90, In vitro DNA binding assays suggested that the repressor exerted its action by causing displacement of the essential non-AP-1-like MCF7 C1 complex, However, the addition of MCF7 nuclear extract did not disrupt binding of the VCREMS jun-Fos C1 complex to the GSTP1 promoter, Furthermore, upstream insertion of the GSTP1 silencer element failed to inhibit activity of a heterologous promoter in MCF7 cells, These results highlighted the cell and promoter specificity of the GSTP1 transcriptional repressor and implicated a functional requirement for contact between the repressor and C1 complex, In this regard, the introduction of half-helical turns between the silencer and the C1 element abrogated repressor activity, thus leading to the hypothesis that a direct interaction between the repressor and C1 complex was required to suppress GSTP1 transcription, Moreover, these findings suggest that cell-specific differences in the composition of the C1 nuclear complex may dictate repressor activity.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,IMPERIAL CANC RES FUND,MOL PHARMACOL UNIT,BIOMED RES CTR,DUNDEE DD1 9SY,SCOTLAND	University of Dundee								ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BATIST G, 1986, J BIOL CHEM, V261, P5544; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CARMICHAEL J, 1988, CARCINOGENESIS, V9, P1617, DOI 10.1093/carcin/9.9.1617; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FIELDS WR, 1994, CARCINOGENESIS, V15, P1155, DOI 10.1093/carcin/15.6.1155; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GORMAN C, 1986, DNA CLONING PRACTICA, V3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAO XY, 1994, CARCINOGENESIS, V15, P1167, DOI 10.1093/carcin/15.6.1167; HEIBERT SW, 1991, J VIROL, V65, P3547; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KODATE C, 1986, GANN, V77, P226; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PETERS WHM, 1989, CARCINOGENESIS, V10, P2371, DOI 10.1093/carcin/10.12.2371; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOFFOLI G, 1992, EUR J CANCER, V28A, P1441, DOI 10.1016/0959-8049(92)90540-I; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Whelan R D, 1989, Cancer Commun, V1, P359; WHELAN RDH, 1992, INT J CANCER, V52, P241, DOI 10.1002/ijc.2910520215	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20740	20747		10.1074/jbc.271.34.20740	http://dx.doi.org/10.1074/jbc.271.34.20740			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702826	hybrid			2022-12-27	WOS:A1996VD33700078
J	Rodriguez, K; Wang, ZG; Friedberg, EC; Tomkinson, AE				Rodriguez, K; Wang, ZG; Friedberg, EC; Tomkinson, AE			Identification of functional domains within the RAD1 center dot RAD10 repair and recombination endonuclease of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; YEAST DNA-REPAIR; PIGMENTOSUM GROUP-F; PROTEINS RAD1; MITOTIC RECOMBINATION; GENE; COMPLEX; ERCC1; PURIFICATION; ASSOCIATION	hSaccharomyces cerevisiae rad1 and rad10 mutants are unable to carry out nucleotide excision repair and are also defective in a mitotic intrachromosomal. recombination pathway. The products of these genes are subunits of an endonuclease which recognizes DNA duplex/single-strand junctions and specifically cleaves the 3' single-strand extension at or near the junction. It has been suggested that such junctions arise as a consequence of DNA lesion processing during nucleotide excision repair and the processing of double-strand breaks during intrachromosomal recombination. In this study we show that the RAD1 . RAD10 complex also cleaves a more complex junction structure consisting of a duplex with a protruding 3' single strand branch that resembles putative recombination intermediates in the RAD1 . RAD10-mediated single-strand annealing pathway of mitotic recombination. Using monoclonal antibodies, we have identified two regions of RAD1 that are required for the cleavage of duplex/single-strand junctions, These reagents also inhibit nucleotide excision repair in vitro, confirming the essential role of the RAD1 . RAD10 endonuclease in this pathway.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL CTR MOL MED,SAN ANTONIO,TX 78245; UNIV TEXAS,SW MED CTR,DEPT PATHOL,LAB MOL PATHOL,DALLAS,TX 75225	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Rodriguez, Karl A/F-2689-2012		NCI NIH HHS [CA/OD67978, CA-12428] Funding Source: Medline; NCRR NIH HHS [RR07187-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012428, R01CA067978, R55CA067978, R37CA012428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AGUILERA A, 1989, GENETICS, V123, P683; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKMAN KW, 1994, ENV MOL MUTAGEN S23, V23, P6; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; ESPEJO RT, 1968, VIROLOGY, V34, P738, DOI 10.1016/0042-6822(68)90094-9; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P233; FUKITA Y, 1993, J BIOL CHEM, V268, P17463; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIGGINS DR, 1983, GENE, V26, P119, DOI 10.1016/0378-1119(83)90181-6; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1995, MOL CELL BIOL, V15, P1993; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRAKASH L, 1977, MOL GEN GENET, V153, P125; QIAN YW, 1993, NATURE, V364, P649; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; REYNOLDS P, 1985, EMBO J, V4, P3548; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; UNRAU P, 1971, MOL GEN GENET, V354, P359; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	51	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20551	20558		10.1074/jbc.271.34.20551	http://dx.doi.org/10.1074/jbc.271.34.20551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702799	hybrid			2022-12-27	WOS:A1996VD33700051
J	Rusciano, D; Lorenzoni, P; Burger, MM				Rusciano, D; Lorenzoni, P; Burger, MM			Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; HGF RECEPTOR; MET/HGF RECEPTOR; EXPRESSION; CANCER; PHOSPHORYLATION; OVEREXPRESSION; COLONIZATION; PROGRESSION	Serial selection in vivo for liver colonization of B16 murine melanoma cells consistently resulted in cell lines expressing elevated amounts of the hepatocyte growth factor/scatter factor receptor (c-Met), which is constitutively activated in the absence of its cognate ligand, In this paper we present evidence suggesting that c-Met constitutive activation in liver specific B16 melanoma cells depends on both receptor concentration on the cell surface and a cytosolic tyrosine phosphatase activity. In fact, c-Met constitutive activation is suddenly lost upon detachment of the cells from the substrate and is dramatically decreased in adherent cells plated at low density, The loss of tyrosine phosphorylation of c-Met in suspension appears to depend, at least partly, on an increased cytosolic tyrosine phosphatase activity, Instead, lower activation of c-Met at low density mostly results from a decrease in receptor concentration on the membrane, Moreover, we show that c-Met activation does not occur homogeneously on the surface of adherent cells, In fact, receptor concentration and activation appear to be higher on the ventral surface (adherent to the substrate) than on the apical surface, Upon detachment, compartmentalization is lost, leading to a decrease in average receptor density on the plasma membrane and hence to a lower activation.			Rusciano, D (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Rusciano, Dario/AAP-7450-2020	Rusciano, Dario/0000-0002-9577-2585				BOSSERT NL, 1990, DEV BIOL, V142, P75, DOI 10.1016/0012-1606(90)90152-9; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FERRACINI R, 1995, ONCOGENE, V10, P739; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; LIAO K, 1991, J BIOL CHEM, V266, P6544; LICHTNER RB, 1990, J CELL PHYSIOL, V144, P303, DOI 10.1002/jcp.1041440217; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; MANSBRIDGE JN, 1992, J CELL PHYSIOL, V151, P433, DOI 10.1002/jcp.1041510302; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; MAUCHAMP J, 1987, J CELL SCI, P345; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PONZETTO C, 1991, ONCOGENE, V6, P553; Prat M, 1995, ANTIBODY IMMUNOCONJ, V8, P341; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; RUSCIANO D, 1995, ONCOGENE, V11, P1979; RUSCIANO D, 1993, INVAS METAST, V13, P212; Tuck AB, 1996, AM J PATHOL, V148, P225; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	28	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20763	20769		10.1074/jbc.271.34.20763	http://dx.doi.org/10.1074/jbc.271.34.20763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702829	hybrid			2022-12-27	WOS:A1996VD33700081
J	Taylor, GA; Jeffers, M; Largaespada, DA; Jenkins, NA; Copeland, NG; VandeWoude, GF				Taylor, GA; Jeffers, M; Largaespada, DA; Jenkins, NA; Copeland, NG; VandeWoude, GF			Identification of a novel GTPase, the inducibly expressed GTPase, that accumulates in response to interferon gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; SIGNAL RECOGNITION PARTICLE; TUMOR-NECROSIS-FACTOR; IFN-GAMMA; TRIPHOSPHATE CONFORMATION; MOLECULAR-CLONING; BINDING PROTEINS; GROWTH-FACTOR; DYNAMIN; GENE	Interferon gamma is a pleiotropic cytokine that regulates many immune functions, We have identified a novel protein, inducibly expressed GTPase (IGTP), whose expression was regulated by interferon gamma in macrophages. In mouse RAW 264.7 macrophages, IGTP mRNA levels were almost undetectable but increased within 1 h of exposure to interferon gamma, peaked at very high levels within 3 h, and remained at high levels to at least 48 h; pretreatment of the cells with cycloheximide blocked the majority of mRNA accumulation, In the mouse, the mRNA was highly expressed in thymus, spleen, lung, and small intestine. Using interspecific backcross analysis, the Igtp gene was mapped to mouse chromosome 11. The IGTP cDNA encoded a putative polypeptide of M(r) 48,507 and pI 7.79 that contained three consensus GTP binding motifs, GXXXXGK(S/T), DXXG, and NTKXD. Both IGTP that had been immunoprecipitated from RAW cells and a glutathione S-transferase IGTP fusion protein were able to convert GTP to GDP in vitro. Subcellular protein fractionation and Western blotting localized IGTP to the cytosol of RAW cells, In addition, the protein was homologous to proteins encoded by three previously cloned cDNAs, IRG-47, TGTP/Mg21, and LRG-47, and thus may be representative of a new family of interferon gamma-regulated GTPases.	NCI,ABL BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Largaespada, David/C-9832-2014					ALTHOFF SM, 1994, MOL CELL BIOL, V14, P7839, DOI 10.1128/MCB.14.12.7839; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; CARLOW DA, 1995, J IMMUNOL, V154, P1724; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DING AH, 1988, J IMMUNOL, V141, P2407; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GILLY M, 1992, J IMMUNOL, V148, P3275; Green EL, 1981, GENETICS PROBABILITY, P77; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANDA K, 1983, J IMMUNOL, V130, P988; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KING DP, 1983, J IMMUNOL, V131, P315; KIRSCHNER MW, 1979, INT REV CYTOL, V54, P1; LAFUSE WP, 1995, J LEUKOCYTE BIOL, V57, P477, DOI 10.1002/jlb.57.3.477; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LIEW FY, 1990, J IMMUNOL, V145, P4306; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MUNRO JM, 1989, AM J PATHOL, V135, P121; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PROCHAZKA M, 1985, VIROLOGY, V145, P273, DOI 10.1016/0042-6822(85)90160-6; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMITH DB, 1991, CURRENT PROTOCOLS MO; SORACE JM, 1995, J LEUKOCYTE BIOL, V58, P477, DOI 10.1002/jlb.58.4.477; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VILCEK J, 1985, LYMPHOKINES, V11, P1; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WARREN MK, 1985, J IMMUNOL, V134, P2462	45	90	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20399	20405		10.1074/jbc.271.34.20399	http://dx.doi.org/10.1074/jbc.271.34.20399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702776	hybrid			2022-12-27	WOS:A1996VD33700028
J	Timerman, AP; Onoue, H; Xin, HB; Barg, S; Copello, J; Wiederrecht, G; Fleischer, S				Timerman, AP; Onoue, H; Xin, HB; Barg, S; Copello, J; Wiederrecht, G; Fleischer, S			Selective binding of FKBP12.6 by the cardiac ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; TERMINAL CISTERNAE; FK-506-BINDING PROTEIN; FKBP-12; FK-506; CALCINEURIN; ASSOCIATION; COMPLEX	The calcium release channels (CRC)/ryanodine receptors of skeletal (Sk) and cardiac (C) muscle sarcoplasmic reticulum (SR) are hetero-oligomeric complexes with the structural formulas (ryanodine recepter (RyR)1 protomer)(4)(FKBP12)(4) and (RyR2 protomer)(4)(FKBP12.6)(4), respectively, where FKBP12 and FKBP12.6 are isoforms of the 12-kDa receptor for the immunosuppressant drug FK506. The sequence similarity between the RyR protomers and FKBP12 isoforms is 63 and 85%, respectively. Using S-35-labeled FKBP12 and S-35-labeled FKBP12.6 as probes to study the interaction with CRC, we find that: 1) analogous to its action in skeletal muscle sarcoplasmic reticulum (SkMSR), FK506 (or analog FK590) dissociates FKBP12.6 from CSR; 2) both FKBP isoforms bind to FKBP-stripped SkMSR and exchange with endogenously bound FKBP12 of SkMSR; and 3) by contrast, only FKBP12.6 exchanges with endogenously bound FKBP12.6 or rebinds to FKBP-stripped CSR. This selective binding appears to explain why the cardiac CRC is isolated as a complex with FKBP12.6, whereas the skeletal muscle CRC is isolated as a complex with FKBP12, although only FKBP12 is detectable in the myoplasm of both muscle types. Also, in contrast to the activation of the channel by removal of FKBP from skeletal muscle, no activation is detected in CRC activity in FKBP-stripped CSR. This differential action of FKBP may reflect a fundamental difference in the modulation of excitation-contraction coupling in heart versus skeletal muscle.	VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; MERCK RES LABS, DEPT IMMUNOL, RAHWAY, NJ 07065 USA	Vanderbilt University; Merck & Company			Barg, Sebastian/F-9523-2010	Barg, Sebastian/0000-0003-4661-5724	NHLBI NIH HHS [HL46681, HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHERN GP, 1994, FEBS LETT, V352, P369, DOI 10.1016/0014-5793(94)01001-3; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; INUI M, 1987, J BIOL CHEM, V262, P15637; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACK MM, 1994, J BIOL CHEM, V269, P23236; MAYRLEITNER M, 1995, CELL CALCIUM, V18, P197, DOI 10.1016/0143-4160(95)90064-0; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Wiederrecht Greg, 1994, Perspectives in Drug Discovery and Design, V2, P57, DOI 10.1007/BF02171737; XIN HB, 1995, BIOCHEM BIOPH RES CO, V214, P263, DOI 10.1006/bbrc.1995.2283	22	209	216	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20385	20391		10.1074/jbc.271.34.20385	http://dx.doi.org/10.1074/jbc.271.34.20385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702774	hybrid			2022-12-27	WOS:A1996VD33700026
J	Bushnell, DA; Bamdad, C; Kornberg, RD				Bushnell, DA; Bamdad, C; Kornberg, RD			A minimal set of RNA polymerase II transcription protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITE SELECTION; FACTOR-B; INITIATION; YEAST; PURIFICATION; IDENTIFICATION; HOLOENZYME; CLONING; SUBUNIT; COMPLEX	All pairwise interactions of RNA polymerase II and general transcription factors (TF) IIB, E, F, and H have been quantitated by surface plasmon resonance with the use of a Ni2+ chelate on the sensor surface where necessary to attain higher sensitivity. Only 4 of 10 possible interactions were found above the detection limit: TFIIB, -E, and -F binding RNA polymerase II and TFIIE binding to TFIIH. These four interactions constitute a minimal set for the formation of a transcription initiation complex and may represent the primary interactions involved in assembly of the complex. Point mutations in TFIIB that alter the location of transcription start sites in vivo markedly diminished the affinity of TFIIB binding to RNA polymerase II. Protein blotting revealed an interaction between the largest subunit of TFIIE and third largest subunit of TFIIH, which may be responsible for the TFIIE binding to TFIIH.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94027; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Stanford University; Harvard University					NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM070276-20, GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; PAN GH, 1994, J BIOL CHEM, V269, P30101; PINTO I, 1994, J BIOL CHEM, V269, P30569; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SOPTA M, 1985, J BIOL CHEM, V260, P353; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TAN SY, 1994, J BIOL CHEM, V269, P25684; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	30	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20170	20174		10.1074/jbc.271.33.20170	http://dx.doi.org/10.1074/jbc.271.33.20170			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702741	hybrid			2022-12-27	WOS:A1996VC66900083
J	Chen, Y; Knudsen, ES; Wang, JYJ				Chen, Y; Knudsen, ES; Wang, JYJ			Cells arrested in G(1) by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; A GENE; MAMMALIAN FIBROBLASTS; CONTACT INHIBITION; PHASE-TRANSITION; TGF-BETA; GROWTH; TRANSCRIPTION; P27(KIP1); SITE	The v-Abl tyrosine kinase encoded by the Abelson murine leukemia virus (A-MuLV) can either stimulate or inhibit cell proliferation, depending on the cell context. In a NIH-3T3-derived cell line, N3T3, v-Abl blocks the serum-induced entry into S phase. In these G(1)-arrested cells v-Abl does not interfere with the activation of cyclin D1 or cyclin E-dependent kinases. As a result, v-Abl does not block the hyperphosphorylation and inactivation of the retinoblastoma protein RE. However, activation of cyclin A-dependent kinase is inhibited due to a v-Abl-induced block in the accumulation of cyclin A mRNA and protein. Ectopic expression of cyclin A enabled the v-Abl-arrested cells to enter S phase, whereas cyclins E and D1, or E2Fs 1 and 4 could not overcome the v-Abl arrest. Taken together, these results suggest that v-Abl tyrosine kinase arrests cell cycle progression in G(1) by inhibiting the expression of cyclin A.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01 CA043054, R01 CA058320, CA50528, CA58320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528, R01CA043054, R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GENE Y, 1996, ONCOGENE, V12, P1173; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kramer A, 1996, J BIOL CHEM, V271, P6579; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19637	19640		10.1074/jbc.271.33.19637	http://dx.doi.org/10.1074/jbc.271.33.19637			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702661	hybrid			2022-12-27	WOS:A1996VC66900002
J	Summerfield, AE; Hudnall, AK; Lukas, TJ; Guyer, CA; Staros, JV				Summerfield, AE; Hudnall, AK; Lukas, TJ; Guyer, CA; Staros, JV			Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FACTOR EGF RECEPTOR; FACTOR-ALPHA; BINDING-SITE; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; EXPRESSION; MUTANT; LOCALIZATION; RESONANCE	A triple mutant of murine epidermal growth factor (mEGF), N1Q/H22Y/R45K-mEGF, was constructed by site-directed mutagenesis, expressed, purified, and characterized for use in an affinity cross-linking study to identify aminoacyl residues of the EGF receptor adjacent to a residue in the carboxyl-terminal domain of bound EGF thought to be important in distinguishing between EGF and transforming growth factor-alpha in their recognition by the receptor. Cyclization of Gln(1) to form pyroglutamate (pE) limited the site of cross-linking in the mutant to Lys(45), permitting identification of receptor residues that are proximal to this residue of bound EGF. The resulting N1pE/H22Y/R45K-mEGF was shown to be comparable to wild-type mEGF in receptor binding and stimulation of receptor autophosphorylation. I-125-Labeled N1pE/H22Y/R45K-mEGF was reacted with the heterobifunctional cross-linking reagent sulfo-N-succinimidyl-4-(fluorosulfonyl)benzoate, and the resulting modified EGF was incubated with A431 membrane vesicles bearing EGF receptors. Incubation resulted in specific cross-linking of the labeled N1pE/H22Y/R45K-mEGF to EGF receptors. The resulting cross-linked complex was then partially purified, denatured, reduced, and carboxyamidomethylated. Digestion with endoprotease LysC resulted in a unique radiolabeled peptide that could be immunoprecipitated using antibodies to mEGF. This immunoprecipitated fragment was purified by gel electrophoresis and subjected to microsequencing. The resulting sequence was matched to that of a LysC fragment of the receptor, which begins with Thr(464) and is near the interface of receptor subdomains III and IV. Loss of signal at cycle 2 suggests that the point of attachment of cross-linked N1pE/H22Y/R45K is Lys(465) of the receptor.	VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; NORTHWESTERN UNIV, SCH MED, DEPT MOL PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA	Vanderbilt University; Northwestern University					NCI NIH HHS [T32 CA09582] Funding Source: Medline; NIDDK NIH HHS [R01 DK25489] Funding Source: Medline; NIGMS NIH HHS [R01 GM30861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANJANEYULU PSR, 1987, INT J PEPT PROT RES, V30, P117; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COHEN S, 1982, J BIOL CHEM, V257, P1523; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HOMMEL U, 1991, BIOCHEMISTRY-US, V30, P8891, DOI 10.1021/bi00100a024; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; ROUSSEAU DL, 1995, BIOCHEMISTRY-US, V34, P14508, DOI 10.1021/bi00044a029; ROUSSEAU DL, 1993, BIOCHEMISTRY-US, V32, P7893, DOI 10.1021/bi00082a009; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; Staros JV, 1995, BIOORG CHEM, V23, P369, DOI 10.1006/bioo.1995.1025; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TAYLOR JM, 1972, J BIOL CHEM, V247, P5928; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; WOLTJER RL, 1992, BIOCHEMISTRY-US, V31, P7341, DOI 10.1021/bi00147a019; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WU DG, 1989, J BIOL CHEM, V264, P17469	36	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19656	19659		10.1074/jbc.271.33.19656	http://dx.doi.org/10.1074/jbc.271.33.19656			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702666	hybrid			2022-12-27	WOS:A1996VC66900007
J	Stefano, GB; Liu, Y; Goligorsky, MS				Stefano, GB; Liu, Y; Goligorsky, MS			Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PHAGOCYTIC-ACTIVITY; MYTILUS-EDULIS; INHIBITION; DELTA-9-TETRAHYDROCANNABINOL; MACROPHAGES; INVITRO; BRAIN; SUPPRESSION; EXPRESSION	The present study demonstrates that stereoselective binding sites for anandamide, a naturally occurring cannabinoid substance, can be found ill invertebrate immunocytes and microglia. The anandamide-binding site is monophasic and of high affinity, exhibiting a K-d of 34.3 nw with a B-max of 441 fmol/mg protein. These sites are highly selective, as demonstrated by the inability of other types of signaling molecules to displace [H-3]anandamide, Furthermore, this binding site is coupled to nitric oxide release in the invertebrate tissues examined as well as in human monocytes, Interestingly, the cannabinoid stimulated release of nitric oxide. initiates cell rounding. Thus, these cannabinoid actions resemble those of opiate alkaloids, In this regard, we demonstrate that these signaling systems use the same effector system, i.e, nitric oxide release, but separate receptors, Last., the presence of a cannabinoid receptor in selected evolutionary diverse organisms indicates that this signaling system has been conserved for more than 500 million years.	SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PHYSIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Stefano, GB (corresponding author), SUNY COLL OLD WESTBURY,NEUROSCI RES INST,POB 210,OLD WESTBURY,NY 11568, USA.		Stefano, George Bogdan/ABD-9152-2021	Stefano, George Bogdan/0000-0002-8146-0740	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T34MH017138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R24DA009010] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 09010] Funding Source: Medline; NIDDK NIH HHS [DK 41573] Funding Source: Medline; NIMH NIH HHS [MH/DA 17138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64, DOI 10.3181/00379727-210-43926; BURROWES WR, 1983, LIFE SCI, V33, P381, DOI 10.1016/0024-3205(83)90522-2; CABRAL GA, 1994, LIFE SCI, V54, P1831, DOI 10.1016/0024-3205(94)90122-8; CHILDERS SR, 1992, ANN NY ACAD SCI, V654, P33, DOI 10.1111/j.1749-6632.1992.tb25954.x; DEVANE WA, 1986, J NEUROCHEM, V46, P1929; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FRIEDMAN M, 1986, P SOC EXP BIOL MED, V182, P225; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; HUGHES TK, 1991, ADV NEUROIMMUNOL, V1, P59, DOI 10.1016/S0960-5428(06)80032-X; HUGHES TK, 1990, P NATL ACAD SCI USA, V87, P4426, DOI 10.1073/pnas.87.12.4426; LIU Y, 1996, IN PRESS BRAIN RES; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCCOY KL, 1995, J PHARMACOL EXP THER, V273, P1216; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OBRIEN CP, 1996, PHARMACOL BASIS THER, P557; OTTAVIANI E, 1993, EUR J PHARM-ENVIRON, V248, P319, DOI 10.1016/0926-6917(93)90006-C; SCHON JC, 1991, ADV NEUROIMMUNOL, V1, P252, DOI 10.1016/S0960-5428(06)80015-X; SHIPP MA, 1991, BLOOD, V78, P1834; SHIVERS SC, 1994, LIFE SCI, V54, P1281, DOI 10.1016/0024-3205(94)00856-6; SONETTI D, 1994, P NATL ACAD SCI USA, V91, P9180, DOI 10.1073/pnas.91.19.9180; SPECTER S, 1991, J LEUKOCYTE BIOL, V50, P423, DOI 10.1002/jlb.50.5.423; STEFANO GB, 1993, P NATL ACAD SCI USA, V90, P11099, DOI 10.1073/pnas.90.23.11099; STEFANO GB, 1994, ELECTRO MAGNETOBIOL, V13, P123, DOI 10.3109/15368379409030706; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P6307, DOI 10.1073/pnas.86.16.6307; STEFANO GB, 1992, P NATL ACAD SCI USA, V89, P9316, DOI 10.1073/pnas.89.19.9316; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; STEFANO GB, 1996, IN PRESS COMP BIOCH; TANG JL, 1992, INT J IMMUNOPHARMACO, V14, P253; WELCH SP, 1994, PHARMACOL BIOCHEM BE, V49, P929, DOI 10.1016/0091-3057(94)90245-3; ZHENG ZM, 1992, INT J IMMUNOPHARMACO, V14, P1445	33	155	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19238	19242		10.1074/jbc.271.32.19238	http://dx.doi.org/10.1074/jbc.271.32.19238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702604	hybrid			2022-12-27	WOS:A1996VB68400038
J	Chigorno, V; Tettamanti, G; Sonnino, S				Chigorno, V; Tettamanti, G; Sonnino, S			Metabolic processing of gangliosides by normal and Salla human fibroblasts in culture - A study performed by administering radioactive G(M3) ganglioside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; LONG-CHAIN BASE; GM1 GANGLIOSIDE; FATTY-ACID; BIOSYNTHESIS; SPHINGOSINE; COMPLEXES; BRAIN; DIFFERENTIATION; FRACTIONATION	Cultured fibroblasts from normal subjects and from subjects affected by Salla disease, characterized by the lack or misfunction of the membrane carrier responsible for the egress of sialic acid from lysosomes, were fed with ganglioside G(M3) labeled at the sialic acid acetyl group, [Neu5Ac-H-3]G(M3), or at C-3 of sphingosine (Sph), [Sph-H-3]G(M3), or at C-1 of stearoyl chain, [stearoyl-C-14]G(M3). After a 15-h pulse the total amount of cell-bound G(M3) corresponded to about 2% of the endogenous ganglioside content. Cells were then subjected to a 72-h chase, and the radioactive products from both ganglioside catabolism and salvage processes of catabolic fragments were measured. These data indicated that about 50% of the cell-bound ganglioside underwent metabolic processing, suggesting a ganglioside half-life of 2-3 days. [Neu5Ac-H-3] formed from [Neu5Ac-H-3]G(M3) degradation was mostly re-cycled for the biosynthesis of gangliosides and sialoglycoproteins, only a minor part being degraded to [H-3]water, which constituted only 1.6% of total metabolite linked radioactivity. [Sph-H-3] from the [Sph-H-3]G(M3) degradation was partly re-cycled for the biosynthesis of gangliosides, neutral glycosphingolipids and sphingomyelin, and partly (about 20% of the total metabolite linked radioactivity) degraded to [H-3]water. In Salla fibroblasts metabolic processing of [Neu5Ac-H-3]G(M3) produced large amounts of free [H-3]Neu5Ac, and a reduced incorporation of radioactivity into glycoconjugates (as compared to normal cells). However, the accumulation of free Neu5Ac was not accompanied by an increase of tritiated water. LacCer and Cer from [stearoyl-C-14]G(M3) catabolism were found to accumulate in Salla fibroblasts, an indication that the enzymes of glycosphingolipid metabolism were affected by the impairment of Neu5Ac egress from lysosomes. Particularly relevant was the accumulation of ceramide which was hardly detectable in control cells.	UNIV MILAN,SCH MED,DEPT MED CHEM & BIOCHEM,STUDY CTR FUNCT BIOCHEM BRAIN LIPIDS,I-20133 MILAN,ITALY	University of Milan			Sonnino, Sandro/R-4154-2017	Sonnino, Sandro/0000-0001-8180-5908				BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; DAWSON G, 1972, J BIOL CHEM, V247, P5944; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; Gazzotti G, 1984, GLYCOCONJUGATE J, V1, P111, DOI 10.1007/bf01213725; GHIDONI R, 1976, J NEUROCHEM, V27, P511, DOI 10.1111/j.1471-4159.1976.tb12275.x; GHIDONI R, 1983, BIOCHEM J, V213, P321, DOI 10.1042/bj2130321; HANCOCK LW, 1983, BIOCHIM BIOPHYS ACTA, V760, P42, DOI 10.1016/0304-4165(83)90122-8; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAUTTECOEUR B, 1985, BIOCHIM BIOPHYS ACTA, V833, P303, DOI 10.1016/0005-2760(85)90202-4; IUB-IUPAC Joint Commission on Biochemical Nomenclature (JCBN), 1982, J BIOL CHEM, V257, P3347, DOI [10.1016/S0021-9258(18)34777-X, DOI 10.1016/S0021-9258(18)34777-X]; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LEON A, 1981, J NEUROCHEM, V37, P350, DOI 10.1111/j.1471-4159.1981.tb00462.x; LEROY JG, 1972, PEDIATR RES, V6, P752, DOI 10.1203/00006450-197210000-00002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIETTINEN T, 1959, ACTA CHEM SCAND, V13, P856, DOI 10.3891/acta.chem.scand.13-0856; Negroni E, 1996, GLYCOCONJUGATE J, V13, P347, DOI 10.1007/BF00731466; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PARTRIDGE SM, 1948, BIOCHEM J, V42, P238, DOI 10.1042/bj0420238; RADSAK K, 1982, H-S Z PHYSIOL CHEM, V363, P263, DOI 10.1515/bchm2.1982.363.1.263; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; RIBONI L, 1993, FEBS LETT, V322, P257, DOI 10.1016/0014-5793(93)81582-K; SAQR HE, 1993, J NEUROCHEM, V61, P395; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SCHWARZMANN G, 1987, NATO ASI SERIES H, V7, P217; SONNINO S, 1986, CHEM PHYS LIPIDS, V42, P3, DOI 10.1016/0009-3084(86)90040-X; SONNINO S, 1985, J LIPID RES, V26, P248; SONNINO S, 1990, CHEM PHYS LIPIDS, V52, P231, DOI 10.1016/0009-3084(90)90119-C; SONNINO S, 1989, BIOCHEMISTRY-US, V28, P77, DOI 10.1021/bi00427a012; SONNINO S, 1984, J NEUROSCI RES, V12, P193, DOI 10.1002/jnr.490120207; STAHL E, 1962, DUNNSCHICHT CHROMATO, P498; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TOMASI M, 1980, EUR J BIOCHEM, V111, P315, DOI 10.1111/j.1432-1033.1980.tb04944.x; TRINCHERA M, 1990, BIOCHEM J, V270, P815, DOI 10.1042/bj2700815; VALSECCHI M, 1992, CHEM PHYS LIPIDS, V60, P247, DOI 10.1016/0009-3084(92)90076-2; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VASKOVSKY VE, 1968, J LIPID RES, V9, P396; VENERANDO B, 1982, BIOCHIM BIOPHYS ACTA, V692, P18, DOI 10.1016/0005-2736(82)90497-7; Wiegandt H., 1985, NEW COMPREHENSIVE BI, P199; 1977, LIPIDS, V12, P455	43	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21738	21744		10.1074/jbc.271.36.21738	http://dx.doi.org/10.1074/jbc.271.36.21738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702969	hybrid			2022-12-27	WOS:A1996VF61200011
J	Deora, R; Misra, TK				Deora, R; Misra, TK			Characterization of the primary sigma factor of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; STREPTOMYCES-COELICOLOR A3(2); RIBONUCLEIC-ACID POLYMERASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; MACROMOLECULAR-SYNTHESIS; GENE; SEQUENCE; PURIFICATION; DNA	RNA polymerase (RNAP) isolated from Staphylococcus aureus is deficient in sigma factor and is poorly active in transcription assays. Based on amino acid sequence homology of the Bacillus subtilis vegetative sigma factor sigma(A) and the predicted product of the chromosomally located plaC gene of S. aureus, it was hypothesized that plaC could encode the vegetative sigma factor. We cloned plaC under a T7 promoter and overexpressed it in Escherichia coli strain BL21(DE3)pLysE. The overproduced protein, present in inclusion bodies, was solubilized with guanidine hydrochloride, renatured, and purified by DEAE-Sephacel and Sephadex G-75 chromatography. The purified protein, designated sigma(SA), cross-reacted with the B. subtilis anti-sigma(A) antibody. E. coli core RNAP, reconstituted with sigma(SA), initiated promoter-specific transcription from the S. aureus promoters hla, sea, and sec and from the E. coli promoters rpoH P1, rpoH P4, and ColE1 RNA-1, which are recognized by the E. coli sigma(70), sigma(SA), when added to the purified RNAP from S. aureus, stimulated transcriptional activity of the RNAP up to 72-fold. As determined by primer extension studies, the 5'-ends of the sigma(SA)-initiated mRNAs synthesized in vitro from the agr P2 and sea promoters are in general agreement with the 5'-ends of the cellular RNAs, Disruption of the plaC gene on the S. aureus chromosome was lethal. We conclude that plaC encodes the primary sigma factor in S. aureus.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson J. C., 1983, Staphylococci and staphylococcal infections. Volume 1., P193; ARAYA T, 1993, BIOSCI BIOTECH BIOCH, V57, P88, DOI 10.1271/bbb.57.88; AVILA J, 1971, EUR J BIOCHEM, V21, P526, DOI 10.1111/j.1432-1033.1971.tb01498.x; BASHEER R, 1991, NUCLEIC ACIDS RES, V19, P4921, DOI 10.1093/nar/19.18.4921; BORST DW, 1994, J BIOL CHEM, V269, P1883; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burgess RR, 1976, RNA POLYMERASE, P69; CHANG BY, 1990, J BACTERIOL, V172, P3257, DOI 10.1128/jb.172.6.3257-3263.1990; CHEUNG AL, 1994, J BACTERIOL, V176, P580, DOI 10.1128/jb.176.3.580-585.1994; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; COWING DW, 1985, P NATL ACAD SCI USA, V82, P2679, DOI 10.1073/pnas.82.9.2679; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; DEORA R, 1995, BIOCHEM BIOPH RES CO, V208, P610, DOI 10.1006/bbrc.1995.1382; DOI RH, 1986, MICROBIOL REV, V50, P227, DOI 10.1128/MMBR.50.3.227-243.1986; EASMON CSF, 1983, STAPHYLOCOCCI STAPHY, V1, P275; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; ERICKSON JW, 1987, GENE DEV, V1, P419, DOI 10.1101/gad.1.5.419; GANSEL X, 1993, CURR MICROBIOL, V27, P267, DOI 10.1007/BF01575990; GITT MA, 1985, J BIOL CHEM, V260, P7178; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HART ME, 1993, J BACTERIOL, V175, P7875, DOI 10.1128/JB.175.24.7875-7879.1993; Heinrichs JH, 1996, J BACTERIOL, V178, P418, DOI 10.1128/jb.178.2.418-423.1996; HELMANN JD, 1988, J BACTERIOL, V170, P1560, DOI 10.1128/jb.170.4.1560-1567.1988; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; IANDOLO JJ, 1990, MOL BASIS BACTERIAL, P399; IORDANESCU S, 1989, J BACTERIOL, V171, P4831, DOI 10.1128/jb.171.9.4831-4835.1989; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KORMANEC J, 1992, GENE, V122, P63, DOI 10.1016/0378-1119(92)90032-K; Kornblum J., 1990, MOL BIOL STAPHYLOCOC, P373; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MARCOS AT, 1995, GENE, V153, P41, DOI 10.1016/0378-1119(94)00759-L; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; METZGER R, 1994, GENE, V151, P161, DOI 10.1016/0378-1119(94)90649-1; MORFELDT E, 1988, MOL GEN GENET, V211, P435, DOI 10.1007/BF00425697; NAOMI B, 1995, P NATL ACAD SCI USA, V92, P1619; NESIN M, 1990, ANTIMICROB AGENTS CH, V34, P2273, DOI 10.1128/AAC.34.11.2273; Oguiza JA, 1996, J BACTERIOL, V178, P550, DOI 10.1128/jb.178.2.550-553.1996; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; RAO L, 1995, J BACTERIOL, V177, P2609, DOI 10.1128/jb.177.10.2609-2614.1995; SAUER U, 1994, J BACTERIOL, V176, P6572, DOI 10.1128/JB.176.21.6572-6582.1994; SHIINA T, 1991, GENE, V107, P145; SHORENSTEIN RG, 1973, J BIOL CHEM, V248, P6170; SMELTZER MS, 1992, J BACTERIOL, V174, P4000, DOI 10.1128/jb.174.12.4000-4006.1992; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TANAKA K, 1988, SCIENCE, V242, P1040, DOI 10.1126/science.3194753; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANWEZEL GP, 1995, J BACTERIOL, V177, P473, DOI 10.1128/jb.177.2.473-476.1995; VERSALOVIC J, 1993, MOL MICROBIOL, V8, P343, DOI 10.1111/j.1365-2958.1993.tb01578.x; [No title captured]	52	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21828	21834		10.1074/jbc.271.36.21828	http://dx.doi.org/10.1074/jbc.271.36.21828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702982	hybrid			2022-12-27	WOS:A1996VF61200024
J	Pan, ZQ; Ge, H; Amin, AA; Hurwitz, J				Pan, ZQ; Ge, H; Amin, AA; Hurwitz, J			Transcription-positive cofactor 4 forms complexes with HSSB (RPA) on single-stranded DNA and influences HSSB-dependent enzymatic synthesis of simian virus 40 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; LARGE TUMOR-ANTIGEN; POLYMERASE-ALPHA; T-ANTIGEN; REPLICATION INVITRO; BINDING-PROPERTIES; SV40 ORIGIN; INITIATION; PROTEIN; DELTA	The replication of simian virus 40 (SV40) DNA in vitro requires a trimeric single-stranded DNA (ssDNA)-binding protein called HSSB or RPA. HSSB supports the unwinding of DNA containing the SV40 origin in the presence of the viral-encoded T antigen and is required for the initiation of RNA primer synthesis as well as processive elongation of DNA catalyzed by the DNA polymerase delta holoenzyme. In this report we show that the transcription positive cofactor 4 (PC4), a ssDNA-binding protein, forms complexes with HSSB on ssDNA and markedly affects the replication functions of HSSB. PC4 supports T antigen-catalyzed unwinding of SV40 origins in lieu of HSSB but inhibits both RNA primer synthesis and polymerase delta-catalyzed DNA chain elongation reactions. These inhibitory effects can be reversed by the addition of excess HSSB. Depending on the concentration of HSSB, PC4 is capable of either inhibiting or activating SV40 DNA replication measured in both mono- and dipolymerase systems. The possible role of PC4 in the initiation of DNA replication is discussed.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892; MEM SLOAN KETTERING CANC CTR,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Memorial Sloan Kettering Cancer Center	Pan, ZQ (corresponding author), MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029, USA.				NIGMS NIH HHS [GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	30	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22111	22116		10.1074/jbc.271.36.22111	http://dx.doi.org/10.1074/jbc.271.36.22111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703021	hybrid			2022-12-27	WOS:A1996VF61200063
J	Rossig, L; Zolyomi, A; Catt, KJ; Balla, T				Rossig, L; Zolyomi, A; Catt, KJ; Balla, T			Regulation of angiotensin II-stimulated Ca2+ oscillations by Ca2+ influx mechanisms in adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; CALCIUM OSCILLATIONS; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; ACINAR-CELLS; CHANNELS; WAVES; MOBILIZATION; ACTIVATION; METABOLISM	In adrenal glomerulosa cells, angiotensin II (Ang II) evokes repetitive [Ca2+](i) transients and increases Ca2+ influx through voltage-sensitive calcium channels (VSCCs) as well as the capacitative Ca2+ entry pathway. This study analyzed the relationships between these Ca2+ influx pathways and intracellular Ca2+ signaling in bovine glomerulosa cells, in which Ca2+ oscillation frequency was regulated by Ang II concentration over the range of 50-300 pM. In the absence of external. Ca2+, such oscillations were maintained for prolonged periods of time, but their frequency was significantly reduced (0.23 min(-1) versus 0.38 min(-1)). Restoration of [Ca2+](o) to 0.6 mM increased the frequency of Ca2+ oscillations in cells that showed narrow spikes of constant amplitude and caused a plateau response in cells with broad spikes of rapidly decreasing amplitude. In the presence of Ca2+, nifedipine reduced the frequency of the oscillatory Ca2+ response to 100 pM Ang II by 49%, and BAY K 8644 increased oscillation frequency by 86%, or caused plateau-type responses typical of higher Ang II concentrations. In contrast to their prominent actions on Ca2+ spiking frequency, dihydropyridines caused only minor changes in Ang II (100 pM)-induced inositol phosphate production. Dihydropyridines also had minimal effects on the nonoscillatory Ca2+ signals evoked by high Ang II concentrations (10 nM). These findings indicate that Ca2+ influx through VSCCs modulates the frequency of Ca2+ oscillations induced by low agonist concentrations by a mechanism that does not involve major changes in inositol trisphosphate formation. However, VSCCs make relatively little contribution to the nonoscillatory Ca2+ signals generated by high agonist concentrations, when Ca2+ influx occurs predominantly through the capacitative Ca2+ entry pathway.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; BALLA T, 1994, J BIOL CHEM, V269, P16101; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN CJ, 1988, P NATL ACAD SCI USA, V85, P2412, DOI 10.1073/pnas.85.7.2412; DURROUX T, 1988, J PHYSIOL-LONDON, V404, P713, DOI 10.1113/jphysiol.1988.sp017315; ELY JA, 1991, J BIOL CHEM, V266, P18635; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOHNSON EIM, 1989, J ENDOCRINOL, V122, P391, DOI 10.1677/joe.0.1220391; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KEIZER J, 1995, MOL BIOL CELL, V6, P945, DOI 10.1091/mbc.6.8.945; MATSUNAGA H, 1987, BIOCHEM BIOPH RES CO, V149, P1049, DOI 10.1016/0006-291X(87)90514-6; MCCARTHY RT, 1993, P NATL ACAD SCI USA, V90, P3260, DOI 10.1073/pnas.90.8.3260; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; QUINN SJ, 1988, P NATL ACAD SCI USA, V85, P5754, DOI 10.1073/pnas.85.15.5754; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROSSIER MF, 1995, J BIOL CHEM, V270, P15137, DOI 10.1074/jbc.270.25.15137; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STOJILKOVIC SS, 1993, J BIOL CHEM, V268, P7713; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; TOMIC M, 1995, ENDOCRINOLOGY, V136, P3422, DOI 10.1210/en.136.8.3422; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	36	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22063	22069						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703014				2022-12-27	WOS:A1996VF61200056
J	Thomas, MJ; Umayahara, Y; Shu, H; Centrella, M; Rotwein, P; McCarthy, TL				Thomas, MJ; Umayahara, Y; Shu, H; Centrella, M; Rotwein, P; McCarthy, TL			Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E(2) in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; ENHANCER-BINDING-PROTEIN; PARATHYROID-HORMONE; CYCLIC-AMP; FACTOR-BETA; IGF-I; DEOXYRIBONUCLEIC-ACID; COLLAGEN-SYNTHESIS; ENRICHED CULTURES; MESSENGER-RNA	Insulin-like growth factor-I (IGF-I), a multifunctional growth factor, plays a key role in skeletal growth and can enhance bone cell replication and differentiation. We previously showed that prostaglandin E(2) (PGE(2)) and other agents that increase cAMP activated IGF-I gene transcription in primary rat osteoblast cultures through promoter 1 (P1), the major IGF-I promoter, and found that transcriptional induction was mediated by protein kinase A. We now have identified a short segment of P1 that is essential for full hormonal regulation and have characterized inducible DNA-protein interactions involving this site. Transient transfections of IGF-I P1 reporter genes into primary rat osteoblasts showed that the 328-base pair untranslated region of exon 1 was required for a full 5.3-fold response to PGE(2); mutation in a previously footprinted site, HS3D (base pairs +193 to +215), reduced induction by 65%. PGE(2) stimulated nuclear protein binding to HS3D. Binding, as determined by gel mobility shift assay, was not seen in nuclear extracts from untreated osteoblast cultures, was detected within 2 h of PGE(2) treatment, and was maximal. by 4 h. This DNA-protein interaction was not observed in cytoplasmic extracts from PGE(2)-treated cultures, indicating nuclear localization of the protein kinase A-activated factor(s). Activation of this factor was not blocked by cycloheximide (Chx), and Chx did not impair stimulation of IGF-I gene expression by PGE(2). In contrast, binding to a consensus cAMP response element (CRE; 5'-TGACGTCA-3') from the rat somatostatin gene was not modulated by PGE(2) or Chx. Competition gel mobility shift analysis using mutated DNA probes identified 5'-CGCAATCG-3' as the minimal sequence needed for inducible binding. All modified IGF-I P1 promoter-reporter genes with mutations within this CRE sequence also showed a diminished functional response to PGE(2). These results identify the CRE within the 5'-untranslated region of IGF-I exon 1 that is required for hormonal activation of IGF-I gene transcription by cAMP in osteoblasts.	YALE UNIV,SCH MED,SECT PLAST SURG,NEW HAVEN,CT 06520; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52246; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Yale University; University of Iowa; Washington University (WUSTL)			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NICHD NIH HHS [HD20805] Funding Source: Medline; NIDDK NIH HHS [DK37449, DK47421] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421, R01DK037449] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; ADAMO ML, 1993, ENDOCRINOLOGY, V132, P935, DOI 10.1210/en.132.2.935; AMANO S, 1994, J BONE MINER RES, V9, P465; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CAO QP, 1989, MOL ENDOCRINOL, V3, P2005, DOI 10.1210/mend-3-12-2005; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1996, IN PRESS NY ACAD SCI; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHYUN YS, 1984, PROSTAGLANDINS, V27, P97, DOI 10.1016/0090-6980(84)90223-5; COLLINS DA, 1991, J BONE MINER RES, V6, P157; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756-3282(90)90078-D; KAJIMOTO Y, 1990, MOL ENDOCRINOL, V4, P217, DOI 10.1210/mend-4-2-217; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; KLEINNULEND J, 1990, ENDOCRINOLOGY, V126, P1070, DOI 10.1210/endo-126-2-1070; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOWE WL, 1992, BIOCHEM BIOPH RES CO, V189, P972, DOI 10.1016/0006-291X(92)92299-D; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1993, ADV EXP MED BIOL, V343, P407; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075; MULLER M, 1990, NUCLEIC ACIDS RES, V18, P364, DOI 10.1093/nar/18.2.364; NGAN P, 1990, ARCH ORAL BIOL, V35, P717, DOI 10.1016/0003-9969(90)90094-Q; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OKAZAKI R, 1995, BIOCHEM BIOPH RES CO, V207, P963, DOI 10.1006/bbrc.1995.1279; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1801; Parker D, 1996, MOL CELL BIOL, V16, P694; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; PUSH JM, 1995, ENDOCRINOLOGY, V136, P33; RAISZ LG, 1974, PROSTAGLANDINS, V8, P377, DOI 10.1016/0090-6980(74)90113-0; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SHAMBLOTT MJ, 1992, P NATL ACAD SCI USA, V89, P8913, DOI 10.1073/pnas.89.19.8913; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711	70	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21835	21841		10.1074/jbc.271.36.21835	http://dx.doi.org/10.1074/jbc.271.36.21835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702983	hybrid			2022-12-27	WOS:A1996VF61200025
J	Blochl, A; Sirrenberg, C				Blochl, A; Sirrenberg, C			Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75(Lntr) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; HIPPOCAMPAL-NEURONS; SUBSTANTIA-NIGRA; MESSENGER-RNA; BINDING CHARACTERISTICS; SIGNAL-TRANSDUCTION; SPHINGOMYELIN CYCLE; 2ND MESSENGER; PC12 CELLS	We analyzed the short term effect of neurotrophins on mesencephalic neuronal cultures of embryonic (E14) rats with respect to which receptors mediate the actions, Brain-derived neurotrophic factor (BDNF) or neurotrophin-3 enhanced within minutes in a dose-dependent manner (2, 20, 100 ng/ml for 5 min) depolarization-induced (KCl, 30 mM 5 min) and basal dopamine release, but nerve growth factor (NGF) was only effective at high doses (100 ng/ml), The effect of BDNF, but not of NGF, was blacked by K252a or K252b, BDNF, but not NGF, phosphorylated trkB receptors, The NGF-induced, but not the BDNF-induced effect upon the release of dopamine was blocked by anti-p75 antibody MC192. C-2-ceramide, an analogue of ceramide, the second messenger of the sphingomyelin pathway, and sphingomyelinase itself induced a release of dopamine comparable with the effect of NGF, NGF, but not BDNF, increased ceramide production, in addition, simultaneous treatment with BDNF and NGF led to a partial prevention of the NGF-stimulated, p75(Lntr)-mediated effect. We conclude that BDNF stimulates the release of dopamine by activation of the trkB receptor, whereas NGF affects the release via the p75(Lntr) receptor inducing the sphingomyelin pathway.			Blochl, A (corresponding author), MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.							ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; ALTAR CA, 1994, EXP NEUROL, V130, P31, DOI 10.1006/exnr.1994.1182; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Berzaghi M. P., 1995, Society for Neuroscience Abstracts, V21, P545; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Blochl A, 1996, MOL CELL NEUROSCI, V7, P173, DOI 10.1006/mcne.1996.0014; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DECHANT G, 1993, DEVELOPMENT, V119, P545; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; GIBBS RB, 1994, J COMP NEUROL, V341, P324, DOI 10.1002/cne.903410304; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; Griesbeck O., 1995, Society for Neuroscience Abstracts, V21, P1046; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KNIPPER M, 1994, EUR J NEUROSCI, V6, P668, DOI 10.1111/j.1460-9568.1994.tb00312.x; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LESSMANN V, 1994, NEUROREPORT, V6, P21; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MARTINIVERSON MT, 1994, J NEUROSCI, V14, P1262, DOI 10.1523/JNEUROSCI.14-03-01262.1994; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; NISHIO T, 1992, EXP NEUROL, V116, P76, DOI 10.1016/0014-4886(92)90178-S; OFFENHAUSER N, 1995, EUR J NEUROSCI, V7, P917, DOI 10.1111/j.1460-9568.1995.tb01079.x; OKAZAWA H, 1992, FEBS LETT, V313, P138, DOI 10.1016/0014-5793(92)81430-T; PALMER MR, 1993, EXP BRAIN RES, V93, P226; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOBREVIELA T, 1994, J COMP NEUROL, V350, P587, DOI 10.1002/cne.903500407; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; STUDER L, 1995, EUR J NEUROSCI, V7, P223, DOI 10.1111/j.1460-9568.1995.tb01058.x; SUTER U, 1992, J NEUROSCI, V12, P306; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	64	150	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21100	21107						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702878				2022-12-27	WOS:A1996VE47700024
J	Eder, PS; Srinivasan, A; Fishman, MC; Altman, S				Eder, PS; Srinivasan, A; Fishman, MC; Altman, S			The RNA subunit of ribonuclease P from the zebrafish, Danio rerio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE; INVITRO; MOIETY; ENZYME; CELLS	A simple strategy has been devised to identify the gene encoding the RNA subunit of RNase P from the zebrafish, Danio rerio. The sequence obtained by amplification of genomic DNA with primers based on sequences common to two other vertebrates was confirmed by reverse transcription and amplification of RNA from a partially purified preparation of the holoenzyme. The 5' and 3' ends were determined by cyclizing the RNA, followed by reverse transcription and sequencing across the ligated RNA junction, The zebrafish sequence is 63% identical to that of Xenopus laevis nuclear RNase P RNA and 69% identical to the human RNase P RNA, A consensus secondary structure was constructed based on these nucleotide identities and on the many compensatory base changes in several regions among these three RNAs. The strategy used to obtain the zebrafish sequence should be useful in deriving analogous gene sequences from diverse classes of eukaryotes.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Yale University; Harvard University; Massachusetts General Hospital								ALTMAN S, 1993, GENOMICS, V18, P418, DOI 10.1006/geno.1993.1488; Altman Sidney, 1995, P67; BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; ERFIELD M, 1995, ZEBRAFISH BOOK GUIDE; GOPALAN V, 1995, RNA PROTEIN INTERACT, P103; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; JAEGER JA, 1993, ANNU REV BIOCHEM, V62, P255; JAYANTHI GP, 1992, ARCH BIOCHEM BIOPHYS, V296, P264, DOI 10.1016/0003-9861(92)90571-D; LI K, 1995, J BIOL CHEM, V270, P25281, DOI 10.1074/jbc.270.42.25281; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; LIU MH, 1994, MOL CELL BIOCHEM, V130, P75, DOI 10.1007/BF01084270; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; SHINSHI H, 1976, BIOCHEMISTRY-US, V15, P2185, DOI 10.1021/bi00655a024; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TRANGUCH AJ, 1993, J BIOL CHEM, V268, P14045; WESTHOF E, 1994, P NATL ACAD SCI USA, V91, P5133, DOI 10.1073/pnas.91.11.5133; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006	27	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21031	21036		10.1074/jbc.271.35.21031	http://dx.doi.org/10.1074/jbc.271.35.21031			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702867	hybrid			2022-12-27	WOS:A1996VE47700013
J	Krippner, A; MatsunoYagi, A; Gottlieb, RA; Babior, BM				Krippner, A; MatsunoYagi, A; Gottlieb, RA; Babior, BM			Loss of function of cytochrome c in Jurkat cells undergoing Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC ATPASE INHIBITOR; TUMOR-NECROSIS-FACTOR; THYMOCYTE APOPTOSIS; MITOCHONDRIA; DEATH; INVOLVEMENT; RECEPTOR; PROTEINS; PROTEASE; F1F0-ATPASE	Mitochondrial function was examined in Jurkat cells undergoing Fas-mediated apoptosis. With succinate or ascorbate/tetramethylphenylenediamine as substrate, oxygen uptake by digitonin-permeabilized apoptotic mitochondria was greatly decreased as compared with control. Assessment of the function of the cytochrome c-cytochrome oxidase segment of the electron transport chain of apoptotic mitochondria showed that the activity of cytochrome oxidase appeared to be normal, but that of cytochrome c was greatly diminished. A death protease was found to participate in the events leading to the loss of cytochrome c activity, but the cytochrome did not seem to be extensively degraded during the course of apoptosis. Our results suggest that a rapid loss in mitochondrial function due at least in part to the inhibition or inactivation of cytochrome c is a potentially fatal component of the apoptosis program of Jurkat cells.			Krippner, A (corresponding author), SCRIPPS RES INST, DEPT MOL & EXPT MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA-01345] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASS WT, 1988, ANAL BIOCHEM, V171, P330, DOI 10.1016/0003-2697(88)90494-0; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHERNYAK BV, 1991, ARCH BIOCHEM BIOPHYS, V286, P604, DOI 10.1016/0003-9861(91)90087-Y; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; DEGOMEZPUYOU MT, 1983, J BIOL CHEM, V258, P3680; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Errede B, 1978, Methods Enzymol, V53, P40; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1983, J BIOCHEM-TOKYO, V94, P715, DOI 10.1093/oxfordjournals.jbchem.a134411; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; ICHIKAWA N, 1990, J BIOL CHEM, V265, P6274; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOPEZMEDIAVILLA C, 1993, EUR J BIOCHEM, V215, P487, DOI 10.1111/j.1432-1033.1993.tb18058.x; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MACHO A, 1995, BLOOD, V86, P2481; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MIMURA H, 1993, J BIOCHEM-TOKYO, V113, P350, DOI 10.1093/oxfordjournals.jbchem.a124050; NEAMATI N, 1995, J IMMUNOL, V154, P3788; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Piacentini M, 1995, Curr Top Microbiol Immunol, V200, P163; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; TAN A, 1989, JOY LUCK CLUB, P102; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; YAMADA EW, 1983, BIOSCIENCE REP, V3, P947, DOI 10.1007/BF01140664; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	35	187	193	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21629	21636		10.1074/jbc.271.35.21629	http://dx.doi.org/10.1074/jbc.271.35.21629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702951	hybrid			2022-12-27	WOS:A1996VE47700097
J	Tougu, K; Marians, KJ				Tougu, K; Marians, KJ			The interaction between helicase and primase sets the replication fork clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-III; COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; HOLOENZYME; PURIFICATION; IDENTIFICATION; CONVERSION; PROTEINS; RECONSTITUTION	The synthesis of an Okazaki fragment occurs once every 1-2 s at the Escherichia coli replication fork and requires precise coordination of the enzymatic activities required. We have shown previously that the primase is recruited anew from solution for each cycle of Okazaki fragment synthesis and that association of primase with the replication fork is via a protein-protein interaction with the helicase, DnaB, We describe here mutant primases that have an altered interaction with DnaB and that direct the synthesis of Okazaki fragments of altered length compared to the wild-type. The mutant primases were deficient only in their ability to participate in replication reactions where their entry to the DNA was provided by the initial protein-protein interaction with DnaB. The primer synthesis capacity of these proteins remained unaffected, as was their ability to interact with the DNA polymerase III holoenzyme. Neither replication fork rate nor the efficiency of primer utilization was affected at replication forks programmed by the mutant enzymes. Thus, the interaction between DnaG and DnaB at the replication fork is the primary regulator of the cycle of Okazaki fragment synthesis.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Tougu, K (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MOK M, 1987, J BIOL CHEM, V262, P16644; MUNN MM, 1991, J BIOL CHEM, V266, P20034; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SELICK HE, 1987, DNA REPLICATION RECO, P183; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P1983; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHEL K, 1975, J BIOL CHEM, V250, P4684; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	33	112	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21398	21405		10.1074/jbc.271.35.21398	http://dx.doi.org/10.1074/jbc.271.35.21398			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702921	hybrid			2022-12-27	WOS:A1996VE47700067
J	Wu, K; Yuan, J; Lasky, LA				Wu, K; Yuan, J; Lasky, LA			Characterization of a novel member of the macrophage mannose receptor type C lectin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SELECTIN-DEFICIENT MICE; BINDING PROTEIN; ANIMAL LECTINS; LIGAND; OLIGOSACCHARIDE; IDENTIFICATION; MUTAGENESIS; EXPRESSION; CLONING	The recognition of a diversity of carbohydrates by the various calcium dependent (type C) lectin family members has been shown to be critical for a variety of processes ranging from cell adhesion to antigen presentation, Examination of the expressed sequence tag (EST) data base for novel type C lectins using E-selectin as a probe resulted in the identification of a distantly related short polypeptide sequence containing many of the conserved residues found in these carbohydrate-binding proteins. Cloning of the full-length murine cDNA containing this region revealed that this protein is a novel member of the family that includes the macrophage mannose, the phospholipase A(2), and the DEC 205 receptors, with a cysteine-rich domain, a fibronectin type 2 domain, eight type C lectin domains, a transmembrane domain, and a short cytoplasmic carboxyl terminus, Genomic Southern analysis suggests that this is a conserved protein, and examination of a human homologue revealed a high degree of sequence homology with the murine form. Northern blot analysis revealed expression of a large transcript in a number of different human and murine tissues and tumor cells and an alternatively spliced smaller transcript with a divergent 5' sequence was expressed specifically in the human fetal liver. Analysis of the genomic structure revealed that the gene encoding this lectin was interrupted by a large number of introns, and the intron structure was similar to the macrophage mannose receptor gene, Finally, in situ hybridization analysis demonstrated that the transcript encoding this lectin was found in a number of highly endothelialized sites as well as in chondrocytes in cartilaginous regions of the embryo.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ALON R, 1995, IN PRESS NATURE; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HARRIS N, 1994, BIOCHEM BIOPH RES CO, V198, P682, DOI 10.1006/bbrc.1994.1099; HARRIS N, 1992, BLOOD, V80, P2363; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; IOBST ST, 1994, J BIOL CHEM, V269, P15505; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KIM SJ, 1992, GENOMICS, V14, P721, DOI 10.1016/S0888-7543(05)80174-0; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	27	77	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21323	21330		10.1074/jbc.271.35.21323	http://dx.doi.org/10.1074/jbc.271.35.21323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702911	hybrid			2022-12-27	WOS:A1996VE47700057
J	Dong, DLY; Xu, ZS; Hart, GW; Cleveland, DW				Dong, DLY; Xu, ZS; Hart, GW; Cleveland, DW			Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTERMEDIATE FILAMENTS; N-ACETYLGLUCOSAMINE MOIETIES; MAMMALIAN NEUROFILAMENTS; PHOSPHORYLATION SITES; AXONAL-TRANSPORT; TRANSGENIC MICE; SCHWANN-CELLS; LINKED GLCNAC; IN-VIVO; IDENTIFICATION	Neurofilaments, the major intermediate filaments in large myelinated neurons, are essential for specifying proper axonal caliber. Mammalian neurofilaments are obligate heteropolymers assembled from three polypeptides, neurofilament (NF)-H, NF-M, and NF-L, each of which undergoes phosphorylation at multiple sites. NF-M and NF-L are known to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (Dong, D. L.-Y., Xu, Z.-S., Chevrier, M. R., Cotter, R. J., Cleveland, D. W., and Hart, G. W. (1993) J. Biol. Chem. 268, 16679-16687), Here we further report that NF-H is extensively modified by O-GlcNAc at Thr(53), Ser(54), and Ser(56) in the head domain and, somewhat surprisingly, at multiple sites within the Lys-Ser-Pro repeat motif in the tail domain, a region in assembled neurofilaments known to be nearly stoichiometrically phosphorylated on each of the similar to 50 KSP repeats. Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr(19) and Ser(34) of NF-M and Ser(34) and Ser(48) of MF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly, The proximity of O-GlcNAc and phosphorylation sites in both head and tail domains of each subunit indicates that these modifications may influence one another and play a role in filament assembly and network formation.	UNIV CALIF SAN DIEGO, LUDWIG INST CANC RES, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, LUDWIG INST CANC RES, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682; Hart, Gerald/0000-0001-7812-4351	NICHD NIH HHS [HD13563] Funding Source: Medline; NINDS NIH HHS [NS27036] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027036, R01NS027036] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1991, J CELL SCI, V99, P335; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHOU CF, 1992, J BIOL CHEM, V267, P3901; Cleveland DW, 1996, CELL, V84, P663, DOI 10.1016/S0092-8674(00)81044-2; Cleveland DW, 1995, RES PER ALZ, P180; COLE JS, 1994, J NEUROSCI, V14, P6956; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DONG DLY, 1994, THESIS J HOPKINS U B; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GOTOW T, 1994, J CELL SCI, V107, P1949; Haltiwanger R S, 1993, Methods Mol Biol, V14, P175; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1995, PURE APPL CHEM, V67, P1637, DOI 10.1351/pac199567101637; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, C MOSBACH, V44, P91; HIRANO A, 1991, ADV NEUROL, V56, P91; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HSIEH ST, 1994, J NEUROSCI, V14, P6392; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; SAKAGUCHI T, 1993, NEUROSCI LETT, V153, P65, DOI 10.1016/0304-3940(93)90078-Y; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SIHAG RK, 1995, MOL BIOL CELL, V6, P375; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; XU ZS, 1990, J NEUROSCI, V10, P1838; Xu ZS, 1996, J CELL BIOL, V133, P1061, DOI 10.1083/jcb.133.5.1061; XU ZS, 1992, J BIOL CHEM, V267, P4467; XU ZS, 1990, THESIS WASHINGTON U; Xu Zuoshang, 1994, Current Opinion in Neurobiology, V4, P655, DOI 10.1016/0959-4388(94)90006-X; YAMASAKI H, 1992, LAB INVEST, V66, P734	58	96	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20845	20852		10.1074/jbc.271.34.20845	http://dx.doi.org/10.1074/jbc.271.34.20845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702840	hybrid			2022-12-27	WOS:A1996VD33700092
J	Horstmeyer, A; Cramer, H; Sauer, T; MullerEsterl, W; Schroeder, C				Horstmeyer, A; Cramer, H; Sauer, T; MullerEsterl, W; Schroeder, C			Palmitoylation of endothelin receptor A - Differential modulation of signal transduction activity by post-translational modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; HAMSTER OVARY CELLS; SMOOTH-MUSCLE CELLS; CHROMOSOMAL ASSIGNMENT; ADENYLATE-CYCLASE; CYTOPLASMIC TAIL; LIGAND-BINDING; ACTIVATION	Post-translational modifications such as phosphorylation and palmitoylation play important roles for the function and regulation of receptors coupled to heterotrimeric guanyl nucleotide binding proteins. Here we demonstrate that the human endothelin receptor A (ET(A)) incorporates [H-3]palmitate, Mutation of a cluster of five cysteine residues present in the cytoplasmic tail of ET(A) into serine or alanine residues completely prevented palmitoylation of the receptor. The ligand binding affinity of the non-palmitoylated ET(A) mutants was essentially unchanged as compared to the palmitoylated wild type ET(A) suggesting that the replacement of the cysteine residues did not alter the overall structure of the receptor, Furthermore, the ligand-induced stimulation of adenylyl cyclase by the mutant ET(A) was unaffected by the mutation, In contrast, the mutated non-palmitoylated receptors but not the wild type receptor failed to stimulate phosphatidylinositol hydrolysis by phospholipase C activation upon challenge by endothelin-1. Furthermore, the mutant receptors failed to stimulate the ligand-induced transient increase in the cytoplasmic calcium seen with the wild type ET(A), Endothelin-1 induced mitogenic stimuli via the wild type receptors but not through the mutated receptors suggesting an important role for phospholipase C in this signal transduction pathway, The differential regulation of distinct signal transduction pathways by post-translational modification suggests that palmitoylation of the ET(A) provides a novel mechanism of modulating ET(A) receptor activity.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-65099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz								ALLA SA, 1993, J BIOL CHEM, V268, P17277; ARAI H, 1993, J BIOL CHEM, V268, P3463; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COLLINS S, 1991, VITAM HORM, V46, P1; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; EISTETTER HR, 1991, CELL REGUL, V2, P767, DOI 10.1091/mbc.2.10.767; FELDER CC, 1989, J BIOL CHEM, V264, P20356; HARTMAN JC, 1995, ANN THORAC SURG, V60, P789, DOI 10.1016/0003-4975(95)00192-N; HASHIDO K, 1993, CELL MOL BIOL RES, V39, P3; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOSODA K, 1992, J BIOL CHEM, V267, P18797; JANAKIDEVI K, 1992, AM J PHYSIOL, V263, pC1295, DOI 10.1152/ajpcell.1992.263.6.C1295; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KHOUJA A, 1992, J DEV PHYSIOL, V18, P263; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; RESINK TJ, 1990, EUR J BIOCHEM, V189, P415, DOI 10.1111/j.1432-1033.1990.tb15504.x; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SUMMER MD, 1987, AGR EXPT STATION B, V1555; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; YAMADA M, 1994, MOL PHARMACOL, V46, P470; YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	44	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20811	20819		10.1074/jbc.271.34.20811	http://dx.doi.org/10.1074/jbc.271.34.20811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702836	hybrid			2022-12-27	WOS:A1996VD33700088
J	Mallardo, M; Dragonetti, E; Baldassarre, F; Ambrosino, C; Scala, G; Quinto, I				Mallardo, M; Dragonetti, E; Baldassarre, F; Ambrosino, C; Scala, G; Quinto, I			An NF-kappa B site in the 5'-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappa B-activating stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR USF; TATA-BINDING PROTEIN; FACTOR-ALPHA; NUCLEAR FACTOR; COOPERATIVE INTERACTION; HIV-1 TRANSCRIPTION; INITIATOR ELEMENT; HUMAN-LYMPHOCYTES	The 5'-untranslated leader region of human immunodeficiency virus, type 1 (HIV-1), includes a complex array of putative regulatory elements whose role in the viral expression is not completely understood. Here we demonstrate the presence of an NF-kappa B-responsive element in the trans-activation response (TAR) region of HIV-1 that confers the full induction of HIV-1 long terminal repeat (LTR) in response to NF-kappa B-activating stimuli, such as DNA alkylating agents, phorbol 12-myristate 13-acetate, and tumor necrosis factor-alpha. The TAR NF-kappa B site GGGAGCTCTC spans from positions +31 to +40 and cooperates with the NF-kappa B enhancer upstream of the TATA box in the NF-kappa B-mediated induction of HIV-1 LTR. The conclusion stems from the following observations: (i) deletion of the two NF-kappa B sites upstream of the TATA box reduces, but does not abolish, the HIV-1 LTR activation by NF-kappa B inducers; (ii) deletion or base pair substitutions of the TAR NF-kappa B site significantly reduce the HIV-1 LTR activation by NF-kappa B inducers; (iii) deletions of both the NF-kappa B sites upstream of the TATA box and the TAR NF-kappa B site abolish the activation of HIV-1 LTR in response to NF-kappa B inducers. Moreover, the p50 . p65 NF-kappa B complex binds to the TAR NF-kappa B sequence and trans-activates the TAR NF-kappa B-directed expression. The identification of an additional NF-kappa B site in the HIV-1 LTR points to the relevance of NF-kappa B factors in the HIV-1 Life cycle.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria			SCALA, GIUSEPPE/A-3280-2009	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ANTONI BA, 1994, VIROLOGY, V202, P684, DOI 10.1006/viro.1994.1390; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DEROSSI A, 1990, EUR J IMMUNOL, V20, P2041, DOI 10.1002/eji.1830200924; DIFAGAGNA FD, 1995, J VIROL, V69, P2765, DOI 10.1128/JVI.69.5.2765-2775.1995; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HARRICH D, 1994, J VIROL, V68, P5899, DOI 10.1128/JVI.68.9.5899-5910.1994; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LI YC, 1994, J BIOL CHEM, V269, P30616; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALLON R, 1990, J VIROL, V64, P6282, DOI 10.1128/JVI.64.12.6282-6285.1990; MARGOLIS DM, 1993, VIROLOGY, V192, P370, DOI 10.1006/viro.1993.1046; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MONROE JE, 1988, J VIROL, V62, P3497, DOI 10.1128/JVI.62.9.3497-3500.1988; Myers G., 1993, HUMAN RETROVIRUSES A; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PARROTT C, 1991, VIROLOGY, V65, P1414; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POPIK W, 1993, J VIROL, V67, P1094, DOI 10.1128/JVI.67.2.1094-1099.1993; QUINTO I, 1993, J BIOL CHEM, V268, P26719; QUINTO I, 1991, LIGHT LASERS SYNCHRO, P247; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823	63	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20820	20827		10.1074/jbc.271.34.20820	http://dx.doi.org/10.1074/jbc.271.34.20820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702837	hybrid			2022-12-27	WOS:A1996VD33700089
J	Olney, JJ; Sellers, JR; Cremo, CR				Olney, JJ; Sellers, JR; Cremo, CR			Structure and function of the 10S conformation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; HEAVY-MEROMYOSIN; ACTIVE-SITE; ATPASE ACTIVITY; GIZZARD MYOSIN; PHOSPHORYLATION; FILAMENTS; IDENTIFICATION; CONTRACTION; TRANSITION	Smooth myosin regulatory light chain (RLC) was exchanged with RLC labeled with benzophenone-4-iodoacetamide at Cys-108. Irradiation under conditions that favor the folded (10 S) conformation resulted in 10 S cross-linked myosin that could not unfold. Purified 10 S cross-linked myosin was cross-linked between the RLC of one head to light meromyosin between leucine 1554 and glutamate 1583, adjacent to a predicted noncoiled region, approximately 60 nn from the tip of the tail. At high ionic strength without actin, product release from one-half of the heads was slow (like 10 S) whereas the other half were activated. This suggests that tail binding to the RLC carboxyl-terminal domain stabilizes ionic interactions important to slow nucleotide release. With actin, product release from both (un)phosphorylated 10 S cross-linked myosin was from one slow population similar to unphosphorylated filaments. 10 S cross-linked myosin weakly bound actin (dissociation constant > 500 mu M) and did not move actin in vitro. Single-headed myosin did not fold or trap nucleotide, These and other data suggest that ''trapping'' occurs only with both heads and the tail binds to a newly formed site, which includes the RLC carboxyl-terminal domain, once trapping has occurred.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA; NHLBI, MOL CARDIOL LAB, NIH, BETHESDA, MD 20892 USA	Washington State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; ANDERSON WL, 1975, ANAL BIOCHEM, V67, P493, DOI 10.1016/0003-2697(75)90323-1; ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; APPLEGATE D, 1992, J CELL BIOL, V117, P1223, DOI 10.1083/jcb.117.6.1223; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blough ER, 1996, ANAL BIOCHEM, V233, P31, DOI 10.1006/abio.1996.0003; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; CITI S, 1989, J CELL BIOL, V109, P549, DOI 10.1083/jcb.109.2.549; COLE DG, 1990, J BIOL CHEM, V265, P22537; COLE DG, 1992, BIOCHEMISTRY-US, V31, P6186, DOI 10.1021/bi00142a003; CRAIG R, 1987, J CELL BIOL, V105, P1319, DOI 10.1083/jcb.105.3.1319; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CREMO CR, 1991, METHOD ENZYMOL, V196, P442; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; CROSS RA, 1988, J MUSCLE RES CELL M, V9, P108, DOI 10.1007/BF01682153; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DREW JS, 1993, CELL MOTIL CYTOSKEL, V26, P291, DOI 10.1002/cm.970260404; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FERAH CS, 1995, FASEB J, V9, P755; HALL LD, 1980, CARBOHYD RES, V78, pC4, DOI 10.1016/S0008-6215(00)83677-0; HIGASHIHARA M, 1989, BIOCHEMISTRY-US, V28, P1642, DOI 10.1021/bi00430a032; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HOROWITZ A, 1994, J CELL BIOL, V126, P1195, DOI 10.1083/jcb.126.5.1195; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; IKEHARA M, 1968, BIOCHIM BIOPHYS ACTA, V155, P82, DOI 10.1016/0005-2787(68)90337-7; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RJC, 1993, J STRUCT BIOL, V110, P99, DOI 10.1006/jsbi.1993.1010; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; OFFER G, 1990, J MOL BIOL, V216, P213, DOI 10.1016/S0022-2836(05)80309-2; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; RAYMENT I, 1993, SCIENCE, V261, P1; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; TAKAHASHI M, 1989, J BIOCHEM-TOKYO, V105, P149, DOI 10.1093/oxfordjournals.jbchem.a122628; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; WHITE HD, 1985, J BIOL CHEM, V260, P982; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	64	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20375	20384		10.1074/jbc.271.34.20375	http://dx.doi.org/10.1074/jbc.271.34.20375			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702773	hybrid			2022-12-27	WOS:A1996VD33700025
J	Freeman, JL; Abo, A; Lambeth, JD				Freeman, JL; Abo, A; Lambeth, JD			Rac ''insert region'' is a novel effector region that is implicated in the activation of NADPH oxidase, but not PAK65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; GTP-BINDING PROTEIN; CELL-FREE SYSTEM; NUCLEOTIDE DISSOCIATION STIMULATOR; HUMAN NEUTROPHIL; FLAVOCYTOCHROME B(558); GUANINE-NUCLEOTIDES; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; FAMILY MEMBERS	The small GTPase Rac assembles with the cytosolic p47(phox) and p67(phox) and the membrane-associated flavocytochrome b(558) to form the multicomponent respiratory burst oxidase. Mutation of amino acids in a region of Rac (residues 26-45), homologous to an effector region in Pas, was previously shown to interfere with Rac binding to the oxidase. Herein wc have elucidated an additional region in Rac involved in regulating oxidase activity. Rho family small GTPases contain a 12-amino acid ''insert'' region (residues 124-135) that is not present in Pas, Point mutations in and deletion of this region were constructed and used for in vitro studies of the activation of PAK65 and NADPH oxidase. Apparent binding constants (based on EC(50) values) of the mutant Rac proteins for the oxidase are at least 13-25-fold higher than for wild-type Rac, Mutations in the insert region versus the 26-45 effector region resulted in distinct kinetic consequences, pointing to different roles for these two protein regions: mutations in the insert region but not the 26-45 effector region resulted in an increase in the EC(50) for p67(phox). Although mutations in the 26-45 amino acid effector region showed markedly diminished activation of both PAK and the NADPH oxidase, insert region mutations did not affect activation of PAK. We propose that the combinatorial use of the 26-45 effector region and the insert region provides the Rho family GTPases with versatility in their specificity for several downstream targets.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; ONYX PHARMACEUT,RICHMOND,CA 94806	Emory University					NIAID NIH HHS [AI22809] Funding Source: Medline; NIGMS NIH HHS [GM08367] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN E, 1995, METHODS ENZYMOLOGY S, P246; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINAN P, 1994, J BIOL CHEM, V269, P13752; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWKAK JY, 1995, J BIOL CHEM, V270, P27093; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LEONARD D, 1994, BIOCHEMISTRY-US, V83, P12323; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XU XM, 1994, J BIOL CHEM, V269, P23569	50	131	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19794	19801		10.1074/jbc.271.33.19794	http://dx.doi.org/10.1074/jbc.271.33.19794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702687	hybrid			2022-12-27	WOS:A1996VC66900028
J	Fukuda, M; Gotoh, I; Gotoh, Y; Nishida, E				Fukuda, M; Gotoh, I; Gotoh, Y; Nishida, E			Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTE MATURATION; NIH 3T3 CELLS; MAP KINASE; MESODERM INDUCTION; PLASMA-MEMBRANE; RAF; CASCADE; PHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION	Mitogen-activated protein kinase (MAPK) is activated in cytoplasm in response to extracellular signals and then is translocated to nucleus. A directed activator for MAPK, MAPK kinase (MAPKK), stays in cytoplasm to transmit the signal from the plasma membrane to MAPK. Here we show that MAPK contains a short amino acid sequence in the N-terminal region (residues 32-44), which acts as a nuclear export signal (NES) and thus is required for cytoplasmic localization of MAPKK. This NES sequence of MAPKK, like that of protein kinase inhibitor of cAMP-dependent protein kinase or Rev, is rich in leucine residues, which are crucial for the NES activity. Furthermore, the NES peptide of protein kinase inhibitor, as well as the NES peptide of MAPKK, inhibited the nuclear export of ovalbumin conjugated to the NES peptide of MAPKK. These results may suggest a common mechanism of nuclear export using a general leucine-rich NES.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Fukuda, Makoto/S-9748-2019; Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKUDA M, 1995, ONCOGENE, V11, P239; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MORIGUCHI T, 1995, EUR J BIOCHEM, V234, P32, DOI 10.1111/j.1432-1033.1995.032_c.x; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; THOMAS G, 1992, CELL, V68, P1; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	43	294	299	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20024	20028		10.1074/jbc.271.33.20024	http://dx.doi.org/10.1074/jbc.271.33.20024			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702720	hybrid			2022-12-27	WOS:A1996VC66900061
J	Vincenz, C; Dixit, VM				Vincenz, C; Dixit, VM			14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ZINC FINGER PROTEIN; IN-VIVO; KAPPA-B; 14-3-3-PROTEINS; RAF; KINASE; CELLS; ACTIVATION; BRAIN	A20, a novel zinc finger protein, is an inhibitor of tumor necrosis factor-induced apoptosis. The mechanism by which A20 exerts its protective effect is currently unknown. Several isoforms of the 14-3-3 proteins were found to interact with A20 in a yeast two-hybrid screen, A20 bound several 14-3-3 isoforms in vitro. Moreover, transfected A20 was found to preferentially bind the endogenous eta 14-3-3 isoform, whereas the beta/zeta isoforms co-immunoprecipitated much less efficiently, and epsilon 14-3-3 had an intermediate affinity. Importantly, c-Raf, a previously described 14-3-3-interacting protein, also preferentially bound the eta isoform. The cellular localization and subcellular fractionation of A20 was dramatically altered by co-transfected 14-3-3, providing the first experimental evidence for the notion that 14-3-3 can function as a chaperone, Furthermore, c-Raf and A20 co-immunoprecipitated in a 14-3-3-dependent manner, suggesting that 14-3-3 can function as a bridging or adapter molecule.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA61348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DU XP, 1994, J BIOL CHEM, V269, P18287; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HARPER JW, 1993, CELL, V75, P805; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jaattela M, 1996, J IMMUNOL, V156, P1166; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KOYAMA S, 1995, FEBS LETT, V368, P321, DOI 10.1016/0014-5793(95)00686-4; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WOLF FW, 1994, J BIOL CHEM, V269, P3633; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	36	154	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20029	20034		10.1074/jbc.271.33.20029	http://dx.doi.org/10.1074/jbc.271.33.20029			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702721	hybrid			2022-12-27	WOS:A1996VC66900062
J	Luttrell, LM; Hawes, BE; vanBiesen, T; Luttrell, DK; Lansing, TJ; Lefkowitz, RJ				Luttrell, LM; Hawes, BE; vanBiesen, T; Luttrell, DK; Lansing, TJ; Lefkowitz, RJ			Role of c-Src tyrosine kinase in G protein-coupled receptor- and G beta gamma subunit-mediated activation of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HETEROTRIMERIC G-PROTEINS; DOMINANT-NEGATIVE MUTANT; GROWTH-FACTOR RECEPTOR; SHC ADAPTER PROTEIN; LYSOPHOSPHATIDIC ACID; MAP KINASE; SIGNALING PATHWAYS; PHOSPHOINOSITIDE-3 KINASE; ANGIOTENSIN-II	Several G protein-coupled receptors that interact with pertussis toxin-sensitive heterotrimeric G proteins mediate Ras-dependent activation of mitogen-activated protein (MAP) kinases, The mechanism involves G beta gamma subunit-mediated increases in tyrosine phosphorylation of the She adapter protein, Shc-Grb2 complex formation, and recruitment of Pas guanine nucleotide exchange factor activity. We have investigated the role of the ubiquitous nonreceptor tyrosine kinase c-Src in activation of the MAP kinase pathway via endogenous G protein-coupled lysophosphatidic acid (LPA) receptors or by transient expression of G beta gamma subunits in COS-7 cells. In vitro kinase assays of She immunoprecipitates following LPA stimulation demonstrated rapid, transient recruitment of tyrosine kinase activity into She immune complexes, Recruitment of tyrosine kinase activity was pertussis toxin sensitive and mimicked by cellular expression of G beta gamma subunits. Immunoblots for coprecipitated proteins in She immunoprecipitates revealed a transient association of Shc and c-Src following LPA stimulation, which coincided with increases in Shc-associated tyrosine kinase activity and She tyrosine phosphorylation. LPA stimulation or expression of G beta gamma subunits resulted in c-Src activation, as assessed by increased c-Src autophosphorylation, Overexpression of wild-type or constitutively active mutant c-Src, but not kinase inactive mutant c-Src, lead to increased tyrosine kinase activity in She immunoprecipitates, increased She tyrosine phosphorylation, and Shc-Grb2 complex formation, MAP kinase activation resulting from LPA receptor stimulation, expression of G beta gamma subunits, or expression of c-Src was sensitive to dominant negatives of mSos, Pas, and Raf. Coexpression of Csk, which inactivates Src family kinases by phosphorylating the regulatory C-terminal tyrosine residue, inhibited LPA stimulation of Shc tyrosine phosphorylation, Shc-Grb2 complex formation, and MAP kinase activation, These data suggest that G beta gamma subunit-mediated formation of Shc-c-Src complexes and c-Src kinase activation are early events in Ras-dependent activation of MAP kinase via pertussis toxin-sensitive G protein coupled receptors.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; GLAXO WELLCOME INC, DEPT MOL CELL BIOL, RES TRIANGLE PK, NC 27709 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; GlaxoSmithKline			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS CP, 1985, J VIROL, V53, P19, DOI 10.1128/JVI.53.1.19-24.1985; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	57	484	489	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19443	19450		10.1074/jbc.271.32.19443	http://dx.doi.org/10.1074/jbc.271.32.19443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702633	hybrid			2022-12-27	WOS:A1996VB68400067
J	Nagaraj, RH; Shipanova, IN; Faust, FM				Nagaraj, RH; Shipanova, IN; Faust, FM			Protein cross-linking by the Maillard reaction - Isolation, characterization, and in vivo detection of a lysine-lysine cross-link derived from methylglyoxal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; N-ALPHA-HIPPURYLLYSINE; ADVANCED GLYCOSYLATION; ALDOSE REDUCTASE; DIABETES-MELLITUS; DIHYDRODIOL DEHYDROGENASE; GLUTATHIONE METABOLISM; EXTRACELLULAR-MATRIX; ALDEHYDE REDUCTASE; GLYOXALASE SYSTEM	The Maillard reaction, initiated by nonenzymatic glycosylation of amino groups on proteins by reducing sugars, has been studied for its potential role in aging and the complications of diabetes. One of the major consequences of the advanced Maillard reaction in proteins is the formation of covalently cross-linked aggregates, The chemical nature of the cross-linking structures is largely unknown, Recently, methylglyoxal has been shown to be a potential glycating agent in vivo and suggested to be a common intermediate in the Maillard reaction involving glucose. Methylglyoxal can form enzymatically or nonenzymatically from glycolytic intermediates and by retro-aldol cleavage of sugars, Its elevation in tissues in diabetes and its high potency to glycate and cross-link proteins led us to investigate the chemical nature of its advanced Maillard products, Using all approach in which a synthetic model peptide was reacted with methylglyoxal, we isolated and purified a cross-linked peptide dimer, Characterization of this dimer revealed that the peptides are linked through epsilon amino groups of lysine residues, The actual cross-link was shown to be a methylimidazolium, formed horn the reaction of tyro lysines and two methylglyoxal molecules, We have named this cross-link imidazolysine. Imidazolysine was detected in proteins by high performance liquid chromatography using a postcolumn derivatization method, Proteins incubated with methylglyoxal showed a time-dependent formation of imidazolysine. Quantification of imidazolysine in human serum proteins revealed a significant increase (p < 0.05) in diabetic samples (mean +/- S.D., 313.8 +/- 52.7 pmol/mg protein) when compared with normal samples (261.3 +/- 50.4), These values correlated with glycohemoglobin (p < 0.05), These results provide chemical evidence for protein cross-linking by dicarbonyl compounds in vivo.	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV HOSP, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	Nagaraj, RH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT OPHTHALMOL, CTR VIS RES, WEARN BLDG, RM 637, CLEVELAND, OH 44106 USA.				NATIONAL EYE INSTITUTE [R01EY009912, R29EY009912] Funding Source: NIH RePORTER; NEI NIH HHS [EY 09912] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRINKMANN E, 1995, J CHEM SOC PERK T 1, P2817, DOI 10.1039/p19950002817; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; DAVIDEK T, 1991, J AGR FOOD CHEM, V39, P1376; DELCORSO A, 1989, J BIOL CHEM, V264, P17653; GANDHI CR, 1979, INDIAN J EXP BIOL, V17, P585; GRUNEWALD RW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P39; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HORIUCHI S, 1994, GERONTOLOGY, V40, P10; IMANISHI H, 1985, MECH AGEING DEV, V32, P57, DOI 10.1016/0047-6374(85)90035-1; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953; LINDSTAD RI, 1993, FEBS LETT, V330, P31, DOI 10.1016/0014-5793(93)80913-F; LO TWC, 1994, J BIOL CHEM, V269, P32299; LOU MF, 1988, EXP EYE RES, V46, P517, DOI 10.1016/S0014-4835(88)80009-5; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MONNIER VM, 1990, ADV LIF SCI, P393; MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36; Monnier VM, 1989, MAILLARD REACTION AG, P410; MURAKAMI K, 1989, METABOLISM, V38, P753, DOI 10.1016/0026-0495(89)90061-9; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; NISHINO T, 1995, HUM PATHOL, V26, P308, DOI 10.1016/0046-8177(95)90063-2; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RATHBUN WB, 1991, EXP EYE RES, V53, P205, DOI 10.1016/0014-4835(91)90075-P; RILEY ML, 1995, BBA-MOL BASIS DIS, V1270, P36, DOI 10.1016/0925-4439(94)00069-3; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SATO K, 1994, J BIOCHEM-TOKYO, V116, P711, DOI 10.1093/oxfordjournals.jbchem.a124585; SELL DR, 1989, J BIOL CHEM, V264, P21597; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI M, 1995, BIOCHEMISTRY-US, V34, P1433, DOI 10.1021/bi00004a038; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VELISEK J, 1989, J FOOD SCI, V54, P1544, DOI 10.1111/j.1365-2621.1989.tb05155.x; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; YAN SD, 1994, J BIOL CHEM, V269, P9889	46	265	269	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19338	19345		10.1074/jbc.271.32.19338	http://dx.doi.org/10.1074/jbc.271.32.19338			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702619	hybrid			2022-12-27	WOS:A1996VB68400053
J	Patel, BKR; Wang, LM; Lee, CC; Taylor, WG; Pierce, JH; LaRochelle, WJ				Patel, BKR; Wang, LM; Lee, CC; Taylor, WG; Pierce, JH; LaRochelle, WJ			Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; SIMIAN SARCOMA-VIRUS; PROTEIN-TYROSINE KINASES; RECEPTOR GAMMA-CHAIN; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; CYTOKINE RECEPTORS; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ELEVATED LEVELS	Both platelet-derived growth factor (PDGF) and interleukin-4 (IL-4) play major roles in cell proliferation, differentiation, chemotaxis, and other functional responses, Here, we demonstrate that Stat6, previously shown to be activated by only IL-4 and IL-3, becomes activated after PDGF stimulation of NIH 3T3 fibroblasts, PDGF BB, and to a lesser extent PDGF AA, rapidly induced DNA binding activity from NIH 3T3 cell lysates utilizing the immunoglobulin heavy chain germ line a promoter (I epsilon) that specifically binds to StatG in an electrophoretic mobility shift assay. DNA binding activity could be detected within 5 min and reached maximum levels at approximately 20 min in parental NIH 3T3 cells, An identical mobility shift and time course of PDGF-mediated I epsilon binding activity was more pronounced in lysates of NIH 3T3 transfectants overexpressing human Stat6 (NIH 3T3-Stat6), The observed radiolabeled I epsilon mobility shift was competed by unlabeled I epsilon as well as by the beta-casein gene promoter but not by the interferon-alpha-stimulated response element or the interferon-gamma response region of the guanylate-binding protein gene, A StatG specific polyclonal antisera also supershifted the PDGF-induced I epsilon mobility shift, After PDGF BB treatment, a 100-kDa tyrosine phosphorylated species was detected in anti-Stat6 immunoprecipitates. Cycloheximide had little effect on Stat6 tyrosine phosphorylation, In addition to State, Stat5a, and Stat5b, PDGF BE also induced Jak1 tyrosine phosphorylation suggesting a potential pathway for Stat activation, Strikingly, the concurrent addition of IL-4 enhanced PDGF BE-induced I epsilon binding activity, Jak1 tyrosine phosphorylation, and [H-3]thymidine incorporation. These results provide evidence that State and Jak1 are common elements in PDGF and IL-4 signaling pathways and suggest that IL-4 could play a role in potentiating certain known PDGF-induced biological responses.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1995, TRENDS GENET, V11, P3951; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAPLAN MH, 1996, IMMUNITY, V4, P1; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NARAYANAN AS, 1983, J BIOL CHEM, V258, P1694; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; PAUL WE, 1991, BLOOD, V77, P1859; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22175	22182		10.1074/jbc.271.36.22175	http://dx.doi.org/10.1074/jbc.271.36.22175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703030	hybrid			2022-12-27	WOS:A1996VF61200072
J	Arrandale, JM; GoreWillse, A; Rocks, S; Ren, JM; Zhu, J; Davis, A; Livingston, JN; Rabin, DU				Arrandale, JM; GoreWillse, A; Rocks, S; Ren, JM; Zhu, J; Davis, A; Livingston, JN; Rabin, DU			Insulin signaling in mice expressing reduced levels of Syp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; RECEPTOR SUBSTRATE-1; RAT ADIPOCYTES; MAP KINASE; SH-PTP2; STIMULATION; ACTIVATION; DEPHOSPHORYLATION; PHOSPHORYLATION	Syp is a protein tyrosine phosphatase implicated in insulin and growth factor signaling. To evaluate the role of syp in insulin's regulation of plasma glucose, we generated knockout mice, Homozygous knockout mice die prior to day 10.5 of embryonic development. Hemizygous mice express half the levels of syp protein compared with their wild type littermates but do not display any gross morphological changes. Total body weight (age 2-10 weeks) and plasma insulin and glucose levels both in fasting and glucose-challenged states were comparable in the wild type and the hemizygous mice. No differences were observed in insulin-induced glucose uptake in soleus muscle and epididymal fat; insulin inhibition of lipolysis was also similar. We injected insulin into the portal vein of the mice to examine upstream events of the insulin signaling cascade. Tyrosine phosphorylation of insulin receptor and insulin receptor substrate-1 (IRS-1) from hemizygous tissue was similar to that of wild type tissue. Association of the p85 subunit of phosphatidylinositol 3-kinase to IRS-1 increased an average of a-fold in both groups, We did not observe an increase of IRS-1/syp association after insulin administration, but we did note a significant basal association in both wild type and hemizygous tissue, Our results do not support a major role for syp in the acute in, vivo meta belie actions of insulin.	BAYER CORP,DIV PHARMACEUT,METAB DISORDERS RES,WEST HAVEN,CT 06516	Bayer AG								AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HOGAN B, 1986, MANIPULATING MOUSE E, P153; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LIVINGSTON JN, 1984, ENDOCRINOLOGY, V115, P55, DOI 10.1210/endo-115-1-55; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOSS AM, 1993, BIOCHEM J, V294, P685, DOI 10.1042/bj2940685; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; REN JM, 1993, J BIOL CHEM, V268, P16113; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P19; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOOWARREN H, 1994, BIOCHEM BIOPH RES CO, V205, P347, DOI 10.1006/bbrc.1994.2671	32	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21353	21358		10.1074/jbc.271.35.21353	http://dx.doi.org/10.1074/jbc.271.35.21353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702915	hybrid			2022-12-27	WOS:A1996VE47700061
J	Beck, K; Boswell, BA; Ridgway, CC; Bachinger, HP				Beck, K; Boswell, BA; Ridgway, CC; Bachinger, HP			Triple helix formation of procollagen type I can occur at the rough endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; EMBRYO BLOOD-VESSELS; AIR-WATER-INTERFACE; THERMAL-STABILITY; PEPTIDE-BONDS; COLLAGEN; TENDON; ISOMERIZATION; SECRETION; PROTEINS	One key problem in understanding the biosynthesis of collagens remains the assembly of the three alpha-chains. How and when are the different gene products selected, aligned, and folded into a triple helix? As the spatial arrangement during biosynthesis might be important, we concentrated on whether the rough endoplasmic reticular membrane is involved in this process. Microsomes were prepared from biosynthetically labeled chick tendon fibroblasts. Vesicles were spread as a monomolecular film which was then transferred over several compartments of a filmbalance containing fresh subphase. Fluorograms of the surface film showed that the monolayer contains procollagen chains. When the monolayer was transferred onto a chymotrypsin/trypsin-containing subphase, the gel bands of the pro alpha-chains were shifted into the position of mature alpha-chains, indicating that only the propeptides were digested and the collagenous regions were protected due to triple helix formation. Our results suggest that newly synthesized pro alpha-chains can associate as trimers and fold into a triple helical conformation while they are still associated with the membranes of the rough endoplasmic reticulum. These processes also occur when interchain disulfide linkage is inhibited, indicating that chain selection and registration is not dependent on formation of covalent bonds among the carboxyl propeptides.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University	Beck, K (corresponding author), SHRINERS HOSP CHILDREN, RES UNIT, 3101 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.		Beck, Konrad/AAX-1351-2020	Beck, Konrad/0000-0001-5098-9484				Adam G., 1968, STRUCTURAL CHEM MOL, P198; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3085, DOI 10.1021/bi00308a036; BORNSTEIN P, 1967, BIOCHEMISTRY-US, V6, P3082, DOI 10.1021/bi00862a015; BORNSTEIN P, 1967, J BIOL CHEM, V242, P2572; BROWNELL AG, 1976, J BIOL CHEM, V251, P7137; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1975, P NATL ACAD SCI USA, V72, P3009, DOI 10.1073/pnas.72.8.3009; CHAPMAN D, 1982, TRENDS BIOCHEM SCI, V7, P67, DOI 10.1016/0968-0004(82)90080-9; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; DELPOZO AM, 1988, COLLAGEN REL RES, V8, P133; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J., 1987, ADV MEAT RES, V4, P145; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; FESSLER LI, 1975, P NATL ACAD SCI USA, V72, P4905, DOI 10.1073/pnas.72.12.4905; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; Gaines GL, 1966, INSOLUBLE MONOLAYERS; GREEN M, 1979, ARCH BIOCHEM BIOPHYS, V195, P368, DOI 10.1016/0003-9861(79)90362-X; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HU G, 1995, J CELL BIOCHEM, V59, P350, DOI 10.1002/jcb.240590307; JIMENEZ S, 1973, BIOCHEM BIOPH RES CO, V52, P106, DOI 10.1016/0006-291X(73)90960-1; JIMENEZ SA, 1978, J BIOL CHEM, V253, P1420; JUVA K, 1966, SCIENCE, V152, P92, DOI 10.1126/science.152.3718.92; KADLER K, 1995, PROTEIN PROFILE, V2, P491; KAO WWY, 1977, J BIOL CHEM, V252, P8391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKENS LN, 1976, J BIOL CHEM, V251, P3530; MARGOLIS RL, 1971, ARCH BIOCHEM BIOPHYS, V147, P612, DOI 10.1016/0003-9861(71)90419-X; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P88, DOI 10.1083/jcb.102.1.88; MORRIS NP, 1979, J BIOL CHEM, V254, P1024; MORRIS NP, 1975, J BIOL CHEM, V250, P5719; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; OLSON BR, 1991, CELL BIOL EXTRACELLU, P177; OZGUNES N, 1988, BIOCHEM MED METAB B, V40, P269, DOI 10.1016/0885-4505(88)90128-4; PEDERSEN BJ, 1994, CLIN CHEM, V40, P811; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; RABINOWI.JL, 1972, ARCH ORAL BIOL, V17, P547, DOI 10.1016/0003-9969(72)90070-2; Ramachandran G. N., 1976, BIOCH COLLAGEN; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SCHINDLER H, 1979, BIOCHIM BIOPHYS ACTA, V555, P316, DOI 10.1016/0005-2736(79)90171-8; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; SCHURHOLZ T, 1991, EUR BIOPHYS J BIOPHY, V20, P71; SMABY JM, 1985, BIOPHYS J, V48, P701, DOI 10.1016/S0006-3495(85)83828-5; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; Trurnit H.J., 1960, J COLLOID SCI, V15, P1, DOI [10.1016/0095-8522(60)90002-7, DOI 10.1016/0095-8522(60)90002-7]; TRURNIT HJ, 1945, FORT CHEM ORG NAT, V4, P347; VEIS A, 1989, J BIOL CHEM, V264, P3884; VEIS A, 1985, P NATL ACAD SCI USA, V82, P3693, DOI 10.1073/pnas.82.11.3693; VERGER R, 1976, CHEM PHYS LIPIDS, V16, P285, DOI 10.1016/0009-3084(76)90023-2; White D.A., 1973, FORM FUNCTION PHOSPH	66	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21566	21573		10.1074/jbc.271.35.21566	http://dx.doi.org/10.1074/jbc.271.35.21566			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702943	hybrid, Green Accepted			2022-12-27	WOS:A1996VE47700089
J	Henle, ES; Luo, YZ; Gassmann, W; Linn, S				Henle, ES; Luo, YZ; Gassmann, W; Linn, S			Oxidative damage to DNA constituents by iron-mediated Fenton reactions - The deoxyguanosine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; DEOXYRIBONUCLEIC-ACID; AQUEOUS-SOLUTION; 2'-DEOXYGUANOSINE; MECHANISM; BASES; DEGRADATION; NUCLEOTIDES; TOXICITY; PRODUCT	2'-Deoxyguanosine, 3'-dGMP, 5'-dGMP, d-GpG, or double-stranded DNA were exposed to H2O2 in the presence of Fe2+ under anaerobic conditions or under aerobic conditions in the presence of Fe3+, Fe2+, Fe2+/NADH, or Fe3+/NADH with and without ethanol. The products were enzymatically digested to nucleosides, separated by high performance liquid chromatography (HPLC), quantified, and characterized by HPLC retention time, radiolabeling, UV absorbance spectrometry, NMR, and mass spectrometry. 20 products, constituting 78-81% of the damage, were distinguished from aerobic reactions of Fe2+/H2O2 with dG and dGMP, 16 of which were identified. The product spectra from dG, 3'-dGMP, and 5'-dGMP differ from one another, and the spectrum of the 5' nucleoside of d-GpG differs from that of the 3' nucleoside, 7,8-Dihydro-8-oxo-2'-deoxyguanosine is the most abundant DNA-bound product aside from abasic sites, and its formation was more closely analyzed. Both NADH, which can reduce Fe3+, and ethanol, which can scavenge some free radicals, change the product profiles, Damage enhancement by NADH follows the sequence dG < d-GpG < 3'-dGMP < 5'-dGMP < DNA; the reverse sequence is observed for ethanol quenching, This sequence of susceptibility and the product differences seen for the 3' and 5' phosphate may reflect localization of iron and the damaging radicals upon the substrate.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Gassmann, Walter/0000-0002-7527-0385	NIEHS NIH HHS [T32ES070075] Funding Source: Medline; NIGMS NIH HHS [R29GM19020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM019020] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN SA, 1994, MUTAT RES, V306, P35, DOI 10.1016/0027-5107(94)90165-1; ARUOMA OI, 1989, J BIOL CHEM, V264, P13024; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; BEERS RF, 1952, J BIOL CHEM, V195, P133; BERGER M, 1985, Z NATURFORSCH B, V40, P1519; BUCHKO GW, 1993, INT J RADIAT BIOL, V63, P669, DOI 10.1080/09553009314552061; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P1; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GROVES JT, 1976, J AM CHEM SOC, V98, P5290, DOI 10.1021/ja00433a039; GUTMAN M, 1968, BIOCHEMISTRY-US, V7, P2778, DOI 10.1021/bi00848a012; HENNER WD, 1983, J BIOL CHEM, V258, P711; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; LANGFINGER D, 1985, Z NATURFORSCH C, V40, P446; LINN S, 1965, J BIOL CHEM, V240, P1287; LUO HZ, 1994, METHOD ENZYMOL, V234, P51; LUO Y, 1996, J BIOL CHEM, P21167; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MARRIAGI N, 1979, RADIAT RES, V79, P431; MCGALL GH, 1992, J AM CHEM SOC, V114, P4958, DOI 10.1021/ja00039a002; PEZZANO H, 1980, CHEM REV, V80, P365, DOI 10.1021/cr60327a001; RUSH JD, 1990, METHOD ENZYMOL, V186, P148; Sissoeff I, 1976, Prog Biophys Mol Biol, V31, P165; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; SUNDQUIST WI, 1991, NUCLEIC ACIDS MOL BI, V2, P1; Tan Z K, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P383; VANDEVORST A, 1978, EFFECTS IONIZING RAD, P3; VONSOUNTAG C, 1987, CHEM BASIS RAD BIOL; WEINFELD M, 1989, NUCLEIC ACIDS RES, V17, P3735, DOI 10.1093/nar/17.10.3735; WINK DA, 1994, P NATL ACAD SCI USA, V91, P6604, DOI 10.1073/pnas.91.14.6604; YAMAZAKI I, 1990, J BIOL CHEM, V265, P13589	32	117	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21177	21186		10.1074/jbc.271.35.21177	http://dx.doi.org/10.1074/jbc.271.35.21177			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702888	hybrid			2022-12-27	WOS:A1996VE47700034
J	Lebendiker, M; Schuldiner, S				Lebendiker, M; Schuldiner, S			Identification of residues in the translocation pathway of EmrE, a multidrug antiporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; PROTEIN; CHANNEL; TRANSPORTER; BACTERIA; PERMEASE; SITE	EmrE is a small, 12-kDa, highly polyspecific antiporter, which exchanges hydrogen ions with aromatic cations such as methyl viologen. EmrE-mediated transport is inhibited by the sulfhydryl-reactive reagent 4-(chloromercuri)benzoic acid (PCMB) but not by a variety of other sulfhydryl reagents. This differential effect is due to the fact that the organic mercurial is a substrate of the transporter and can reach domains otherwise inaccessible to the different reagents. To find out which of the three cysteine residues in EmrE is reacting with PCMB, each was replaced with serine and it was shown that none of them is essential for transport activity, A protein completely devoid of Cys residues (CL) is also capable of substrate accumulation albeit at a slower rate. Mutated proteins in which only one of the native cysteines was left whereas the other changed to serine were also constructed. The use of these proteins demonstrated that two of the three Cys in EmrE, Cys-41 and Cys-95, but not Cys-39, react with PCMB. A related mercurial, 4-(chloromercuri)benzenesulfonic acid (PCMBS), is only a very poor inhibitor, probably because of the negative charge it bears. PCMBS reacts with EmrE in an asymmetric and unique way. It reacts with the mutant bearing a single Cys residue in position 95 (CL-C95) only when the reagent is present in the outside face of the membrane and with the mutant CL-C41 only when allowed to permeate to the cell interior; as expected, it does not react with the mutant protein bearing a single Cys at position 39 (CL-C39). It is concluded that PCMB permeates through the substrate pathway of EmrE and covalently reacts with the two exposed residues, Cys-95 and Cys-41, but not with Cys-39, located on the opposite face of the helix relative to residue 41. In addition, because of the asymmetric reactivity to PCMBS, an inhibitor that does not permeate through the protein, it is concluded that Cys-41 is closer to the cytoplasmic face than Cys-95. The results demonstrate the existence of a domain accessible only to substrates and provide a unique tool for studying the substrate permeation pathway of an ion-coupled transporter.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; CULOTTA E, 1994, SCIENCE, V264, P362, DOI 10.1126/science.8153617; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOX CF, 1965, P NATL ACAD SCI USA, V54, P891, DOI 10.1073/pnas.54.3.891; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	30	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21193	21199		10.1074/jbc.271.35.21193	http://dx.doi.org/10.1074/jbc.271.35.21193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702890	hybrid			2022-12-27	WOS:A1996VE47700036
J	Linder, M; Salovuori, I; Ruohonen, L; Teeri, TT				Linder, M; Salovuori, I; Ruohonen, L; Teeri, TT			Characterization of a double cellulose-binding domain - Synergistic high affinity binding to crystalline cellulose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REESEI CELLOBIOHYDROLASE-I; NUCLEAR-MAGNETIC-RESONANCE; TRICHODERMA-REESEI; ESCHERICHIA-COLI; ADSORPTION; FIMI	Most cellulose-degrading enzymes have a two-domain structure that consists of a catalytic and a cellulose-binding domain (CBD) connected by a linker region. The linkage and the interactions of the two domains represent one of the key questions for the understanding of the function of these enzymes. The CBDs of fungal cellulases are small peptides folding into a rigid, disulfide-stabilized structure that has a distinct cellulose binding face. Here we describe properties of a recombinant double CBD, constructed by fusing the CBDs of two trichoderma reesei cellobiohydrolases via a linker peptide similar to the natural cellulase linkers. After expression in Escherichia coli, the protein was purified from the culture medium by reversed phase chromatography and the individual domains obtained by trypsin digestion. Binding of the double CBD and its single CBD components was investigated on different types of cellulose substrates as well as chitin. Under saturating conditions, nearly 20 mu mol/g of the double CBD was bound onto microcrystalline cellulose. The double CBD exhibited much higher affinity on cellulose than either of the single CBDs, indicating an interplay between the two components. A two-step model is proposed to explain the binding behavior of the double CBD. A similar interplay between the domains the the native enzyme is suggested for its binding to cellulase.			Linder, M (corresponding author), VTT BIOTECHNOL & FOOD RES, BOX 1500, FIN-02044 ESPOO, FINLAND.		Linder, Markus/N-8043-2019; Teeri, Tuula T/E-7509-2013; Linder, Markus B/E-5879-2011	Linder, Markus/0000-0002-7271-6441; Linder, Markus B/0000-0002-7271-6441				ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; AHO S, 1991, EUR J BIOCHEM, V200, P643, DOI 10.1111/j.1432-1033.1991.tb16227.x; BELSHAW NJ, 1993, EUR J BIOCHEM, V211, P717, DOI 10.1111/j.1432-1033.1993.tb17601.x; BLACKWELL J, 1988, METHOD ENZYMOL, V161, P435; Cantor C.R, 1980, BIOPHYSICAL CHEM 3, P874; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; EK R, 1994, INT J PHARM, V111, P43, DOI 10.1016/0378-5173(94)90400-6; GILKES NR, 1992, J BIOL CHEM, V267, P6743; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JOHANSSON G, 1989, FEBS LETT, V243, P389, DOI 10.1016/0014-5793(89)80168-1; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LINDER M, 1995, FEBS LETT, V372, P96, DOI 10.1016/0014-5793(95)00961-8; NEVALAINEN H, 1995, MYCOTA, V2, P303; ONG E, 1993, BIOTECHNOL BIOENG, V42, P401, DOI 10.1002/bit.260420402; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; REINIKAINEN T, 1992, PROTEINS, V14, P475, DOI 10.1002/prot.340140408; REINIKAINEN T, 1995, PROTEINS, V22, P392, DOI 10.1002/prot.340220409; REINIKAINEN T, 1996, IN PRESS ENZYME MICR; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNELLMANN J, 1994, MOL MICROBIOL, V13, P807, DOI 10.1111/j.1365-2958.1994.tb00473.x; SHOEMAKER S, 1983, BIO-TECHNOL, V1, P691, DOI 10.1038/nbt1083-691; SRISODSUK M, 1993, J BIOL CHEM, V268, P20756; STAHLBERG J, 1991, BIO-TECHNOL, V9, P286, DOI 10.1038/nbt0391-286; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TEERI TT, 1983, BIOTECHNOLOGY, V1, P670; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; TOMME P, 1995, J BACTERIOL, V177, P4356, DOI 10.1128/jb.177.15.4356-4363.1995; VANTILBEURGH H, 1986, FEBS LETT, V204, P223, DOI 10.1016/0014-5793(86)80816-X; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	32	120	122	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21268	21272		10.1074/jbc.271.35.21268	http://dx.doi.org/10.1074/jbc.271.35.21268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702902	hybrid			2022-12-27	WOS:A1996VE47700048
J	Orth, K; ORourke, K; Salvesen, GS; Dixit, VM				Orth, K; ORourke, K; Salvesen, GS; Dixit, VM			Molecular ordering of apoptotic mammalian CED-S/ICE-like proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; CLEAVAGE; ENZYME	Apoptosis is executed by cysteine proteases belonging to the CED-3/ICE family, which, unlike other mammalian cysteine proteases, cleave their substrates following aspartate residues. Proteases belonging to this family exist in the cytosol as zymogens that require accurate processing at internal aspartate residues to generate the two-chain active enzymes. As such, CED-S/ICE family members are capable of activating each other in a manner analogous to the protease zymogens of the coagulation or complement cascades. At present, it is unknown whether such mutual processing exists in vivo, and if so whether it is sequential, implying an order to the death pathway. Using a cell-free apoptosis system, recombinant ICE proteases and both biochemical and morphological criteria, we demonstrate an ordering of the mammalian ICEs that are most related to the Caenorhabditis elegans death protease CED-3.	UNIV MICHIGAN,DEPT PATHOL,SCH MED,ANN ARBOR,MI 48109; BURNHAM INST,LA JOLLA,CA 92037	University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute			dixit, vishva m/A-4496-2012; Orth, Kim/AAV-4421-2021	dixit, vishva m/0000-0001-6983-0326; Orth, Kim/0000-0002-0678-7620	NCI NIH HHS [CA64803, CA68769] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064803, F32CA068769] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DUAN H, 1996, J BIOL CHEM, V271, P35013; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251	27	184	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20977	20980		10.1074/jbc.271.35.20977	http://dx.doi.org/10.1074/jbc.271.35.20977			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702858	hybrid			2022-12-27	WOS:A1996VE47700002
J	Ribeiro, CMP; Putney, JW				Ribeiro, CMP; Putney, JW			Differential effects of protein kinase C activation on calcium storage and capacitative calcium entry in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; PHORBOL ESTER; CA2+ ENTRY; ENDOPLASMIC-RETICULUM; CHEMOTACTIC PEPTIDE; RBL-2H3 CELLS; RECEPTOR; ASSOCIATION; PATHWAY; FIBROBLASTS	In NIH 3T3 cells, treatment with phorbol 12-myristate 13-acetate (PMA) reduced the release of Ca2+ by thapsigargin, but did not activate Ca2+ entry; Ca2+ influx was triggered after the residual pool was emptied by thapsigargin, and this Ca2+ influx was similar to that induced by thapsigargin in control cells. The effect of PMA was clue to decreased Ca2+ storage because 1) Ca2+ release by ionomycin was similarly affected by PMA, and in both control and PMA-treated cells, ionomycin did not release Ca2+ following thapsigargin treatment; 2) PMA reduced Ca-45(2+) accumulation; and 3) studies with Ca2+ indicator compartmentalized into the endoplasmic reticulum indicated that stored Ca2+ was reduced by PMA. Although PMA did not itself activate Ca2+ entry, PMA potentiated Ca2+ entry with low concentrations of cyclopiazonic acid. With a somewhat higher concentration of cyclopiazonic acid, PMA had no effect on calcium entry. Thus, protein kinase C has two apparent actions on calcium signaling in NIH 3T3 cells: 1) reduced intracellular Ca2+ storage capacity and 2) augmented calcium entry with submaximal intracellular Ca2+ pool depletion. These actions indicate a complex and potentially important role for the protein kinase C system in calcium homeostasis in this cell type.			Ribeiro, CMP (corresponding author), NIEHS,NATL INST HLTH,POB 12233,MAIL DROP 7-10,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Ribeiro, Carla Maria P/A-6955-2009	Putney, James W/0000-0002-3379-4789; 				BARANSKA J, 1995, CELL CALCIUM, V17, P207, DOI 10.1016/0143-4160(95)90035-7; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEDBERG KK, 1994, J CELL PHYSIOL, V158, P337, DOI 10.1002/jcp.1041580216; JAFFE LA, 1993, DEV BIOL, V156, P566, DOI 10.1006/dbio.1993.1103; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDON RE, 1994, AM J PHYSIOL, V266, pC1313, DOI 10.1152/ajpcell.1994.266.5.C1313; LUDOWYKE RI, 1994, CELL MOTIL CYTOSKEL, V29, P354, DOI 10.1002/cm.970290408; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1994, J BIOL CHEM, V269, P3963; Murphy CT, 1996, BIOCHEM J, V313, P83, DOI 10.1042/bj3130083; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; TORNQUIST K, 1993, BIOCHEM J, V290, P443; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21522	21528		10.1074/jbc.271.35.21522	http://dx.doi.org/10.1074/jbc.271.35.21522			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702937				2022-12-27	WOS:A1996VE47700083
J	Richardson, LV; Richardson, JP				Richardson, LV; Richardson, JP			Rho-dependent termination of transcription is governed primarily by the upstream Rho utilization (rut) sequences of a terminator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; LAMBDA-PR PROMOTER; CRO MESSENGER-RNA; PROTEIN-RHO; RELEASE; REGION; SITES; BACTERIOPHAGE-T7; INVITRO; SIGNAL	A Rho-dependent transcription terminator in Escherichia coli DNA consists of an upstream part for Rho utilization (rut) and the transcription stop point (tsp) region. To test the role of the tsp region variants of the coliphage lambda cro gene terminator, tR1, containing inserts of non-terminator sequences between its rot and tsp regions were tested for termination function. The results showed that termination occurred with high efficiency at multiple sites in each of the new sequences with the positions of the sites coinciding with transcriptional pause points in the insert sequence and that the efficiency of termination was not directly proportional to the extent of pausing at those points. Thus, in contrast to the rut sequences, which are relatively rare in DNA, many different sequence segments can function as a tsp region, Studies with isolated transcripts showed that a rat element and sequences 3' of the rut element were both needed to activate ATP hydrolysis by Rho factor with the degree of activation depending on the length and the specific sequence of the 3' segment, These results support models for Rho action in which ATP hydrolysis is coupled to interactions of Rho protein with RNA 3' of the rut region.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIAID NIH HHS [AI10142] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010142, R37AI010142] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CONE KC, 1983, J BIOL CHEM, V258, P1296; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLUPPI G, 1976, RNA POLYMERASE, P657; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1989, METHOD ENZYMOL, V183, P281; LAU LF, 1984, NUCLEIC ACIDS RES, V12, P1287, DOI 10.1093/nar/12.2.1287; LAU LF, 1983, J BIOL CHEM, V258, P9391; LAU LF, 1985, J BIOL CHEM, V260, P574; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SHIGESADA K, 1980, NUCLEIC ACIDS RES, V8, P3355, DOI 10.1093/nar/8.15.3355; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; ZALATAN F, 1993, J BIOL CHEM, V268, P17051; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	37	60	61	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21597	21603		10.1074/jbc.271.35.21597	http://dx.doi.org/10.1074/jbc.271.35.21597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702947	hybrid			2022-12-27	WOS:A1996VE47700093
J	Yuan, D; Ma, XG; Ma, J				Yuan, D; Ma, XG; Ma, J			Sequences outside the homeodomain of bicoid are required for protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; STEROID-HORMONE RECEPTORS; HOMEO DOMAIN PROTEIN; SINGLE AMINO-ACID; DROSOPHILA EMBRYO; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVATION; COOPERATIVE INTERACTIONS; POSITIVE CONTROL; RECOGNITION	The Drosophila morphogenetic protein Bicoid (Bcd) is required for the development of anterior structures of the embryo. Bcd, a homeodomain protein, is distributed as an anterior-to-posterior gradient ill the embryo. It stimulates the expression of the hunchback (hb) gene in the anterior half in an all-or-none fashion. We have recently shown that Bcd binds cooperatively to a hb enhancer element and proposed that cooperative DNA binding is facilitated by an interaction between Bcd molecules. In this report, we further analyze the interaction between Bcd molecules and define regions important for protein-protein interaction. We show that the homeodomain of Bcd alone fails to interact with another Bcd molecule efficiently. The protein sequence flanking either side of the homeodomain restores the protein-protein interaction function. Mutations in the homeodomain that affect DNA binding do not adversely affect the protein-protein interaction function, suggesting that the surfaces for DNA binding and protein-protein interaction are separable. Finally, we demonstrate that the homeodomain of Bcd alone, unlike the intact Bcd, fails to bind DNA cooperatively. These results further support the notion that cooperative DNA binding is facilitated by the interaction between Bcd molecules. They strongly suggest that protein-protein interaction is an important property of Bcd for its biological activities.	UNIV CINCINNATI,CHILDRENS HOSP RES FDN,COLL MED,DIV DEV BIOL,GRAD PROGRAM DEV BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Cincinnati			Ma, Jun/GLT-4809-2022	Ma, Jun/0000-0002-1609-3294				ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Driever W., 1992, TRANSCRIPTIONAL REGU, P1221; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Ma XG, 1996, DEVELOPMENT, V122, P1195; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maniatis T., 1982, MOL CLONING; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RICHARDFOY H, 1994, NATURE, V370, P417, DOI 10.1038/370417a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TREISMAN J, 1989, CELL, V59, P553; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	62	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21660	21665		10.1074/jbc.271.35.21660	http://dx.doi.org/10.1074/jbc.271.35.21660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702955	hybrid			2022-12-27	WOS:A1996VE47700101
J	Ahuja, SK; Murphy, PM				Ahuja, SK; Murphy, PM			The CXC chemokines growth-regulated oncogene (GRO) alpha, GRO beta, GRO gamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CHEMOTACTIC CYTOKINES; STIMULATORY ACTIVITY; A RECEPTOR; IL-8; BINDING; CHEMOATTRACTANT; IDENTIFICATION; LYMPHOTACTIN	Interleukin-8 (IL-8), growth-related oncogene (GRO) alpha, GRO beta, GRO gamma, neutrophil-activating peptide-2 (NAP-2), epithelial cell-derived neutrophil activating peptide-78 (ENA-78), and granulocyte chemoattractant protein-2 are potent neutrophil chemoattractants 40-90% identical in amino acid sequence that comprise a subgroup of human CXC chemokines defined by the conserved sequence motif glutamic acid-leucine-arginine (ELR). Two human chemotactic receptor subtypes for IL-8, named IL-8 receptors (IL8R) A and B, have been cloned. They are 78% identical in amino acid sequence, coexpressed in neutrophils, and distinguished by their different se selectivities for GRO alpha and NAP-2. Their selectivity for other ELR(+) CXC chemokines has not been previously reported. By measuring calcium flux in human embryonic kidney 293 cells transfected with plasmids encoding IL8RA or IL8RB, we have now defined receptor selectivity for GRO beta, GRO gamma, and ENA-78. The rank order of agonist potency, based on inspection of the mean effective concentration values (EC(50)), for IL8RB was GRO gamma (1 nM) > IL-8 (4 nM) similar to GRO alpha (5 nM) similar to GRO beta (4 nM) similar to NAP-2 (7 nM) > ENA-78 (11 nM), and for IL8RA was IL-8 (4 nM) >>> ENA-78 (40 nM) similar to NAP-2 (45 nM) > GRO alpha (63 nM) similar to GRO gamma (65 nM) >> GRO beta. The maximal response of IL8RA to IL-8 was at least a-fold greater than the other five chemokines. All six agonists for IL8RB competed for high affinity I-125-IL-8, -GRO alpha NAP-2, and -ENA-78 binding sites at IL8RB. GRO alpha, GRO beta, GP gamma, NAP-2, and ENA-78 competed weakly for the high affinity IL-8 binding site at IL8RA. Thus, IL8RA and IL8RB are both highly selective for IL-8 and have similar sequences but differ dramatically in their selectivity for all other ELR(+) CXC chemokines tested. These findings have important implications for developing novel neutrophil-specific anti-inflammatory drugs directed against the CXC chemokine signaling system.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; AHUJA SK, 1994, J BIOL CHEM, V269, P26381; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BOZIC CR, 1994, J BIOL CHEM, V269, P29355; BROADDUS VC, 1994, J IMMUNOL, V152, P2960; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GEISER T, 1993, J BIOL CHEM, V268, P15419; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Kunkel SL, 1996, J LEUKOCYTE BIOL, V59, P6, DOI 10.1002/jlb.59.1.6; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; METCALF JA, 1986, LABORATORY MANUAL NE, P1; MOSER B, 1991, J BIOL CHEM, V266, P10666; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; PROOST P, 1993, J IMMUNOL, V150, P1000; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809	35	315	326	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20545	20550		10.1074/jbc.271.34.20545	http://dx.doi.org/10.1074/jbc.271.34.20545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702798	hybrid			2022-12-27	WOS:A1996VD33700050
J	Hardig, Y; Dahlback, B				Hardig, Y; Dahlback, B			The amino-terminal module of the C4b-binding protein beta-chain contains the protein S-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT; ENZYMATIC AMPLIFICATION; LIMITED PROTEOLYSIS; CLASSICAL PATHWAY; HUMAN-PLASMA; ULTRASTRUCTURE; PURIFICATION; POLYMERASE; CLONING; DNA	Human C4b-binding protein (C4BP) is composed of multiple alpha-chains associated with a single beta-chain, Each chain is composed of homologous, tandemly arranged repeats of so-called short consensus repeats (SCRs), We have previously shown that the three SCR modules of the beta-chain contain a high affinity binding site for anti-coagulant vitamin K-dependent protein S, On the basis of experiments using synthetic peptides, residues 31-45 of the amino-terminal SCR (SCR-1) in the beta-chain were suggested to be involved in protein S binding, but it is not known whether SCR-1 contains the entire protein S-binding site, To address this question, two different truncated forms of the beta-chain (beta 1,2 and beta 2,3) were expressed in a prokaryotic expression system. The beta 1,2 construct (SCR-1 + SCR-2) contained the high affinity binding site for protein S in contrast to beta 2,3 (SCR-2 + SCR-3), which did not bind protein S, Unfortunately, it was not possible to express SCR-1 alone in this system. To further elucidate whether the protein S-binding site is fully contained in SCR-1 or whether SCR-2 is also required, recombinant alpha/beta-chain chimeras were constructed, These chimeras were composed of alpha-chains with one, two, or three of the amino-terminal SCR modules replaced by the beta-chain counterpart and were expressed in a eukaryotic expression system, All recombinant variants were retained within the cells and could be extracted in biologically active forms, The three alpha/beta-chain chimeras bound protein S equally well, with a K-alpha of similar to 2.3 x 10(8) +/- 0.2 M(-1) as compared with 2.1 x 10(8) +/- 0.3 M(-1) for plasma-purified C4BP. These results show that the entire protein S-binding site on C4BP is contained within beta-chain SCR-1.	LUND UNIV,MALMO UNIV HOSP,DEPT CLIN CHEM,S-20502 MALMO,SWEDEN	Lund University; Skane University Hospital				Dahlback, Bjorn/0000-0003-1546-0328				BLOBEL GG, 1975, J CELL BIOL, V17, P835; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; FERNANDEZ JA, 1994, J BIOL CHEM, V269, P2535; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HARDIG Y, 1995, BIOCHEM J, V308, P795; HARDIG Y, 1993, J BIOL CHEM, V268, P3033; HILLARP A, 1987, J BIOL CHEM, V262, P11300; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; Maizel JV, 1971, METHOD VIROL, V5, P179; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Villoutreix BO, 1995, PROTEIN ENG, V8, P1253, DOI 10.1093/protein/8.12.1253; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	27	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20861	20867		10.1074/jbc.271.34.20861	http://dx.doi.org/10.1074/jbc.271.34.20861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702842	hybrid			2022-12-27	WOS:A1996VD33700094
J	Cully, DF; Paress, PS; Liu, KK; Schaeffer, JM; Arena, JP				Cully, DF; Paress, PS; Liu, KK; Schaeffer, JM; Arena, JP			Identification of a Drosophila melanogaster glutamate-gated chloride channel sensitive to the antiparasitic agent avermectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS RNA; LOCUST MUSCLE-FIBERS; XENOPUS-OOCYTES; INSECT MUSCLE; RECEPTORS; EXPRESSION; BINDING; ACID; MEMBRANE; SEQUENCE	Glutamate-gated chloride channels, members of the ligand-gated ion channel superfamily, have been shown in nematodes and in insects to be a target of the antiparasitic agent avermectin. Two subunits of the Caenorhabditis elegans glutamate-gated chloride channel have been cloned: GluCl-alpha and GluCl-beta. We report the cloning of a Drosophila melanogaster glutamate-gated chloride channel, DrosGluCl-alpha, which shares 48% amino acid and 60% nucleotide identity with the C. elegans GluCl channels. Expression of DrosGluCl-alpha in Xenopus oocytes produces a homomeric chloride channel that is gated by both glutamate and avermectin. The DrosGluCl-alpha channel has several unique characteristics not observed in C. elegans GluCl: dual gating by avermectin and glutamate, a rapidly desensitizing glutamate response, and a lack of potentiation of the glutamate response by avermectin. The pharmacological data support the hypothesis that the DrosGluCl-alpha channel represents the arthropod H-receptor and an important target for the avermectin class of insecticides.	MERCK RES LABS,DEPT CELLULAR BIOCHEM & PHYSIOL,RAHWAY,NJ 07065	Merck & Company	Cully, DF (corresponding author), MERCK RES LABS,DEPT MOL BIOL & GENET,POB 2000,RM 80M-213,RAHWAY,NJ 07065, USA.							ARENA JP, 1995, J PARASITOL, V81, P286, DOI 10.2307/3283936; ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; BERMUDEZ I, 1991, J RECEPTOR RES, V11, P221, DOI 10.3109/10799899109066401; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CLARK JM, 1995, ANNU REV ENTOMOL, V40, P1, DOI 10.1146/annurev.en.40.010195.000245; CLARK RB, 1979, BRIT J PHARMACOL, V66, P267, DOI 10.1111/j.1476-5381.1979.tb13675.x; CULLCANDY SG, 1973, NATURE-NEW BIOL, V246, P62, DOI 10.1038/newbio246062a0; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V255, P449, DOI 10.1113/jphysiol.1976.sp011289; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DELGADO R, 1989, FEBS LETT, V243, P337, DOI 10.1016/0014-5793(89)80157-7; DENG YL, 1992, PESTIC BIOCHEM PHYS, V43, P116, DOI 10.1016/0048-3575(92)90025-U; DUCE IR, 1985, BRIT J PHARMACOL, V85, P395, DOI 10.1111/j.1476-5381.1985.tb08874.x; DUDEL J, 1989, BRAIN RES, V481, P215, DOI 10.1016/0006-8993(89)90796-8; FRASER SP, 1990, MOL BRAIN RES, V8, P331, DOI 10.1016/0169-328X(90)90047-H; GILES D, 1985, COMP BIOCHEM PHYS C, V80, P231, DOI 10.1016/0742-8413(85)90047-7; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HORSEMAN BG, 1988, NEUROSCI LETT, V85, P65, DOI 10.1016/0304-3940(88)90430-2; HUTTON ML, 1993, FEBS LETT, V326, P112, DOI 10.1016/0014-5793(93)81773-S; JAN LY, 1976, J PHYSIOL-LONDON, V262, P215, DOI 10.1113/jphysiol.1976.sp011593; LEA T J, 1973, Comparative and General Pharmacology, V4, P351, DOI 10.1016/0010-4035(73)90046-3; LEA T J, 1973, Comparative and General Pharmacology, V4, P333, DOI 10.1016/0010-4035(73)90045-1; LINGLE C, 1981, BRAIN RES, V212, P481, DOI 10.1016/0006-8993(81)90482-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOFIELD PR, 1989, FEBS LETT, V244, P361, DOI 10.1016/0014-5793(89)80563-0; SCOTT RH, 1985, PESTIC SCI, V16, P599, DOI 10.1002/ps.2780160605; WAFFORD KA, 1989, J EXP BIOL, V144, P449	28	212	229	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20187	20191		10.1074/jbc.271.33.20187	http://dx.doi.org/10.1074/jbc.271.33.20187			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702744	hybrid			2022-12-27	WOS:A1996VC66900086
J	Karlsson, A; Mesnildrey, S; Xu, YW; Morera, S; Janin, J; Veron, M				Karlsson, A; Mesnildrey, S; Xu, YW; Morera, S; Janin, J; Veron, M			Nucleoside diphosphate kinase - Investigation of the intersubunit contacts by site-directed mutagenesis and crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CRYSTAL-STRUCTURE; DICTYOSTELIUM-DISCOIDEUM; LETHAL INTERACTION; HEXAMERIC ENZYME; TUMOR-METASTASIS; ESCHERICHIA-COLI; ACTIVE-SITE; DROSOPHILA; RESOLUTION	NDP kinase from Dictyostelium was mutated by site-directed mutagenesis at positions indicated by structural data to be involved in the trimer interface. The mutants were substitutions at residue Pro-100 (P100S and P100G) and deletions of 1-5 residues at the C terminus. Single mutants yielded proteins that kept both activity and hexameric structure. However, they were severely affected in their stability toward temperature and urea denaturation. When the P100S mutation was combined with any of the C-terminal deletions, the enzyme lost most of its activity and dissociated into dimers. Crystallographic analysis of the P100S protein was performed at 2.6 Angstrom resolution. The x-ray structure showed no direct alteration of intersubunits contacts at residue 100, but an induced disruption of the interaction between Asp-115 and the C terminus of another subunit. The substitution of proline 100 to serine corresponds to the Killer-of-prune mutation in Drosophila. Consequences of the mutation are discussed in view of the structural and biochemical properties observed in the mutant Dictyostelium protein.	INST PASTEUR,UNITE REGULAT ENZYMAT ACT CELLULAIRES,CNRS,URA 1149,F-75724 PARIS 15,FRANCE; LAB ENZYMOL & BIOCHIM STRUCT,CNRS,UPR 9063,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Karlsson, Anna/E-7945-2018; Janin, Joel/I-2958-2012	Karlsson, Anna/0000-0001-6843-6685				ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; GIARTOSIO A, 1996, IN PRESS J BIOL CHEM; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; Inoue H, 1996, BIOCHEM BIOPH RES CO, V218, P887, DOI 10.1006/bbrc.1996.0158; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; Leslie AGW, 1986, PROTEIN CRYSTALLOGR, V18, P33; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; OHTSUKI K, 1984, BIOCHEM INT, V8, P715; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; POSTEL EH, 1996, IN PRESS P NATL ACAD; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STURTEVANT AH, 1956, GENETICS, V41, P118; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TIMMONS L, 1995, J BIOL CHEM, V270, P23021, DOI 10.1074/jbc.270.39.23021; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	36	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19928	19934		10.1074/jbc.271.33.19928	http://dx.doi.org/10.1074/jbc.271.33.19928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702707	hybrid			2022-12-27	WOS:A1996VC66900048
J	Wang, LH; MatijevicAleksic, N; Hsu, PW; Ruan, KH; Wu, KK; Kulmacz, RJ				Wang, LH; MatijevicAleksic, N; Hsu, PW; Ruan, KH; Wu, KK; Kulmacz, RJ			Identification of thromboxane A(2), synthase active site residues by molecular modeling-guided site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN STRUCTURES; OXYGEN ACTIVATION; MESSENGER-RNA; INSECT CELLS; EXPRESSION; CYTOCHROME-P-450; PROSTAGLANDIN; ACID; CDNA	Human thromboxane A(2) synthase (TXAS) exhibits spectral characteristics of cytochrome P450 but lacks monooxygenase activity, Its distinctive amino acid sequence makes TXAS the sole member of family 5 in the P450 superfamily. To better understand the structure-function relationship of this unusual P450, we have recently constructed a three-dimensional model for TXAS using P450(BM-3) as the template (Ruan, K.-H., Milfeld, K., Kulmacz, R. J., and Wu, K. K. (1994) Protein Eng. 7, 1345-1551) and have identified a potential active site region. The catalytic roles of several putative active site residues were evaluated using selectively mutated recombinant TXAS expressed in COS-1 cells. Mutation of Ala-408 to Glu or Arg-413 to Gly led to a complete loss of enzyme activity despite expression of mutant. protein levels equivalent to that of the wild-type TXAS. Mutation of Ala-408 to Gly or Leu retained the enzyme activity at levels of 30 or 40%, respectively. This suggests that Ala-408 provides a hydrophobic environment for substrate binding. Mutation of Arg-413 to Lys or Gln completely abolished the enzyme. activity, indicating that this residue is essential to catalytic activity and supports its identification as an active site residue. Mutation of Arg-410 to Gly or Glu-433 to Ala resulted in > 50% reduction in the enzyme activity without appreciably altering mutant protein expression, consistent with a more subtle effect of these residues on TXAS catalytic efficiency, Mutation of residues predicted to be involved in binding the heme prosthetic group, including the heme thiolate ligand Cys-480, Arg-478, Phe-127, and Asn-110, each markedly reduced the expressed protein level and abolished enzyme activity, This suggests that proper heme binding is important to synthesis or stability of recombinant TXAS. Mutation of ILe-346, which corresponds to P450(cam)-Thr-252, an essential amino acid involved in dioxygen bond scission, to Thr increased the enzymatic activity by 40%, suggesting that oxygen bond cleavage is not a rate-limiting step in thromboxane A(2) biosynthesis. The present results from site-directed mutagenesis support the overall structure of the TXAS active site predicted by homology modeling and have allowed refinement of the position of bound substrate.	UNIV TEXAS,SCH MED,DEPT INTERNAL MED,VASC BIOL RES CTR,HOUSTON,TX 77030	University of Texas System	Wang, LH (corresponding author), UNIV TEXAS,SCH MED,DIV HEMATOL,6431 FANNIN,HOUSTON,TX 77030, USA.		Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKINS PW, 1992, PHYSICAL CHEM, P115; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; CLAESSENS M, 1989, PROTEIN ENG, V2, P335, DOI 10.1093/protein/2.5.335; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HECKER M, 1987, EUR J BIOCHEM, V169, P563, DOI 10.1111/j.1432-1033.1987.tb13646.x; HECKER M, 1989, J BIOL CHEM, V264, P141; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OHASHI K, 1992, J BIOL CHEM, V267, P789; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUAN KH, 1993, J BIOL CHEM, V268, P19483; RUAN KH, 1994, PROTEIN ENG, V7, P1345, DOI 10.1093/protein/7.11.1345; RUAN KH, 1994, J BIOL CHEM, V269, P20938; SHEN RF, 1994, GENE, V140, P261, DOI 10.1016/0378-1119(94)90555-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; TONE Y, 1994, FEBS LETT, V340, P241, DOI 10.1016/0014-5793(94)80146-0; WANG LH, 1991, BIOCHEM BIOPH RES CO, V177, P286, DOI 10.1016/0006-291X(91)91980-Q; WANG LH, 1994, ARCH BIOCHEM BIOPHYS, V315, P273, DOI 10.1006/abbi.1994.1500; WU KK, 1981, J CLIN INVEST, V67, P1801, DOI 10.1172/JCI110221; XIA Z, 1993, BIOCHEM J, V295, P457, DOI 10.1042/bj2950457; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; ZHANG LQ, 1993, BIOCHEM BIOPH RES CO, V194, P741, DOI 10.1006/bbrc.1993.1884	36	36	36	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19970	19975		10.1074/jbc.271.33.19970	http://dx.doi.org/10.1074/jbc.271.33.19970			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702713	hybrid			2022-12-27	WOS:A1996VC66900054
J	Allen, PB; Wiedemann, LM				Allen, PB; Wiedemann, LM			An activating mutation in the ATP binding site of the ABL kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; HEMATOPOIETIC-CELL LINE; MURINE LEUKEMIA-VIRUS; C-ABL; TYROSINE KINASE; REGULATORY DOMAIN; TRANSFORMING ABILITY; CARBOXY TERMINUS; GENE-PRODUCTS; BCR SEQUENCES	A number of structural alterations have been shown to activate the leukemogenic potential of the ABL oncogene, but there is little understanding of the regulatory mechanisms that are subverted by such changes. We have used directed mutagenesis to examine a potential regulatory motif in cABL, which could directly influence ABL tyrosine kinase activity. A tyrosine to phenylalanine substitution within the ATP binding fold of the ABL kinase domain is sufficient to activate cABL enzymatic activity, and the mutant protein will alleviate growth factor dependence when expressed in the BA/F3 cell line. This growth promotion is dependent upon the structure of the amino terminus of the protein, and the ABL mutation will cooperate with certain BCR sequences in BCR/ABL fusion proteins to deregulate ABL kinase activity.	INST CANC RES, LEUKAEMIA RES FUND CTR, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				ABELSON HT, 1970, CANCER RES, V30, P2213; ALLEN PB, 1992, BAILLIERE CLIN HAEM, V5, P897, DOI 10.1016/S0950-3536(11)80051-X; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PENDERGAST AM, 1987, CHRONIC MYELOID LEUK, P1001; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981	56	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19585	19591		10.1074/jbc.271.32.19585	http://dx.doi.org/10.1074/jbc.271.32.19585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702653	hybrid			2022-12-27	WOS:A1996VB68400087
J	Dahmus, ME				Dahmus, ME			Reversible phosphorylation of the C-terminal domain of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR TFIIH; CDK-ACTIVATING KINASE; TATA-BINDING PROTEIN; DNA-REPAIR; NONPHOSPHORYLATED FORM; MAMMALIAN-CELLS; LARGEST SUBUNIT; CTD; HOLOENZYME; ELONGATION				Dahmus, ME (corresponding author), UNIV CALIF DAVIS,DIV BIOL SCI,SECT MOLEC & CELLULAR BIOL,DAVIS,CA 95616, USA.							ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; BUERMEYER AB, 1995, J BIOL CHEM, V270, P6798, DOI 10.1074/jbc.270.12.6798; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; KIM YJ, 1994, CELL, V77, P59; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P8624; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1993, J BIOL CHEM, V268, P80; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHANG J, 1991, J BIOL CHEM, V266, P2290	56	460	464	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19009	19012		10.1074/jbc.271.32.19009	http://dx.doi.org/10.1074/jbc.271.32.19009			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8759772	hybrid			2022-12-27	WOS:A1996VB68400001
J	Jiracek, J; Yiotakis, A; Vincent, B; Checler, F; Dive, V				Jiracek, J; Yiotakis, A; Vincent, B; Checler, F; Dive, V			Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ENZYME-INHIBITORS; PZ-PEPTIDASE; RAT-BRAIN; MICROSOMAL ENDOPEPTIDASE; PROCESSING PROPROTEINS; BACTERIAL COLLAGENASE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; SLOW-BINDING; PURIFICATION	A mew systematic approach, based on combinatorial chemistry of phosphinic peptides, is proposed for rapid development of highly potent and selective inhibitors of zinc metalloproteases. This strategy first evaluates the effects on the inhibitory potency and selectivity of the following parameters: 1) size of the phosphinic peptides, 2) position of the phosphinic bond in the sequence, and 3) the state (free or blocked) of the peptide extremities. After this selection step, the influence of the inhibitor sequence is analyzed in order to determine the identity of the residues that optimized both the potency and the selectivity, We demonstrate the efficiency of this novel approach in rapid identification of the first potent inhibitor of the mammalian zinc endopeptidase neurolysin (24-16), able to discriminate between this enzyme and the related zinc endopeptidase thimet oligopeptidase (24-15). The most potent and selective inhibitor developed in this study, Pro-LPhe Psi(PO2CH2)Gly-Pro, displays a K-i value of 4 nM for 24-16 and is 2000 times less potent on 24-15. The specific recognition of such a free phosphinic tetrapeptide by 24-16, as well as the unique specificity of the 24-16 S-2 and S-2' subsites for proline, unveiled by this study, are discussed ill terms of their possible significance for the function of this enzyme and its related zinc endopeptidase activities.	CENS,CEA,DEPT INGN & ETUD PROT,DSV,F-91191 GIF SUR YVETTE,FRANCE; UNIV ATHENS,ORGAN CHEM LAB,DEPT ORGAN CHEM,ZOGRAFOS 15771,ATHENS,GREECE; UNIV NICE,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; National & Kapodistrian University of Athens; UDICE-French Research Universities; Universite Cote d'Azur			Jiracek, Jiri/Y-6703-2019; Jiracek, Jiri/A-7124-2008; Checler, Frederic/C-1241-2009	Jiracek, Jiri/0000-0003-3848-2773; Jiracek, Jiri/0000-0003-3848-2773; Checler, Frederic/0000-0003-2098-1750; Vincent, Bruno/0000-0003-3876-2118				ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; ASWANIKUMAR S, 1975, BIOCHIM BIOPHYS ACTA, V384, P194, DOI 10.1016/0005-2744(75)90108-4; BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BARELLI H, 1991, NEUROCHEM LIFE SCI A, V10, P115; BARRETT AJ, 1989, BIOCHEM J, V261, P1047, DOI 10.1042/bj2611047; CAMPBELL DA, 1995, J AM CHEM SOC, V117, P5381, DOI 10.1021/ja00124a030; CHECLER F, 1986, J BIOL CHEM, V261, P1274; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; DAUCH P, 1991, BIOCHEM J, V280, P421, DOI 10.1042/bj2800421; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; GRECO WR, 1979, J BIOL CHEM, V254, P2104; GROBELNY D, 1989, BIOCHEMISTRY-US, V28, P4948, DOI 10.1021/bi00438a006; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; ITO A, 1987, CLIN CHIM ACTA, V170, P291, DOI 10.1016/0009-8981(87)90139-2; JIRACEK J, 1995, J BIOL CHEM, V270, P21701, DOI 10.1074/jbc.270.37.21701; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; MORALES TI, 1977, J BIOL CHEM, V252, P4855; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PETRILLO EW, 1983, PEPTIDES STRUCTURE F, P541; Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391; SAKYO K, 1983, J BIOCHEM, V94, P1913, DOI 10.1093/oxfordjournals.jbchem.a134545; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; Smith, 1989, DESIGN ENZYME INHIBI; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; TILSJAR U, 1990, ANAL BIOCHEM, V186, P112; TISLJAR U, 1990, BIOCHEM J, V267, P531, DOI 10.1042/bj2670531; VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x; WUNSH E, 1963, HOPPESEYLERS Z PHYSL, V349, P171; YIOTAKIS A, 1994, BIOCHEM J, V303, P323, DOI 10.1042/bj3030323; YIOTAKIS A, 1994, J MED CHEM, V37, P2713, DOI 10.1021/jm00043a011	36	86	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19606	19611		10.1074/jbc.271.32.19606	http://dx.doi.org/10.1074/jbc.271.32.19606			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702656	hybrid			2022-12-27	WOS:A1996VB68400090
J	Nakamura, N; Chin, H; Miyasaka, N; Miura, O				Nakamura, N; Chin, H; Miyasaka, N; Miura, O			An epidermal growth factor receptor Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTORS; PROTEIN-KINASE; BETA(C) CHAIN; ACTIVATION; INTERLEUKIN-3; ASSOCIATION; MITOGENESIS; EXPRESSION	The Jak family of tyrosine kinases and the Stat family of transcription factors have been implicated in transducing signals from the hematopoietic growth factor receptors. To explore the role played by a member of the Jak family, Jak2, in hematopoietic cell growth signaling, we constructed a chimeric cDNA coding for the Jak2 tyrosine kinase domain linked to the extracellular and transmembrane regions of the epidermal growth factor (EGF) receptor (EGFR) and expressed the chimera in an interleukin (IL)-3-dependent cell line, 32D. When deprived of IL-3, EGF prevented apoptosis of the transfected cells, induced dose dependent proliferation, and supported long-term growth. EGF stimulation of the transfectants induced dose-dependent tyrosine phosphorylation of the EGFR/Jak2 chimera and Stat5, which correlated with the EGF dose dependence of cell proliferation. On the other hand, EGF did not induce tyrosine phosphorylation of other factors implicated in cytokine receptor signaling, including the IL-3 receptor beta subunit, Jak kinases, Stat proteins other than Stat5, Shc, Syp, and mitogen-activated protein kinases. These results suggest that the activation of Jak2 may be sufficient for transducing a growth signal in hematopoietic cells by activating the Stat5 pathway or previously unidentified signaling pathways. In addition, because EGF induces homodimerization of the EGFR to activate its tyrosine kinase activity, the present study, which shows EGF-dependent activation of the EGFR/Jak2 chimera, implies that Jak2 may also become activated by homodimerization.	TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)				Miura, Osamu/0000-0002-0981-3054				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHNANG H, 1994, J BIOL CHEM, V269, P21411; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	42	74	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19483	19488		10.1074/jbc.271.32.19483	http://dx.doi.org/10.1074/jbc.271.32.19483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702638	hybrid			2022-12-27	WOS:A1996VB68400072
J	Vexler, ZS; Symons, M; Barber, DL				Vexler, ZS; Symons, M; Barber, DL			Activation of Na+-H+ exchange is necessary for RhoA-induced stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; BINDING PROTEIN; DICTYOSTELIUM-DISCOIDEUM; RAS TRANSFORMATION; HL-60 CELLS; ANTIPORTER; GROWTH; KINASE; FIBROBLASTS; DEPENDENCE	The ubiquitously expressed Na+-H+ exchanger isoform, NHE1, functions in regulating intracellular pH and cell volume, We recently determined that the GTPase G alpha 13 stimulates NHE1 activity through a RhoA-dependent mechanism (Hooley, R., Yu, C.-Y., Symons, M., and Barber, D. L. (1996) J. Biol. Chem. 271, 6152-6158). RhoA belongs to the Ras superfamily of GTPases and is a key regulator of actin stress fiber formation. We therefore investigated the relationship between RhoA, NHE1 activity, and the regulation of stress fiber assembly, Using two independent approaches, pharmacological inhibition of NHE1 and NHE1-deficient cells, we determined that the induction of stress fibers by lysophosphatidic acid and RhoA is dependent on increased NHE1 activity. These results indicate that stimulation of NHE1 acts downstream of RhoA in a pathway that controls stress fiber formation.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; ONYX PHARMACEUT,RICHMOND,CA 94806	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40259] Funding Source: Medline; NIGMS NIH HHS [GM 47413] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; HAZAV P, 1989, CANCER RES, V49, P72; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KITRAMURA K, 1995, AM J PHYSIOL, V268, pC101; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MALY K, 1989, J BIOL CHEM, V264, P11839; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHMIDT JM, 1993, BIOCHEM BIOPH RES CO, V197, P660, DOI 10.1006/bbrc.1993.2530; SCHWARTZ MA, 1990, J BIOL CHEM, V265, P1327; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	30	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22281	22284		10.1074/jbc.271.37.22281	http://dx.doi.org/10.1074/jbc.271.37.22281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798382	hybrid			2022-12-27	WOS:A1996VG67200001
J	Darmon, AJ; Bleackley, RC				Darmon, AJ; Bleackley, RC			An interleukin-1 beta converting enzyme-like protease is a key component of Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; GRANZYME-B; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; DNA FRAGMENTATION; INVOLVEMENT; HYBRIDOMAS; ENCODES	Cytotoxic T lymphocytes (CTLs) are able to kill target cells bearing foreign antigen through two distinct mechanisms: granule- and Fas-mediated cytotoxicity. The exact events involved in the induction of target cell apoptosis remain elusive, but research indicates a role for members of the interleukin-lp converting enzyme (ICE)/Ced-3 family of cysteine proteases, The exact nature of the protease(s) involved is yet to be determined. Here we use activity assays and peptide inhibitors of ICE/Ced-3 proteases to study their role in Fas-mediated killing. We find that while certain inhibitors block DNA fragmentation and chromium release, others do not. Most notably, potent inhibitors of CPP32 and ICE could not inhibit DNA fragmentation during all cases of Fas-mediated cytotoxicity although an ''ICE'' inhibitor could suppress Cr-51 release. Additionally, we find that CPP32 is not cleaved in all target cells during Fas killing. Although ICE activity (as measured by a fluorogenic substrate) is present in cell lysates from anti-Fas-treated cells, we found no pro-IL-1 beta-cleaving activity in these lysates. Taken together, our results suggest that an alternate pathway to DNA fragmentation exists, which does not involve CPP32 activity, and that CPP32 and ICE activities are not essential to Fas-mediated killing.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GARNER R, 1994, J IMMUNOL, V153, P5413; HELGASON CD, 1992, EUR J IMMUNOL, V22, P3187, DOI 10.1002/eji.1830221225; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2502, DOI 10.1073/pnas.78.4.2502; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Podack E R, 1995, Curr Top Microbiol Immunol, V198, P121; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21699	21702		10.1074/jbc.271.36.21699	http://dx.doi.org/10.1074/jbc.271.36.21699			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702962	hybrid			2022-12-27	WOS:A1996VF61200004
J	Hayashida, W; Horiuchi, M; Dzau, VJ				Hayashida, W; Horiuchi, M; Dzau, VJ			Intracellular third loop domain of angiotensin II type-2 receptor - Role in mediating signal transduction and cellular function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SMOOTH-MUSCLE CELLS; G-PROTEIN; CYTOPLASMIC DOMAINS; TRANSCRIPTION FACTOR; MAP KINASE; INHIBITION; EXPRESSION; PHOSPHATASE; CLONING	The present study tests the hypothesis that the unique intracellular third loop domain of angiotensin II type-2 (AT2) receptor is essential for the subsequent intracellular signaling and plays an important role in mediating receptor function, Synthetic intracellular third loop peptide of the AT2 receptor (AT2-3LP, 22 amino acids) and control peptide consisting of the same amino acid composition in random sequence were delivered into adult rat aortic vascular smooth muscle cells by cationic liposome-mediated transfection. Successful intracellular peptide delivery was confirmed by microscopic localization of the fluorescein-labeled AT2-3LP within the cells and also by co-immunoprecipitation of the I-125-labeled 3LP complexed with G(i) protein using anti-G(i) alpha antibody. The AT2-3LP-transfected cells showed reduction of serum-stimulated DNA synthesis and cell proliferation as well as a decrease in mitogen-activated protein kinase activity, simulating the effects of AT2 receptor stimulation. The antagonistic effect of the AT2-3LP on mitogen-activated protein kinase activity and DNA synthesis were reversed by pertussis toxin and sodium orthovanadate. Thus, our data suggest that the intracellular third loop domain of the AT2 receptor is closely linked with the cellular signaling pathways of vascular smooth muscle cells in which G(i) and protein-phosphotyrosine phosphatase are involved, resulting in the alteration of mitogen-activated protein kinase activity and in growth inhibition.	STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035252, R01HL035610, R37HL035610, R01HL046631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35252, HL46631, HL35610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; ELLWART J, 1985, CYTOMETRY, V6, P513, DOI 10.1002/cyto.990060605; FLOIO T, 1992, J BIOL CHEM, V267, P24169; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; HAWES BE, 1994, J BIOL CHEM, V269, P15776; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1995, AM J PHYSIOL-CELL PH, V268, pC278, DOI 10.1152/ajpcell.1995.268.1.C278; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; LIN MF, 1993, BIOCHEM BIOPH RES CO, V192, P413, DOI 10.1006/bbrc.1993.1431; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; SADOSHIMA J, 1995, CIRC RES, V76, P1; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZHANG JS, 1995, HYPERTENSION, V26, P567	35	94	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21985	21992		10.1074/jbc.271.36.21985	http://dx.doi.org/10.1074/jbc.271.36.21985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703004				2022-12-27	WOS:A1996VF61200046
J	Knofler, M; Krapp, A; Hagenbuchle, O; Wellauer, PK				Knofler, M; Krapp, A; Hagenbuchle, O; Wellauer, PK			Constitutive expression of the gene for the cell-specific p48 DNA-binding subunit of pancreas transcription factor 1 in cultured cells is under control of binding sites for transcription factors Sp1 and alpha Cbf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PTF1; DIFFERENTIAL EXPRESSION; INSULIN GENE; FORK-HEAD; PROMOTER; FAMILY; MYOD; RECOGNITION; DROSOPHILA; PROTEINS	We have cloned and characterized the rat gene that encodes the p48 DNA-binding subunit of pancreas transcription factor 1 (Ptf1), a cell-specific basic region helix-loop-helix (bHLH) protein, The ptf1-p48 gene measures 1.8 kilobases in size and occurs as a single copy in the haploid genome. Run-on transcription assays suggest that this gene is subject to transcriptional control since no activity of its promoter is detected in nonproducing cells. The gene specifies two mRNAs that encode the same protein and originate from transcription initiation at alternative sites. Expression analysis of hybrid genes bearing deletions of the gene's 5'-flanking region fused to a reporter gene defines a promoter region within the gene-proximal 260 base pairs of DNA. The cis-acting elements that control promoter activity include binding sites for transcription factors Sp1 and alpha Cbf, a 60-kDa CCAAT box-binding protein. The gene promoter, however, functions not only in exocrine pancreatic cells but also in cells of other origin. No cell-specific transcriptional control element was detected in as much as 10 kilobases of 5'-flanking region. We discuss models of how the cell-specific expression of the endogenous ptf1-p48 gene might be established during development of the animal.	SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research								BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GROUDINE M, 1982, CELL, V30, P131, DOI 10.1016/0092-8674(82)90019-8; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HAGENBUCHLE O, 1984, CELL, V38, P737, DOI 10.1016/0092-8674(84)90269-1; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; KRAPP A, 1996, IN PRESS EMBO J, V15; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PETRUCCO S, 1990, MOL CELL BIOL, V10, P254, DOI 10.1128/MCB.10.1.254; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WELLAUER PK, 1977, CELL, V10, P193, DOI 10.1016/0092-8674(77)90214-8; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0	47	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21993	22002						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703005				2022-12-27	WOS:A1996VF61200047
J	Ludlow, LB; Schick, BP; Budarf, ML; Driscoll, DA; Zackai, EH; Cohen, A; Konkle, BA				Ludlow, LB; Schick, BP; Budarf, ML; Driscoll, DA; Zackai, EH; Cohen, A; Konkle, BA			Identification of a mutation in a GATA binding site of the platelet glycoprotein Ib beta promoter resulting in the Bernard-Soulier Syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LEUCINE-RICH REPEAT; GPIB-BETA; CHROMOSOMAL REGION; POINT MUTATION; IX COMPLEX; CELL-LINE; GENE; ALPHA; EXPRESSION	Bernard-Soulier Syndrome (BSS) is a rare congenital bleeding disorder due to absent or decreased expression of the glycoprotein Ib-IX-V (GpIb-IX-V) receptor complex on the platelet surface. To date, only mutations in GpIb alpha or GpIX have been reported in patients with BSS. GpIb beta differs from the other proteins in this receptor in that the gene is more complex, and an alternative form is expressed in cells of non-megakaryocytic lineage, including endothelial cells. It appears that the megakaryocytic and endothelial cell mRNA species are transcribed from different start sites and have different proximal promoter regions. We have identified a patient with ESS who has a deletion on one chromosome 22, resulting in velocardiofacial syndrome. The GpIb beta gene has been mapped to this deleted (22q11.2) region of chromosome 22. The patient has greatly reduced levels of GpIb beta mRNA and no detectable platelet GpIb beta protein, suggesting that his BSS results from a mutation in his remaining GpIb beta allele. Sequence analysis revealed that the coding region of GpIb beta is normal, but the 5'-upstream region contains a C to G transversion at base -133 from the transcription start site used in megakaryocytes. The mutation changes a GATA consensus binding site, disrupts GATA-1 binding to the mutated site, and decreases promoter activity by 84%. Thus, in this patient, Bernard-Soulier syndrome results from a deletion of one copy of GpIb beta and a mutated GATA binding site in the promoter of the remaining allele, resulting in decreased promoter function and GpIb beta gene transcription.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOL BIOL,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA 19104	Jefferson University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Konkle, Barbara A/AAD-7712-2022; Konkle, Barbara/GPX-3325-2022	Konkle, Barbara A/0000-0002-3959-8797; 	NHLBI NIH HHS [HL51533, HL44956] Funding Source: Medline; NIDCD NIH HHS [DC02027] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044956, P50HL051533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC002027] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BASTIAN LS, 1994, BLOOD, V84, pA471; BLOCK KL, 1994, BLOOD, V84, P3385; BUDARF ML, 1995, HUM MOL GENET, V4, P763, DOI 10.1093/hmg/4.4.763; CLEMETSON JM, 1994, BLOOD, V84, P1124; DELASALLE C, 1995, BRIT J HAEMATOL, V89, P386, DOI 10.1111/j.1365-2141.1995.tb03316.x; DEMARCO L, 1986, ACTA HAEMATOL-BASEL, V75, P203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DA, 1993, J MED GENET, V30, P813, DOI 10.1136/jmg.30.10.813; Emanuel Beverly S., 1993, V384, P207; FUGMAN DA, 1990, BLOOD, V75, P1252; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GOLDMUNTZ E, 1993, J MED GENET, V30, P807, DOI 10.1136/jmg.30.10.807; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; KELLY MD, 1994, J CLIN INVEST, V93, P2417, DOI 10.1172/JCI117249; KONKLE BA, 1994, BLOOD S, V84, P319; KUNISHIMA S, 1994, BLOOD, V84, P3356; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MILLER JL, 1992, BLOOD, V79, P439; NARAYANAN R, 1986, BIOCHEM BIOPH RES CO, V141, P1018, DOI 10.1016/S0006-291X(86)80146-2; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; SIMESK S, 1994, THROMB HAEMOSTASIS, V72, P444; SIMESK S, 1994, BRIT J HAEMATOL, V88, P839; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; UZAN G, 1991, J BIOL CHEM, V266, P8932; VIEILLEGROSJEAN I, 1995, J BIOL CHEM, V270, P4544, DOI 10.1074/jbc.270.9.4544; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WARE J, 1990, P NATL ACAD SCI USA, V87, P2026, DOI 10.1073/pnas.87.5.2026; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WRIGHT SD, 1993, BLOOD, V81, P2339; YAGI M, 1994, J BIOL CHEM, V269, P17424	37	117	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22076	22080		10.1074/jbc.271.36.22076	http://dx.doi.org/10.1074/jbc.271.36.22076			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703016	hybrid			2022-12-27	WOS:A1996VF61200058
J	Wang, HY; Johnson, GL; Liu, XX; Malbon, CC				Wang, HY; Johnson, GL; Liu, XX; Malbon, CC			Repression of adipogenesis by adenylyl cyclase stimulatory G-protein alpha subunit is expressed within region 146-220	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL LINE; NEOPLASTIC TRANSFORMATION; 3T3 CELLS; DIFFERENTIATION; MUTANT; FIBROBLASTS; ACTIVATION; CONVERSION; ADIPOCYTES; CULTURE	The heterotrimeric G-protein alpha subunit stimulatory with respect to adenylyl cyclase (G(s alpha)) represses adipogenesis of 3T3-L1 mouse embryonic fibroblasts. Derepression occurs in response to inducers, to oligodeoxynucleotides antisense to G(s alpha), and to overexpression of heterotrimeric G-protein alpha subunit 2, inhibitory with respect to adenylyl cyclase (G(i alpha 2)). Constitutive expression of G(s alpha) blocks adipogenesis and was exploited as an assay, in which chimeras of G(i alpha 2) and G(s alpha) were expressed stably in 3T3-L1 cells to define the region controlling adipogenesis. N-terminal analysis revealed region 146-220 of G(s alpha) as a repressor of adipogenesis; substitution of G(i alpha 2) abolished the ability of the chimera to repress adipogenesis in response to inducers. Expression of a chimera in which the 146-235 region of G(s alpha) was embedded in G(i alpha 2) fully repressed adipogenesis in response to the inducers. C-terminal analysis revealed no loss of function for truncated G(s alpha), lacking the terminal 38 residues. The repressor domain for adipogenesis maps to a region that includes switch domains I and II and is spatially distinct from the regions mapped for control of adenylyl cyclase.	SUNY STONY BROOK, UNIV MED CTR, DIABET & METAB DIS RES PROGRAM, DEPT MOL PHARMACOL, STONY BROOK, NY 11794 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT BASIC SCI, DENVER, CO 80206 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; National Jewish Health	Wang, HY (corresponding author), SUNY STONY BROOK, UNIV MED CTR, DEPT PHYS & BIOPHYS, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1996, INT J OBESITY, V20, pS26; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WATKINS DC, 1989, J BIOL CHEM, V264, P4186; WONG YH, 1995, ONCOGENE, V10, P1927	28	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22022	22029		10.1074/jbc.271.36.22022	http://dx.doi.org/10.1074/jbc.271.36.22022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703008				2022-12-27	WOS:A1996VF61200050
J	Arselin, G; Vaillier, J; Graves, PV; Velours, J				Arselin, G; Vaillier, J; Graves, PV; Velours, J			ATP synthase of yeast mitochondria - Isolation of the subunit h and disruption of the ATP14 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL GENE; ADENOSINE-TRIPHOSPHATASE; MEMBRANE SYSTEM; PURIFICATION; F1-ATPASE; PROTEINS; COMPLEX	A new subunit of the yeast ATP synthase (termed subunit h) has been isolated. Amino acid composition and N-terminal sequencing were determined by chemical methods. These data were in agreement with the sequence of the hypothetical protein L8003.20 whose primary structure was deduced from DNA sequencing of the yeast chromosome XII. The amino acid sequence encoded by ATP14 gene is 32 amino acids longer than the mature protein, which contains 92 amino acids corresponding to a calculated mass of 10,408 Da. The protein is hydrophilic and acidic with a calculated pH(i) of 4.08. It is not apparently related to any subunit described in other ATP synthases. A null mutant was constructed. The mutation was recessive and the mutant strain was unable to grow on glycerol medium. A high percentage of rho(-) cells arose spontaneously. The mutant mitochondria had no detectable oligomycin-sensitive ATPase activity, but still contained ATPase activity with a catalytic sector dissociated from the membranous components. The mutant mitochondria did not contain subunit h, and the mitochondrially encoded hydrophobic subunit 6 was not present.	UNIV BORDEAUX 2,INST BIOCH & GENET CELLULAIRES,CNRS,F-33077 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								ANSORGE W, 1983, ELECTROPHORESIS 82, P235; ARSELIN G, 1991, J BIOL CHEM, V266, P723; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; DELEAGE G, 1988, COMPUT APPL BIOSCI, V4, P351; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; ENNS RK, 1977, ARCH BIOCHEM BIOPHYS, V182, P587, DOI 10.1016/0003-9861(77)90540-9; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LANG B, 1977, ANAL BIOCHEM, V77, P110, DOI 10.1016/0003-2697(77)90295-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; Maniatis T., 1982, MOL CLONING; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; NORAIS N, 1991, J BIOL CHEM, V266, P16541; PAUL MF, 1992, EUR J BIOCHEM, V205, P163, DOI 10.1111/j.1432-1033.1992.tb16764.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PAUL MF, 1994, J BIOL CHEM, V269, P26158; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALTZGABERMULLER J, 1983, J BIOL CHEM, V258, P1465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SIERRA MF, 1973, P NATL ACAD SCI USA, V70, P3155, DOI 10.1073/pnas.70.11.3155; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; UH M, 1990, J BIOL CHEM, V265, P19047; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; VELOURS J, 1987, EUR J BIOCHEM, V164, P579, DOI 10.1111/j.1432-1033.1987.tb11166.x; VELOURS J, 1984, EMBO J, V3, P207, DOI 10.1002/j.1460-2075.1984.tb01785.x; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007	39	82	86	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20284	20290		10.1074/jbc.271.34.20284	http://dx.doi.org/10.1074/jbc.271.34.20284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702761	hybrid			2022-12-27	WOS:A1996VD33700013
J	Liu, CL; Hart, RP; Liu, XJ; Clevenger, W; Maki, RA; DeSouza, EB				Liu, CL; Hart, RP; Liu, XJ; Clevenger, W; Maki, RA; DeSouza, EB			Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; B-CELLS; EXPRESSION	Two types of interleukin (IL)-1 receptors with three extracellular immunoglobulin-like domains, limited homology (28%), and different pharmacological characteristics termed type I and type II have been cloned from mouse and human cell lines. Both receptors exist in transmembrane and soluble forms; the soluble IL-1 receptor is thought to be post-translationally derived from cleavage of the extracellular portion of the membrane receptors. In preliminary cross-linking studies with radiolabeled IL-1, we found that monkey kidney COS1 cells express a soluble receptor with molecular mass of similar to 55-60 kDa, which is different from previously reported soluble IL-1 receptors. This soluble IL-1 receptor protein from COS1 cells was purified to homogeneity by affinity chromatography using recombinant IL-1 beta as the ligand and shown to have an affinity for human I-125-IL-1 beta (K-D similar to 2-3 nM) comparable to the human type II IL-1 receptor (IL-1RII). The purified protein was microsequenced, and the sequence information was used to design primers to clone the COS1 IL-1RII using reverse transcription-coupled polymerase chain reaction; the DNA comparison with monkey COS1 and human IL-1RII indicate that they are 95% identical at the nucleic acid and amino acid levels. In addition, another cDNA, which represents an alternatively processed mRNA of the IL-1RII gene, was also cloned both from monkey COS1 and human Raji cells and was shown to have similar to 95% sequence identity between these species, While the cDNA of the novel alternatively processed gene has a 5' end identical to the IL-1RII, the 200 base pairs at the 3' end are different and the sequence predicts a soluble IL-1 receptor protein of 296 amino acids, Radioligand binding studies of the alternatively processed IL-1RII mRNA demonstrated kinetic and pharmacological characteristics similar to the known type II IL-1 receptor, COS7 cells (which lack IL-1 receptor) transfected with the transmembrane form of the human IL-1RII cDNA showed I-125-IL-1 beta binding in both the membrane fractions and supernatant, In contrast, COS7 cells transfected with the alternatively processed human IL-1RII cDNA showed high affinity I-125-IL-1 beta binding (K-i similar to 1.2 nM) predominantly in the supernatant; a very small amount of detectable membrane IL-1 binding activity was also observed presumably due to association of the soluble IL-1 receptor and membrane-integrated proteins. In cross-linking and ligand blot studies, the alternatively processed human IL-1RII cDNA-transfected COS7 cells expressed a soluble IL-1 receptor with molecular masses ranging from 60 to 160 kDa, further indicating the association between this soluble IL-1 receptor and other soluble proteins, In summary, we report the purification and characterization of a soluble IL-1 receptor expressed by COS1 cells and the cloning of an alternatively processed type II IL-1 receptor mRNA from both human and COS1 cells, The alternative splicing of a primary transcript leading to a secreted protein provides a potentially important mechanism by which soluble IL-1RII can be produced.	NEUROCRINE BIOSCI INC,SAN DIEGO,CA 92121; RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102	Neurocrine Biosciences; Rutgers State University Newark; Rutgers State University New Brunswick			Hart, Ronald P/D-5219-2009; Hart, Ronald P/G-6530-2019	Hart, Ronald P/0000-0003-4836-8712; Hart, Ronald P/0000-0003-4836-8712	NIMH NIH HHS [MH 00855, MH 51568] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051568] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DINARELLO CA, 1991, BLOOD, V77, P1627; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; LIU C, 1996, IN PRESS NEUROIMMUNO; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; Sambrook J., 2002, MOL CLONING LAB MANU; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SVENSON M, 1993, CYTOKINE, V5, P427, DOI 10.1016/1043-4666(93)90032-Z; TAKAO T, 1993, ENDOCRINOLOGY, V132, P1497, DOI 10.1210/en.132.4.1497	18	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20965	20972		10.1074/jbc.271.34.20965	http://dx.doi.org/10.1074/jbc.271.34.20965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702856	hybrid			2022-12-27	WOS:A1996VD33700108
J	Mould, AP; Akiyama, SK; Humphries, MJ				Mould, AP; Akiyama, SK; Humphries, MJ			The inhibitory anti-beta 1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy - Evidence for allosteric inhibition of integrin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; SITE-DIRECTED MUTAGENESIS; HUMAN-PLASMA FIBRONECTIN; LEUKOCYTE INTEGRINS; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; DIVALENT-CATIONS; ACTIVATION; ALPHA-5-BETA-1; IDENTIFICATION	Integrin-ligand binding causes conformational changes in the integrin, as evidenced by the increased expression of epitopes known as ligand-induced binding sites. Some monoclonal antibodies (mAbs) that recognize ligand-induced binding sites stimulate ligand binding, possibly by stabilizing the ligand-occupied conformation of the integrin. Here we have investigated the effect of ligand recognition by alpha 5 beta 1 on the binding of a mAb that inhibits beta 1 integrin function (mAb 13). Ligand (fibronectin fragment or GRGDS peptide) decreased the binding of mAb 13 to alpha 5 beta 1. Analysis of this inhibition showed that at high ligand concentrations, approximately 50% of the total integrin bound mAb 13 with >50-fold lower affinity than in the absence of ligand. The concentration of ligand required for half-maximal inhibition of antibody binding was independent of antibody concentration, suggesting that ligand acts as an allosteric inhibitor of mAb 13 binding. Hence, ligand and mAb 13 did not appear to compete directly for binding to alpha 5 beta 1. The stimulatory anti-beta 1 mAb 9EG7 was found to increase the maximum level of ligand binding similar to 2-fold, indicating that up to 50% of the total integrin could not bind ligand without 9EG7 stimulation. Analysis of mAb 13 binding in the presence of 9EG7 and ligand (i.e. maximal ligand occupancy) demonstrated that essentially all of the integrin bound mAb 13 with very low or zero affinity. Our results demonstrate that mAb 13 recognizes an epitope that is dramatically attenuated in the ligand-occupied form of alpha 5 beta 1. Hence, since mAb 13 preferentially recognizes the unoccupied conformation of the integrin, the antibody may inhibit ligand binding by stabilizing the unoccupied state of alpha 5 beta 1. In addition, we present evidence that the binding of mAb 13 to ligand-occupied alpha 5 beta 1 may also induce a conformational change in the integrin, resulting in the displacement of ligand.	NIDR,NIH,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Mould, AP (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,2205 STOPFORD BLDG,MANCHESTER M13 9PT,LANCS,ENGLAND.			Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1991, J BIOL CHEM, V266, P15938; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KILMARTIN IV, 1976, BR MED B, V32, P209; KOUNS WC, 1994, BLOOD, V84, P1108; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOSTER K, 1995, FEBS LETT, V373, P234, DOI 10.1016/0014-5793(95)01053-H; MAHLER HR, 1966, BIOL CHEM, P250; MOULD AP, 1995, BIOCHEM SOC T, V23, pS395, DOI 10.1042/bst023395s; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MULLER B, 1993, J BIOL CHEM, V268, P6800; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; SACHS DH, 1972, P NATL ACAD SCI USA, V69, P3790, DOI 10.1073/pnas.69.12.3790; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	46	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20365	20374		10.1074/jbc.271.34.20365	http://dx.doi.org/10.1074/jbc.271.34.20365			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702772	hybrid			2022-12-27	WOS:A1996VD33700024
J	Voorhorst, WGB; Eggen, RIL; Geerling, ACM; Platteeuw, C; Siezen, RJ; deVos, WM				Voorhorst, WGB; Eggen, RIL; Geerling, ACM; Platteeuw, C; Siezen, RJ; deVos, WM			Isolation and characterization of the hyperthermostable serine protease, pyrolysin, and its gene from the hyperthermophilic archaeon Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPEPTIDYL-PEPTIDASE-II; DODECYL SULFATE-RESISTANT; PROTEOLYTIC ACTIVITY; LACTOCOCCUS-LACTIS; HUMAN-ERYTHROCYTES; BETA-GLUCOSIDASE; SUBTILISIN-LIKE; PURIFICATION; PROTEINASES; MICROORGANISMS	The hyperthermostable serine protease pyrolysin from the hyperthermophilic archaeon Pyrococcus furiosus was purified from membrane fractions. Two proteolytically active fractions were obtained, designated high (HMW) and low (LMW) molecular weight pyrolysin, that showed immunological cross-reaction and identical NH2-terminal sequences in which the third residue could be glycosylated, The HMW pyrolysin showed a subunit mass of 150 kDa after acid denaturation. Incubation of HMW pyrolysin at 95 degrees C resulted in the formation of LMW pyrolysin, probably as a consequence of COOH-terminal autoproteolysis. The 4194-base pair pls gene encoding pyrolysin was isolated and characterized, and its transcription initiation site was identified. The deduced pyrolysin sequence indicated a prepro-enzyme organization, with a 1249-residue mature protein composed of an NH2-terminal catalytic domain with considerable homology to subtilisin-like serine proteases and a COOH-terminal domain that contained most of the 32 possible N-glycosylation sites, The archaeal pyrolysin showed highest homology with eucaryal tripeptidyl peptidases II on the amino acid level but a different cleavage specificity as shown by its endopeptidase activity toward caseins, casein fragments including alpha(S1)-casein and synthetic peptides.	WAGENINGEN UNIV AGR,DEPT MICROBIOL,NL-6703 CT WAGENINGEN,NETHERLANDS; NIZO,DEPT BIOPHYS CHEM,EDE,NETHERLANDS	Wageningen University & Research; NIZO Food Research			Siezen, Roland J/P-5745-2015					ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; CONNARIS H, 1991, J GEN MICROBIOL, V137, P1193, DOI 10.1099/00221287-137-5-1193; COWAN DA, 1987, BIOCHEM J, V247, P121, DOI 10.1042/bj2470121; Dalgaard JZ, 1993, BIOCH ARCHAEA, P535, DOI 10.1016/S0167-7306(08)60266-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; EXTERKATE FA, 1991, BIOCHEM J, V273, P135, DOI 10.1042/bj2730135; FUSEK M, 1990, J BIOL CHEM, V265, P1496; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; Gibson T., 1984, STUDIES EPSTEIN BARR; KELLY RM, 1994, ANTON LEEUW INT J G, V66, P247, DOI 10.1007/BF00871643; KENGEN SWM, 1994, BIOCATALYSIS, V11, P79, DOI 10.3109/10242429409034379; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KLINGEBERG M, 1995, APPL ENVIRON MICROB, V61, P3098, DOI 10.1128/AEM.61.8.3098-3104.1995; KUCHINO Y, 1982, NATURE, V298, P684, DOI 10.1038/298684a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LIN XL, 1990, J BIOL CHEM, V265, P1490; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MORIKAWA M, 1994, APPL ENVIRON MICROB, V60, P4559, DOI 10.1128/AEM.60.12.4559-4566.1994; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; PETERS J, 1995, J MOL BIOL, V245, P385, DOI 10.1006/jmbi.1994.0032; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Sambrook J., 2002, MOL CLONING LAB MANU; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SIEZEN RJ, 1993, PROTEIN ENG, V6, P927, DOI 10.1093/protein/6.8.927; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIEZEN RJ, 1995, INTRAMOLECULAR CHAPE, P238; SNOWDEN LJ, 1992, APPL ENVIRON MICROB, V58, P1134, DOI 10.1128/AEM.58.4.1134-1141.1992; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; TOMKINSON B, 1994, ARCH BIOCHEM BIOPHYS, V314, P276, DOI 10.1006/abbi.1994.1442; VOLKL P, 1994, PROTEIN SCI, V3, P1329; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VOORHORST WGB, 1995, J BACTERIOL, V177, P7105, DOI 10.1128/JB.177.24.7105-7111.1995; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	44	51	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20426	20431		10.1074/jbc.271.34.20426	http://dx.doi.org/10.1074/jbc.271.34.20426			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702780	hybrid, Green Published			2022-12-27	WOS:A1996VD33700032
J	Yang, WD; Wang, HY; Fliegel, L				Yang, WD; Wang, HY; Fliegel, L			Regulation of Na+/H+ exchanger gene expression - Role of a novel poly(dA center dot dT) element in regulation of the NHE1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENTS; INTRACELLULAR PH; HL-60 CELLS; METABOLIC-ACIDOSIS; PROXIMAL TUBULE; RETINOIC ACID; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; PROTEIN	In this study we examine regulation of expression of the Na+/H+ exchanger promoter in L6 and NIH 3T3 cells. We have identified a highly conserved poly(dA . dT)-rich region that appears to be important in regulation of expression of the NHE1 gene, Deletion or mutation of this region results in dramatic decreases in promoter activity in both L6 and NIH 3T3 cells, In addition, DNase I footprinting experiments demonstrated that this region is protected by nuclear extracts from both cell types, and gel mobility shift assays showed that a protein or proteins specifically binds to the poly(dA . dT)rich element, Using Southwestern blotting, we determined that a 33-kDa protein binds 60 the poly(dA . dT)containing region. Mutations that abolished protein binding to this element diminished activity of the promoter. Insertion of the poly(dA . dT)-rich element into a plasmid containing the SV40 promoter demonstrated that this element can also enhance the activity of a foreign promoter. Together, the results we have presented here show that the poly(dA . dT) rich region is important in regulation of NHE1 expression in different cell types.	UNIV ALBERTA,DEPT PEDIAT,CARDIOVASC DIS RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,FAC MED,DEPT BIOCHEM,CARDIOVASC DIS RES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								ALTENBERG GA, 1989, CLIN SCI, V76, P649, DOI 10.1042/cs0760649; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; BLAUROCK MC, 1995, BBA-GENE STRUCT EXPR, V1262, P159, DOI 10.1016/0167-4781(95)00075-R; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; DYCK JRB, 1995, J BIOL CHEM, V270, P10420, DOI 10.1074/jbc.270.18.10420; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; HAZAV P, 1989, CANCER RES, V49, P72; HORI R, 1994, NUCLEIC ACIDS RES, V22, P5099, DOI 10.1093/nar/22.23.5099; HORIE S, 1992, J CLIN INVEST, V89, P365, DOI 10.1172/JCI115594; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; KRAPF R, 1991, J CLIN INVEST, V87, P747, DOI 10.1172/JCI115057; KWASTWELFELD J, 1993, J BIOL CHEM, V268, P19581; LADOUX A, 1987, J BIOL CHEM, V262, P811; MILLER RT, 1991, J BIOL CHEM, V266, P10813; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; SWARTZMAN E, 1993, J BIOL CHEM, V268, P16706; VAIRO G, 1993, CELL GROWTH DIFFER, V4, P461; WANG YX, 1992, MOL CELL BIOL, V12, P3399, DOI 10.1128/MCB.12.8.3399; YANG W, 1995, AM J PHYSIOL, V270, pH259	25	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20444	20449		10.1074/jbc.271.34.20444	http://dx.doi.org/10.1074/jbc.271.34.20444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702783	hybrid			2022-12-27	WOS:A1996VD33700035
J	Digel, JG; Kishinevsky, A; Ong, AM; McCarty, RE				Digel, JG; Kishinevsky, A; Ong, AM; McCarty, RE			Differences between two tight ADP binding sites of the chloroplast coupling factor 1 and their effects on ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; FACTOR-I; CHANGE MECHANISM; CATALYTIC SITE; NUCLEOTIDE; F1-ATPASE; SUBUNIT; ENZYME	Purified chloroplast ATP synthase (CF1) contains 1.2-2 mol of tightly bound ADP/mol of enzyme that resists removal by gel filtration or dialysis. CF1 was depleted of its endogenous nucleotide by treatment with alkaline phosphatase. Tightly bound nucleotide was demonstrated not to have all essential structural role, CF1 depleted of endogenous nucleotide retains its ability to catalyze Ca2+- and Mg2+-dependent ATPase activity and is not more sensitive to cold inactivation than untreated CF1. 2'(3')-O-Trinitrophenyladenosille 5'-diphosphate (TNP-ADP) binds tightly to two sites on nucleotide-depleted CF1, binding to either site at a faster rate than that of exchange of bound nucleotide for medium nucleotide. The nucleotide-depleted enzyme binds about one additional mol of TNP-ADP/mol of CF1, indicating that there is a tight TNP-ADP binding site that does not exchange readily with medium nucleotide, It is MgADP in this nonexchanging site, not the easily exchanging ADP binding site, that is responsible for the MgADP-induced inhibition of the ATPase activity. The rate of exchange of tightly bound ADP from CF1 matches the rate at which the Mg2+-ATPase activity of CF1 is activated but is not itself responsible for the activation.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University								BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CARMELI C, 1981, BIOCHEMISTRY-US, V20, P3940, DOI 10.1021/bi00516a042; CERIONE RA, 1982, BIOCHEMISTRY-US, V21, P745, DOI 10.1021/bi00533a026; DIGEL JG, 1995, BIOCHEMISTRY-US, V34, P14482, DOI 10.1021/bi00044a026; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; Hightower KE, 1996, BIOCHEMISTRY-US, V35, P4852, DOI 10.1021/bi952914h; HOCHMAN Y, 1981, BIOCHEMISTRY-US, V20, P6288; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P78, DOI 10.1016/S0005-2728(89)80405-0; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYLAN AN, 1994, SOV SCI REV D, V12, P1; MCCARTY RE, 1992, J EXP BIOL, V172, P431; MCCARTY RE, 1966, BROOKHAVEN SYM BIOL, P202; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MOAL J, 1989, COMP BIOCHEM PHYS B, V93, P307, DOI 10.1016/0305-0491(89)90086-2; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; POSORSKE L, 1976, ARCH BIOCHEM BIOPHYS, V177, P276, DOI 10.1016/0003-9861(76)90437-9; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X	29	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19976	19982		10.1074/jbc.271.33.19976	http://dx.doi.org/10.1074/jbc.271.33.19976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702714	hybrid			2022-12-27	WOS:A1996VC66900055
J	Zhou, XB; Ruth, P; Schlossmann, J; Hofmann, F; Korth, M				Zhou, XB; Ruth, P; Schlossmann, J; Hofmann, F; Korth, M			Protein phosphatase 2A is essential for the activation of Ca2+-activated K+ currents by cGMP-dependent protein kinase in tracheal smooth muscle and Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; POTASSIUM CHANNELS; NITRIC-OXIDE; BASOLATERAL MEMBRANE; LARGE CONDUCTANCE; PATCH-CLAMP; RAT-BRAIN; POTENT; PHOSPHORYLATION; CHARYBDOTOXIN	The regulation of Ca2+ activated K+ channels (K-Ca channels) by cGMP-dependent protein kinase (cGMP kinase) and its molecular mechanism were investigated in Chinese hamster ovary (CHO) and tracheal smooth muscle cells, In CHO wild-type cells (CHO-WT cells) and in CHO cells stably transfected with cGMP kinase I alpha (CHO-cGK cells), K-Ca channels with intermediate conductance (similar to 50 picosiemens) were identified, Due to the basal activity of cGMP kinase, Ca2+-activated K+ currents had a higher sensitivity toward the cytosolic Ca2+ concentration in CHO-cGK cells than in CHO-WT cells. Dialysis of the active fragment of cGMP kinase (300 nM) into CHO-WT cells or of cGMP into CHO-cGK cells increased the Ca2+-activated K+ current, while the catalytic subunit of cAMP-dependent protein kinase (cAMP kinase) was without effect, In cell-attached patches obtained from freshly isolated bovine tracheal smooth muscle cells, the open state probability (NPo) of maxi-K-Ca channels (conductance of similar to 260 picosiemens) was enhanced by 300 mu M 8-(4-chlorophenylthio)-cGMP, a specific and potent activator of cGMP kinase. In contrast, 1 mu M isoprenaline, 20 mu M forskolin, and 3 mM 8-bromo-cAMP failed to enhance K-Ca channel activity. In excised inside-out patches, only the active fragment of cGMP kinase (but not that of cAMP kinase) increased NPo when applied to the cytosolic side of the patch. The enhancement of NPo by cGMP kinase was inhibited in CHO cells as well as in tracheal smooth muscle cells by the cGMP kinase inhibitor MT 5823 (1 mu M) and the protein phosphatase (PP) inhibitors microcystin (5 mu M) and okadaic acid (10 nM). The catalytic subunit of PP2A (but not that of PP1) mimicked the effect of cGMP kinase on NPo in excised, inside-out patches. The results show that cGMP kinase regulates two different K-Ca channels in two unrelated cell types by the same indirect mechanism, which requires the activity of PP2A. The regulation of the K-Ca channel is specific for cGMP kinase and is not mimicked by cAMP kinase.	TECH UNIV MUNICH, INST PHARMAKOL & TOXIKOL, D-80802 MUNICH, GERMANY	Technical University of Munich			Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839				ALIOUA A, 1995, AM J PHYSIOL-LUNG C, V268, pL1057, DOI 10.1152/ajplung.1995.268.6.L1057; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; CARL A, 1991, AM J PHYSIOL, V261, pC387, DOI 10.1152/ajpcell.1991.261.2.C387; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARLEY J, 1988, BIOPHYS J, V53, P919, DOI 10.1016/S0006-3495(88)83173-4; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GARBERS DL, 1992, CELL, V71, P1; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GREEN KA, 1991, BRIT J PHARMACOL, V102, P871, DOI 10.1111/j.1476-5381.1991.tb12269.x; HAMAGUCHI M, 1992, J PHARMACOL EXP THER, V262, P263; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIRSCH J, 1993, PFLUG ARCH EUR J PHY, V424, P470, DOI 10.1007/BF00374910; HIRSCH J, 1995, PFLUG ARCH EUR J PHY, V429, P338, DOI 10.1007/BF00374148; ISHII K, 1989, AM J PHYSIOL, V256, pC495, DOI 10.1152/ajpcell.1989.256.3.C495; ITO Y, 1978, J PHARMACOL EXP THER, V207, P1022; ITO Y, 1980, BRIT J PHARMACOL, V70, P197, DOI 10.1111/j.1476-5381.1980.tb07925.x; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KOLB HA, 1990, REV PHYSIOL BIOCH P, V115, P51; KOTLIKOFF MI, 1993, PHARMACOL THERAPEUT, V58, P1, DOI 10.1016/0163-7258(93)90064-K; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MEECH RW, 1974, J PHYSIOL-LONDON, V237, P259, DOI 10.1113/jphysiol.1974.sp010481; MERMI J, 1991, BRIT J PHARMACOL, V104, P705, DOI 10.1111/j.1476-5381.1991.tb12492.x; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; REINHART PH, 1995, J NEUROSCI, V15, P4572; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SLAUGHTER RS, 1987, BIOCHIM BIOPHYS ACTA, V904, P92, DOI 10.1016/0005-2736(87)90090-3; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WISGIRDA ME, 1994, P NATL ACAD SCI USA, V91, P2858, DOI 10.1073/pnas.91.7.2858	50	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19760	19767		10.1074/jbc.271.33.19760	http://dx.doi.org/10.1074/jbc.271.33.19760			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702682	hybrid			2022-12-27	WOS:A1996VC66900023
J	Arai, H; Charo, IF				Arai, H; Charo, IF			Differential regulation of G-protein-mediated signaling by chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN INTERLEUKIN-8 RECEPTOR; BETA-GAMMA-SUBUNITS; FUNCTIONAL EXPRESSION; THROMBIN RECEPTOR; CHEMOTACTIC CYTOKINES; MOLECULAR-CLONING; PHOSPHOLIPASE-C; CELLS; TRANSDUCTION	Monocyte chemoattractant protein-1 (MCP-1) is a member of a family of chemotactic cytokines that induce directed migration of leukocytes via activation of seven-transmembrane domain receptors. To identify G-proteins that couple to the two forms of the MCP-1 receptor, as well as to related chemokine receptors, we have performed cotransfection experiments in mammalian cells. In COS-7 cells, the type A and type B MCP-1 receptors coupled to G alpha(i), G alpha(q), and G alpha(16), whereas the macrophage inflammatory protein-1 alpha/RANTES (regulated on activation, normal T cell-expressed and secreted) receptor (C-CR1) coupled to G alpha(i) and G alpha(q) but failed to couple to G alpha(16). In HEK-293 cells, however, the MCP-1 receptors and C-CR1 coupled to G alpha(q) but failed to couple to G alpha(16). In contrast, the interleukin-8 and C5a receptors did not couple to G alpha(q) in either COS-7 or HEK-293 cells but did couple to G alpha(16). Exchange of intracellular loops between the MCP-1 and interleukin-8 receptors to create chimeric receptors revealed that the third loop of the MCP-1 receptor accounted for virtually all of the coupling to G alpha(q). We conclude that the MCP-1 and related chemokine receptors couple to multiple G-proteins, that coupling is cell type-specific, and that the third intracellular loop of the C-C type receptors mediates G alpha(q) coupling.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849	NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1993, J BIOL CHEM, V268, P9780; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kuang YN, 1996, J BIOL CHEM, V271, P3975; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SOZZANI S, 1991, J IMMUNOL, V147, P2215; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAUB DD, 1993, CYTOKINE, V5, P175, DOI 10.1016/1043-4666(93)90001-L; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; VANZEE KJ, 1992, J IMMUNOL, V148, P1746; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	37	167	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21814	21819		10.1074/jbc.271.36.21814	http://dx.doi.org/10.1074/jbc.271.36.21814			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702980	hybrid			2022-12-27	WOS:A1996VF61200022
J	Jacquemin, P; Hwang, JJ; Martial, JA; Dolle, P; Davidson, I				Jacquemin, P; Hwang, JJ; Martial, JA; Dolle, P; Davidson, I			A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; SOMATOMAMMOTROPIN GENE ENHANCER; HEAVY-CHAIN GENE; UBIQUITOUS NUCLEAR PROTEINS; ALPHA-ACTIN GENE; SV40 ENHANCER; M-CAT; SACCHAROMYCES-CEREVISIAE; PLACENTAL-LACTOGEN; FACTOR TEF-1	We describe the molecular cloning of two novel human and murine transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m)TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos, Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the gut and the nephrogenic region of the kidney. These observations suggest additional roles for the TEF proteins in central nervous system development and organogenesis.	COLL FRANCE, CNRS INSERM ULP, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV LIEGE, INST CHIM B6, LAB BIOL MOL & GENIE GENET, B-4000 Sart Tilman Par Liege, BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Liege			Jacquemin, Patrick/ABA-7932-2021; Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090; Davidson, Irwin/0000-0001-5533-1171				ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CASAZ P, 1991, J VIROL, V65, P6535, DOI 10.1128/JVI.65.12.6535-6543.1991; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GRUDA MC, 1991, J VIROL, V65, P3553, DOI 10.1128/JVI.65.7.3553-3558.1991; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INAMDAR M, 1993, J NEUROGENET, V9, P123, DOI 10.3109/01677069309083454; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KELLY JJ, 1991, NUCLEIC ACIDS RES, V19, P6799, DOI 10.1093/nar/19.24.6799; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LALOUX I, 1994, NUCLEIC ACIDS RES, V22, P999, DOI 10.1093/nar/22.6.999; LYTRAS A, 1994, MOL ENDOCRINOL, V8, P478, DOI 10.1210/me.8.4.478; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649	66	107	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21775	21785		10.1074/jbc.271.36.21775	http://dx.doi.org/10.1074/jbc.271.36.21775			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702974	hybrid			2022-12-27	WOS:A1996VF61200016
J	LuKuo, JM; Austen, KF; Katz, HR				LuKuo, JM; Austen, KF; Katz, HR			Post-transcriptional stabilization by interleukin-1 beta of interleukin-6 mRNA induced by c-kit ligand and interleukin-10 in mouse bone marrow-derived mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); TUMOR-NECROSIS-FACTOR; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; 3' UNTRANSLATED REGION; STIMULATORY FACTOR-II; MESSENGER-RNA; IL-6 PRODUCTION; RICH SEQUENCES; EXPRESSION; GENE	We demostrate that a specific combination of cytokines elicits high levels of interleukin (IL)-6 gene expression in mast cells and define the cellular mechanisms of the exogenous cytokine action, The addition of c-hit ligand (KL) and IL-10 to IL-3-derived mouse bone marrow mast cells (BMMC) elicited an similar to 2-fold increase in steady-state IL-6 mRNA levels that peaked after 0.5 h and was followed by the release of similar to 0.2 ng of IL-6/10(6) cells by 5-7 h. The addition of IL-1 beta to KL + IL-10 elicited a prolonged similar to 12-fold increase in the level of IL-6 mRNA by 3-5 h and an similar to 50-fold increase in the level of IL-6 protein released by 7 h. As determined by nuclear run-on analysis, KL + IL-10 stimulated IL-6 gene transcription within 0.5 h, and the addition of IL-1 beta did not increase transcription. Instead, IL-1 beta slowed by similar to 8-fold the decay of IL-6 mRNA as compared to its decay in BMMC stimulated with KL + IL-10 alone, The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by similar to 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1 beta induces the synthesis of a protein that stabilizes IL-6 mRNA. The stabilization of IL-6 mRNA was inhibited by the addition of actinomycin D at 0.5 but not 3 h after BMMC were stimulated with IL-1 beta in combination with KL + IL-10, suggesting that once transcribed, the stabilizing protein is long-lived, The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1 beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA. Thus, there exists a novel Fc epsilon receptor type I-independent mechanism by which a mast cell can provide substantial amounts of IL-6 protein in response to the synergistic action of KL and IL-10 to induce IL-6 gene transcription, and IL-1 beta to stabilize otherwise short-lived IL-6 transcripts.	BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	LuKuo, JM (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,250 LONGWOOD AVE,RM 607,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, R37AI022531, R01AI022531, U01AI031599, T32AI007306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07306, AI-22531, AI-31599] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belasco J. G., 1993, CONTROL MESSENGER RN, P475; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1993, J IMMUNOL, V151, P3853; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CLARK SC, 1989, ANN NY ACAD SCI, V557, P438; ELIAS JA, 1991, J IMMUNOL, V146, P3437; ELIAS JA, 1990, J IMMUNOL, V145, P161; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NG SB, 1994, J BIOL CHEM, V269, P19021; OKADA S, 1995, J ALLERGY CLIN IMMUN, V95, P1236, DOI 10.1016/S0091-6749(95)70081-1; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAKAI Y, 1988, J IMMUNOL, V140, P508; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	34	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22169	22174		10.1074/jbc.271.36.22169	http://dx.doi.org/10.1074/jbc.271.36.22169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703029	hybrid			2022-12-27	WOS:A1996VF61200071
J	Pantaloni, C; Brabet, P; Bilanges, B; Dumuis, A; Houssami, S; Spengler, D; Bockaert, J; Journot, L				Pantaloni, C; Brabet, P; Bilanges, B; Dumuis, A; Houssami, S; Spengler, D; Bockaert, J; Journot, L			Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; SYMPATHETIC NEUROBLASTS; STRUCTURAL REQUIREMENTS; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; CHROMAFFIN CELLS; VIP RECEPTOR; I RECEPTOR; RAT-BRAIN	Pituitary adenylate cyclase-activating polypeptide (PACAP)-27 and PACAP-38 are neuropeptides of the vasoactive intestinal peptide/secretin/glucagon family. We previously described alternative splicing of the region encoding the third intracellular loop of the PACAP receptor generating six isoforms with differential signal transduction properties (Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H., and Journot, L. (1993) Nature 365, 170-175). In addition, we demonstrated that She potencies of the two forms of PACAP are similar for adenylate cyclase stimulation, whereas PACAP-38 is more potent than PACAP-27 in phospholipase C activation. In the present work, we document the existence of a new splice variant of the PACAP receptor that was characterized by a 21-amino-acid deletion in the N-terminal extracellular domain. We demonstrate that this domain modulates receptor selectivity with respect to PACAP-27 and -38 binding and controls the relative potencies of the two agonists in phospholipase C stimulation.	CNRS,INSERM,CTR PHARMACOL ENDOCRINOL,UPR 9023,F-34094 MONTPELLIER 05,FRANCE; MAX PLANCK INST PSYCHIAT,D-80804 MUNICH,GERMANY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Max Planck Society			Journot, Laurent/T-9652-2018; Brabet, Philippe/AAO-8522-2020; Bilanges, Benoit/AAP-6078-2020	Journot, Laurent/0000-0003-3499-8887; Brabet, Philippe/0000-0003-2739-1622; Bilanges, Benoit/0000-0003-4400-3716				AINO H, 1995, GENE, V164, P301, DOI 10.1016/0378-1119(95)00391-I; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; BASILLE M, 1995, J NEUROCHEM, V65, P1318; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLSON P, 1992, AM J PHYSIOL, V263, pE1054; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FAVIT A, 1995, NEUROENDOCRINOLOGY, V61, P377, DOI 10.1159/000126859; FRODIN M, 1995, NEUROSCIENCE, V65, P599, DOI 10.1016/0306-4522(94)00522-7; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; GOURLET P, 1991, EUR J BIOCHEM, V193, P535; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; HOU X, 1994, NEUROPHARMACOLOGY, V33, P1189, DOI 10.1016/S0028-3908(05)80009-7; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; ISOKOBE K, 1993, ENDOCRINOLOGY, V132, P1757; JOURNOT L, 1994, SEMIN CELL BIOL, V5, P283; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; RAWLINGS SR, 1994, J BIOL CHEM, V269, P5680; RAWLINGS SR, 1993, ENDOCRINOLOGY, V132, P1447, DOI 10.1210/en.132.4.1447; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V195, P881, DOI 10.1006/bbrc.1993.2127; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; VIGH S, 1993, PEPTIDES, V14, P59, DOI 10.1016/0196-9781(93)90011-5; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; YADA T, 1993, PEPTIDES, V14, P235, DOI 10.1016/0196-9781(93)90035-F	41	186	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22146	22151		10.1074/jbc.271.36.22146	http://dx.doi.org/10.1074/jbc.271.36.22146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703026	hybrid			2022-12-27	WOS:A1996VF61200068
J	Ernstsson, S; Pierrou, S; Hulander, M; Cederberg, A; Hellqvist, M; Carlsson, P; Enerback, S				Ernstsson, S; Pierrou, S; Hulander, M; Cederberg, A; Hellqvist, M; Carlsson, P; Enerback, S			Characterization of the human forkhead gene FREAC-4 - Evidence for regulation by Wilms' tumor suppressor gene (WT-1) and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING MOTIF; CASEIN KINASE-II; TRANSCRIPTION FACTOR; ALVEOLAR RHABDOMYOSARCOMA; HEAD DOMAIN; WT1 GENE; MOUSE EMBRYOGENESIS; EXPRESSION; FAMILY; PROTEIN	We describe the cloning and sequence analysis of a nearly full-length cDNA as well as a corresponding 5.2-kilobase pair genomic fragment encoding FREAC-4, a member of the forkhead family of transcription factors, The cDNA is collinear with respect to the coding region of the intronless genomic clone. The conceptual translation product predicts a protein of 465 amino acids with a hyperacidic amino-terminal end, a DNA binding forkhead domain and a carboxyl-terminal part that is rich in homopolymeric runs of prolines and alanines. The transcription start is identified using an RNase protection assay. A 2.7-kilobase pair genomic DNA fragment, located immediately upstream of the translation start, was fused to a luciferase reporter gene. Significant levels of luciferase activity were detected when this construct was transfected into two kidney-derived cell lines, 293 and COS-7 cells, whereas only background reporter gene expression was observed in a cell line of nonkidney origin. Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with mutated p53, and a 4-fold repression with wild-type p53. A 5'-promoter deletion series delimits a DNA fragment necessary for WT-1 inducibility in cotransfection experiments. This fragment is shown to contain at least one cis-element that is capable of interacting with recombinant WT-1.	GOTHENBURG UNIV,DEPT MOL BIOL,LUNDBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg			Carlsson, Peter/B-5551-2008	Carlsson, Peter/0000-0001-6535-5927				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BRESLAUSIDERIUS EJ, 1993, HUM GENET, V92, P481, DOI 10.1007/BF00216455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DOWNING JR, 1995, AM J PATHOL, V146, P626; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; Frazier Gail C., 1994, Journal of Biological Chemistry, V269, P8892; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFMANN W, 1993, ONCOGENE, V8, P3123; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1993, ONCOGENE, V8, P1713; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MCGILLIVRAY BC, 1990, AM J MED GENET, V35, P10, DOI 10.1002/ajmg.1320350103; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER S, 1993, HUM GENET, V91, P599; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHARMA PM, 1992, CANCER RES, V52, P6407; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	56	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21094	21099		10.1074/jbc.271.35.21094	http://dx.doi.org/10.1074/jbc.271.35.21094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702877	hybrid			2022-12-27	WOS:A1996VE47700023
J	Lechner, MS; Dressler, GR				Lechner, MS; Dressler, GR			Mapping of Pax-2 transcription activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED DOMAIN; TRANSACTIVATION PROPERTIES; SEQUENCE RECOGNITION; DNA-BINDING; WILMS-TUMOR; GENE; PROTEIN; CONSERVATION; MUTATION; ANIRIDIA	Pax genes encode transcription factors known to play crucial roles during the development of specific embryonic tissues. In humans and mice, several abnormalities have been linked to deficiencies in Pax gene dosage, indicating that normal development is particularly sensitive to the level of Pax gene expression. Despite these facts, relatively little is known about how these proteins act as transcriptional regulators, In this study we define the transactivation domains of murine Pax-2, an essential factor in kidney organogenesis. Within the COOH terminus of Pax-2, amino acids 279-373 are essential for transactivation. However, this region alone is insufficient for full transactivation when fused to the paired domain alone or to a heterologous DNA binding domain. Mutation or deletion of the conserved octapeptide sequence results in increased transactivation by Pax proteins. The octapeptide-mediated repression is also seen within a heterologous context using the GAL4 DNA binding domain. Thus transactivation by Pax-2 relies upon several regions within the COOH terminus and is down-modulated by the octapeptide element.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLST BD, 1994, J BIOL CHEM, V269, P22245; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Song DL, 1996, DEVELOPMENT, V122, P627; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; STUART ET, 1993, ANNU REV GENET, V27, P219; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Torres M, 1995, DEVELOPMENT, V121, P4057; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	32	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21088	21093		10.1074/jbc.271.35.21088	http://dx.doi.org/10.1074/jbc.271.35.21088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702876	hybrid			2022-12-27	WOS:A1996VE47700022
J	Shih, ML; Malbon, CC				Shih, ML; Malbon, CC			Protein kinase C deficiency blocks recovery from agonist-induced desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CHROMOSOMAL LOCALIZATION; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT; CALCINEURIN; ACTIVATION; PATHWAYS; CLONING; CELLS	Protein phosphorylation is central. to agonist-induced attenuation of the function of G-protein-linked receptors. Stable expression of RNA antisense to specific protein kinase mRNAs permitted analysis of loss-of-function mutants of A431 human epidermoid carcinoma cells, lacking protein kinase A, protein kinase C, or beta-adrenergic receptor kinase. Deficiency of protein kinase C, but not the others, amplified rather than attenuated agonist-induced desensitization. In wild-type cells, the t1/2 for recovery from desensitization was similar to 25 min following removal of agonist, In the protein kinase C-deficient cells, no resensitization was observed even 60 min after agonist removal. Like protein kinase C-deficiency, inhibition of protein kinase C with bisindolylmaleimide or calphostin C blocked resensitization. Resensitization was suppressed by FK506, all inhibitor of protein phosphatase 2B, mimicking protein kinase C-deficiency, but in a non-additive manner, The data reveal protein kinase C and protein phosphatase 2B to be critical elements of resensitization.	SUNY STONY BROOK,CTR MED,DEPT MOL PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1996, J BIOL CHEM, V271, P14939; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BURNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	33	27	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21478	21483		10.1074/jbc.271.35.21478	http://dx.doi.org/10.1074/jbc.271.35.21478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702931	hybrid			2022-12-27	WOS:A1996VE47700077
J	Tougu, K; Marians, KJ				Tougu, K; Marians, KJ			The extreme C terminus of primase is required for interaction with DnaB at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; POLYMERASE-III HOLOENZYME; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; IDENTIFICATION; PROTEINS; GENE; TRANSFORMATION; EFFICIENCY; MECHANISM	We have shown previously that a protein-protein interaction between DnaG and DnaB is required to attract the primase to the replication fork. This interaction was mediated by the C-terminal 16 kDa domain (p16) of the primase. A screen was developed that allowed the detection of mutant p16 proteins that did not interact with DnaB. Various mutagenesis protocols were used to localize this interaction domain to the extreme C terminus of the primase. A mutant primase missing only the C-terminal 16 amino acids was isolated and its activities examined. This mutant enzyme was fully active as a primase, but was incapable of interacting with DnaB. Thus, the mutant primase could not support DNA synthesis in either the general priming reaction or during phi X174 complementary strand DNA replication. Alanine cluster mutagenesis and deletion analysis in p16 allowed the further localization of the interaction domain to the extreme C-terminal 8 amino acids in primase.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Tougu, K (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GROMPE M, 1991, J BACTERIOL, V173, P1268, DOI 10.1128/jb.173.3.1268-1278.1991; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Miller J.H., 1972, EXPT MOL GENETICS; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; MORTON RM, 1989, GENE, V77, P61; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SELICK HE, 1987, DNA REPLICATION RECO, P183; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	34	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21391	21397		10.1074/jbc.271.35.21391	http://dx.doi.org/10.1074/jbc.271.35.21391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702920	hybrid			2022-12-27	WOS:A1996VE47700066
J	Wang, N; Weng, W; Breslow, JL; Tall, AR				Wang, N; Weng, W; Breslow, JL; Tall, AR			Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores - In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE UPTAKE; ESTERS; RAT; MECHANISM; LIVER; CELLS	Scavenger receptor BI (SR-BI), a putative high density lipoprotein (HDL) receptor, mediates the selective uptake of HDL cholesteryl ester into cells and is highly expressed in adrenal gland (Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996) Science 271, 518-520). Apolipoprotein A-I knock-out (apoA-I0) mice have decreased HDL cholesterol, depleted adrenal cholesterol stores and impaired corticosteroid synthesis (Plump, A. S., Erickson, S. K., Weng, W., Partin, J. S., Breslow, J. L., and Williams, D. L. (1996) J. Clin. Invest. 97, 2660-2671). We now show up-regulation of adrenal SR-BI mRNA and protein in apoA-I0 mice, but not in apoA-II0, LDL receptor 0, apoE0, or cholesteryl ester transfer protein transgenic mice. Adrenal SR-BI mRNA and protein are also increased and cholesterol stores decreased in female mice with knockout of hepatic lipase, an enzyme previously shown to increase selective uptake in cell culture. SR-BI mRNA is increased in stressed wild type mice and in Y1 adrenal cells treated with adrenocorticotropic hormone; the latter effect is inhibited by HDL. These findings provide in vivo evidence showing SR-BI is a functional HDL receptor under feedback control. The action of hepatic lipase on apoA-I-containing lipoproteins may facilitate the SR-BI-mediated uptake of HDL lipid.	COLUMBIA UNIV,DIV MOL MED,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NHLBI NIH HHS [HL22682, HL54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; EISENBERG S, 1984, J LIPID RES, V25, P1017; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; NEWNHAM HH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P57, DOI 10.1016/0005-2760(90)90218-M; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; SMYTHE GA, 1983, ENDOCRINOLOGY, V113, P1062, DOI 10.1210/endo-113-3-1062; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837	16	194	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21001	21004		10.1074/jbc.271.35.21001	http://dx.doi.org/10.1074/jbc.271.35.21001			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8798380	hybrid			2022-12-27	WOS:A1996VE47700008
J	Arora, PD; McCulloch, CAG				Arora, PD; McCulloch, CAG			Dependence of fibroblast migration on actin severing activity of gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH MUSCLE ACTIN; F-ACTIN; BINDING PROTEIN; THIN-FILAMENTS; CELLS; EXPRESSION; POLYMERIZATION; LOCALIZATION; MODULATION; MOTILITY	Gelsolin nucleates actin filament assembly, blocks the fast-exchanging ends of actin filaments, and severs filaments, processes that may play an important role in cell mobility. We studied the relationship between cell migration, ion, gelsolin content, and actin severing activity in human gingival fibroblasts. These cells were keratin negative and desmin negative but expressed vimentin and myosin II. Cells were separated by their ability to migrate in response to a chemoattractant stimulus. Northern analysis of mRNA, [S-35]methionine incorporation into immunoprecipitated gelsolin, immunoblots of cell lysates, and quantitative confocal microscopy showed 1.4-2-fold higher levels of gelsolin in nonmigrant compared with migrant cells. Because the concentration of intracellular gelsolin did not appear to be a central determinant of cell migration, we assessed its requirement for motility, Cells that were electroinjected with a gelsolin antibody that inhibits actin severing by gelsolin in vitro showed a 72% reduction of the number of migrant cells compared with controls treated with an irrelevant antibody, Cells that were electroinjected with free gelsolin exhibited a 33% increase in migration compared with cells electroinjected with bovine serum albumin. Compared with nonmigrant cells, migrant cells contained abundant free gelsolin and exhibited gelsolin-dependent F-actin severing activity, which required Ca2+. Serum stimulation of cell migration required increases in [Ca2+](i) because incubation with 3 mu M 1,2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl)-ester blocked calcium flux and cell migration, Serum also stimulated the recruitment of gelsolin into the supernatants of lysates from migrant but not from nonmigrant cells, In fibroblasts, gelsolin concentration alone does not apparently determine migratory capacity, Instead, the Ca2+-dependent actin severing activity of free gelsolin appears to be a major determinant of cell migration.	UNIV TORONTO, FAC DENT, MED RES COUNCIL GRP PERIODONTAL PHYSIOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto								ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; ANKENBAUER T, 1988, J CELL BIOL, V107, P1489, DOI 10.1083/jcb.107.4.1489; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202; ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BAYREUTHER K, 1988, J CELL SCI, P115; BELLOWS CG, 1981, J CELL SCI, V50, P299; BORDIN S, 1984, SCIENCE, V223, P171, DOI 10.1126/science.6691142; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CARRON CP, 1986, J CELL BIOL, V102, P237, DOI 10.1083/jcb.102.1.237; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHAPONNIER C, 1990, EUR J BIOCHEM, V190, P559, DOI 10.1111/j.1432-1033.1990.tb15610.x; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; EBISAWA K, 1985, BIOMED RES-TOKYO, V6, P161; GLOGAUER M, 1992, EXP CELL RES, V200, P227, DOI 10.1016/0014-4827(92)90168-8; GONSIOR S, 1995, CELL MOTIL CYTOSKEL, V31, P196, DOI 10.1002/cm.970310303; HARRIS HE, 1983, BIOCHEMISTRY-US, V22, P2728, DOI 10.1021/bi00280a022; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; HINSSEN H, 1987, J CELL BIOL, V105, P1425, DOI 10.1083/jcb.105.3.1425; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWE JG, 1981, J BIOL CHEM, V256, P2836; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; HUGHES FJ, 1991, J HISTOCHEM CYTOCHEM, V39, P243, DOI 10.1177/39.2.1987269; IRWIN CR, 1994, J CELL SCI, V107, P1333; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KANNO K, 1989, J CELL PHYSIOL, V139, P58, DOI 10.1002/jcp.1041390110; KNOWLES GC, 1992, J HISTOCHEM CYTOCHEM, V40, P1605, DOI 10.1177/40.10.1527379; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH MC, 1984, J BIOL CHEM, V259, P7473; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MANIATIS T, 1992, MOL CLONING LABORATO, P545; MULLAUER L, 1990, BIOCHEM BIOPH RES CO, V171, P852, DOI 10.1016/0006-291X(90)91224-G; ONJI T, 1988, BIOCHEM BIOPH RES CO, V155, P91, DOI 10.1016/S0006-291X(88)81053-2; PENDER N, 1991, J CELL SCI, V100, P187; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POSTLETHWAITE AE, 1978, P NATL ACAD SCI USA, V75, P871, DOI 10.1073/pnas.75.2.871; SCHOLZ A, 1995, EXP CELL RES, V219, P384, DOI 10.1006/excr.1995.1243; SCHOR SL, 1987, J CELL SCI, P165; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YAMAGUCHI O, 1993, UROL RES, V21, P429, DOI 10.1007/BF00300081; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409	62	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20516	20523		10.1074/jbc.271.34.20516	http://dx.doi.org/10.1074/jbc.271.34.20516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702793	hybrid			2022-12-27	WOS:A1996VD33700045
J	King, JS; Fairley, CF; Morgan, WF				King, JS; Fairley, CF; Morgan, WF			DNA end joining by the Klenow fragment of DNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND-BREAKS; ESCHERICHIA-COLI; NONHOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL INSTABILITY; MAMMALIAN-CELLS; ILLEGITIMATE RECOMBINATION; TRANSFECTED DNA; KU AUTOANTIGEN; HELICASE-II	DNA end joining is a type of illegitimate recombination characterized by the joining of two DNA ends that lack homology. Using oligonucleotides as substrate, we found that an exonuclease-free derivative of the Klenow fragment of Escherichia coli DNA polymerase I can mediate DNA end joining in vitro. DNA sequence analysis of product DNA indicated that overlap products were formed between direct repeat sequences at the termini of the oligonucleotides. Formation of recombinant products was dependent on the strandedness of the substrate DNA, and the rate of product formation was dependent on the size of the potential overlap. With one to three complementary bases available for pairing at the 3' termini, there was an absolute requirement that one of the oligonucleotides be double-stranded, whereas with four complementary bases, products were also formed in reactions with single-stranded oligonucleotides. When noncomplementary nucleotides were added to the terminus of one of the oligonucleotides, product formation was delayed but not blocked. These data indicate that a DNA polymerase can mediate DNA double strand break rejoining in the absence of other proteins.	UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [T32CA009215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09215-12] Funding Source: Medline; NIEHS NIH HHS [5 T32 ES07106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLARK JM, 1991, GENE, V104, P75, DOI 10.1016/0378-1119(91)90467-P; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; FONTANEL ML, 1993, ANAL BIOCHEM, V214, P338, DOI 10.1006/abio.1993.1501; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOEDECKE W, 1994, NUCLEIC ACIDS RES, V22, P2094, DOI 10.1093/nar/22.11.2094; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; KING JS, 1994, J BIOL CHEM, V269, P13061; Kornberg A., 1992, DNA REPLICATION; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEHMAN CW, 1994, NUCLEIC ACIDS RES, V22, P434, DOI 10.1093/nar/22.3.434; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; MEZARD C, 1994, MOL CELL BIOL, V14, P1278, DOI 10.1128/MCB.14.2.1278; MORGAN WF, 1988, MOL CELL BIOL, V8, P4204, DOI 10.1128/MCB.8.10.4204; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; NAEGELI H, 1993, J BIOL CHEM, V268, P10386; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; PHILLIPS JW, 1992, RAD RES 20TH CENTURY, V2, P207; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SEN D, 1992, METHOD ENZYMOL, V211, P191; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOLFF S, 1973, ADV RAD RES, P457; ZDZIENICKA MZ, 1995, MUTAT RES-DNA REPAIR, V336, P203, DOI 10.1016/0921-8777(95)00003-3	46	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20450	20457		10.1074/jbc.271.34.20450	http://dx.doi.org/10.1074/jbc.271.34.20450			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702784	hybrid			2022-12-27	WOS:A1996VD33700036
J	Liu, YZ; Dawson, SJ; Gerster, T; Friedl, E; Pengue, G; Matthias, P; Lania, L; Latchman, DS				Liu, YZ; Dawson, SJ; Gerster, T; Friedl, E; Pengue, G; Matthias, P; Lania, L; Latchman, DS			The ability of the inhibitory domain of the POU family transcription factor Oct-2 to interfere with promoter activation by different classes of activation domains is dependent upon the nature of the basal promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; IMMEDIATE-EARLY GENES; INFECTABLE SENSORY NEURONS; RNA-POLYMERASE-II; B-CELL; IMMUNOGLOBULIN GENES; REMOTE ENHANCER; MAMMALIAN GENE; OCTAMER MOTIF; PROTEIN	The Oct-2 transcription factor contains an inhibitory domain which is able to repress transcription following DNA binding, Here we show that within the neuronally expressed Oct-2.5 form, the inhibitory domain can strongly inhibit activation by transcription factor activation domains which are either composed predominantly of acidic residues or contain the HOB motif, whereas it has a weaker effect or no effect on proline-rich activation domains and on a glutamine rich domain, In contrast, the isolated inhibitory domain of Oct-2 can efficiently repress all types of activation domains, This effect is observed however, only on TATA box containing promoters and not on promoters containing an initiator motif. This widespread inhibition of different activation domains and its dependence on the nature of the basal promoter elements indicate that the inhibitory domain is likely to act by contacting a common downstream target of activation domains within the basal transcriptional complex bound at the TATA box rather than quenching specific activation domains by direct interaction, These effects are discussed in terms of the functional role of the inhibitory domain within Oct-2.5 and the mechanism by which it acts.	UCL, SCH MED, DEPT MOL PATHOL, LONDON W1P 6DB, ENGLAND; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND; UNIV NAPLES FEDERICO II, DIPARTIMENTO GENET, I-80134 NAPLES, ITALY	University of London; University College London; UCL Medical School; Friedrich Miescher Institute for Biomedical Research; University of Basel; University of Naples Federico II				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BZIK DJ, 1986, NUCLEIC ACIDS RES, V14, P929, DOI 10.1093/nar/14.2.929; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAWSON SJ, 1994, NUCLEIC ACIDS RES, V22, P1023, DOI 10.1093/nar/22.6.1023; DENT CL, 1991, BIOCHEM J, V277, P541, DOI 10.1042/bj2770541; DENT CL, 1991, MOL CELL BIOL, V11, P3925, DOI 10.1128/MCB.11.8.3925; FRIEDL EM, 1995, EUR J BIOCHEM, V234, P308, DOI 10.1111/j.1432-1033.1995.308_c.x; GELMAN IH, 1987, J VIROL, V61, P3167, DOI 10.1128/JVI.61.10.3167-3172.1987; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LALLI E, 1994, J BIOL CHEM, V269, P17359; LATCHMAN DS, 1990, J EXP PATHOL, V71, P133; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILLYCROP KA, 1995, MOL BIOL REP, V21, P87, DOI 10.1007/BF00986498; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LILLYCROP KA, 1992, J BIOL CHEM, V267, P24960; LILLYCROP KA, 1993, VIROLOGY, V196, P888, DOI 10.1006/viro.1993.1552; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MADDEN SL, 1993, ONCOGENE, V8, P1713; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROIZMAN B, 1987, ANNU REV MICROBIOL, V41, P543, DOI 10.1146/annurev.mi.41.100187.002551; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH RL, 1992, VIROLOGY, V188, P311, DOI 10.1016/0042-6822(92)90760-M; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STOYKOVA AS, 1992, NEURON, V841, P841; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHEATLEY SC, 1992, MOL BRAIN RES, V12, P149, DOI 10.1016/0169-328X(92)90078-P; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	61	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20853	20860		10.1074/jbc.271.34.20853	http://dx.doi.org/10.1074/jbc.271.34.20853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702841	hybrid			2022-12-27	WOS:A1996VD33700093
J	Piras, G; Dittmer, J; Radonovich, MF; Brady, JN				Piras, G; Dittmer, J; Radonovich, MF; Brady, JN			Human T-cell leukemia virus type I tax protein transactivates RNA polymerase III promoter in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TROPICAL SPASTIC PARAPARESIS; PRIMARY HUMAN-LYMPHOCYTES; RECEPTOR GENE-EXPRESSION; CAMP-RESPONSIVE ELEMENT; 2 FUNCTIONAL COMPONENTS; HORMONE-RELATED PROTEIN; HTLV-I; TRANSCRIPTIONAL ACTIVATION; 21-BASE-PAIR REPEATS	Tax protein of the human T-cell lymphotropic virus type 1 (HTLV-I) is critical for viral replication and is a potent transcriptional activator of viral and cellular polymerase II (pol II) genes, We report here that Tax is able to transactivate a classical pol III promoter, VA-I. In cotransfection experiments, Tax is shown to increase transcription of the VA-I promoter approximately 25-fold. Moreover, Tax is able to activate VA-I transcription when added exogenously to an in vitro transcription reaction, Using Tax affinity column chromatography, we demonstrate that Tax is able to deplete a HeLa cell extract for components required for transcription of VA-I. The transcriptional activity of the Tax-depleted extract can be restored by the 0.6 M phosphocellulose fraction. Interestingly, a consensus binding site for cAMP-responsive element binding protein (CREB) is located upstream of the VA-I promoter, and deletion of this element results in the loss of Tax responsiveness, When this CREB binding site is replaced by a Gal-4 binding site, the VA-I promoter can be transactivated by a Gal4-Tax fusion protein, Taken together, these results suggest that Tax may activate pol III and pol II promoter through a similar mechanism involving the CREB activation pathway, It is also possible that Tax affects pol III transcription by direct interaction with a component of the pol III transcriptional machinery.	NCI,MOL VIROL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dittmer, Juergen/G-1160-2011					ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BERGER SL, 1985, NUCLEIC ACIDS RES, V13, P1413, DOI 10.1093/nar/13.4.1413; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BREDOW S, 1990, NUCLEIC ACIDS RES, V18, P6779, DOI 10.1093/nar/18.23.6779; CHANG DC, 1992, VIROLOGY, V189, P821, DOI 10.1016/0042-6822(92)90615-V; CONNOR LM, 1993, VIROLOGY, V195, P569, DOI 10.1006/viro.1993.1408; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUILFOYLE R, 1981, P NATL ACAD SCI-BIOL, V78, P3378, DOI 10.1073/pnas.78.6.3378; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JOSEPHS SF, 1984, VIROLOGY, V139, P340, DOI 10.1016/0042-6822(84)90379-9; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P, 1991, J BIOCHEM BIOPH METH, V222, P233; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NYBORG JK, 1990, J BIOL CHEM, V265, P8237; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PIRAS G, 1994, J VIROL, V68, P6170, DOI 10.1128/JVI.68.10.6170-6179.1994; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG HD, 1995, MOL CELL BIOL, V15, P6720; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; YOSHINAGA S, 1986, EMBO J, V5, P342; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	74	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20501	20506		10.1074/jbc.271.34.20501	http://dx.doi.org/10.1074/jbc.271.34.20501			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702791	hybrid			2022-12-27	WOS:A1996VD33700043
J	Specht, B; Bartetzko, N; Hohoff, C; Kuhl, H; Franke, R; Borchers, T; Spener, F				Specht, B; Bartetzko, N; Hohoff, C; Kuhl, H; Franke, R; Borchers, T; Spener, F			Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART; DEVELOPMENTAL REGULATION; COMPLEMENTARY-DNA; MESSENGER-RNA; EXPRESSION; GLAND; IDENTIFICATION; CLONING; TISSUE; DIFFERENTIATION	The amino acid sequence of the mammary derived growth inhibitor (MDGI) from bovine mammary gland (Bohmer, F.-D., Kraft, R., Otto, A., Wernstedt, C., Hell man, U., Kurtz, A., Muller, T., Rohde, K., Etzold, G., Lehmann, W., Langen, P., Heldin, C.-H., and Grosse, R. (1987) J. Biol. Chem. 262, 15137-15143) revealed 95% identity to bovine heart fatty acid-binding protein (H-FABP), explaining the observed immunocross-reactivity. However, a cDNA encoding MDGI has not been found to date. Artificial MDGI cDNA was expressed in an in vitro transcription/translation assay. Analysis by isoelectric focusing of the immunoprecipitated in vitro translation products of lactating bovine mammary gland mRNA did not indicate a protein corresponding to the in vitro translation product of artificial MDGI mRNA. Moreover, two-dimensional electrophoresis of bovine mammary gland proteins confirmed the absence of a protein with the pi of the in vitro translated artificial MDGI mRNA in bovine mammary gland and instead revealed, apart from H-FABP, an unknown protein that was recognized by anti-H-FABP antibodies. From lactating bovine mammary gland the cDNA for adipocyte fatty acid-binding protein (A-FABP) was cloned. The in vitro translation of recombinant mRNA derived from this cDNA yielded a polypeptide that behaved like the unknown immunoreactive protein. Western blotting and immunofluorescence using monospecific antibodies demonstrated the coexistence of H-FABP and A-FABP in the lactating mammary gland. Taking into account that deviations of the MDGI sequence from the bovine H-FABP sequence correspond with A-FABP we attribute the structure originally reported as MDGI to a mix of these proteins.	INST CHEM & BIOCHEM SENSOR RES,D-48149 MUNSTER,GERMANY; UNIV MUNSTER,DEPT BIOCHEM,D-48149 MUNSTER,GERMANY	University of Munster								BANSAL MP, 1993, BIOCHEM BIOPH RES CO, V191, P61, DOI 10.1006/bbrc.1993.1184; BARTETZKO N, 1993, EUR J BIOCHEM, V215, P555, DOI 10.1111/j.1432-1033.1993.tb18065.x; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BEATTIE DS, 1987, MITOCHONDRIA PRACTIC, P283; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BINAS B, 1992, IN VITRO CELL DEV-AN, V28A, P625; BOHMER FD, 1987, BIOCHEM BIOPH RES CO, V148, P1425, DOI 10.1016/S0006-291X(87)80291-7; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BOHMER FD, 1985, BIOCHIM BIOPHYS ACTA, V846, P145, DOI 10.1016/0167-4889(85)90120-X; BORCHERS T, 1994, CURR TOP MEMBR, V40, P261, DOI 10.1016/S0070-2161(08)60984-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GLATZ JFC, 1993, PROSTAG LEUKOTR ESS, V48, P33, DOI 10.1016/0952-3278(93)90007-J; GROSSE R, 1991, GENES ONCOGENES HORM, P69; HENNESSEY ES, 1991, EUR J BIOCHEM, V197, P345, DOI 10.1111/j.1432-1033.1991.tb15917.x; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; HUYNH HT, 1995, CANCER RES, V55, P2225; ISEKI S, 1991, ANAT REC, V229, P51, DOI 10.1002/ar.1092290107; JAGSCHIES G, 1985, EUR J BIOCHEM, V152, P537, DOI 10.1111/j.1432-1033.1985.tb09229.x; JONES PD, 1988, BIOCHEM J, V251, P919, DOI 10.1042/bj2510919; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LEHMANN W, 1989, BIOMED BIOCHIM ACTA, V48, P143; MAATMAN RGHJ, 1992, BIOCHEM J, V288, P285, DOI 10.1042/bj2880285; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NIELSEN SU, 1993, J LIPID RES, V34, P1355; NIELSEN SU, 1994, BBA-LIPID LIPID MET, V1211, P189, DOI 10.1016/0005-2760(94)90268-2; PALMITER RD, 1977, J BIOL CHEM, V252, P8781; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P1354; Rump R, 1996, EUR J CELL BIOL, V69, P135; Sambrook J., 2002, MOL CLONING LAB MANU; SHIELDS HM, 1986, J LIPID RES, V27, P549; SPECHT B, 1994, J BIOTECHNOL, V33, P259, DOI 10.1016/0168-1656(94)90074-4; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TREUNER M, 1994, GENE, V147, P237, DOI 10.1016/0378-1119(94)90073-6; TWEEDIE S, 1989, NUCLEIC ACIDS RES, V17, P4374, DOI 10.1093/nar/17.11.4374; UNTERBERG C, 1990, J BIOL CHEM, V265, P16255; VEERKAMP JH, 1993, PROSTAG LEUKOTR ESS, V49, P887, DOI 10.1016/0952-3278(93)90174-U; WOLD F, 1984, TRENDS BIOCHEM SCI, V9, P256, DOI 10.1016/0968-0004(84)90158-0; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	44	53	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19943	19949		10.1074/jbc.271.33.19943	http://dx.doi.org/10.1074/jbc.271.33.19943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702709	hybrid			2022-12-27	WOS:A1996VC66900050
J	Ferbeyre, G; Bratty, J; Chen, H; Cedergren, R				Ferbeyre, G; Bratty, J; Chen, H; Cedergren, R			Cell cycle arrest promotes trans-hammerhead ribozyme action in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; INHIBITION; PROTEIN; PHEROMONE; KINASE; DESTRUCTION; ANTISENSE; CATALYSIS	A hammerhead ribozyme designed to cleave the yeast ADE1 mRNA has been expressed in yeast under the control of a galactose-inducible promoter, RNA prepared from the galactose-induced yeast cultures possesses an activity that cleaves ADE1 mRNA in vitro, However, in spite of high expression levels of the ribozyme, no cleavage activity could be demonstrated in vivo. On the other hand, when the yeast cells expressing hammerhead RNA were treated with the alpha-factor mating pheromone, the level of ADE1 mRNA was reduced by 50%, Similar reductions were observed when this strain was cultured in the presence of lithium acetate or in nitrogen-free medium, Moreover, control experiments ill which disabled hammerhead genes were expressed showed no such reductions, Extension of the length of the flanking recognition arms of the ribozyme from a total of 10 to 16 or 24 nucleotides diminished the inhibitory effect of the ribozyme. These data suggest that ribozymes are able to cleave a trans-RNA target in yeast.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal			Ferbeyre, Gerardo/A-1569-2010	Ferbeyre, Gerardo/0000-0002-2146-618X				ATKINS D, 1994, BIOL CHEM H-S, V375, P721; Beck J, 1995, NUCLEIC ACIDS RES, V23, P4954, DOI 10.1093/nar/23.24.4954; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; CRISELL P, 1993, NUCLEIC ACIDS RES, V21, P3513; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; EGLI CM, 1994, J BIOL CHEM, V269, P27378; ELLIS J, 1993, NUCLEIC ACIDS RES, V21, P5171, DOI 10.1093/nar/21.22.5171; FERBEYRE G, 1995, GENE, V155, P45, DOI 10.1016/0378-1119(94)00891-U; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GUTHRIE C, 1986, TRENDS BIOCHEM SCI, V11, P430, DOI 10.1016/0968-0004(86)90179-9; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; LAW RHP, 1988, BIOCHEM INT, V17, P673; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; LO KMS, 1992, VIROLOGY, V190, P176, DOI 10.1016/0042-6822(92)91203-7; MARSCHALL P, 1994, CELL MOL NEUROBIOL, V14, P523, DOI 10.1007/BF02088835; MOORE SA, 1984, J BIOL CHEM, V259, P1004; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; Rose MD., 1990, METHODS YEAST GENETI; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; RUSO P, 1989, P NATL ACAD SCI USA, V86, P8348; Sambrook J., 2002, MOL CLONING LAB MANU; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SMITH BE, 1995, BIOCHEM BIOPH RES CO, V206, P401, DOI 10.1006/bbrc.1995.1055; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	42	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19318	19323		10.1074/jbc.271.32.19318	http://dx.doi.org/10.1074/jbc.271.32.19318			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702616	hybrid			2022-12-27	WOS:A1996VB68400050
J	Nimmesgern, E; Fox, T; Fleming, MA; Thomson, JA				Nimmesgern, E; Fox, T; Fleming, MA; Thomson, JA			Conformational changes and stabilization of inosine 5'-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMP DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; TRITRICHOMONAS-FETUS; ESCHERICHIA-COLI; CELL LINES; EXPRESSION; PROTEINS; PURIFICATION; MOFETIL; EC-1.1.1.205	The effects of substrate, product, and inhibitor (mycophenolic acid) binding on the conformation and stability of hamster type II inosine 5'-monophosphate dehydrogenase (IMPDH) have been examined. The protein in various states of ligand occupancy was compared by analyzing susceptibility to in vitro proteolysis, the degree of binding of a hydrophobic fluorescent dye, secondary structure content as determined by far-UV circular dichroism spectra, and urea-induced denaturation curves, These analysis methods revealed consistent evidence that IMPDH undergoes a local reorganization when IMP or XMP bind, NAD(+) produced no such effect, In fact, no evidence was found for NAD(+) binding independently of IMP. It is proposed that IMPDH adopts an open conformation around its nucleotide binding sites in the absence of substrates and that binding of IMP stabilizes a closed conformation that has a higher affinity for NAD(+). The data also suggest the enzyme remains in the closed configuration throughout the catalytic steps and then reverts to the open conformation with XMP release, thereby consummating the enzyme cycle. Mycophenolic acid inhibition appeared to impart even greater stability. We propose that localized conformational changes occur during the normal and mycophenolic acid-inhibited reaction sequences of IMPDH.			Nimmesgern, E (corresponding author), VERTEX PHARMACEUT INC, 130 WAVERLY ST, CAMBRIDGE, MA 02139 USA.							ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; BECK JT, 1994, EXP PARASITOL, V78, P101, DOI 10.1006/expr.1994.1010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROX LW, 1968, BIOCHEMISTRY-US, V7, P2589, DOI 10.1021/bi00847a021; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CARR SF, 1993, J BIOL CHEM, V268, P27286; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; CRABTREE GW, 1971, CANCER RES, V31, P985; DANOVITCH GM, 1995, KIDNEY INT, V48, pS93; DAYTON JS, 1994, J IMMUNOL, V152, P984; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; FERSHT A, 1984, ENZYME STRUCTURE MEC, P390; Fleming MA, 1996, BIOCHEMISTRY-US, V35, P6990, DOI 10.1021/bi9607416; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gosio B., 1896, RIV DIGIENE SANITA P, V7, P825; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GRINYO J, 1995, LANCET, V345, P1321; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KONNO Y, 1991, J BIOL CHEM, V266, P506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Morris RE, 1996, KIDNEY INT, V49, pS26; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NAKAMURA H, 1992, LEUKEMIA RES, V16, P561, DOI 10.1016/0145-2126(92)90002-O; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; Pace C N, 1986, Methods Enzymol, V131, P266; SANDALOVA T, 1993, FEBS LETT, V327, P361, DOI 10.1016/0014-5793(93)81021-Q; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SKARZYNSKI T, 1988, J MOL BIOL, V203, P1097, DOI 10.1016/0022-2836(88)90130-1; SNYDER FF, 1972, BIOCHEM PHARMACOL, V21, P2351, DOI 10.1016/0006-2952(72)90386-3; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOUMADJE A, 1992, ANAL BIOCHEM, V200, P321, DOI 10.1016/0003-2697(92)90473-K; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; WEBER G, 1983, CANCER RES, V43, P3466; WHITE JL, 1976, J MOL BIOL, V102, P759, DOI 10.1016/0022-2836(76)90290-4; WU JC, 1994, PERSPECT DRUG DISCOV, V2, P184; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057	52	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19421	19427		10.1074/jbc.271.32.19421	http://dx.doi.org/10.1074/jbc.271.32.19421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702630	hybrid			2022-12-27	WOS:A1996VB68400064
J	Brzeska, H; Korn, ED				Brzeska, H; Korn, ED			Regulation of class I and class II myosins by heavy chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIN-ACTIVATED ATPASE; ACANTHAMOEBA MYOSIN; DICTYOSTELIUM MYOSIN; MG-2+-ATPASE ACTIVITY; SYNTHETIC PEPTIDES; PLASMA-MEMBRANES; BINDING-SITES; KINASE; CASTELLANII; LOCALIZATION		NHLBI, CELL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; ATKINSON MAL, 1989, J BIOL CHEM, V264, P4127; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, BIOPHYS J, V70, pWP315; BRZESKA H, 1988, J BIOL CHEM, V263, P427; BRZESKA H, 1989, J BIOL CHEM, V264, P4127; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COTE GP, 1985, J BIOL CHEM, V260, P4543; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; GANGULY C, 1990, J BIOL CHEM, V265, P9993; GANGULY C, 1992, J BIOL CHEM, V267, P20900; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HAMMER JA, 1994, J CELL BIOL, V127, P1779, DOI 10.1083/jcb.127.6.1779; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; KELLEY CA, 1995, J BIOL CHEM, V270, P1395, DOI 10.1074/jbc.270.3.1395; Kolman MF, 1996, J CELL BIOL, V132, P101, DOI 10.1083/jcb.132.1.101; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KORN ED, 1991, CURR TOP MEMBR, V38, P13; KULESZALIPKA D, 1993, J BIOL CHEM, V268, P17995; KULESZALIPKA D, 1991, J CELL BIOL, V115, P109, DOI 10.1083/jcb.115.1.109; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1995, MOL BIOL CELL, V6, P863; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Murakami N, 1995, BIOCHEMISTRY-US, V34, P16046, DOI 10.1021/bi00049a019; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAU DC, 1993, J BIOL CHEM, V268, P4612; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REDOWICZ MJ, 1994, J BIOL CHEM, V269, P13558; Redowicz MJ, 1996, J BIOL CHEM, V271, P12401, DOI 10.1074/jbc.271.21.12401; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SINARD JH, 1989, J CELL BIOL, V109, P1537, DOI 10.1083/jcb.109.4.1537; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; SWANLJUNGCOLLIN.H, 1994, ACTIN BIOPHYSICS BIO, P205; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1994, J MUSCLE RES CELL M, V15, P587, DOI 10.1007/BF00121066; WANG ZY, 1995, J BIOL CHEM, V270, P27969, DOI 10.1074/jbc.270.46.27969; WILLIAMS R, 1995, BIOCHEM BIOPH RES CO, V216, P90, DOI 10.1006/bbrc.1995.2596; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	63	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16983	16986		10.1074/jbc.271.29.16983	http://dx.doi.org/10.1074/jbc.271.29.16983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8707782	hybrid			2022-12-27	WOS:A1996UX94300001
J	Kosovsky, MJ; Huan, BF; Siddiqui, A				Kosovsky, MJ; Huan, BF; Siddiqui, A			Purification and properties of rat liver nuclear proteins that interact with the hepatitis B virus enhancer 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; DNA-BINDING SPECIFICITY; GENE-EXPRESSION; FORK-HEAD; HEPATOCELLULAR-CARCINOMA; POLYACRYLAMIDE GELS; DEFINITIVE ENDODERM; NUCLEOCAPSID GENE; PROMOTER ACTIVITY; CORE PROMOTER	The hepatitis B virus enhancer 1 element plays a fundamental role in the liver-specific regulation of hepatitis B virus gene expression. A central region of enhancer 1, the enhancer core domain, contains at least four cis-acting sequence motifs that are essential for enhancer 1 activity, In this study, we have investigated an essential motif within the core domain previously defined as footprint V (FPV). Transient transfection analyses demonstrate that FPV is capable of independently functioning in a liver-specific manner to activate transcription, Therefore, to further examine the liver-specific properties of FPV-mediated enhancer 1 activity, we have carried out the biochemical purification and characterization of FPV binding activity from rat liver nuclei. This study has conclusively identified hepatocyte nuclear factor 3 beta (HNF-3 beta), a liver-enriched member of the HNF-3/forkhead gene family, as the predominant purified protein that interacts with the FPV motif. Moreover, a cellular protein(s) that copurified with HNF-3 beta specifically interacts with a novel sequence motif that partially overlaps FPV. Since this novel motif contains a palindromic sequence, we have tentatively referred to the protein(s) that binds to this site as palindrome-binding factor (PBF), Additional evidence indicates that HNF-3 beta and PBF cooperatively interact with enhancer 1. Therefore, this study supports the hypothesis that FPV-mediated enhancer activity involves a cooperative interplay between HNF-3 beta and at least one other enhancer 1-binding protein, PBF.	UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM MOL BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA65671] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065671] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; ANTONUCCI TK, 1989, J VIROL, V63, P579, DOI 10.1128/JVI.63.2.579-583.1989; BEASLEY RP, 1981, LANCET, V2, P1129; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; CHEN M, 1994, VIROLOGY, V205, P127, DOI 10.1006/viro.1994.1627; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEGROOTE J, 1978, GUT, V19, P510, DOI 10.1136/gut.19.6.510; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUSTIN K, 1993, VIROLOGY, V193, P653, DOI 10.1006/viro.1993.1173; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; HU KQ, 1991, VIROLOGY, V181, P721, DOI 10.1016/0042-6822(91)90906-R; HUAN BF, 1995, J VIROL, V69, P547, DOI 10.1128/JVI.69.1.547-551.1995; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOSOVSKY MJ, 1996, IN PRESS HEPATITIS B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; ORI A, 1995, VIROLOGY, V207, P98, DOI 10.1006/viro.1995.1055; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PATEL NU, 1989, J VIROL, V63, P5293, DOI 10.1128/JVI.63.12.5293-5301.1989; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAUL Y, 1991, MOL BIOL HEPATITIS B, P193; SIDDIQUI A, 1991, MOL BIOL HEPATITIS B, P95; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; Szmuness W, 1978, Prog Med Virol, V24, P40; TOGNONI A, 1985, NUCLEIC ACIDS RES, V13, P7457, DOI 10.1093/nar/13.20.7457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VALLET V, 1995, MOL CELL BIOL, V15, P5453; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YEN TSB, 1993, SEMIN VIROL, V4, P33; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990; ZHANG P, 1992, VIROLOGY, V191, P31, DOI 10.1016/0042-6822(92)90163-J; ZHANG P, 1994, VIROLOGY, V202, P430, DOI 10.1006/viro.1994.1359	76	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21859	21869		10.1074/jbc.271.36.21859	http://dx.doi.org/10.1074/jbc.271.36.21859			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702987	hybrid			2022-12-27	WOS:A1996VF61200029
J	Sando, GN; Howard, EJ; Madison, KC				Sando, GN; Howard, EJ; Madison, KC			Induction of ceramide glucosyltransferase activity in cultured human keratinocytes - Correlation with culture differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; FETAL-RAT EPIDERMIS; BARRIER FUNCTION; BETA-GLUCOCEREBROSIDASE; PERMEABILITY BARRIER; LAMELLAR GRANULES; LIPID-COMPOSITION; STRATUM-CORNEUM; GAUCHER DISEASE; CHOLESTEROL SULFOTRANSFERASE	Ceramides are the major component of the extracellular lipids that comprise the epidermal permeability barrier. They are derived from glucosylceramides (GlcCer) upon their extrusion from lamellar granules into the extracellular space in the upper layers of the epidermis. To better understand the regulation of the unique pathway for ceramide production in epidermis, we have studied the activity of the enzyme responsible for GlcCer synthesis, ceramide glucosyltransferase (CerGlc transferase), during keratinocyte culture differentiation. Human keratinocyte cultures were expanded in low calcium keratinocyte growth medium (KGM) and then switched to either normal calcium KGM (nKGM) or ''complete'' Dulbecco's modified Eagle's medium/Ham's F-12 (3:1) supplemented with 10% fetal bovine serum (cDMEM). At 7 and 10 days after the medium switch, electron microscopy revealed that cDMEM cultures were more fully differentiated morphologically and contained numerous lamellar granules. The GlcCer/DNA content of cDMEM cultures increased to 6 times that of day 0 cultures and was nearly 4 times greater than that of nKGM cultures, whereas the total lipid/DNA content of cDMEM cultures increased to only 1.8 times that of day 0 cultures and was similar to 1.2 times that of nKGM cultures. CerGlc transferase activity/DNA increased 6 times in cDMEM cultures but <1.5 times in nKGM cultures. By contrast, beta-glucocerebrosidase activity, which is responsible for the conversion of GlcCer to ceramide, increased to a similar extent in both differentiating culture systems. Treatment of cultures with the reversible CerGlc transferase inhibitor. DL-threo-1-phenyl-2-(palmitoylamino)3-morpholino-1-propanol, prevented the increase of GlcCer in cDMEM cultures, and blocked conversion of exogenously added ceramide to GlcCer. A low level of CerGlc transferase activity, relative to that in differentiated keratinocytes, was detected in cultures of other human cell types. These results indicate that CerGlc transferase activity is induced during epidermal differentiation and that regulation of this enzyme may be an important determinant of the specialized production and compartmentalization of epidermal sphingolipids.			Sando, GN (corresponding author), UNIV IOWA, COLL MED, DEPT DERMATOL, MARSHALL DERMATOL RES LABS, 270 ML, IOWA CITY, IA 52242 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041728, R55AR041728] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41728] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BJARE U, 1988, INT J BIOCHEM, V20, P1291, DOI 10.1016/0020-711X(88)90234-0; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHANG F, 1993, COMP BIOCHEM PHYS A, V105, P251; CONSTANTINOCECC.E, 1989, J NEUROCHEM, V53, P205; DIDONATO S, 1988, NEUROLOGY, V38, P1107; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; DOWNING DT, 1992, J LIPID RES, V33, P301; DURIEUX I, 1990, INT J BIOCHEM, V22, P709, DOI 10.1016/0020-711X(90)90005-N; DURIEUX I, 1990, BIOCHIM BIOPHYS ACTA, V1024, P263, DOI 10.1016/0005-2736(90)90352-O; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; FIELD FJ, 1987, J LIPID RES, V28, P1057; FREINKEL RK, 1985, J INVEST DERMATOL, V85, P295, DOI 10.1111/1523-1747.ep12276831; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRAYSON S, 1985, J INVEST DERMATOL, V85, P289, DOI 10.1111/1523-1747.ep12276826; HEDBERG CL, 1988, J INVEST DERMATOL, V91, P169, DOI 10.1111/1523-1747.ep12464438; HOLLERAN WM, 1992, J LIPID RES, V33, P1201; HOLLERAN WM, 1990, J LIPID RES, V31, P1655; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; ICHIKAWA S, 1996, P NATL ACAD SCI USA, V93, P2287; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; JETTEN AM, 1990, J INVEST DERMATOL, V95, pS44, DOI 10.1111/1523-1747.ep12505757; JIN K, 1994, ACTA DERM-VENEREOL, V74, P337; KAGEHARA M, 1994, BBA-LIPID LIPID MET, V1215, P183, DOI 10.1016/0005-2760(94)90109-0; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANDMANN L, 1988, ANAT EMBRYOL, V178, P1, DOI 10.1007/BF00305008; LEIGH IM, 1994, KERATINOCYTE HDB, P43; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON KC, 1989, J INVEST DERMATOL, V93, P10, DOI 10.1111/1523-1747.ep12277335; MADISON KC, 1995, J INVEST DERMATOL, V104, P561; MADISON KC, 1990, J INVEST DERMATOL, V95, P657, DOI 10.1111/1523-1747.ep12514333; MAK VHW, 1991, J INVEST DERMATOL, V96, P323, DOI 10.1111/1523-1747.ep12465212; MATSUO N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P97, DOI 10.1016/0304-4165(92)90105-4; MELNIK B, 1990, ARCH DERMATOL RES, V282, P549, DOI 10.1007/BF00371952; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MILNER ME, 1992, J INVEST DERMATOL, V99, P824, DOI 10.1111/1523-1747.ep12614791; MOTTA S, 1994, ARCH DERMATOL, V130, P452, DOI 10.1001/archderm.130.4.452; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PONEC M, 1988, J LIPID RES, V29, P949; PONEC M, 1994, KERATINOCYTE HDB, P351; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROBSON KJ, 1994, J LIPID RES, V35, P2060; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; SANDO GN, 1985, J BIOL CHEM, V260, P5186; SCHURER NY, 1989, J INVEST DERMATOL, V92, P196, DOI 10.1111/1523-1747.ep12276723; SIDRANSKY E, 1992, PEDIATR RES, V32, P494, DOI 10.1203/00006450-199210000-00023; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANT HOF W, 1994, CURR TOP MEMBR, V40, P539, DOI 10.1016/S0070-2161(08)60995-8; VANTHOF W, 1990, J CELL BIOL, V111, P977, DOI 10.1083/jcb.111.3.977; WERTZ PW, 1992, SEMIN DERMATOL, V11, P106; WERTZ PW, 1984, J INVEST DERMATOL, V83, P193, DOI 10.1111/1523-1747.ep12263553; WILLIAMS ML, 1993, ARCH DERMATOL, V129, P626, DOI 10.1001/archderm.129.5.626	65	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22044	22051		10.1074/jbc.271.36.22044	http://dx.doi.org/10.1074/jbc.271.36.22044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703011	hybrid			2022-12-27	WOS:A1996VF61200053
J	AvidorReiss, T; Nevo, I; Levy, R; Pfeuffer, T; Vogel, Z				AvidorReiss, T; Nevo, I; Levy, R; Pfeuffer, T; Vogel, Z			Chronic opioid treatment induces adenylyl cyclase V superactivation - Involvement of G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT-BRAIN; DEPENDENT ACTIVATION; CELL-LINES; RECEPTOR; EXPRESSION; CLONING; SUBUNITS; STIMULATION; MORPHINE	It has been known for some time that chronic treatment of neuronal cells and tissues with opioids, contrary to their acute effect, leads to an increase in cAMP accumulation. This phenomenon, defined as adenylyl cyclase superactivation, has been implicated in opiate addiction, yet the mechanism by which it is induced remains unclear. Here, we show that this phenomenon can be reproduced and studied in COS-7 cells cotransfected with adenylyl cyclase type V and mu-opioid receptor cDNAs. These cells display acute opioid inhibition of adenylyl cyclase activity, whereas prolonged exposure to the mu-agonist morphine or [D-Ala(2), N-methyl-Phe(4), Gly-ol(5)]enkephalin leads to a time-dependent superactivation of adenylyl cyclase. This superactivated state is reversible, because it is gradually lost following agonist withdrawal, Adenylyl cyclase superactivation can be prevented by pertussis toxin pretreatment, indicating the involvement of G(i/o) proteins, or by cotransfection with the carboxyl terminus of beta-adrenergic receptor kinase or with alpha-transducin (scavengers of G(beta gamma) dimers), indicating a role for the G protein beta gamma dimers in adenylyl cyclase superactivation. However, contrary to several other G(beta gamma)-dependent signal transduction mechanisms (e.g. the extracellular signal-regulated kinase 2/MAP kinase pathway), adenylyl cyclase superactivation is not affected by the Has dominant negative mutant N17-Ras.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; UNIV DUSSELDORF, DEPT PHYSIOL CHEM 2, D-40225 DUSSELDORF, GERMANY	Weizmann Institute of Science; Heinrich Heine University Dusseldorf			Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NIDA NIH HHS [DA-06265] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMMER H, 1993, MOL PHARMACOL, V43, P556; AVIDORREISS T, 1995, FEBS LETT, V361, P70, DOI 10.1016/0014-5793(95)00154-2; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIES TJ, 1991, EUR J PHARM-MOLEC PH, V208, P97, DOI 10.1016/0922-4106(91)90059-Q; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FURUYAMA T, 1993, MOL BRAIN RES, V19, P165, DOI 10.1016/0169-328X(93)90163-J; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GRIFFIN MT, 1985, J NEUROCHEM, V45, P1585, DOI 10.1111/j.1471-4159.1985.tb07230.x; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LIM K, 1989, BIOTECHNIQUES, V7, P576; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANVLIET BJ, 1991, EUR J PHARM-MOLEC PH, V208, P105, DOI 10.1016/0922-4106(91)90060-U; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WANG Z, 1994, LIFE SCI, V54, P339; WESTLINDDANIELSSON A, 1988, J NEUROCHEM, V51, P38, DOI 10.1111/j.1471-4159.1988.tb04832.x; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x	63	160	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21309	21315		10.1074/jbc.271.35.21309	http://dx.doi.org/10.1074/jbc.271.35.21309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702909	hybrid			2022-12-27	WOS:A1996VE47700055
J	Hagstrom, JE; Fautsch, MP; Perdok, M; Vrabel, A; Wieben, ED				Hagstrom, JE; Fautsch, MP; Perdok, M; Vrabel, A; Wieben, ED			Exons lost and found - Unusual evolution of a seminal vesicle transglutaminase substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN; HUMAN-SEMEN; ELASTASE INHIBITOR; GENE; SEQUENCE; IDENTIFICATION; SEMENOGELIN; CLONING; ELAFIN; ACID	The GP1G gene codes for three of the four abundant androgen-regulated secretory proteins produced by the guinea pig seminal vesicle, Sequencing of the entire 6.3-kilobase gene and comparison with other mammalian seminal vesicle secretory protein genes reveals a common three-exon, two-intron organization, However, significant sequence similarity between this group of genes is largely limited to their 5'-flanking regions and first exons, which code almost exclusively for signal peptides in each case, The first intron of GP1G does contain a region with high similarity to the coding exon of a human seminal vesicle secretory protein gene, semenogelin II. The 3' half of the GP1G gene appears to share a common ancestry with the human SKALP/elafin gene. Sequences related to the elafin promoter, coding, untranslated regions, and introns are clearly identifiable within the GP1G sequence. The elafin gene codes for a serine protease inhibitor and is expressed in a variety of different human tissues. To determine if the GP1G gene was also active outside of the seminal vesicle, RNA from a variety of guinea pig tissues was hybridized to a GP1G cDNA probe, At least three novel RNA bands hybridizing to the GP1G probe were detected in testis RNA samples, and GP1G-related mRNAs were also found in other tissues. These data suggest that these seminal vesicle secretory proteins may have functional roles outside the reproductive system.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic								ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN YH, 1987, MOL ENDOCRINOL, V1, P707, DOI 10.1210/mend-1-10-707; DIMICCO B, 1994, BIOCHEM PHARMACOL, V48, P345, DOI 10.1016/0006-2952(94)90106-6; DODD JG, 1986, MOL CELL ENDOCRINOL, V47, P191, DOI 10.1016/0303-7207(86)90112-7; *GEN COMP GROUP IN, 1994, PROGR MAN WISC PACK; HAGSTROM JE, 1989, MOL ENDOCRINOL, V3, P1797, DOI 10.1210/mend-3-11-1797; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; HARRIS SE, 1983, P NATL ACAD SCI-BIOL, V80, P6460, DOI 10.1073/pnas.80.21.6460; LILJA H, 1992, P NATL ACAD SCI USA, V89, P4559, DOI 10.1073/pnas.89.10.4559; LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070; MCDONALD CJ, 1984, EMBO J, V3, P2517, DOI 10.1002/j.1460-2075.1984.tb02166.x; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NOTIDES AC, 1967, P NATL ACAD SCI USA, V58, P1991, DOI 10.1073/pnas.58.5.1991; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SALLENAVE JM, 1993, AM J RESP CELL MOL, V8, P439, DOI 10.1165/ajrcmb/8.4.439; SWANSON WJ, 1995, P NATLA CAD SCI US, V92, P49557; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; VENEZIALE CM, 1976, ANDROLOGIA, V8, P73; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; WILLIAMS L, 1985, NUCLEIC ACIDS RES, V13, P659, DOI 10.1093/nar/13.3.659; YOOWARREN H, 1993, J EXP ZOOL, V265, P653, DOI 10.1002/jez.1402650607	30	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21114	21119		10.1074/jbc.271.35.21114	http://dx.doi.org/10.1074/jbc.271.35.21114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702880	hybrid			2022-12-27	WOS:A1996VE47700026
J	Li, H; Ko, HP; Whitlock, JP				Li, H; Ko, HP; Whitlock, JP			Induction of phosphoglycerate kinase 1 gene expression by hypoxia - Roles of Arnt and HIF1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; HYDROCARBON DIOXIN RECEPTOR; PROTEIN-DNA INTERACTIONS; LIGANDED AH RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ENHANCER; INDUCIBLE FACTOR-1; FUNCTIONAL DOMAINS; IDENTIFICATION; CLONING	To identify new dimerization partners for the aromatic hydrocarbon receptor nuclear translocator (Arnt), we used its N-terminal region (amino acids 1-470) as a target in a two-hybrid screening procedure, and we cloned the murine form of hypoxia-inducible factor 1 alpha (HIF1 alpha). Sequence comparisons reveal substantial identity between mouse and human HIF1 alpha. Hypoxia induces a 10-fold accumulation of phosphoglycerate kinase 1 mRNA in wild type mouse hepatoma (Hepa 1c1c7) cells; the induction mechanism is Arnt dependent because induction does not occur in Arnt-defective cells, Furthermore, induction of phosphoglycerate kinase 1 mRNA requires Arnt's N-terminal region, which mediates DNA binding and heterodimerization; in contrast, induction does not require Arnt's C-terminal region, which mediates transactivation. We also show that a GAL4-HIF1 alpha fusion protein transactivates a GAL4-dependent gene in the absence of Arnt, that HIF1 alpha's transactivation capability is inducible by hypoxia, and that both hypoxia responsiveness and transactivation capability reside within the C-terminal 83 amino acids of HIF1 alpha. Our findings generate new insights into the mechanism by which Amt and HIF1 alpha induce transcription in response to hypoxia.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R35CA053887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005665] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA53887] Funding Source: Medline; NIEHS NIH HHS [NRSA ES 05665] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BACSI SG, 1995, MOL PHARMACOL, V47, P432; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CONNEY AH, 1982, CANCER RES, V42, P4875; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEAR WS, 1996, IN PRESS METHODS GEN; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SHEN ES, 1989, J BIOL CHEM, V264, P17754; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157	47	138	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21262	21267		10.1074/jbc.271.35.21262	http://dx.doi.org/10.1074/jbc.271.35.21262			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702901	hybrid			2022-12-27	WOS:A1996VE47700047
J	Neufeld, EB; Cooney, AM; Pitha, J; Dawidowicz, EA; Dwyer, NK; Pentchev, PG; BlanchetteMackie, EJ				Neufeld, EB; Cooney, AM; Pitha, J; Dawidowicz, EA; Dwyer, NK; Pentchev, PG; BlanchetteMackie, EJ			Intracellular trafficking of cholesterol monitored with a cyclodextrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; LEYDIG TUMOR-CELLS; PLASMA-MEMBRANE; CULTURED FIBROBLASTS; GOLGI-APPARATUS; C FIBROBLASTS; BREFELDIN-A; SPHINGOMYELIN DEGRADATION; RAT-LIVER	The sterol binding agent 2-hydroxypropyl-beta-cyclodextrin is shown to be a convenient and useful experimental tool to probe intracellular pathways of cholesterol transport. Biochemical and cytochemical studies reveal that cyclodextrin specifically removes plasma membrane cholesterol. Depletion of plasma membrane sphingomyelin greatly accelerated cyclodextrin-mediated cholesterol removal. Cholesterol arriving at the plasma membrane from lysosomes and the endoplasmic reticulum was also removed by cyclodextrin. Cellular cholesterol esterification linked to the mobilization of cholesterol from lysosomes was strongly attenuated by cyclodextrin, suggesting that the major portion of endocytosed cholesterol is delivered from lysosomes to the endoplasmic reticulum via the plasma membrane. Evidence for translocation of lysosomal cholesterol to the endoplasmic reticulum by a plasma membrane-independent pathway is provided by the finding that cyclodextrin loses its ability to suppress esterification when plasma membrane sphingomyelin is depleted. The Golgi apparatus appears to play an active role in directing the relocation of lysosomal cholesterol to the plasma membrane since brefeldin A also abrogated cyclodextrin-mediated suppression of cholesterol esterification. Using cyclodextrin we further show that attenuated esterification of lysosomal cholesterol in Niemann-Pick C cells reflects defective translocation of cholesterol to the plasma membrane that may be linked to abnormal Golgi trafficking.	NINCDS, DEV & METAB NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; NIA, GERONTOL RES CTR, NIH, BALTIMORE, MD 21224 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Marine Biological Laboratory - Woods Hole	Neufeld, EB (corresponding author), NIDDK, LIPID CELL BIOL SECT,LAB CELL BIOCHEM & BIOL,NIH, BLDG 8,RM 427, 8 CTR DR, BETHESDA, MD 20892 USA.		Neufeld, Edward/R-3819-2019					ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLOCH K, 1991, BIOCH LIPIDS LIPOPRO, P363; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; COXEY RA, 1993, J LIPID RES, V34, P1165; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GAMBLE W, 1978, J LIPID RES, V19, P1068; GERLOCZY A, 1994, J PHARM SCI, V83, P193, DOI 10.1002/jps.2600830215; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIEGER M, 1986, METHOD ENZYMOL, V128, P608; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1988, ENDOCRINOLOGY, V123, P81, DOI 10.1210/endo-123-1-81; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NAGY L, 1990, BIOCHEM J, V271, P809, DOI 10.1042/bj2710809; OKWU AK, 1994, J LIPID RES, V35, P644; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PENTCHEV PG, 1986, J BIOL CHEM, V261, P2772; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; PORN MI, 1995, BIOCHEM J, V308, P269; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rothblat G H, 1986, Methods Enzymol, V129, P628; SILBERKANG M, 1983, J BIOL CHEM, V258, P8503; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; SZETLI J, 1988, CYCLODEXTRIN TECHNOL, P79; TABAS I, 1988, J BIOL CHEM, V263, P1266; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284	57	320	322	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21604	21613		10.1074/jbc.271.35.21604	http://dx.doi.org/10.1074/jbc.271.35.21604			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702948	hybrid			2022-12-27	WOS:A1996VE47700094
J	Reyes, JG; Robayna, IG; Delgado, PS; Gonzalez, IH; Aguiar, JQ; Rosas, FE; Fanjul, LF; deGalarreta, CMR				Reyes, JG; Robayna, IG; Delgado, PS; Gonzalez, IH; Aguiar, JQ; Rosas, FE; Fanjul, LF; deGalarreta, CMR			c-Jun is a downstream target for ceramide-activated protein phosphatase in A431 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SPHINGOLIPID BREAKDOWN PRODUCTS; SIGNAL-TRANSDUCTION; CELLULAR-REGULATION; FACTOR-ALPHA; HA-RAS; NEUTRAL SPHINGOMYELINASE; GRANULOSA-CELLS; KINASE-ACTIVITY; PHORBOL ESTER	Stimulation of [H-3]serine-labeled A431 cells with tumor necrosis factor-alpha (TNF alpha) or bacterial sphingomyelinase (SMase) resulted in a rapid decrease (similar to 50% by 15 min) in cellular [H-3]sphingomyelin content and generation of the lipid moiety [H-3]ceramide, which remained elevated 60 min later, Sphingomyelin hydrolysis in response to TNF alpha or bacterial SMase resulted in a time-dependent decrease in the phosphorylation state of c-Jun protein, an effect that was also observed in cells treated with the membrane-permeable ceramide analogue N-hexanoylsphingosine (C-6-ceramide). The rapid dephosphorylation of the c-Jun gene product in response to TNF alpha, SMase, or C-6-ceramide was not observed in A431 cells treated with the serine-threonine phosphatase inhibitor okadaic acid. After the initial steps of previously described methods for the purification of a ceramide-activated protein phosphatase termed CAPP (Dobrowsky, R, T., Kamibayashi, C,, Mumby, M, C., and Hannun, Y. A, (1993) J, Biol, Chen. 268, 15523-15530), we obtained a cytosolic fraction from A431 cells that specifically dephosphorylated P-32(i)-labeled c-Jun protein used as substrate in an immunocomplex phosphatase assay, Phosphatase activity in vitro was apparent only in the presence of ceramide (5 mu m) and was specifically abrogated when okadaic acid (1 nM) was included in the immunocomplex phosphatase assay, These results provide strong evidence for c-Jun as a downstream target for CAPP activated in response to post-TNF signaling in A431 cells.	UNIV LAS PALMAS,SCH MED,DEPT ENDOCRINOL CELULAR & MOL,LAS PALMAS 35016,SPAIN	Universidad de Las Palmas de Gran Canaria			Gonzalez Robayna, Ignacio/K-9671-2014; Quintana, José/K-5709-2014; Estévez, Francisco/K-5125-2014; Gonzalez, Ignacio/ABG-2221-2020	Gonzalez Robayna, Ignacio/0000-0002-7650-4454; Quintana, José/0000-0001-8225-4538; Estévez, Francisco/0000-0002-9728-2774; Gonzalez, Ignacio/0000-0002-7838-4329; Santana-Delgado, Pino/0000-0002-4093-2692; Hernandez, Inmaculada/0000-0002-9305-1442				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAI TN, 1995, ONCOGENE, V10, P849; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEGROOT RP, 1992, ONCOGENE, V7, P841; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOBROWSKI T, 1994, ADV PROTEIN PHOSPHAT, V8, P27; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FANJUL LF, 1992, BIOCHEM BIOPH RES CO, V188, P198, DOI 10.1016/0006-291X(92)92369-9; GOODE N, 1992, J BIOL CHEM, V267, P16878; HAKAMORI S, 1981, ANNU REV BIOCHEM, V50, P733; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1994, J BIOL CHEM, V269, P4125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WESTWICK JK, 1995, J BIOL CHEM, V270, P22699; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P241; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P423	59	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21375	21380		10.1074/jbc.271.35.21375	http://dx.doi.org/10.1074/jbc.271.35.21375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702918	hybrid			2022-12-27	WOS:A1996VE47700064
J	Wong, L; Johnson, GR				Wong, L; Johnson, GR			Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; FACTOR RECEPTOR; RAS; INSULIN; KINASE; CORKSCREW; SH-PTP2; SYP; PHOSPHORYLATION	The Src homology 2 (SH2) and SH3 domain-containing adaptor protein GRB2 and the SH2 domain-containing protein-tyrosine phosphatase 1D (PTP1D, also called SHPTP2, PTP2C, SHPTP3, Syp, or SHP-2) function as positive mediators of growth factor-induced mitogenesis, Epidermal growth factor (EGF) is a potent mitogen for MCF-10A human mammary epithelial cells and EGF receptor-expressing mouse NR6 fibroblasts, Western blot analysis of anti-PTP1D immune complexes derived from EGF-treated cells demonstrated a ligand-dependent coupling between the phosphatase and GRB2 in vivo. Probing of lysates from these cells with glutathione S-transferase (GST) fusion proteins corresponding to the individual domains of GRB2 revealed that this interaction was mediated exclusively by the COOH-terminal SH3 domain of GRB2. Importantly, a GST fusion protein containing the PTP1D SH2 domains was not capable of generating the EGF-induced linkage to GRB2. Additional experiments indicated that neither the binding of the nucleotide exchange factor Sos to GRB2 nor tyrosine phosphorylation of PTP1D was required for EGF-stimulated coupling of PTP1D to GRB2. This is the first demonstration of a growth factor- or cytokine-induced coupling of a protein through an SH3 domain and suggests that GRB2 functions to target PTP1D, in addition to Sos, to the plasma membrane in response to EGF.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Allard JD, 1996, DEVELOPMENT, V122, P1137; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	28	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20981	20984		10.1074/jbc.271.35.20981	http://dx.doi.org/10.1074/jbc.271.35.20981			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702859	hybrid			2022-12-27	WOS:A1996VE47700003
J	Belogrudov, GI; Tomich, JM; Hatefi, Y				Belogrudov, GI; Tomich, JM; Hatefi, Y			Membrane topography and near-neighbor relationships of the mitochondrial ATP synthase subunits e, f, and g	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION SYSTEM; COMPLEX-V; INHIBITOR PROTEIN; F1-ATPASE; RECONSTITUTION; IDENTIFICATION; PURIFICATION; MECHANISM; STALK	The well characterized subunits of the bovine ATP synthase complex are the alpha, Rho, gamma, delta, and epsilon subunits of the catalytic sector, F-1; the ATPase inhibitor protein; and subunits a, b, c, and d, OSCP (oligomycin Sensitivity-conferring protein), F-6, and A6L, which are present in the membrane sector, F-0, and the 45-Angstrom-long stalk that connects F-1 to F-0. It has been shown recently that bovine ATP synthase preparations also contain three small polypeptides, designated e, f, and g, with respective molecular masses of 8.2, 10.2, and 11.3 kDa. To ascertain their involvement as bonafide subunits of the ATP synthase and to investigate their membrane topography and proximity to the above ATP synthase subunits, polyclonal antipeptide antibodies were raised in the rabbit to the COOH-terminal amino acid residues 57-70 of e, 75-86 off, and 91-102 of g. It was shown that (i) e, f, and g could be immunoprecipitated with anti-OSCP IgG from a fraction of bovine submitochondrial particles enriched in oligomycin-sensitive ATPase; (ii) the NH2 termini of f and g are exposed on the matrix side of the mitochondrial inner membrane and can be curtailed by proteolysis; (iii) the COOH termini of all three polypeptides are exposed on the cytosolic side of the inner membrane; and (iv) f cross links to A6L and to g, and e crosslinks to g and appears to form an e-e dimer. Thus, the bovine ATP synthase complex appears to have 16 unlike subunits, twice as many as its counterpart in Escherichia coli.	SCRIPPS RES INST, DIV BIOCHEM, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Scripps Research Institute; Kansas State University				TOMICH, JOHN M./0000-0001-7848-8307	NIDDK NIH HHS [DK08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; Errede B, 1978, Methods Enzymol, V53, P40; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALANTE YM, 1981, ARCH BIOCHEM BIOPHYS, V211, P643, DOI 10.1016/0003-9861(81)90500-2; GALANTE YM, 1979, J BIOL CHEM, V254, P2372; GALANTE YM, 1981, BIOCHEMISTRY-US, V20, P2671, DOI 10.1021/bi00512a048; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HATEFI Y, 1958, BIOCHIM BIOPHYS ACTA, V27, P83, DOI 10.1016/0006-3002(58)90294-4; Hatefi Y, 1978, Methods Enzymol, V53, P3; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P82; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; RACKER E, 1967, J BIOL CHEM, V242, P2547; ROBBINS BA, 1981, ARCH BIOCHEM BIOPHYS, V210, P489, DOI 10.1016/0003-9861(81)90213-7; SAH JF, 1993, BIOCHEM BIOPH RES CO, V194, P1521, DOI 10.1006/bbrc.1993.1997; STIGGALL DL, 1978, J BIOL CHEM, V253, P956; TOWBIN H, 1982, P NATL ACAD SCI USA, V93, P97; VANHEEKE G, 1993, BIOCHEMISTRY-US, V32, P10140, DOI 10.1021/bi00089a033; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007	29	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20340	20345		10.1074/jbc.271.34.20340	http://dx.doi.org/10.1074/jbc.271.34.20340			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702768	hybrid			2022-12-27	WOS:A1996VD33700020
J	Smith, JA; Francis, SH; Walsh, KA; Kumar, S; Corbin, JD				Smith, JA; Francis, SH; Walsh, KA; Kumar, S; Corbin, JD			Autophosphorylation of type I beta cGMP-dependent protein kinase increases basal catalytic activity and enhances allosteric activation by cGMP or cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOPHOSPHATE-BINDING-PROTEINS; PEPTIDE-STIMULATED NEUTROPHILS; PIG CORONARY-ARTERIES; CYCLIC-GMP; REGULATORY SUBUNIT; BOVINE AORTA; RAT-TISSUES; SMOOTH-MUSCLE; ADENOSINE; PHOSPHORYLATION	Autophosphorylation of purified bovine I beta isozyme of cGMP-dependent protein kinase (I beta cGK) in the presence of cGMP or cAMP increased basal kinase activity (-cGMP) as much as 4-fold and reduced the R(alpha) for both cGMP and cAMP; maximum catalytic activity (+cGMP) was not altered. Autophosphorylation proceeded with at least two rate components. The faster rate correlated with phosphorylation of Ser-63. The slower rate, as well as the increase in basal kinase activity and decrease in K-alpha for cyclic nucleotides, correlated with phosphorylation of Ser-79. Autophosphorylation of either residue was an intramolecular reaction. Autophosphorylation of a proteolytically generated I beta cGK monomer lacking amino-terminal residues 1-64 increased basal activity (3-fold) and decreased K-alpha for cAMP (15-fold). This indicated that autophosphorylation of Ser-79 did not require dimeric cGK and that the phosphorylation of Ser-79 in the monomer was sufficient to alter enzymatic characteristics of I beta cGK. These studies suggested that increases in intracellular cGMP or cAMP could result in autophosphorylation of I beta cGK; which would increase basal kinase activity as well as the sensitivity of cGK to activation by cGMP or to cross-activation by cAMP. Autophosphorylation could also prolong the increased kinase activity after decline of the second messenger.	VANDERBILT UNIV, SCH MED, DEPT MOL PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Vanderbilt University; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; CHAVANIEU A, 1994, EUR J BIOCHEM, V224, P115, DOI 10.1111/j.1432-1033.1994.tb20002.x; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P1; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; ERNEUX C, 1986, BIOCHEM J, V234, P193, DOI 10.1042/bj2340193; FLOCKHART DA, 1980, J BIOL CHEM, V255, P4435; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FRANCIS S, 1993, FASEB J, V7, pA1123; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; GEAHLEN RL, 1982, ADV ENZYME REGUL, V20, P195, DOI 10.1016/0065-2571(82)90016-4; GEAHLEN RL, 1981, J BIOL CHEM, V256, P4536; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFMANN F, 1983, FEBS LETT, V164, P350, DOI 10.1016/0014-5793(83)80315-9; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HOFMANN F, 1983, FEBS LETT, V151, P71, DOI 10.1016/0014-5793(83)80345-7; JIANG H, 1992, J BIOL CHEM, V267, P1015; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1989, CELL SIGNAL, V1, P303, DOI 10.1016/0898-6568(89)90049-1; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; MCCUNE RW, 1979, J BIOL CHEM, V254, P5083; MILLER JP, 1981, BIOCHEM PHARMACOL, V30, P509, DOI 10.1016/0006-2952(81)90637-7; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PRYZWANSKY KB, 1990, BLOOD, V76, P612; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SMITH J, 1993, FASEB J, V7, pA1123; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; SMITH JA, 1992, FASEB J, V6, pA315; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALTER U, 1981, EUR J BIOCHEM, V118, P339; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; WYATT TA, 1991, J BIOL CHEM, V266, P21274	56	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20756	20762		10.1074/jbc.271.34.20756	http://dx.doi.org/10.1074/jbc.271.34.20756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702828	hybrid			2022-12-27	WOS:A1996VD33700080
J	Tian, Y; Wu, LH; Oxender, DL; Chung, FZ				Tian, Y; Wu, LH; Oxender, DL; Chung, FZ			The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SUBSTANCE-P; NEUROKININ-3 RECEPTOR; MOLECULAR-CLONING; NK3 RECEPTORS; K RECEPTORS; BINDING; EXPRESSION; GENE; RAT; IDENTIFICATION	Three chimeric receptors were constructed by exchanging exon sequences between human NK1 and NK3 receptor genes. The resulting chimeric receptors not only retained high affinities for their natural ligands substance P and neurokinin B but also exhibited surprisingly high affinities for other naturally occurring tachykinins including neurokinin A, neuropeptide K, neuropeptide gamma, eledoisin, kassinin, physalaemin, and phyllomedusin. In contrast, these chimeric receptors displayed a wide range of variability in their affinities for non-naturally occurring ligands including selective agonists and antagonists of NK1, NK2, and NK3 receptors. Since the only common feature among these naturally occurring neurokinin peptides is the conserved C-terminal sequences, our data suggest that these conserved sequences must play the major role in conferring high affinity binding to the chimeric receptors. To explain the apparently ''improved'' affinities of these naturally occurring ligands for the chimeric receptors as compared with their affinities for the parent NK1 and NK3 receptors, we are proposing that certain inhibitory domains that are present in the NK1 and/or NK3 receptors are compromised in these chimeric receptors. Upon disruption of these inhibitory domains during the formation of chimeras, the naturally occurring ligands can interact more favorably with chimeric receptors through their conserved C-terminal sequences. Based on this hypothesis, the binding affinities of natural tachykinin ligands may be largely determined by their conserved C-terminal sequences, whereas receptor selectivities of these ligands are influenced more by the presence or absence of inhibitory domains rather than specific binding domains on their target receptors.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT BIOTECHNOL,ANN ARBOR,MI 48105	Pfizer								BANNON MJ, 1995, BRAIN RES, V695, P19, DOI 10.1016/0006-8993(95)00791-N; BERGSTROM L, 1987, J NEUROCHEM, V48, P125, DOI 10.1111/j.1471-4159.1987.tb13136.x; BUELL G, 1992, FEBS LETT, V299, P90, DOI 10.1016/0014-5793(92)80107-R; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; CHUNG FZ, 1994, BIOCHEM BIOPH RES CO, V198, P967, DOI 10.1006/bbrc.1994.1138; CHUNG FZ, 1995, MOL PHARMACOL, V48, P711; FONG TM, 1995, CAN J PHYSIOL PHARM, V73, P860, DOI 10.1139/y95-118; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GETHER U, 1993, J BIOL CHEM, V268, P7893; GRAHAM A, 1991, BIOCHEM BIOPH RES CO, V177, P8, DOI 10.1016/0006-291X(91)91940-E; HEUILLET E, 1993, J NEUROCHEM, V60, P868, DOI 10.1111/j.1471-4159.1993.tb03231.x; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; Krause James E., 1994, P165; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MANTYH PW, 1991, ANN NY ACAD SCI, V632, P263, DOI 10.1111/j.1749-6632.1991.tb33114.x; MAUZY CA, 1992, BIOCHEM BIOPH RES CO, V186, P277, DOI 10.1016/S0006-291X(05)80804-6; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MUSSAP CJ, 1993, J NEUROCHEM, V60, P1987, DOI 10.1111/j.1471-4159.1993.tb03484.x; OURYDONAT F, 1995, J PHARMACOL EXP THER, V274, P148; PATACCHINI R, 1995, ARCH INT PHARMACOD T, V329, P161; PATACCHINI R, 1995, EUR J PHARMACOL, V278, P17, DOI 10.1016/0014-2999(95)00090-8; PRADIER L, 1994, MOL PHARMACOL, V45, P287; REGOLI D, 1994, PHARMACOL REV, V46, P551; SADOWSKI S, 1993, NEUROPEPTIDES, V24, P317, DOI 10.1016/0143-4179(93)90001-Q; SUMANCHAUHAN N, 1994, EUR J PHARM-MOLEC PH, V269, P65, DOI 10.1016/0922-4106(94)90027-2; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; WU LH, 1994, BIOCHEM BIOPH RES CO, V198, P961, DOI 10.1006/bbrc.1994.1137; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	30	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20250	20257		10.1074/jbc.271.34.20250	http://dx.doi.org/10.1074/jbc.271.34.20250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702757	hybrid			2022-12-27	WOS:A1996VD33700009
J	Becker, MA; Taylor, W; Smith, PR; Ahmed, M				Becker, MA; Taylor, W; Smith, PR; Ahmed, M			Overexpression of the normal phosphoribosylpyrophosphate synthetase 1 isoform underlies catalytic superactivity of human phosphoribosylpyrophosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SUBUNIT-II; PURINE OVERPRODUCTION; HUMAN-FIBROBLASTS; X-CHROMOSOME; CLONING; PRPS1; GENES; LOCALIZATION; METABOLISM	To define the enzymatic and genetic basis of X-linked phosphoribosylpyrophosphate synthetase (PRS) catalytic superactivity, we measured concentrations of X-linked PRS1 and PRS2 isoforms in cultured fibroblasts and lymphoblasts by immunoblotting after separation by polyacrylamide-urea isoelectric focusing. PRS1 comprised >80% of measurable PRS isoforms in all fibroblast strains, but PRS1 concentrations in cells from six affected males exceeded those in normal cells by 2-6-fold, PRS absolute specific activities (activity per mg of PRS isoforms) were comparable in all fibroblast strains and in purified recombinant normal PRS1, confirming selectively increased levels of PRS1 isoform as the enzymatic basis of PRS catalytic superactivity, Cloning, sequencing, and expression of normal subject- and patient-derived PRS cDNAs predicted normal translated region sequences for both PRS isoforms and revealed no differences in catalytic properties of recombinant PRS1. Normal and patient PRPS1 transcribed but untranslated DNA sequences were also identical. Northern blot analysis showed selective increase in relative concentrations of PRS1 transcripts in patient fibroblasts. In PRS catalytic superactivity, overexpression of the normal PRS1 isoform thus appears to result from an altered pretranslational mechanism of PRPS1 expression. In lymphoblasts, however, expression of this alteration is attenuated, explaining the absence of phenotypic expression of PRS catalytic superactivity in these cells.			Becker, MA (corresponding author), UNIV CHICAGO,MED CTR,RHEUMATOL SECT,DEPT MED,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK 28554] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028554] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAOKA I, 1981, J RHEUMATOL, V8, P563; AUSUBEL FM, 1987, CURRENT PROTOLS MOL; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BECKER MA, 1980, J CLIN INVEST, V65, P109, DOI 10.1172/JCI109640; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1991, ADV EXP MED BIOL, V309, P129; BECKER MA, 1975, J BIOL CHEM, V250, P6822; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; BECKER MA, 1987, J BIOL CHEM, V262, P14531; BECKER MA, 1988, AM J MED, V85, P383, DOI 10.1016/0002-9343(88)90591-8; BECKER MA, 1990, GENOMICS, V8, P555, DOI 10.1016/0888-7543(90)90043-T; BECKER MA, 1973, SCIENCE, V179, P1123, DOI 10.1126/science.179.4078.1123; BECKER MA, 1982, J LAB CLIN MED, V99, P485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON BL, 1991, AM J HUM GENET, V48, P951; IIZASA T, 1989, FEBS LETT, V244, P47, DOI 10.1016/0014-5793(89)81159-7; ISHIZUKA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P139, DOI 10.1016/0167-4781(92)90521-Z; KITA K, 1994, J BIOL CHEM, V269, P8334; LOSMAN MJ, 1985, J CLIN INVEST, V76, P1657, DOI 10.1172/JCI112151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; ROESSLER BJ, 1993, J BIOL CHEM, V268, P26476; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMMONDS HA, 1985, NEUROPEDIATRICS, V16, P106, DOI 10.1055/s-2008-1052552; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; SPERLING O, 1972, EUR J CLIN BIOL RES, V17, P703; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; YEN RCK, 1978, P NATL ACAD SCI USA, V75, P482, DOI 10.1073/pnas.75.1.482; ZOREF E, 1975, J CLIN INVEST, V56, P1093, DOI 10.1172/JCI108183	31	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19894	19899		10.1074/jbc.271.33.19894	http://dx.doi.org/10.1074/jbc.271.33.19894			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702702	hybrid			2022-12-27	WOS:A1996VC66900043
J	Nazareth, LV; Weigel, NL				Nazareth, LV; Weigel, NL			Activation of the human androgen receptor through a protein kinase A signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; EPIDERMAL GROWTH-FACTOR; PROSTATE-CANCER; GENE-EXPRESSION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; PHOSPHORYLATION SITES; BREAST-CANCER	Aberrant activation of the androgen receptor through signaling pathways independent of androgen may be responsible for the progression of prostate tumors to the rapidly proliferating androgen-independent state. In this study, the effects of protein kinase A modulators on human androgen receptor activity were tested. Using an adenoviral DNA delivery system, we demonstrate that the androgen receptor can be activated by a protein kinase A activator, forskolin, in the absence of androgen when androgen receptor is co-transfected into monkey kidney CV1 cells or human prostate PC-3 cells with androgen-responsive reporters. Immunoblotting reveals that there is no significant change in androgen receptor protein level following forskolin treatment, suggesting that the enhanced activity is clue to activation of the. receptor. This activation can be blocked by a protein kinase A inhibitor peptide. Two potent anti-androgens, casodex and flutamide, can significantly reduce this activation, confirming that the ligand-independent pathway is an androgen receptor-mediated phenomenon. An. intact DNA binding domain of the receptor is critical for this alternate signaling pathway since mutants with reduced DNA binding ability are inactive. The phosphorylation status of the androgen receptor or associated. proteins may critically modulate receptor activity and should be considered when designing improved approaches to prostate cancer therapy.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NCI NIH HHS [CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ALLGOOD VE, 1994, 76 END SOC M, P631; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER HB, 1990, PROSTATE, V16, P39; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; HOECK W, 1990, J BIOL CHEM, V265, P5403; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MOYER ML, 1993, J BIOL CHEM, V268, P22933; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SADI MV, 1993, CANCER, V71, P2574, DOI 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; TILLEY WD, 1990, CANCER RES, V50, P5382; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VERHELST J, 1994, CLIN ENDOCRINOL, V41, P525, DOI 10.1111/j.1365-2265.1994.tb02585.x; VOELLER HJ, 1991, MOL ENDOCRINOL, V5, P209, DOI 10.1210/mend-5-2-209; WONG CI, 1993, J BIOL CHEM, V268, P19004; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YUAN SX, 1993, CANCER RES, V53, P1304; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZOPPI S, 1992, MOL ENDOCRINOL, V6, P409, DOI 10.1210/me.6.3.409	41	352	379	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19900	19907		10.1074/jbc.271.33.19900	http://dx.doi.org/10.1074/jbc.271.33.19900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702703	hybrid			2022-12-27	WOS:A1996VC66900044
J	Widmann, C; Dolci, W; Thorens, B				Widmann, C; Dolci, W; Thorens, B			Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-KINASE-C; BETA-2-ADRENERGIC RECEPTOR; ADENYLYL-CYCLASE; ARRESTIN; IDENTIFICATION; STIMULATION; EXPRESSION; HORMONE; FAMILY	Glucagon-like peptide-1 stimulates glucose-induced insulin secretion by binding to a specific G protein-coupled receptor that activates the adenylyl cyclase pathway, We previously demonstrated that heterologous desensitization of the receptor by protein kinase C correlated with phosphorylation in a 33-amino acid-long segment of the receptor carboxyl-terminal cytoplasmic tail. Here, we determined that the in vivo sites of phosphorylation are four serine doublets present at positions 431/432, 441/442, 444/445, and 451/452. In vitro phosphorylation of fusion proteins containing mutant receptor C-tails, however, indicated that whereas serines at position 431/432 were good substrates for protein kinase C (PKC), serines 444/445 and 451/452 were poor substrates, and serines 441/442 were not substrates. In addition, serine 416 was phosphorylated on fusion protein but not in intact cells. This indicated that in vivo a different PKC isoform or a PKC-activated kinase may phosphorylate the receptor. The role of phosphorylation on receptor desensitization was assessed using receptor mutants expressed in COS cells or Chinese hamster lung fibroblasts. Mutation of any single serine doublet to alanines reduced the extent of phorbol ia-myristate 13-acetate-induced desensitization, whereas substitution of any combination of two serine doublets suppressed it. Our data thus show that the glucagon-like peptide-1 receptor can be phosphorylated in response to phorbol 12-myristate 13-acetate on four different sites within the cytoplasmic tail. Furthermore, phosphorylation of at least three sites was required for desensitization, although maximal desensitization was only achieved when all four sites were phosphorylated.	UNIV LAUSANNE,DEPT PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	University of Lausanne			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREUTZFELDT W, 1992, DIABETES METAB REV, V8, P149, DOI 10.1002/dmr.5610080206; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Thorens Bernard, 1994, P357; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; Widmann C, 1996, MOL ENDOCRINOL, V10, P62, DOI 10.1210/me.10.1.62; YUAN NY, 1994, J BIOL CHEM, V269, P23032	27	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19957	19963		10.1074/jbc.271.33.19957	http://dx.doi.org/10.1074/jbc.271.33.19957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702711	hybrid			2022-12-27	WOS:A1996VC66900052
J	Zhang, SY; Coso, OA; Collins, R; Gutkind, JS; Simonds, WF				Zhang, SY; Coso, OA; Collins, R; Gutkind, JS; Simonds, WF			A C-terminal mutant of the G protein beta subunit deficient in the activation of phospholipase C-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; BINDING PROTEINS; DICTYOSTELIUM-DISCOIDEUM; LIMITED PROTEOLYSIS; ADENYLYL CYCLASE; IDENTIFICATION; PATHWAY; STIMULATION	The molecular mechanism by which the G protein py complex modulates multiple mammalian effector pathways is unknown. Homolog-scanning mutagenesis of the G protein beta subunit was employed to identify residues critical for the activation of phospholipase C-beta(2) (PLC-beta(2)). A series of chimeras was made by introducing small segments of the Dictyostelium beta subunit into a background of mammalian beta(1) and tested in COS cell cotransfection assays for their ability ito activate PLC-beta(2), and assemble with mammalian gamma(2). A chimera that contained four Dictyostelium beta substitutions within the C-terminal 14 residues was unable to activate PLC beta(2), when cotransfected with gamma, despite its demonstrable expression in a gamma-dependent manner. Cotransfection of the mutant blocked m2 muscarinic receptor activation of PLC by a pertussis toxin-sensitive pathway. This C-terminal mutant retained the ability, however, to stimulate the mitogen-activated protein kinase pathway. These results imply that activation of different beta gamma-responsive effectors is mediated by distinct domains.	NIDDK,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOMINAAR AA, 1994, BIOCHEM J, V297, P189, DOI 10.1042/bj2970189; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CORIA R, 1995, FEBS LETT, V367, P122, DOI 10.1016/0014-5793(95)00526-F; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; DRAYER AL, 1994, EMBO J, V13, P1601, DOI 10.1002/j.1460-2075.1994.tb06423.x; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRISHIN AV, 1994, GENETICS, V138, P1081; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPIEGEL AM, 1994, PROTEINS; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	52	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20208	20212		10.1074/jbc.271.33.20208	http://dx.doi.org/10.1074/jbc.271.33.20208			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702747	hybrid			2022-12-27	WOS:A1996VC66900089
J	Huang, QL; Neuenschwander, PF; Rezaie, AR; Morrissey, JH				Huang, QL; Neuenschwander, PF; Rezaie, AR; Morrissey, JH			Substrate recognition by tissue factor-factor VIIa - Evidence for interaction of residues Lys(165) and Lys(166) of tissue factor with the 4-carboxyglutamate-rich domain of factor X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-VII; COFACTOR FUNCTION; BLOOD-COAGULATION; PROTEOLYTIC ACTIVATION; ENZYME COMPLEXES; FACTOR-IX; BINDING; CALCIUM; PROTEIN	Tissue factor (TF) is the protein cofactor for factor VIIa (FVIIa), the first serine protease of the clotting cascade. Previous studies using alanine mutagenesis have identified TF residues Lys(165) and Lys(166) as important for factor X (FX) activation, hypothesizing either that these residues interact with phospholipid head groups or that they directly or indirectly promote macromolecular substrate binding. In the recently reported x-ray crystal structure of the isolated extracellular domain of TF, both Lys(165) and Lys(166) are solvent-exposed and predicted to be near the phospholipid surface in intact TF. We hypothesized that these residues may in fact be ideally positioned to interact with the 4-carboxy-glutamate-rich domain (Gla domain) of FX. We therefore predicted that mutations at Lys(165) and Lys(166) should have no effect on the activation of Gla domainless FX. To test this hypothesis, we mutated both residues Lys(165) and Lys(166) of TF to Ala, Glu, or Gln and examined the ability of these double mutants to support FVIIa-mediated activation of FX, Gla domainless FX, and factor IX (FM). Each TF mutant was equivalent to wild-type TF in both FVIIa binding and promotion of FVIIa amidolytic activity, However, all three mutants were markedly deficient in supporting FIX and FX activation, with FX activation rates decreased more than FIX activation rates. In both reactions, the TF mutants exhibited different extents of activity: Gln(165)-Gln(166) > Ala(165)-Ala(166) > Glu(165)-Glu(166). In sharp contrast, all three TF mutants were equivalent to wild-type TF in supporting activation of Gla domainless FX by FVIIa. Interestingly, the deficiency of the mutants in FX activation was less pronounced when Gla domainless FVIIa was used in place of native FVIIa, Together, these findings suggest that TF residues Lys(165) and Lys(166) contribute to a binding site for the Gla domain of FX (and perhaps other substrates) and that this interaction may be facilitated by the presence of the Gla domain of FVIIa.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014, P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804, R01 HL47014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FIORE MM, 1992, BLOOD, V80, P3127; FIORE MM, 1994, J BIOL CHEM, V269, P143; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P16983; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PERSSON E, 1991, J BIOL CHEM, V266, P2453; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO LVM, 1995, BIOCHEMISTRY-US, V34, P10867, DOI 10.1021/bi00034a020; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SAKAI T, 1990, J BIOL CHEM, V265, P1890; THOMPSON AR, 1977, J CLIN INVEST, V59, P900, DOI 10.1172/JCI108712; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; ZUR M, 1978, J BIOL CHEM, V253, P2203	44	80	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21752	21757		10.1074/jbc.271.36.21752	http://dx.doi.org/10.1074/jbc.271.36.21752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702971				2022-12-27	WOS:A1996VF61200013
J	McCright, B; Rivers, AM; Audlin, S; Virshup, DM				McCright, B; Rivers, AM; Audlin, S; Virshup, DM			The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; DNA-REPLICATION; TUMOR-ANTIGEN; T-ANTIGEN; KINASE-A; FORMS; PHOSPHORYLATION; ASSOCIATION; EXPRESSION; MECHANISM	Protein phosphatase 2A is a heterotrimeric protein serine/threonine phosphatase consisting of a 36-kDa catalytic C subunit, a 65-kDa structural A subunit, and a variable regulatory B subunit. The B subunits determine the substrate specificity of the enzyme. There have been three families of cellular B subunits identified to date: B55, B56 (B'), and PR72/130, We have now cloned five genes encoding human B56 isoforms. Polypeptides encoded by all but one splice variant (B56 gamma 1) are phosphoproteins, as shown by mobility shift after treatment with alkaline phosphatase and metabolic labeling with [P-32]phosphate. All labeled isoforms contain solely phosphoserine. Indirect immunofluorescence microscopy demonstrates distinct patterns of intracellular targeting by different B56 isoforms. Specifically, B56 alpha, B56 beta, and B56 epsilon complexed with the protein phosphatase 2A A and C subunits localize to the cytoplasm, whereas B56 delta, B56 gamma 1, and B56 gamma 3 are concentrated in the nucleus. Two isoforms (B56 beta and B56 delta) are highly expressed in adult brain; here we show that mRNA for these isoforms in creases severalfold when neuroblastoma cell lines are induced to differentiate by retinoic acid treatment, These studies demonstrate an increasing diversity of regulatory mechanisms to control the activity of this key intracellular protein phosphatase and suggest distinct functions for isoforms targeted to different intracellular locations.	UNIV UTAH, SCH MED, DEPT ONCOL SCI, DIV MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, PROGRAM HUMAN MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, COMBINED PROGRAM MOL BIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [P30 CA42014, T32-CA09602] Funding Source: Medline; NIAID NIH HHS [R01 AI-31657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GARDNER J, 1995, SEQVU 1 0; *GEN COMP GROUP IN, 1994, PROGR MAN WISC PACK; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MCCRIGHT B, 1996, IN PRESS GENOMICS; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NISHIKAWA M, 1994, CANCER RES, V54, P4879; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SHU YM, 1995, MOL CELL BIOL, V15, P5618; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	44	318	333	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22081	22089		10.1074/jbc.271.36.22081	http://dx.doi.org/10.1074/jbc.271.36.22081			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703017	hybrid			2022-12-27	WOS:A1996VF61200059
J	Chatila, T; Anderson, KA; Ho, N; Means, AR				Chatila, T; Anderson, KA; Ho, N; Means, AR			A unique phosphorylation-dependent mechanism for the activation of Ca2+/calmodulin-dependent protein kinase type IV/GR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CAM-KINASE; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; B-LYMPHOCYTES; CDNA SEQUENCE; IV KINASE; CALMODULIN; GENE; GR	The activity of the Ca2+/calmodulin-dependent protein kinase IV/Gr (CaMKIV/Gr) is shown to be strictly regulated by phosphorylation of three residues both in vitro and in response to antigen receptor-mediated signaling in lymphocytes. One residue, Thr-200, is indispensable for enhancement of Ca2+/calmodulin-dependent basal activity by CaMKIV/Gr kinase. This event requires Ca2+/calmodulin in the full-length CaMKIV/Gr but is Ca2+/calmodulin-independent when a truncated version of CaMKIV/Gr is used as a substrate (Delta CaMKIV/Gr(1-317) (Delta 1-317)). The other two residues, Ser(12) and Ser(13), are apparently autophosphorylated by the Ca2+/calmodulin-bound CaMKIV/Gr. Phosphorylation of neither Ser(12)-Ser(13) nor Thr(312) (the residue in a homologous position to Thr(286) of CaMKII alpha influences the development of Ca2+/calmodulin-independent activity or any other property of CaMKIV/Gr examined. Similarly, removal of the NH2-terminal 20 amino acids has no effect on the activation or function of CaMKIV/Gr. However, mutation of both Ser(12) and Ser(13) residues to Ala in Delta 1-317 completely abrogates activity, while individual substitutions have no effect. These results indicate that the NH2-terminal Ser cluster mediates a novel type of intrasteric inhibition and suggest that three events are required for CaMKIV/Gr activation: 1) Ca2+/calmodulin binding; 2) phosphorylation of the Ca2+/calmodulin-bound enzyme on Thr(200) by a Ca2+/calmodulin-dependent protein kinase kinase; and 3) autophosphorylation of Ser(12)-Ser(13). This three-step requirement is unique among the multifunctional Ca2+/calmodulin-dependent kinases.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University	Chatila, T (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL RHEUMATOL,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.			Chatila, Talal/0000-0001-7439-2762				BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LOU LL, 1989, J NEUROSCI, V9, P2020; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MATHEWS RP, 1994, MOL CELL BIOL, V14, P6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MENEZES J, 1975, BIOMEDICINE, V22, P276; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER CL, 1993, J VIROL, V67, P3087, DOI 10.1128/JVI.67.6.3087-3094.1993; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIKELA JM, 1990, GENOMICS, V8, P579, DOI 10.1016/0888-7543(90)90048-Y; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN ZM, 1995, J BIOL CHEM, V270, P29507, DOI 10.1074/jbc.270.49.29507; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903	45	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21542	21548		10.1074/jbc.271.35.21542	http://dx.doi.org/10.1074/jbc.271.35.21542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702940	hybrid			2022-12-27	WOS:A1996VE47700086
J	Yankovskaya, V; Sablin, SO; Ramsay, RR; Singer, TP; Ackrell, BAC; Cecchini, G; Miyoshi, H				Yankovskaya, V; Sablin, SO; Ramsay, RR; Singer, TP; Ackrell, BAC; Cecchini, G; Miyoshi, H			Inhibitor probes of the quinone binding sites of mammalian complex II and Escherichia coli fumarate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE	The structural and catalytic properties of beef heart succinate dehydrogenase (succinate-ubiquinone oxidoreductase, complex II) and Escherichia coli fumarate reductase are remarkably similar, One exception is that whereas electron exchange between the mammalian enzyme and its quinone pool is inhibited by thenoyltrifluoroacetone. and carboxanilides, the enzyme from E. coli is not sensitive to these inhibitors, The lack of good inhibitors has seriously hampered the elucidation of the mechanism of quinone oxidation/reduction in the E. coli enzyme, We have previously reported (Tan, A. K., Ramsay, R. R., Singer, T. P., and Miyoshi, H. (1993) J. Biol. Chem. 268, 19328-19333) that 2-alkyl-4,6-dinitrophenols inhibit mammalian complexes I, II, and III, but with different potencies and kinetic characteristics. Based on these studies we have selected a series of 2-alkyl-4,6-dinitrophenols which proved to be very effective noncompetitive inhibitors of mammalian complex II, particularly when acting in the direction of quinone reduction, the physiological event. These compounds turned out to be even more potent inhibitors E. coli fumarate reductase, particularly when acting in the direction of quinol oxidation, again, the physiological event. Kinetic analysis revealed that with both enzymes 2 inhibitor binding sites seem to be involved in the oxidation of succinate by quinone, but one seems to be functioning when fumarate is reduced by external quinol, Since the E. coli enzyme can be modified by site-directed mutagenesis, these studies were extended to four mutants of fumarate reductase, impaired by single amino acid substitutions at either of the putative quinone binding sites (Q(A) or Q(B)) of the enzyme. The results were analyzed in terms of the model of these dual sites of quinone binding in fumarate reductase, as well as the nature of the substituent in the 2-position of the dinitrophenol inhibitors.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT SCI,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DIV MOL BIOL,SAN FRANCISCO,CA 94121; KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kyoto University			Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16251] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1977, ARCH BIOCHEM BIOPHYS, V182, P107, DOI 10.1016/0003-9861(77)90288-0; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; CHOUDHRY ZM, 1986, BIOCHIM BIOPHYS ACTA, V850, P131, DOI 10.1016/0005-2728(86)90017-4; Hansch C, 1979, SUBSTITUENT CONSTANT; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; TAN AK, 1993, J BIOL CHEM, V268, P19328; TAPPEL AL, 1960, BIOCHEM PHARMACOL, V3, P289, DOI 10.1016/0006-2952(60)90094-0; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WHITE GA, 1971, BIOCHEM BIOPH RES CO, V44, P1212, DOI 10.1016/S0006-291X(71)80215-2	12	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21020	21024		10.1074/jbc.271.35.21020	http://dx.doi.org/10.1074/jbc.271.35.21020			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702865	hybrid			2022-12-27	WOS:A1996VE47700011
J	Eden, A; Simchen, G; Benvenisty, N				Eden, A; Simchen, G; Benvenisty, N			Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; INDUCED APOPTOSIS; DNA-BINDING; CELL-CYCLE; PROTEIN; GENE; SEQUENCE; TRANSFORMATION; MAX; RAT	ECA39 was isolated as a target gene for c-Myc regulation in mice. We identified two homologs for the murine ECA39 in the yeast Saccharomyces cerevisiae, ECA39 and ECA40, as well as two human homologs. These genes show a significant homology to prokaryotic branched-chain amino acid aminotransferase (BCAT) (EC 2.6.1.42). To understand the function of eukaryotic ECA39 and ECA40, we deleted either gene hom the yeast genome. Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates. The results demonstrate that in S. cerevisiae ECA39 and ECA40 code for mitochondrial and cytosolic branched-chain amino acid aminotransferases, respectively. ECA39 is highly expressed during log phase and is downregulated during the stationary phase of growth, while ECA40 shows an inverse pattern of gene expression. In agreement with these results, while we previously showed that deletion of ECA39 affected the cell cycle in proliferating cells, me do not observe a growth phenotype in eca40 Delta cells. We suggest that BCAT is a target for c-Myc activity and discuss the evolutionary conservation of prokaryotic and eukaryotic BCATs and their possible involvement in regulation of cell proliferation.	HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT GENET, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD MJ, 1989, BIOCHEMISTRY-US, V28, P5306, DOI 10.1021/bi00438a058; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HALL TR, 1993, J BIOL CHEM, V268, P3092; HARTMANN C, 1991, NATURE, V352, P762, DOI 10.1038/352762b0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUTSON SM, 1993, J BIOL CHEM, V268, P3084; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; ICHIHARA A, 1966, J BIOCHEM-TOKYO, V59, P160, DOI 10.1093/oxfordjournals.jbchem.a128277; ICHIHARA A, 1975, ANN NY ACAD SCI, V259, P347, DOI 10.1111/j.1749-6632.1975.tb25431.x; Ichihara A, 1985, TRANSAMINASES, P430; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENKINS WT, 1970, METHOD ENZYMOL, V17, P802; KADOWAKI H, 1982, BIOCHEM J, V202, P777, DOI 10.1042/bj2020777; KURAMITSU S, 1985, J BIOCHEM-TOKYO, V97, P993, DOI 10.1093/oxfordjournals.jbchem.a135176; LIAO CL, 1978, LAB INVEST, V38, P122; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSE MD, 1990, METHODS YEAST GENETI, P114; ROTH SL, 1977, CANCER RES, V37, P1147; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER F, 1994, GENOMICS, V22, P118, DOI 10.1006/geno.1994.1352; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; TANIZAWA K, 1989, J BIOL CHEM, V264, P2450; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	51	96	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20242	20245		10.1074/jbc.271.34.20242	http://dx.doi.org/10.1074/jbc.271.34.20242			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702755	hybrid			2022-12-27	WOS:A1996VD33700007
J	Ekberg, M; Sahlin, M; Eriksson, M; Sjoberg, BM				Ekberg, M; Sahlin, M; Eriksson, M; Sjoberg, BM			Two conserved tyrosine residues in protein R1 participate in an intermolecular electron transfer in ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; PROMOTER SYSTEM; IRON CENTER; SUBUNIT; PROGRAM; PURIFICATION; INACTIVATION; INVOLVEMENT	The enzyme ribonucleotide reductase consists of two nonidentical proteins, R1 and R2, which are each inactive alone, R1 contains the active site and R2 contains a stable tyrosyl radical essential for catalysis, The reduction of ribonucleotides is radical based, and a long range electron transfer chain between the active site in R1 and the radical in R2 has been suggested, To find evidence for such an electron transfer chain in Escherichia coli ribonucleotide reductase, we converted two conserved tyrosines in R1 into phenylalanines by site-directed mutagenesis. The mutant proteins were shown to be enzymatically inactive, In addition, the mechanism-based inhibitor 2'-azido-2'-deoxy-CDP was incapable of scavenging the R2 radical, and no azido-CDP-derived radical intermediate was formed, We also shaw that the loss of enzymatic activity was not due to impaired R1-R2 complex formation or substrate binding, Based on these results, we predict that the two tyrosines, Tyr-730 and Tyr-731, are part of a hydrogenbonded network that constitutes an electron transfer pathway in ribonucleotide reductase, It is demonstrated that there is no electron delocalization over these tyrosines in the resting wild-type complex.	UNIV STOCKHOLM, DEPT MOL BIOL, S-10691 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOL BIOL, S-75124 UPPSALA, SWEDEN	Stockholm University; Swedish University of Agricultural Sciences				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DEREGE PJF, 1995, SCIENCE, V269, P1409, DOI 10.1126/science.7660123; ERIKSSON S, 1977, J BIOL CHEM, V252, P6132; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MINOIR W, 1993, XDISPLAYF PROGRAM; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUN L, 1992, MOL BIOL CELL, V3, P1095, DOI 10.1091/mbc.3.10.1095; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER L, 1973, J BIOL CHEM, V248, P4591; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003	41	116	119	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20655	20659		10.1074/jbc.271.34.20655	http://dx.doi.org/10.1074/jbc.271.34.20655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702814	hybrid			2022-12-27	WOS:A1996VD33700066
J	Frankel, G; Lider, O; Hershkoviz, R; Mould, AP; Kachalsky, SG; Candy, DCA; Cahalon, L; Humphries, MJ; Dougan, G				Frankel, G; Lider, O; Hershkoviz, R; Mould, AP; Kachalsky, SG; Candy, DCA; Cahalon, L; Humphries, MJ; Dougan, G			The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOTUBERCULOSIS INVASIN PROTEIN; HUMAN T-CELLS; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; MAMMALIAN-CELLS; TYROSINE PHOSPHORYLATION; YERSINIA-ENTEROCOLITICA; FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY	Bacteria interact with mammalian cells surface mole cules, such as integrins, to colonize tissues and evade immunological detection. Herein, the ability of intimin, an outer membrane protein from enteropathogenic Escherichia coli, to bind beta(1) integrins was investigated. Solid-phase binding assays revealed binding of the carboxyl-terminal 280 amino acids of intimin (Int280) to alpha(4) beta(1) and alpha(5) beta(1) integrins. The binding required divalent ions (in particular, it was enhanced by Mn2+) and was inhibited by an RGD-containing peptide. Nonderivatized Int280, but not Int280CS (like Int280 but with Cys-937 replaced by Ser) blocked the binding of biotinylated Int280 to integrins. Int280 did not efficiently inhibit beta(1), integrin binding of invasin from Yersinia pseudotuberculosis. Both intimin and invasin, immobilized on plastic surfaces, mediated adherence of resting or phorbol 12-myristate 13-acetate-activated human CD4(+) T cells, whereas fibronectin mediated the adherence of only activated T cells. T cell binding to intimin and invasin was integrin mediated because it was specifically blocked by an RGD containing peptide and by antibodies directed against the integrin subunits beta(1), alpha(4) and alpha(5). These results demonstrate a specific integrin binding activity for intimin that is related to, but distinct from, that of invasin.	WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; UNIV MANCHESTER, SCH BIOL SCI, WELLCOME TRUST CTR CELL MATRIX RES, MANCHESTER M13 9PT, LANCS, ENGLAND	Weizmann Institute of Science; University of Manchester	Frankel, G (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND.			Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALON R, 1994, J IMMUNOL, V152, P1304; ALON R, 1993, EUR J IMMUNOL, V23, P893, DOI 10.1002/eji.1830230419; BANK I, 1989, CELL IMMUNOL, V122, P416, DOI 10.1016/0008-8749(89)90088-9; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANIL C, 1993, INFECT IMMUN, V61, P2755, DOI 10.1128/IAI.61.7.2755-2762.1993; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; DONNENBERG MS, 1993, J BACTERIOL, V175, P4670, DOI 10.1128/JB.175.15.4670-4680.1993; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; ENNIS E, 1993, J EXP MED, V177, P207, DOI 10.1084/jem.177.1.207; FAGUNDESNETO U, 1995, ACTA PAEDIATR, V84, P453, DOI 10.1111/j.1651-2227.1995.tb13670.x; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; Frankel G, 1995, MICROB PATHOGENESIS, V19, P421, DOI 10.1006/mpat.1995.0076; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUMPHRIES MJ, 1993, BIOESSAYS, V15, P391, DOI 10.1002/bies.950150605; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KENNY B, 1995, P NATL ACAD SCI USA, V92, P7991, DOI 10.1073/pnas.92.17.7991; KERN A, 1994, J BIOL CHEM, V269, P22811; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; MIRON S, 1992, CELL IMMUNOL, V144, P182, DOI 10.1016/0008-8749(92)90235-H; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NHIEU GTV, 1993, EMBO J, V12, P1887; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PEPE JC, 1995, INFECT IMMUN, V63, P4837, DOI 10.1128/IAI.63.12.4837-4848.1995; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SPITZ J, 1995, AM J PHYSIOL-GASTR L, V268, pG374, DOI 10.1152/ajpgi.1995.268.2.G374; ULSHEN MH, 1980, NEW ENGL J MED, V302, P99, DOI 10.1056/NEJM198001103020207; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x	51	159	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20359	20364		10.1074/jbc.271.34.20359	http://dx.doi.org/10.1074/jbc.271.34.20359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702771	hybrid			2022-12-27	WOS:A1996VD33700023
J	Song, JP; Hirschman, J; Gunn, G; Dohlman, HG				Song, JP; Hirschman, J; Gunn, G; Dohlman, HG			Regulation of membrane and subunit interactions by N-myristoylation of a G protein alpha subunit in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; KINASE-C SUBSTRATE; SACCHAROMYCES-CEREVISIAE; LIPID MODIFICATIONS; PHEROMONE RESPONSE; PLASMA-MEMBRANE; MAJOR SUBSTRATE; MYRISTIC ACID; BOVINE BRAIN	Initiation of the mating process in yeast Saccharomyces cerevisiae requires the action of secreted pheromones and G protein-coupled receptors. As in other eu karyotes, the yeast G protein alpha subunit undergoes N-myristoylation (GPA1 gene product, Gpa1p). This modification appears to be essential for function, since a myristoylation site mutation exhibits the null phenotype in vivo (gpa1(G2A)). Here we examine how myristoylation affects Gpa1p activity in vitro. We show that the G2A mutant of Gpa1p, when fused with glutathione S-transferase, can still form a complex with the G protein beta gamma subunits. The complex is stabilized by GDP and is dissociated upon treatment with guanosine 5'-O-(thiotriphosphate). In addition, there is no apparent difference in the relative binding affinity of G(beta gamma) for mutant and wild-type Gpa1p. Using sucrose density gradient fractionation of cell membranes, Gpa1p associates normally with the plasma membrane whereas Gpa1p(G2A) is mislocalized to a microsomal membrane fraction. A portion of G(beta gamma) is also mislocalized in these cells, as it is in a gpa1 Delta strain. In contrast, wild-type Gpa1p reaches the plasma membrane in cells that do not express G(beta gamma) or cell surface receptors. These findings indicate that mislocalization of Gpa1p(G2A) is not caused by a redistribution of G(beta gamma), nor is it the result of any difference in G(beta gamma) binding affinity. These data suggest that myristoylation is required for specific targeting of Gpa1p to the plasma membrane, where it is needed to interact with the receptor and to regulate the release of G(beta gamma).	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PHARMACOL & MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01655 USA	Yale University; University of Massachusetts System; University of Massachusetts Worcester				Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM AA, 1988, P NATL ACAD SCI USA, V85, P6310, DOI 10.1073/pnas.85.17.6310; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CLARK KL, 1993, MOL CELL BIOL, V13, P1; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; Harlow E., 1988, ANTIBODIES LAB MANUA; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JUSTICE JM, 1995, J BIOL CHEM, V270, P17970, DOI 10.1074/jbc.270.30.17970; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MASTERSON WJ, 1992, PROTEIN TARGETING PR; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMONDS WF, 1989, BIOCHEM BIOPH RES CO, V164, P46, DOI 10.1016/0006-291X(89)91680-X; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	64	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20273	20283		10.1074/jbc.271.34.20273	http://dx.doi.org/10.1074/jbc.271.34.20273			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702760	hybrid			2022-12-27	WOS:A1996VD33700012
J	Gardella, TJ; Luck, MD; Jensen, GS; Usdin, TB; Juppner, H				Gardella, TJ; Luck, MD; Jensen, GS; Usdin, TB; Juppner, H			Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-8 receptor agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; HUMORAL HYPERCALCEMIA; EXPRESSION CLONING; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; BINDING DOMAINS; COMMON RECEPTOR; FRAGMENT 1-34; ROS 17/2.8; PROTEIN	Most of the bone and kidney-related functions of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) are thought to be mediated by the PTH/PTHrP receptor. Recently, a homologous receptor, the PTH-2 receptor, was obtained from rat and human brain cDNA libraries. This receptor displayed the remarkable property of responding potently to PTH, but not to PTHrP. To begin to define residues involved in the ligand specificity of the PTH-2 receptor, we studied the interaction of several PTH/PTHrP hybrid ligands and other related peptide analogs with the human PTH-2 receptor The results showed that two sites in PTH and PTHrP fully account for the different potencies that the tu o ligands exhibited with PTH-2 receptors; residue 5 (His in PTHrP and Ile in PTH) determined signaling capability, while residue 23 (Phe in PTHrP and Trp in PTH) determined binding affinity. By changing these two residues of PTHrP to the corresponding residues of PTH, we were able to convert PTHrP into a ligand that avidly bound to the PTH-2 receptor and fully and potently stimulated cAMP formation, Changing residue 23 alone yielded [Trp(23)]hPTHrP-(1-36), which was an antagonist for the PTH-2 receptor, but a fall agonist for the PTH/PTHrP receptor. Residues 5 and 23 in PTH and PTHrP thus play keg roles in signaling and binding interactions, respectively, with the PTH-2 receptor. Receptor-selective agonists and antagonists derived hom these studies could help to identify the biological role of the PTH-2 receptor and to map specific sites of ligand-receptor interaction.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; NIMH, CELL BIOL LAB, BETHESDA, MD 20892 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Gardella, TJ (corresponding author), MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, R01DK050708] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-50708, DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Broadus Arthur E., 1994, P259; BUNDI A, 1978, EUR J BIOCHEM, V91, P201, DOI 10.1111/j.1432-1033.1978.tb20952.x; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CAULFIELD MP, 1990, TRENDS ENDOCRINO JAN, P164; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; GARDELLA TJ, 1992, INT CONGR SER, V1003, P218; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KRONENBERG HM, 1993, HDB EXPT PHARM, P185; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; NAKAMOTO C, 1995, BIOCHEMISTRY-US, V34, P10546, DOI 10.1021/bi00033a029; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; ROSENBLATT M, 1977, ENDOCR RES COMMUN, V4, P115, DOI 10.3109/07435807709073917; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; URENA P, 1994, ENDOCRINOLOGY, V134, P451, DOI 10.1210/en.134.1.451; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455	30	76	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19888	19893		10.1074/jbc.271.33.19888	http://dx.doi.org/10.1074/jbc.271.33.19888			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702701	hybrid			2022-12-27	WOS:A1996VC66900042
J	Gerlitz, B; Grinnell, BW				Gerlitz, B; Grinnell, BW			Mutation of protease domain residues Lys(37-39) in human protein C inhibits activation by the thrombomodulin-thrombin complex without affecting activation by free thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; SERINE PROTEASES; RESISTANT; ANTICOAGULANT; MUTANT; MODELS; PAI-1; CA2+; CDNA	Activated protein C (aPC) is an important feedback regulator of the clotting cascade. In vivo, the conversion of protein C (PC) from its zymogen to activated form is mediated primarily by thrombin bound to thrombomodulin (TM), an endothelial cell surface protein, Molecular modeling suggests residues Lys(37)-Lys(38)-Lys(39) of protein C's serine protease domain reside in a surface-exposed loop (variable region 1) whose high concentration of positive charge might be involved in protein-protein interactions, In this study, we have examined the role of the conserved tribasic Lys(37-39) charge center in human protein C activation, This sequence was changed to acidic by substitution with Asp(37)-Glu(38)-Asp(39) (DED) and Glu(37)-Glu(38)-Glu(39) (EEE), or to neutrality by substitution with Gly(37)-Gly(38)-Gly(39) (GGG). These mutant PCs, expressed and purified from recombinant human 293 cells, appeared normal with regard to intracellular processing, ability to be secreted, and formation of a viable active site for tripeptidyl-p-nitroanilide substrate cleavage, For activation by free thrombin, wild-type (wt) and mutant PCs displayed equivalent activation rates, as well as identical calcium-dependent inhibition of such activation, Activation of wt-PC with a soluble TM-thrombin complex yielded a 2,000-fold faster rate compared with that by free thrombin at the same (physiological) calcium level, In contrast,the acidic mutants DED and EEE exhibited virtually no TM-mediated increase in activation rate, while the neutral mutant GGG was somewhat intermediate with a 30-fold stimulation of activation rate, These reductions in activation rate were independent of the presence of chondroitin sulfate on TM, Our observations represent the first identification of residues whose mutation essentially uncouples activation by the TM-thrombin complex without affecting activation by free thrombin, Further, our results suggest that VR1 residues within the zymogen form of a serine protease can be important for recognition by physiological activators.	LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC RES,INDIANAPOLIS,IN 46285	Eli Lilly								ADAMS DS, 1991, J BIOL CHEM, V266, P8476; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; COOPER ST, 1995, BIOCHEMISTRY-US, V34, P12991, DOI 10.1021/bi00040a009; DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P139; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FISHER CL, 1994, PROTEIN SCI, V3, P588; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LIU LW, 1994, J BIOL CHEM, V269, P11807; LONG GL, 1984, P NATL ACAD SCI-BIOL, V81, P5653, DOI 10.1073/pnas.81.18.5653; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RICHARDSON MA, 1994, PROTEIN SCI, V3, P711; TADA N, 1992, J BIOCHEM-TOKYO, V111, P491, DOI 10.1093/oxfordjournals.jbchem.a123785; TESTA JE, 1995, FIBRINOLYSIS, V9, P93, DOI 10.1016/S0268-9499(95)80070-0; TOMA K, 1989, J MOL GRAPHICS, V7, P146, DOI 10.1016/0263-7855(89)80018-9; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655	28	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22285	22288		10.1074/jbc.271.37.22285	http://dx.doi.org/10.1074/jbc.271.37.22285			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798383	hybrid			2022-12-27	WOS:A1996VG67200002
J	Franzke, CW; Baici, A; Bartels, J; Christophers, E; Wiedow, O				Franzke, CW; Baici, A; Bartels, J; Christophers, E; Wiedow, O			Antileukoprotease inhibits stratum corneum chymotryptic enzyme - Evidence for a regulative function in desquamation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCUS PROTEINASE-INHIBITOR; AMINO-ACID-SEQUENCE; LEUKOCYTE PROTEASE INHIBITOR; ELASTASE-SPECIFIC INHIBITOR; HUMAN SKIN; HUSI-I; PURIFICATION; HOMOLOGY; ELAFIN	The stratum corneum chymotryptic enzyme (SCCE) has been previously purified from human stratum corneum and resembles a chymotryptic serine endopeptidase involved in physiological detachment of corneocytes from human stratum corneum. From human stratum corneum two inhibitory activities of SCCE could be extracted. These were due to serine protease inhibitors already known to be present in human epidermis, antileukoprotease (secretory leukocyte protease inhibitor) and elafin (skin-derived antileukoprotease). The Inhibition of SCCE by antileukoprotease shows a hyperbolic, mixed type inhibition with an equilibrium dissociation constant of 63 nM. Antileukoprotease also inhibits detachment of corneocytes from human plantar callus in vitro almost completely (>96%). In addition, elafin was shown to be a weak inhibitor for SCCE activity, and elafin significantly reduces the shedding of corneocytes. Thus, antileukoprotease, which is known to be produced by human keratinocytes, is likely to be the major physiological inhibitor of SCCE in the epidermis. It seems to be involved in the regulation of desquamation under physiological and pathophysiological conditions.	CHRISTIAN ALBRECHTS UNIV KIEL,DEPT DERMATOL,D-24105 KIEL,GERMANY; UNIV ZURICH HOSP,DEPT RHEUMATOL,CH-8091 ZURICH,SWITZERLAND	University of Kiel; University of Zurich; University Zurich Hospital			Bartels, Joachim H./B-2802-2009; Wiedow, Oliver/B-7414-2009	Baici, Antonio/0000-0002-2980-0541; Bartels, Joachim/0000-0003-4395-4552				BAICI A, 1981, EUR J BIOCHEM, V119, P9, DOI 10.1111/j.1432-1033.1981.tb05570.x; BOTTS J, 1953, T FARADAY SOC, V49, P696, DOI 10.1039/tf9534900696; BOUDIER C, 1992, J BIOL CHEM, V267, P4370; BRAUN NJ, 1987, BIOL CHEM H-S, V368, P299, DOI 10.1515/bchm3.1987.368.1.299; CHRISTENSEN MS, 1978, J INVEST DERMATOL, V71, P289, DOI 10.1111/1523-1747.ep12529180; EGELRUD T, 1993, ACTA DERM-VENEREOL, V73, P181; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; FRITZ H, 1988, BIOL CHEM H-S, V369, P79; HANNSON L, 1994, BIOCH MOL BIOL, V269, P19420; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; SALLENAVE JM, 1991, BIOL CHEM H-S, V372, P13, DOI 10.1515/bchm3.1991.372.1.13; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SONDELL B, 1995, J INVEST DERMATOL, V104, P819, DOI 10.1111/1523-1747.ep12607007; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459, DOI 10.1177/42.4.7510318; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SZEDLACSEK SE, 1987, BIOCHEM J, V254, P311; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; WIEDOW O, 1993, J INVEST DERMATOL, V101, P305, DOI 10.1111/1523-1747.ep12365430; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WIEDOW O, 1995, ISOLIERUNG CHARAHTER	23	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21886	21890		10.1074/jbc.271.36.21886	http://dx.doi.org/10.1074/jbc.271.36.21886			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702990	hybrid			2022-12-27	WOS:A1996VF61200032
J	Henry, NL; Bushnell, DA; Kornberg, RD				Henry, NL; Bushnell, DA; Kornberg, RD			A yeast transcriptional stimulatory protein similar to human PC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GENE-TRANSCRIPTION; PURIFICATION; ACTIVATION; COACTIVATOR; INITIATION; BINDING; IDENTIFICATION; HOLOENZYME; ALIGNMENT	A yeast protein has been identified that stimulates basal transcription by RNA polymerase II, binds both single- and double-stranded DNA, and interacts with both a general transcription factor and a transcriptional activator. Phosphorylation appears to regulate these interactions. The gene for the transcriptional stimulatory protein, termed TSP1, was cloned and found to be dispensable for yeast cell viability. The deduced amino acid sequence is similar to that of mammalian coactivator protein PC4.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659, GM07276-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C., 1991, METHODS ENZYMOLOGY G; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SOMA GI, 1984, BIOCHEM BIOPH RES CO, V124, P164, DOI 10.1016/0006-291X(84)90931-8; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	33	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21842	21847		10.1074/jbc.271.36.21842	http://dx.doi.org/10.1074/jbc.271.36.21842			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702984	hybrid			2022-12-27	WOS:A1996VF61200026
J	Ingham, CJ; Hunter, IS; Smith, MCM				Ingham, CJ; Hunter, IS; Smith, MCM			Isolation and sequencing of the rho gene from Streptomyces lividans ZX7 and characterization of the RNA-dependent NTPase activity of the overexpressed protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; TRANSCRIPTION TERMINATION; ESCHERICHIA-COLI; ATPASE ACTIVITY; IDENTIFICATION; BICYCLOMYCIN; EFFICIENCY; HELICASE; BACTERIA; DOMAIN	The gene for transcription termination factor Rho was isolated from Streptomyces lividans ZX7, It encoded a 77-kDa polypeptide (Rho 77) with considerable homology to known Rho factors. An atypical hydrophilic region of 228 residues was found within the N-terminal RNA-binding domain. Only Rho from Micrococcus luteus and Mycobacterium leprae (closely related GC-rich Gram-positive bacteria) had an analogous sequence, Rho 77 was overexpressed in Escherichia coli and purified using an N-terminal hexahistidine-tag. Rho 77 displayed a broad RNA-dependent ATPase activity, with poly(C) RNA being no more than 4-fold more effective than poly(A). This contrasts with the ATPase activity of Rho from E. coli which is stimulated primarily by poly(C) RNA. Rho 77 was a general RNA-dependent NTPase, apparent K-m values for NTPs were: GTP 0.13 mM, ATP 0.17 mM, UTP 1.1 mM, and CTP >2 mM. Rho 77 poly(C)-dependent ATPase activity was inhibited by heparin, unlike the E. coli Rho. The antibiotic bicyclomycin inhibited the in vitro RNA-dependent ATPase activity of Rho 77, did not inhibit growth of streptomycetes but delayed the development of aerial mycelia, N-terminal deletion analysis to express a truncated form of Rho (Rho 72, 72 kDa) indicated that the first 42 residues of Rho 77 were not essential for RNA-dependent NTPase activity and were not the targets of inhibition by heparin or bicyclomycin.	UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV MOL GENET,GLASGOW G12,LANARK,SCOTLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND	University of Glasgow; University of Nottingham								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEKTESH SL, 1981, BIOCHIM BIOPHYS ACTA, V655, P96, DOI 10.1016/0005-2787(81)90071-X; BIBB MJ, 1985, MOL GEN GENET, V199, P26, DOI 10.1007/BF00327505; BIVILLE F, 1985, J GEN MICROBIOL, V131, P2953; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHILLON N, 1990, FEBS LETT, V262, P189, DOI 10.1016/0014-5793(90)80186-M; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; Hopwood D.A., 1985, GENETIC MANIPULATION; HUNTER IS, 1989, DNA CLONING PRACTICA, V1, P19; KIESER HM, 1992, J BACTERIOL, V174, P5496, DOI 10.1128/JB.174.17.5496-5507.1992; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWERY C, 1977, J BIOL CHEM, V252, P1375; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; NISHIDA M, 1972, J ANTIBIOT, V25, P582, DOI 10.7164/antibiotics.25.582; *NOV INC, 1995, PET SYST MAN; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; QUIRK PG, 1993, J BACTERIOL, V175, P647, DOI 10.1128/JB.175.3.647-654.1993; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RUTESHOUSER EC, 1989, J MOL BIOL, V208, P23, DOI 10.1016/0022-2836(89)90085-5; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH MCM, 1991, MOL MICROBIOL, V5, P2833, DOI 10.1111/j.1365-2958.1991.tb01992.x; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; WOESTYN S, 1994, J BACTERIOL, V176, P1561, DOI 10.1128/jb.176.6.1561-1569.1994	34	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21803	21807		10.1074/jbc.271.36.21803	http://dx.doi.org/10.1074/jbc.271.36.21803			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702978	hybrid			2022-12-27	WOS:A1996VF61200020
J	Tischer, E; Cordell, B				Tischer, E; Cordell, B			beta-amyloid precursor protein - Location of transmembrane domain and specificity of gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; TRANSGENIC MICE; CULTURED-CELLS; CATHEPSIN-D; MUTATION; PEPTIDE; GENERATION; DEPOSITS; AMINO; TERMINUS	The formation of beta-amyloid by processing of its precursor protein is a characteristic of Alzheimer's disease. Two proteolytic cleavages produce the amino and carboxyl termini of beta-amyloid, with the latter cleavage site located within the transmembrane domain. Using DNA mutagenesis, we investigated the membrane position and sequence requirements for carboxyl-terminal processing of the beta-amyloid domain. Substitution of negatively charged residues across positions 40-46 of the beta-amyloid domain precluded both beta-amyloid formation and precursor maturation associated with secretory protein transport. In contrast, identical substitutions from positions 48-50 had no adverse effects. Since charged residues typically prevent protein membrane insertion, these data define the membrane boundary to position 46/47, a location allowing greater access to carboxyl-terminal processing of beta-amyloid, possibly without membrane destruction. Deletions within the carboxyl-terminal domain, including 4 residues spanning positions 39-42 of beta-amyloid, resulted in formation of the beta-amyloid peptide. Substituting residues 38-47 or 39-56 of the beta-amyloid domain in the precursor with a transmembrane sequence from another protein yielded a similar to 4-kDa beta-amyloid peptide, reflecting a loose residue specificity for carboxyl-terminal processing to beta-amyloid.	SCIOS NOVA INC,MT VIEW,CA 94043	Scios								ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P1072; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; ISHIURA S, 1990, NEUROSCI LETT, V115, P329, DOI 10.1016/0304-3940(90)90477-Q; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LADROR US, 1994, J BIOL CHEM, V269, P18422; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MUNDY DI, 1994, BIOCHEM BIOPH RES CO, V204, P333, DOI 10.1006/bbrc.1994.2464; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; ZHONG ZY, 1994, J BIOL CHEM, V269, P627; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	42	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21914	21919		10.1074/jbc.271.36.21914	http://dx.doi.org/10.1074/jbc.271.36.21914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702994	hybrid			2022-12-27	WOS:A1996VF61200036
J	Kim, CG; Park, D; Rhee, SG				Kim, CG; Park, D; Rhee, SG			The role of carboxyl-terminal basic amino acids in G(q)alpha-dependent activation, particulate association, and nuclear localization of phospholipase C-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDASE-C-BETA; PROTEIN ALPHA-SUBUNIT; BOVINE BRAIN; EXPRESSION SYSTEM; VACCINIA VIRUS; DNA-POLYMERASE; CELLS; PURIFICATION; ISOZYMES	The phospholipase C (PLC)-beta isozymes differ from the PLC-gamma and PLC-delta isozymes in that they possess a long COOH-terminal sequence downstream of their catalytic domain, are activated by alpha subunits of the G(q) class of G proteins, associate with the particulate subcellular fraction, and are present in the nucleus. Most of the COOH-terminal domain of PLC-beta isozymes is predicted to be helical, and three regions in this domain, PLC-beta 1 residues 911-928 (region 1), 1055-1072 (region 2), and 1109-1126 (region 3), contain a high proportion of basic residues that are highly conserved. Projection of the sequences of these three regions in helical wheels reveals clustering of the basic residues. The role of the COOH terminus and the clustered basic residues in PLC-beta 1 was investigated by either truncating the entire COOH-terminal domain (mutant Delta C) or replacing two or three clustered basic residues with isoleucine (or methionine), and expressing the mutant enzymes in CV-1, Rat-2, or Swiss 3T3 cells. The Delta C mutant no longer showed the ability to be activated by G(q) alpha, to translocate to the nucleus, or to associate with the particulate fraction. Substitution of clusters of basic residues in regions 1 and 2 generally reduced the extent of activation by G(q) alpha, whereas substitution of a basic cluster in region 3 had no effect. Substitution of the cluster of lysine residues 914, 921, and 925 in region 1 had the most marked effect, reducing G(q) alpha-dependent activity to 10% of that of wild type. All substitution mutants, with the exception of that in which lysine residues 1056, 1063, and 1070 in region 2 were substituted with isoleucine, behaved like the wild-type enzyme in showing an approximately equal distribution between cytoplasm and nucleus; only 12% of the region 2 mutant was present in the nucleus. None of the basic clusters appeared critical for particulate association; however, replacement of each cluster reduced the amount of PLC-beta 1 in the particulate fraction by some extent, suggesting that all the basic residues contribute to the association, presumably by interacting with acidic residues in the particulate fraction, Membrane localization of PLC-beta isozymes is therefore likely mediated by both the COOH-terminal domain and the pleckstrin homology domain, the latter of which is known to bind phosphatidylinositol 4,5-biphosphate.	NHLBI,LAB CELL SIGNALING,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P720, DOI 10.1016/0006-291X(89)90054-5; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1995, BIOCHEM J, V312, P63, DOI 10.1042/bj3120063; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUKUI T, 1988, J BIOL CHEM, V263, P17730; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JHON DY, 1993, J BIOL CHEM, V268, P8654; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LASKEY RA, 1993, CELL, V74, P385; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEE SB, 1993, J BIOL CHEM, V268, P25952; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MARTELLI AM, 1994, CANCER RES, V54, P2536; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WU DQ, 1993, J BIOL CHEM, V268, P3704; YORK JD, 1994, J BIOL CHEM, V269, P7847	41	188	191	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21187	21192		10.1074/jbc.271.35.21187	http://dx.doi.org/10.1074/jbc.271.35.21187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702889	hybrid			2022-12-27	WOS:A1996VE47700035
J	Kridel, SJ; Chan, WW; Knauer, DJ				Kridel, SJ; Chan, WW; Knauer, DJ			Requirement of lysine residues outside of the proposed pentasaccharide binding region for high affinity heparin binding and activation of human antithrombin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE CHEMICAL MODIFICATION; THROMBIN REACTION; SITE; IDENTIFICATION; PURIFICATION; ACCELERATION; MECHANISM; CELLS; GLYCOSYLATION; ARGININE-129	Variant forms of human antithrombin III with glutamine or threonine substitutions at Lys(114), Lys(125), Lys(133), Lys(136), and Lys(139) were expressed in insect cells to evaluate their roles in heparin binding and activation. Recombinant native ATIII and all of the variants had very similar second order rate constants for thrombin inhibition in the absence of heparin, ranging from 1.13 x 10(5) M(-1)min(-1) to 1.66 x 10(5) M(-1)min(-1). Direct binding studies using I-125-fluoresceinamine-heparin yielded a K-d of 6 nM for the recombinant native ATIII and K136T, whereas R114Q and K139Q bound heparin so poorly that a K-d could not be determined. K125Q had a moderately reduced affinity. Heparin binding affinity correlated directly with heparin cofactor activity. Recombinant native ATIII was nearly identical to plasma-purified ATIII, whereas K114Q and K139Q were severely impaired in heparin cofactor activity. K125Q and K136T were only slightly impaired. Based on these data, Lys(114) and Lys(139) which are outside of the putative pentasaccharide binding site, play pivotal roles in the high affinity binding of heparin to ATIII and the activation of thrombin inhibitory activity.	UNIV CALIF IRVINE,SCH BIOL SCI,DEPT DEV & CELL BIOL,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01-GM34001-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETHELL GS, 1979, J BIOL CHEM, V254, P2572; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DD, 1987, BEHAV RES THER, V25, P223, DOI 10.1016/0005-7967(87)90049-0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG JY, 1989, J BIOL CHEM, V264, P3111; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P494; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DUCHANGE N, 1987, THROMB RES, V45, P115, DOI 10.1016/0049-3848(87)90263-5; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; Higuchi R, 1988, NUCLEIC ACIDS RES, V16, P7352; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LIU CS, 1987, J BIOL CHEM, V262, P17356; LIU CS, 1987, EUR J BIOCHEM, V167, P247, DOI 10.1111/j.1432-1033.1987.tb13330.x; MEAGHER JL, 1996, INT S CHEM BIOL SERP; MOLLOY C, 1989, THROMB RES, V55, P657, DOI 10.1016/0049-3848(89)90399-X; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OWEN MC, 1987, BLOOD, V69, P1275; PECON JM, 1984, J BIOL CHEM, V259, P935; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENFELD L, 1987, BIOCHEMISTRY-US, V12, P639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; WICKHAM TJ, 1993, BIOTECHNOL PROGR, V9, P25, DOI 10.1021/bp00019a004	41	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20935	20941		10.1074/jbc.271.34.20935	http://dx.doi.org/10.1074/jbc.271.34.20935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702852	hybrid			2022-12-27	WOS:A1996VD33700104
J	Gustafson, KS; Ginder, GD				Gustafson, KS; Ginder, GD			Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1 alpha to a distinct interferon-gamma-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENES; PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; MUTANT-CELL LINE; IFN-BETA-GENE; TRANSCRIPTION FACTOR; DNA-BINDING; REGULATORY FACTOR; SIGNAL-TRANSDUCTION; HLA-E	Expression of the human major histocompatibility complex (MHC) class I genes has been shown previously to increase at the transcriptional level following exposure to interferon-gamma (IFN-gamma). In this report we have examined the molecular mechanisms involved in the IFN gamma-induced transcription of the human MHC class I gene, HLA-E. Functional analysis of CAT reporter gene constructs under the control of the HLA-E promoter transfected into U937 cells revealed the presence of a distinct IFN-gamma-responsive element, termed the interferon response region (IRR), that was necessary and sufficient to mediate the response to IFN-gamma. This cis-acting regulatory sequence contains an imperfect inverted repeat; the 5'-half of the IRR resembles the IFN-gamma activation site (GAS), and the 3'-half of the IRR resembles the interferon-stimulated response element (ISRE). Gel mobility shift assays demonstrated that the IRR bound a single, specific, IFN-gamma-induced complex (IRR-AC), which was formed rapidly following treatment with IFN-gamma and was independent of protein synthesis. Competition experiments with GAS and ISRE sequences from other IFN-inducible genes showed that GAS sequences competed for the IRR-AC, whereas ISRE sequences did not compete. Mutational analysis demonstrated that point mutations in either the 5'-half or 3'-half of the IRR prevented binding of the complex and abrogated or markedly reduced the IFN-gamma responsiveness of reporter gene constructs. Supershift analysis revealed that the IRR-AC contains a factor that was recognized by antibodies specific for the protein STAT1 alpha (signal transducer and activator of transcription). Taken together, these findings suggest that the mechanism of IFN-gamma-induced transcription of the HLA-E gene is distinct from that of other MHC class I genes.	UNIV MINNESOTA,INST HUMAN GENET,DIV ONCOL,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR CANC,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R01CA045634] Funding Source: NIH RePORTER; NCI NIH HHS [CA45634] Funding Source: Medline; NIGMS NIH HHS [GM08244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEN E, 1986, MOL CELL BIOL, V6, P1698, DOI 10.1128/MCB.6.5.1698; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GUYER NB, 1995, J IMMUNOL, V155, P3472; HAKEM R, 1991, J IMMUNOL, V147, P2384; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOLLER BH, 1988, J IMMUNOL, V141, P897; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; QUILLET A, 1988, J IMMUNOL, V141, P17; RAZ R, 1994, J BIOL CHEM, V269, P24391; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; ULBRECHT M, 1992, J IMMUNOL, V149, P2945; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; WARING JF, 1995, J BIOL CHEM, V270, P12276, DOI 10.1074/jbc.270.20.12276; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	76	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20035	20046		10.1074/jbc.271.33.20035	http://dx.doi.org/10.1074/jbc.271.33.20035			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702722	hybrid			2022-12-27	WOS:A1996VC66900063
J	Itagaki, K; Carver, GT; Philpot, RM				Itagaki, K; Carver, GT; Philpot, RM			Expression and characterization of a modified flavin-containing monooxygenase 4 from humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN LIVER; ESCHERICHIA-COLI; PRIMARY SEQUENCE; RABBIT LIVER; GUINEA-PIG; FORM-II; CLONING; DISTINCT; LUNG; GENE	The inability to obtain flavin-containing monooxygenase 4 (FMO4) in heterologous systems lass hampered efforts to characterize this isoform of the FMO gene family. Neither the human nor the rabbit ortholog of FMO4, each of which has been cloned and sequenced, has been expressed. Attempts to achieve expression of FMO4 have beets made with Escherichia coli, baculovirus, yeast, and COS systems. The cDNAs encoding FMO4 have extended coding regions compared with those encoding other FMO isoforms, The derived amino acid sequences of FMO1, -2, -3, and -5 from all species examined contain about the same number of residues (531-535 residues), whereas the derived sequences of human and rabbit FMO4 contain 558 and 555 residues, respectively. We have investigated whether the elongation of the FMO4 coding region is related to the inability to achieve expression, The cDNA encoding human FMO4 has been modified by a single base change that introduces a stop codon at the consensus position. This modification allows for expression in E. coli, Lack of expression of intact FMO4 is caused by a problem that occurs following transcription, a problem that is overcome completely by relocation of the stop codon 81 bases to 5' of its normal position, Truncated FMO4 is expressed as an active enzyme with characteristics typical of an FMO isoform. Possible functional changes resulting from altering the 3'-end of an FMO were investigated with human FMO3. Elongation of the coding region of the FMO3 cDNA to the next available stop codon (FMO3*) resulted in the expression of an enzyme with properties very similar to those of unmodified FMO3. Elongation of FMO3 lowered the level of expression in E. coli but did not eliminate it. As with FMO4, the difference in expression levels between FMO3 and elongated FMO3 (FMO3*) appears to be related to translation rather than transcription, The functional characteristics of FMO3 and FMO3* are not significantly different.	NIEHS,MOL PHARMACOL SECT,CELLULAR & MOL PHARMACOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Itagaki, Kiyoshi/M-5501-2015	Itagaki, Kiyoshi/0000-0002-6033-1122				ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; AYESH R, 1990, PHARMACOL THERAPEUT, V45, P387, DOI 10.1016/0163-7258(90)90074-C; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BURNETT VL, 1994, J BIOL CHEM, V269, P14314; CASHMAN JR, 1995, CHEM-BIOL INTERACT, V96, P33, DOI 10.1016/0009-2797(94)03581-R; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; DOLPHIN C, 1991, J BIOL CHEM, V266, P12379; DOLPHIN CT, 1992, BIOCHEM J, V287, P261, DOI 10.1042/bj2870261; DOMIN BA, 1984, ANAL BIOCHEM, V136, P390, DOI 10.1016/0003-2697(84)90234-3; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER R, 1990, BIOCHEMISTRY-US, V29, P119, DOI 10.1021/bi00453a014; ITOH K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P165, DOI 10.1016/0167-4781(93)90177-F; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAWTON MP, 1994, ARCH BIOCHEM BIOPHYS, V308, P254, DOI 10.1006/abbi.1994.1035; LAWTON MP, 1993, J BIOL CHEM, V268, P5728; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LOMRI N, 1993, CHEM RES TOXICOL, V6, P425, DOI 10.1021/tx00034a006; LOMRI N, 1995, P NATL ACAD SCI USA, V92, P9910, DOI 10.1073/pnas.92.21.9910; LOMRI N, 1992, P NATL ACAD SCI USA, V89, P1685, DOI 10.1073/pnas.89.5.1685; LOMRI N, 1993, CHEM RES TOXICOL, V6, P800, DOI 10.1021/tx00036a008; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIKBAKHT KN, 1992, PHARMACOGENETICS, V2, P207, DOI 10.1097/00008571-199210000-00003; OVERBY LH, 1995, ARCH BIOCHEM BIOPHYS, V317, P275, DOI 10.1006/abbi.1995.1163; PARKER BL, 1996, CHEM-BIOL INTERACT, V99, P253; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; PETTIT FH, 1964, BIOCHEM BIOPH RES CO, V16, P444, DOI 10.1016/0006-291X(64)90373-0; PHILLIPS IR, 1995, CHEM-BIOL INTERACT, V96, P17, DOI 10.1016/0009-2797(94)03580-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYNES RE, 1985, BIOCHEM BIOPH RES CO, V126, P1069, DOI 10.1016/0006-291X(85)90294-3; WILLIAMS DE, 1984, BIOCHEM BIOPH RES CO, V125, P116, DOI 10.1016/S0006-291X(84)80342-3; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1; ZIEGLER DM, 1972, ARCH BIOCHEM BIOPHYS, V150, P116, DOI 10.1016/0003-9861(72)90017-3; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617	38	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20102	20107		10.1074/jbc.271.33.20102	http://dx.doi.org/10.1074/jbc.271.33.20102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702731	hybrid			2022-12-27	WOS:A1996VC66900072
J	Shields, JM; Christy, RJ; Yang, VW				Shields, JM; Christy, RJ; Yang, VW			Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEINS; DNA-BINDING DOMAINS; NUCLEAR PROTEINS; TRANSCRIPTIONAL PROPERTIES; MULTIGENE FAMILY; CACCC ELEMENT; C-FOS; SEQUENCES; CELLS; ACID	A cDNA clone, named gut-enriched Kruppel-like factor (GKLF), was isolated from an NIH 3T3 library using a probe encoding the zinc finger region of the immediate-early transcription factor zif/268. The deduced GKLF amino acid sequence contains three tandem zinc fingers that are related to members of the Kruppel family of transcription factors. By indirect immunofluorescence, GKLF is localized to the cell nucleus. In cultured fibroblasts, GKLF mRNA is found in high levels in growth-arrested cells and is nearly undetectable in cells that are in the exponential phase of proliferation. The growth-arresting nature of GKLF is demonstrated by an inhibition of DNA synthesis in cells transfected with a GKLF-expressing plasmid construct. In the mouse, GKLF mRNA is present in select tissues and is most abundant in the colon, followed by the testis, lung, and small intestine. In situ hybridization experiments indicate that GKLF mRNA is enriched in epithelial cells located in the middle to upper crypt region of the colonic mucosa. Taken together, these results suggest that GKLF is potentially a negative regulator of cell growth in tissues such as the gut mucosa, where cell proliferation is intimately coupled to growth arrest and differentiation.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOL MED,SAN ANTONIO,TX 78250	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Health San Antonio					NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, P01DK044484] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [P01 DK044484-100005, R01 DK052230-03, R01 DK052230] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEVAILLIER P, 1993, INT J BIOCHEM, V25, P479, DOI 10.1016/0020-711X(93)90653-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRASER PD, 1993, BIOCHEM J, V291, P687, DOI 10.1042/bj2910687; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAMIL KG, 1994, ENDOCRINOLOGY, V134, P1205, DOI 10.1210/en.134.3.1205; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OLIVA MM, 1993, ARCH BIOCHEM BIOPHYS, V302, P183, DOI 10.1006/abbi.1993.1197; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TIETJEN TG, 1994, HISTOCHEM J, V26, P526, DOI 10.1007/BF00157898; TIETJEN TG, 1994, J HISTOCHEM CYTOCHEM, V42, P745, DOI 10.1177/42.6.8189036; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	63	534	577	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20009	20017		10.1074/jbc.271.33.20009	http://dx.doi.org/10.1074/jbc.271.33.20009			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702718	hybrid, Green Accepted			2022-12-27	WOS:A1996VC66900059
J	Tsakiridis, T; Taha, C; Grinstein, S; Klip, A				Tsakiridis, T; Taha, C; Grinstein, S; Klip, A			Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RAC; PP70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ACTIN NETWORK; SH3 DOMAIN; FAMILY; STIMULATION	Insulin activates rapidly a complex cascade of lipid and protein kinases leading to stimulation of mitogenic and metabolic events. Mere we describe a renaturable kinase of 65 kDa (PK65) that becomes rapidly activated by insulin in differentiated L6 muscle cells (myotubes) and can phosphorylate histones immobilized in polyacrylamide gels. Insulin activation of PK65 was abolished by the tyrosine kinase inhibitor erbstatin and by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin, but was unaffected by inhibitors of protein kinase C or of the activation of p70(S6K). Recently, a number of protein kinases have been described which become activated through interaction with the small GTP-binding proteins Rac and Cdc42 (p21-activated kinases, or PAKs) and lead to activation of the stress-induced mitogen-activated protein kinase (MAPK) p38 MAPK. Two different polyclonal antibodies recognizing the carboxyl-terminal or the Rac-binding domain of a 65-kDa PAK (PAK65) immunoprecipitated the myotube PK65. The insulin-induced activation of PK65 in myotubes was detectable following immunoprecipitation of the kinase, Furthermore, PK65 associated with and became activated by glutathione S-transferase-Cdc42Hs in the presence of GTP gamma S (guanosine 5'-3-O-(thio)triphosphate). In myotubes insulin also induced tyrosine phosphorylation of p38 MAPK. However, this phosphorylation was insensitive to wortmannin, indicating that p38 MAPK is not activated by PK65 in insulin-stimulated cells. The results suggest that insulin activates in muscle cells a renaturable kinase (PK65) closely related to PAK65. Tyrosine kinases and PI 3-kinase act upstream of PK65 in the insulin signaling cascade, Insulin activates p38 MAPK in myotubes, but this occurs by a pathway independent of PI 3-kinase and PK65.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERGERING BM, 1995, NATURE, V376, P599; BRUMELL JH, 1994, AM J PHYSIOL-CELL PH, V267, pC1574, DOI 10.1152/ajpcell.1994.267.6.C1574; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DING JB, 1994, FEBS LETT, V348, P149, DOI 10.1016/0014-5793(94)00593-1; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KNAUS UG, 1995, NATURE, V269, P221; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAHA C, 1995, J BIOL CHEM, V270, P24678, DOI 10.1074/jbc.270.42.24678; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	46	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19664	19667		10.1074/jbc.271.33.19664	http://dx.doi.org/10.1074/jbc.271.33.19664			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702668	hybrid			2022-12-27	WOS:A1996VC66900009
J	BrownAugsburger, P; Chang, D; Rust, K; Crouch, ED				BrownAugsburger, P; Chang, D; Rust, K; Crouch, ED			Biosynthesis of surfactant protein D - Contributions of conserved NH2-terminal cysteine residues and collagen helix formation to assembly and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HISTOCOMPATIBILITY COMPLEX-MOLECULES; ALVEOLAR MACROPHAGES; ENDOPLASMIC-RETICULUM; DISULFIDE BOND; CARBOHYDRATE; CALNEXIN; MEMBRANE; BINDING; OLIGOSACCHARIDE	Surfactant protein D (SP-D) is preferentially secreted as dodecamers consisting of four collagenous trimers cross-linked by disulfide bonds, In these studies, we examined the biosynthesis of wild-type rat SP-D (RrSP-D) and selected mutants by stably transfected CHO-KI cells to determine the roles of a conserved N-linked oligosaccharide, the collagen helix, and interchain disulfide bonds in SP-D assembly and secretion, The major intracellular form of RrSP-D accumulated in the RER as complexes containing up to four trimeric subunits. Disulfide cross-link formation and RrSP-D secretion were selectively inhibited by 2,2'-dipyridyl, an inhibitor of prolyl and lysyl hydroxylase, and by 2 mM dithiothreitol, but unaffected by tunicamycin or elimination of the consensus sequence for glycosylation at Asn(70), Although mutants with serine substituted for Cys(15) and Cys(20) (RrSP-Dser15/20) are secreted as trimeric subunits, proteins with single cysteine substitutions were retained in the cell, Surprisingly, the secretion of RrSP-Dser15/20 was unaffected by 2,2'-dipyridyl. These studies strongly suggest that the most important and rate-limiting step for the secretion of SP-D involves the association of crosslinked trimeric subunits to form dodecamers stabilized by specific inter-subunit disulfide cross-links, Interference with collagen helix formation prevents secretion by interfering with efficient disulfide cross-linking of the NH2-terminal domain.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL29594, 5T32HL07317, HL44015] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015, T32HL007317, P01HL029594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1992, AM J PHYSIOL, V262, pL437, DOI 10.1152/ajplung.1992.262.4.L437; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BROWNAUGSBURGER P, 1996, IN PRESS J BIOL CHEM; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; COLLEY KJ, 1987, J BIOL CHEM, V262, P3415; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1991, AM J PATHOL, V139, P765; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1994, J BIOL CHEM, V269, P15808; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P456, DOI 10.1042/bst0210456; Hartshorn KL, 1996, BLOOD, V87, P3450, DOI 10.1182/blood.V87.8.3450.bloodjournal8783450; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; LIMPER AH, 1995, J LAB CLIN MED, V126, P416; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MAGARGAL WW, 1978, J BIOL CHEM, V253, P8311; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MORAND JN, 1986, ANAL BIOCHEM, V159, P157, DOI 10.1016/0003-2697(86)90321-0; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WRIGHT JR, 1995, AM J PHYSIOL-LUNG C, V268, pL772, DOI 10.1152/ajplung.1995.268.5.L772; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	44	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18912	18919		10.1074/jbc.271.31.18912	http://dx.doi.org/10.1074/jbc.271.31.18912			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8756121	hybrid			2022-12-27	WOS:A1996VB68300091
J	Quitschke, WW; Matthews, JP; Kraus, RJ; Vostrov, AA				Quitschke, WW; Matthews, JP; Kraus, RJ; Vostrov, AA			The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid beta-protein precursor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; REGULATORY ELEMENTS; BASAL TRANSCRIPTION; LESS PROMOTERS; DNA-BINDING; GENE; EXPRESSION	The TATA-less human amyloid beta-protein precursor promoter contains an initiator element with the sequence CGTCA(+1)GTT. Primary transcriptional start sites were identified at positions +1 and -4, Deletion of the upstream activator elements APB beta and APB alpha did not affect the selection of transcriptional start sites, although total transcriptional activity was reduced both in vitro and in vivo. Mutations within the initiator element shifted the transcriptional start sites and reduced transcriptional activity. Mutations between positions -6 and -35 changed the relative utilization of start sites +1 and -4 without affecting the total level of transcriptional activity, A 10-base pair deletion between position -40 and -31 increased in vitro transcriptional activity with a preeminent utilization of the start site at position -4. In contrast, a 20-base pair deletion between position -40 and -21. resulted in a reduction in transcriptional activity and in the primary utilization of the start site at position +1. Furthermore, transactivation by APB beta and APB alpha was eliminated. DNase I footprinting provided evidence for the existence of two binding domains designated UE (position -12 to -30) and Inr (position +7 to -7). The positions of these binding domains are altered in mutations and deletions that affect transcriptional activity.	UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Quitschke, WW (corresponding author), SUNY STONY BROOK, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA.				NCI NIH HHS [CA22443] Funding Source: Medline; NINDS NIH HHS [NS30994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASO T, 1994, J BIOL CHEM, V269, P26575; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; GAJDUSEK DC, 1991, BRAIN RES REV, V16, P83, DOI 10.1016/0165-0173(91)90021-Y; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOFFMAN PW, 1995, NUCLEIC ACIDS RES, V23, P2229, DOI 10.1093/nar/23.12.2229; HOFFMAN PW, 1994, BIOCHEM BIOPH RES CO, V201, P610, DOI 10.1006/bbrc.1994.1745; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LANS MS, 1994, J BIOL CHEM, V269, P14170; Maniatis T, 1989, MOL CLONING; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Maxam A M, 1980, Methods Enzymol, V65, P499; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; POLLWEIN P, 1993, BIOCHEM BIOPH RES CO, V190, P637, DOI 10.1006/bbrc.1993.1096; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Quitschke Wolfgang W., 1995, P79, DOI 10.1016/B978-012286965-5/50007-8; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; ROBAKIS NK, 1987, LANCET, V1, P384; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAIN DH, 1995, NUCLEIC ACIDS RES, V23, P1696, DOI 10.1093/nar/23.10.1696; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; Sucharov C, 1995, GENE EXPRESSION, V5, P93; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	53	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22231	22239		10.1074/jbc.271.36.22231	http://dx.doi.org/10.1074/jbc.271.36.22231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703038	hybrid			2022-12-27	WOS:A1996VF61200080
J	Saad, MJA; Carvalho, CRO; Thirone, ACP; Velloso, LA				Saad, MJA; Carvalho, CRO; Thirone, ACP; Velloso, LA			Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOTYROSINE PROTEIN; SIGNAL-TRANSDUCTION; JANUS KINASE; CELLS; ACTIVATION; IDENTIFICATION; STIMULATION	The Janus kinase family of protein tyrosine kinases constitutes a novel type of signal transduction pathway activated in response to a wide variety of polypeptide ligands and has four known members: JAK1, JAK2, JAK3, and Tyk2. In this study, we examined the ability of insulin to stimulate JAK2 tyrosine phosphorylation in insulin-sensitive tissues of the intact rat using immunoprecipitation and immunoblotting. The results demonstrate that after an infusion of insulin, JAK2 is rapidly tyrosine phosphorylated (and the kinase is activated) in the liver, adipose tissue, skeletal muscle, heart, and isolated adipocytes. The presence of phosphorylated JAK2 was detectable after an infusion of insulin that increased serum insulin to physiological postprandial levels (40-70 microunits/ml). Co-immunoprecipitation with anti-insulin receptor antibody, anti JAK2 antibody, and anti-IRS-1 antibody showed that JAK2 interacts with the insulin receptor and IRS-1 to form stable complexes following stimulation by insulin. In two animal models of insulin resistance the regulation of JAK2 tyrosine phosphorylation after insulin infusion paralleled the phosphorylation of the insulin receptor and of IRS-1. In conclusion, our data indicate that after physiological stimulation by insulin in the intact animal, JAK2 associates with the insulin receptor and is tyrosine phosphorylated in insulin sensitive tissues in a time- and dose-dependent fashion.			Saad, MJA (corresponding author), UNIV ESTADUAL CAMPINAS,UNICAMP,FAC CIENCIAS MED,DEPT CLIN MED,CIDADE UNIV ZEFERINO VAZ,BR-13081970 CAMPINAS,SP,BRAZIL.		Carvalho, Carla R. O./H-6476-2018; Saad, Mario/ABD-8262-2020; Velloso, Licio/AAJ-3778-2020	Carvalho, Carla R. O./0000-0001-5824-8656; 				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvalho CRO, 1996, ENDOCRINOLOGY, V137, P151, DOI 10.1210/en.137.1.151; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FLIER JS, 1983, ANNU REV MED, V34, P145, DOI 10.1146/annurev.me.34.020183.001045; FRIEDENBERG GR, 1985, J BIOL CHEM, V260, P12444; GRICHTING G, 1983, ENDOCRINOLOGY, V113, P1111, DOI 10.1210/endo-113-3-1111; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUI H, 1994, J BIOL CHEM, V269, P5364; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P1787; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKOLNIK EY, 1993, EMBO J, V12, P1926; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22100	22104		10.1074/jbc.271.36.22100	http://dx.doi.org/10.1074/jbc.271.36.22100			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703019	hybrid			2022-12-27	WOS:A1996VF61200061
J	Sumimoto, H; Hata, K; Mizuki, K; Ito, T; Kage, Y; Sakaki, Y; Fukumaki, Y; Nakamura, M; Takeshige, K				Sumimoto, H; Hata, K; Mizuki, K; Ito, T; Kage, Y; Sakaki, Y; Fukumaki, Y; Nakamura, M; Takeshige, K			Assembly and activation of the phagocyte NADPH oxidase - Specific interaction of the N-terminal Src homology 3 domain of p47(phox) with p22(phox) is required for activation of the NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; CYTOSOLIC PROTEINS P47-PHOX; NEUTROPHIL CYTOCHROME-B; BINDING-SITE; SH3 DOMAINS; DEFECTIVE TRANSLOCATION; FLAVOCYTOCHROME B(558); COMPONENTS P47(PHOX)	The phagocyte NADPH oxidase is activated during phagocytosis to produce superoxide, a precursor of microbicidal oxidants. The activation involves assembly of membrane-integrated cytochrome b(558) comprising gp91(phox) and p22(phox), two specialized cytosolic proteins (p47(phox) and p67(phox)), each containing two Src homology 3 (SH3) domains, and the small G protein Rac. In the present study, we show that the N-terminal SH3 domain of p47(phox) binds to the C-terminal cytoplasmic tail of p22(phox) with high affinity (K-D = 0.34 mu M). The binding is specific to this domain among several SH3 domains including the C-terminal one of p47(phox) and the two of p67(phox) and requires the Pro(156)-containing proline-rich sequence but not other putative SH3 domain-binding sites of p22(phox). Replacement of Trp(193) by Arg in the N-terminal SH3 domain completely abrogates the association with p22(phox). A mutant p47(phox) with this substitution is incapable of supporting superoxide production under cell-free activation conditions. These findings provide direct evidence that the interaction between the N-terminal SH3 domain of p47(phox) and the proline-rich region of p22(phox) is essential for activation of the NADPH oxidase.	UNIV TOKYO,INST MED SCI,CTR HUMAN GENOME,TOKYO 108,JAPAN; NAGASAKI UNIV,INST TROP MED,NAGASAKI 852,JAPAN; KYUSHU UNIV,INST GENET INFORMAT,FUKUOKA 812,JAPAN	University of Tokyo; Nagasaki University; Kyushu University	Sumimoto, H (corresponding author), KYUSHU UNIV,SCH MED,DEPT BIOCHEM,HIGASHI KU,3-1-1 MAIDASHI,FUKUOKA 81282,JAPAN.			Ito, Takashi/0000-0001-6097-2803				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; AOYAGI K, 1991, BIOCHEM BIOPH RES CO, V186, P391; BRIDGE RB, 1993, SCIENCE, V262, P1522; CHALKLEY GE, 1994, EUR J BIOCHEM, V221, P167, DOI 10.1111/j.1432-1033.1994.tb18726.x; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MIZUNO T, 1992, J BIOL CHEM, V267, P10125; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NOZAKI M, 1990, EUR J BIOCHEM, V187, P335, DOI 10.1111/j.1432-1033.1990.tb15310.x; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WANG W, 1995, NAT GENET, V10, P194; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	55	155	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22152	22158		10.1074/jbc.271.36.22152	http://dx.doi.org/10.1074/jbc.271.36.22152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703027	hybrid			2022-12-27	WOS:A1996VF61200069
J	Domin, J; Dhand, R; Waterfield, MD				Domin, J; Dhand, R; Waterfield, MD			Binding to the platelet-derived growth factor receptor transiently activates the p85 alpha-p110 alpha phosphoinositide 3-kinase complex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PDGF BETA-RECEPTOR; MIDDLE-T-ANTIGEN; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; TYROSINE PHOSPHORYLATION; 85-KDA SUBUNIT; SH2 DOMAINS; REGULATORY SUBUNIT	Ligand stimulation of the platelet-derived growth factor (PDGF) receptor results in its association with phosphoinositide 3-kinase activity and a corresponding synthesis of 3'-phosphorylated lipids, Early studies that examined this interaction in vivo employed anti-phosphotyrosine antiserum or antiserum against the PDGF receptor. The recent identification of multiple isoforms of both the regulatory and the catalytic subunit of the enzyme have led us to utilize antisera against p85 alpha and p110 alpha to characterize the association of this particular phosphoinositide 3-kinase complex with the PDGF receptor following ligand stimulation of murine fibroblasts. Both the p85 alpha and p110 alpha subunits rapidly associated with the ligand-activated receptor resulting in a transient, 2-fold increase in the total pool of p110 alpha lipid kinase activity. This association was stable for 15 min after initial stimulation. Subsequently, both subunits began to dissociate from the receptor with similar kinetics. By 60 min this process was complete, demonstrating that p85 alpha and p110 alpha both associate with the receptor and dissociate from the receptor as a dimeric complex. At this time, marked PDGF receptor down-regulation was observed. Immunoprecipitation from metabolically labeled cells revealed that p85 alpha is constitutively phosphorylated on serine residues in quiescent cultures. Upon PDGF stimulation, this phosphorylation upon serine residues was maintained in addition to tyrosine phosphorylation of this subunit. No phosphorylation of the p110 alpha subunit was detected in either quiescent or PDGF-stimulated cells. Quantitation of Western blot analysis demonstrated that only 5% of the total pool of p85 alpha associated with the PDGF receptor upon ligand stimulation. The 2-fold increase in the lipid kinase activity measured in immunoprecipitates using either anti-p85 alpha or anti-p110 alpha) antiserum therefore reflects a far greater increase inn the specific activity of the enzyme upon its association with the PDGF receptor.	UCL, DEPT BIOCHEM & MOL BIOL, LONDON WCE 6BT, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	University of London; University College London; Ludwig Institute for Cancer Research								AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHOUDHURY GG, 1991, BIOCHEM BIOPH RES CO, V172, P154; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOMIN J, 1992, J BIOL CHEM, V267, P15217; DOWNING JR, 1991, ONCOGENE, V6, P607; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OKAMOTO M, 1993, BIOCHEM J, V290, P327, DOI 10.1042/bj2900327; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1992, J BIOL CHEM, V267, P12266; PONS S, 1995, MOL CELL BIOL, V15, P4453; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RANKIN S, 1994, J BIOL CHEM, V269, P704; REIF K, 1993, J BIOL CHEM, V268, P10780; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SHEPEINER H, 1996, J CELL BIOL, V132, P595; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WESTERMARK B, 1991, CANCER RES, V51, P5087; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	69	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21614	21621		10.1074/jbc.271.35.21614	http://dx.doi.org/10.1074/jbc.271.35.21614			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702949	hybrid			2022-12-27	WOS:A1996VE47700095
J	Galera, P; Park, RW; Ducy, P; Mattei, MG; Karsenty, G				Galera, P; Park, RW; Ducy, P; Mattei, MG; Karsenty, G			c-Krox binds to several sites in the promoter of both mouse type I collagen genes - Structure/function study and developmental expression analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; OSTEOGENESIS IMPERFECTA; REGULATORY FACTORS; HUMAN-FIBROBLASTS; MESSENGER-RNAS; CULTURED-CELLS; DNA-BINDING; ELEMENTS	We have previously shown that c-Krox is a zinc finger protein that can increases the transcriptional activity of the mouse alpha 1(I) collagen promoter through its binding to two GC-rich sequences (Galera, P,, Musso, Ri,, Ducy, P,, and Karsenty, G, (1994) Proc, Natl, Acad, Sci, U, S. A, 91, 9372-9376), In this report we show that c-Krox can bind to an additional site in the promoter of the alpha 1(I) collagen gene and to three sites in the promoter of the alpha 2(I) collagen gene, the other gene coding for type I collagen, One of the binding sites present in both promoters is adjacent to the CCAAT box, We have performed a structure/function analysis of c-Krox locating the transactivation domain in the zinc finger and C-terminal domains and the dimerization domain in the C-terminal end of the protein, We also demonstrate that c-Krox is an early response gene, whose expression is detectable as early as 9.5-day postcoitum in mouse embryos, Whole-mount in situ hybridization shows that c-Krox is expressed in dermatomes, the somite derivatives that generate dermis, and section in situ hybridization shows that c-Krox and alpha 1(I) collagen mRNAs colocalized in skin but not in bone during development, This result is consistent with the predominant expression of c-Krox in skin in postnatal life, Thus, our findings suggest that c-Krox is one transcription factor controlling the coordinated expression of the two type I collagen genes in skin.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; HOP ENFANTS LA TIMONE,INSERM,CTR GENET MED,U242,F-13385 MARSEILLE,FRANCE	University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille					NIAMS NIH HHS [AR-41059] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041059] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMSON ED, 1979, CELL, V16, P953, DOI 10.1016/0092-8674(79)90110-7; BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; BUCHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEWET WJ, 1983, J BIOL CHEM, V258, P4385; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KAHARI VM, 1987, ACTA DERM-VENEREOL, V67, P199; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; UITTO J, 1985, P NATL ACAD SCI USA, V82, P5935, DOI 10.1073/pnas.82.17.5935; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P257; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	53	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21331	21339		10.1074/jbc.271.35.21331	http://dx.doi.org/10.1074/jbc.271.35.21331			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702912	hybrid			2022-12-27	WOS:A1996VE47700058
J	Moore, JL; Gorshkova, II; Brown, JW; McKenney, KH; Schwarz, FP				Moore, JL; Gorshkova, II; Brown, JW; McKenney, KH; Schwarz, FP			Effect of cAMP binding site mutations on the interaction of cAMP receptor protein with cyclic nucleoside monophosphate ligands and DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; ENTHALPY-ENTROPY COMPENSATION; ESCHERICHIA-COLI; TRANSCRIPTION ACTIVATION; LAC PROMOTER; AMP; CAP; COMPLEX; MUTANTS; RECOGNITION	Although cAMP binding to wild type cAMP receptor protein (CRP) induces specific DNA binding and activates transcription, cyclic nucleoside monophosphate (cNMP) binding to the CRP mutant Ser(128) --> Ala does not, whereas the double CRP mutant Thr(127) --> Leu/ Ser(128) --> Ala activates transcription even in the absence of cNMP. Isothermal titration calorimetry measurements on the cNMP binding reactions to the S128A and T127L/S128A mutants show that the reactions are mainly entropically driven as is cAMP binding to CRP. In contrast to cAMP binding to CRP, the binding reactions are noncooperative and exothermic with binding enthalpies (Delta H-b) ranging from -23.4 +/- 0.9 kJ mol(-1) for cAMP binding to S128A at 39 degrees C to -4.1 +/- 0.6 kJ mol(-1) for cAMP binding to T127L/S128A at 24 degrees C and exhibit enthalpy-entropy compensation. To account for the inactivity of the S128A mutant, in vitro and in vivo DNA binding experiments were performed on the cAMP-ligated S128A mutant. The cAMP-ligated S128A mutant binds to the consensus DNA binding site with approximately the same affinity as that of cAMP-ligated CRP but forms a different type of complex, which may account for loss of transcriptional activity by the mutant, Energy minimization computations on the cAMP-ligated S128A mutant show that amino acid conformational differences between S128A and CRP occur at Ser(179), Glu(181), and Thr(182) in the center of the DNA binding site, implying that these conformational changes may account for the difference in DNA binding.	NIST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; RUSSIAN ACAD SCI,INST BIOORGAN CHEM,NOVOSIBIRSK 630090,RUSSIA	National Institute of Standards & Technology (NIST) - USA; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences								AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BLAZY B, 1986, J BIOL CHEM, V261, P1645; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHAN B, 1989, GENE, V84, P227, DOI 10.1016/0378-1119(89)90496-4; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GARGES S, 1987, J BACTERIOL, V170, P1417; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; HARMAN JG, 1988, J BIOL CHEM, V263, P8072; HARMAN JG, 1986, J BIOL CHEM, V261, P6332; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; KOOP AH, 1985, BIOCHIMIE, V67, P161, DOI 10.1016/S0300-9084(85)80244-3; LANG L, 1966, ABSORPTION SPECTRA U, V1, P326; LODGE J, 1990, FEMS MICROBIOL LETT, V67, P221, DOI 10.1016/0378-1097(90)90199-Z; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; Miller JH, 1972, EXPT MOL GENETICS, P47; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; MOORE JL, 1993, THESIS G WASHINGTON; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; REN YL, 1990, NUCLEIC ACIDS RES, V18, P5127, DOI 10.1093/nar/18.17.5127; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIMPSON RB, 1980, NUCLEIC ACIDS RES, V8, P759; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	43	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21273	21278		10.1074/jbc.271.35.21273	http://dx.doi.org/10.1074/jbc.271.35.21273			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702903	hybrid			2022-12-27	WOS:A1996VE47700049
J	Wangsgard, WP; Meixell, GE; Dasgupta, M; Blumenthal, DK				Wangsgard, WP; Meixell, GE; Dasgupta, M; Blumenthal, DK			Activation and inhibition of phosphorylase kinase by monospecific antibodies raised against peptides from the regulatory domain of the gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ANTIPEPTIDE ANTIBODY; CATALYTIC DOMAIN; I RECEPTOR; IDENTIFICATION; PURIFICATION; SUBSTRATE; COMPLEXES	The C terminus of the catalytic gamma-subunit of phosphorylase kinase comprises a regulatory domain that contains regions important for subunit interactions and autoinhibitory functions. Monospecific antibodies raised against four synthetic peptides from this region, PhK1 (362-368), PhK5 (342-366), PhK9 (322-346), and PhK13 (302-326), were found to have significant effects on the catalytic activities of phosphorylase kinase holoenzyme and the gamma .delta complex. Antibodies raised against the very C terminus of the gamma-subunit, anti-PhK1 and anti-PhK5, markedly activated both holoenzyme and the gamma .delta complex, in the presence and absence of Ca2+. In the presence of Ca2+ at pH 8.2, anti-PhK1 activated the holoenzyme more than 11-fold and activated the gamma .delta complex 2.5-fold. Activation of the holoenzyme and the gamma .delta complex by anti-PhK5 was 50-70% of that observed with anti-PhK1. Prior phosphorylation of the holoenzyme by the cAMP-dependent protein kinase blocked activation by both anti-PhK1 and anti-PhK5. Antibodies raised against the peptides from the N terminus of the regulatory domain, anti-PhK9 and anti-PhK13, were inhibitory, with their greatest effects on the gamma .delta complex. These data demonstrate that the binding of antibodies to specific regions within the regulatory domain of the gamma-subunit can augment or inhibit structural changes and subunit interactions important in regulating phosphorylase kinase activity.	UNIV UTAH, DEPT PHARMACOL & TOXICOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA; UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, TYLER, TX 75710 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)				/0000-0002-7260-3746; Blumenthal, Donald/0000-0002-8614-1167	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039290] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29-GM39290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN KFJ, 1982, J BIOL CHEM, V257, P5939; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; CRABB JW, 1984, J BIOL CHEM, V259, P6346; DASGUPTA M, 1995, J BIOL CHEM, V270, P22283, DOI 10.1074/jbc.270.38.22283; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Fasman G.D., 1989, PRACTICAL HDB BIOCH; FISCHER EH, 1962, METHOD ENZYMOL, V5, P369, DOI 10.1016/S0076-6879(62)05243-X; GIBSON AL, 1988, PROTEINS, V3, P155, DOI 10.1002/prot.340030304; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HERRERA R, 1986, J BIOL CHEM, V261, P2489; HESSOVA Z, 1985, J BIOL CHEM, V260, P111; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; JENNISSEN HP, 1985, EUR J BIOCHEM, V147, P619; KALIMAN P, 1992, J BIOL CHEM, V267, P10645; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1986, J BIOL CHEM, V261, P4732; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; NEWSHOLME P, 1992, BIOCHEM J, V283, P845, DOI 10.1042/bj2830845; NUNNALLY MH, 1987, BIOCHEMISTRY-US, V26, P5885, DOI 10.1021/bi00392a046; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; Pickett-Gies CA., 1986, ENZYMES, V17, P395; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SEGEL IH, 1975, ENZYME KINETICS BEHA, P166; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; WILKINSON DA, 1994, FASEB J, V8, pA1225; WILKINSON DA, 1993, THESIS U TENNESSEE M	32	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21126	21133		10.1074/jbc.271.35.21126	http://dx.doi.org/10.1074/jbc.271.35.21126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702882				2022-12-27	WOS:A1996VE47700028
J	Pratt, MAC; Deonarine, D; Teixeira, C; Novosad, D; Tate, BF; Grippo, JF				Pratt, MAC; Deonarine, D; Teixeira, C; Novosad, D; Tate, BF; Grippo, JF			The AF-2 region of the retinoic acid receptor alpha mediates retinoic acid inhibition of estrogen receptor function in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; GROWTH-FACTOR-ALPHA; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; THYROID-HORMONE; CARCINOMA CELLS; PROGESTERONE-RECEPTOR; BINDING DOMAIN; MCF-7 CELLS	The growth of estrogen receptor (ER)-positive breast cancer cells is inhibited by all-trans-retinoic acid (RA). In the present study, estrogen (E2) induction of pS2 mRNA levels was significantly reduced within 6 h following cotreatment with RA. In transient transfection experiments, RA repressed transactivation from a vitellogenin E2-responsive element by approximately 50% and wild-type RA receptor alpha (RAR alpha) or RAR beta enhanced this inhibition. Transfection of truncated RAR alpha mutants terminating before or at amino acid 412 markedly decreased RA inhibition of E2-induced reporter gene activity. Expression of RARs with deletions of amino acids 413 and 414 in the transactivation-2 (AF-2) domain also reduced RA inhibition, while deletions and point mutations beyond amino acid 414 behaved like the wild-type RAR alpha. RA-treated MCF-7 cells transfected with an RAR alpha AF-2 region mutant were twice as sensitive to growth inhibition as untransfected and vector-transfected control cells. Thus, the AF-2 domain in the C terminus of the RAR alpha mediates RA inhibition of ER-induced transcription in breast cancer cells. In addition, transcriptional interference between RARs and ERs may contribute to RA inhibition of ER-positive breast cancer cell growth.	HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Roche Holding	Pratt, MAC (corresponding author), UNIV OTTAWA, DEPT PHARMACOL, 451 SMYTH RD, OTTAWA, ON K1H 8M5, CANADA.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BREITMAN TR, 1981, BLOOD, V57, P1000; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CLARKE CL, 1991, J BIOL CHEM, V266, P18969; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEMIRPENCE E, 1992, BIOCHEM BIOPH RES CO, V183, P100, DOI 10.1016/0006-291X(92)91614-V; DEMIRPENCE E, 1994, CANCER RES, V54, P1458; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONTANA JA, 1990, CANCER RES, V50, P1977; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FONTANA JA, 1992, CANCER RES, V52, P3938; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1988, AFFINITY LABELLING C, P252; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HALTER SA, 1993, J CELL PHYSIOL, V156, P80, DOI 10.1002/jcp.1041560112; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; UEDA H, 1980, CANCER-AM CANCER SOC, V46, P2203, DOI 10.1002/1097-0142(19801115)46:10<2203::AID-CNCR2820461017>3.0.CO;2-A; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x	55	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20346	20352		10.1074/jbc.271.34.20346	http://dx.doi.org/10.1074/jbc.271.34.20346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702769	hybrid			2022-12-27	WOS:A1996VD33700021
J	Beslu, N; LaRose, J; Casteran, N; Birnbaum, D; Lecoq, E; Dubreuil, P; Rottapel, R				Beslu, N; LaRose, J; Casteran, N; Birnbaum, D; Lecoq, E; Dubreuil, P; Rottapel, R			Phosphatidylinositol-3' kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR-RECEPTOR; HEMATOPOIETIC STEM-CELLS; GTPASE-ACTIVATING PROTEIN; FACTOR-BETA-RECEPTOR; C-KIT RECEPTOR; MYELOID-DERIVED CELLS; SIGNAL-TRANSDUCTION; BINDING-SITE; SH2 DOMAIN; 3-KINASE ACTIVITY	Flt3/Flk2 is a receptor tyrosine kinase that is expressed on early hematopoietic progenitor cells. Flt3/Flk2 belongs to a family of receptors, including Kit and colony-stimulating factor-1R, which support growth and differentiation within the hematopoietic system, The Flt3/Flk2 ligand, in combination with other growth factors, tors, stimulates the proliferation of hematopoietic progenitors of both lymphoid and myeloid lineages in vitro. We report that phosphatidylinositol 3'-kinase (PI3K) binds to a unique site in the carboxy tail of murine Flt3/Flk2. In distinction to Kit and colony-stimulating factor-1R, mutant receptors unable to couple to PI3K and expressed in rodent fibroblasts or in the interleukin 3-dependent cell line Ba/F3 provide a mitogenic signal comparable to wild-type receptors, Flt3/Flk2 receptors that do not bind to PI3K also normally down-regulate, a function ascribed to PI3K in the context of other receptor systems, These data point to the existence of other unidentified pathways that, alone or in combination with PI3K, transduce these cellular responses following the activation of Flt3/Flk2.	INSERM, U119, MOL HEMATOL LAB, F-13009 MARSEILLE, FRANCE; INSERM, U119, MOL ONCOL LAB, F-13009 MARSEILLE, FRANCE; UNIV TORONTO, WELLESLEY HOSP, RES INST, TORONTO, ON M4Y 1J3, CANADA; UNIV TORONTO, DEPT MED, TORONTO, ON M56 1A1, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON M56 1A1, CANADA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto			dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BERNSTEIN SE, 1959, P SOC EXP BIOL MED, V101, P769; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EERMAN PK, 1991, CELL, V64, P425; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIXMAN ED, 1995, ONCOGENE, V10, P237; FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HE TC, 1993, BLOOD, V82, P3530; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI NX, 1994, ONCOGENE, V9, P3457; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUENCH MO, 1995, BLOOD, V85, P963, DOI 10.1182/blood.V85.4.963.bloodjournal854963; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; OKADA S, 1991, BLOOD, V78, P1706; OKADA S, 1992, BLOOD, V80, P3044; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PAPAYANNOPOULOU T, 1991, BLOOD, V78, P1403; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Ray RJ, 1996, EUR J IMMUNOL, V26, P1504, DOI 10.1002/eji.1830260715; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SERVE H, 1994, J BIOL CHEM, V269, P6026; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG WK, 1994, J BIOL CHEM, V269, P32514; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEE NS, 1994, J BIOL CHEM, V269, P31991; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZEIGLER FC, 1994, BLOOD, V84, P2422, DOI 10.1182/blood.V84.8.2422.bloodjournal8482422; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	106	29	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20075	20081		10.1074/jbc.271.33.20075	http://dx.doi.org/10.1074/jbc.271.33.20075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702727	hybrid			2022-12-27	WOS:A1996VC66900068
J	Himawan, JS; Richardson, CC				Himawan, JS; Richardson, CC			Amino acid residues critical for the interaction between bacteriophage T7 DNA polymerase and Escherichia coli thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID; REPLICATION INVITRO; GENE-5 PROTEIN; EXONUCLEASE ACTIVITIES; MUTANT THIOREDOXINS; PURIFICATION; SEQUENCE; PROCESSIVITY; SUBUNITS; CONSTRUCTION	Upon infection of Escherichia coli, bacteriophage T7 annexes a host protein, thioredoxin, to serve as a processivity factor for its DNA polymerase, T7 gene 5 protein, In a previous communication (Himawan, J., and Richardson, C. C. (1992) Proc, Natl. Acad. Sci. U. S. A. 89, 9774-9778), we reported that an E. coli strain encoding a Gly-74 to Asp-74 (G74D) thioredoxin mutation could not support wild type T7 growth and that in vivo, six mutations in T7 gene 5 could individually suppress this G74D thioredoxin defect, In the present study, we report the purification and biochemical characterization of the G74D thioredoxin mutant and two suppressor gene 5 proteins, a Glu-319 to Lys-319 (E319K) mutant of gene 5 protein and an Ala-45 to Thr-45 (A45T) mutant, The suppressor E319K mutation, positioned within the DNA polymerization domain of gene 5 protein, appears to suppress the parental thioredoxin mutation by compensating for the binding defect that was caused by the G74D alteration, We suggest that the Glu-319 residue of T7 gene 5 protein and the Gly-74 residue of E. coli thioredoxin define a contact point or site of interaction between the two proteins. In contrast, the A45T mutation in gene 5 protein, located within the 3' to 5' exonuclease domain, does not suppress the G74D thioredoxin mutation by simple restoration of binding affinity, Based upon our understanding of the mechanisms of suppression, we propose a model for the T7 gene 5 protein-E, coli thioredoxin interaction.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER S, 1983, J BIOL CHEM, V258, P6956; ADLER S, 1979, J BIOL CHEM, V254, P1605; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHATTERJEE DK, 1991, GENE, V97, P13, DOI 10.1016/0378-1119(91)90004-U; DAS SK, 1979, J BIOL CHEM, V254, P1227; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; Ellis EL, 1939, J GEN PHYSIOL, V22, P365, DOI 10.1085/jgp.22.3.365; FUJIMURA RK, 1976, J BIOL CHEM, V251, P2168; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; HIMAWAN JS, 1996, THESIS HARVARD U CAM; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HORI K, 1979, J BIOL CHEM, V254, P1598; HORI K, 1979, J BIOL CHEM, V254, P1591; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JENG MF, 1995, BIOCHEMISTRY-US, V34, P611, DOI 10.1021/bi00002a028; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LOPEZ P, 1989, J BIOL CHEM, V264, P4255; LUNN CA, 1984, J BIOL CHEM, V259, P469; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; Miller JH, 1972, EXPT MOL GENETICS, P201; MINARIK P, 1993, J BASIC MICROB, V33, P213, DOI 10.1002/jobm.3620330314; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OEY JL, 1971, EUR J BIOCHEM, V23, P497, DOI 10.1111/j.1432-1033.1971.tb01646.x; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; RUSSEL M, 1983, J BACTERIOL, V154, P1064, DOI 10.1128/JB.154.3.1064-1076.1983; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SLABY I, 1989, J BIOL CHEM, V264, P16502; STENT GS, 1963, MOL BIOL BACTERIAL V, P74; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, J BIOL CHEM, V262, P15330; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; WALKER JR, 1982, P NATL ACAD SCI-BIOL, V79, P3340, DOI 10.1073/pnas.79.10.3340; WYMAN C, 1995, CURR BIOL, V5, P334, DOI 10.1016/S0960-9822(95)00065-0; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YEHLE CO, 1973, J BIOL CHEM, V248, P7456	64	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19999	20008		10.1074/jbc.271.33.19999	http://dx.doi.org/10.1074/jbc.271.33.19999			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702717	Green Published, hybrid			2022-12-27	WOS:A1996VC66900058
J	Wang, GF; Nikovits, W; Schleinitz, M; Stockdale, FE				Wang, GF; Nikovits, W; Schleinitz, M; Stockdale, FE			Atrial chamber-specific expression of the slow myosin heavy chain 3 gene in the embryonic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN PROMOTER; TROPONIN-C GENE; MUSCLE-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENE; CARDIAC-MUSCLE; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; TRANSGENIC MICE; REGULATORY ELEMENTS; T-GENE	The quail slow myosin heavy chain 3 (slow MyHC 3) gene is expressed in the developing heart and in slow muscles of the developing limb. It is first expressed in the pulsatile cardiac tube in the embryo, and as the heart chamberizes its expression becomes restricted to the atria. To identify regulatory elements responsible for atrial-specific expression, the 5' upstream region of slow MyHC 3 gene was investigated. An atrial regulatory domain (ARD1) between -840 and -680 acts as an atrial cell-specific enhancer in primary cardiocyte cultures. ARD1 also specifies atrial-specific expression in vivo when the ARD1/heterologous promoter was introduced into developing chick embryos by a replication-competent retroviral vector. ARD1 is the first atrial cell-specific enhancer to be identified. Fine deletion and mutation analysis within ARD1 defined a 40)-base pair vitamin D-3 receptor-like element that controls atrial cell-specific expression of the slow MyHC 3 gene by inhibiting its expression in ventricular cardiocytes.	STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE ON AGING [R01AG002822] Funding Source: NIH RePORTER; NIA NIH HHS [AG02822] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; BARRY WH, 1986, J GEN PHYSIOL, V88, P393, DOI 10.1085/jgp.88.3.393; BODMER R, 1990, DEVELOPMENT, V110, P661; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEPKO CL, 1992, CURRENT PROTOCOLS MO, V1; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; CROW MT, 1986, DEV BIOL, V118, P333, DOI 10.1016/0012-1606(86)90002-3; DEJONG F, 1990, ANAT REC, V226, P213, DOI 10.1002/ar.1092260211; DIMARIO JX, 1993, NATURE, V362, P165, DOI 10.1038/362165a0; EPPENBERGER HM, 1994, TRENDS CARDIOVAS MED, V4, P187, DOI 10.1016/1050-1738(94)90056-6; EVANS D, 1988, DEV BIOL, V127, P376, DOI 10.1016/0012-1606(88)90324-7; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter E, 1979, Methods Enzymol, V58, P379; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LI Q, 1994, J BIOL CHEM, V269, P4934; LIBBY P, 1984, J MOL CELL CARDIOL, V16, P803, DOI 10.1016/S0022-2828(84)80004-8; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; Miller J. H, 1972, EXPT MOL GENETICS; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; MOSS JB, 1994, J BIOL CHEM, V269, P12731; NIKOVITS W, 1996, IN PRESS J BIOL CHEM; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; PAGE S, 1992, DEV BIOL, V154, P118, DOI 10.1016/0012-1606(92)90053-J; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PETROPOULOS CJ, 1992, J VIROL, V66, P3391, DOI 10.1128/JVI.66.6.3391-3397.1992; RINDT H, 1993, J BIOL CHEM, V268, P5332; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; SALTER DW, 1987, VIROLOGY, V157, P236, DOI 10.1016/0042-6822(87)90334-5; Sambrook J., 2002, MOL CLONING LAB MANU; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SEIDMAN CE, 1991, CAN J PHYSIOL PHARM, V69, P1486, DOI 10.1139/y91-223; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WANG GS, 1994, J BIOL CHEM, V269, P30595; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZADEH BJ, 1986, DEV BIOL, V115, P204, DOI 10.1016/0012-1606(86)90241-1; ZHOU MD, 1993, MOL CELL BIOL, V13, P1222, DOI 10.1128/MCB.13.2.1222; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	65	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19836	19845		10.1074/jbc.271.33.19836	http://dx.doi.org/10.1074/jbc.271.33.19836			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702693	hybrid			2022-12-27	WOS:A1996VC66900034
J	Yang, Z; DeVeer, MJ; Gardiner, EE; Devenish, RJ; Handley, CJ; Underwood, JR; Robinson, HC				Yang, Z; DeVeer, MJ; Gardiner, EE; Devenish, RJ; Handley, CJ; Underwood, JR; Robinson, HC			Rabbit polymorphonuclear neutrophils form S-35-labeled S-sulfo-calgranulin C when incubated with inorganic [S-35]sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; MYELOID DIFFERENTIATION; INTERMEDIATE FILAMENTS; GEL-ELECTROPHORESIS; PLASMA-MEMBRANE; MRP14; PURIFICATION; COMPLEX; MRP-8; IDENTIFICATION	Rabbit peritoneal polymorphonuclear neutrtophils reduced inorganic [S-35]suIfate to [S-35]sulfite in vitro, concomitant with incorporation of S-35 into a 10.68-kDa cytosolic protein as a S-[S-35]sulfo-derivative. Amino-terminal sequencing of the purified protein identified calgranulin C, a member of the S100 protein family. cDNA clones of calgranulins B and C were isolated using oligonucleotide primers based on the established amino acid sequences of other mammalian calgranulins. The complete amino acid sequence of rabbit calgranulin C was deduced from the nucleotide sequence of the corresponding cDNA. It comprises 91 amino acid residues, has a calculated molecular mass of 10.52 kDa, has 74% identity with porcine calgranulin C, and shows high homology with other S100 calcium-binding proteins, Rabbit calgranulim C has a single cysteine residue at position 30, which we believe to be modified to S-[S-35]sulfo-cysteine as a consequence of sulfate reduction by neutrophils. The formation of S-[S-35]sulfo-calgranulin C appears to be a reaction specific to neutrophils. The specific radioactivity of calgranulin C from the neutrophil culture medium was 50-fold greater than that of the calgranulin C within the cells, suggesting that S-sulfation of calgranulin C might be associated with its secretion.	MONASH UNIV,DEPT BIOCHEM & MOL BIOL,CLAYTON,VIC 3168,AUSTRALIA	Monash University			Gardiner, Elizabeth/P-8716-2019; Gardiner, Elizabeth/E-7774-2011	Gardiner, Elizabeth/0000-0001-9453-9688; Yang, Zheng/0000-0003-4275-0590				ANDERSSON KB, 1988, SCAND J IMMUNOL, V28, P241, DOI 10.1111/j.1365-3083.1988.tb02437.x; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; Cecil R., 1963, PROTEINS COMPOSITION, V1, P379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN ZA, 1960, J EXP MED, V112, P983, DOI 10.1084/jem.112.6.983; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DIANOUX AC, 1992, BIOCHEMISTRY-US, V31, P5859; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; ELLIS RJ, 1966, NATURE, V211, P1266, DOI 10.1038/2111266a0; Fagerhol M. K., 1990, STIMULUS RESPONSE CO, P187; GARDINER EE, 1992, BIOCHEM J, V288, P577, DOI 10.1042/bj2880577; GOEBELER M, 1995, BIOCHEM J, V309, P419, DOI 10.1042/bj3090419; GUIGNARD F, 1995, BIOCHEM J, V309, P395, DOI 10.1042/bj3090395; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; IMAMICHI T, 1993, BIOCHEM BIOPH RES CO, V194, P819, DOI 10.1006/bbrc.1993.1895; KLETZIN A, 1989, J BACTERIOL, V171, P1638, DOI 10.1128/jb.171.3.1638-1643.1989; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LEMARCHAND P, 1992, J BIOL CHEM, V267, P19379; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MURAO S, 1994, ACTA HISTOCHEM CYTOC, V27, P107, DOI 10.1267/ahc.27.107; MURPHY ARK, 1993, J IMMUNOL, V151, P6291; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; ROBINSON HC, 1964, BIOCHEM J, V93, P487, DOI 10.1042/bj0930487; ROTH J, 1993, BLOOD, V82, P1875; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWENN JD, 1988, ARCH MICROBIOL, V150, P313, DOI 10.1007/BF00408300; SCOUTEN WH, 1974, BIOCHIM BIOPHYS ACTA, V336, P421, DOI 10.1016/0005-2795(74)90423-1; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; WORTMAN B, 1963, BIOCHIM BIOPHYS ACTA, V77, P65, DOI 10.1016/0006-3002(63)90469-4; YUI S, 1995, J LEUKOCYTE BIOL, V58, P307, DOI 10.1002/jlb.58.3.307	36	17	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19802	19809		10.1074/jbc.271.33.19802	http://dx.doi.org/10.1074/jbc.271.33.19802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702688	hybrid			2022-12-27	WOS:A1996VC66900029
J	Bai, M; Quinn, S; Trivedi, S; Kifor, O; Pearce, SHS; Pollak, MR; Krapcho, K; Hebert, SC; Brown, EM				Bai, M; Quinn, S; Trivedi, S; Kifor, O; Pearce, SHS; Pollak, MR; Krapcho, K; Hebert, SC; Brown, EM			Expression and characterization of inactivating and activating mutations in the human Ca-0(2+)-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; EXTRACELLULAR CA2+-SENSING RECEPTOR; GLUTAMATE RECEPTORS; MOLECULAR-CLONING; GENE; CALCIUM; CELLS; CA2+	Nearly 30 mutations have been identified to date in the coding region of the extracellular calcium-sensing receptor (CaR) that are associated with inherited human hypo- and hypercalcemic disorders, To understand the mechanisms by which the mutations alter the function of the receptor may help to discern the structure-function relationships in terms of ligand-binding and G protein coupling. In the present studies, we transiently expressed eight known CaR mutations in HEK293 cells. The effects of the mutations on extracellular calcium- and gadolinium-elicited increases in the cytosolic calcium concentration were then examined. Seven inactivating mutations, which cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism, show a reduced functional activity of the receptor because they may 1) reduce its affinity for agonists; 2) prevent conversion of the receptor from a putatively immature, high mannose form into the fully glycosylated and biologically active form of the CaR, in addition to lowering its affinity for agonists; or 3) fail to couple the receptor to and/or activate its respective G protein(s). Conversely, one activating mutation, which causes a form of autosomal dominant hypocalcemia, appears to increase the affinity of the receptor for its agonists.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MOL ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; NPS PHARMACEUT INC,SALT LAKE CITY,UT 84108; BRIGHAM & WOMENS HOSP,DIV RENAL,BOSTON,MA 02115	Imperial College London; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Bai, M (corresponding author), BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,DEPT MED,221 LONGWOOD AVE,BOSTON,MA 02115, USA.		Pearce, Simon/AAB-3692-2019	Pearce, Simon/0000-0001-8384-8063	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009436, R01DK041415, R01DK044588] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44588, DK09436, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIDA K, 1995, J CLIN ENDOCR METAB, V80, P2594, DOI 10.1210/jc.80.9.2594; AIDA K, 1995, BIOCHEM BIOPH RES CO, V214, P524, DOI 10.1006/bbrc.1995.2318; AUSUBEL FM, 1993, ENDOGLYCOSIDASE GLYC; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOU YHW, 1995, AM J HUM GENET, V56, P1075; Cochran W.G., 1967, STAT METHODS; DUKSIN D, 1982, EUR J BIOCHEM, V129, P77, DOI 10.1111/j.1432-1033.1982.tb07022.x; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; ERICKSON PA, 1993, POSTEMBEDDING IMMUNO, P283; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; HAMMERLAND LG, 1995, J BONE MINER RES, V10, pS156; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; JANICIC N, 1995, AM J HUM GENET, V56, P880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITHAL A, 1995, ENDOCRINOLOGY, V136, P3087, DOI 10.1210/en.136.7.3087; MORENCY CA, 1987, BIOTECHNIQUES, V5, P444; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; SUN GY, 1988, NEUROCHEM INT, V12, P69, DOI 10.1016/0197-0186(88)90150-7; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341	27	346	361	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19537	19545		10.1074/jbc.271.32.19537	http://dx.doi.org/10.1074/jbc.271.32.19537			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702647	hybrid			2022-12-27	WOS:A1996VB68400081
J	Gilchrist, RL; Ryu, KS; Ji, IH; Ji, TH				Gilchrist, RL; Ryu, KS; Ji, IH; Ji, TH			The luteinizing hormone chorionic gonadotropin receptor has distinct transmembrane conductors for cAMP and inositol phosphate signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE PRECOCIOUS PUBERTY; THYROTROPIN RECEPTOR; ACTIVATION; GENE; BINDING; MUTATIONS; PROTEINS; ASP(397); CYCLASE; LOOP	The luteinizing hormone/chorionic gonadotropin receptor is a member of the seven-transmembrane receptor family. It is coupled, presumably via G(s) and G(q), to two signal pathways involving adenylyl cyclase/cAMP and phospholipase C/inositol phosphate (IF). Little is known about the events prior to G-protein coupling: for example, whether these signals are generated from a single or multiple independent origins and mechanisms, when and where they diverge, and how they are transduced, We report novel observations that the cAMP signal and the IP signal originate and diverge upstream of G-protein coupling, The generation of these two signals independently involves Lys(583) in exoloop 3 of the rat receptor. For this study, Lys(583) Of the receptor was substituted with a panel of amino acids, and mutant receptors were assayed for hormone binding and induction of cAMP, inositol monophosphate, inositol bisphosphate, and inositol trisphosphate, No substitutions for Lys(583) were permissible for cAMP induction, despite successful surface expression and hormone binding. In contrast, several substitutions were permissible for IP induction, Our results suggest two distinct transmembrane signal conductors for cAMP and inositol phosphate signals and imply particular models of receptor activation not previously suggested.	UNIV WYOMING,DEPT MOL BIOL,LARAMIE,WY 82071	University of Wyoming					NICHD NIH HHS [HD-18702] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1993, J BIOL CHEM, V268, P20851; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KOSUGI S, 1994, FEBS LETT, V349, P89, DOI 10.1016/0014-5793(94)00646-6; LAPETINA EG, 1987, METHOD ENZYMOL, V141, P176; LAUE L, 1995, HUM MOL GENET, V4, P1429, DOI 10.1093/hmg/4.8.1429; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; XIE YB, 1990, J BIOL CHEM, V265, P21411; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; ZHU X, 1994, MOL PHARMACOL, V46, P460	26	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19283	19287		10.1074/jbc.271.32.19283	http://dx.doi.org/10.1074/jbc.271.32.19283			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702611	hybrid			2022-12-27	WOS:A1996VB68400045
J	Hu, B; Trinh, K; Figueira, WF; Price, PA				Hu, B; Trinh, K; Figueira, WF; Price, PA			Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS WL-12; ARTICULAR CHONDROCYTES; IDENTIFICATION; CELLS; CHITOTRIOSIDASE; GLYCOPROTEIN; CLONING	We describe the isolation of a novel protein from the conditioned medium of human articular cartilage chondrocytes in primary culture, This 39-kDa protein has the N-terminal sequence YKL, which we have termed YKL-39, The 1434-nucleotide sequence of the YKL-39 cDNA predicts a 385-residue initial translation product and a 364-residue mature YKL-39, The amino acid sequence of YKL-39 is most closely related to YKL-40, followed by macrophage chitotriosidase, oviductal glycoprotein, and macrophage YM-1, All five proteins share significant sequence identity with bacterial chitinases and have the probable structure of an (alpha beta)(8) barrel, YKL-39 lacks the active site glutamate, which is essential for the activity of chitinases, and as expected has no chitinase activity, The highest level of YKL-39 mRNA expression is seen in chondrocytes, followed by synoviocytes, lung, and heart, YKL-39 accounts for 4% of the protein in chondrocyte-conditioned medium, prostromelysin accounts for 17%, and YKL-40 accounts for 33%, In contrast to YKL-40, YRL-39 is not a glycoprotein and does not bind to heparin.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Figueira, Will/A-5163-2009	Figueira, Will/0000-0001-9472-8710	NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER; NIA NIH HHS [AG07996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; COULSON AFW, 1994, FEBS LETT, V354, P41, DOI 10.1016/0014-5793(94)01084-6; FARBER GK, 1993, CURR OPIN STRUC BIOL, V3, P409, DOI 10.1016/S0959-440X(05)80114-9; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAIER R, 1993, J BIOL CHEM, V268, P21527; MORRISON BW, 1994, ONCOGENE, V9, P3417; MYASHITA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1691; NYIRKOS P, 1990, BIOCHEM J, V268, P265; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992	21	165	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19415	19420		10.1074/jbc.271.32.19415	http://dx.doi.org/10.1074/jbc.271.32.19415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702629	hybrid			2022-12-27	WOS:A1996VB68400063
J	Alonso, CR; Pesce, CG; Kornblihtt, AR				Alonso, CR; Pesce, CG; Kornblihtt, AR			The CCAAT-binding proteins CP1 and NF-I cooperate with ATF-2 in the transcription of the fibronectin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; RNA-POLYMERASE-II; DNA-BINDING; YEAST HAP2; PROMOTER; EXPRESSION; CAMP; BOX; ACTIVATION; MOUSE	We have previously proposed a molecular interaction between the liver factors that bind to the cyclic AMP response element (CRE) and CCAAT sites of the fibronectin (FN) gene based on the following evidence: (i) the close spacing of 20 base pairs between CRE and CCAAT elements is conserved in the FN genes from rats, mice, and humans; (ii) footprinting competitions showed that CRE oligonucleotides are able to detach both liver factors; (iii) CCAAT binding and transcriptional activity of liver extracts are reduced when the distance between the CRE and CCAAT elements is increased; and (iv) CCAAT-binding is stimulated by the addition of a liver extract fraction containing the CRE-binding factor ATF-2. This report provides binding and immunochemical evidence that nuclear factor I (CTF/NF-I) and CP1 (NF-Y or CBF) are the only liver factors that bind to the -150 CCAAT element of the FN gene, forming distinct complexes, We show that these factors bind less efficiently to the CCAAT site of a FN promoter in which the -170 CRE has been disrupted by site directed mutagenesis and that each element contributes positively to the liver transcriptional activity assessed in vitro with a G-less cassette construct and in vivo by transfection of hepatoma cells with CAT constructs, Furthermore, using a method that combines UV crosslinking and immunoprecipitation, we show that antibodies specific to ATF-2 are able to specifically precipitate protein-protein-DNA complexes containing NF-I and CP1. This simple method preserves weak macromolecular interactions, avoiding the disruptive electrophoresis conditions of gel mobility shifts assays.	CONSEJO NACL INVEST CIENT & TECN ARGENTINA,INST INVEST INGN GENET & BIOL MOL,RA-1428 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,DEPT CIENCIAS BIOL,RA-1428 BUENOS AIRES,DF,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires				Kornblihtt, Alberto/0000-0003-4322-0831				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ANDRISANI O, 1990, J BIOL CHEM, V265, P3212; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BERNATH VA, 1990, J BIOL CHEM, V265, P18219; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hynes RO, 1990, FIBRONECTINS; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; JONES KA, 1987, CELL, V48, P78; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MIAO S, 1993, HEPATOLOGY, V17, P882, DOI 10.1002/hep.1840170519; MURO AF, 1993, TRENDS GENET, V9, P337, DOI 10.1016/0168-9525(93)90025-D; MURO AF, 1992, J BIOL CHEM, V267, P12767; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHWEIZERGROYER G, 1994, NUCLEIC ACIDS RES, V22, P1583, DOI 10.1093/nar/22.9.1583; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	46	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22271	22279		10.1074/jbc.271.36.22271	http://dx.doi.org/10.1074/jbc.271.36.22271			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703044	hybrid			2022-12-27	WOS:A1996VF61200086
J	Tozer, EC; Liddington, RC; Sutcliffe, MJ; Smeeton, AH; Loftus, JC				Tozer, EC; Liddington, RC; Sutcliffe, MJ; Smeeton, AH; Loftus, JC			Ligand binding to integrin alpha(IIb)beta(3) is dependent on a MIDAS-like domain in the beta(3) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ARG-GLY-ASP; DIVALENT-CATION REGULATION; INTERCELLULAR-ADHESION MOLECULE-1; PLATELET GPIIB-IIIA; I-DOMAIN; FIBRINOGEN-BINDING; GLANZMANNS THROMBASTHENIA; ALPHA-2-BETA-1 VLA-2; MONOCLONAL-ANTIBODY	Substitution of beta(3) residue Asp(119), Ser(121), or Ser(123) results in a loss of the ligand binding function of integrin alpha(IIb)beta(3). Homologous residues in other integrin beta subunits are similarly critical for ligand binding function. This DXSXS motif is also present in the I domain of certain integrin iv subunits, where it constitutes a portion of the unique metal ion-dependent adhesion site (MIDAS). In this report, we have utilized the crystal structure of the recombinant alpha(M) I domain to produce a three-dimensional model of the homologous region in the integrin beta(3) subunit. We performed mutagenesis of candidate amino acid residues predicted from this model to be involved in cation coordination and ligand binding. We report the identification of Asp(217) and Glu(220) as residues essential for the ligand binding function of alpha(IIb)beta(3). Alanine substitution of these residues did not affect receptor expression but abolished the binding of activation-dependent (PAC1) and -independent (OPG2) ligand mimetic antibodies. In our proposed model, beta(3) Asp(217) is analogous to a metal-coordinating residue in the alpha(M) MIDAS domain, while Glu(220) does not correspond to a functional MIDAS domain residue. Substitution of the highly conserved beta(3) residue Thr(197) corresponding to a critical MIDAS metal-coordinating Thr residue did not affect ligand binding function, suggesting that this region of beta(3) adopts a structure that is very similar to but not identical to that of the MIDAS domain. These data support a functional linkage between these two sequences and further define a common feature of ligand binding to integrins.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; UNIV LEICESTER, DEPT CHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	Scripps Research Institute; University of Leicester; University of Leicester			Smeeton, Allister/AAE-9526-2019	Sutcliffe, Mike/0000-0003-0414-1700	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTACHUL SF, 1990, J MOL BIOL, V215, P403; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHARO IF, 1991, J BIOL CHEM, V266, P1415; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EDWARDS JG, 1988, J CELL SCI, V89, P507; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GINSBERG MH, 1990, BLOOD, V76, P2017; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG X, 1994, MOL BIOL CELL, V4, P283; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PONCZ M, 1987, J BIOL CHEM, V262, P8476; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1994, J BIOL CHEM, V269, P960; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAUB R, 1989, J BIOL CHEM, V264, P259; TOMIYAMA Y, 1992, BLOOD, V79, P2303; TUCKWELL D, 1995, J CELL SCI, V108, P1629; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	69	160	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21978	21984		10.1074/jbc.271.36.21978	http://dx.doi.org/10.1074/jbc.271.36.21978			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703003	hybrid			2022-12-27	WOS:A1996VF61200045
J	Ilg, T; Stierhof, YD; Craik, D; Simpson, R; Handman, E; Bacic, A				Ilg, T; Stierhof, YD; Craik, D; Simpson, R; Handman, E; Bacic, A			Purification and structural characterization of a filamentous, mucin-like proteophosphoglycan secreted by Leishmania parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-PHOSPHATASE; DONOVANI LIPOPHOSPHOGLYCAN; MONOCLONAL-ANTIBODIES; PHLEBOTOMUS-PAPATASI; DENTIN PHOSPHOPHORYN; MAJOR PROMASTIGOTES; N-GLYCOSYLATION; MEXICANA; BIOSYNTHESIS; PSYCHODIDAE	Parasitic protozoa of the genus Leishmania secrete a filamentous macromolecule that forms networks and appears to be associated with cell aggregation. We report here the purification of this parasite antigen from Leishmania major culture supernatant and its compositional (75.6% carbohydrate, 20% phosphate, 4.4% amino acids, w/w), structural, and ultrastructural characterization as a highly unusual proteophosphoglycan (PPG). Mild acid hydrolysis, which cleaves preferentially hexose 1-phosphate bonds, releases the PPG glycans. Their structures are Gal beta 1-4Man, Man alpha 1-2Man, Gal beta 1-3Gal beta 1-4Man, PO4-6(Gal beta 1-3)(0-2)Gal beta 1-4Man, and PO4-6(Ara beta 1-2Gal beta 1-3)Gal beta 1-4Man. These glycans are also components of the parasite glycolipid lipophosphoglycan, but their relative abundance and structural organization in PPG are different. Some of them represent novel forms of protein glycosylation. P-31 NMR on native PPG demonstrates that phosphate is exclusively in phosphodiester bonds and that the basic structure R-Man alpha 1-PO4-6-Gal-R connects the glycans. A phosphodiester linkage to phosphoserine (most likely R-Man alpha 1-PO4-Ser) anchors the PPG oligosaccharides to the polypeptide. PPG has a unique amino acid composition; glycosylated phosphoserine (>43 mol %), serine, alanine, and proline account for more than 87 mol % and appear to be clustered in large proteinase-resistant domains. Electron microscopy of purified PPG reveals cable-like, flexible, long (to 6 mu m), and unbranched filaments. The overall structure of PPG shows many similarities to mammalian mucins. Potential functions of this novel mucin-like molecule for the parasites are discussed.	MAX PLANCK INST BIOL,D-72076 TUBINGEN,GERMANY; UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA; LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,JOINT PROT STRUCT LAB,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,SCH BOT,PLANT CELL BIOL RES CTR,PARKVILLE,VIC 3052,AUSTRALIA	Max Planck Society; University of Queensland; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; University of Melbourne	Ilg, T (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Simpson, Richard/A-6947-2012; Craik, David/B-1695-2010	Craik, David/0000-0003-0007-6796; Simpson, Richard/0000-0002-9834-0796; Bacic, Tony/0000-0001-7483-8605				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BAX A, 1988, CARBOHYD RES, V173, P53, DOI 10.1016/S0008-6215(00)90802-4; BEACH R, 1985, AM J TROP MED HYG, V34, P278; *BOEHR MANNH, 1987, BOEHR MANN BIOCH INF; BYRNE BM, 1984, BIOCHEMISTRY-US, V23, P4275, DOI 10.1021/bi00314a003; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CORFIELD T, 1992, GLYCOCONJUGATE J, V9, P217; ERUN R, 1979, ACTA TROP, V36, P289; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FOX A, 1989, ANAL CARBOHYDRATES G; GREIS KD, 1992, J BIOL CHEM, V267, P5876; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HELANDER A, 1992, CARBOHYD RES, V230, P299; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HO C, 1969, BIOCHEMISTRY-US, V8, P2074, DOI 10.1021/bi00833a044; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1995, EUR J CELL BIOL, V66, P205; ILG T, 1994, J BIOL CHEM, V269, P24073; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; ILG T, 1992, J BIOL CHEM, V267, P6834; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; ILG T, 1992, THESIS EBERHARD KARL; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; JAFFE CL, 1990, MOL BIOCHEM PARASIT, V41, P233, DOI 10.1016/0166-6851(90)90186-P; JEFFERIES D, 1986, ACTA TROP, V43, P43; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KILLICKKENDRICK R, 1988, PARASITOL RES, V74, P586, DOI 10.1007/BF00531639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG T, 1991, EUR J CELL BIOL, V55, P362; LAU E, 1993, J CHROMATOGR, V637, P100, DOI 10.1016/0021-9673(93)83104-Z; LAWYER PG, 1990, AM J TROP MED HYG, V43, P31, DOI 10.4269/ajtmh.1990.43.31; LAWYER PG, 1987, J MED ENTOMOL, V24, P347, DOI 10.1093/jmedent/24.3.347; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LOVELACE JK, 1986, AM J TROP MED HYG, V35, P1121, DOI 10.4269/ajtmh.1986.35.1121; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MOODY SF, 1993, J BIOL CHEM, V268, P18457; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; OXLEY D, 1995, GLYCOBIOLOGY, V5, P517, DOI 10.1093/glycob/5.5.517; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRESCOTT DJ, 1969, J BIOL CHEM, V244, P4517; RICKWOOD D, 1984, CENTRIFUGATION PRACT, P95; ROSE M, 1992, AM J PHYSIOL, V7, pL413; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; SHAW N, 1974, BIOCHEM J, V143, P461, DOI 10.1042/bj1430461; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; STIERHOF YD, 1994, J CELL BIOL, V125, P321, DOI 10.1083/jcb.125.2.321; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Taborsky G, 1974, Adv Protein Chem, V28, P1, DOI 10.1016/S0065-3233(08)60230-2; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; TYLER JM, 1980, J CELL BIOL, V85, P489, DOI 10.1083/jcb.85.2.489; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; WALTERS LL, 1989, AM J TROP MED HYG, V40, P19, DOI 10.4269/ajtmh.1989.40.19; WALTERS LL, 1987, AM J TROP MED HYG, V36, P294, DOI 10.4269/ajtmh.1987.36.294; WALTERS LL, 1989, AM J TROP MED HYG, V41, P295, DOI 10.4269/ajtmh.1989.41.295; WARBURG A, 1986, AM J TROP MED HYG, V35, P926, DOI 10.4269/ajtmh.1986.35.926; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; [No title captured]	73	100	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21583	21596		10.1074/jbc.271.35.21583	http://dx.doi.org/10.1074/jbc.271.35.21583			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702946	hybrid			2022-12-27	WOS:A1996VE47700092
J	Nishitoh, H; Ichijo, H; Kimura, M; Matsumoto, T; Makishima, F; Yamaguchi, A; Yamashita, H; Enomoto, S; Miyazono, K				Nishitoh, H; Ichijo, H; Kimura, M; Matsumoto, T; Makishima, F; Yamaguchi, A; Yamashita, H; Enomoto, S; Miyazono, K			Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEINS; SERINE THREONINE KINASE; TGF-BETA; OSTEOGENIC PROTEIN-1; ACTIVIN RECEPTOR; EXPRESSION CLONING; SUPERFAMILY; DIFFERENTIATION; FAMILY	Growth/differentiation factor-5 (GDF-5) is a member of the bone morphogenetic protein (BMP) family, which plays an important role in bone development in vivo. Mutations in the GDF-5 gene result in brachypodism in mice and Hunter-Thompson type chondrodysplasia in human. BMPs transduce their effects through binding to two different types of serine/threonine kinase receptors, type I and type II. However, binding abilities appear to be different among the members of the BMP family. BMP-4 binds to two different type I receptors, BMP receptors type IA (BMPR-IA) and type IB (BMPR-IB), and a type II receptor, BMP receptor type II (BMPR-II). In addition to these receptors, osteogenic protein-1 (OP-1, also known as BMP-7) binds to activin type I receptor (ActR-I) as well as activin type II receptors (ActR-II and ActR-IIB). Here we investigate the binding and signaling properties of GDF-5 through type I and type II receptors. GDF-5 induced alkaline phosphatase activity in a rat osteoprogenitor-like cell line, ROB-C26. I-125-GDF-5 bound to BMPR-IB and BMPR-II but not to BMPR-IA in ROB-C26 cells and other nontransfected cell lines. Analysis using COS-1 cells transfected with the receptor cDNAs revealed that GDF-5 bound to BMPR-IB but not to the other type I receptors when expressed alone. When COS-1 cells were transfected with type II receptor cDNAs, GDF-5 bound to ActR-II, ActR-IIB, and BMPR-II but not to transforming growth factor-beta type II receptor, In the presence of type II receptors, GDF-5 bound to different sets of type I receptors, but the binding was most efficient to BMPR-IB compared with the other type I receptors. Moreover, a transcriptional activation signal was efficiently transduced by BMPR-IB in the presence of BMPR-II or ActR-II after stimulation by GDF-5. These results suggest that BMPR-IB mediates certain signals for GDF-5 after forming the heteromeric complex with BMPR-II or ActR-II.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; TOKYO MED & DENT UNIV,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN; HOECHST JAPAN LTD,DRUG DISCOVERY RES LABS,PHARMA RES & DEV DIV,KAWAGOE,SAITAMA 35011,JAPAN; SHOWA UNIV,SCH DENT,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN; UNIV TOKYO,FAC MED,DEPT OPHTHALMOL,BUNKYO KU,TOKYO 113,JAPAN	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU); Showa University; University of Tokyo				Nishitoh, Hideki/0000-0002-8652-4109; Ichijo, Hidenori/0000-0002-5005-6438				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; ASAHINA I, 1993, J CELL BIOL, V123, P921, DOI 10.1083/jcb.123.4.921; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHANG SC, 1994, J BIOL CHEM, V269, P28227; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HOTTEN G, 1994, BIOCHEM BIOPH RES CO, V204, P646, DOI 10.1006/bbrc.1994.2508; Hotten GC, 1996, GROWTH FACTORS, V13, P65, DOI 10.3109/08977199609034567; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; NISTER M, 1991, J BIOL CHEM, V266, P16755; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1994, J BIOL CHEM, V269, P765; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VERSCHUEREN K, 1995, MECH DEVELOP, V52, P109, DOI 10.1016/0925-4773(95)00395-H; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	56	273	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21345	21352		10.1074/jbc.271.35.21345	http://dx.doi.org/10.1074/jbc.271.35.21345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702914	hybrid			2022-12-27	WOS:A1996VE47700060
J	Patten, M; Hartogensis, WE; Long, CS				Patten, M; Hartogensis, WE; Long, CS			Interleukin-1 beta is a negative transcriptional regulator of alpha(1)-adrenergic induced gene expression in cultured cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; PROTEIN-KINASE-C; ALPHA-ACTIN GENE; ISOLATED MESENTERIC-ARTERY; RAT MYOCARDIAL-CELLS; HEAVY-CHAIN PROMOTER; ENHANCER FACTOR-I; NITRIC-OXIDE; GROWTH-FACTOR; RETINOBLASTOMA PROTEIN	We recently reported that interleukin-1 beta (IL-1 beta) induces a novel form of cardiac myocyte hypertrophy characterized by an increase in protein content but an absence of the fetal program of skeletal alpha-actin or beta-myosin heavy chain (beta-MHC) gene expression (Palmer, J. N., Hartogensis, W. E., Fatten, M., Fortuin, F. D., and Long, C. S. (1995) J. Clin. Invest. 95, 2555-2564). Because of the apparent disparity between this myocardial phenotype and that seen with other hypertrophic agents in culture, such as catecholamines, we investigated the effect of IL-1 beta on alpha(1)-induced cardiomyocyte hypertrophy. Although there was no augmentation in total protein when IL-1 beta and phenylephrine were given simultaneously, IL-1 beta attenuated the increase in contractile protein mRNAs (skeletal alpha-actin and beta-MHC) in response to phenylephrine. Transient transfection studies with skeletal alpha-actin and beta-MHC promoter constructs linked to the chloramphenicol acetyltransferase (CAT)-reporter gene indicate that repression occurred at the level of gene transcription. In view of the previously reported activity of the zinc finger protein YY1 in the negative regulation of the skeletal alpha-actin promoter in cardiomyocytes (MacLellan, W. R., Lee, T. C., Schwartz, R. J., and Schneider, M. D. (1994) J. Biol. Chem. 269, 16754-16760), we investigated the potential role of this factor in the IL-1 beta-mediated effects. Using transient transfection, we found that a mutation in the YY1 binding site of the skeletal alpha-actin promoter abolished the inhibitory effect of IL-1 beta. We further found that the 127-base pair fragment of the skeletal alpha-actin promoter required for the IL-1 beta effect is also required for inhibition by the overexpression of YY1 in the myocytes. Furthermore, increased levels of YY1 protein are found in IL-1 beta treated myocytes. Taken together these results suggest that the repression of contractile protein gene transcription by IL-1 beta may be due, at least in part, to activation of the negative transcription factor YY1.	VET AFFAIRS MED CTR, DIV CARDIOL 111C8, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, RES SERV, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco				Long, Carlin/0000-0001-7251-2847				BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; COREA L, 1984, AM J CARDIOL, V53, P1299, DOI 10.1016/0002-9149(84)90083-3; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; FINKEL MS, 1993, AM J CARDIOL, V71, P1231, DOI 10.1016/0002-9149(93)90654-U; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GULICK T, 1988, BIOCHEM BIOPH RES CO, V150, P1, DOI 10.1016/0006-291X(88)90478-0; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KINUGAWA K, 1994, CIRC RES, V75, P285, DOI 10.1161/01.RES.75.2.285; LANGE LG, 1992, TRENDS CARDIOVAS MED, V2, P145, DOI 10.1016/1050-1738(92)90022-K; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1994, ONCOGENE, V9, P1047; LIU S, 1995, AM J PHYSIOL-CELL PH, V268, pC339, DOI 10.1152/ajpcell.1995.268.2.C339; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MARCEAU F, 1991, BRIT J PHARMACOL, V103, P1367, DOI 10.1111/j.1476-5381.1991.tb09795.x; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NOSE PS, 1993, J CARDIAC SURG, V8, P305; PALMER JN, 1995, J CLIN INVEST, V95, P2555, DOI 10.1172/JCI117956; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PETITCLERC E, 1994, J PHARMACOL EXP THER, V268, P1419; PETITCLERC E, 1992, J CARDIOVASC PHARM, V19, P821; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; ROKOSH DG, 1994, BIOCHEM BIOPH RES CO, V200, P1177, DOI 10.1006/bbrc.1994.1575; SHINDO T, 1995, CARDIOVASC RES, V29, P813, DOI 10.1016/S0008-6363(96)88617-2; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; TRINKLE LA, 1992, AM J PHYSIOL, V262, pC828, DOI 10.1152/ajpcell.1992.262.4.C828; TSUJINO M, 1994, CIRCULATION, V90, P375, DOI 10.1161/01.CIR.90.1.375; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WESTLIN W, 1989, CIRCULATION, V80, P1828, DOI 10.1161/01.CIR.80.6.1828; WU CJ, 1992, TRANSPLANTATION, V54, P326, DOI 10.1097/00007890-199208000-00024; Wu P. S., 1995, Journal of Investigative Medicine, V43, p224A; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834	52	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21134	21141		10.1074/jbc.271.35.21134	http://dx.doi.org/10.1074/jbc.271.35.21134			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702883	hybrid			2022-12-27	WOS:A1996VE47700029
J	Brash, AR; Boeglin, WE; Chang, MS; Shieh, BH				Brash, AR; Boeglin, WE; Chang, MS; Shieh, BH			Purification and molecular cloning of an 8R-lipoxygenase from the coral Plexaura homomalla reveal the related primary structures of R- and S-lipoxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ARACHIDONIC-ACID; SOYBEAN LIPOXYGENASE; HUMAN 5-LIPOXYGENASE; LINOLEIC-ACID; STRONGYLOCENTROTUS-PURPURATUS; RNA ISOLATION; SEA-URCHIN; BIOSYNTHESIS; EICOSANOIDS	Lipoxygenases that form S configuration fatty acid hydroperoxides have been purified or cloned from plant and mammalian sources. Our objectives were to characterize one of the lipoxygenases with R stereospecificity, many of which are described in marine and freshwater invertebrates. Characterization of the primary structure of an R-specific enzyme should help provide a new perspective to consider the enzyme-substrate interactions that are the basis of the specificity of all lipoxygenases, We purified an 8R-lipoxygenase of the prostaglandin-containing coral Plexaura homomalla by cation and anion exchange chromatography. This yielded a colorless enzyme preparation, a band of similar to 100 kDa on SDS-polyacrylamide gel electrophoresis, and turnover num- bers of 4000 min(-1) of 8R-lipoxygenase activity in peak chromatographic fractions., The full-length cDNA was cloned by PCR using peptide sequence from the purified protein and by 5'- and 3'-rapid amplification of cDNA ends. The cDNA encodes a polypeptide of 715 amino acids, including over 70 amino acids identified by peptide microsequencing. A peptide presequence of 52 amino acids is cleaved to give the mature protein of 76 kDa; the difference from the estimated size by SDS-PAGE implies a post-translational modification of the P. homomalla enzyme. All of the iron-binding histidines of S-lipoxygenases are conserved in the 8R-lipoxygenase. However, the C terminal amino acid is a threonine, as opposed to the isoleucine that provides the carboxylate ligand to the iron in all known S-lipoxygenases. These results establish that the 8R-lipoxygenase is related in primary structure to the S-lipoxygenases. A model of the basis of R and S stereospecificity is described.			Brash, AR (corresponding author), VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA.				NICHD NIH HHS [HD-05797] Funding Source: Medline; NIGMS NIH HHS [GM-49502, GM-15431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD005797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431, R01GM049502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAKURA T, 1994, J OCUL PHARMACOL, V10, P525, DOI 10.1089/jop.1994.10.525; BAER AN, 1991, J LIPID RES, V32, P341; BELL E, 1993, PLANT PHYSIOL, V103, P1133, DOI 10.1104/pp.103.4.1133; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; BUNDY GL, 1986, J BIOL CHEM, V261, P747; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; DEPETROCELLIS L, 1994, PROSTAG LEUKOTR ESS, V51, P215, DOI 10.1016/0952-3278(94)90183-X; DIMARZO V, 1993, BIOCHEM J, V295, P23, DOI 10.1042/bj2950023; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; EGMOND MR, 1972, BIOCHEM BIOPH RES CO, V48, P1055, DOI 10.1016/0006-291X(72)90815-7; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GERMAN JB, 1990, LIPIDS, V25, P849, DOI 10.1007/BF02535908; GERWICK WH, 1994, BBA-LIPID LIPID MET, V1211, P243, DOI 10.1016/0005-2760(94)90147-3; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; HAMPSON AJ, 1992, BIOCHIM BIOPHYS ACTA, V1124, P143, DOI 10.1016/0005-2760(92)90090-I; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HAWKINS DJ, 1989, FEBS LETT, V247, P9, DOI 10.1016/0014-5793(89)81228-1; HILL EM, 1992, P ROY SOC B-BIOL SCI, V247, P41, DOI 10.1098/rspb.1992.0007; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; ISHII S, 1992, BIOCHEM BIOPH RES CO, V182, P1482, DOI 10.1016/0006-291X(92)91901-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHNS H, 1987, ADV ENZYMOL RELAT AR, V58, P273; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; Liu Qing Yan, 1994, Molecular Marine Biology and Biotechnology, V3, P206; MEIJER L, 1986, J BIOL CHEM, V261, P7040; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; NUGTEREN DH, 1966, NATURE, V212, P38, DOI 10.1038/212038a0; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PENG YL, 1994, J BIOL CHEM, V269, P3755; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; RAMACHANDRAN S, 1995, BIOCHEMISTRY-US, V34, P14868, DOI 10.1021/bi00045a030; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; ROUX KH, 1994, BIOTECHNIQUES, V16, P812; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SKRZYPCZAKJANKU.E, 1994, 9TH ORG CRYST CHEM S, P112; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; SU X, 1988, ANAL BIOCHEM, V174, P650, DOI 10.1016/0003-2697(88)90068-1; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; VANOS CPA, 1979, BIOCHIM BIOPHYS ACTA, V575, P479, DOI 10.1016/0005-2760(79)90120-6; Vliegenthart J. F. G., 1982, FREE RADICAL BIO MED, P29; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185; WEINHEIMER AJ, 1974, PROSTAGLANDINS PLEXA, P17; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; YAMAMOTO S, 1989, PROSTAG LEUKOTR ESS, V35, P219, DOI 10.1016/0952-3278(89)90005-7	60	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20949	20957		10.1074/jbc.271.34.20949	http://dx.doi.org/10.1074/jbc.271.34.20949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702854	hybrid			2022-12-27	WOS:A1996VD33700106
J	Garippa, RJ; Johnson, A; Park, J; Petrush, RL; McGraw, TE				Garippa, RJ; Johnson, A; Park, J; Petrush, RL; McGraw, TE			The carboxyl terminus of GLUT4 contains a serine-leucine-leucine sequence that functions as a potent internalization motif in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; TRANSFERRIN RECEPTOR; INTRACELLULAR SEQUESTRATION; CYTOPLASMIC DOMAIN; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; INSULIN STIMULATION; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; NH2 TERMINUS	To characterize the trafficking motifs contained in the carboxyl terminus of GLUT4, a chimera (GTCTR) was constructed in which the carboxyl-terminal 30 amino acids of GLUT4 were substituted for the amino-terminal cytoplasmic domain of the transferrin receptor (TR), The endocytic behavior of this chimera was characterized in Chinese hamster ovary cells, The GTCTR chimera had a more predominant intracellular distribution compared to the TR. Only 20% of the GTCTR chimera is on the surface at steady-state compared to 35% of the TR. The GTCTR chimera is internalized 50% more rapidly and recycled 20% more slowly than the TR, Acidification of the cytosol inhibited internalization of the GTCTR chimera, indicating that the chimera is internalized through clathrin-coated pits, Mutations of GTCTR were constructed in which a di-leucine sequence of the carboxyl domain of GLUT4 was mutated to a di-alanine sequence (GTCTR-AA) and serine residue 488, immediately preceding the di-leucine sequence, was mutated to either an alanine or aspartate residue, In each case, albeit to varying degrees, the substitutions shifted the distribution of the mutated GTCTR constructs toward the surface. The shift in the distribution of GTCTR-AA resulted from a 10-fold reduction in internalization, and the shift of serine 488 mutants resulted from a 3-fold reduction in the internalization rate compared to GTCTR, None of these mutations affected the recycling rate, These results demonstrate that the carboxyl terminus of GLUT4 contains a serine-leucine-leucine-based motif that, when expressed in non-insulin responsive cells, functions as a potent internalization motif which promotes more rapid internalization than does the native TR internalization motif.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University								ASANO T, 1992, J BIOL CHEM, V267, P19636; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1992, P NATL ACAD SCI USA, V89, P3493, DOI 10.1073/pnas.89.8.3493; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROTH MG, 1993, ENDOSOMES LYSOSOMES, P19; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1989, METHOD CELL BIOL, V32, P365; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; YANG J, 1993, J BIOL CHEM, V268, P4600	42	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20660	20668		10.1074/jbc.271.34.20660	http://dx.doi.org/10.1074/jbc.271.34.20660			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702815	hybrid			2022-12-27	WOS:A1996VD33700067
J	Lassalle, P; Molet, S; Janin, A; VanderHeyden, J; Tavernier, J; Fiers, W; Devos, R; Tonnel, AB				Lassalle, P; Molet, S; Janin, A; VanderHeyden, J; Tavernier, J; Fiers, W; Devos, R; Tonnel, AB			ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; ADHESION MOLECULE-1; INTERFERON-GAMMA; FACTOR-ALPHA; T-CELL; SEQUENCE; DEGRADATION; INDUCTION; SELECTIN	We here report the identification of a novel human endothelial cell-specific molecule (called ESM-1) cloned from a human umbilical vein endothelial cell (HUVEC) cDNA library. Constitutive ESM-1 gene expression (as demonstrated by Northern blot and reverse transcription-polymerase chain reaction analysis) was found in HUVECs but not in the other human cell lines tested. The cDNA sequence contains an open reading frame of 552 nucleotides and a 1398-nucleotide 3'-untranslated region including several domains involved in mRNA instability and five putative polyadenylation consensus sequences. The deduced 184-amino acid sequence defines a cysteine-rich protein with a functional NH2-terminal hydrophobic signal sequence. Searches in several data bases confirmed the unique identity of this sequence. A rabbit immune serum raised against the 14-kDa COOH-terminal peptide of ESM-1 immunoprecipitated a 20-kDa protein only in ESM-1-transfected COS cells. Immunoblotting and immunoprecipitation of HU-VEC lysates revealed a specific 20-kDa band corresponding to ESM-1. In addition, constitutive ESM-1 gene expression was shown to be tissue-restricted to the human lung. Southern blot analysis suggests that a single gene encodes ESM-1. A time-dependent up-regulation of ESM-1 mRNA was seen after addition of tumor necrosis factor alpha (TNF alpha) or interleukin (IL)-1 beta but not with IL-4 or interferon gamma (IFN gamma) alone. In addition, when IFN gamma was combined with TNF alpha, IFN gamma inhibited the TNF alpha-induced increase of ESM-1 mRNA level. These data suggest that ESM-1 may have potent implications in the areas of vascular cell biology and human lung physiology.	HOP ST LOUIS,ANAT PATHOL LAB,F-75010 PARIS,FRANCE; ROCHE RES GENT,B-9000 GHENT,BELGIUM; STATE UNIV GHENT,MOL BIOL LAB,B-9000 GHENT,BELGIUM	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Ghent University	Lassalle, P (corresponding author), INST PASTEUR,INSERM U416,1 BLVD A CALMETTE,F-59000 LILLE,FRANCE.		Lassalle, Philippe/L-6705-2018	lassalle, philippe/0000-0001-6434-0344				AGHIB DF, 1990, ONCOGENE, V5, P707; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DOUKAS J, 1990, J IMMUNOL, V145, P1727; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GUISEZ Y, 1993, FEBS LETT, V331, P49, DOI 10.1016/0014-5793(93)80295-6; HEBBAR M, 1995, ARTHRITIS RHEUM, V38, P406, DOI 10.1002/art.1780380318; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASSALLE P, 1992, EUR J IMMUNOL, V22, P425, DOI 10.1002/eji.1830220221; LASSALLE P, 1993, EUR J IMMUNOL, V23, P796, DOI 10.1002/eji.1830230404; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PROODFOOT NJ, 1976, NATURE, V263, P211; SAMBROOK E, 1989, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRINGER TA, 1994, CELL, V56, P907; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; STRIETER RM, 1989, SCIENCE, V243, P1487; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	27	296	334	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20458	20464		10.1074/jbc.271.34.20458	http://dx.doi.org/10.1074/jbc.271.34.20458			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702785	hybrid			2022-12-27	WOS:A1996VD33700037
J	Roher, AE; Chaney, MO; Kuo, YM; Webster, SD; Stine, WB; Haverkamp, LJ; Woods, AS; Cotter, RJ; Tuohy, JM; Krafft, GA; Bonnell, BS; Emmerling, MR				Roher, AE; Chaney, MO; Kuo, YM; Webster, SD; Stine, WB; Haverkamp, LJ; Woods, AS; Cotter, RJ; Tuohy, JM; Krafft, GA; Bonnell, BS; Emmerling, MR			Morphology and toxicity of A beta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; CEREBROSPINAL-FLUID; MAMMALIAN BRAIN; PEPTIDE; CELLS; MICROGLIA; PHAGOCYTOSIS; AGGREGATION; RELEASE; INJURY	In the course of analyzing the chemical composition of Alzheimer's disease neuritic and vascular amyloid, we have purified stable dimeric and trimeric components of A beta peptides, These peptides (molecular mass 9.0 and 13.5 kDa) were separated by size exclusion chromatography in the presence of 80% formic acid or 5 M. guanidine thiocyanate, pH 7.4, The average ratio of monomers, dimers, and trimers was 55:30:15, respectively, Similar structures were produced over time upon incubation of synthetic A beta-(1-42) at pH 7.4, The stability of these oligomeric forms was also demonstrated by Western blot and mass spectrometry, Atomic force microscopy and electron microscopy rotary shadowing revealed that the monomers polymerized into 8-10-nm filaments, whereas the dimers generated prolate ellipsoids measuring 3-4 nm in diameter, The pathogenic effects of the dimeric A beta-(1-40/42) were tested in cultures of rat hippocampal neuron glia cells. Only in the presence of microglia did the dimer elicit neuronal killing. It is possible that these potentially pathogenic A beta-(1-40/42) dimers and trimers from Alzheimer's disease amyloid represent the soluble oligomers of A beta recently described in Alzheimer's disease brains (Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H,, Ball, M. J., and Roher, A. E. (1996) J. Biol, Chem., 271, 4077-4081).	ELI LILLY & CO,LILLY RES LABS,BIOTECHNOL CORE,INDIANAPOLIS,IN 46285; ABBOTT LABS,DEPT CELLULAR & MICROSCOP RES,ABBOTT PK,IL 60064; BAYLOR COLL MED,DEPT NEUROL,ALZHEIMERS DIS RES CTR,HOUSTON,TX 77030; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL SCI,CHICAGO,IL 60611; ARIZONA STATE UNIV,DEPT ZOOL,TEMPE,AZ 85287; PARKE DAVIS CO,ANN ARBOR,MI 48106	Eli Lilly; Abbott Laboratories; Baylor College of Medicine; Johns Hopkins University; Northwestern University; Arizona State University; Arizona State University-Tempe; Pfizer	Roher, AE (corresponding author), SUN HLTH RES INST,HALDEMAN LAB ALZHEIMERS DIS RES,10515 W SANTA FE DR,SUN CITY,AZ 85372, USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482	NATIONAL INSTITUTE ON AGING [R01AG011925, P50AG008664, R01AG012548] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11925, AG-08664, AG-12548] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BONNELL B, 1990, J STRUCT BIOL, V105, P123, DOI 10.1016/1047-8477(90)90106-M; COPANI A, 1991, NEUROREPORT, V2, P763, DOI 10.1097/00001756-199112000-00008; DAVIS TL, 1989, BRAIN RES, V504, P216, DOI 10.1016/0006-8993(89)91360-7; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Giulian D., 1992, CURR TOP NEUROL, V12, P23; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARIGAYA Y, 1995, BIOCHEM BIOPH RES CO, V211, P1015, DOI 10.1006/bbrc.1995.1912; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Kuo YM, 1996, J BIOL CHEM, V271, P4077; MANN DMA, 1988, NEUROPATH APPL NEURO, V14, P177, DOI 10.1111/j.1365-2990.1988.tb00880.x; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; MIYAKAWA T, 1992, ACTA NEUROPATHOL, V83, P340, DOI 10.1007/BF00713523; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; ROGERS J, 1996, IN PRESS NEUROBIOL A, V17; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; VINORES SA, 1993, J NEUROIMMUNOL, V43, P169, DOI 10.1016/0165-5728(93)90088-G; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8	36	446	478	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20631	20635		10.1074/jbc.271.34.20631	http://dx.doi.org/10.1074/jbc.271.34.20631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702810	hybrid			2022-12-27	WOS:A1996VD33700062
J	Amara, FM; Sun, J; Wright, JA				Amara, FM; Sun, J; Wright, JA			Defining a novel cis-element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA - cis-trans-interactions and message stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; PROTEIN-BINDING; CELLS; EXPRESSION; R1; KINASE; DNA; FIBROBLASTS	Mammalian ribonucleotide reductase is a highly regulated activity essential for DNA synthesis and repair. The 3'-untranslated region (3'-UTR) of mammalian ribonucleotide reductase R2 mRNA has been implicated in the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate-mediated stabilization of mouse BALB/c 3T3 R2 message. We investigated the possibility that the 3'-UTR contains regulatory information for R2 mRNA turnover. Using 3'-end-labeled RNA in gel shift and UV cross-linking analyses, we detected in the 3'-UTR a novel 9-nucleotide cis-element, 5'UCGUGUGCU-3', which interacted with a widely distributed cellular cytosolic protease-sensitive factor(s) in a sequence-specific manner to form a 45-kDa R2 binding protein complex. The binding activity was redox-sensitive and down-regulated by 12-O-tetradecanoylphorbol-13-acetate and okadaic acid in a dose-dependent manner. Insertion of a 154-base pair fragment containing the cis-element led to markedly reduced accumulation of chloramphenicol acetyltransferase hybrid mRNA relative to the same insert carrying a series of G --> A mutations within this element that eliminated binding. We suggest that the 9-nucleotide region functions as a destabilizing element. These results provide a model for ribonucleotide reductase gene expression through a novel and specific mRNA cis-trans-interaction involving a phosphorylation signal pathway that leads to changes in the stability of R2 message.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0V9,CANADA	University of Manitoba; University of Manitoba								AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; AMARA FM, 1994, J BIOL CHEM, V269, P6709; AMARA FM, 1995, CANCER RES, V55, P4503; BLOMANIS R, 1987, CANCER RES, V47, P1273; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONIN PD, 1990, J BIOL CHEM, V265, P18643; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN FY, 1994, BIOCHEM J, V302, P125, DOI 10.1042/bj3020125; CHEN FY, 1994, NUCLEIC ACIDS RES, V22, P4796, DOI 10.1093/nar/22.22.4796; CHOY BK, 1989, BIOCHEM BIOPH RES CO, V162, P1417, DOI 10.1016/0006-291X(89)90832-2; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; HURTA RAR, 1991, J BIOL CHEM, V266, P24097; IWAI Y, 1991, J BIOL CHEM, V266, P17959; LEE W, 1987, NATURE, V311, P433; LELBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SCHONTHAL A, 1991, ONCOGENE, V6, P423; WEBER G, 1983, CANCER RES, V43, P3466; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1989, INT ENCY PHARM THERA, V128, P89; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	33	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20126	20131		10.1074/jbc.271.33.20126	http://dx.doi.org/10.1074/jbc.271.33.20126			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702735	hybrid			2022-12-27	WOS:A1996VC66900076
J	GuptaRoy, B; Beckingham, K; Griffith, LC				GuptaRoy, B; Beckingham, K; Griffith, LC			Functional diversity of alternatively spliced isoforms of Drosophila Ca2+/calmodulin-dependent protein kinase II - A role for the variable domain in activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CA2+-BINDING SITES; LIGHT-CHAIN KINASE; CA2+ BINDING; 2 SERIES; POINT MUTATIONS; CALMODULIN; EXPRESSION; SUBUNIT; CLONING; MUTANTS	Isoforms of calcium/calmodulin-dependent protein kinase II from Drosophila (R1-R6 and R3A) showed differential activation by two series of mutant calmodulins, B1K-B4K and B1Q-B4Q. These mutant calmodulins were generated by changing a glutamic acid in each of the four calcium binding sites to either glutamine or lysine, altering their calcium binding properties. All mutations produced activation defects, with the binding site 4 and B1Q mutants the most severe. Activation differed substantially between isoforms, R4, R5, and R6 were the least sensitive to mutations in calmodulin, while R1, R3, and R3A were the most sensitive, activation of R1 and R2 by B4K and activation of R3 and R3A by B2K and B2Q produced significant (6-fold and almost 3-fold, respectively) differences in K-act between isoforms that differ stracturally by a single amino acid. These differences could not be accounted for by differential binding, as all isoforms showed almost identical binding patterns with the mutants. High binding affinity did not always correlate with ability to increase enzyme activity, implying that activation occurs in at least two steps. The isoform-specific differences seen in this study reflect a role for the COOH-terminal variable region in activation of CaM kinase II.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Brandeis University; Brandeis University; Rice University				Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408, R01GM049155, R55GM049155, P01GM033205] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49155, R01 GM054408, GM33205] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BENSON DL, 1991, J NEUROSCI, V11, P31; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; COHEN P, 1988, CALMODULIN, V5, P35; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; LEVINE H, 1985, P NATL ACAD SCI USA, V82, P287, DOI 10.1073/pnas.82.2.287; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1985, J BIOL CHEM, V260, P9039; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; PRATT WB, 1990, PRINCIPLES DRUG ACTI, P56; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SU ZH, 1994, J BIOL CHEM, V269, P16761; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YOSHIDA M, 1983, J BIOCHEM-TOKYO, V94, P1925, DOI 10.1093/oxfordjournals.jbchem.a134546; ZOT HG, 1990, J BIOL CHEM, V265, P14796	24	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19846	19851		10.1074/jbc.271.33.19846	http://dx.doi.org/10.1074/jbc.271.33.19846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702694	hybrid			2022-12-27	WOS:A1996VC66900035
J	Kraus, R; Reichl, B; Kimball, SD; Grabner, M; Murphy, BJ; Catterall, WA; Striessnig, J				Kraus, R; Reichl, B; Kimball, SD; Grabner, M; Murphy, BJ; Catterall, WA; Striessnig, J			Identification of benz(othi)azepine-binding regions within L-type calcium channel alpha 1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZOTHIAZEPINE BINDING DOMAIN; SODIUM DODECYL-SULFATE; SKELETAL-MUSCLE; MOLECULAR DETERMINANTS; GEL-ELECTROPHORESIS; DILTIAZEM-BINDING; CA-2+ CHANNELS; CA2+ CHANNELS; DIHYDROPYRIDINE; RECEPTORS	To identify the binding domain for diltiazem-like Ca2+ antagonists on L-type Ca2+ channel alpha 1 subunits we synthesized the benzazepine [H-3]benziazem as a novel photoaffinity probe. [H-3]Benziazem reversibly labeled the benzothiazepine (BTZ)-binding domain of partially purified skeletal muscle Ca2+ channels with high affinity (K-d = 12 nM) and photoincorporated into its binding domain with high yield (>66%). Antibody mapping of proteolytic labeled fragments revealed specific labeling of regions associated with transmembrane segments S6 in repeats III and IV. More than 50% of the labeling was found in the tryptic fragment alanine 1023-lysine 1077 containing IIIS6 together with extracellular and intracellular amino acid residues. The remaining labeling was identified in a second site comprising segment S6 in repeat IV and adjacent residues. Unlike for dihydropyridines, no labeling was observed in the connecting IIIS5-IIIS6 linker. The [H-3]benziazem photolabeled regions must be in close contact to the drug molecule when bound to the channel. We propose that the determinants for high affinity BTZ binding are located within or in close proximity to segments IIIS6 and/or IVS6. Therefore the binding domain for BTZs, like for the other main classes of Ca2+ antagonists, must be located in close proximity to pore-forming regions of the channel.	UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA	University of Innsbruck; University of Washington; University of Washington Seattle; Bristol-Myers Squibb			Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAUNS T, 1995, BIOCHEMISTRY-US, V34, P3461, DOI 10.1021/bi00010a039; Brauns T., 1995, Biophysical Journal, V68, pA258; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; GARCIA ML, 1986, J BIOL CHEM, V261, P8146; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GLOSSMANN H, 1983, FEBS LETT, V160, P226, DOI 10.1016/0014-5793(83)80972-7; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HERING S, 1993, MOL PHARMACOL, V43, P820; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KIMBALL SD, 1992, J MED CHEM, V35, P780, DOI 10.1021/jm00082a020; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAITO K, 1989, J BIOL CHEM, V264, P21211; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; OLSZEWSKI JD, 1995, BIOCONJUGATE CHEM, V6, P395, DOI 10.1021/bc00034a009; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEYDL K, 1993, PFLUG ARCH EUR J PHY, V424, P552, DOI 10.1007/BF00374922; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1986, FEBS LETT, V197, P204, DOI 10.1016/0014-5793(86)80327-1; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1990, J BIOL CHEM, V265, P363; STRIESSNIG J, 1991, METHODS NEUROSCI, V4, P210; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; WATANABE T, 1993, FEBS LETT, V334, P261, DOI 10.1016/0014-5793(93)80690-V	30	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20113	20118		10.1074/jbc.271.33.20113	http://dx.doi.org/10.1074/jbc.271.33.20113			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702733	hybrid			2022-12-27	WOS:A1996VC66900074
J	Lin, S; Akinbi, HT; Breslin, JS; Weaver, TE				Lin, S; Akinbi, HT; Breslin, JS; Weaver, TE			Structural requirements for targeting of surfactant protein B (SP-B) to secretory granules in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PULMONARY SURFACTANT; II CELLS; EPITHELIAL-CELLS; LUNG SURFACTANT; SORTING SIGNAL; DISULFIDE BOND; CHROMOGRANIN-B; PATHWAY; PROOPIOMELANOCORTIN	Human surfactant protein B (SP-B) is synthesized by type II cells as a 381-residue preproprotein which is proteolytically processed to a 79-residue mature peptide and targeted to lamellar bodies for secretion. To identify secretory granule targeting determinants, constructs encoding the SP-B preproprotein (SP-B), COOH-terminally deleted SP-B (SP-B-Delta C), the NH2-terminal propeptide (SP-B-N), and a chimeric molecule consisting of albumin and the mature peptide (ALB/SP-B-M) were transfected into AtT-20 and PC12 cells. Pulse-chase studies demonstrated that 10-30% of SP-B and SP-B-Delta C remained in cells in an endoglycosidase H-resistant form. Secretion of stored SP-B was stimulated by forskolin/12-O-tetradecanoylphorbol-13-acetate and intracellular SP-B was localized to secretory granules by immunoelectron microscopy. In contrast, SP-B-N and ALB/SP-B-M were constitutively secreted and not detected in secretory granules. Specific processing of SP-B was not detected in either AtT-20 or PC12 cells. Expression of SP-B-Delta C in transgenic mice resulted in secretion of fully processed mature SP-B, indicating correct processing and targeting of this construct in vivo. We conclude that 1) SP-B processing occurs in a cell-specific manner, 2) the proprotein contains secretory granule targeting determinants that are not cell-specific, 3) the NH2-terminal propeptide and the mature peptide are required for targeting SP-B to lamellar body, and 4) the COOH-terminal propeptide is not required for processing or sorting of SP-B.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056285, R01HL036055, R37HL056285] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56285, HL36055] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAYAN M, 1983, J HISTOCHEM CYTOCHEM, V31, P101, DOI 10.1177/31.1.6187796; Bonnard C, 1984, IMMUNOLABELING ELECT; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHANDER A, 1990, AM J PHYSIOL, V258, pL241, DOI 10.1152/ajplung.1990.258.6.L241; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; HOOK GER, 1982, J BIOL CHEM, V257, P9211; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650, DOI 10.1152/ajplung.1996.270.4.L650; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; LIN S, 1996, IN PRESS BIOCH BIOPH, V1312; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MITRA A, 1994, J BIOL CHEM, V269, P19876; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sambrook J., 2002, MOL CLONING LAB MANU; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; SUWABE A, 1991, AM J RESP CELL MOL, V5, P80, DOI 10.1165/ajrcmb/5.1.80; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WHITSETT JA, 1986, PEDIATR RES, V20, P744, DOI 10.1203/00006450-198608000-00009; WRIGHT JR, 1990, AM J PHYSIOL, V259, pL1, DOI 10.1152/ajplung.1990.259.2.L1; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169	49	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19689	19695		10.1074/jbc.271.33.19689	http://dx.doi.org/10.1074/jbc.271.33.19689			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702672	hybrid			2022-12-27	WOS:A1996VC66900013
J	Liu, GY; Hinch, B; DavatolHag, H; Lu, Y; Powers, M; Beavis, AD				Liu, GY; Hinch, B; DavatolHag, H; Lu, Y; Powers, M; Beavis, AD			Temperature dependence of the mitochondrial inner membrane anion channel - The relationship between temperature and inhibition by protons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; HEART-MITOCHONDRIA; TRANSPORT PROTEINS; LIGHT-SCATTERING; KINETICS; CARRIER; MATRIX; CONTRACTION; CONDUCTANCE; MITOPLASTS	In this paper, we investigate the temperature and pH dependence of the mitochondrial inner membrane an ion channel (IMAC) that is believed to be involved in mitochondrial volume homeostasis, At pH 7.4, the flux oil malonate is highly temperature-dependent with rates; increasing from 1 nmol/min . mg at 5 degrees C to 1900 nmol/min . mg at 45 degrees C, The Arrhenius plot is nonlinear with the activation energy increasing from 21 kJ/mol (Q(10) = 1.3) to 193 kJ/mol (Q(10) = 13) as the temperature is decreased. This temperature dependence is unusual and not seen with solutes that are transported through the bilayer such as NH4OAc, malonamide, and KSCN (plus valinomycin) or even for cytochrome c oxidase-depend ent uptake of potassium (plus valinomycin), The temperature dependence of IMAC is closely related to the inhibition of IMAC by protons, Thus, we find that the pIC(50) for protons decreases from 9.3 (Hill coefficient = 1.0) at 5 degrees C to 7.1 (Hill coefficient = 2.5) at 45 degrees C, This behavior is explained on the basis of a new kinetic model for IMAC in which the net open probability is not only modulated by the binding of three protons but also by temperature via effects on the open probability of the unprotonated channel and the pK of one of the inhibitory protonation sites.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047735] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONENKO YN, 1994, BBA-BIOMEMBRANES, V1194, P247, DOI 10.1016/0005-2736(94)90306-9; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; Beavis A. D., 1995, Biophysical Journal, V68, pA144; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1991, BIOCHIM BIOPHYS ACTA, V1013, P111; BEAVIS AD, 1994, MOL BIOL MITOCHONDRI, P137; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CORREA AM, 1992, BIOPHYS J, V61, P1332, DOI 10.1016/S0006-3495(92)81941-0; DILGER JP, 1991, BIOCHIM BIOPHYS ACTA, V1063, P253, DOI 10.1016/0005-2736(91)90379-M; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GRYGORCZYK R, 1987, BIOCHIM BIOPHYS ACTA, V902, P159, DOI 10.1016/0005-2736(87)90291-4; HAYMAN KA, 1993, J MEMBRANE BIOL, V136, P181, DOI 10.1007/BF02505762; HILLE B, 1992, IONIC CHANNELS EXCIT, P272; INDIVERI C, 1989, BIOCHIM BIOPHYS ACTA, V977, P187, DOI 10.1016/S0005-2728(89)80070-2; INDIVERI C, 1987, BIOCHIM BIOPHYS ACTA, V890, P310, DOI 10.1016/0005-2728(87)90158-7; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KLITSCH T, 1991, J MEMBRANE BIOL, V122, P69, DOI 10.1007/BF01872740; KRAMER R, 1982, BIOCHIM BIOPHYS ACTA, V693, P296, DOI 10.1016/0005-2736(82)90435-7; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LEE SC, 1990, BIOPHYS J, V57, P49, DOI 10.1016/S0006-3495(90)82506-6; Liu G., 1995, Biophysical Journal, V68, pA144; MENDE P, 1982, EUR J BIOCHEM, V128, P91; MURRAY AG, 1988, EBEC REP, V5, P206; POWERS MF, 1994, J BIOL CHEM, V269, P10614; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SHEN WK, 1993, BIOPHYS J, V65, P747, DOI 10.1016/S0006-3495(93)81100-7; SITSAPESAN R, 1991, J PHYSIOL-LONDON, V434, P469, DOI 10.1113/jphysiol.1991.sp018481; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; STEIN WD, 1986, TRANSPORT DIFFUSION, P25	38	22	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19717	19723		10.1074/jbc.271.33.19717	http://dx.doi.org/10.1074/jbc.271.33.19717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702676	hybrid			2022-12-27	WOS:A1996VC66900017
J	Sarkar, S; Schlottmann, K; Cooney, D; Coggeshall, KM				Sarkar, S; Schlottmann, K; Cooney, D; Coggeshall, KM			Negative signaling via Fc gamma RIIB1 in B cells blocks phospholipase C gamma 2 tyrosine phosphorylation but not Syk or Lyn activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; LYMPHOCYTES-B; MEMBRANE IMMUNOGLOBULIN; ANTIGEN RECEPTOR; SURFACE-IMMUNOGLOBULIN; SH2 DOMAIN; KINASES; PHOSPHATASE; CALCIUM; IG	Crosslinking of the B cell antigen receptor surface immunoglobulin induces tyrosine phosphorylation and activation of the Src family and Syk tyrosine protein kinases, tyrosine phosphorylation of phospholipase C gamma 2 (PLC gamma 2) and increases in intracellular second messengers inositol phosphates and Ca2+. These activation events, in conjunction with other pathways, culminate in the induction of B cell proliferation and differentiation. In contrast, co-crosslinking surface Ig with the B cell IgG Fc receptor prevents many of these activation events, including B cell proliferation and differentiation. The precise nature of the negative signal(s) derived from Fc receptors that prevent B cell activation is not known. Here, early activation events were examined in B cells stimulated via the antigen receptor alone or under co-crosslinking conditions. The data indicated a selective block in the tyrosine phosphorylation and activation of PLC gamma 2 hut not in activation of the upstream kinases, Syk and Lyn, under co-crosslinking conditions. We conclude that the negative signal acts directly on PLC gamma 2 and is consistent with recent studies describing an activation-induced association of a phosphotyrosine phosphatase with tyrosine-phosphorylated B cell Fc receptor.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University			Cooney, Damon/J-4762-2014	Cooney, Damon/0000-0002-2786-287X				BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; COGGESHALL KM, 1985, J IMMUNOL, V134, P101; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOLD MR, 1992, J IMMUNOL, V148, P2012; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KLAUS GGB, 1984, IMMUNOLOGY, V53, P693; LANE PJL, 1991, J IMMUNOL, V146, P715; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MUTA T, 1994, NATURE, V369, P340, DOI 10.1038/369340a0; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RANSOM JT, 1986, J IMMUNOL, V136, P66; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SINCLAIR MR, 1987, IMMUNOL TODAY, V6, P76; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	30	30	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20182	20186		10.1074/jbc.271.33.20182	http://dx.doi.org/10.1074/jbc.271.33.20182			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702743	hybrid			2022-12-27	WOS:A1996VC66900085
J	Si, JT; Luo, ZJ; Mei, L				Si, JT; Luo, ZJ; Mei, L			Induction of acetylcholine receptor gene expression by ARIA requires activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; EPSILON-SUBUNIT GENE; NEUROMUSCULAR-JUNCTION; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; NDF HEREGULIN; MAP KINASE; DIFFERENTIATION	Transcription of genes encoding nicotinic acetylcholine receptor (AChR) subunits (alpha, beta, gamma or epsilon, and delta) is highest in nuclei localized to the synaptic region of the muscle, which contributes to maintain a high density of AChRs at the postjunctional membrane. ARIA (AChR inducing activity) is believed to be the trophic factor utilized by motor neurons to stimulate AChR synthesis in the subsynaptic area. To elucidate the signaling mechanism initiated by ARIA, we established stable C2C12 cell lines carrying the nuclear lacZ gene under the control of the mouse epsilon subunit promoter or chicken ru subunit promoter. ARIA stimulated tyrosine phosphorylation of erbB proteins in these C2C12 cells within 15 s with a peak at 5 min. Immediately following tyrosine phosphorylation of erbB proteins, mitogen-activated protein (MAP) kinase was activated which occurred within 30 s and peaked at 8 min after ARIA stimulation. Concomitantly, expression of AChR genes was induced by ARIA. ARIA-induced AChR subunit transgene expression was observed only in differentiated myotubes and not in myoblasts, suggesting that downstream signaling component(s) are regulated in a manner dependent on the myogenic program. Inhibition of the MAP kinase activity by using a specific MAP kinase kinase inhibitor or by overexpressing dominant negative mutants of Raf or MAP kinase kinase attenuated or abolished the ARIA-induced activation of AChR alpha and epsilon subunit gene expression. These results indicate that regulation of AChR gene expression by ARIA ill C2C12 cells requires activation of the MAP kinase signaling pathway.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; MASSACHUSETTS GEN HOSP,DIABET UNIT,CHARLESTOWN,MA 02129	University of Virginia; Harvard University; Massachusetts General Hospital			Luo, Zhijun/AAE-9302-2019; Mei, Lin/G-8755-2012	Luo, Zhijun/0000-0001-8105-5289; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34062] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMONT FJ, 1994, J CELL PHYSIOL, V160, P141, DOI 10.1002/jcp.1041600117; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARTE BM, 1995, ONCOGENE, V10, P167; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MEI L, 1995, LIFE SCI, V57, P1459, DOI 10.1016/0024-3205(95)02118-3; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1991, DEVELOPMENT, V113, P1181; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	55	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19752	19759		10.1074/jbc.271.33.19752	http://dx.doi.org/10.1074/jbc.271.33.19752			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702681	hybrid			2022-12-27	WOS:A1996VC66900022
J	Chabardes, D; Firsov, D; Aarab, L; Clabecq, A; Bellanger, AC; SiaumePerez, S; Elalouf, JM				Chabardes, D; Firsov, D; Aarab, L; Clabecq, A; Bellanger, AC; SiaumePerez, S; Elalouf, JM			Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule - Functional consequences for regulation of the cAMP content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-KIDNEY; COLLECTING TUBULE; PREDOMINANT EXPRESSION; EXTRACELLULAR CALCIUM; NCB-20 CELLS; GLIOMA-CELLS; INHIBITION; CLONING; ACCUMULATION	Expression of Ca2+-inhibitable types V and VI adenylyl cyclases was studied by reverse transcription-polymerase chain reaction in rat renal glomeruli and nephron segments isolated by microdissection. Quantitation of each mRNA was achieved using a mutant cRNA which differed from the wild type by substituting two bases to create a new restriction site in the corresponding cDNA. Type VI mRNA was present all along the nephron but was more abundant in distal than in proximal segments. The expression of type V mRNA was restricted to the glomerulus and to the initial portions of the collecting duct. Expression of the Ca2+-insensitive type IV mRNA studied on the same samples was evidenced only in the glomerulus, The functional relevance of the expression of Ca2+-inhibitable isoforms was studied by measuring cAMP content in the microdissected enter medullary collecting duct which expressed both type V mRNA (2367 +/- 178 molecules/mm tubular length; n = 8) and type VI mRNA (5658 +/- 543 molecules/mm, n = 8). Agents known to increase intracellular Ca2+ in this segment induced a Ca2+-dependent inhibition on either arginine vasopressin- or glucagon-stimulated cAMP level. The characteristics of these inhibitions suggest a functional and differential expression of types V and VI adenylyl cyclases in two different cell types of the rat outer medullary collecting duct.	COLL FRANCE, LAB PHYSIOL CELLULAIRE, F-75231 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France	Chabardes, D (corresponding author), CEA SACLAY, DEPT BIOL CELLULAIRE & MOL, SBCE, LAB BIOL INTEGREE CELLULES RENALES, BAT 520, F-91191 GIF SUR YVETTE, FRANCE.		Elalouf, Jean-Marc/C-4351-2014	Elalouf, Jean-Marc/0000-0003-0151-6423				AARAB L, 1993, PFLUG ARCH EUR J PHY, V425, P417, DOI 10.1007/BF00374867; AARAB L, 1993, PFLUG ARCH EUR J PHY, V423, P397, DOI 10.1007/BF00374933; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BREYER MD, 1991, AM J PHYSIOL, V260, pF1, DOI 10.1152/ajprenal.1991.260.1.F1; CHABARDES D, 1984, MOL CELL ENDOCRINOL, V37, P263, DOI 10.1016/0303-7207(84)90096-0; CHABARDES D, 1990, MOL CELL ENDOCRINOL, V73, P111, DOI 10.1016/0303-7207(90)90124-Q; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Costanzo LS, 1992, KIDNEY PHYSL PATHOPH, P2375; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARG LC, 1981, AM J PHYSIOL, V240, pF536, DOI 10.1152/ajprenal.1981.240.6.F536; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACKSON BA, 1988, MOL CELL ENDOCRINOL, V57, P199, DOI 10.1016/0303-7207(88)90075-5; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kriz W, 1992, KIDNEY PHYSL PATHOPH, P707; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KUSANO E, 1985, AM J PHYSIOL, V249, pF956, DOI 10.1152/ajprenal.1985.249.6.F956; MADSEN KM, 1986, AM J PHYSIOL, V250, pF1, DOI 10.1152/ajprenal.1986.250.1.F1; MARCHETTI J, 1990, PFLUG ARCH EUR J PHY, V416, P561, DOI 10.1007/BF00382690; MERCIER O, 1989, AM J PHYSIOL, V257, pF1003, DOI 10.1152/ajprenal.1989.257.6.F1003; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Ross BD, 1982, METABOLIC COMPARTMEN, P363; STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU HJ, 1993, MOL PHARMACOL, V44, P689; YU HJ, 1995, FEBS LETT, V374, P89	38	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19264	19271		10.1074/jbc.271.32.19264	http://dx.doi.org/10.1074/jbc.271.32.19264			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702608	hybrid			2022-12-27	WOS:A1996VB68400042
J	Dizhoor, AM; Hurley, JB				Dizhoor, AM; Hurley, JB			Inactivation of EF-hands makes GCAP-2 (p24) a constitutive activator of photoreceptor guanylyl cyclase by preventing a Ca2+-induced ''activator-to-inhibitor'' transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; PROTEIN; RECOVERIN; CLONING; BINDING; TRANSDUCTION; EXPRESSION; CALMODULIN; TERMINUS; RETGC	Guanylyl cyclase activator proteins GCAP-1 and GCAP-2 (Dizhoor et al, 1995, Gorczyca et al,, 1995) are members of a recently identified subclass of EF-hand type Ca2+-binding proteins that respond to Ca2+ differently than any other known members of the EF-hand superfamily. GCAPs acquire an activating conformation only in their Ca2+-free form. Free Ca2+ concentrations corresponding to levels in dark-adapted vertebrate photoreceptors inhibit the ability of GCAPs to activate photoreceptor guanylyl cyclases (RetGCs). We studied the effects of mutations that block binding of Ca2+ to the EF-hands of GCAP-2. Unlike other EF-hand proteins, which fail to activate their target when their EF-hands are inactivated by mutations, GCAP-2 with any single EF-hand inactivated remains active and is 3-6 times less sensitive to the inhibitory effect off Ca2+. Inactivation of any two or all three EF-hands produces active forms of GGAP-2 that are insensitive to inhibition by physiological intracellular concentrations of Ca2+. Unexpectedly we also found that activation of RetGCs by a Ca2+-insensitive mutant is inhibited by Ca2+-loaded wild type GCAP-2. We propose the following, 1) GCAP-2 can exist in two extreme functional forms: an apo form that activates RetGCs and a Ca2+-loaded form that blocks activation of RetGCs, 2) All three EF-hands of GCAP-2 contribute to the inhibitory effect of Ca2+. 3) Inactivation of two off three EF-hands is sufficient to shift the ''activator-inhibitor'' transition outside the physiological range of intracellular free Ca2+.	UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Dizhoor, AM (corresponding author), UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, POB 357370, SEATTLE, WA 98195 USA.			Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [EY11522, EY06641] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BABU A, 1992, J BIOL CHEM, V267, P15469; CHASIN WJ, 1995, NATURE SRUCT BIOL, V2, P707; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; KOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V196, P1017, DOI 10.1006/bbrc.1993.2351; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	28	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19346	19350		10.1074/jbc.271.32.19346	http://dx.doi.org/10.1074/jbc.271.32.19346			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702620	hybrid			2022-12-27	WOS:A1996VB68400054
J	Li, B; Ouyang, B; Pan, HQ; Reissmann, PT; Slamon, DJ; Arceci, R; Lu, L; Dai, W				Li, B; Ouyang, B; Pan, HQ; Reissmann, PT; Slamon, DJ; Arceci, R; Lu, L; Dai, W			prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MEGAKARYOCYTIC DIFFERENTIATION; DROSOPHILA POLO; GENE; IDENTIFICATION; CLONING; LOCALIZATION; INHIBITORS; CANCER; CDC5	We have cloned and characterized a putative protein serine/threonine kinase termed prk through a combination of polymerase chain reaction and conventional cDNA library screening approaches. There are apparently two distinct domains within pll protein deduced from its nucleotide sequences. The amino-terminal portion has the feature of the catalytic domain of a serine/threonine kinase and shows strong homology to mouse fnk and other polo family kinases including mouse snk, human and murine plk, Drosophila polo, and yeast Cdc5, The carboxyl-terminal portion, presumably the regulatory domain, shares extensive homology to mouse fnk, Northern blotting analyses reveal that prk expression is restricted to a very limited number of tissues with placenta, ovaries, and lung containing detectable amounts of prk mRNA. prk mRNA expression is also detected at a low level in the megakaryocytic cell line Dami, MO7e, and three brain glioma cell lines, In addition, refeeding of serum-deprived MO7e, Dami, and K562 cells of hematopoietic origin and GMOO637D of lung fibroblasts rapidly activates prk, mRNA expression with its peak induction around 2 h after serum addition, pl-fi gene activation by the serum requires no new protein synthesis, The recombinant cytokines such as interleukin-3 and thrombopoietin also activate prk mRNA expression in MO7e cells, Furthermore, a survey of RNAs isolated from the tumor and the uninvolved tissues from 18 lung cancer patients reveals that prk mRNA expression is significantly down-regulated in tumor tissues, Southern blotting analysis indicates that the pl h gene is present in a single copy in the genome of tumors and normal cells, Taken together, these results suggest that prk expression may be restricted to proliferating cells and involved in the regulation of cell cycle progression, The molecular cloning- of prk cDNA will facilitate the study of its biological role as well as its potential role in tumorigenesis.	UNIV CINCINNATI,COLL MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,CINCINNATI,OH 45267; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; WRIGHT STATE UNIV,DEPT PHYSIOL & BIOPHYS,DAYTON,OH 45435	University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; Wright State University Dayton					NATIONAL CANCER INSTITUTE [R01CA059985] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA59985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHENG T, 1995, LEUKEMIA, V9, P1257; CHENG T, 1994, J BIOL CHEM, V269, P30848; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; DAI W, 1994, ONCOGENE, V9, P975; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GRANA X, 1994, ONCOGENE, V9, P2097; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KUROSAWA M, 1994, J PHARMACOL TOXICOL, V31, P135, DOI 10.1016/1056-8719(94)90075-2; LEVIN WJ, 1995, ONCOGENE, V11, P1261; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILD D, 1980, GENETICS, V96, P859; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WILHIDE CC, 1995, BLOOD, V86, P294, DOI 10.1182/blood.V86.1.294.bloodjournal861294	26	125	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19402	19408		10.1074/jbc.271.32.19402	http://dx.doi.org/10.1074/jbc.271.32.19402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702627	hybrid			2022-12-27	WOS:A1996VB68400061
J	Selkoe, DJ				Selkoe, DJ			Amyloid beta-protein and the genetics of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							APOLIPOPROTEIN-E GENOTYPE; PRECURSOR PROTEIN; SENILE PLAQUES; CEREBRAL-HEMORRHAGE; TAU-PHOSPHORYLATION; MISSENSE MUTATIONS; NEURITE OUTGROWTH; TYPE-4 ALLELE; DOWN-SYNDROME; PEPTIDE		HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ALZHEIMER A, 1907, CENTRALBLATT NERVENH, V80, P177; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Biere AL, 1995, NEUROBIOL DIS, V2, P177, DOI 10.1006/nbdi.1995.0019; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P3055; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAMES D, 1995, SOC NEUR ABSTR, V21, P258; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1996, MOL GENETIC BASIS NE; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HEINONEN O, 1994, ARCH NEUROL-CHICAGO, V51, P799, DOI 10.1001/archneur.1994.00540200075019; HENDRIKS L, 1992, NAT GENET, V1, P213; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; IKEDA M, 1993, NEUROSCI LETT, V150, P159, DOI 10.1016/0304-3940(93)90525-P; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KALARIA RN, 1992, RES IMMUNOL, V143, P637, DOI 10.1016/0923-2494(92)80048-P; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LEE VMY, 1995, CURR OPIN NEUROBIOL, V5, P663, DOI 10.1016/0959-4388(95)80073-5; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mann DMA, 1996, AM J PATHOL, V148, P1257; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1992, J NEUROSCI, V12, P379; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PIKE CJ, 1994, NEUROSCIENCE, V63, P517, DOI 10.1016/0306-4522(94)90547-9; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4450; REBECK GW, 1993, NEURON, V11, P575; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHEUNER D, 1996, IN PRESS NATURE MED; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SINHA S, 1990, J BIOL CHEM, V265, P8983; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SNOW AD, 1988, AM J PATHOL, V133, P456; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUEBERT P, 1993, NATURE, V361, P260; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Yamazaki T, 1996, J CELL SCI, V109, P999; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	93	743	779	2	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18295	18298		10.1074/jbc.271.31.18295	http://dx.doi.org/10.1074/jbc.271.31.18295			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8756120	hybrid			2022-12-27	WOS:A1996VB68300001
J	Delporte, C; OConnell, BC; He, XJ; Ambudkar, IS; Agre, P; Baum, BJ				Delporte, C; OConnell, BC; He, XJ; Ambudkar, IS; Agre, P; Baum, BJ			Adenovirus-mediated expression of aquaporin-5 in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; WATER CHANNELS; GENE-TRANSFER; CDNA; ERYTHROCYTE; SALIVARY; VECTOR	A recombinant adenovirus coding for rat aquaporin-5 was constructed and plaque purified. The recombinant adenovirus (AdrAQP5) mediated the expression of aquaporin-5 in rat and human salivary cell lines and in dog kidney cells in vitro as demonstrated by Northern blot and Western blot analyses, and by confocal microscopy after immunofluorescent labeling. In kidney cells, expression of the transgene was optimal if cells were infected at their basolateral surface, a phenomenon associated with the distribution of integrin receptors on these cells. The expressed aquaporin-5 protein was functionally active because viral-mediated gene transfer resulted in a significant increase in the osmotically directed net fluid secretion rate across monolayers of kidney cells. AdrAQP5 should provide an efficient and useful means to impart facilitated water permeability to cells lacking such a pathway.	NIDR, CLIN INVEST & PATIENT CARE BRANCH, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Johns Hopkins University			Delporte, Christine/A-5733-2012	O'Connell, Brian/0000-0003-4529-7664; Delporte, Christine/0000-0003-0385-5824	NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; DAI YS, 1991, AM J PHYSIOL, V261, pC1063, DOI 10.1152/ajpcell.1991.261.6.C1063; DENKER BM, 1988, J BIOL CHEM, V263, P15634; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HE X, 1989, J CELL PHYSL, V138, P5294; HE XJ, 1990, BIOCHEM BIOPH RES CO, V170, P336, DOI 10.1016/0006-291X(90)91279-2; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; MASTRANGELI A, 1994, AM J PHYSIOL, V266, pG1146, DOI 10.1152/ajpgi.1994.266.6.G1146; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MITANI K, 1994, HUM GENE THER, V5, P941, DOI 10.1089/hum.1994.5.8-941; Neufeld TK, 1991, J TISS CULT METHODS, V13, P229; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SILVERBERG M, 1978, J BIOL CHEM, V253, P95	23	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22070	22075		10.1074/jbc.271.36.22070	http://dx.doi.org/10.1074/jbc.271.36.22070			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703015	hybrid			2022-12-27	WOS:A1996VF61200057
J	Park, DS; Stefanis, L; Yan, CYI; Farinelli, SE; Greene, LA				Park, DS; Stefanis, L; Yan, CYI; Farinelli, SE; Greene, LA			Ordering the cell death pathway - Differential effects of BCL2, an interleukin-1-converting enzyme family protease inhibitor, and other survival agents on JNK activation in serum nerve growth factor-deprived PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMPATHETIC NEURONS; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENE CED-3; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IL-1-BETA-CONVERTING ENZYME; PHEOCHROMOCYTOMA CELLS; PROTOONCOGENE BCL-2; FACTOR DEPRIVATION; SENSORY NEURONS	Previous studies indicate that activation of c-Jun kinase (JNK) is necessary for apoptosis of trophic factor-deprived PC12 cells and that death in this system is suppressed by multiple agents, including BCL2, inhibitors of the interleukin-1-converting enzyme (ICE) family of proteases, blockers of transcription, and a variety of small molecules with differing modes of action. Here, we determine the order in which these agents block apoptosis relative to JNK activation. Overexpression of BCL2 promotes PC12 cell survival and blocks JNK activation caused by trophic factor withdrawal. Similarly, the survival-promoting agents aurintricarboxylic acid, N-acetylcysteine, the nitric oxide generator diethylenetriamine nitric oxide, 8-bromo-cGMP, and 8-(4-chlorophenylthio)-cAMP act upstream to inhibit JNK activation. In contrast, zVAD-fluoromethylketone (a permeant ICE family inhibitor), actinomycin D, and the G(1)/S cell cycle inhibitor deferoxamine, all promote survival after trophic factor withdrawal, but do not affect JNK activation. These findings are consistent with the presence of an ordered cell death pathway triggered by trophic factor deprivation in which 1) BCL2 and a number of survival-promoting agents act upstream of JNK, 2) ICE family protease actions, regulated genes required for cell death, and certain cell cycle blockers lie either downstream of JNK or on independent pathways required for apoptotic death.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	Park, DS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Yan, Chao Yun Irene/B-4700-2011; Stefanis, Leonidas/AAD-7192-2019	Yan, Chao Yun Irene/0000-0003-0527-5719; Park, David/0000-0002-4490-3784				BASTITATOU A, 1991, J CELL BIOL, V115, P461; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BURNSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LIU A, 1995, SCIENCE, V268, P286; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WANG HG, 1994, ONCOGENE, V9, P2751; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; YAN CYI, 1995, SOC NEUR ABSTR; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	64	200	200	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21898	21905		10.1074/jbc.271.36.21898	http://dx.doi.org/10.1074/jbc.271.36.21898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702992	hybrid			2022-12-27	WOS:A1996VF61200034
J	Agrawal, RK; Burma, DP				Agrawal, RK; Burma, DP			Sites of ribosomal RNAs involved in the subunit association of tight and loose couple ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; PROTEIN-SYNTHESIS; 70S RIBOSOMES; 50S RIBOSOMES; 16S; NUCLEOTIDES; INITIATION; MECHANISM; PROBES; TRANSLOCATION	It was demonstrated previously by kethoxal treatment studies that tight (TC) and loose (LC) couple ribosomes use different sites of the 16 S and 23 S RNAs for subunit association (Burma, D. P., Srivastava, A. K., Srivastava, S., and Dash, D. (1985) J. Biol. Chem. 260, 10517-10525). To localize these sites, a number of oligodeoxynucleotides complementary to the suspected sites of the 16 S and 23 S RNAs were synthesized, and their binding to ribosomes and effects on subunit association were studied, Some of the probes inhibit the association of both TC and LC ribosomes, some inhibit the association of TC but not LC ribosomes, and some inhibit the association of LC but not TC ribosomes. It appears that both TC and LC ribosomes use one common site of association, bases 818-823 of the 16 S and 2308-2313 of the 23 S RNA. The second site, 788-793 of the 16 S RNA and 2753-2758 of the 23 S RNA for TC ribosomes, and 783-791 of the 16 S RNA and 2295-2303 of the 23 S RNA for LC ribosomes, is not shared. This suggests a spatial movement of the ribosomal subunits with respect to one another and lends further support to the model of translocation based on the interconversion of TC and LC ribosomes.	BANARAS HINDU UNIV,INST MED SCI,MOL BIOL UNIT,VARANASI 221005,UTTAR PRADESH,INDIA	Banaras Hindu University (BHU)								AGRAWAL RK, 1992, INDIAN J BIOCHEM BIO, V29, P148; BURMA DP, 1985, J BIOL CHEM, V260, P517; BURMA DP, 1983, P NATL ACAD SCI-BIOL, V80, P4875, DOI 10.1073/pnas.80.16.4875; BURMA DP, 1984, BIOCHEM BIOPH RES CO, V124, P970, DOI 10.1016/0006-291X(84)91053-2; BURMA DP, 1988, INDIAN J BIOCHEM BIO, V25, P467; BURMA DP, 1985, J BIOSCIENCE, V8, P757, DOI 10.1007/BF02702774; BURMA DP, 1984, J BIOSCIENCE, V6, P419, DOI 10.1007/BF02703897; Chaconas G, 1980, Methods Enzymol, V65, P75; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DASH D, 1987, J BIOSCIENCE, V11, P561, DOI 10.1007/BF02704705; DASH D, 1988, INDIAN J BIOCHEM BIO, V25, P226; DEY DN, 1991, INDIAN J BIOCHEM BIO, V28, P369; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HILL WE, 1986, STRUCTURE FUNCTION G, P233; LANGER JA, 1984, BIOCHEMISTRY-US, V23, P6171, DOI 10.1021/bi00320a043; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MURALIKRISHNA P, 1989, BIOCHEMISTRY-US, V28, P7505, DOI 10.1021/bi00445a002; NAG B, 1985, IND J CHEM SOC, V62, P1008; NAG B, 1983, CURR SCI, V51, P1158; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OAKES MI, 1990, J MOL BIOL, V211, P897, DOI 10.1016/0022-2836(90)90082-W; SANTER M, 1990, P NATL ACAD SCI USA, V87, P3700, DOI 10.1073/pnas.87.10.3700; SONENBERG N, 1975, P NATL ACAD SCI USA, V72, P4332, DOI 10.1073/pnas.72.11.4332; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; VANDIGGELEN OP, 1973, EUR J BIOCHEM, V39, P511; Wahba A. J, 1967, METHOD ENZYMOL, V12, P524; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	34	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21285	21291		10.1074/jbc.271.35.21285	http://dx.doi.org/10.1074/jbc.271.35.21285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702905	hybrid			2022-12-27	WOS:A1996VE47700051
J	Aletta, JM; Selbert, MA; Nairn, AC; Edelman, AM				Aletta, JM; Selbert, MA; Nairn, AC; Edelman, AM			Activation of a calcium-calmodulin-dependent protein kinase I cascade in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; RAT-BRAIN; SUBSTRATE RECOGNITION; PHOSPHORYLATION SITES; CDNA CLONING; AUTOPHOSPHORYLATION; IDENTIFICATION; PURIFICATION; EXPRESSION; TRANSCRIPTION	It has been observed that the activity of Ca2+-calmodulin (CaM)-dependent protein kinase I is enhanced up to 50-fold by its phosphorylation in vitro by a distinct CaM kinase I kinase (Lee, J. C., and Edelman, A. M. (1994) J, Biol. Chem. 269, 2158-2164). It has, however, been unclear whether this event represents an acute form of cellular regulation. We demonstrate here the phosphorylation and activation of CaM kinase I in PC12 pheochromocytoma cells in response to elevation of intracellular Ca2+. Treatment of PC12 cells with the Ca2+-ionophore, ionomycin, or with a depolarizing concentration of KCl, led to rapid, biphasic phosphorylation of CaM kinase I and to increases in CaM kinase I activity of 5.1- and 7.3-fold, respectively. Depolarization-induced activation of CaM kinase I was reduced by similar to 80% by blockade of Ca2+ influx through L-type voltage-dependent Ca2+ channels and completely abolished by removal of extracellular Ca2+. The ability of PC12 cell CaM kinase I to be phosphorylated and activated by purified CaM kinase I kinase in vitro was markedly reduced by prior depolarization of the cells, consistent-with intracellular phosphorylation and activation of CaM kinase I by CaM kinase I kinase. These results demonstrate the existence in PC12 cells of a CaM kinase I cascade, the function of which may be to sensitize cells to signal-induced elevations of intracellular Ca2+.	ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Rockefeller University	Aletta, JM (corresponding author), SUNY BUFFALO,DEPT PHARMACOL & TOXICOL,BUFFALO,NY 14214, USA.			Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24738] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; EDELMAN AM, 1995, PROTEIN KINASE FACTS, P128; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1994, ADV 2 MESSENGER PHOS, V30, P1; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOLEM M, 1995, J NEUROSCI, V15, P5966; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TENG KK, 1993, J NEUROSCI, V13, P3124; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOKUMITSU H, 1996, J BIOL CHEM, V271, P6617; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG WY, 1995, J CELL PHYSIOL, V162, P348, DOI 10.1002/jcp.1041620307; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	56	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20930	20934		10.1074/jbc.271.34.20930	http://dx.doi.org/10.1074/jbc.271.34.20930			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702851	hybrid			2022-12-27	WOS:A1996VD33700103
J	Furster, C; Zhang, J; Toll, A				Furster, C; Zhang, J; Toll, A			Purification of a 3 beta-hydroxy-Delta(5)-C-27-steroid dehydrogenase from pig liver microsomes active in major and alternative pathways of bile acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; 3-BETA-HYDROXY-5-CHOLENOIC ACID; CHENODEOXYCHOLIC ACID; POLYACRYLAMIDE GELS; BICINCHONINIC ACID; PROTEINS; MITOCHONDRIA; METABOLISM; RABBIT; CHILD	A 3 beta-hydroxy-Delta(5)-C-27-steroid dehydrogenase active in bile acid biosynthesis was purified from pig liver microsomes by solubilization with sodium cholate and by chromatography on DEAE-Sepharose, aminohexyl-Sepharose, and blue Sepharose. The last step in the purification procedure was preparative isoelectric focusing in a Rotofor cell. The final enzyme preparation showed only one protein band upon SDS-polyacrylamide gel electrophoresis. The isoelectric point was estimated to about 7.0 and the apparent M(r) was 36,000. The purified enzyme catalyzed the conversion of 7 alpha-hydroxycholesterol, 7 alpha,25-dihydroxycholesterol, 7 alpha,27-dihydroxycholesterol, and 3 beta,7 alpha-dihydroxy-5-cholestenoic acid into the corresponding 3-oxo-Delta(4) compounds. The enzyme was inactive with C-19 and C-21 steroids as substrates. The enzyme was also inactive with C-27 steroids having the 7-hydroxy group in beta- instead of alpha-position. The K-m was found to be 0.30 and 0.32 mu M with 7 alpha-hydroxycholesterol and 7 alpha 27-dihydroxycholesterol as substrates, respectively. NAD(+) was the preferred cofactor. A monoclonal antibody raised against the 3 beta-hydroxy-Delta(5)-C-27,,-steroid dehydrogenase was prepared. After coupling to Sepharose, the antibody was able to bind the dehydrogenase and to decrease the conversion of 7 alpha-hydroxycholesterol into 7 alpha-hydroxy-4-cholest-3-one by more than 90%. The N-terminal amino acid sequence was determined and found to be similar but not identical with those of known 3 beta-hydroxy-Delta(5)-steroid dehydrogenases active in steroid hormone biosynthesis. Thus, the purified enzyme active toward C-27 steroids in bile acid biosynthesis appears to represent a novel type of 3 beta-hydroxy-Delta(5)-steroid dehydrogenase.	KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, STOCKHOLM, SWEDEN	Karolinska Institutet	Furster, C (corresponding author), UPPSALA UNIV, DEPT PHARMACEUT BIOSCI, DIV BIOCHEM, UPPSALA, SWEDEN.							ANDERSSON S, 1986, J BIOL CHEM, V261, P6932; ANDERSSON S, 1985, METHOD ENZYMOL, V111, P364; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BJORKHEM I, 1973, EUR J BIOCHEM, V36, P8, DOI 10.1111/j.1432-1033.1973.tb02878.x; BJORKHEM I, 1969, EUR J BIOCHEM, V8, P337, DOI 10.1111/j.1432-1033.1969.tb00533.x; BJORKHEM I, 1985, NEW COMPREHENSIVE BI, V12, P231; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; BUCHMANN MS, 1990, J CLIN INVEST, V86, P2034, DOI 10.1172/JCI114939; CHEETHAM PSJ, 1979, ANAL BIOCHEM, V92, P447, DOI 10.1016/0003-2697(79)90683-3; ICHIMIYA H, 1991, J LIPID RES, V32, P829; JAVITT NB, 1986, J BIOL CHEM, V261, P2486; LABRIE F, 1992, J STEROID BIOCHEM, V43, P805, DOI 10.1016/0960-0760(92)90308-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MITROPOULOS K A, 1972, Biochemical Journal, V130, P363; MITROPOULOS KA, 1967, BIOCHEM J, V103, P472, DOI 10.1042/bj1030472; MOOS M, 1988, J BIOL CHEM, V263, P6005; SHODA J, 1993, HEPATOLOGY, V17, P395; SHODA J, 1993, STEROIDS, V58, P119, DOI 10.1016/0039-128X(93)90048-R; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOLL A, 1992, FEBS LETT, V296, P73, DOI 10.1016/0014-5793(92)80406-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER M, 1991, METHOD ENZYMOL, V206, P631; WIKVALL K, 1981, J BIOL CHEM, V256, P3376; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	25	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20903	20907		10.1074/jbc.271.34.20903	http://dx.doi.org/10.1074/jbc.271.34.20903			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702847	hybrid			2022-12-27	WOS:A1996VD33700099
J	Bennett, BL; Lacson, RG; Chen, CC; Cruz, R; Wheeler, JS; Kletzien, RF; Tomasselli, AG; Heinrikson, RL; Manning, AM				Bennett, BL; Lacson, RG; Chen, CC; Cruz, R; Wheeler, JS; Kletzien, RF; Tomasselli, AG; Heinrikson, RL; Manning, AM			Identification of signal-induced I kappa B-alpha kinases in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DEPENDENT PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; INDUCED PHOSPHORYLATION; REGULATORY SYSTEM; TRANSFORMED-CELLS; AP-1 ACTIVITY; E-SELECTIN; ACTIVATION	Activation of the nuclear transcription factor-kappa B is an early event in endothelial activation. NF-kappa B activation is regulated by the inducible phosphorylation and subsequent degradation of the inhibitory subunit I kappa B-alpha. We identified two discrete kinases of approximately 36 and 41 kDa in the cytoplasm of human umbilical vein endothelial cells that specifically bind to and phosphorylate the I kappa B-alpha subunit. I kappa B-alpha kinase activity is transiently elevated following treatment with either tumor necrosis factor alpha, interleukin-1 beta, or bacterial lipopolysaccharides and precedes activation of either mitogen-activated kinase or Jun kinase. Furthermore, activation of the I kappa B-alpha kinases precedes both the appearance of hyperphosphorylated I kappa B-alpha and its subsequent degradation, as well as the translocation of NF-kappa B to the nucleus, Deletion mutagenesis of the I kappa B-alpha polypeptide revealed that these kinases bind in or around the ankyrin repeat domains and phosphorylate residues within the C terminus. These kinases, however, were not identical to casein kinase II and displayed a pharmacologic profile distinct from other known kinases. These kinases may represent components of a signal transduction pathway regulating I kappa B-alpha levels in vascular endothelium.	UPJOHN LABS,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49007; UPJOHN LABS,BIOCHEM,KALAMAZOO,MI 49007; UPJOHN LABS,ENDOCRINE PHARMACOL & METAB,KALAMAZOO,MI 49007									AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bell F. P., 1996, FASEB Journal, V10, pA810; BENNETT V, 1992, J BIOL CHEM, V267, P8703; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; COTRAN RS, 1989, PROG IMMUNOL, V8, P747; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Essani NA, 1996, J IMMUNOL, V156, P2956; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIROKAWA K, 1991, J CELL PHYSIOL, V147, P157, DOI 10.1002/jcp.1041470120; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Lindner V, 1996, AM J PATHOL, V148, P427; Manning AM, 1995, J INFLAMM, V45, P283; MANNING AM, 1994, ANNU REP MED CHEM, V29, P235; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MUGANDA PM, 1995, BIOCHEM BIOPH RES CO, V207, P740, DOI 10.1006/bbrc.1995.1249; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; PROWALD K, 1984, FEBS LETT, V176, P479, DOI 10.1016/0014-5793(84)81222-3; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; Sambrook J., 2002, MOL CLONING LAB MANU; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZWAGINGA JJ, 1990, ARTERIOSCLEROSIS, V10, P49, DOI 10.1161/01.ATV.10.1.49	60	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19680	19688		10.1074/jbc.271.33.19680	http://dx.doi.org/10.1074/jbc.271.33.19680			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702671	hybrid			2022-12-27	WOS:A1996VC66900012
J	He, ZH; Fujiki, M; Kohorn, BD				He, ZH; Fujiki, M; Kohorn, BD			A cell wall-associated, receptor-like protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH; EXPRESSION; MEMBRANE; PHOSPHORYLATION; SPECIFICITY; HOMOLOG; PLANTS	Physical connections between higher plant cell walls and the plasma membrane have been identified visually, but the molecules involved in the contact are unknown. We describe here an Arabidopsis thaliana protein kinase, designated Wak1 for wall-associated kinase, whose predicted extracytoplasmic domain contains several epidermal growth factor repeats and identity with a viral movement protein. Wak1 fractionates with insoluble material when plant tissue is ground in a variety of buffers and detergents, suggesting a tight association with the plant extracellular matrix. Immunocytochemistry confirms that Wak1 is associated with the cell wall. Enzymatic digestion of the cell wall allows the release of Wak1 from the insoluble cell wall fraction, and protease experiments indicate that Wak1 likely has a cytoplasmic kinase domain, and the EGF containing domain is extracellular. Wak1 is found in all vegetative tissues of Arabidopsis, and has relatives in other angiosperms, but not Chlamydomonas. We suggest that Wak1 is a good candidate for a physical continuum between the cell wall and the cytoplasm, and since the kinase is cytoplasmic, it also has the potential to mediate signals to the cytoplasm from the cell wall.	DUKE UNIV, DEV CELL & MOLEC BIOL GRP, LEVINE SCI RES CTR, DURHAM, NC 27708 USA	Duke University								CITOVSKY V, 1993, GENE DEV, V7, P904, DOI 10.1101/gad.7.5.904; CULL M, 1990, METHOD ENZYMOL, V182, P147; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; JENKINS WT, 1991, ANAL BIOCHEM, V194, P136, DOI 10.1016/0003-2697(91)90160-U; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; KOHORN BD, 1995, PROTEIN PHOSPHORYLAT, P297; Kohorn Bruce D., 1993, Methods (Orlando), V5, P156, DOI 10.1006/meth.1993.1020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MASSON J, 1992, PLANT J, V2, P829, DOI 10.1111/j.1365-313X.1992.tb00153.x; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; PONTLEZICA RF, 1993, PLANT CELL ENVIRON, V16, P111, DOI 10.1111/j.1365-3040.1993.tb00853.x; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Roberts K, 1989, CURR OPIN CELL BIOL, V1, P1020, DOI 10.1016/0955-0674(89)90074-4; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; SANDERS LC, 1991, PLANT CELL, V3, P629, DOI 10.1105/tpc.3.6.629; SCHINDLER M, 1989, J CELL BIOL, V108, P1955, DOI 10.1083/jcb.108.5.1955; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WHEELER JJ, 1991, BIOCHIM BIOPHYS ACTA, V1086, P310, DOI 10.1016/0005-2760(91)90175-H; Wyatt Sarah E., 1993, Trends in Cell Biology, V3, P413, DOI 10.1016/0962-8924(93)90022-S; ZHU JK, 1994, PLANT CELL, V6, P393, DOI 10.1105/tpc.6.3.393; ZHU JK, 1993, PLANT J, V3, P637, DOI 10.1111/j.1365-313X.1993.00637.x	28	173	190	1	28	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19789	19793		10.1074/jbc.271.33.19789	http://dx.doi.org/10.1074/jbc.271.33.19789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702686	hybrid			2022-12-27	WOS:A1996VC66900027
J	Hu, DD; Barbas, CF; Smith, JW				Hu, DD; Barbas, CF; Smith, JW			An allosteric Ca2+ binding site on the beta 3 integrins that regulates the dissociation rate for RGD ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATION REGULATION; BONE-RESORPTION; CELL-ADHESION; CRYSTAL-STRUCTURE; CALCIUM-BINDING; IN-VITRO; GLYCOPROTEIN; SUBUNIT; DOMAIN; ALPHA(V)BETA(3)	Here we use a model RGD-containing ligand to study how Ca2+ and Mg2+ regulate ligand binding to beta 3-integrins, Fab-9, an antibody that contains an optimized RGD loop in its antigen binding site (Barbas, C. F., Languino, L., and Smith, J. W. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10003-10007), was used as the model ligand. Across a physiologic range of Mg2+, Fab-9 bound to both alpha v beta 3 and alpha IIb beta 3 with a monophasic binding isotherm. Across the same range of Ca2+, the binding of Fab-9 to the beta 3-integrins was biphasic. Low concentrations of Ca2+ (mu M) promoted the binding of Fab-9. Higher concentrations of Ca2+ (mM) blocked Fab-9 binding. These data suggest that Ca2+ binds to two distinct classes of sites on the beta 3-integrins, with the low affinity Ca2+ binding site(s) being an inhibitory site. We designate this inhibitory site(s) as the I site. Further biochemical characterization showed that the I site has the following characteristics: 1) it is specific for Ca2+; 2) it is allosteric to the ligand binding site; 3) its occupation increases the dissociation rate between integrin and RGD ligand; and 4) occupation of the I site can induce cellular deadhesion.	BURNHAM INST, CTR CANC RES, PROGRAM CELL ADHES, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOL BIOL MB11, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56483] Funding Source: Medline; NIAMS NIH HHS [AR 42750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; GULINO D, 1992, J BIOL CHEM, V267, P1001; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MIYAUCHI A, 1993, OSTEOPOROSIS INT, V3, pS132; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MULLER B, 1993, J BIOL CHEM, V268, P6800; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; ROSS FP, 1993, J BIOL CHEM, V268, P9901; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUIVER I, 1996, IN PRESS J CELL PHYS; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003; ZAIDI M, 1991, J CELL PHYSIOL, V149, P422, DOI 10.1002/jcp.1041490310	35	80	81	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21745	21751		10.1074/jbc.271.36.21745	http://dx.doi.org/10.1074/jbc.271.36.21745			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702970	hybrid			2022-12-27	WOS:A1996VF61200012
J	Onodera, H; Motto, DG; Koretzky, GA; Rothstein, DM				Onodera, H; Motto, DG; Koretzky, GA; Rothstein, DM			Differential regulation of activation-induced tyrosine phosphorylation and recruitment of SLP-76 to Vav by distinct isoforms of the CD45 protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; T-CELL; PHOSPHOTYROSINE PHOSPHATASE; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; EXCHANGE PROTEIN; SH2 DOMAIN; KINASE; EXPRESSION	The CD45 family of transmembrane protein-tyrosine phosphatases plays a critical role in T cell activation signaling by regulating the tyrosine phosphorylation of protein-tyrosine kinases and their substrates. Multiple alternatively spliced CD45 isoforms, differing only in their extracellular domains, are differentially expressed by subsets of T cells with distinct functional repertoires. However, the physiological function of the various iso forms remains elusive, Using a novel panel of Jurkat T cell clones that uniquely express either the smallest (CD45(0)) or the largest (CD45(ABC)) isoform, we previously demonstrated CD45 isoform-specific differences in interleukin-a secretion and tyrosine phosphorylation of Vav. We now demonstrate differential activation-induced tyrosine phosphorylation of a 76-kDa Vav-associated protein (pp76) by cells expressing distinct CD45 isoforms. The tyrosine phosphorylation of Vav and associated pp76 follow parallel kinetics. pp76 interacts with the SH2 and SH3 domains of Vav. We have identified pp76 as SLP-76, a recently cloned Grb2-binding protein. After activation with anti-CD3, CD45(ABC) transfectants demonstrate increased tyrosine phosphorylation and physical association of SLP-76 with Vav compared to transfectants expressing CD45(0). These results establish a novel physical link between Vav and SLP-76 that is differentially regulated by CD45 isoform expression.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEPHROL SECT,NEW HAVEN,CT 06520; UNIV IOWA,SCH MED,DEPT INTERNAL MED,IOWA CITY,IA	Yale University; University of Iowa			Koretzky, Gary/AAU-5381-2021					AKBAR AN, 1988, J IMMUNOL, V140, P2171; ANDERSON P, 1988, IMMUNOL TODAY, V9, P199, DOI 10.1016/0167-5699(88)91213-3; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURNS CM, 1994, J BIOL CHEM, V269, P13594; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BYRNE JA, 1988, J IMMUNOL, V141, P3249; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FURAKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; MACHIDE M, 1995, ONCOGENE, V11, P619; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATSUYAMA T, 1988, EUR J IMMUNOL, V18, P1473, DOI 10.1002/eji.1830180926; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24949, DOI 10.1074/jbc.270.42.24949; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REIF K, 1994, J BIOL CHEM, V269, P14081; ROTHSTEIN DM, 1993, INT IMMUNOL, V5, P409, DOI 10.1093/intimm/5.4.409; ROTHSTEIN DM, 1990, CELL IMMUNOL, V129, P449, DOI 10.1016/0008-8749(90)90220-L; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; RUDD CE, 1987, J EXP MED, V166, P1758, DOI 10.1084/jem.166.6.1758; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHASTRY L, 1995, ONCOGENE, V11, P1107; SMITH SH, 1986, IMMUNOLOGY, V58, P63; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TEDDER TF, 1985, J IMMUNOL, V134, P2983; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WENG WK, 1994, J BIOL CHEM, V269, P32514; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	61	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22225	22230		10.1074/jbc.271.36.22225	http://dx.doi.org/10.1074/jbc.271.36.22225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703037	hybrid			2022-12-27	WOS:A1996VF61200079
J	Ouyang, XM; Gulliford, T; Zhang, HY; Huang, GC; Epstein, R				Ouyang, XM; Gulliford, T; Zhang, HY; Huang, GC; Epstein, R			Human cancer cells exhibit protein kinase C-dependent c-erbB-2 transmodulation that correlates with phosphatase sensitivity and kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR PHOSPHORYLATION; NORMAL HUMAN-FIBROBLASTS; HUMAN BREAST-CANCER; TYROSINE KINASE; NEU ONCOGENE; DOWN-REGULATION; EGF RECEPTOR; PHORBOL ESTERS; TUMOR PROMOTER	The c-erbB-2 receptor tyrosine kinase is often overexpressed in human tumors, but the functional implications of this phenotype remain unclear. We previously used phosphorylation-specific antibodies to define major differences in c-erbB-2 tyrosine kinase activity between overexpressing human tumor cell lines (Epstein, R. J., Druker, B. J., Roberts, T.M., and Stiles, C. D. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 10435-10439). Here we extend this approach to define the relationship between c-erbB-2 tyrosine phosphorylation and protein kinase C (PRC)-dependent transmodulation. Phosphorylation-specific antibodies to the juxtamembrane PKC site Thr(686) recognize tyrosine-dephosphorylated wild-type c-erbB-2 following G8/DHFR 3T3 cell treatment with PKC agonists. B104-1-1 cells transformed by activated c-erbB-2 express a subset of tyrosine-phosphorylated receptors that are homologously phosphorylated on Thr(686), indicating that Thr(686) phosphorylation alone is insufficient to abrogate receptor tyrosine phosphorylation, Similarly, the c-erbB-2-overexpressing human cancer cell lines SK-Ov-3 and BT-474 express constitutively Thr(686)-phosphorylated receptors. SK-Ov-3 cells express predominantly kinase-inactive c-erbB-2 that is heavily Thr(686)-phosphorylated, indicating that Thr(686) phosphorylation in this line is heterologous in origin. In contrast, BT-474 cells express constitutively autophosphorylated c-erbB-2 despite Thr(686) phosphorylation. These results indicate that Thr(686) phosphorylation does not directly abolish c-erbB-2 activity and suggest that such phosphorylation reflects constitutive PKC activity induced by either receptor-activating mutations or heterologous growth factors. The latter possibility suggests in turn that c-erbB-2 interacts in an as yet undefined way with heterologous growth factor receptors in human tumor cells.	CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND; CHARING CROSS HOSP,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND; UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DIV CELL MOL & ONCOL RES,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of London					NCI NIH HHS [R01 CA61953] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CAO HN, 1991, ONCOGENE, V6, P705; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P4080, DOI 10.1073/pnas.82.12.4080; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DUMONT JA, 1992, CANCER RES, V52, P1195; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1995, ONCOGENE, V11, P315; EPSTEIN RJ, 1992, CELL GROWTH DIFFER, V3, P157; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KING AC, 1982, J BIOL CHEM, V257, P3053; KING CS, 1986, J BIOL CHEM, V261, P73; LEMOINE NR, 1990, ONCOGENE, V5, P237; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUND KA, 1990, J BIOL CHEM, V265, P20517; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEE NS, 1994, J BIOL CHEM, V269, P31991	52	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21786	21792		10.1074/jbc.271.36.21786	http://dx.doi.org/10.1074/jbc.271.36.21786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702975	hybrid			2022-12-27	WOS:A1996VF61200017
J	DellaLonga, S; Ascone, I; Bianconi, A; Bonfigli, A; Castellano, AC; Zarivi, O; Miranda, M				DellaLonga, S; Ascone, I; Bianconi, A; Bonfigli, A; Castellano, AC; Zarivi, O; Miranda, M			The dinuclear copper site structure of Agaricus bisporus tyrosinase in solution probed by X-ray absorption spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOCYANIN ACTIVE-SITE; NEAR-EDGE STRUCTURE; NEUROSPORA TYROSINASE; FINE-STRUCTURE; XANES; OXYHEMOCYANIN; COORDINATION; LACCASE; SUSCEPTIBILITY; COMPLEXES	We have measured the x-ray absorption near edge structure (XANES) spectra of the enzyme tyrosinase from the mushroom Agaricus bisporus in solution in the oxy and deoxy forms, The spectra, obtained under the same conditions as the analogous forms of mollusc hemocyanin (Hc), show that the oxidation state of copper changes from Cu(II) (oxy form) to Cu(I) (deoxy form), and the copper active site(s) of A. bisporus tyrosinase in solution undergoes the same main conformational changes as Hc. We have applied the multiple scattering theory to simulate the XANES spectra of various alternative geometries of the copper site, accounting for the residual differences between Hc and tyrosinase. While oxy-Hc is reasonably fitted only by the pseudo-square-pyramidal geometry reported by its crystallographic data, oxytyrosinase can be fitted, starting from the Hc coordinates, either by distortions toward a pseudo-tetrahedral geometry, with inequivalent copper sites, or by an apically distorted square-pyramidal geometry (with an elongation of the apical distance of no more than 0.2 Angstrom).	UNIV AQUILA,DIPARTIMENTO BIOL BASE APPLICATA,I-67100 LAQUILA,ITALY; CNRS,CEA,MEN,LAB UTILISAT,RAYONNEMENT ELECTROMAGNET,F-91405 ORSAY,FRANCE; UNIV ROMA LA SAPIENZA,DIPARTIMENTO FIS,I-00185 ROME,ITALY	University of L'Aquila; CEA; Centre National de la Recherche Scientifique (CNRS); Sapienza University Rome	DellaLonga, S (corresponding author), UNIV AQUILA,DIPARTIMENTO MED SPERIMENTALE,VIA VETOIO,LOC COPPITO II,I-67100 LAQUILA,ITALY.		Bianconi, Antonio/J-3997-2013; Zarivi, Osvaldo/AAB-2150-2022; Zarivi, Osvaldo/ABG-8795-2021; Zarivi, Osvaldo/V-2939-2018; Ascone, Isabella/A-8599-2010	Bianconi, Antonio/0000-0001-9795-3913; Zarivi, Osvaldo/0000-0002-8312-9955; Zarivi, Osvaldo/0000-0002-8312-9955; della longa, stefano/0000-0002-8157-9530				BIANCONI A, 1988, TOP CURR CHEM, V145, P29; BIANCONI A, 1985, NATURE, V318, P685, DOI 10.1038/318685a0; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BROWN JM, 1980, J AM CHEM SOC, V102, P4210, DOI 10.1021/ja00532a037; CO MS, 1981, J AM CHEM SOC, V103, P3200, DOI 10.1021/ja00401a044; CO MS, 1981, J AM CHEM SOC, V103, P984, DOI 10.1021/ja00394a066; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DELLALONGA S, 1995, PHYSICA B, V208, P743, DOI 10.1016/0921-4526(94)01020-2; DELLALONGA S, 1993, BIOPHYS J, V65, P2680, DOI 10.1016/S0006-3495(93)81330-4; DELLALONGA S, 1995, COMP MATER SCI, V4, P199, DOI 10.1016/0927-0256(95)00027-N; DELLALONGA S, 1994, EUR BIOPHYS J BIOPHY, V23, P361, DOI 10.1007/BF00188660; DOOLEY DM, 1978, P NATL ACAD SCI USA, V75, P3019, DOI 10.1073/pnas.75.7.3019; DURHAM PJ, 1982, COMPUT PHYS COMMUN, V25, P193, DOI 10.1016/0010-4655(82)90035-2; DURHAM PJ, 1988, XRAY ABSORPTION, P53; EISENSTEIN O, 1992, ARCH BIOCHEM BIOPHYS, V296, P247, DOI 10.1016/0003-9861(92)90569-I; ELLERTON HD, 1983, PROG BIOPHYS MOL BIO, V41, P143, DOI 10.1016/0079-6107(83)90028-7; FEITERS MC, 1990, COMMENTS INORG CHEM, V11, P131; FRANSSON G, 1974, ACTA CHEM SCAND A, VA 28, P578, DOI 10.3891/acta.chem.scand.28a-0578; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P7339, DOI 10.1021/ja00544a031; HITCHCOCK AP, 1984, J CHEM PHYS, V80, P3927, DOI 10.1063/1.447274; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; JIMBOW K, 1976, J INVEST DERMATOL, V67, P72, DOI 10.1111/1523-1747.ep12512500; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; LARRABEE JA, 1980, J AM CHEM SOC, V102, P4217, DOI 10.1021/ja00532a038; LERCH K, 1983, MOL CELL BIOCHEM, V52, P125; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MAGNUS K, 1992, Journal of Inorganic Biochemistry, V47, P20, DOI 10.1016/0162-0134(92)84091-Z; MIRANDA M, 1988, BIOCHIM BIOPHYS ACTA, V966, P276, DOI 10.1016/0304-4165(88)90077-3; Natoli C. R., 1983, EXAFS and Near Edge Structures. Proceedings of the International Conference, P43; PALLADINO L, 1993, J CHEM PHYS, V98, P2720, DOI 10.1063/1.464153; PARAK F, 1987, EUR BIOPHYS J BIOPHY, V15, P237, DOI 10.1007/BF00577072; PATE JE, 1989, J AM CHEM SOC, V111, P5198, DOI 10.1021/ja00196a029; PIN S, 1994, METHOD ENZYMOL, V232, P266; ROBB DA, 1984, COPPER PROTEINS COPP, V2, P207; SALVATO B, 1990, LIFE CHEM REPORTS, V8, P1; SOLOMON EI, 1976, J AM CHEM SOC, V98, P1029, DOI 10.1021/ja00420a035; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; Volbeda A., 1986, P135; WOOLERY GL, 1984, J AM CHEM SOC, V106, P86, DOI 10.1021/ja00313a019; WOOLERY GL, 1984, BIOCHIM BIOPHYS ACTA, V788, P155, DOI 10.1016/0167-4838(84)90257-7	44	26	26	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21025	21030						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702866				2022-12-27	WOS:A1996VE47700012
J	Gaffen, SL; Lai, SY; Ha, M; Liu, XW; Henninghausen, L; Greene, WC; Goldsmith, MA				Gaffen, SL; Lai, SY; Ha, M; Liu, XW; Henninghausen, L; Greene, WC; Goldsmith, MA			Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; GAMMA-CHAIN; IL-2 RECEPTOR; CELL-PROLIFERATION; STAT PROTEINS; C-FOS; ERYTHROPOIETIN RECEPTOR; FUNCTIONAL COMPONENT; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAINS	To explore the basis for interleukin (IL)-2 receptor (IL-2R) signaling specificity, the roles of tyrosine-based sequences located within the cytoplasmic tails of the beta and gamma(c) chains were examined in the murine helper T cell line HT-2, Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, cellular proliferation, and the induction of various genes were monitored, All four of the cytoplasmic tyrosine residues as well as the distal portion of the gamma(c) proved dispensable for the entire spectrum of IL-2R signaling responses studied. Conversely, select tyrosine residues within the beta chain were essential and differentially required for various signaling events, Specifically, activation of c-fos gene expression was found to occur exclusively through the most membrane proximal tyrosine, Tyr-338, whereas proliferation and the activation of STAT-5 were induced either through Tyr-338 or through the two C-terminal tyrosine residues, Tyr-392 and Tyr-510, These tyrosine residues mediated the induction of two different STAT-5 isoforms, which were found to form heterodimers upon receptor activation, In contrast to the tyrosine dependence of c-fos and STAT-5 induction, bcl-2 gene induction proceeded independently of all IL-2R beta tyrosine residues, Thus, the tyrosine-based modules present within the IL-2R beta cytoplasmic tail play a critical role in IL-2R signaling, mediating specificity, redundancy, and multifunctionality.	GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; NIDDK, LAB BIOCHEM & METAB, NATL INST HLTH, BETHESDA, MD 20892 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041; Hennighausen, Lothar/0000-0001-8319-9841; Lai, Stephen/0000-0001-8301-7286	NIAID NIH HHS [R01 AI36452] Funding Source: Medline; NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; COFFER P, 1995, ONCOGENE, V10, P985; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH M, 1994, INTERLEUKIN 2 INTERL; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21381	21390		10.1074/jbc.271.35.21381	http://dx.doi.org/10.1074/jbc.271.35.21381			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702919	hybrid			2022-12-27	WOS:A1996VE47700065
J	ReifelMiller, AE; Conarty, DM; Valasek, KM; Iversen, PW; Burns, DJ; Birch, KA				ReifelMiller, AE; Conarty, DM; Valasek, KM; Iversen, PW; Burns, DJ; Birch, KA			Protein kinase C isozymes differentially regulate promoters containing PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; PLASMINOGEN-ACTIVATOR; SIGNAL TRANSDUCTION; CELLULAR-REGULATION; COLLAGENASE GENE; MAMMALIAN-CELLS; PHORBOL-ESTER; LLC-PK1 CELLS; LAMIN-B; EXPRESSION	To investigate the regulation of promoters containing classical phorbol ester response sequences (PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs) by protein kinase C (PRC) isozymes, co-transfections were performed in human dermal fibroblasts with a plasmid containing either the human collagenase promoter or the porcine urokinase plasminogen activator (uPA) promoter linked to the chloramphenicol acetyl-transferase gene and a plasmid expressing an individual PRC isozyme. Using this experimental design, seven PKC isozymes were analyzed for their ability to transactivate the collagenase and uPA promoters. Our results demonstrate that only PKC delta, epsilon, and eta trans-activated the collagenase promoter and that binding of Ap-l family members to the collagenase 12-O-tetradecanoylphorbol-13-acetate response element (TRE) was not responsible for the isozyme-specific trans-activation. in contrast, the uPA promoter was stimulated by all of the PKC isozymes examined (PKC alpha, beta II, gamma, delta, zeta, and eta) These results indicate that PKC isozymes differentially regulate promoters containing PEA-3/TRE motifs and suggest that individual isozymes play unique roles within the cell.	ELI LILLY & CO,LILLY RES LABS,DEPT STAT & MATH SCI,INDIANAPOLIS,IN 46285; SPHINX PHARMACEUT CORP,DURHAM,NC 27712	Eli Lilly	ReifelMiller, AE (corresponding author), ELI LILLY & CO,LILLY RES LABS,DEPT DIABET RES,BLDG 98-C,RM 2330,LILLY CORP CTR,INDIANAPOLIS,IN 46285, USA.							ABATE C, 1991, ONCOGENE, V6, P2179; ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P1761, DOI 10.1073/pnas.86.6.1761; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BIRCH KA, 1996, DIABETES, V42, P642; BORNER C, 1992, J BIOL CHEM, V267, P12892; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIERKSVENTLING C, 1989, INT J CANCER, V44, P865, DOI 10.1002/ijc.2910440520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODE N, 1992, J BIOL CHEM, V267, P16878; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMILTON JA, 1991, BLOOD, V77, P616; HATA A, 1993, J BIOL CHEM, V268, P9122; HE CJ, 1992, J CELL PHYSIOL, V150, P475, DOI 10.1002/jcp.1041500307; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IDO M, 1987, FEBS LETT, V219, P215, DOI 10.1016/0014-5793(87)81219-X; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KIESER A, 1995, FEBS LETT, V372, P189, DOI 10.1016/0014-5793(95)00975-F; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; NIEDBALA MJ, 1993, BLOOD, V81, P2608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1994, J BIOL CHEM, V269, P17495; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAJABI MR, 1992, AM J OBSTET GYNECOL, V167, P194, DOI 10.1016/S0002-9378(11)91657-3; RICE JW, 1993, BIOTECHNIQUES, V15, P1052; RONDEAU E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P165, DOI 10.1016/0167-4889(90)90117-V; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	55	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21666	21671		10.1074/jbc.271.35.21666	http://dx.doi.org/10.1074/jbc.271.35.21666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702956	hybrid			2022-12-27	WOS:A1996VE47700102
J	Sasner, M; Buonanno, A				Sasner, M; Buonanno, A			Distinct N-methyl-D-aspartate receptor 2B subunit gene sequences confer neural and developmental specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMERIC NMDA RECEPTORS; TRANSGENIC MICE; RAT-BRAIN; MOLECULAR CHARACTERIZATION; NEURONAL MIGRATION; 5'-FLANKING REGION; MAMMALIAN-CELLS; MESSENGER-RNAS; I GENE; CHANNEL	Expression of the N-methyl-D-aspartate (NMDA) receptor 2B (NR2B) subunit is neural-specific and differentially regulated. It is expressed in the forebrain and in cerebellar granule cells at early postnatal stages and selectively repressed in the cerebellum after the second postnatal week, where it is replaced by the NR2C subunit. This switch confers distinct properties to the receptor. In order to understand the molecular mechanisms that differentially regulate the NR2B gene in the forebrain and cerebellum during development, we have isolated and characterized the promoter region of the NR2B gene. Two 5' noncoding exons and multiple transcription start sites were identified. Transcriptional analysis in transgenic mice reveals that an upstream 800-base pair region, which includes the first exon, is sufficient to direct neural-specific transcription. Developmental repression of the gene in the cerebellum requires additional regulatory elements residing in the first intron or second exon. Sequence elements that may participate in the regulation of the NR2B gene were identified by comparison to other neural genes. These studies provide insight into the molecular mechanisms regulating the switch of NMDA receptor subunit expression in the cerebellum, which ultimately account for the physiological changes in receptor function during development.	NICHHD,DEV NEUROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Sasner, Michael/0000-0002-6612-6111	NICHD NIH HHS [HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUDINAT E, 1994, EUR J NEUROSCI, V6, P1792, DOI 10.1111/j.1460-9568.1994.tb00572.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BANERJEE BS, 1993, MOL CELL BIOL, V13, P7019; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; Hogan B, 1994, MANIPULATING MOUSE E; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ishiguro H, 1995, MOL BRAIN RES, V34, P251, DOI 10.1016/0169-328X(95)00170-W; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; MADARNAS AR, 1994, MAMM GENOME, V5, P115, DOI 10.1007/BF00292339; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MOLINOFF PB, 1994, PROG BRAIN RES, V100, P39; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORAN J, 1989, BRAIN RES, V486, P15, DOI 10.1016/0006-8993(89)91272-9; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEDIVI E, 1992, J NEUROSCI, V12, P691; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; ROSSI DJ, 1993, NEUROPHARMACOLOGY, V32, P1239, DOI 10.1016/0028-3908(93)90018-X; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; Vallano ML, 1996, J NEUROSCI, V16, P631; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; WANG YH, 1995, J NEUROCHEM, V65, P176; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZHONG J, 1995, J NEUROCHEM, V64, P531; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	53	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21316	21322		10.1074/jbc.271.35.21316	http://dx.doi.org/10.1074/jbc.271.35.21316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702910				2022-12-27	WOS:A1996VE47700056
J	Creedon, DJ; Johnson, EM; Lawrence, JC				Creedon, DJ; Johnson, EM; Lawrence, JC			Mitogen-activated protein kinase-independent pathways mediate the effects of nerve growth factor and cAMP on neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TRK PROTOONCOGENE PRODUCT; SERINE THREONINE KINASES; PC12 CELLS; MAP KINASE; SYMPATHETIC NEURONS; CYCLIC-AMP; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; B-RAF	Components of the mitogen-activated protein kinase (MAP kinase) signaling pathway, including Pas, Raf, and MAP kinase, are necessary for nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. We have investigated the role of this pathway in promoting survival of primary sympathetic neurons that die when deprived of NGF. NGF caused rapid and sustained increases (approximately 4-fold) in the activities of the ERK-1 and ERK-2 isoforms of MAP kinase. PD 098059, an inhibitor of MAP kinase kinase activation, blocked the effects of NGF on both kinase isoforms. However, PD 098059 did not attenuate the effects of NGF on neuronal survival, In addition, MAP kinase activity was not increased by chlorophenylthio-cAMP, a cell-permeable analog of cAMP that supports neuronal survival in the absence of NGF. These findings indicate that activation of MAP kinase is not required for the actions of either cAMP or NGF on neuronal survival.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NIA NIH HHS [R37 AG12947] Funding Source: Medline; NIDDK NIH HHS [DK 28312] Funding Source: Medline; NINDS NIH HHS [R01 NS24679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHN NG, 1990, J BIOL CHEM, V265, P11487; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1990, NEUROSCI LETT, V108, P207, DOI 10.1016/0304-3940(90)90732-O; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CHENG HC, 1986, J BIOL CHEM, V261, P989; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DOHERTY P, 1989, NEUROSCI LETT, V96, P1, DOI 10.1016/0304-3940(89)90233-4; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GORIN PD, 1980, DEV BIOL, V80, P313, DOI 10.1016/0012-1606(80)90407-8; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRIGHT LL, 1983, J NEUROCYTOL, V12, P727, DOI 10.1007/BF01258147; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	68	170	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20713	20718		10.1074/jbc.271.34.20713	http://dx.doi.org/10.1074/jbc.271.34.20713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702822	hybrid			2022-12-27	WOS:A1996VD33700074
J	Gachhui, R; Presta, A; Bentley, DF; AbuSoud, HM; McArthur, R; Brudvig, G; Ghosh, DK; Stuehr, DJ				Gachhui, R; Presta, A; Bentley, DF; AbuSoud, HM; McArthur, R; Brudvig, G; Ghosh, DK; Stuehr, DJ			Characterization of the reductase domain of rat neuronal nitric oxide synthase generated in the methylotrophic yeast Pichia pastoris - Calmodulin response is complete within the reductase domain itself	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; ADENINE-DINUCLEOTIDE PHOSPHATE; DEPENDENT PROTEIN-KINASE; ELECTRON-TRANSFER; SPECTRAL CHARACTERIZATION; SULFITE REDUCTASE; ESCHERICHIA-COLI; HEME-BINDING; L-ARGININE; CALCIUM	Rat neuronal NO synthase (nNOS) is comprised of a flavin-containing reductase domain and a heme-containing oxygenase domain, Calmodulin binding to nNOS increases the rate of electron transfer from NADPH into its flavins, triggers electron transfer from flavins to the heme, activates NO synthesis, and increases reduction of artificial electron accepters such as cytochrome c. To investigate what role the reductase domain plays in calmodulin's activation of these functions, we overexpressed a form of the nNOS reductase domain (amino acids 724-1429) in the yeast Pichia pastoris that for the first time exhibits a complete calmodulin response, The reductase domain was purified by 2',5'-ADP affinity chromatography yielding 25 mg of pure protein per liter of culture. It contained 1 FAD and 0.8 FMN per molecule. Most of the protein as isolated contained an air-stable flavin semiquinone radical that was sensitive to FeCN6 oxidation. Anaerobic titration of the FeCN6-oxidized reductase domain with NADPh indicated the flavin semiquinone re-formed after addition of 1-electron equivalent and the flavins could accept up to 3 electrons from NADPH. Calmodulin binding to the recombinant reductase protein increased its rate of NADPH-dependent flavin reduction and its rate of electron transfer to cytochrome c, FeCN6, or dichlorophenolindophenol to fully match the rate increases achieved when calmodulin bound to native full-length nNOS. Calmodulin's activation of the reductase protein was associated with an increase in domain tryptophan and flavin fluorescence. We conclude that many of calmodulin's actions on native nNOS can be fully accounted for through its interaction with the nNOS reductase domain itself.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Yale University; Case Western Reserve University	Gachhui, R (corresponding author), CLEVELAND CLIN,RES INST,DEPT IMMUNOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN L, 1991, BIOCHEM BIOPH RES CO, V180, P238, DOI 10.1016/S0006-291X(05)81282-3; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; Dawson TM, 1995, NEUROSCIENTIST, V1, P7; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; FREY C, 1994, J BIOL CHEM, V269, P26083; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1994, J BIOL CHEM, V269, P1674; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; MASTERS BSS, 1975, BIOCHEMISTRY-US, V14, P607, DOI 10.1021/bi00674a022; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; POU S, 1992, J BIOL CHEM, V267, P24173; SANE PV, 1987, PHYTOCHEMISTRY, V26, P1289, DOI 10.1016/S0031-9422(00)81796-3; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	43	128	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20594	20602		10.1074/jbc.271.34.20594	http://dx.doi.org/10.1074/jbc.271.34.20594			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702805	hybrid			2022-12-27	WOS:A1996VD33700057
J	Kim, DR; McHenry, CS				Kim, DR; McHenry, CS			In vivo assembly of overproduced DNA polymerase III - Overproduction, purification, and characterization of the alpha, alpha-epsilon, and alpha-epsilon-theta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; BETA-SUBUNIT; HOLOENZYME; IDENTIFICATION; REPLICATION; EXONUCLEASE; ORGANIZATION; PROTEIN; COMPLEX	The genes for the polymerase core (alpha epsilon theta) of the DNA polymerase III holoenzyme map to widely separated loci on the Escherichia coli chromosome. To enable efficient overproduction and in vivo assembly of DNA polymerase III core, artificial operons containing the three structural genes, dnaE, dnaQ, and holE, were placed in an expression plasmid. The proteins alpha, alpha epsilon and alpha epsilon theta were overexpressed and assembled in E. coli and purified to homogeneity. The three purified polymerases had a similar specific activity of about 6.0 x 10(6) units/mg in a gap-filling assay. Kinetics studies showed that neither epsilon nor theta influenced the K-m of alpha for deoxynucleotide triphosphate and only slightly decreased the K-m of alpha for DNA, although epsilon was absolutely required for maximal DNA synthesis. The rate of DNA synthesis by alpha-reconstituted holoenzyme using tau complex was about 5-fold less than that of alpha epsilon or alpha epsilon theta-reconstituted holoenzyme as determined by a gel analysis. The processivity of alpha-reconstituted holoenzyme was very similar to that of alpha epsilon theta-reconstituted holoenzyme when tau complex was used as a clamp loader.			Kim, DR (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80262 USA.							BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAY PJ, 1981, J BIOL CHEM, V256, P976; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HORIUCHI T, 1981, P NATL ACAD SCI-BIOL, V78, P3770, DOI 10.1073/pnas.78.6.3770; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON OK, 1981, STRUCTURE DNA PROTEI, P425; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1972, NATURE, V2270, P70; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1985, J BIOL CHEM, V260, P2987; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TOMASIEWICZ H, 1991, THESIS U COLORADO HL; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WELCH MM, 1982, J BACTERIOL, V152, P351; WU CA, 1992, J BIOL CHEM, V267, P4074; WU YH, 1984, J BIOL CHEM, V259, P2117; YOU JC, 1993, J BIOL CHEM, V268, P16519	39	53	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20681	20689		10.1074/jbc.271.34.20681	http://dx.doi.org/10.1074/jbc.271.34.20681			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702818	hybrid			2022-12-27	WOS:A1996VD33700070
J	Ryeom, SW; Silverstein, RL; Scotto, A; Sparrow, JR				Ryeom, SW; Silverstein, RL; Scotto, A; Sparrow, JR			Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID EXTRUSION PROCEDURE; ROD OUTER SEGMENTS; VESICLES; RAT; PHAGOCYTOSIS; MACROPHAGES; MEMBRANES; CELLS	The specific recognition of negatively charged phospholipids in cell membranes has been suggested to play an important role in a variety of physiological and pathophysiological processes. Recent work (Rigotti, A., Acton, S. L., and Krieger, M. (1995) J. Biol. Chem. 270, 16221-16224) has described specific and tight binding of anionic phospholipids, such as phosphatidylserine (PS) and phosphatidylinositol (PI), to the class B scavenger receptors, CD36 and SR-B1. We have previously reported that CD36 is present on retinal pigment epithelium (RPE) and plays a role in the phagocytosis of photoreceptor outer segments (ROS), a function critical to the normal visual process (Ryeom, S. W., Sparrow, J. R., and Silverstein, R. L. (1996) J. Cell Sci. 109, 387-395). We now report that phospholipid liposomes PS and PI, but not phosphatidylethanolamine, bind specifically to RPE. Cross competition experiments suggest that PS and PI recognize the same receptor on RPE, while immunoinhibition studies indicate that the receptor is CD36. RPE cells isolated from a mutant rat strain, the RPE of which does not express CD36 (Sparrow, J. R., Ryeom, S. W., Abumrad, N., Ibrahimi, A., and Silverstein, R. L. (1996) Exp. Eye Res., in press), did not bind PS or PI, further confirming the role of CD36. We also showed that purified ROS blocked binding and uptake of anionic phospholipid liposomes by RPE and that PS and PI liposomes blocked ROS uptake by RPE, suggesting that PS and PI on the ROS membrane may be the ligands on ROS recognized by CD36. This is the first demonstration that CD36-phospholipid interactions may play a role in normal physiology.	CORNELL UNIV,COLL MED,DEPT OPHTHALMOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DIV HEMATOL & ONCOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DIV DIGEST DIS,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Cornell University					NATIONAL EYE INSTITUTE [R01EY010967] Funding Source: NIH RePORTER; NEI NIH HHS [EY10967] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BIBB C, 1974, J CELL BIOL, V61, P327, DOI 10.1083/jcb.61.2.327; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOK D, 1989, RETINA, P69; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; CLARK VM, 1982, EXP EYE RES, V34, P847, DOI 10.1016/0014-4835(82)90065-3; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1992, J IMMUNOL, V148, P2207; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huh HY, 1996, BLOOD, V87, P2020; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LUBIN B, 1981, J CLIN INVEST, V67, P1643, DOI 10.1172/JCI110200; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCLAUGHLIN BJ, 1994, PROG RETIN EYE RES, V13, P147, DOI 10.1016/1350-9462(94)90008-6; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Roelofsen Ben, 1994, V40, P7; Ryeom SW, 1996, J CELL SCI, V109, P387; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SPARROW JR, 1996, IN PRESS EXP EYE RES; [No title captured]	26	122	124	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20536	20539		10.1074/jbc.271.34.20536	http://dx.doi.org/10.1074/jbc.271.34.20536			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702796	hybrid			2022-12-27	WOS:A1996VD33700048
J	Simon, I; Zerial, M; Goody, RS				Simon, I; Zerial, M; Goody, RS			Kinetics of interaction of Rab5 and Rab7 with nucleotides and magnesium ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; GDP-DISSOCIATION INHIBITOR; GTPASE-ACTIVATING PROTEIN; ENDOCYTIC PATHWAY; BINDING-PROTEINS; MECHANISM; MEMBRANE; HYDROLYSIS; EXCHANGE; FAMILY	We describe here the kinetics of the interaction of GTP and GDP with the small GTP-binding proteins Rab5 and Rab7. It was possible to make use of the intrinsic fluorescence of these proteins, since Rab5 contains two and Rab7 three tryptophan residues, respectively, With both enzymes, there is a significant decrease in fluorescence on binding GTP and an increase on binding GDP, As with the small GTP-binding protein Ha-Ras p21 and with EF-Tu, nucleotide binding occurs in at least two steps and is describable in terms of a relatively weak initial interaction followed by a highly irreversible isomerization of the protein-nucleotide complex, which results in a change in the fluorescence properties, Dissociation of GDP and GTP could be followed in a time-dependent manner using fluorescently labeled GDP (methylanthraniloyl GDP) as displacing agent and taking advantage of substantial fluorescent energy transfer from tryptophan to the nucleotide. Fluorescence techniques could also be used to quantitate the interaction of Mg2+ ions with the GTP and GDP forms of Rab7, and it was shown that the metal ion was bound similar to 1000-fold more strongly to the GTP than the GDP form. The rate of GTP cleavage by the two proteins differed by a factor of similar to 20 (2 x 10(-3) s(-1) for Rab5 and 9 x 10(-4) s(-1) for Rab7 at 37 degrees C), Both proteins showed significant discrimination against xanthosine 5'-O-diphosphate (K-d similar to 10(3)-fold higher than that of GDP) and dramatic discrimination against ADP or ATP (K-d similar to 10(6)-fold higher than that of GDP), The results demonstrate a high degree of mechanistic similarity between the Rab proteins and other GTP-binding proteins, which have been examined in detail, including Ha-Ras p21, Ran, and EF-Tu.	MAX PLANCK INST MOL PHYSIOL, PHYS BIOCHEM ABT, D-44139 DORTMUND, GERMANY; EUROPEAN MOL BIOL LAB, D-60912 HEIDELBERG, GERMANY	Max Planck Society; European Molecular Biology Laboratory (EMBL)			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; EIGEN M, 1960, J AM CHEM SOC, V82, P5951, DOI 10.1021/ja01507a041; FENG Y, 1995, J CELL BIOL, V131, P1; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GOODY RS, 1994, NATURE, V372, P220, DOI 10.1038/372220a0; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; JOHN J, 1989, NATO ADV SCI I A-LIF, V165, P209; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3652; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SCHEIDIG AJ, 1994, ACTA CRYSTALLOGR D, V50, P512, DOI 10.1107/S090744499301443X; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WAGNER A, 1995, BIOCHEMISTRY-US, V34, P12535, DOI 10.1021/bi00039a007; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	46	98	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20470	20478		10.1074/jbc.271.34.20470	http://dx.doi.org/10.1074/jbc.271.34.20470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702787	hybrid			2022-12-27	WOS:A1996VD33700039
J	Weitzmann, MN; Woodford, KJ; Usdin, K				Weitzmann, MN; Woodford, KJ; Usdin, K			The development and use of a DNA polymerase arrest assay for the evaluation of parameters affecting intrastrand tetraplex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERE-BINDING-PROTEIN; GENE; SEQUENCE; QUADRUPLEX; HAIRPIN; REGION; MODEL; ACID; CHROMOSOME; EXPRESSION	We show here that a K+-dependent block to DNA synthesis is a sensitive and specific indicator of intrastrand tetraplex formation that can be used, both to identify sequences with tetraplex-forming potential and to examine parameters that affect tetraplex formation, We show that tetraplex formation is determined by a complex combination of factors including the size and base composition of its constituent loops and stems, In the process of carrying out this study we have found that the number of sequences with the ability to form tetraplexes is larger than previously thought, and that such sequences are ubiquitous in eukaryote genomes.	NIDDK,NIH,BIOCHEM PHARMACOL LAB,SECT GENOM STRUCT & FUNCT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ABRAMSON RD, 1991, GENOMICS, V10, P126, DOI 10.1016/0888-7543(91)90492-W; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GUO Q, 1993, BIOCHEMISTRY-US, V32, P3596, DOI 10.1021/bi00065a010; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HAMMONDKOSACK MCU, 1992, J MOL ENDOCRINOL, V9, P221, DOI 10.1677/jme.0.0090221; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; Howell RM, 1996, J BIOL CHEM, V271, P5208; KANG S, 1992, J BIOL CHEM, V267, P1259; KASPAR P, 1989, NUCLEIC ACIDS RES, V17, P3616, DOI 10.1093/nar/17.9.3616; KEIME S, 1990, EUR J BIOCHEM, V190, P195, DOI 10.1111/j.1432-1033.1990.tb15564.x; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; LAU YT, 1988, SCIENCE, V240, P1321, DOI 10.1126/science.3375816; LEONARD GA, 1995, STRUCTURE, V3, P335, DOI 10.1016/S0969-2126(01)00165-4; LEWIS CD, 1988, GENE DEV, V2, P833; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VOLOSHIN ON, 1992, J BIOMOL STRUCT DYN, V9, P643, DOI 10.1080/07391102.1992.10507945; WARE VC, 1983, NUCLEIC ACIDS RES, V11, P7795, DOI 10.1093/nar/11.22.7795; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	37	91	95	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20958	20964		10.1074/jbc.271.34.20958	http://dx.doi.org/10.1074/jbc.271.34.20958			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702855	hybrid			2022-12-27	WOS:A1996VD33700107
J	Gaits, F; Li, RY; Bigay, J; Ragab, A; RagabThomas, JMF; Chap, H				Gaits, F; Li, RY; Bigay, J; Ragab, A; RagabThomas, JMF; Chap, H			G-protein beta gamma subunits mediate specific phosphorylation of the protein-tyrosine phosphatase SH-PTP1 induced by lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; ACTIVATED PLATELETS; THROMBIN-RECEPTOR; MAP KINASE; SH2 DOMAIN; CELLS; PATHWAY	SH-PTP1 is a protein-tyrosine phosphatase preferentially expressed in hematopoietic cells and bearing two SH2 ((s) under bar rc (h) under bar omology-(2) under bar) domains. In the human megakaryocytic cell line Dami, lysophosphatidic acid (LPA) promoted a rapid increase in SH-PTP1 phosphorylation on both serine and tyrosine residues. Only tyrosine phosphorylation was significantly inhibited by pertussis toxin and by the protein kinase C inhibitor GF109203X. Moreover, SH-PTP1 was phosphorylated upon challenge with other agonists acting via G-protein-coupled receptors such as alpha-thrombin, epinephrine, and ADP, whereas the closely related protein-tyrosine phosphatase SH-PTP2 failed to share such a regulation in Dami cells. We developed an in vitro assay that reproduced LPA-dependent phosphorylation of SH-PTP1 in a cell-free system. The fusion protein glutathione S-transferase-beta-adrenergic receptor kinase 1-(495-689) or the transducin subunit G alpha(t)-GDP, which act as specific antagonists of G beta gamma, inhibited SH-PTP1 phosphorylation. Moreover, purified transducin G beta gamma subunits mimicked the effect of LPA. Finally, stable expression of beta-adrenergic receptor kinase 1-(495-689) in Dami cells resulted in the inhibition of SH-PTP1 phosphorylation evoked by LPA. Our data thus identify SH-PTP1 as a specific target of protein kinases linked to G-protein-coupled receptors via G beta gamma subunits.	UNIV TOULOUSE 3,INST FED RECH IMMUNOL CELLULAIRE & MOL,F-31059 TOULOUSE,FRANCE; HOP PURPAN,INSERM,U326,CTR HOSP UNIV TOULOUSE,F-31059 TOULOUSE,FRANCE; CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur				Gaits-Iacovoni, Frederique/0000-0002-9853-0442; Joelle, BIGAY/0000-0002-7487-3416				AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; CHEN YH, 1994, J BIOL CHEM, V269, P27372; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FAURE M, 1994, J BIOL CHEM, V269, P7851; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LI FY, 1995, EMBO J, V14, P2519; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SALLES JP, 1993, J BIOL CHEM, V268, P12805; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	46	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20151	20155						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8798377				2022-12-27	WOS:A1996VC66900080
J	Haq, S; Kubo, T; Kurata, S; Kobayashi, A; Natori, S				Haq, S; Kubo, T; Kurata, S; Kobayashi, A; Natori, S			Purification, characterization, and cDNA cloning of a galactose-specific C-type lectin from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA HUMORAL LECTIN; MANNOSE-BINDING PROTEIN; SARCOPHAGA-PEREGRINA; PERIPLANETA-AMERICANA; HEMOLYMPH; COCKROACH; MECHANISM; IMMUNITY; OPSONIN; DEFENSE	We purified a lectin from a pupal extract of Drosophila melanogaster. This lectin agglutinated trypsinized and glutaraldehyde-fixed bovine red blood cells in the presence of calcium or magnesium, The hapten sugar of this lectin was galactose, The molecular mass of the intact lectin was determined to be 41 kDa, and it comprised 14- and 17-kDa subunits, The 17-kDa subunit was shown to be a glycosylated form of the 14-kDa subunit. Analysis of the cDNA for this lectin revealed that the 14-kDa subunit consists of 163 amino acid residues and contains all residues conserved in various C-type lectins. It was suggested that the Drosophila lectin and Sarcophaga lectin share some properties and function similarly in defense and development, but probably they are not structural homologues.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Kubo, Takeo/0000-0002-5914-5269				Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BALDO BA, 1978, BIOCHEM J, V175, P467, DOI 10.1042/bj1750467; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; GIGA Y, 1985, BIOCHEMISTRY-US, V24, P4461, DOI 10.1021/bi00337a030; HAMMARSTROM S, 1969, BIOCHEMISTRY-US, V8, P2629; JOMORI T, 1992, FEBS LETT, V296, P283, DOI 10.1016/0014-5793(92)80305-Z; KAWAGUCHI N, 1991, DEV BIOL, V144, P86, DOI 10.1016/0012-1606(91)90481-H; KOMANO H, 1981, J BIOL CHEM, V256, P7087; KOMANO H, 1983, J BIOL CHEM, V258, P2143; KOMANO H, 1980, J BIOL CHEM, V255, P2919; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; KUBO T, 1990, INSECT BIOCHEM, V20, P585, DOI 10.1016/0020-1790(90)90070-B; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACKIE AM, 1980, PARASITOLOGY, V80, P393, DOI 10.1017/S0031182000000846; LACKIE AM, 1981, J INSECT PHYSIOL, V27, P139, DOI 10.1016/0022-1910(81)90120-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MARSHALL RD, 1974, BIOCH SOC S, V40, P7; MURAMOTO K, 1986, BIOCHIM BIOPHYS ACTA, V874, P285, DOI 10.1016/0167-4838(86)90027-0; NATORI S, 1990, RES IMMUNOL, V141, P938, DOI 10.1016/0923-2494(90)90198-8; Natori Shunji, 1994, P67; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; TAKAHASHI H, 1986, J INSECT PHYSIOL, V32, P771, DOI 10.1016/0022-1910(86)90080-6; TAKAHASHI H, 1985, J BIOL CHEM, V260, P2228; TEICHBERG VI, 1975, P NATL ACAD SCI USA, V72, P1383, DOI 10.1073/pnas.72.4.1383; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YEATON RW, 1981, DEV COMP IMMUNOL, V5, P391, DOI 10.1016/S0145-305X(81)80052-3	34	47	52	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20213	20218		10.1074/jbc.271.33.20213	http://dx.doi.org/10.1074/jbc.271.33.20213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702748	hybrid			2022-12-27	WOS:A1996VC66900090
J	Klauck, TM; Xu, XQ; Mousseau, B; Jaken, S				Klauck, TM; Xu, XQ; Mousseau, B; Jaken, S			Cloning and characterization of a glucocorticoid-induced diacylglycerol kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; HIGH-AFFINITY BINDING; ARACHIDONOYL-DIACYLGLYCEROL; PHOSPHATIDIC-ACID; MOLECULAR-CLONING; ZINC-FINGER; LYSOPHOSPHATIDIC ACID; INDUCED TRANSLOCATION; REGULATORY DOMAIN; HAND MOTIFS	Diacylglycerol kinase (DGK) plays a key role in cellular processes by regulating the intracellular concentra tion of the second messenger diacylglycerol. We screened a hamster DDT1 smooth muscle cell library and isolated a unique, glucocorticoid-inducible cDNA with substantial homology to known DGKs, DGK activity was increased in lysates of insect cells infected with recombinant baculovirus containing this cDNA. Antibodies raised against expressed sequences recognized a glucocorticoid-inducible 130-140-kDa protein on immunoblots of DDT1 cell lysates. Thus, this sequence appears to be a new member of the DGK family that we refer to as DGK eta. Homology to other DGKs was apparent in domains that are thought to be important for DGK function including the cysteine-rich motifs and potential catalytic domains, DGK eta shares substantial homology with DGK delta including the N terminal pleckstrin homology domain. The tissue distribution of DGK eta message (determined by ribonuclease protection assays) and protein (determined by immunoblots) was broader than reported for other DGKs, indicating that DGK eta may play a more general role in regulating cellular DG levels than other DGKs. Heterogeneity among DGK family members indicates that individual DGKs may have unique functions.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NCI NIH HHS [CA65874, CA53841] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053841, R01CA065874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHOSH F, 1994, J BIOL CHEM, V269, P1000; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; INOUE H, 1989, J BIOL CHEM, V264, P5996; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KILEY S, 1990, J BIOL CHEM, V265, P15704; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHAAP D, 1995, BIOCHEM J, V304, P661; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YADA Y, 1990, J BIOL CHEM, V265, P19237; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; YAMADA K, 1988, BIOCHEM J, V255, P601; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; ZEINER M, 1995, BIOTECHNIQUES, V17, P1050; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19781	19788		10.1074/jbc.271.33.19781	http://dx.doi.org/10.1074/jbc.271.33.19781			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702685	hybrid			2022-12-27	WOS:A1996VC66900026
J	Kojima, N; Tachida, Y; Yoshida, Y; Tsuji, S				Kojima, N; Tachida, Y; Yoshida, Y; Tsuji, S			Characterization of mouse ST8Sia II (STX) as a neural cell adhesion molecule-specific polysialic acid synthase - Requirement of core alpha 1,6-linked fucose and a polypeptide chain for polysialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; N-CAM; LINKED OLIGOSACCHARIDES; ALPHA-2,8-SIALYLTRANSFERASE; EXPRESSION; CLONING; FAMILY; BRAIN; MIGRATION; GENE	We previously showed that mouse ST8Sia II (STX) exhibits polysialic acid (PSA) synthase activity in vivo as well as in vitro (Kojima, N., Yoshida, Y., and Tsuji, S. (1995) FEBS Lett. 373, 119-122, 1995). In this paper, we reported that the neural cell adhesion molecule (NCAM) was specifically polysialylated by a single enzyme, ST8Sia II. PSA-expressing Neuro2a cells (N2a-STX) were established by stable transfection of the mouse ST8Sia II gene. Only the 140- and 180-kDa isoforms of NCAM in N2a-STX cells were specifically polysialylated in vivo, although other membrane proteins of N2a-STX were polysialylated in vitro, A recombinant soluble mouse ST8Sia II synthesized PSA on a recombinant soluble NCAM fused with the Fc region of human IgG1 (NCAM-Fc) as well as fetuin, However, NCAM Fe served as a 1500-fold better acceptor for ST8Sia II than fetuin, Treatment of NCAM-Fe with Charonia lampas alpha-fucosidase, which is able to cleave alpha 1,6-linked fucose, clearly reduced the polysialylation of NCAM-Fe by ST8Sia II, PSA was not synthesized on the N-glycanase-treated NCAM-Fc polypeptide or the free N-glycans of NCAM-Fc, When fetuin and its glycopeptide and N-glycans of fetuin were used as substrates for ST8Sia II, PSA was found to be synthesized on native fetuin and its glycopeptide but not on free N-glycans, These results strongly suggested that core alpha 1,6-fucose on N-glycans as well as the antennary structures of N-glycans and the polypeptide regions are required for the polysialylation by ST8Sia II, Furthermore, oligo and single alpha 2,8-sialylated glycoproteins were no longer polysialylated by mouse ST8Sia II. Therefore, the single enzyme, ST8Sia II, directly transferred all alpha 2,8-sialic acid residues on the alpha 2,3-linked sialic acids of N-glycans of specific NCAM isoforms to yield PSA-NCAM. Polysialylation did not require any initiator alpha 2,8-sialyltransferase but did depend on the carbohydrate and protein structures of NCAM.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,DEPT MOL GLYCOBIOL,WAKO,SAITAMA 35101,JAPAN	RIKEN								Bruses JL, 1995, J NEUROSCI, V15, P8310; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1985, ANN REV BIOCH, V54, P15; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; Johnston D. E., 1976, RNA POLYMERASE, P413; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KITAJIMA K, 1995, GLYCOCONJUGATE J, V12, P508; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1994, EXP CELL RES, V214, P537, DOI 10.1006/excr.1994.1291; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MIZUOCHI T, 1980, BIOCHEM BIOPH RES CO, V97, P772, DOI 10.1016/0006-291X(80)90331-9; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; OKA S, 1995, J BIOL CHEM, V270, P17171; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; TNAG J, 1994, NEURON, V13, P405; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WALSH FS, 1989, BIOESSAYS, V11, P83, DOI 10.1002/bies.950110402; WANG C, 1994, J NEUROSCI, V14, P4446; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	33	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19457	19463		10.1074/jbc.271.32.19457	http://dx.doi.org/10.1074/jbc.271.32.19457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702635	hybrid			2022-12-27	WOS:A1996VB68400069
J	Olofsson, B; Pajusola, K; vonEuler, G; Chilov, D; Alitalo, K; Eriksson, U				Olofsson, B; Pajusola, K; vonEuler, G; Chilov, D; Alitalo, K; Eriksson, U			Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; PDGF RECEPTOR; CDNA CLONING; EXPRESSION; PLACENTA; PROTEIN; ANGIOGENESIS; BINDING; DIFFERENTIATION; VASCULOGENESIS	A second isoform and the genomic structures of mouse and human vascular endothelial growth factor B are described. Both genes consist of seven coding exons and span about 4 kilobases of DNA. The two identified isoforms of vascular endothelial growth factor B are generated by alternative splicing where different, splice acceptor sites in exon 6 introduce a frameshift and a partial use of different but overlapping reading frames, Consequently, the COOK-terminal domains in the two isoforms show no resemblance, Mouse and human cDNA clones for the novel isoform of vascular endothelial growth factor B encoded a secreted protein of 186 amino acid residues. Expression in transfected cells generated a protein of 25 kDa which upon secretion was modified by O-linked glycosylation and displayed a molecular mass of 32 kDa under reducing conditions. The protein was expressed as a disulfide-linked homodimer, and heterodimers were generated when coexpressed with vascular endothelial growth factor. The entirely different COOH-terminal domains in the two isoforms of vascular endothelial growth factor B imply that some functional properties of the two proteins are distinct.	LUDWIG INST CANC RES,STOCKHOLM BRANCH,S-17177 STOCKHOLM,SWEDEN; MOL CANC BIOL LAB,HELSINKI 00014,FINLAND; HAARTMAN INST,HELSINKI 00014,FINLAND	Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; chilov, dmitri/0000-0002-2279-0854				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BREIER G, 1992, DEVELOPMENT, V114, P521; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; Joukov V, 1996, EMBO J, V15, P290; Konat Gregory W., 1994, P37; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARK JE, 1994, J BIOL CHEM, V269, P25646; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	35	165	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19310	19317		10.1074/jbc.271.32.19310	http://dx.doi.org/10.1074/jbc.271.32.19310			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702615	hybrid			2022-12-27	WOS:A1996VB68400049
J	Clarke, EM; Peterson, CL; Brainard, AV; Riggs, DI				Clarke, EM; Peterson, CL; Brainard, AV; Riggs, DI			Regulation of the RNA polymerase I and III transcription systems in response to growth conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TIF-IA; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; HORMONAL-REGULATION; GENE-TRANSCRIPTION; 5S RNA; MEDIATED TRANSCRIPTION; CELL-DIFFERENTIATION; PHORBOL ESTER; YEAST-CELLS	To better understand the mechanisms that regulate stable RNA synthesis, we have analyzed the RNA polymerase I and III transcriptional activities of extracts isolated from cells propagated under a variety of conditions, Under balanced growth conditions the levels of both RNA polymerase I- and III-specific transcription increased proportionally with growth rate, Upon nutritional starvation, RNA polymerase I transcription rapidly declined, followed by 5 S rDNA and eventually tDNA transcription, Transcriptional activities in extracts were restored when the nongrowing cultures were resuspended in fresh medium, although growth did not resume. The differential expression of 5 S rDNA and tDNA genes in extracts prepared from cells subjected to partial starvation was traced to a 5 S rDNA-specific inhibitor and not to a defect in any RNA polymerase III transcription factor. Characterization of this inhibitor indicated that it was not 5 S rRNA. It was sensitive to phenol extraction and resistant to RNase, and its target did not appear to be transcription factor IIIA. Not all treatments that slowed or stopped growth down-regulated the stable RNA transcription apparatus, Cells that have been subjected to either energy starvation or cycloheximide treatment still retain the ability to synthesize stable RNA in vitro, suggesting the presence of alternative regulatory mechanisms.	UNIV OKLAHOMA,DEPT BOT & MICROBIOL,NORMAN,OK 73019	University of Oklahoma System; University of Oklahoma - Norman					NIGMS NIH HHS [GM47881] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047881] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BROW DA, 1987, J BIOL CHEM, V262, P13953; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1983, J BIOL CHEM, V258, P9768; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GARBER M, 1991, J BIOL CHEM, V266, P20598; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GRANOT D, 1993, YEAST, V9, P465, DOI 10.1002/yea.320090503; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; GRUMMT I, 1981, P NATL ACAD SCI-BIOL, V78, P727, DOI 10.1073/pnas.78.2.727; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KERMEKCHIEV M, 1993, NUCLEIC ACIDS RES, V21, P447, DOI 10.1093/nar/21.3.447; KIEF DR, 1981, MOL CELL BIOL, V1, P1007, DOI 10.1128/MCB.1.11.1007; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LUDWIG JR, 1977, MOL GEN GENET, V158, P117; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16244; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MATTHEWS JL, 1995, MOL CELL BIOL, V15, P3327; MCGOLDRICK EM, 1989, J GEN MICROBIOL, V135, P2407; OLIVER SG, 1977, MOL GEN GENET, V154, P145, DOI 10.1007/BF00330830; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PAULE MR, 1993, TRANSCRIPTION, P83; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; REEDER RH, 1992, TRANSCRIPTIONAL REGU, V1, P315; RIGGS DL, 1995, J BIOL CHEM, V270, P6205, DOI 10.1074/jbc.270.11.6205; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SETHY I, 1995, J BIOL CHEM, V270, P28463; SHULMAN RW, 1977, J BIOL CHEM, V252, P1344; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VALLETT SM, 1993, MOL CELL BIOL, V13, P928, DOI 10.1128/MCB.13.2.928; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WALDRON C, 1977, J GEN MICROBIOL, V98, P215, DOI 10.1099/00221287-98-1-215; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983	45	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22189	22195		10.1074/jbc.271.36.22189	http://dx.doi.org/10.1074/jbc.271.36.22189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703032	hybrid			2022-12-27	WOS:A1996VF61200074
J	Fourier, TM; Kamikura, D; Teng, K; Park, M				Fourier, TM; Kamikura, D; Teng, K; Park, M			Branching tubulogenesis but not scatter of Madin-Darby canine kidney cells requires a functional Grb2 binding site in the met receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-CELLS; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; SH2 DOMAINS; MOTILITY; RAS	Hepatocyte growth factor is a multifunctional cytokine that induces mitogenesis, motility, invasion, and branching tubulogenesis of several epithelial and endothelial cell lines in culture. The receptor for hepatocyte growth factor has been identified as the Met tyrosine kinase, To investigate the signaling pathways that are involved in these events, we have generated chimeric receptors containing the colony stimulating factor-1 receptor fused to the transmembrane and intracellular domains of the Met receptor. Madin-Darby canine kidney epithelial cells expressing the Met chimera dissociate scatter and form branching tubules in response to colony stimulating factor-1. From structure-function analyses, tyrosine residue 1356 within the carboxyl terminus of the Met receptor is critical for these events. The amino acid sequence downstream from tyrosine 1356 represents a consensus binding site for the Grb2 adaptor protein and forms a multisubstrate binding site for the p85 subunit of phosphatidylinositol 3-kinase, phospholipase C gamma, and the Shc adaptor protein. To distinguish which of these signaling pathways are required, we generated a mutant receptor that selectively fails to associate with the Grb2 adaptor protein. Cells expressing this mutant receptor scattered but were unable to form branching tubules, indicating that a Grb2 binding site in the Met receptor is critical for morphogenic responses.	MCGILL UNIV, ROYAL VICTORIA HOSP, MOL ONCOL GRP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, MOL ONCOL GRP, DEPT MED, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, MOL ONCOL GRP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; FALETTO DL, 1989, HEPATOCYTE GROWTH FA, P107; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALABAN R, 1992, ONCOGENE, V7, P2195; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KOMADA M, 1993, ONCOGENE, V8, P2381; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1993, EXS, V65, P225; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAISHI K, 1994, ONCOGENE, V9, P273; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	61	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22211	22217		10.1074/jbc.271.36.22211	http://dx.doi.org/10.1074/jbc.271.36.22211			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703035	hybrid			2022-12-27	WOS:A1996VF61200077
J	Kohn, AD; Takeuchi, F; Roth, RA				Kohn, AD; Takeuchi, F; Roth, RA			Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL; REGION	Akt is a serine/threonine kinase that is stimulated by receptor tyrosine kinases and contains a pleckstrin homology domain. One model proposed to explain this activation suggests that receptor tyrosine kinases stimulate a phosphatidylinositol 3-kinase whose lipid products directly activate Akt kinase by interacting with its pleckstrin homology domain. In the present study, we show, in three cell types, that Akt does not require its pleckstrin homology domain to respond to either insulin or platelet-derived growth factor. Moreover, attachment of the are myristoylation signal to target Akt, without its pleckstrin homology domain, to the membrane constitutively activates Akt by causing an increase in its basal level of phosphorylation, This constitutively active form of Akt can also activate p70(S6K), indicating that the pleckstrin homology domain is not necessary for downstream interactions. Fusion of the inter src homology 2 domain from the p85 regulatory subunit of the phosphatidylinositol 3-kinase to Akt also constitutively activated Akt and induced an association with the lipid kinase. Phosphorylation of this fusion protein still critically contributes toward its increased activity. The sum of these results indicates that the primary mechanism of Akt activation is via protein phosphorylation.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R37DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED NN, 1992, ONCOGENE, V8, P1957; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1996, ADV CELL REGUL, V8, P153; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FRANKE TF, 1995, CELL, V81, P757; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	17	402	407	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21920	21926		10.1074/jbc.271.36.21920	http://dx.doi.org/10.1074/jbc.271.36.21920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702995	hybrid			2022-12-27	WOS:A1996VF61200037
J	Libby, RD; Beachy, TM; Phipps, AK				Libby, RD; Beachy, TM; Phipps, AK			Quantitating direct chlorine transfer from enzyme to substrate in chloroperoxidase-catalyzed reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; KINETIC-ANALYSIS; HALOGENATION; MECHANISM; MYELOPEROXIDASE; INTERMEDIATE; OXIDATION; HOCL	Substrate competition methods that were previously used to quantitate the involvement of free Cl-2 in the chloride-dependent peroxidatic reactions catalyzed by chloroperoxidase (CPO) (Libby, R, D., Shedd, A. L., Phipps, K. A., Beachy, T.M., and Gerstberger, S. M., (1992) J. Biol. Chem. 267, 1769-1775) are extended to CPO-catalyzed halogenation reactions. Relative substrate specificities of halogen acceptor substrates (RHs) antipyrine tap), NADH, 2-chlorodimedone (2cd), and barbituric acid (ba) are compared with previously studied peroxidatic substrates catechol (cat) and 2,4,6-trimethylphenol (tmp) in their reactions with the CPO-H2O2-Cl system versus the hypochlorite-Cl system. Studies were carried out at pH 2.75 over a chloride concentration range of 1-100 mM and at pH 4.80 over a chloride concentration range of 100-400 mM. Competition studies involved successive pairwise comparisons of substrates of increasing enzyme specificity. The orders of specificities, ba > 2cd > ap > cat > tmp at pH 2.75 and ha > 2cd > NADH > ap > cat > tmp at pH 4.80, are the same for both the CPO-H2O2-Cl and hypochlorite-Cl systems. However, the magnitudes of the specificities are different between the two systems. In all comparisons except ap versus cat, the specificity of the CPO-H2O2-Cl system toward the preferred substrate is higher than that of the hypochlorite-Cl system. Quantitative comparisons between specificities of CPO-H2O2-Cl and hypochlorite-Cl systems indicate that at least 98% of the CPO-catalyzed halogenation reactions of ba, 2cd, NADH, and ap occur by mechanisms in which the substrate reacts directly with the enzyme. Thus, less than 2% of any of the CPO reactions could possibly involve a free oxidized halogen intermediate. All data are consistent with a mechanism in which RH binds to the CPO chlorinating intermediate (EOCl), and the chlorine atom is transferred directly from EOCl to RH. Further, the results indicate that any halogenation substrate with a higher CPO specificity than ap must also undergo direct chlorine transfer from the enzyme. These results underscore the critical need for quantitative kinetic evidence in establishing the extent of involvement of any potential reaction intermediate. Finally, this work calls into question the long held assumption of the obligatory involvement of hypochlorite as an intermediate in myeloperoxidase reactions. It supports the recent kinetic evidence presented by Marquet and Dunford for direct chlorine transfer in myeloperoxidase-catalyzed chlorination of tuarine.	COLBY COLL,DEPT CHEM,WATERVILLE,ME 04901	Colby College	Libby, RD (corresponding author), MORAVIAN COLL,DEPT CHEM,BETHLEHEM,PA 18018, USA.				NIGMS NIH HHS [7 R15 GM42078-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM042078] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAISO T, 1981, CAN J BIOCHEM CELL B, V59, P233, DOI 10.1139/o81-031; CARMICHAEL R, 1985, BIOTECHNOL LETT, V7, P289, DOI 10.1007/BF01042380; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DUNFORD HB, 1987, ARCH BIOCHEM BIOPHYS, V252, P292, DOI 10.1016/0003-9861(87)90034-8; GEIGERT J, 1986, BIOCHEM BIOPH RES CO, V136, P778, DOI 10.1016/0006-291X(86)90507-3; GEIGERT J, 1983, J BIOL CHEM, V258, P2273; GRIFFIN BW, 1985, ARCH BIOCHEM BIOPHYS, V239, P305, DOI 10.1016/0003-9861(85)90840-9; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HAGER LP, 1973, OXIDASES RELATED RED, P311; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; LAMBEIR AM, 1983, J BIOL CHEM, V258, P3558; LIBBY RD, 1992, J BIOL CHEM, V267, P1769; LIBBY RD, 1990, J BIOL CHEM, V265, P14808; LIBBY RD, 1989, J BIOL CHEM, V264, P15284; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MCCARTHY MB, 1983, J BIOL CHEM, V258, P9153; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; RAMAKRISHNAN K, 1983, BIOCHEMISTRY-US, V22, P3271, DOI 10.1021/bi00282a036; SHOEMAKER DP, 1989, EXPT PHYSICAL CHEM, P57; THOMAS JA, 1970, J BIOL CHEM, V245, P3135; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; WOLFRAM S, 1991, MATH SYSTEM DOING MA, P88	24	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21820	21827		10.1074/jbc.271.36.21820	http://dx.doi.org/10.1074/jbc.271.36.21820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702981	hybrid			2022-12-27	WOS:A1996VF61200023
J	Ahn, BC; Grossman, L				Ahn, BC; Grossman, L			The binding of UvrAB proteins to bubble and loop regions in duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRAB; EXCISION NUCLEASE; ATPASE ACTIVITY; RNA-POLYMERASE; HELICASE-II; DAMAGED DNA; REPAIR; ENDONUCLEASE; COMPLEX; INCISION	Based on the binding of the UvrAB complex to a promoter region in transcription open complexes (Ahn, B., and Grossman, L, (1996) J. Biol. Chem. 271, 21453-21461) and the requirement of a single-stranded region for UVrAB helicase activity, we examined the binding of UvrAB proteins to synthetic bubble or loop regions in duplex DNA and the role of these regions in translocation of the UvrAB complex as well as incision of DNA damage. We found that the UvrAB complex was able to bind to bubble and loop regions with an affinity similar to that for damaged DNA in the absence of RNAP. The preferential recognition and incision of damaged sites by the UvAB complex was observed downstream of the bubble or loop region in the strand complementary to the strand along which the UVrAB complex translocates. These results imply that the bubble region generated in duplex DNA by RNAP serves as a preferred entry site for the translocation of the UvrAB complex, and that preferential binding and unidirectional translocation of the UvrAB complex predetermine where incision is to occur.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022846, R01GM122846, R37GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22846, GM RO-1-22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21453, DOI 10.1074/jbc.271.35.21453; AIYAR SE, 1994, J BIOL CHEM, V269, P13179; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; FRIEDBERG EC, 1995, DNA REPAIR; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Kornberg A., 1992, DNA REPLICATION; KOVALSKY OI, 1994, J BIOL CHEM, V269, P27421; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LINN SM, 1985, NUCLEASES; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OH EY, 1987, THESIS J HOPKINS U B; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; REARDON JT, 1993, J BIOL CHEM, V268, P21301; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; WANG JT, 1994, J BIOL CHEM, V269, P10771; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	39	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21462	21470		10.1074/jbc.271.35.21462	http://dx.doi.org/10.1074/jbc.271.35.21462			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702929	hybrid			2022-12-27	WOS:A1996VE47700075
J	Jahroudi, N; Ardekani, AM; Greenberger, JS				Jahroudi, N; Ardekani, AM; Greenberger, JS			An NF1-like protein functions as a repressor of the von Willebrand factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; HUMAN VONWILLEBRAND-FACTOR; DNA-BINDING PROTEIN; GENE-EXPRESSION; COLLAGEN PROMOTER; RECOGNITION SITE; NEGATIVE CONTROL; HELA-CELLS; SEQUENCE; BETA	The expression of the von Willebrand factor (vWf) gene is restricted to endothelial cells and megakaryocytes, We have previously reported the identification of a region of the vWf gene that regulates its cell-type-specific expression in cell culture, This region (spanning nucleotides -487 to +247) consists of a core promoter (spanning nucleotides -90 to +22), a positive regulatory region (spanning nucleotides +155 to +247), and a negative regulatory region spanning nucleotides -312 to -487. To identify the trans-acting factor(s) that interacts with the negative regulatory region, we carried out gel mobility and DNase1 footprint analyses of sequences -312 to -487, These analyses demonstrated that an NF1-like protein interacts with DNA sequences spanning -440 to -470 nucleotides in the negative regulatory region of the vWf promoter, Base substitution mutations of the NF1 binding site abolished the NF1-DNA interaction, Furthermore, mutation of the NF1 binding site in the promoter fragment (-487 to +155) that contained the core and the negative regulatory region resulted in activation of the mutant promoter in both endothelial and nonendothelial cells, The wild type promoter fragment (-487 to +155) was not activated in either cell type. These results demonstrate that an NF1-like protein functions as a repressor of vWf promoter activity, In contrast, the mutation of the same NF1 binding site, but now in the context of the larger 734-base pair endothelial cell-specific promoter fragment (-487 to +247), did not result in promoter activation in nonendothelial cells, The data indicate that there are additional repressor elements within the vWf promoter region suppressing its activity specifically, in nonendothelial cells, and suggest that there is a secondary repressor element(s) that is located in the terminal region of the first exon of this gene.	UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jahroudi, N (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT RADIAT ONCOL,PITTSBURGH,PA 15213, USA.				NATIONAL CANCER INSTITUTE [R01CA039851, R37CA039851] Funding Source: NIH RePORTER; NCI NIH HHS [CA39851] Funding Source: Medline; BHP HRSA HHS [PE08798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BHP HRSA HHS		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; DAVIES PF, 1988, ENDOTHELIAL CELLS, V2, P123; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; GANDER I, 1988, BIOCHIM BIOPHYS ACTA, V951, P411, DOI 10.1016/0167-4781(88)90114-5; GIMBRONE MA, 1990, ANN NY ACAD SCI, V598, P77, DOI 10.1111/j.1749-6632.1990.tb42279.x; GIRMA JP, 1987, BLOOD, V70, P605; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MACIAG T, 1982, PROG HEMOSTASIS THRO, V7, P167; MACIAG T, 1988, ENDOTHELIAL CELLS, V2, P3; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; NOMURA S, 1989, J BIOL CHEM, V264, P12201; ORKIN SH, 1992, BLOOD, V80, P575; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PIOVELLA F, 1987, BRIT J HAEMATOL, V39, P209; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUGGERI ZM, 1987, BLOOD, V70, P895; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TUDDENHAM EGD, 1989, BLOOD REV, V3, P251, DOI 10.1016/0268-960X(89)90032-5	39	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21413	21421		10.1074/jbc.271.35.21413	http://dx.doi.org/10.1074/jbc.271.35.21413			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702923	hybrid			2022-12-27	WOS:A1996VE47700069
J	Trejo, J; Connolly, AJ; Coughlin, SR				Trejo, J; Connolly, AJ; Coughlin, SR			The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts - Loss of responses in fibroblasts from receptor knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; HAMSTER FIBROBLASTS; MAP KINASE; PROTEOLYTIC MECHANISM; SIGNALING PATHWAYS; PHOSPHOLIPASE-C; ALPHA-THROMBIN; GROWTH-FACTORS; CELLS; PEPTIDES	The mitogenic activity of thrombin on fibroblasts and smooth muscle cells may contribute to embryonic development and normal wound healing, and it may also play a role in pathological responses to vascular injury. To examine the importance of thrombin signaling in vivo and to define the cloned thrombin receptor's role, we disrupted the thrombin receptor gene (tr) in mice. Platelets from tr(-/-) mice responded normally to thrombin, but tr(-/-) fibroblasts showed no thrombin-induced calcium mobilization or phosphoinositide hydrolysis. Thus distinct thrombin receptors act in different tissues. This study focuses on the role of the thrombin receptor in thrombin-induced mitogenesis and mitogen-activated protein (MAP) kinase activation in mesenchymal cells. Thrombin and thrombin receptor agonist peptide both stimulated DNA synthesis and MAP kinase activation in fibroblasts derived from wild-type mice. These responses were selectively lost in fibroblasts from tr(-/-) mice. Activation of the cloned thrombin receptor is therefore necessary and sufficient for thrombin-induced mitogenesis and MAP kinase activation in mouse lung fibroblasts. The tr(-/-) mouse thus provides a valuable model for defining the role of thrombin-induced proliferative events in vivo. Because thrombin-induced MAP kinase activation was attributable to a single receptor expressed at natural levels, mouse lung fibroblasts presented an opportunity to define the pathways that normally mediate activation of MAP kinase by the thrombin receptor. Elimination of phorbol-sensitive protein kinase C by prolonged exposure to phorbol ester only partially inhibited MAP kinase activation by thrombin but completely blocked c-Raf kinase activation. Pertussis toxin partially inhibited MAP kinase activation by thrombin but had no significant effect on c-Raf kinase activation. Thus in mouse lung fibroblasts, one thrombin receptor utilizes two pathways for MAP kinase activation: one is protein kinase C- and c-Raf dependent, and a second is G(i)-dependent and c-Raf-independent.	UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline; NIDDK NIH HHS [DK50267] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLER BS, 1992, BIOCHEMISTRY-US, V31, P11713, DOI 10.1021/bi00162a007; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PARIS S, 1988, J BIOL CHEM, V263, P12893; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WINITZ S, 1993, J BIOL CHEM, V268, P19196	35	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21536	21541		10.1074/jbc.271.35.21536	http://dx.doi.org/10.1074/jbc.271.35.21536			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702939	hybrid			2022-12-27	WOS:A1996VE47700085
J	Banerjee, A; Barry, VA; DasGupta, BR; Martin, TFJ				Banerjee, A; Barry, VA; DasGupta, BR; Martin, TFJ			N-ethylmaleimide-sensitive factor acts at a profusion ATP-dependent step in Ca2+-activated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ADRENAL CHROMAFFIN CELLS; NSF ATTACHMENT PROTEINS; MEMBRANE-FUSION COMPLEX; IN-VITRO; SECRETION; TRANSPORT; SYNTAXIN; DOCKING	An ATP-dependent activity of NSF (N-ethylmaleimide-sensitive factor) that rearranges soluble NSF attachment protein (SNAP) receptor (SNARE) protein complexes was proposed to be the driving force for membrane fusion. The Ca2+-activated fusion of secretory vesicles with the plasma membrane in permeable PC12 cells requires ATP; however, the ATP requirement is for a priming step that precedes the Ca2+-triggered fusion reaction. While phosphoinositide phosphorylation is a key reaction required for priming, additional ATP-dependent reactions are also necessary. Here we report that the NSF-catalyzed rearrangement of SNARE protein complexes occurs during ATP-dependent priming, NSF with alpha-SNAP (soluble NSF attachment protein) were required for ATP-dependent priming but not Ca2+-triggered fusion, indicating that NSF acts at an ATP-dependent prefusion step rather than at fusion itself. NSF-catalyzed activation of SNARE proteins may reorganize membranes to generate a vesicle-plasma membrane prefusion intermediate that is poised for conversion to full fusion by Ca2+-dependent mechanisms.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025861, R37DK025861, R01DK040428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40428, DK25861] Funding Source: Medline; NINDS NIH HHS [NS17742] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHAFER T, 1987, BIOSCIENCE REP, V7, P269, DOI 10.1007/BF01121448; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	26	187	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20223	20226		10.1074/jbc.271.34.20223	http://dx.doi.org/10.1074/jbc.271.34.20223			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702750	hybrid			2022-12-27	WOS:A1996VD33700002
J	Buczylko, J; Saari, JC; Crouch, RK; Palczewski, K				Buczylko, J; Saari, JC; Crouch, RK; Palczewski, K			Mechanisms of opsin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; SCHIFF-BASE COUNTERION; CONSTITUTIVELY ACTIVE MUTANTS; VISUAL PIGMENT ANALOGS; ROD OUTER SEGMENT; METARHODOPSIN-II; BOVINE RHODOPSIN; TRANSDUCIN ACTIVATION; G-PROTEIN; SUBSTRATE-SPECIFICITY	Rhodopsin is constrained in an inactive conformation by interactions with 11-cis-retinal including formation of a protonated Schiff base with Lys(296). Upon photoisomerization, major structural rearrangements that involve protonation of the active site Glu(113) and cytoplasmic acidic residues, including Glu(134), lead to the formation of the active form of the receptor, metarhodopsin II b, which decays to opsin. However, an activated receptor may be generated without illumination by addition of all-trans-retinal or its analogues to opsin, as measured in this study by the increased phosphorylation of opsin by rhodopsin kinase, The potency of stimulation depended on the chemical and isomeric nature of the analogues and the length of the polyene chain with all-trans-C17 aldehyde and all-trans-retinal being the most active and trans-C12 aldehyde being the least active. Certain cis-isomers, 11-cis-13-demethyl-retinal and 9-cis-C17 aldehyde, were also active. Most of the retinal analogues tested did not regenerate a spectrally identifiable pigment, and many were incapable of Schiff base formation (ketone, stable oximes, and Schiff base-derivatives of retinal), Thus, receptor activation resulted from formation of non-covalent complexes with opsin. pH titrations suggested that an equilibrium exists between partially active (protonated) and inactive (deprotonated) forms of opsin, These findings are consistent with a model in which protonation of one or more cytoplasmic carboxyl groups of opsin is essential for activity. Upon addition of retinoids, the partially active conformation of opsin is converted to a more active intermediate similar to metarhodopsin II b. The model provides an understanding of the structural requirements for opsin activation and an interpretation of the observed activities of natural and experimental opsin mutants.	UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA; MED UNIV S CAROLINA, DEPT OPHTHALMOL, CHARLESTON, SC 29425 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Medical University of South Carolina	Buczylko, J (corresponding author), UNIV WASHINGTON, SCH MED, DEPT OPHTHALMOL, BOX 356485, SEATTLE, WA 98195 USA.				NEI NIH HHS [EY08161, EY04939, EY02317] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004939, R43EY008161] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; BENNETT N, 1980, EUR J BIOCHEM, V111, P99; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; COOPER A, 1981, FEBS LETT, V123, P324, DOI 10.1016/0014-5793(81)80319-5; CORNWALL MC, 1995, J GEN PHYSIOL, V106, P543, DOI 10.1085/jgp.106.3.543; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; CORSON DW, 1994, P NATL ACAD SCI USA, V91, P6958, DOI 10.1073/pnas.91.15.6958; CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823; Corson DW, 1996, PHOTOCHEM PHOTOBIOL, V63, P595, DOI 10.1111/j.1751-1097.1996.tb05661.x; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; EBREY T, 1980, FEBS LETT, V116, P217, DOI 10.1016/0014-5793(80)80647-8; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FAHMY K, 1994, BIOCHEMISTRY-US, V33, P13700, DOI 10.1021/bi00250a021; FLOCCO MW, 1995, J MOL BIOL, V254, P96, DOI 10.1006/jmbi.1995.0602; FUKADA Y, 1981, BIOCHIM BIOPHYS ACTA, V675, P195, DOI 10.1016/0304-4165(81)90226-9; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GANTER UM, 1991, BIOPHYS J, V59, P640, DOI 10.1016/S0006-3495(91)82279-2; GOVARDHAN CP, 1994, J BIOL CHEM, V269, P6524; Granit R, 1939, J PHYSIOL-LONDON, V96, P31, DOI 10.1113/jphysiol.1939.sp003755; HAN M, 1995, BIOPHYS CHEM, V56, P23, DOI 10.1016/0301-4622(95)00011-L; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; HUBBARD R, 1971, METHOD ENZYMOL, V33, P615; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; JONES GJ, 1993, J GEN PHYSIOL, V102, P483, DOI 10.1085/jgp.102.3.483; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KROPF A, 1973, EXP EYE RES, V17, P591, DOI 10.1016/0014-4835(73)90088-2; LACY M, 1992, VISION RES, V22, P1451; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LEWIS JW, 1992, J BIOENERG BIOMEMBR, V24, P201, DOI 10.1007/BF00762678; LIN SW, 1992, BIOCHEMISTRY-US, V31, P5105, DOI 10.1021/bi00137a003; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LONGSTAFF C, 1985, BIOCHEMISTRY-US, V24, P8137, DOI 10.1021/bi00348a045; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MORRISON DF, 1995, J BIOL CHEM, V270, P6718, DOI 10.1074/jbc.270.12.6718; NELSON R, 1970, P NATL ACAD SCI USA, V66, P531, DOI 10.1073/pnas.66.2.531; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; Ohguro H, 1996, J BIOL CHEM, V271, P5215; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PALCZEWSKI K, 1993, METH NEUROSCI, V15, P217; QUINTANA DG, 1995, BIOPHYS J, V69, P1077, DOI 10.1016/S0006-3495(95)79981-7; RAO MJ, 1994, METHOD ENZYMOL, V231, P246; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHICHIDA Y, 1981, BIOCHEMISTRY-US, V20, P1962, DOI 10.1021/bi00510a035; STEINBERG G, 1993, BIOPHYS J, V64, P1499, DOI 10.1016/S0006-3495(93)81518-2; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; TOKUNAGA F, 1977, BIOPHYS J, V19, P191, DOI 10.1016/S0006-3495(77)85580-X; TOWNER P, 1981, EUR J BIOCHEM, V117, P353, DOI 10.1111/j.1432-1033.1981.tb06345.x; VANDENTEMPEL PJ, 1966, TETRAHEDRON, V46, P233; VANKUIJK FJGM, 1985, J CHROMATOGR, V348, P241, DOI 10.1016/S0021-9673(01)92458-6; VONISLER O, 1956, HELV CHIM ACTA, V39, P259; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046	80	92	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20621	20630		10.1074/jbc.271.34.20621	http://dx.doi.org/10.1074/jbc.271.34.20621			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702809	hybrid			2022-12-27	WOS:A1996VD33700061
J	Lee, FJS; Pristupa, ZB; Ciliax, BJ; Levey, AI; Niznik, HB				Lee, FJS; Pristupa, ZB; Ciliax, BJ; Levey, AI; Niznik, HB			The dopamine transporter carboxyl-terminal tail - Truncations/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; GLUT4 GLUCOSE-TRANSPORTER; BRAIN GABA TRANSPORTER; H-3 WIN 35,428; SEROTONIN TRANSPORTER; RAT-BRAIN; NOREPINEPHRINE TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; RADIATION INACTIVATION; COCAINE RECEPTORS	In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [H-3]dopamine uptake kinetics and [H-3]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted, Complete truncation of the carboxyl tail from Ser(582) allowed for the expression of biphasic [H-3]dopamine uptake kinetics displaying both a low capacity (V-max similar to-0.4 pmol/10(5) cells/min) high affinity (K-m similar to 300 nM) component and one exhibiting low affinity (K-m similar to 15 mu M) and high capacity (V-max similar to 5 pmol/10(5) cells/min) with a concomitant 40% decrease in overall apparent V-max relative to wild type (WT) DAT. Truncation of the last 22 amino acids or substitution of the DAT-COOH tail with sequences encoding the intracellular carboxyl-terminal of either dopamine D1 or D5 receptors produced results that were identical to those with the fully truncated DAT, suggesting that the induction of biphasic dopamine uptake kinetics is likely conferred by removal of DAT-specific sequence motifs distal to Pro(597). The attenuation of WT transport activity, either by lowering levels of DAT expression or by pretreatment of cells with phorbol 12-myristate 13- acetate (1 mu M), did not affect the kinetics of [H-3]dopamine transport. The estimated affinity of dopamine (K-i similar to 180 nM) for all truncated/substituted DAT mutants was 10-fold lower than that of WT DAT (similar to 2000 nM) and appears selective for the endogenous substrate, since the estimated inhibitory constants for numerous putative substrates or uptake inhibitors were virtually identical to those obtained for WT DATs. In marked contrast, DAT truncation/substitution mutants displayed significantly reduced high affinity [H-3]CFT binding interactions with estimated K-i values for dopamine and numerous other substrates and inhibitors tested from 10-100-fold lower than that observed for WT DAT, Moreover, co-expression of truncated and/or substituted DATs with WT transporter failed to reconstitute functional or pharmacological activities associated with both transporters. Instead, complete restoration of uniphasic low affinity [H-3]dopamine uptake kinetics (K-m similar to 2000 nM) and high affinity substrate and inhibitor [H-3]CFT binding interactions attributable to WT DATs were evident. These data clearly suggest the functional independence and differential regulation of the dopamine translocation process from the characteristics exhibited by its ligand binding domain. The lack of functional phenotypic ex pression of mutant DAT activities in cells co-expressing WT transporter is consistent with the contention that native DATs may exist as multisubunit complexes, the formation and maintenance of which is dependent upon sequences encoded within the carboxyl tail.	CLARKE INST PSYCHIAT,MOL NEUROBIOL LAB,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A8,CANADA; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; Emory University			Levey, Allan/F-2104-2011; Lee, Frank J.S./D-5899-2017	Levey, Allan/0000-0002-3153-502X; Lee, Frank J.S./0000-0002-5768-3776				BARKER EL, 1994, MOL PHARMACOL, V46, P799; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BERGER SP, 1994, MOL PHARMACOL, V46, P726; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1993, MOL BIOL FUNCTION CA, P284; BOJA JW, 1992, NEUROREPORT, V3, P247, DOI 10.1097/00001756-199203000-00007; BOJA JW, 1994, DOPAMINE RECEPTORS T, P611; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; CLINE EJ, 1992, J PHARMACOL EXP THER, V260, P1174; CODERRE PE, 1995, BIOCHEMISTRY-US, V34, P9762, DOI 10.1021/bi00030a014; COONS DM, 1995, J BACTERIOL, V177, P3251, DOI 10.1128/jb.177.11.3251-3258.1995; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; COREY JL, 1994, J BIOL CHEM, V269, P14759; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; DONOVAN DM, 1995, MOL BRAIN RES, V30, P327, DOI 10.1016/0169-328X(95)00018-N; DUE AD, 1995, BIOCHEMISTRY-US, V34, P5462, DOI 10.1021/bi00016a017; EDVARDSEN O, 1994, MOL BRAIN RES, V27, P265, DOI 10.1016/0169-328X(94)90009-4; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; ESHLEMAN AJ, 1995, J PHARMACOL EXP THER, V274, P276; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; GRACZ LM, 1995, J PHARMACOL EXP THER, V273, P1224; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HABERLAND N, 1987, J NEURAL TRANSM, V68, P289, DOI 10.1007/BF02098504; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Hoffman B. J, 1994, DOPAMINE RECEPTORS T, P645; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; KATZ JL, 1993, J PHARMACOL EXP THER, V264, P183; KAUFMAN MJ, 1992, SYNAPSE, V12, P99, DOI 10.1002/syn.890120203; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MASSERANO JM, 1994, J PHARMACOL EXP THER, V270, P133; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RITZ MC, 1993, BIOCHEM SOC SYMP, P51; ROSENZWEIGLIPSON S, 1992, PSYCHOPHARMACOLOGY, V107, P186, DOI 10.1007/BF02245136; ROTHMAN RB, 1992, PHARMACOL BIOCHEM BE, V43, P1135, DOI 10.1016/0091-3057(92)90493-Y; SAADOUNI S, 1994, EUR J PHARM-MOLEC PH, V268, P187, DOI 10.1016/0922-4106(94)90188-0; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SNYDER SH, 1986, NEUROLOGY, V36, P250, DOI 10.1212/WNL.36.2.250; SPEALMAN RD, 1989, J PHARMACOL EXP THER, V251, P142; STALEY JK, 1994, J PHARMACOL EXP THER, V271, P1678; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TATE CG, 1994, J BIOL CHEM, V269, P26303; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VALCHAR M, 1993, J NEUROCHEM, V60, P469, DOI 10.1111/j.1471-4159.1993.tb03174.x; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; VAUGEOIS JM, 1993, EUR J PHARMACOL, V230, P195, DOI 10.1016/0014-2999(93)90802-O; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; VEHYL M, 1993, J BIOL CHEM, V268, P25041; WALL SC, 1995, MOL PHARMACOL, V47, P544; WILSON JM, 1996, IN PRESS ANN NEUROL; WITKIN JM, 1994, NEUROSCI BIOBEHAV R, V18, P121, DOI 10.1016/0149-7634(94)90042-6; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; XU C, 1995, BIOCHEM PHARMACOL, V49, P339, DOI 10.1016/0006-2952(94)00485-5; ZAMANILLO D, 1995, NEUROSCI LETT, V188, P183, DOI 10.1016/0304-3940(95)11428-Y; ZOTTOLA RJ, 1995, BIOCHEMISTRY-US, V34, P9734, DOI 10.1021/bi00030a011	85	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20885	20894		10.1074/jbc.271.34.20885	http://dx.doi.org/10.1074/jbc.271.34.20885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702845	hybrid			2022-12-27	WOS:A1996VD33700097
J	Pastuszak, I; Drake, R; Elbein, AD				Pastuszak, I; Drake, R; Elbein, AD			Kidney N-acetylgalactosamine (GalNAc)-1-phosphate kinase, a new pathway of GalNAc activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED GLYCOSYLATION; EXPRESSION; ANTIGENS; RECEPTOR; MUCINS	A new enzyme that phosphorylates GalNAc at position 1 to form GalNAc-alpha-1P was purified similar to 1275-fold from the cytosolic fraction of pig kidney, and the properties of the enzyme were determined. The kinase is quite specific for GalNAc as the phosphate acceptor and is inactive with GlcNAc, ManNAc, glucose, galactose, mannose, GalN, and GlcN, This enzyme is clearly separated from galactokinase by chromatography on phenyl-Sepharose. The GalNAc kinase has a pH optimum between 8.5 and 9.0 and requires a divalent cation in the order Mg2+ > Mn2+ > Co2+, with optimum Mg2+ concentration at similar to 5 mM. The enzyme was most active with ATP as the phosphate donor, but slight activity was observed with ITP, acetyl-P, and phosphoenolpyruvate, Enzyme activity was highest in porcine and human kidney and porcine liver, but was low in most other tissues, Cultured HT-29 cells also had high activity for this kinase, The purified enzyme fraction was incubated with azido-[P-32]ATP, exposed to UV light, and run on SDS gels, A 50-kDa protein was labeled, and this labeling showed saturation kinetics with increasing amounts of the probe and was inhibited by unlabeled ATP, Although the most purified GalNAc kinase preparation still had two bands that labeled with ATP, maximum labeling of the 5O-kDa protein, but not the 66-kDa band, was coincident with maximum GalNAc kinase activity on a column of DEAE-Cibacron blue, On Sephacryl S-300, the native enzyme has a molecular mass of 48-51 kDa, indicating that the active kinase is a monomer, The product of the reaction was characterized as GalNAc-alpha-1-P by various chemical procedures.			Pastuszak, I (corresponding author), UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOL BIOL, LITTLE ROCK, AR 72205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17783] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; DAVIDSON E, 1996, AMINOSUGARS, P2; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DUA VK, 1986, J BIOL CHEM, V261, P1599; FUKUDA MN, 1989, BLOOD, V73, P84; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; ILYAS AA, 1985, P NATL ACAD SCI USA, V82, P6697, DOI 10.1073/pnas.82.19.6697; KAUSHAL GP, 1990, BIOCHEMISTRY-US, V29, P2168, DOI 10.1021/bi00460a030; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1968, BIOCHEM J, V107, P637, DOI 10.1042/bj1070637; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; PASTUSZAK I, 1996, IN PRESS J BIOL CHEM; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V50, P129, DOI 10.1016/0006-3002(61)91068-X; RAO BNN, 1988, CARBOHYD RES, V180, P111; REDDY P, 1989, J BIOL CHEM, V264, P17329; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SADLER JE, 1979, J BIOL CHEM, V254, P2112; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147	22	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20776	20782		10.1074/jbc.271.34.20776	http://dx.doi.org/10.1074/jbc.271.34.20776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702831	hybrid			2022-12-27	WOS:A1996VD33700083
J	Arion, D; Borkow, G; Gu, ZG; Wainberg, MA; Parniak, MA				Arion, D; Borkow, G; Gu, ZG; Wainberg, MA; Parniak, MA			The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TEMPLATE; BINDING; INHIBITION; RESISTANCE; 3'-AZIDO-3'-DEOXYTHYMIDINE; 5'-TRIPHOSPHATE; TERMINATION; MECHANISM; SUBSTRATE	The K65R mutation in HIV-1 reverse transcriptase (RT) is associated with viral cross-resistance to 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 2',3'-dideoxy-3'-thiacytidine. We have found that in vitro DNA synthesis by K65R RT is significantly more processive than that of wild type (wt) RT. Depending on the template/ primer (T/P) used, the total incorporation of nucleotides under single processive cycle conditions was 20-50% higher with K65R RT than with wt RT. With heteropolymeric T/P, the total incorporation of dNMP by K65R and wt RT was similar under continuous DNA synthesis reaction conditions. However, under single processive cycle conditions, the rate of full-length polymerization product synthesis by K65R RT was about S-fold higher than that by wt RT. We also found a decreased rate of T/P dissociation during K65R RT DNA synthesis, which is consistent with the increased processivity of the enzyme. We postulate that the increased processivity of the R65R RT may be a compensatory response to the decreased affinity of this mutant for certain dNTP substrates, allowing normal viral replication kinetics.	SMBD JGH,LADY DAVIS INST MED RES,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,AIDS CTR,SIR MORTIMER B DAVIS JEWISH GEN HOSP,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University			Borkow, Gadi/W-4294-2019					ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; CHENG N, 1993, BIOCHEMISTRY-US, V32, P7630, DOI 10.1021/bi00081a005; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DUBE DK, 1976, BIOCHEMISTRY-US, V15, P3605, DOI 10.1021/bi00661a031; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RICHMAN DD, 1993, ANNU REV PHARMACOL, V33, P149, DOI 10.1146/annurev.pa.33.040193.001053; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WU J, 1993, J BIOL CHEM, V268, P9980	25	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19860	19864		10.1074/jbc.271.33.19860	http://dx.doi.org/10.1074/jbc.271.33.19860			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702696	hybrid			2022-12-27	WOS:A1996VC66900037
J	Ekena, K; Weis, KE; Katzenellenbogen, JA; Katzenellenbogen, BS				Ekena, K; Weis, KE; Katzenellenbogen, JA; Katzenellenbogen, BS			Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING; CRYSTAL-STRUCTURE; PROMOTER-CONTEXT; MUTAGENESIS; ANTIESTROGENS; CYSTEINES; RESIDUES; MUTANTS	The initial step in the regulation of the transcriptional activity of the estrogen receptor (ER) is the binding of hormone, Previous studies have suggested that the region between amino acids 515 and 535 near the C terminus of the human ER is likely to be important in ligand binding. In order to explicitly define which amino acids in this region are critical for ligand recognition and binding, we have utilized alanine-scanning mutagenesis over the complete 515-535 region, The ability of these 21 mutants to activate transcription in response to the natural estrogen, 17 beta-estradiol (E(2)), was evaluated in cell co-transfection assays with estrogen-responsive reporter genes, In addition, their ability to bind E(2) was also tested. Mutations at four sites in the 521-528 region had the greatest effects on E(2)-induced transcription, with L525A reducing responsiveness 250-fold, G521A and H524A 35-fold, and M528A 11-fold. Mutations at other sites had either no effect or a 4-fold or lesser reduction in sensitivity to E(2) (M517A, Y526A, N532A, and P535A). Three of the mutants most affected in their transcriptional response, G521A, H524A, and M528A, showed a coordinate reduction in E(2) binding affinity, E(2) binding by the most affected mutant, L525A, could not be detected, Thus, the altered transcriptional response of these ER mutants appears to derive solely from an alteration in their affinity for the ligand E(2). The four sites most affected by alanine substitution, 521, 524, 525, and 528, follow an alpha-helical periodicity, such that they would be positioned on one face of an alpha-helix, Furthermore, they correspond precisely to residues in an alpha-helix shown to be in contact with ligand in the recently described x-ray crystal structures of two other members of the nuclear hormone receptor superfamily, namely the retinoic acid receptor- and thyroid hormone receptor-ligand complexes. Our findings, which broaden observations to the steroid receptor family within the superfamily of nuclear receptors, suggest that this region of the estrogen receptor is in contact with its cognate ligand in a similar fashion.	UNIV ILLINOIS, DEPT MOL & INTEGRAT PHYSIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT CHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CANCER INSTITUTE [F32CA068653, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015556] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA68653, 2R37CA18119] Funding Source: Medline; NIDDK NIH HHS [2R37DK15556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; PAKDEL F, 1993, MOL ENDOCRINOL, V7, P1408, DOI 10.1210/me.7.11.1408; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; READ LD, 1991, ADV CELLULAR MOL BIO, P277; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; REESE JC, 1991, J BIOL CHEM, V266, P10880; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sarrel P.M., 1994, SCI MED, V1, P44; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	33	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20053	20059		10.1074/jbc.271.33.20053	http://dx.doi.org/10.1074/jbc.271.33.20053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702724	hybrid			2022-12-27	WOS:A1996VC66900065
J	Lavie, Y; Cao, HT; Bursten, SL; Giuliano, AE; Cabot, MC				Lavie, Y; Cao, HT; Bursten, SL; Giuliano, AE; Cabot, MC			Accumulation of glucosylceramides in multidrug-resistant cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID SYNTHESIS; P-GLYCOPROTEIN; TUMOR PROGRESSION; LEUKEMIA-CELLS; BIOSYNTHESIS; INHIBITION; SYNTHASE; MELANOMA; CERAMIDE; GENE	Multidrug-resistant (MDR) tumors and cancer cell lines demonstrate a wide variety of biochemical changes. In this study we used drug-sensitive wild-type (wt) cancer cell lines and respective MDR subclones, and we demonstrate the accumulation of distinct lipids in MDR cells. These lipids were either absent or present at very low levels in drug-sensitive cells. The compounds, termed lipid-1 and lipid-2, migrated on thin-layer chromatography as a doublet. They could be radiolabeled by incubating MCF-7-AdrR (Adriamycin-resistant) breast cancer cells with [H-3]serine, [H-3]palmitic acid, or [H-3]galactose. Utilization of these precursors by MCF-7-wt cells for synthesis of lipid-1 and -2 was minimal. Two inhibitors of sphingolipid biosynthesis, L-cycloserine and fumonisin B-1, prevented the observed accumulation of the lipid compounds. An inhibitor of glucosylceramide synthesis, 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, completely abolished the formation of lipid-1 and -2 in MCF-7-AdrR cells and, to a lesser extent, inhibited the formation of lactosylceramides and gangliosides. Utilizing mass spectrometry, the multidrug resistance-associated lipids were further characterized as monoglycosylceramides of two major species that contained either 16-carbon (palmitic) or 24-carbon (lignoceric and nervonic) fatty acids. The carbohydrate head group of glycosylceramides was identified as glucose, not galactose, thus designating the accumulated lipids as glucosylceramides. Incorporation of [H-3]palmitic acid into glucosylceramide was strikingly higher (8-10 times) in MCF-7-AdrR cells compared with MCF-7-wt cells. Since the rate of glucosylceramide degradation in MCF-7-AdrR cells was not attenuated, accelerated glycosphingolipid synthesis in MDR cells is suggested. Glucosylceramide also accumulated in KBV-1, a vinblastine-resistant epidermoid carcinoma but not in KB-3-1, drug-sensitive wt cells. MDR ovarian adenocarcinoma cells (NIH:OVCAR-3) also contained elevated levels of glucosylceramide. Our results demonstrate a correlation between cellular drug resistance and alterations in glucosylceramide metabolism.	ST JOHNS HOSP,JOHN WAYNE CANC INST,SANTA MONICA,CA 90404; CTR HLTH,SANTA MONICA,CA 90404	John Wayne Cancer Institute								ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; BIEDLER JL, 1983, CANCER TREAT REP, V67, P859; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; FURUYA S, 1995, J NEUROCHEM, V65, P1551; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRABOWSKI GA, 1990, CRC CRIT REV BIOCH M, V25, P384; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAREL R, 1993, J BIOL CHEM, V268, P14476; HOLLERAN WM, 1986, CANCER CHEMOTH PHARM, V17, P11, DOI 10.1007/BF00299859; LEE KJ, 1985, CARBOHYD RES, V144, P148, DOI 10.1016/0008-6215(85)85015-1; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MORTON DL, 1994, PROG BRAIN RES, V101, P251; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RAMU A, 1984, CANCER TREAT REP, V68, P637; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SABBATINI ARM, 1994, INT J CANCER, V59, P208, DOI 10.1002/ijc.2910590212; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; TAKI T, 1986, J BIOL CHEM, V261, P3075; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; Vance DE., 1985, BIOCH LIPIDS MEMBRAN; VOLM M, 1993, CANCER, V71, P3981, DOI 10.1002/1097-0142(19930615)71:12<3981::AID-CNCR2820711231>3.0.CO;2-A; WANG E, 1991, J BIOL CHEM, V266, P14486; WELSH CJ, 1994, BIOCHEM BIOPH RES CO, V202, P211, DOI 10.1006/bbrc.1994.1914; WELSH CJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P41, DOI 10.1006/abbi.1994.1468; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836	44	299	321	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19530	19536		10.1074/jbc.271.32.19530	http://dx.doi.org/10.1074/jbc.271.32.19530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702646	hybrid			2022-12-27	WOS:A1996VB68400080
J	Minami, Y; Hohfeld, J; Ohtsuka, K; Hartl, FU				Minami, Y; Hohfeld, J; Ohtsuka, K; Hartl, FU			Regulation of the heat-shock protein 70 reaction cycle by the mammalian DnaJ homolog, Hsp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; NASCENT POLYPEPTIDE-CHAINS; SUBSTRATE-BINDING; ATPASE ACTIVITY; MOLECULAR CHAPERONE; PEPTIDE-BINDING; ENDOPLASMIC-RETICULUM; SECONDARY STRUCTURE; HSP70; TRANSLOCATION	The effects of the human DnaJ homolog, Hsp40, on the ATPase and chaperone functions of the constitutively expressed Hsp70 homolog, Hsc70, were analyzed. Hsp40 stimulates the hydrolysis of ATP by Hsc70, causing a similar to 7-fold increase in its steady-state ATPase activity, In contrast to the prokaryotic Hsp70 system, ATP-hydrolysis and not the release of bound ADP is the rate-limiting step in the overall ATPase cycle of mammalian Hsc70. The ability to activate the Hsc70 ATPase is partially preserved in a deletion mutant containing the J-domain and the G/F region of Hsp40 but not in a deletion mutant that contains the J-domain alone, As a result of its ATPase stimulating activity, addition of Hsp40 allows Hsc70 to bind peptide in the presence of ATP, whereas in the absence of Hsp40, peptide is efficiently released upon ATP binding to Hsc70. The functional cooperation of Hsp40 with Hsc70 is essential to ensure the ATP hydrolysis-dependent binding of aggregation-sensitive denatured polypeptides, such as thermally denatured firefly luciferase and chemically denatured rhodanese, Binding of these proteins results in the formation of ternary complexes of Hsc70, Hsp40, and substrates. Hsc70 and Hsp40 cooperate with further factors in protein renaturation, as demonstrated by the finding that luciferase, thermally denatured in the presence of Hsc70, Hsp40, and ATP, refolds upon addition of rabbit reticulocyte cytosol, Our results indicate that Hsp40 has a critical regulatory function in the Hsc70 ATPase cycle that is required for the efficient loading of peptide substrate onto Hsc70.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Aichi Cancer Center			Hartl, F. Ulrich/Y-8206-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048742] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48742] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE S, V77, P3; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; HOHFELD J, 1995, CELL, V83, P589; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MORGHAUSER RC, 1995, BIOCHEMISTRY-US, V24, P6261; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; QUIAN YQ, 1996, IN PRESS J MOL BIOL; SAMBROOK J, 1989, MOL CLONING LAB MOL; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TANDON S, 1986, J BIOL CHEM, V261, P5615; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WANG TF, 1993, J BIOL CHEM, V268, P26049; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	52	277	298	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19617	19624		10.1074/jbc.271.32.19617	http://dx.doi.org/10.1074/jbc.271.32.19617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702658	hybrid			2022-12-27	WOS:A1996VB68400092
J	Clark, R; Olson, K; Fuh, G; Marian, M; Mortensen, D; Teshima, F; Chang, S; Chu, H; Mukku, V; CanovaDavis, E; Somer, T; Cronin, M; Winkler, M; Wells, JA				Clark, R; Olson, K; Fuh, G; Marian, M; Mortensen, D; Teshima, F; Chang, S; Chu, H; Mukku, V; CanovaDavis, E; Somer, T; Cronin, M; Winkler, M; Wells, JA			Long-acting growth hormones produced by conjugation with polyethylene glycol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT INTERLEUKIN-2; BINDING-PROTEIN; MOLECULAR-BASIS; RECEPTOR; CLEARANCE; DOMAIN; SERUM; RATS	Derivatives of human growth hormone (hGH) of in creasing size were produced by reaction with the N-hydroxysuccinimide ester of polyethylene glycol-5000 (PEG(5000)), a 5-kDa reagent that selectively conjugates to primary amines, By adjusting the reaction conditions and purification procedure, it was possible to isolate hGH derivatives containing up to seven PEG moieties that altered the Stokes radius and thereby the effective molecular masses of the unmodified hormone from 22 to 300 kDa. Fortunately, the most reactive amines were ones that did not lie in either of the two sites important for receptor binding, Nonetheless, increasing the level of PEG modification linearly reduced the affinity of hGH for its receptor and increased the EC(50) in a cell-based assay up to 1500-fold. Most of the reduction in affinity was the result of slowing the association rate for the receptor, The clearance rate of hGH in rats was inversely proportional to effective molecular weight and closely fit a filtration model, We have tested the potency of these analogs by injecting them daily or every 6 days into hypophysectomized rats and determining the effects on body and organ growth, The efficacy of these analogs was optimal for hGH conjugated with 5 eq of PEG(5000), and the potency was increased by about 10-fold compared with unmodified hGH. Such PEG-hGH derivatives show promise as long-acting alternatives to daily injections of hGH. More generally these studies show that improving hormone clearance properties, even at the expense of reducing receptor binding affinity, can lead to dramatic increases in hormone efficacy.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT RECOVERY SCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACOKINET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT QUAL CONTROL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOORGAN CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582; ALBINI CH, 1991, PEDIATR RES, V29, P619, DOI 10.1203/00006450-199106010-00019; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BUCKMANN AF, 1981, MAKROMOL CHEM, V182, P1379; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOODSON RJ, 1990, BIO-TECHNOL, V8, P343, DOI 10.1038/nbt0490-343; GROESBECK MD, 1987, ENDOCRINOLOGY, V120, P1963, DOI 10.1210/endo-120-5-1963; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; JOHNSON V, 1977, AM J PHYSIOL, V233, P185; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KOHR WJ, 1982, ANAL BIOCHEM, V122, P348, DOI 10.1016/0003-2697(82)90294-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIEBERMAN SA, 1992, J CLIN ENDOCR METAB, V75, P30, DOI 10.1210/jc.75.1.30; MORDENTI J, 1991, PHARMACEUT RES, V8, P1351, DOI 10.1023/A:1015836720294; PERRIN DD, 1965, INT UNION PURE APPL, P353; ROBINSON ICA, 1987, GROWTH HORMONE BASIC, P109; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; VENKATACHALAM MA, 1978, CIRC RES, V43, P337, DOI 10.1161/01.RES.43.3.337; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; Zalipsky S., 1992, POLYETHYLENE GLYCOL, P347	25	212	367	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21969	21977		10.1074/jbc.271.36.21969	http://dx.doi.org/10.1074/jbc.271.36.21969			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703002	hybrid			2022-12-27	WOS:A1996VF61200044
J	Kojima, N; Kono, M; Yoshida, Y; Tachida, Y; Nakafuku, M; Tsuji, S				Kojima, N; Kono, M; Yoshida, Y; Tachida, Y; Nakafuku, M; Tsuji, S			Biosynthesis and expression of polysialic acid on the neural cell adhesion molecule is predominantly directed by ST8Sia II/STX during in vitro neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; IN-VITRO; CLONING; FAMILY; STX; ALPHA-2,8-SIALYLTRANSFERASE; POLYSIALYLTRANSFERASE; MIGRATION; SYSTEM; BRAIN	We have reported recently that ST8Sia II/STX as well as ST8Sia IV/PST-1 is a neural cell, adhesion molecule (NCAM)-specific polysialic acid (PSA) synthase (Kojima, N., Tachida, Y., Yoshida, Y., and Tsuji, S. (1996) J. Biol. Chem. 271, 19457-19463). To investigate which of two PSA synthase (ST8Sia II and IV) are involved in the biosynthesis of PSA associated with NCAM, the expressions of PSA, PSA synthase activity, and the genes of two PSA synthases during in vitro neuronal differentiation of mouse embryonal carcinoma P19 cells were determined. PSA was not expressed on undifferentiated cells (day 0) or cell aggregates (days 1-3) induced with retinoic acid. Expression of PSA began after cell aggregates had been dissociated and re-plated on a dish (day 4) and increased up to day 7. The expression of the mouse ST8Sia II gene was negligible in both undifferentiated and aggregated cells, it beginning at day 4 then dramatically increasing, and reaching the maximum level at days 6-7. On the other hand, transcription of the ST8Sia IV gene remained at a very low level throughout the entire period, a significant increase in its expression during differentiation not being observed. PSA synthase activity was not detected in undifferentiated or aggregated P19 cells, it increasing in parallel with ST8Sia II gene expression during differentiation. In addition, the cells at day 7 were stained with an anti-mouse ST8Sia II antiserum. Similar up-regulation of the ST8Sia II gene were observed during the differentiation of rat MNS-8 cells, which were derived from E-12 rat neuroepithelium of the neural tube and shown to differentiate into neurons. These results indicate that ST8Sia II predominantly directs PSA expression during neuronal differentiation rather than ST8Sia IV.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; NARA INST SCI & TECHNOL,GRAD SCH BIOL SCI,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN	RIKEN; Nara Institute of Science & Technology			Nakafuku, Masato/J-3068-2013; Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Kono, Mari/0000-0003-2447-4350; Nakafuku, Masato/0000-0001-7783-9005				BOER PH, 1993, EXP CELL RES, V207, P421, DOI 10.1006/excr.1993.1210; Bruses JL, 1995, J NEUROSCI, V15, P8310; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HUSMANN M, 1989, DEV BIOL, V136, P194, DOI 10.1016/0012-1606(89)90141-3; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; TNAG J, 1994, NEURON, V13, P405; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WANG C, 1994, J NEUROSCI, V14, P4446; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	25	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22058	22062		10.1074/jbc.271.36.22058	http://dx.doi.org/10.1074/jbc.271.36.22058			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703013	hybrid			2022-12-27	WOS:A1996VF61200055
J	Johnson, JL; Fenton, S; Sheffield, LG				Johnson, JL; Fenton, S; Sheffield, LG			Prolactin inhibits epidermal growth factor-induced Ras-MAPK signaling in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EGF-RECEPTOR; TYROSINE PHOSPHORYLATION; INDUCED PROLIFERATION; PLASMA-MEMBRANE; DNA-SYNTHESIS; SH2 DOMAIN; MOUSE; ACTIVATION; DIFFERENTIATION	Previously, our laboratory has shown that prolactin (PRL) inhibits epidermal growth factor (EGF)-induced DNA synthesis. One pathway for the initiation of DNA synthesis is EGF-receptor (EGF-R) signaling through Ras and mitogen-activated protein kinase (MAPK). To determine the effects of PRL on EGF-induced MAPK activation and phosphorylation, MAPK or phosphotyrosine (Tyr(P)) was immunoprecipitated from normal murine mammary epithelial (NMuMG) cells treated with PRL (100 ng/ml) and/or EGF (10 ng/ml) for 10-min periods. EGF-induced phosphorylation and activation were then examined by Western analysis and a myelin basic protein (MBP)-specific kinase assay. The p42 isoform of MAPK showed a distinct decrease in activity and phosphorylation when cells were treated with PRL. Concluding that PRL affects EGF signaling upstream of MAPK, we examined the effect of PRL on EGF-induced Ras activity. NMuMG cells were incubated with [P-32]orthophosphoric acid, treated as described above, immunoprecipitated with an antibody specific to Ras, and nucleotides were eluted and separated by TLC. Ras activity as measured by GTP:GDP ratio was increased by EGF, but not by PRL. Additionally, PRL, in combination with EGF abolished the ability of EGF to induce Ras activity, Those studies suggest that PRL alters the EGF signaling pathway upstream of Ras. Because Ras activation by EGF involves EGF-stimulated association of EGF-R with Grb2, the EGF-R was immunoprecipitated and a Western blot was probed for Grb2. As expected we found that EGF stimulated an association of EGF-R with Grb2, PRL, however, blocked this association. When we looked at the ability of Shc to associate with the EGF-R, we found that PRL and EGF had little effect on this association. The studies demonstrate that PRL either directly or indirectly inhibits the ability of EGF to induce EGF-R association with Grb2, to activate Ras, and to activate and phosphorylate MAPK.	UNIV WISCONSIN, ENDOCRINOL REPROD PHYSIOL PROGRAM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD031532, R29HD024094] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24094, HD 31532] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANERJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61, DOI 10.1016/0303-7207(92)90102-C; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FENTON SE, 1993, MOL BIOL CELL, V4, P773, DOI 10.1091/mbc.4.8.773; FENTON SE, 1991, BIOCHEM BIOPH RES CO, V181, P1063, DOI 10.1016/0006-291X(91)92045-L; FENTON SE, 1994, EXP CELL RES, V210, P102, DOI 10.1006/excr.1994.1015; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GILL GN, 1987, J CELL PHYSIOL, P35; Gill J.L., 1978, DESIGN ANAL EXPT ANI, V1st; Gotoh N, 1995, ONCOGENE, V11, P2525; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OWENS RB, 1974, J NATL CANCER I, V52, P1375, DOI 10.1093/jnci/52.4.1375; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; TAKETANI Y, 1983, ENDOCRINOLOGY, V113, P871, DOI 10.1210/endo-113-3-871; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERBOOM RJ, 1993, J CELL PHYSIOL, V156, P367, DOI 10.1002/jcp.1041560220; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; YANG J, 1980, ENDOCRINOLOGY, V107, P35, DOI 10.1210/endo-107-1-35; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	40	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21574	21578		10.1074/jbc.271.35.21574	http://dx.doi.org/10.1074/jbc.271.35.21574			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702944	hybrid			2022-12-27	WOS:A1996VE47700090
J	LeGac, NT; Villani, G; Hoffmann, JS; Boehmer, PE				LeGac, NT; Villani, G; Hoffmann, JS; Boehmer, PE			The UL8 subunit of the herpes simplex virus type-1 DNA helicase-primase optimizes utilization of DNA templates covered by the homologous single-strand DNA-binding protein ICP8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCTS; PRIMER SYNTHESIS; INSECT CELLS; REPLICATION; COMPLEX; POLYMERASE; BACTERIOPHAGE-T4; IDENTIFICATION; PURIFICATION; ASSOCIATION	The herpes simplex virus type-1 DNA helicase-primase is a heterotrimer encoded by the UL5, UL8, and UL52 genes. The core enzyme, specified by the UL5 and UL52 genes, retains DNA helicase, DNA-dependent nucleoside triphosphatase, and primase activities. The UL8 subunit has previously been implicated in increasing primer stability and in stimulating primer synthesis by the core enzyme. To further characterize the function of the UL8 subunit, we have examined its effect on the activities of the UL5/52 core enzyme using DNA templates covered by the herpes simplex virus type-1 single-strand DNA-binding protein ICP8. We found that while ICP8 stimulated the DNA helicase activity of the UL5/52 proteins up to 3-fold, maximum stimulation by ICP8 required the presence of UL8 protein. Moreover, UL8 protein was required to reverse the inhibitory effect of ICP8 on the DNA-dependent ATPase and primase activities of the UL5/52 proteins. These observations were specific for ICPS since the heterologous Escherichia coli single-strand DNA-binding protein could not substitute for ICP8. These data suggest that UL8 protein mediates an interaction between the UL5/52 core enzyme and ICP8 that optimizes the utilization of ICP8-covered DNA templates during DNA replication.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; CNRS,INST PHARMACOL & BIOL STRUCT,F-31077 TOULOUSE,FRANCE	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARADARAN K, 1994, J VIROL, V68, P4251, DOI 10.1128/JVI.68.7.4251-4261.1994; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; GUPTE SS, 1991, J BIOL CHEM, V266, P11413; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Kornberg A., 1992, DNA REPLICATION; LEE CK, 1985, J VIROL, V54, P731, DOI 10.1128/JVI.54.3.731-738.1985; Liptak LM, 1996, J VIROL, V70, P1759, DOI 10.1128/JVI.70.3.1759-1767.1996; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; PARRY ME, 1993, J GEN VIROL, V74, P607, DOI 10.1099/0022-1317-74-4-607; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; THOMAS MS, 1992, J VIROL, V66, P1152, DOI 10.1128/JVI.66.2.1152-1161.1992; VAUGHAN PJ, 1985, J VIROL, V53, P501, DOI 10.1128/JVI.53.2.501-508.1985; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	39	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21645	21651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702953				2022-12-27	WOS:A1996VE47700099
J	Riikonen, A; Rouvinen, J; Tikkanen, R; Julkunen, I; Peltonen, L; Jalanko, A				Riikonen, A; Rouvinen, J; Tikkanen, R; Julkunen, I; Peltonen, L; Jalanko, A			Primary folding of aspartylglucosaminidase - Significance of disulfide bridges and evidence of early multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; DIHYDROFOLATE-REDUCTASE; DNA-TRANSFECTION; MUTATION; CONSEQUENCES; PROTEASOME; COMPLEX; DISEASE; CDNA	Aspartylglucosaminidase (AGA) is a lysosomal enzyme involved in the degradation of N-linked glycoproteins in lysosomes. AGA is synthesized as an inactive precursor molecule, which is rapidly activated in the endoplasmic reticulum by a proteolytic cleavage into alpha- and beta-subunits. We have recently determined the three-dimensional structure of AGA and shown that it is a globular molecule with a heterotetrameric (alpha beta)(2) structure, On the basis of structural and functional analyses, AGA seems to be the first mammalian protein belonging to a newly described protein family, the N-tepminal nucleophile hydrolases, Because the activation of the prokaryotic members of the N-terminal nucleophile hydrolase family seems to be triggered by the assembly of the subunits, we have studied the initial folding and oligomerization of AGA and provide evidence that dimerization of two precursor molecules in the endoplasmic reticulum is a prerequisite for the activation of AGA To gain further information on the structural determinants influencing the early folding of AGA, we used site-specific mutagenesis of cysteine residues to define the role of intrachain disulfide bridges in the folding and activation of the enzyme. The N-terminal disulfide bridges in both the alpha- and beta-subunits seem to have only a stabilizing role, whereas the C-terminal disulfide bridge in both subunits evidently plays an important role in the early folding and activation of AGA.	NATL PUBL HLTH INST,DEPT HUMAN MOL GENET,FIN-00300 HELSINKI,FINLAND; NATL PUBL HLTH INST,DEPT VIROL,FIN-00300 HELSINKI,FINLAND; UNIV JOENSUU,DEPT CHEM,FIN-80101 JOENSUU,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Eastern Finland				Tikkanen, Ritva/0000-0002-8393-1825				BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Peltola M, 1996, HUM MOL GENET, V5, P737, DOI 10.1093/hmg/5.6.737; POLLITT RJ, 1968, LANCET, V2, P253; RIIKONEN A, 1994, DNA CELL BIOL, V13, P257, DOI 10.1089/dna.1994.13.257; RUKONEN A, 1995, J BIOL CHEM, V270, P4903; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; Tikkanen R, 1996, PROTEINS, V24, P253; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	24	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21340	21344		10.1074/jbc.271.35.21340	http://dx.doi.org/10.1074/jbc.271.35.21340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702913	hybrid			2022-12-27	WOS:A1996VE47700059
J	Schaufele, F				Schaufele, F			CCAAT/Enhancer-binding protein alpha activation of the rat growth hormone promoter in pituitary progenitor GNFT1-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-ZIPPER; GENE-EXPRESSION; ANTERIOR-PITUITARY; THYROID-HORMONE; TRANSCRIPTION FACTORS; RESPONSE ELEMENTS; TRANSGENIC MICE; MESSENGER-RNA; C/EBP-ALPHA; DNA-BINDING	High level, anterior pituitary-specific expression of the sat growth hormone (rGH) promoter requires cooperative actions of several different transcription factors, Previously, we described a series of multisubunit, tissue-general, transcription factor complexes that bound to the GHF3 activation site and strongly regulated rGH promoter activity, A 43-kDa DNA-binding subunit common to each of the different GHF3 complexes is identified here as the transcription factor, CCAAT/Enhancer-binding Protein alpha (C/EBP alpha). In human monocyte U937 cells, which do not express the endogenous or transfected GH genes, co-expression of C/EBP alpha and Pit-1 synergistically activated the transfected rGH promoter. Full-length C/EBP alpha was present in the GH-secreting GC, and prolactin-secreting 235-1, pituitary cell lines, but not in GNFT1-5 cells, which are transformed at a stage in development immediately prior to GH expression, Transient expression of C/EBP alpha in GHFTI-5 cells strongly activated the co-transfected rGH promoter through the GHF3 binding site; a second activation site mapped to evolutionary conserved GP promoter sequences between -106 and -33. C/EBP alpha activation was synergistic with phorbol 12-myristate 13-acetate and forskolin, activators of protein kinases C and A, respectively. Thus, C/EBP alpha is an important regulator of rGH promoter activity that appears to function in synergy with Pit-1, activators of A and C protein kinases and possibly other factors.			Schaufele, F (corresponding author), UNIV CALIF SAN FRANCISCO,METAB RES UNIT,HSW-1141,SAN FRANCISCO,CA 94143, USA.							ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KUO CF, 1990, DEVELOPMENT, V109, P473; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE KAW, 1992, J CELL SCI, V103, P9; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NISHIZUKA Y, 1983, TRENDS BIOCHEM SCI, V8, P13, DOI 10.1016/0968-0004(83)90061-0; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SCHAUFELE F, 1990, NUCLEIC ACIDS RES, V18, P5235, DOI 10.1093/nar/18.17.5235; SCHAUFELE F, 1994, PITUITARY GLAND, P91; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YE ZS, 1987, J BIOL CHEM, V262, P6313	54	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21484	21489		10.1074/jbc.271.35.21484	http://dx.doi.org/10.1074/jbc.271.35.21484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702932	hybrid			2022-12-27	WOS:A1996VE47700078
J	Gately, DP; Howell, SB				Gately, DP; Howell, SB			Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SP1-MEDIATED TRANSCRIPTION; TYROSINE PHOSPHORYLATION; GENOTOXIC STRESS; DNA DAMAGE; GENE; INDUCTION; CELLS; PROTEINS; FAMILY	The GADD153 promoter is transcriptionally activated by paclitaxel-induced injury. Promoter deletion from -786 to -85 base pairs relative to the start of transcription had no significant effect on activation, but deletion to the TATA box abolished it. Placement of the 39 bases from -74 to the TATA box (cellular injury response element, CIRE) upstream of the adenovirus E4 TATA box conferred paclitaxel inducibility. The only consensus sequence present in the CIRE is an Sp1 site; mutation of this site inhibited paclitaxel activation. Paclitaxel failed to activate a SV40-driven luciferase construct containing five Sp1 sequences, and Sp1 sites further upstream in the GADD153 promoter were not essential for activation. Pure Sp1 and nuclear extracts from uninjured and paclitaxel-injured cells protected the same region from -62 to -48 bases on the noncoding strand and -74 to -53 on the coding strand. Nuclear extracts shifted the CIRE to the same extent as purified Sp1 but had no effect on a CIRE with a mutated Sp1 site in gel shift assays. Immunodepletion of Sp1 abolished the shift; antibody to Sp1 produced a supershift. These data indicate that paclitaxel activates the GADD153 promoter through a constitutively occupied Sp1 site at -61 bases.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Gately, DP (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOMED SCI, 9500 GILMAN DR 0812, LA JOLLA, CA 92093 USA.							BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; LUETHY JD, 1992, CANCER RES, V52, P5; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	34	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20588	20593		10.1074/jbc.271.34.20588	http://dx.doi.org/10.1074/jbc.271.34.20588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702804	hybrid			2022-12-27	WOS:A1996VD33700056
J	Kim, DR; McHenry, CS				Kim, DR; McHenry, CS			Biotin tagging deletion analysis of domain limits involved in protein-macromolecular interactions - Mapping the tau binding domain of the DNA polymerase III alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; ESCHERICHIA-COLI; GAMMA-SUBUNIT; ACCESSORY PROTEINS; REPLICATION FORK; EPSILON-SUBUNIT; THETA-SUBUNIT; SIZE CLASSES; HOLOENZYME; GENE	The tau subunit dimerizes DNA polymerase III via interaction with the alpha subunit, snowing DNA polymerase III holoenzyme to synthesize both leading and lagging strands simultaneously at the DNA replication forb. Here, we report a general method to map the limits of domains required for heterologous protein-protein interactions using surface plasmon resonance. The method employs fusion of a short biotinylation sequence at either the NH2 or COOH terminus of the protein to be immobilized on streptavidin-derivatized biosensor chips. inclusion of a hexahistidine sequence permits rapid purification and separation of the fusion protein from the endogenous Escherichia coli biotin carboxyl carrier protein. Ten deletions of the alpha subunit were constructed and purified by Ni2+-nitrilotriacetic acid chromatography and, when required, monomeric avidin chromatography. Each alpha deletion protein was captured by streptavidin immobilized on a Pharmacia Biosensor BIAcore chip, and the tau binding activity of each alpha deletion was analyzed using surface plasmon resonance. The tau subunit bound very tightly to a full-length amino-terminal fusion of the biotinylation sequence with alpha (K-D similar to 70 pM). Four additional NH2-terminal alpha deletion proteins (60, 240, 360, and 542 residues deleted) retained strong binding activity to the tau subunit (K-D = 0.19-0.39 nM), whereas deletion of 705 residues or more from the NH2 terminus of the alpha subunit abolished tau binding activity. Full-length alpha that contained a carboxyl-terminal fusion with the biotinylation sequence bound tau strongly (K-D = 0.37 nM). However, deletion of 48 amino acids from the COOH terminus totally eliminated tau binding. These results indicate that the COOH-terminal half of the alpha subunit is involved in tau interaction.			Kim, DR (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262, USA.							BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; CROMAN JE, 1990, J BIOL CHEM, V265, P10327; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; KORNBERG A, 1988, J BIOL CHEM, V263, P1; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LANZER M, 1988, THESIS U HEIDELBERG; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1985, J BIOL CHEM, V260, P2982; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WELCH MM, 1982, J BACTERIOL, V152, P351; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074	41	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20690	20698		10.1074/jbc.271.34.20690	http://dx.doi.org/10.1074/jbc.271.34.20690			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702819	hybrid			2022-12-27	WOS:A1996VD33700071
J	Schinke, T; Amendt, C; Trindl, A; Poschke, O; MullerEsterl, W; JahnenDechent, W				Schinke, T; Amendt, C; Trindl, A; Poschke, O; MullerEsterl, W; JahnenDechent, W			The serum protein alpha(2)-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells - A possible role in mineralization and calcium homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-HS GLYCOPROTEIN; HUMAN ALPHA-2-HS-GLYCOPROTEIN; BOVINE FETUIN; CRYSTAL-FORMATION; INSULIN-RECEPTOR; HS-GLYCOPROTEIN; TYROSINE KINASE; HUMAN-BONE; A-CHAIN; RAT	We present data suggesting a function of alpha(2)-HS glycoproteins/fetuins in serum and in mineralization, namely interference with calcium salt precipitation. Fetuins occur in high serum concentration during fetal life. They accumulate in bones and teeth as a major fraction of noncollagenous bone proteins, The expression pattern in fetal mice confirms that fetuin is predominantly made in the liver and is accumulated in the mineralized matrix of bones, We arrived at a hypothesis on the molecular basis of fetuin function in bones using primary rat calvaria osteoblast cultures and salt precipitation assays. Our results indicate that fetuins inhibit apatite formation both in cell culture and in the test tube, This inhibitory effect is mediated by acidic amino acids clustering in cystatin-like domain D1, Fetuins account for roughly half of the capacity of serum to inhibit salt precipitation. We propose that fetuins inhibit phase separation in serum and modulate apatite formation during mineralization.	UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Jahnen-Dechent, Willi/A-7608-2011	Jahnen-Dechent, Willi/0000-0003-1315-4407				ASHTON BA, 1976, CALC TISS RES, V22, P27; BELLOWS CG, 1994, ENDOCRINOLOGY, V134, P2221, DOI 10.1210/en.134.5.2221; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BLUMENTHAL NC, 1975, CALC TISS RES, V18, P81, DOI 10.1007/BF02546228; BROWN WM, 1992, EUR J BIOCHEM, V205, P321, DOI 10.1111/j.1432-1033.1992.tb16783.x; CLARK G, 1981, STAINING PROCEDURES, P187; COLCLASURE GC, 1988, J CLIN ENDOCR METAB, V66, P187, DOI 10.1210/jcem-66-1-187; DICKSON IR, 1985, CONNECT TISSUE RES, V14, P77, DOI 10.3109/03008208509089845; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; Dziegielewska K., 1995, MOL BIOL INTELLIGENC; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; ELZANOWSKI A, 1988, FEBS LETT, V227, P167, DOI 10.1016/0014-5793(88)80890-1; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FALQUERHO L, 1991, GENE, V98, P209, DOI 10.1016/0378-1119(91)90175-B; GARNETT J, 1990, BIOCHEM J, V266, P863; HAYASE T, 1992, BIOCHEMISTRY-US, V31, P4915, DOI 10.1021/bi00135a024; HOGAN BL, 1995, MANIPULATING MOUSE E; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; MBUYI JM, 1982, CALCIFIED TISSUE INT, V34, P229, DOI 10.1007/BF02411242; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; NAGADOME H, 1993, FEBS LETT, V317, P128, DOI 10.1016/0014-5793(93)81506-U; OHNISHI T, 1993, J BONE MINER RES, V8, P367; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; RAJ PA, 1992, J BIOL CHEM, V267, P5968; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; Sambrook J, 1987, MOL CLONING LAB MANU; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; SUZUKI M, 1994, J EXP ZOOL, V270, P501, DOI 10.1002/jez.1402700603; TAKAGI Y, 1990, CALCIFIED TISSUE INT, V47, P40, DOI 10.1007/BF02555864; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; TRIFFITT JT, 1978, CALC TISS RES, V26, P155, DOI 10.1007/BF02013251; WATZLAWICK H, 1992, BIOCHEMISTRY-US, V31, P12198, DOI 10.1021/bi00163a032; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G; YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167-4781(92)90522-2	38	307	313	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20789	20796		10.1074/jbc.271.34.20789	http://dx.doi.org/10.1074/jbc.271.34.20789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702833	hybrid			2022-12-27	WOS:A1996VD33700085
J	Ueda, A; Yoshimura, T				Ueda, A; Yoshimura, T			Characterization of cis-acting elements of the gene for macrophage-stimulating protein from the human - The involvement of positive and negative regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-GROWTH-FACTOR; CCAAT-BINDING PROTEIN; TRANSCRIPTION FACTOR; TYROSINE KINASE; DNA-BINDING; MOLECULAR-CLONING; EUKARYOTIC TRANSCRIPTION; HETEROLOGOUS SUBUNITS; SEQUENCE IDENTITY; NUCLEAR FACTOR	To analyze the promotor region of the human macrophage-stimulating protein (MSP) gene, the 5'-flanking region of this gene was cloned. The major initiation site was determined at T located 49 base pairs upstream of the translation initiation site by primer extention with mRNA from HepG2 and Hep3B cells. There was no TATA sequence in this region. Transient transfection assay with 5'-deletion constructs showed that the transcription of this gene was regulated by positive and negative regulatory elements (PRE and NRE). The PRE (-34 to +2) was essential for the maximal transcription of this gene, and the NRE (-141 to -34) appeared to be responsible for the tissue-specific expression of the gene. The PRE contained the CCAAT sequence and a mutation from CCAAT to CTGAT resulted in a significant loss of the transcriptional activity. Electrophoretic mobility shift assay suggested that two different proteins bound to the PRE (MSP-PRE-binding protein-1 (MSP-PREB1) and 2). MSP-PREB1 and 2 were detected in various cell types, and the CCAAT sequence was involved in these bindings. These findings indicate that MSP-PREB1 and 2 are positive regulators. Further characterization also revealed that MSP-PREB2 was identical to CCAAT binding transcription factor, also known as NF-Y.			Ueda, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702, USA.			Yoshimura, Teizo/0000-0002-3853-2075				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEZERRA JA, 1994, BIOCHEM BIOPH RES CO, V203, P666, DOI 10.1006/bbrc.1994.2234; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FIGUEIREDO MS, 1995, J BIOL CHEM, V270, P11828, DOI 10.1074/jbc.270.20.11828; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HARRISON P, 1994, LANCET, V344, P27, DOI 10.1016/S0140-6736(94)91050-2; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PANG JH, 1993, J BIOL CHEM, V268, P2909; RONSIN C, 1993, ONCOGENE, V8, P1195; ROY B, 1995, MOL CELL BIOL, V15, P2263; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; THERY C, 1995, DEV GENET, V17, P90, DOI 10.1002/dvg.1020170110; UEDA A, 1994, J IMMUNOL, V153, P2052; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, J BIOL CHEM, V269, P13806; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WELCH HM, 1989, GENOMICS, V5, P423, DOI 10.1016/0888-7543(89)90005-0; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZANNIS VI, 1994, LIVER GENE EXPRESSIO, P63; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	51	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20265	20272		10.1074/jbc.271.34.20265	http://dx.doi.org/10.1074/jbc.271.34.20265			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702759	hybrid			2022-12-27	WOS:A1996VD33700011
J	Farfel, Z; Iiri, T; Shapira, H; Roitman, A; Mouallem, M; Bourne, HR				Farfel, Z; Iiri, T; Shapira, H; Roitman, A; Mouallem, M; Bourne, HR			Pseudohypoparathyroidism, a novel mutation in the beta gamma-contact region of G(s)alpha impairs receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; GTP HYDROLYSIS; ALPHA-SUBUNIT; G-PROTEIN; G(I-ALPHA-1); ACTIVATION; MECHANISM	Pseudohypoparathyroidism, type Ia (PHP-Ia), is a dominantly inherited endocrine disorder characterized by resistance to hormones that act by stimulating adenylyl cyclase. It is caused by inheritance of an autosomal mutation that inactivates the alpha subunit (alpha(s)) of G(s), the stimulatory regulator of adenylyl cyclase. In three members of a family, the PHP-Ia phenotype is associated with a mutation (R231H) that substitutes histidine for an arginine at position 231 in alpha(s). We assessed signaling function of alpha(s)-WT versus alpha(s)-R231H transiently transfected in HEK293 cells. Hormone receptor-dependent stimulation of cAMP accumulation in cells expressing alpha(s)-R231H is reduced by similar to 75% in comparison to cAMP accumulation in cells expressing alpha(s)-WT. A second mutation, alpha(s)-R201C, inhibits the GTPase turnoff reaction of alpha(s), thus producing receptor-independent stimulation of cAMP accumulation. The double mutant, alpha(s)-R231H/R201C, stimulates cAMP accumulation almost as well (similar to 80%) as does alpha(s)-R201C itself, indicating that the R231H mutation selectively impairs receptor-dependent signaling. In three-dimensional structures of G protein heterotrimers, Arg-231 is located in a region, switch 2, that is thought to interact with the beta gamma subunit rather than with the hormone receptor. Thus, the R231H phenotype suggests that switch 2 (perhaps in concert with beta gamma) mediates G protein activation by receptors at a site distant from the receptor-G protein contact surface.	TEL AVIV UNIV,CHAIM SHEBA MED CTR,BIOCHEM PHARMACOL LAB,IL-52621 TEL HASHOMER,ISRAEL; MACCABI SICK FUND,TEL AVIV,ISRAEL; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	Chaim Sheba Medical Center; Tel Aviv University; University of California System; University of California San Francisco	Farfel, Z (corresponding author), TEL AVIV UNIV,CHAIM SHEBA MED CTR,DEPT MED E,IL-52621 TEL HASHOMER,ISRAEL.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FARFEL Z, 1980, NEW ENGL J MED, V303, P237, DOI 10.1056/NEJM198007313030501; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVINE MA, 1980, BIOCHEM BIOPH RES CO, V94, P1319, DOI 10.1016/0006-291X(80)90563-X; LEVINE MA, 1995, ENDOCRINOLOGY, P1136; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; Shapira H, 1996, HUM GENET, V97, P73; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	19	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19653	19655		10.1074/jbc.271.33.19653	http://dx.doi.org/10.1074/jbc.271.33.19653			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702665	hybrid			2022-12-27	WOS:A1996VC66900006
J	Bass, J; Kurose, T; Pashmforoush, M; Steiner, DF				Bass, J; Kurose, T; Pashmforoush, M; Steiner, DF			Fusion of insulin receptor ectodomains to immunoglobulin constant domains reproduces high-affinity insulin binding in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; STRUCTURAL BASIS; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; LIGAND-BINDING; EFFICIENT NEUTRALIZATION; NEGATIVE COOPERATIVITY; ENDOPLASMIC-RETICULUM; EXTRACELLULAR DOMAIN	A unique feature of the insulin receptor is that it is dimeric in the absence of ligand, Dimerization of two adjacent transmembrane domain (TMD) alpha helices has been shown to be critical in receptor kinase activation, Moreover, previous work has suggested that the TMD is involved in stabilizing the high-affinity binding site; soluble receptors expressed after simple truncation at the ectodomain-TMD junction have reduced affinity for insulin. To further examine this issue, we have replaced the TMD and intracellular domain of the soluble human insulin receptor (HIRs) with constant domains from immunoglobulin Fc and lambda subunits (HIRs-Fc and HIRs-lambda), Studies of receptor biosynthesis and binding characteristics were performed following transient transfection of receptor cDNAs into human embryonal kidney 293 cells. Each hybrid receptor was initially synthesized as a single chain proreceptor, followed by cleavage into alpha- and beta-Fc or beta-lambda subunits. The majority of secreted protein appeared in the cell medium as fully processed heterotetramer, Fe fragments released from HIRs-Fc by papain digestion and analyzed by nonreducing SDS-polyacrylamide gel electrophoresis were dimeric, Furthermore, dissociation constants for both chimeras were similar to those for the full-length holoreceptor (wild-type receptor, K-d1 = 200 pM and K-d2 = 2 nM; HIRs-Fc, K-d1 = 200 pM and K-d2 = 40 nM; and HIRs-lambda, K-d1 = 200 pw and K-d2 = 5 nM). These results extend previous observations that dimerization of the membrane-proximal ectodomain is necessary to maintain an intact high-affinity insulin-binding site.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; Howard Hughes Medical Institute; University of Chicago	Bass, J (corresponding author), UNIV CHICAGO,DEPT MED,ENDOCRINOL SECT,5841 S MARYLAND AVE,MC 1028,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK 13914, T32 DK07011, DK 20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007011, R37DK013914, P60DK020595, P30DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1992, J BIOL CHEM, V267, P586; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; Harlow E., 1988, ANTIBODIES LAB MANUA; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KASUGA M, 1982, J BIOL CHEM, V257, P392; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; KLEIN M, 1977, BIOCHEMISTRY-US, V16, P552, DOI 10.1021/bi00622a032; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LAURELL CB, 1975, J EXP MED, V141, P453, DOI 10.1084/jem.141.2.453; LEE JS, 1993, J BIOL CHEM, V268, P4092; Maniatis T, 1989, DECONTAMINATION DILU; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MEINICK J, 1994, NATURE, V370, P373; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PILCH PF, 1980, J BIOL CHEM, V255, P1722; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; Taylor Simeon I., 1994, P1; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMADA K, 1995, BIOCHEMISTRY-US, V34, P946, DOI 10.1021/bi00003a029; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	68	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19367	19375		10.1074/jbc.271.32.19367	http://dx.doi.org/10.1074/jbc.271.32.19367			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702623	hybrid			2022-12-27	WOS:A1996VB68400057
J	Kusakabe, T; Richardson, CC				Kusakabe, T; Richardson, CC			The role of the zinc motif in sequence recognition by DNA primases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIMASE; RNA PRIMER SYNTHESIS; T7 DEOXYRIBONUCLEIC-ACID; LAGGING-STRAND SYNTHESIS; COORDINATED LEADING-STRAND; 63-KDA GENE-4 PROTEIN; REPLICATION FORK; BACTERIOPHAGE-T7 DNA; TRANSCRIPTION FACTORS; TEMPLATE RECOGNITION	The DNA primase of bacteriophage T7 has a zinc-binding motif that is essential for the recognition of the sequence 3'-CTG-5'. The T7 primase also catalyzes helicase activity, a reaction coupled to nucleotide hydrolysis. We have replaced the zinc motif of the T7 primase with those found in the gene 61 primase of phage T4 and the DnaG primase of Escherichia coli. The T4 and E. coli primases recognize the sequences 3'-T(C/T)G-5' and 3'-GTC-5', respectively. Both chimeric proteins can partially replace T7 primase in vivo. The two chimeric primases catalyze the synthesis of oligoribonucleotides albeit at a reduced rate and DNA dependent dTTPase activity is reduced by 3-10-fold. Both chimeric proteins recognize 3'-(A/G)CG-5' sites on single-stranded DNA, sites that differ from those recognized by the T7, T4, or E. coli primases, indicating that the zinc motif is only one determinant in site-specific recognition.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HINE AV, 1994, P NATL ACAD SCI USA, V91, P12327, DOI 10.1073/pnas.91.25.12327; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KORNBERG A, 1992, DNA REPLICATION, P275; KRUGER DH, 1981, MICROBIOL REV, V45, P9; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MACDONALD PM, 1984, EMBO J, V3, P2863, DOI 10.1002/j.1460-2075.1984.tb02221.x; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10628; MUSTAEV AA, 1995, J BIOL CHEM, V270, P15711, DOI 10.1074/jbc.270.26.15711; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27196; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEKI T, 1979, NUCLEIC ACIDS RES, V7, P1603, DOI 10.1093/nar/7.6.1603; SMILEY BL, 1982, P NATL ACAD SCI-BIOL, V79, P4550, DOI 10.1073/pnas.79.15.4550; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; SWART JR, 1993, J BIOL CHEM, V268, P12970; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; TOUGU K, 1994, J BIOL CHEM, V269, P4675; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	57	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19563	19570		10.1074/jbc.271.32.19563	http://dx.doi.org/10.1074/jbc.271.32.19563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702650	Green Published, hybrid			2022-12-27	WOS:A1996VB68400084
J	Pang, L; Sivaram, P; Goldberg, IJ				Pang, L; Sivaram, P; Goldberg, IJ			Cell-surface expression of an amino-terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST GROWTH-FACTOR; ENDOTHELIAL-CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; IDENTIFICATION; DEGRADATION; SECRETION; TRANSLOCATION; MUTAGENESIS	Previous studies (Sivaram, P., Choi, S. Y., Curtiss, L. K., and Goldberg, I. J. (1994) J. Biol. Chem. 269, 9409-9412) from this laboratory showed that the NH2-terminal region of apoB (NTAB) has binding domains for lipoprotein lipase (LPL), LPL binding to endothelial cells, we hypothesize, involves interaction both with heparan sulfate proteoglycans and with a protein that has homology to NTAB. To test whether cell-surface NTAB would increase the amount and affinity of LPL binding to cells, we produced stable Chinese hamster ovary cell Lilies that have NTAB anchored to the cell surface, A cDNA encoding the amino-terminal 17% of apoB (apoB17) was fused to a cDNA coding for the last 37 amino acids of decay-accelerating factor (DAF), which contains the signal for glycosylphosphatidylinositol anchor attachment, The fused construct was sequence-verified and cloned into expression vector pCMV5, The pCMV5-apoB17-DAF plasmid was cotransfected with a neomycin resistance gene into wild-type (WT) cells and mutant heparan sulfate proteoglycan-deficient Chinese hamster ovary cells (745 cells), and stable cell lines mere established, Expression of apoB17 on the cell surface was confirmed by the release of apoB17 by phosphatidylinositol-specific phospholipase C. LPL binding to WT and apoB17-DAF-transfected cells was determined, Using 0.8-6 mu g of LPL, 1.3-2.2-foId more LPL associated with apoB17-DAF WT cells compared with WT cells; apoB17-DAF also increased LPL binding to 745 cells, After heparinase treatment, LPL binding to apoB17-DAF cells was still greater than to treated WT cells, This increased binding to apoB17-DAF cells was almost abolished by treatment of cells with phosphatidylinositol-specific phospholipase C or anti-apoB monoclonal antibody, LPL dissociated from WT cells with k(-1) = 2.55 x 10(-2) min(-1), whereas LPL dissociated more slowly from apoB17-DAF-containing cells with k(-1) = 1.08 x 10(-2) min(-1), Furthermore, almost 95% of the LPL on WT cells was dissociated by 1 nr NaCl, while only 65% of the LPL dissociated from apoB17-DAF cells at the same high salt concentration. Similarly, in high salt, more LPL remained associated with apoB17-DAF cells than with nontransfected 745 cells, These data show that NTAB on cell surfaces can function as a LPL binding protein, Moreover, they demonstrate that LPL association with cells can be increased by simultaneously binding to both proteoglycan and non-proteoglycan binding sites.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,DIV PREVENT MED,NEW YORK,NY 10032	Columbia University					NHLBI NIH HHS [HL21006, HL45095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, P50HL021006, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CUPP M, 1987, J BIOL CHEM, V262, P6383; DENNINGTON PM, 1994, CLIN EXP PHARMACOL P, V21, P349, DOI 10.1111/j.1440-1681.1994.tb02527.x; DU EZ, 1994, J BIOL CHEM, V269, P24169; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; FRIEDMAN G, 1983, BIOCHIM BIOPHYS ACTA, V752, P106, DOI 10.1016/0005-2760(83)90238-2; HATA A, 1993, J BIOL CHEM, V268, P8447; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; JI ZS, 1993, J BIOL CHEM, V268, P10160; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MA YH, 1994, J LIPID RES, V35, P2049; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MURRAY EJ, 1991, GENE TRANSFER EXPRES, V7, P245; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P12880; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; Sivaram P, 1996, J BIOL CHEM, V271, P15261, DOI 10.1074/jbc.271.25.15261; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; STINS MF, 1992, ARTERIOSCLER THROMB, V12, P1437, DOI 10.1161/01.ATV.12.12.1437; STINS MF, 1993, J LIPID RES, V34, P1853; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; WALLINDER L, 1979, BIOCHIM BIOPHYS ACTA, V575, P166, DOI 10.1016/0005-2760(79)90142-5; WANGIVERSON P, 1980, ATHEROSCLEROSIS, V5, P375; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	45	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19518	19523		10.1074/jbc.271.32.19518	http://dx.doi.org/10.1074/jbc.271.32.19518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702644	hybrid			2022-12-27	WOS:A1996VB68400078
J	Bochkareva, E; Seluanov, A; Bibi, E; Girshovich, A				Bochkareva, E; Seluanov, A; Bibi, E; Girshovich, A			Chaperonin-promoted post-translational membrane insertion of a multispanning membrane protein lactose permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC CARRIER PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; GROEL; PURIFICATION; INVITRO; GENE; TRANSLOCATION; CHANNEL; HELIX	Using an in vitro membrane-free translation system from Escherichia coli, it is shown that chaperonin GroEL added cotranslationally interacts with newly synthesized lactose permease (LacY), a polytopic membrane protein, thereby preventing aggregation, Subsequently, when the isolated GroEL-LacY complex is incubated with inverted membrane vesicles, the permease is inserted into the membrane in a MgATP-dependent manner. Post-translational membrane insertion is also observed when aggregation of newly synthesized LacY is prevented by addition of the nonionic detergent n-dodecyl-beta,D-maltoside during translation in place of GroEL. No membrane integration occurs with right-side-out vesicles, indicating that LacY interacts specifically only with the cytosolic face of the membrane. Ligand thiodigalactoside protection against alkylation of the Cys-148 residue in the permease shows proper posttranslational insertion. Moreover, limited proteolysis of soluble LacY either complexed with GroEL or in detergent indicates that the newly synthesized protein assumes a conformation that is comparable to that of native, membrane-embedded permease prior to insertion into the membrane.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Bibi, Eitan/0000-0003-3700-2707; Seluanov, Andrei/0000-0003-3400-538X				AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; BEYREUTHER K, 1982, METHODS PROTEIN SEQU, P139; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BIESELER B, 1985, ANN NY ACAD SCI, V456, P309, DOI 10.1111/j.1749-6632.1985.tb14882.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CARTER JR, 1968, P NATL ACAD SCI USA, V60, P725, DOI 10.1073/pnas.60.2.725; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; EHRING R, 1980, NATURE, V283, P537, DOI 10.1038/283537a0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; GOVEZENSKY D, 1994, J BIOL CHEM, V269, P14003; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KABACK HR, 1983, J MEMBRANE BIOL, V76, P95; KNUDSEN P, 1978, MEMBRANE BIOCHEM, V1, P297, DOI 10.3109/09687687809063853; LEMAIRE M, 1983, EUR J BIOCHEM, V129, P525; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MORIMOTO T, 1983, METHOD ENZYMOL, V96, P121; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; PEBAYPEYROULA E, 1995, STRUCTURE, V3, P1051, DOI 10.1016/S0969-2126(01)00241-6; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SATO K, 1994, BIOCHEM BIOPH RES CO, V202, P258, DOI 10.1006/bbrc.1994.1921; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, TRENDS BIOCHEM SCI, V15, P369, DOI 10.1016/0968-0004(90)90230-9; STOCHAJ U, 1986, EUR J BIOCHEM, V158, P423, DOI 10.1111/j.1432-1033.1986.tb09770.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WRIGHT JK, 1983, METHOD ENZYMOL, V97, P158; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020	47	35	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22256	22261		10.1074/jbc.271.36.22256	http://dx.doi.org/10.1074/jbc.271.36.22256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703042	hybrid			2022-12-27	WOS:A1996VF61200084
J	Brauchle, M; Funk, JO; Kind, P; Werner, S				Brauchle, M; Funk, JO; Kind, P; Werner, S			Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PERMEABILITY FACTOR; TYROSINE KINASE; CELL MITOGEN; ACTIVATION; RECEPTOR; GENE; UV; ANGIOGENESIS; PURIFICATION	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is strongly expressed by epidermal keratinocytes during wound healing, in psoriasis, and in bullous diseases such as erythema multiforme and bullous pemphigoid. All of these disorders are characterized by increased microvascular permeability and angiogenesis. Since the development of erythema as a result of hyperpermeable blood vessels is also a common feature after excess sun exposure, we speculated about an up-regulation of VEGF expression by ultraviolet (UV) light. To test this hypothesis, we analyzed the effect of UVB irradiation on VEGF expression in cultured keratinocytes. Thereby we found a large increase in VEGF mRNA and protein levels upon irradiation of quiescent keratinocytes with sublethal and physiologically relevant doses of UVB. Although H2O2 was also a potent inducer of VEGF expression, the effect of UVB irradiation is unlikely to be mediated by reactive oxygen species as determined by the use of antioxidants. Further experiments revealed that the UVB-induced overexpression of VEGF is dependent on de novo protein synthesis and might occur via release of soluble mediators, which subsequently turn on VEGF expression. In summary, our results suggest a novel role of VEGF in the induction of erythema after excess sun exposure.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOL BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,ABT MOL PATHOL,D-80337 MUNICH,GERMANY	Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich				Werner, Sabine/0000-0001-7397-8710				ANSEL JC, 1983, J INVEST DERMATOL, V81, P519, DOI 10.1111/1523-1747.ep12522862; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; BUSCHER M, 1988, ONCOGENE, V3, P301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FUNK JO, 1994, J AM ACAD DERMATOL, V31, P999, DOI 10.1016/S0190-9622(94)70272-1; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; KRUTMANN J, 1995, J INVEST DERMATOL, V105, pS67, DOI 10.1111/1523-1747.ep12316095; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER CC, 1994, J BIOL CHEM, V269, P3529; PENTLAND AP, 1994, ADV EXP MED BIOL, V366, P87; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SENGER DR, 1987, FED PROC, V46, P2102; SHEA CR, 1982, ARCH DERMATOL RES, V273, P233, DOI 10.1007/BF00409251; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	45	149	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21793	21797		10.1074/jbc.271.36.21793	http://dx.doi.org/10.1074/jbc.271.36.21793			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702976	hybrid			2022-12-27	WOS:A1996VF61200018
J	Charlet, M; Chernysh, S; Philippe, H; Hetru, C; Hoffmann, JA; Bulet, P				Charlet, M; Chernysh, S; Philippe, H; Hetru, C; Hoffmann, JA; Bulet, P			Innate immunity - Isolation of several cysteine-rich antimicrobial peptides from the blood of a mollusc, Mytilus edulis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; INSECT DEFENSIN-A; SEQUENCE HOMOLOGY; HOST-DEFENSE; SEA HARE; DROSOPHILA; PURIFICATION; SNAIL; MUCUS; TREES	We have isolated fi om the blood of immune-challenged and untreated mussels (Mytilus edulis) antibacterial and antifungal peptides. We have characterized two isoforms of a novel 34-residue, cysteine-rich, peptide with potent bactericidal activity and partially characterized a novel 6.2-kDa antifungal peptide containing 12 cysteines. We report the presence of two members of the insect defensin family of antibacterial peptides and provide a phylogenetic analysis that indicates that mollusc and arthropod defensins have a common ancestry. Our data argue that circulating antimicrobial peptides represent an ancient host defense mechanism that predated the separation between molluscs and arthropods at the root of the Cambrian, about 545 million years ago.	INST BIOL MOL & CELLULAIRE,CNRS,UNITE PROPRE RECH RESPONSE IMMUNITAIRE & DEV INSE,F-67084 STRASBOURG,FRANCE; ST PETERSBURG STATE UNIV,ENTOMOL LAB,ST PETERSBURG 198904,RUSSIA; UNIV PARIS 11,CNRS,UNITE RECH ASSOCIE DEV & MORPHOGENESE 1134,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Saint Petersburg State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			BULET, Philippe/C-8557-2014; Tulin, Dmitry/N-1039-2013	BULET, Philippe/0000-0001-9016-265X; Tulin, Dmitry/0000-0001-6357-0228				BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Hetru Charles, 1994, P43; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; IGUCHI SMM, 1982, COMP BIOCHEM PHYS A, V72, P571, DOI 10.1016/0300-9629(82)90123-2; KAMIYA H, 1984, EXPERIENTIA, V40, P947, DOI 10.1007/BF01946452; KUBOTA Y, 1985, COMP BIOCHEM PHYS C, V82, P345, DOI 10.1016/0742-8413(85)90173-2; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LERCHER RI, 1994, PHYLOGENETIC PERSPEC, P19; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; LOWENBERGER C, 1995, INSECT BIOCHEM MOLEC, V25, P867, DOI 10.1016/0965-1748(95)00043-U; MALOY LW, 1995, BIOPOLYMERS, V37, P105; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; OTSUKAFUCHINO H, 1992, COMP BIOCHEM PHYS C, V101, P607, DOI 10.1016/0742-8413(92)90094-N; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; Philippe Herve, 1996, P41; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SWOFFORD DL, 1993, PAUP VERSION 3 1 ILL; YAMAZAKI M, 1990, DEV COMP IMMUNOL, V14, P379, DOI 10.1016/0145-305X(90)90030-I	32	295	338	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21808	21813		10.1074/jbc.271.36.21808	http://dx.doi.org/10.1074/jbc.271.36.21808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702979	hybrid			2022-12-27	WOS:A1996VF61200021
J	Kandror, KV; Pilch, PF				Kandror, KV; Pilch, PF			The insulin-like growth factor II mannose 6-phosphate receptor utilizes the same membrane compartments as GLUT4 for insulin-dependent trafficking to and from the rat adipocyte cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER-CONTAINING VESICLES; GLUCOSE-TRANSPORTER; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; GLUT4-ENRICHED VESICLES; SUBCELLULAR TRAFFICKING; TRANSFERRIN RECEPTORS; LYSOSOMAL-ENZYMES	The insulin-like growth factor II (IGF-II)/mannose 6-phosphate (Man-6-P) receptor recycles in adipose cells between the cell surface and an intracellular storage pool, and the rate of this trafficking is markedly enhanced by insulin, We show here that the IGF-II/Man-6-P receptor is a constituent of the GLUT4-containing compartment (''GLUT4 vesicles'') where it represents gp230, a major recycling protein detected earlier by cell surface biotinylation (Kandror, K. V., and Pilch, P. F. (1994) J. Biol. Chem. 269, 138-142). The GLUT4 vesicles include 10-15% of the total and all of the acutely insulin-responsive recycling population of the IGF-II/Man-6-P receptor. The main part of the IGF-II/Man-6-P receptor population is excluded from the pathway of GLUT4 trafficking and either resides permanently in intracellular membranes or has a much slower rate of cycling to the cell surface. Thus, GLUT4 vesicles mediate the insulin-dependent delivery to the cell surface of the IGF-II/Man-6-P receptor as well as the other recyclable proteins with extracellular functional domains (GLUT4 and the aminopeptidase gp160).	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Kandror, Konstantin/0000-0002-8601-9313; Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK44269, P30 DK46200, DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, P01DK044269, R01DK030425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DELVECCHIO RL, 1991, J BIOLL CHEM, V266, P23865; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; OKA Y, 1986, J BIOL CHEM, V261, P9090; OKA Y, 1985, J BIOL CHEM, V260, P9435; OKA Y, 1988, J BIOL CHEM, V263, P13432; OPPENHEIMER CL, 1983, J BIOL CHEM, V258, P4824; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P4379, DOI 10.1073/pnas.73.12.4379; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	54	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21703	21708		10.1074/jbc.271.36.21703	http://dx.doi.org/10.1074/jbc.271.36.21703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702963	hybrid			2022-12-27	WOS:A1996VF61200005
J	Kurata, SI				Kurata, SI			Sensitization of the HIV-1-LTR upon long term low dose oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; KAPPA-B; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; ACTIVATION; SEQUENCES; PROMOTER; TYPE-1; ALPHA	Human lymphoid cell lines were transfected with HIV-1-LTR-CAT DNA and permanently transformed cell lines were obtained. These transformed cell lines were treated with 0.01 mM H2O2 for 25 days and the chloramphenicol acetyltransferase (CAT) activities of these cell lines were measured. The CAT activities of transformed cell lines were latent in normal culture conditions, but were activated by retreatment with 0.2 mM H2O2 for 1 h. On treatment with 0.05 mM H2O2 for 1 h, the CAT activity of these cell lines maintained in normal conditions remained latent, whereas cell lines pretreated with 0.01 mM H2O2 for 25 days were greatly activated by this treatment. Here, the HIV-1 promoter seemed latent in normal culture conditions, but it could be activated by a comparatively low concentration (0.05 mM) of H2O2 after treatment with a dilute H2O2 (0.01 mM) for about 1 month. Many patients infected with human immunodeficiency virus 1 (HIV-1) show a long latent period before development of AIDS. During this latent period, their infected cells may be subjected to oxidative stress due to metabolism and physical movement. The present results indicate that oxidative stress may cause activation of the HIV-1 promoter in patients with latent HIV-1.			Kurata, SI (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT BIOCHEM GENET,BUNKYO KU,TOKYO 113,JAPAN.							BLATTNER WA, 1985, ANN INTERN MED, V103, P665, DOI 10.7326/0003-4819-103-5-665; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAUCI AS, 1993, NEW ENGL J MED, V328, P429, DOI 10.1056/NEJM199302113280610; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; KURATA S, 1993, FEBS LETT, V321, P201, DOI 10.1016/0014-5793(93)80108-7; KURATA S, 1994, J BIOL CHEM, V269, P24553; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; METZGER S, 1993, J BIOL CHEM, V268, P16831; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571	19	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21798	21802		10.1074/jbc.271.36.21798	http://dx.doi.org/10.1074/jbc.271.36.21798			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702977	hybrid			2022-12-27	WOS:A1996VF61200019
J	Talanian, RV; Dang, LC; Ferenz, CR; Hackett, MC; Mankovich, JA; Welch, JP; Wong, WW; Brady, KD				Talanian, RV; Dang, LC; Ferenz, CR; Hackett, MC; Mankovich, JA; Welch, JP; Wong, WW; Brady, KD			Stability and oligomeric equilibria of refolded interleukin-1 beta converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; MICE DEFICIENT; IN-VIVO; APOPTOSIS; INHIBITION	We report the preparation and characterization of interleukin-1 beta converting enzyme (ICE) refolded from its p20 and p10 protein fragments, Refolded ICE heterodimer (p20p10) was catalytically active but unstable, and in size exclusion chromatography eluted at an apparent molecular mass of 30 kDa, The mechanisms of the observed instability were pH-dependent dissociation at low enzyme concentrations, and autolytic degradation of the p10 subunit at high concentrations, Binding and subsequent removal of a high affinity peptidic inhibitor increased the apparent molecular mass to 43 kDa (by size exclusion chromatography), and significantly increased its stability and specific activity. Chemical cross-linking and SDS-polyacrylamide gel electrophoresis analysis of the 43-kDa size exclusion chromatography conformer revealed a 60-kDa species, which was absent in the 30-kDa conformer, suggesting that inhibitor binding caused formation of a (p20p10), homodimer, The observation of a reversible equilibrium between ICE (p20p10) and (p20p10)(2) suggests that analogous associations, possibly between ICE and ICE homologs, can occur in vivo, resulting in novel oligomeric protease species.			Talanian, RV (corresponding author), BASF BIORES CORP,WORCESTER,MA 01605, USA.							AYAIA JM, 1994, J IMMUNOL, V153, P2592; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ELFORD PR, 1995, BRIT J PHARMACOL, V115, P601, DOI 10.1111/j.1476-5381.1995.tb14974.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; POE M, 1991, J BIOL CHEM, V266, P98; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry Nancy A., 1995, Perspectives in Drug Discovery and Design, V2, P389, DOI 10.1007/BF02172032; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	37	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21853	21858		10.1074/jbc.271.36.21853	http://dx.doi.org/10.1074/jbc.271.36.21853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702986	hybrid			2022-12-27	WOS:A1996VF61200028
J	Imai, T; Yoshida, T; Baba, M; Nishimura, M; Kakizaki, M; Yoshie, O				Imai, T; Yoshida, T; Baba, M; Nishimura, M; Kakizaki, M; Yoshie, O			Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-3; COLONY FORMATION INVITRO; FUNCTIONAL EXPRESSION; MESSENGER-RNA; SECRETED PROTEINS; ENDOTHELIAL-CELLS; PROGENITOR CELLS; DUFFY ANTIGEN; RECEPTOR; GENE	Precursors of most secreted and cell surface molecules carry signal sequences at their amino termini. Here we describe an efficient signal sequence trap method and isolation of a novel CC chemokine. An expression library was constructed by inserting 5' portion-enriched cDNAs from phytohemagglutinin-stimulated peripheral blood mononuclear cells into upstream of signal sequence deleted CD4 cDNA in an Epstein-Barr virus shuttle vector. After electroporation into Raji cells, CD4 antigen-positive cells were enriched by repeated cell sorting and plasmids were recovered in Escherichia coli. Out of 100 plasmid clones examined, 42 clones directed expression of CD4 antigen on the cell surface. Among them were signal sequences of CD6, beta(2)-microglobulin, MGC-24, and T cell receptor epsilon-chain, and at least four novel potential signal sequences. A cDNA clone encoding a novel CC chemokine was isolated by using one of the trapped fragments. The gene designated as TARC from Thymus and Activation-Regulated Chemokine was expressed transiently in phytohemagglutinin-stimulated peripheral blood mononuclear cells and constitutively in thymus. Radiolabeled recombinant TARC specifically bound to T cell lines and peripheral T cells but not to monocytes or granulocytes. The binding of radiolabeled TARC to the high-affinity receptor (K-d, 2.1 nM) on Jurkat was displaced by TARC but not by interleukin-8, MIP-1 alpha, RANTES, or MCP-1. TARC also bound to the promiscuous chemokine receptor on erythrocytes (K-d, 17 nM). TARC induced chemotaxis in T cell lines Hut78 and Hut102. Pretreatment of Hut78 with pertussis toxin abolished the TARC-induced cell migration. Collectively, T cells express a highly selective receptor for TARC that is coupled to pertussis toxin-sensitive G-protein. TARC may a factor playing important roles in T cell development in thymus as well as in trafficking and activation of mature T cells.			Imai, T (corresponding author), SHIONOGI INST MED RES, 2-5-1 MISHIMA, SETTSU, OSAKA 566, JAPAN.			Yoshie, Osamu/0000-0003-4353-5809				ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.3.CO;2-L; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORGAN KJ, 1991, CURRENT PROTOCOLS IM; HORUK R, 1994, J BIOL CHEM, V269, P17730; IMAI T, 1995, J IMMUNOL, V155, P1229; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MASUZAWA Y, 1992, J BIOCHEM-TOKYO, V112, P609, DOI 10.1093/oxfordjournals.jbchem.a123948; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MILLER MD, 1989, J IMMUNOL, V143, P2907; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TURNER L, 1995, J IMMUNOL, V155, P2437; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	58	259	282	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21514	21521		10.1074/jbc.271.35.21514	http://dx.doi.org/10.1074/jbc.271.35.21514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702936	hybrid			2022-12-27	WOS:A1996VE47700082
J	Schumaker, KS; Gizinski, MJ				Schumaker, KS; Gizinski, MJ			G proteins regulate dihydropyridine binding to moss plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PERMEABLE CHANNELS; INWARD K+ CHANNEL; ALPHA-SUBUNIT; WHEAT ROOTS; FUNARIA; VESICLES; CELLS; SITES; TRANSDUCTION; PROTOPLASTS	The role of calcium as an activator and regulator of many biological processes is linked to the ability of the cell to rapidly change its cytoplasmic calcium levels, Calcium acts as an intracellular messenger in hormone-induced bud formation during the development of the moss Physcomitrella patens. Calcium transport and ligand binding studies have implicated plasma membrane-localized 1,4-dihydropyridine (DHP)-sensitive calcium channels in this increase in cellular calcium. To understand the regulation of the moss calcium channel, we investigated the involvement of GTP binding regulatory proteins (G proteins). Guanosine 5'-(gamma-thio)triphosphate (GTP gamma S), a nonhydrolyzable GTP analog that locks G proteins into their active state, stimulated DHP binding to high affinity receptors in the moss plasma membrane. DHP binding was measured as the ability of the DHP agonist Bay K8644 or the DHP antagonist nifedipine to compete with the DHP arylazide [H-3]azidopine for binding to moss plasma membranes, G protein stimulation of binding was seen when competition was carried out with either nifedipine or Bay K8644. G proteins regulated the rates of association and dissociation of bound [H-3]azidopine, and stimulation was dependent on GTP gamma S concentration. Guanosine 5'-(beta-thio)diphosphate, a GDP analog that locks G proteins into their inactivated state, did not affect the dose dependence of either the agonist or the antagonist. These results suggest that G proteins may act via a membrane-delimited pathway to regulate calcium channels in the moss plasma membrane.			Schumaker, KS (corresponding author), UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721, USA.							BERGAMASCHI S, 1988, BIOCHEM BIOPH RES CO, V156, P1279, DOI 10.1016/S0006-291X(88)80771-X; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; Boyd PJ, 1988, METHODS BRYOLOGY, P47; BRANDES H, 1986, PLANT PHYSIOL, V43, P827; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CONRAD PA, 1988, PLANT PHYSIOL, V86, P684, DOI 10.1104/pp.86.3.684; DUNN SMJ, 1991, BIOCHEMISTRY-US, V30, P5716, DOI 10.1021/bi00237a012; FAIRLEYGRENOT K, 1991, PLANT CELL, V3, P1037; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; GOTTWALD R, 1988, METHODS BRYOLOGY, P73; HAHM SH, 1991, CELL CALCIUM, V12, P675, DOI 10.1016/0143-4160(91)90037-F; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HUANG JWW, 1994, P NATL ACAD SCI USA, V91, P3473, DOI 10.1073/pnas.91.8.3473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA H, 1991, GENE, V107, P189; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MARKMANNMULISCH U, 1987, J PLANT PHYSIOL, V129, P155, DOI 10.1016/S0176-1617(87)80112-8; MARSHALL J, 1994, PLANT J, V5, P683, DOI 10.1111/j.1365-313X.1994.00683.x; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PINEROS M, 1995, PLANTA, V195, P478, DOI 10.1007/BF00195704; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SAUNDERS MJ, 1982, SCIENCE, V217, P943, DOI 10.1126/science.217.4563.943; SAUNDERS MJ, 1983, DEV BIOL, V99, P41, DOI 10.1016/0012-1606(83)90252-X; SAUNDERS MJ, 1981, PLANTA, V152, P272, DOI 10.1007/BF00385156; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMAKER KS, 1993, P NATL ACAD SCI USA, V90, P10937, DOI 10.1073/pnas.90.23.10937; SCHUMAKER KS, 1995, J BIOL CHEM, V270, P23461, DOI 10.1074/jbc.270.40.23461; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TERRYN N, 1993, PLANT MOL BIOL, V22, P143, DOI 10.1007/BF00039002; THULEAU P, 1994, EMBO J, V13, P5843, DOI 10.1002/j.1460-2075.1994.tb06928.x; THULEAU P, 1994, EMBO J, V13, P2970, DOI 10.1002/j.1460-2075.1994.tb06595.x; WU WH, 1994, P NATL ACAD SCI USA, V91, P6310, DOI 10.1073/pnas.91.14.6310; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887	35	13	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21292	21296		10.1074/jbc.271.35.21292	http://dx.doi.org/10.1074/jbc.271.35.21292			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702906	hybrid			2022-12-27	WOS:A1996VE47700052
J	VoynoYasenetskaya, TA; Faure, MP; Ahn, NG; Bourne, HR				VoynoYasenetskaya, TA; Faure, MP; Ahn, NG; Bourne, HR			G alpha 12 and G alpha 13 regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-DEPENDENT ACTIVATION; MUTANT ALPHA-SUBUNITS; BETA-GAMMA-SUBUNITS; MAP KINASE; TRANSFORMATION; EXCHANGE; CAMP; TRANSDUCTION; FIBROBLASTS	Many growth factors and agonists for G protein-coupled receptors activate mitogen-activated protein (MAP) kinase pathways, including the extracellular signal-regulated kinase (ERK) pathway and the c-Jun kinase (JNK) pathway. Transient transfection of dominant negative and constitutively active pathway components in COS-7 cells shows that two G protein subunits, G alpha 12 and G alpha 13, inhibit the ERK pathway and stimulate the JNK pathway. Constitutively active (GTPase-deficient) G alpha 12 and G alpha 13 both inhibit ERK pathway activation by epidermal growth factor. A G alpha 13/alpha z chimera, which responds to stimulation by G(i)-coupled receptors, mediates inhibition of ERK via such a receptor, the dopamine-2 receptor. In addition, expression of a dominant negative mutant of the GTPase, Cdc42, blocks activation of the JNK pathway by G alpha 12 and G alpha 13 but does not alter inhibition of ERK activation by the same G alpha proteins; conversely, mutationally activated Cdc42 stimulates the JNK pathway but has no effect on the ERK pathway, Our results show that different mechanisms mediate two effects of G alpha 12 and G alpha 13: the ERK pathway inhibition is mediated at the level of MAP kinase kinase in a Ras- and Raf-independent fashion, whereas the JNK pathway stimulation is mediated by Cdc42.	UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL & MED,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; EGER R, 1995, FASEB J, V9, P726; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HART MJ, 1994, J BIOL CHEM, V269, P62; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MALY K, 1989, J BIOL CHEM, V264, P11839; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QUI RG, 1995, NATURE, V374, P457; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAN MH, 1994, NATURE, V372, P798	48	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21081	21087		10.1074/jbc.271.35.21081	http://dx.doi.org/10.1074/jbc.271.35.21081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702875	hybrid			2022-12-27	WOS:A1996VE47700021
J	Waltner, M; Hammen, PK; Weiner, H				Waltner, M; Hammen, PK; Weiner, H			Influence of the mature portion of a precursor protein on the mitochondrial signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; F1-ATPASE BETA-SUBUNIT; ALDEHYDE DEHYDROGENASE; PROCESSING PEPTIDASE; TERMINAL REGION; IMPORT; PRESEQUENCE; CLEAVAGE; CONFORMATION; SUFFICIENT	Most mitochondrial proteins are synthesized with an N-terminal signal sequence that targets these proteins to various compartments within the mitochondria. Signal sequences have been shown to be functional by fusing them to a nonmitochondrial passenger protein and observing import. In many cases, a signal sequence has been fused to passenger proteins, such as dihydrofolate reductase, and import occurred. There are, though, several unexplained instances in which a signal sequence was attached to a passenger protein and import was not observed. In this study, the N-terminal 23 residues of the matrix enzyme rhodanese could import several passenger proteins but were unable to import the mature form of mitochondrial aldehyde dehydrogenase (mALDH). However; if these same 23 residues were fused to the middle portion of mALDH, import was recovered, suggesting that the rhodanese signal sequence and N terminus of mALDH were incompatible for import. Circular dichroism data indicated that a peptide corresponding to the region of fusion between rhodanese and mALDH had less structure than corresponding peptides hom imported fusion proteins, suggesting that mALDH may alter the helix in the rhodanese signal sequence, thus preventing import.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAAA NIH HHS [AA05812] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HAMMEN PK, 1996, IN PRESS J BIOL CHEM, V271; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.tb20294.x; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KIMURA T, 1993, PLANT CELL PHYSIOL, V34, P345; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PAK YK, 1990, J BIOL CHEM, V265, P14298; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; SANGER F, 1977, P NATL ACAD SCI USA, V89, P11930; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VANSTEEG H, 1986, EMBO J, V5, P3643, DOI 10.1002/j.1460-2075.1986.tb04694.x; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1993, J BIOL CHEM, V268, P4759; YANG JT, 1986, METHOD ENZYMOL, V130, P208	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21226	21230		10.1074/jbc.271.35.21226	http://dx.doi.org/10.1074/jbc.271.35.21226			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702895	hybrid			2022-12-27	WOS:A1996VE47700041
J	Andrake, MD; Skalka, AM				Andrake, MD; Skalka, AM			Retroviral integrase, putting the pieces together	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING DOMAIN; HIV-1 INTEGRASE; CRYSTAL-STRUCTURE; TYPE-1 INTEGRASE; ESCHERICHIA-COLI; VIRAL-DNA; REVERSE-TRANSCRIPTASE; SUBSTRATE-BINDING; CATALYTIC DOMAIN		FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927, CA-47486] Funding Source: Medline; NIAID NIH HHS [5F32 AI08642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; BLACK CB, 1994, INORG CHEM, V33, P5805, DOI 10.1021/ic00103a030; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Cannon PM, 1996, J VIROL, V70, P651, DOI 10.1128/JVI.70.1.651-657.1996; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; Craigie R, 1996, CELL, V85, P137, DOI 10.1016/S0092-8674(00)81089-2; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JONES KS, 1992, J BIOL CHEM, V267, P16037; JONSSON CB, 1993, J VIROL, V67, P5562, DOI 10.1128/JVI.67.9.5562-5571.1993; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	59	109	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19633	19636		10.1074/jbc.271.33.19633	http://dx.doi.org/10.1074/jbc.271.33.19633			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702660	hybrid			2022-12-27	WOS:A1996VC66900001
J	Vostal, JG; Shafer, B				Vostal, JG; Shafer, B			Thapsigargin-induced calcium influx in the absence of detectable tyrosine phosphorylation in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PROTEIN-KINASE-C; PLASMA-MEMBRANE; CA-2+ ENTRY; GENISTEIN; ACTIVATION; INHIBITORS; RECEPTOR; MOBILIZATION; MECHANISMS	Tyrosine phosphorylation is a potential mechanism for mediating store-operated calcium (SOC) influx in platelets and other nonexcitable cells. Thapsigargin induces calcium-dependent tyrosine phosphorylation and SOC influx in platelets. We prevented thapsigargin-induced tyrosine phosphorylation by buffering cytosolic calcium rise with the calcium chelator 1,2-bis-(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-acetomethoxyester (BAPTA-AM). Calcium influx, induced by thapsigargin and measured by Ca-45(2+) accumulation, persisted in BAPTA-loaded platelets in the absence of tyrosine phosphorylation. This calcium influx was blocked by the SOC influx inhibitor SKF-96365. Tyrosine kinase inhibitors have been used to demonstrate a role for tyrosine phosphorylation in SOC influx. We compared the effects of four tyrosine kinase inhibitors genistein, methyl-2,5-dihydroxycinnamate (erbstatin analog), tyrphostin A47, and lavendustin A, on thapsigargin-induced tyrosine phosphorylation in control platelets and on thapsigargin-induced SOC influx into BAPTA-loaded platelets in absence of tyrosine phosphorylation, Tyrphostin A47 prevented all measurable tyrosine phosphorylation in control platelets, but did not decrease calcium influx into BAPTA-loaded platelets. Genistein and the erbstatin analog were poor inhibitors of tyrosine phosphorylation but decreased SOC influx into BAPTA-loaded platelets to 55.8 +/- 3% and 51.9 +/- 7.5% of control, respectively. Lavendustin A did not decrease tyrosine phosphorylation or calcium influx. Thus, thapsigargin-induced SOC influx can occur without detectable tyrosine phosphorylation and the inhibition of SOC influx by tyrosine kinase inhibitors does not correlate with their ability to prevent tyrosine phosphorylation.			Vostal, JG (corresponding author), US FDA,CBER,DIV HEMATOL,LAB CELLULAR HEMATOL,BLDG 29,RM 323,HFM 335,BETHESDA,MD 20892, USA.							ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; FALET H, 1994, FEBS LETT, V345, P87, DOI 10.1016/0014-5793(94)00414-5; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GARCIASANCHO J, 1992, TRENDS PHARMACOL SCI, V13, P12, DOI 10.1016/0165-6147(92)90007-S; GOIDEN A, 1986, P NATL ACAD SCI USA, V83, P852; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JONAS JC, 1995, BRIT J PHARMACOL, V114, P872, DOI 10.1111/j.1476-5381.1995.tb13285.x; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEVY LA, 1987, AM J PHYSIOL, V252, pC441, DOI 10.1152/ajpcell.1987.252.4.C441; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MCNICOL A, 1993, PROSTAG LEUKOTR ESS, V48, P379, DOI 10.1016/0952-3278(93)90118-G; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NAKAMURA K, 1995, AM J PHYSIOL, V267, pC958; OZAKI Y, 1993, BIOCHEM PHARMACOL, V46, P395; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; VOSTAL JG, 1993, BIOCHEM J, V294, P675, DOI 10.1042/bj2940675; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; VOSTAL JG, 1993, BIOCHEM J, V295, P525, DOI 10.1042/bj2950525; WIJETUNGE S, 1992, BIOCHEM BIOPH RES CO, V189, P1620, DOI 10.1016/0006-291X(92)90262-J; YUIE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19524	19529		10.1074/jbc.271.32.19524	http://dx.doi.org/10.1074/jbc.271.32.19524			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702645	hybrid			2022-12-27	WOS:A1996VB68400079
J	Komiya, T; Mihara, K				Komiya, T; Mihara, K			Protein import into mammalian mitochondria - Characterization of the intermediates along the import pathway of the precursor into the matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; INNER MEMBRANE; OUTER-MEMBRANE; DYNAMIC INTERACTION; STIMULATION FACTOR; TRANSLOCATION; YEAST; ATP; PRESEQUENCE; RECEPTOR	We have characterized several intermediates in the mitochondrial import stimulation factor (MSF)-dependent import into mammalian mitochondria of a matrix-targeted precursor, preadrenodoxin (pAd). In the first step, pAd docks onto the 37-kDa protein of the outer membrane (OM37) as a complex with MSF (stage I intermediate). It is then transferred to the import pore of OM in the presence of ATP, but in the absence of Delta psi across the inner membrane (IM), to form stage II intermediate. Depletion of matrix ATP in the presence of both extramitochondrial ATP and Delta psi, induces accumulation of stage III intermediate, which is a mixture of the precursor with different intramitochondrial localizations: the precursor whose presequence had crossed either OM (IIIa) or both OM and IM (IIIb), but with a bulk portion remaining exposed to the cytosol and the precursor whose presequence had crossed both membranes, but with a residual portion staying within the intermembrane space (IIIc). These intermediates are on the correct import pathway and are characteristic in their protease accessibility, salt extractability, and antibody accessibility, as well as in their energy requirement for the chase reaction.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOL BIOL,FUKUOKA 812,JAPAN	Kyushu University								ALAM R, 1994, J BIOCHEM-TOKYO, V116, P416, DOI 10.1093/oxfordjournals.jbchem.a124541; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BEASLEY E M, 1992, Current Opinion in Cell Biology, V4, P646, DOI 10.1016/0955-0674(92)90084-P; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1993, J BIOL CHEM, V268, P23751; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; IWAHASHI J, 1992, J BIOCHEM-TOKYO, V111, P451, DOI 10.1093/oxfordjournals.jbchem.a123778; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KOMIYA T, 1994, J BIOL CHEM, V269, P30893; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4202; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PFANNER N, 1987, J BIOL CHEM, V262, P7528; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TERADA K, 1995, MOL CELL BIOL, V15, P3708; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465	40	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22105	22110		10.1074/jbc.271.36.22105	http://dx.doi.org/10.1074/jbc.271.36.22105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703020	hybrid			2022-12-27	WOS:A1996VF61200062
J	McCallum, SJ; Wu, WJ; Cerione, RA				McCallum, SJ; Wu, WJ; Cerione, RA			Identification of a putative effector for Cdc42Hs with high sequence similarity to the RasGAP-related protein IQGAP1 and a Cdc42Hs binding partner with similarity to IQGAP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GDP-DISSOCIATION INHIBITOR; GTPASE-ACTIVATING PROTEIN; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; MOLECULAR-CLONING; CELL POLARITY; KINASE; RHO; RAC	Cdc42 is a Ras-related GTP-binding protein that has been implicated in the regulation of the actin cytoskeleton and cell morphology. In this study, we have identified a protein with a molecular mass similar to 180 kDa from rabbit Liver cytosol (designated p180), which binds preferentially to the GTP- and guanosine 5'-3-O-(thio)triphosphate-bound forms of Cdc42. Binding of p180 to GTP-bound Cdc42 maintains it in the GTP-bound state. Another cytosolic protein, with an apparent molecular mass of 175 kDa (p175), was also found to interact with Cdc42, but this association showed less dependence on guanine nucleotides. Both p180 and p175 were capable of binding to Rad but not to RhoA or Ha-Ras. The limit functional domain of the Cdc42 GAP protein did not compete with p180 or p175 for binding 60 Cdc42. However, the Cdc42-binding domain from mPAK-3, a member of the PAK (p21 activated kinase) family of serine/threonine kinases, competed with both proteins. The binding of p180 or p175 was inhibited by mutations of the putative effector loop of Cdc42. p180 and p175 also bound less effectively to a Cdc42/Ras chimera in which loop 8 from Ras was substituted for the predicted loop 8 in Cdc42 that includes a 13-amino acid insert present in all Rho family members but absent in Ras. Microsequencing of a p180 peptide revealed 92% identity with the human IQGAP1 protein, while two peptides derived from p175 were 89 and 100% identical to human IQGAP2, These findings identify IQGAP1 and IQGAP2 as a new class of target/effectors that utilize both regions of the switch I domain and an insert region distinct to Rho proteins for binding to Cdc42.	CORNELL UNIV,CTR VET MED,DEPT PHARMACOL,ITHACA,NY 14853; CORNELL UNIV,CTR VET MED,DEPT BIOCHEM,ITHACA,NY 14853; CORNELL UNIV,CTR VET MED,DEPT MOL & CELL BIOL,ITHACA,NY 14853	Cornell University; Cornell University; Cornell University					NIGMS NIH HHS [GM08210] Funding Source: Medline; PHS HHS [47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008210] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Best A, 1996, J BIOL CHEM, V271, P3756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ERICKSON JW, 1996, IN PRESS J BIOL CHEM, V271; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HART MJ, 1991, J BIOL CHEM, V266, P20840; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; SUTCLIFFE MJ, 1994, PROTEIN PEPTIDE LETT, V1, P84; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	37	128	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21732	21737		10.1074/jbc.271.36.21732	http://dx.doi.org/10.1074/jbc.271.36.21732			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702968				2022-12-27	WOS:A1996VF61200010
J	VasquezLaslop, N; Tenney, K; Bowman, BJ				VasquezLaslop, N; Tenney, K; Bowman, BJ			Characterization of a vacuolar protease in Neurospora crassa and the use of gene RIPing to generate protease-deficient strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEINASE-A; PEP4 GENE; YEAST; ATPASE; INACTIVATION; PURIFICATION; HYDROLASES; PATHWAY; ENCODES	We have isolated a gene from Neurospora crassa that appears to encode a pepstatin-sensitive protease found both in membranes and in soluble contents of vacuoles. The gene contains two introns and encodes a 396-residue protein with a molecular mass of 42,900 Da. Because of the similarity of the protein to proteinase A in Saccharomyces cerevisiae the gene has been named pep-4. Strains with mutations in the pep-4 gene were generated in vivo by the gene RIPing procedure described by Selker and Garrett (Selker, E. U., and Garrett, P. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 6870-6874). The mutant strains were deficient in pepstatin-sensitive protease activity and did not appear to produce a major 42-kDa polypeptide in the vacuole. The mutant strains grew at the same rate as the wild type and had no other observable phenotype. When compared with inactivation of the PEP4 gene of S. cerevisiae, inactivation of the pep-4 gene in N. crassa produced a phenotype that was different in several ways, In N. crassa the mutant strains did not exhibit reduced sporulation or reduced viability after nitrogen starvation, and they had elevated level of proteinase B and carboxypeptidase activities, The pep-4 gene appears to encode the N. crassa, homolog of proteinase A, but the maturation of vacuolar hydrolases appeared to be less dependent on this protease than has been observed in S. cerevisiae.	UNIV CALIF SANTA CRUZ, DEPT BIOL, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028703, S06GM008132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08132, GM28703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BOWMAN BJ, 1992, J EXP BIOL, V172, P57; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BOWMAN J, 1996, MYCOTA, V3, P57; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DAVIS RH, 1970, J BACTERIOL, V102, P299, DOI 10.1128/JB.102.2.299-305.1970; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; FREDERICK GD, 1993, GENE, V125, P57, DOI 10.1016/0378-1119(93)90745-O; JONES EW, 1990, METHOD ENZYMOL, V185, P372; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1989, ANN REV CELL BIOL, V5, P488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; Melnik VI, 1996, BBA-BIOENERGETICS, V1273, P77, DOI 10.1016/0005-2728(95)00144-1; MEUSSDOERFFER F, 1980, J BIOL CHEM, V255, P2087; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; OAKLEY CE, 1987, GENE, V53, P293, DOI 10.1016/0378-1119(87)90019-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SMITH TL, 1989, P NATL ACAD SCI USA, V86, P7063, DOI 10.1073/pnas.86.18.7063; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; VANDENHAZEL HB, 1995, J BIOL CHEM, V270, P8602, DOI 10.1074/jbc.270.15.8602; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; WECHSER MA, 1995, MOL GEN GENET, V249, P317, DOI 10.1007/BF00290533; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990	31	17	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21944	21949		10.1074/jbc.271.36.21944	http://dx.doi.org/10.1074/jbc.271.36.21944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702999	hybrid			2022-12-27	WOS:A1996VF61200041
J	Hammen, PK; Waltner, M; Hahnemann, B; Heard, TS; Weiner, H				Hammen, PK; Waltner, M; Hahnemann, B; Heard, TS; Weiner, H			The role of positive charges and structural segments in the presequence of rat liver aldehyde dehydrogenase in import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; SIGNAL PEPTIDE; PROCESSING PEPTIDASE; MALATE-DEHYDROGENASE; PRECURSOR PROTEIN; TRANSIT PEPTIDE; CHEMICAL-SHIFT; SPECTROSCOPY; MEMBRANES	Most mitochondrial proteins are nucleus-encoded and translated in the cytosol. They have an N-terminal presequence that allows recognition by the mitochondrial import apparatus and subsequent import into mitochondria. These presequences are rich in positive charges, mainly arginines. The role of these positive charges in the 19-amino acid presequence of rat liver aldehyde dehydrogenase was investigated by systematically replacing them with the polar but uncharged residue, glutamine. The single substitution of any of the four Arg residues in the helical segments did not affect import. Substitution of both Arg residues in the N-terminal segment (R3Q/R10Q) caused a dramatic decrease in import competence. This could be restored by using the mutant lacking the three-amino acid (RGP) linker that separates the two helical domains, determined by two-dimensional NMR (Thornton, K., Wang, Y., Weiner, H., and Gorenstein, D. G. (1993) J. Biol. Chem. 268, 19906-19914), CD and NMR spectra of the peptide corresponding to the linker deleted presequence showed that it was substantially more prone to helix formation than the native peptide over its entire length. A similar analysis of the peptide corresponding to the R3Q/R10Q presequence revealed that this peptide was only somewhat more helical than the native peptide and that the greater helicity did not include the residues near the N terminus. It is concluded that positively charged residues in the presequence play a vital role in the import of precursor aldehyde dehydrogenase. One of the positive charges in the N terminal helical segment of the presequence is necessary for import competence. However, if both positive charges are removed, import competence can be retained as long as the presequence is capable of forming a relatively more stable alpha-helix near its N terminus.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00028, AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHU TW, 1987, J BIOL CHEM, V262, P12806; DEKROON AIP, 1993, NEW COMP BIOCH, V25, P107; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HOYT DW, 1991, J BIOL CHEM, V266, P21693; HTORNTON KH, 1988, THESIS PURDUE U W LA; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; JONES JD, 1994, BIOPHYS J, V67, P1546, DOI 10.1016/S0006-3495(94)80628-9; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer Thomas, 1994, V26, P53; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PAK YK, 1990, J BIOL CHEM, V265, P14298; PARK SH, 1993, BIOCHEMISTRY-US, V32, P12901, DOI 10.1021/bi00210a044; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5468; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; TAKAKUBO F, 1995, AM J HUM GENET, V57, P772; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VANHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; WANG TTY, 1989, ARCH BIOCHEM BIOPHYS, V272, P440, DOI 10.1016/0003-9861(89)90238-5; WANG Y, 1994, BIOCHEMISTRY-US, V33, P12860, DOI 10.1021/bi00209a018; WANG Y, 1993, J BIOL CHEM, V268, P4759; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; ZHOU JZ, 1995, J BIOL CHEM, V270, P16689, DOI 10.1074/jbc.270.28.16689; [No title captured]	42	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21041	21048		10.1074/jbc.271.35.21041	http://dx.doi.org/10.1074/jbc.271.35.21041			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702869				2022-12-27	WOS:A1996VE47700015
J	Luo, YZ; Henle, ES; Linn, S				Luo, YZ; Henle, ES; Linn, S			Oxidative damage to DNA constituents by iron-mediated Fenton reactions - The deoxycytidine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED BASE DAMAGE; HYDROGEN-PEROXIDE; MAMMALIAN CHROMATIN; RADIATION; CYTOSINE; REPAIR; PATTERN	Damage by iron-mediated Fenton reactions under aerobic or anaerobic conditions to deoxycytidine, deoxycytidine 5'-monophosphate, d-CpC, d-CpCpC, and dCMP residues in DNA resulted in at least 26 distinguishable products. Of these, 24 were identified by high performance liquid chromatography retention times, radiolabeling, UV absorption spectra, chemical synthesis, fast atom bombardment mass spectrometry, high resolution fast atom bombardment mass spectrometry, and/or NMR. The nature of the products was qualitatively similar for each substrate except for d-CpC (and possibly d-CpCpC) under anaerobic conditions for which 5-hydroxy-deoxycytidine was uniquely present and 1-carbamoyl-1-carboxy-4-(2-deoxy-beta-D-erythropentofuranosyl) glycinamide was uniquely absent. Damage to dC, d-CpC, and d-CpCpC but not to dCMP or DNA was largely quenched by ethanol, indicating that iron is strongly associated only with dCMP and DNA. The presence of oxygen had little effect with dC or dCMP but had quantitative and qualitative effects with d-CpC and a significantly quantitative but not a qualitative effect with DNA. NADH could drive the Fenton reaction to cause damage to the dC family in vitro, consistent with a previous proposal that NADH was the reducing agent for the Fenton reaction in vivo (Imlay, J.A., and Linn, S. (1988) Science 240, 1302-1309). Finally, the damage spectrum of the dC family by the Fenton reaction is compared with that by ionizing radiation and chemical mechanisms leading to the formation of the 24 identified products are proposed.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM019020] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32ES070075] Funding Source: Medline; NIGMS NIH HHS [R29GM19020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUOMA OI, 1989, J BIOL CHEM, V264, P13024; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; BIAKELY WF, 1990, RADIAT RES, V121, P338; BIEDERMANN G, 1957, ACTA CHEM SCAND, V11, P731, DOI 10.3891/acta.chem.scand.11-0731; CADET J, 1981, CAN J CHEM, V59, P3313, DOI 10.1139/v81-490; DANIELS M, 1967, BIOCHIM BIOPHYS ACTA, V134, P481, DOI 10.1016/0005-2787(67)90031-7; DIZDAROGLU M, 1985, ANAL BIOCHEM, V144, P593, DOI 10.1016/0003-2697(85)90158-7; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P317, DOI 10.1016/0003-9861(91)90366-Q; DIZDAROGLU M, 1986, ANAL BIOCHEM, V156, P182, DOI 10.1016/0003-2697(86)90171-5; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1984, RADIAT RES, V100, P41, DOI 10.2307/3576519; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GRAF E, 1984, J BIOL CHEM, V259, P3620; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAZRA DK, 1983, J AM CHEM SOC, V105, P4380, DOI 10.1021/ja00351a042; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; HISSUNG A, 1978, Z NATURFORSCH B, V33, P321; HURST RO, 1952, J BIOL CHEM, V204, P847; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; KHATTAK MN, 1966, INT J RADIAT BIOL RE, V11, P131, DOI 10.1080/09553006614550891; LEUSSING DL, 1953, J AM CHEM SOC, V75, P2476, DOI 10.1021/ja01106a058; LUO HZ, 1994, METHOD ENZYMOL, V234, P51; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MYERS LS, 1970, J AM CHEM SOC, V92, P2871, DOI 10.1021/ja00712a045; POLVEREL.M, 1974, Z NATURFORSCH C, VC 29, P16; POLVEREL.M, 1974, Z NATURFORSCH C, VC 29, P12; POLVERELLI M, 1976, Z NATURFORSCH B, V31, P580; PONNAMPERUMA C, 1962, SCIENCE, V137, P605, DOI 10.1126/science.137.3530.605; Pullman B, 1969, Prog Nucleic Acid Res Mol Biol, V9, P327, DOI 10.1016/S0079-6603(08)60772-2; Sambrook J., 2002, MOL CLONING LAB MANU; SPIRO TG, 1974, IRON BIOCH MED, V1, P1; SUNG W, 1980, ENVIRON SCI TECHNOL, V14, P561, DOI 10.1021/es60165a006; Tan Z K, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P383; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; Van de Vorst A, 1978, Mol Biol Biochem Biophys, V27, P3; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WAGNER JR, 1990, METHOD ENZYMOL, V186, P502; WAGNER JR, 1988, THESIS U SHERBROOKE	44	102	102	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21167	21176		10.1074/jbc.271.35.21167	http://dx.doi.org/10.1074/jbc.271.35.21167			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702887	hybrid			2022-12-27	WOS:A1996VE47700033
J	Mundlos, S; Chan, D; Weng, YM; Sillence, DO; Cole, WG; Bateman, JF				Mundlos, S; Chan, D; Weng, YM; Sillence, DO; Cole, WG; Bateman, JF			Multiexon deletions in the type I collagen COL1A2 gene in osteogenesis imperfecta type IB - Molecules containing the shortened alpha 2(I) chains show differential incorporation into the bone and skin extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) CHAIN; TRIPLE-HELIX; CULTURED FIBROBLASTS; MESSENGER-RNA; CROSS-LINKING; N-PROPEPTIDE; LETHAL FORM; 3' END; SUBSTITUTION; PROCOLLAGEN	Osteogenesis imperfecta (OI) type IB is a rare subset of the mildest form of OI, clinically characterized by moderate bone fragility, blue sclera, and dentinogenesis imperfecta. Cultured skin fibroblasts from two unrelated individuals (OI-197 and OI-165) with the typical features of OI type IB produced shortened alpha 2(I) chains, Reverse transcription-polymerase chain reaction of the alpha 2(I)-cDNA revealed deletions in the triple helical domain of 5 exons (exons 7-11) in OI-197, and 8 exons (exons 10-17) in OI-165. This exon skipping was caused by genomic deletions in one allele of COL1A2 with the breakpoints located in introns 6 and 11 in OI-197, and introns 9 and 17 in OI-165, The secretion and deposition of the mutant collagen into the matrix was measured in vitro in cultures of skin fibroblasts and bone osteoblasts, grown in the presence of ascorbic acid to induce collagen matrix formation and maturation, as well as in collagen extracts from skin and bone. The secretion of mutant collagen was impaired and long term cultures of fibroblasts showed that the mutant collagen was not incorporated into the mature collagenous matrix produced in vitro by skin fibroblasts from both patients. Likewise, the shortened alpha 2(I) chain was not demonstrable in skin extracts. In contrast, bone extracts from OI-197 showed the presence of the mutant collagen, This incorporation of the abnormal collagen into the mature matrix was also demonstrated in long term cultures of the patient's osteoblasts, The deposition of the mutant collagen by bone osteoblasts but not by skin fibroblasts demonstrates a tissue specificity in the incorporation of mutant collagen into the matrix which may explain the primary involvement of bone and not skin in these patients.	UNIV MELBOURNE, ROYAL CHILDRENS HOSP, DEPT PAEDIAT, ORTHOPAED MOL BIOL RES UNIT, PARKVILLE, VIC 3052, AUSTRALIA; NEW CHILDRENS HOSP, DEPT CLIN GENET, PARRAMATTA, NSW 2124, AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne			Mundlos, Stefan/ABH-9585-2020; Chan, Danny/C-4203-2009	Bateman, John/0000-0001-8542-0730; Chan, Danny/0000-0003-3824-5778				BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1993, AM J MED GENET, V45, P233, DOI 10.1002/ajmg.1320450216; BATEMAN JF, 1988, ANAL BIOCHEM, V168, P171, DOI 10.1016/0003-2697(88)90025-5; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1994, BIOCHEM J, V302, P729, DOI 10.1042/bj3020729; BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BIENKOWSKI RS, 1983, BIOCHEM J, V214, P1; Byers Peter H., 1993, P317; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHIPMAN SD, 1992, J BONE MINER RES, V7, P793; CHU ML, 1983, NATURE, V304, P78, DOI 10.1038/304078a0; COHN DH, 1988, J BIOL CHEM, V263, P14605; DEAK SB, 1991, J BIOL CHEM, V266, P21827; DEWET W, 1987, J BIOL CHEM, V262, P16032; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; DOUGLAS AM, 1992, ANAL BIOCHEM, V201, P362, DOI 10.1016/0003-2697(92)90352-8; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FEDARKO NS, 1992, J BONE MINER RES, V7, P921; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; KATZ EP, 1992, J MOL BIOL, V228, P963, DOI 10.1016/0022-2836(92)90878-N; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOTTES M, 1994, HUM GENET, V93, P681; MOTTES M, 1992, HUM GENET, V89, P480; MYERS JC, 1983, J BIOL CHEM, V258, P128; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; NIYIBIZI C, 1992, J BIOL CHEM, V267, P23108; OTSUBO K, 1992, BIOCHEMISTRY-US, V31, P396, DOI 10.1021/bi00117a013; PATERSON CR, 1983, J MED GENET, V20, P203, DOI 10.1136/jmg.20.3.203; SHAPIRO JR, 1992, J CLIN INVEST, V89, P567, DOI 10.1172/JCI115622; SILLENCE D, 1993, AM J MED GENET, V45, P183, DOI 10.1002/ajmg.1320450207; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; Steinmann Beat, 1993, P351; SUPERTIFURGA A, 1993, CONNECT TISSUE RES, V29, P31, DOI 10.3109/03008209309061964; SYKES B, 1990, AM J HUM GENET, V46, P293; VALLI M, 1993, EUR J BIOCHEM, V217, P77, DOI 10.1111/j.1432-1033.1993.tb18220.x; VASAN NS, 1991, AM J HUM GENET, V48, P305; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; WILLING MC, 1993, AM J MED GENET, V45, P223, DOI 10.1002/ajmg.1320450214; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WILLING MC, 1994, AM J HUM GENET, V55, P638; WILLING MC, 1988, J BIOL CHEM, V263, P8398; Yamauchi M, 1988, COLLAGEN, P157; ZHUANG JP, 1993, HUM GENET, V91, P210	55	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21068	21074		10.1074/jbc.271.35.21068	http://dx.doi.org/10.1074/jbc.271.35.21068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702873	hybrid			2022-12-27	WOS:A1996VE47700019
J	Rudd, MD; Luse, DS				Rudd, MD; Luse, DS			Amanitin greatly reduces the rate of transcription by RNA polymerase II ternary complexes but fails to inhibit some transcript cleavage modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; MAJOR LATE PROMOTER; ALPHA-AMANITIN; NASCENT RNA; ABORTIVE INITIATION; TERMINATION SITES; LARGEST SUBUNIT; BETA' SUBUNIT; CALF THYMUS; C-MYC	The toxin alpha-amanitin is frequently employed to completely block RNA synthesis by RNA polymerase II. However, we find that polymerase II ternary transcription complexes stalled by the absence of NTPs resume RNA synthesis when NTPs and amanitin are added. Chain elongation with amanitin can continue for hours at approximately 1% of the normal rate. Amanitin also greatly slows pyrophosphorolysis by elongation-competent complexes. Complexes which are arrested (that is, which have paused in transcription for long periods in the presence of excess NTPs) are essentially incapable of resuming transcription in the presence of alpha-amanitin. Complexes traversing sequences that can provoke arrest are much more likely to stop transcription in the presence of the toxin. The substitution of IMP for GMP at the 3' end of the nascent RNA greatly increases the sensitivity of stalled transcription complexes to amanitin. Neither arrested nor stalled complexes display detectable SII-mediated transcript cleavage following amanitin treatment. However, arrested complexes possess a low level, intrinsic transcript cleavage activity which is completely amanitin-resistant; furthermore, pyrophosphorolytic transcript cleavage in arrested complexes is not affected by amanitin.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BARTOLOMEI MS, 1995, MOL GEN GENET, V246, P778, DOI 10.1007/BF00290727; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; COPPOLA JA, 1984, J MOL BIOL, V178, P415, DOI 10.1016/0022-2836(84)90151-7; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; GREENLEAF AL, 1983, J BIOL CHEM, V258, P3403; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JOB C, 1992, BIOCHEM J, V285, P85, DOI 10.1042/bj2850085; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUTTER LC, 1982, J BIOL CHEM, V257, P1577; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1991, NUCLEIC ACIDS RES, V19, P1783, DOI 10.1093/nar/19.8.1783; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VAISIUS AC, 1982, BIOCHEMISTRY-US, V21, P3097, DOI 10.1021/bi00256a010; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	49	57	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21549	21558		10.1074/jbc.271.35.21549	http://dx.doi.org/10.1074/jbc.271.35.21549			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702941	hybrid			2022-12-27	WOS:A1996VE47700087
J	Wolf, MJ; Gross, RW				Wolf, MJ; Gross, RW			The calcium-dependent association and functional coupling of calmodulin with myocardial phospholipase A(2) - Implications for cardiac cycle-dependent alterations in phospholipolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CALMODULIN; ARACHIDONIC-ACID; NUCLEOTIDE PHOSPHODIESTERASE; INDEPENDENT PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A2; PURIFICATION; BINDING; CELLS; PROTEIN; MUSCLE	Herein we demonstrate the calcium-dependent regulation of myocardial phospholipase A(2) activity, which is mediated by a cytosolic protein constituent that can be chromatographically resolved from, and subsequently reconstituted with, purified myocardial phospholipase A(2). Purification of this protein by sequential column chromatographies revealed an 18-kDa doublet, which was identified as calmodulin by Western blotting, calcium-dependent precipitation with W-7 agarose beads, and reconstitution of calcium-mediated phospholipase A(2) inhibition with authentic homogeneous calmodulin, Calcium-induced calmodulin-mediated inhibition of myocardial phospholipase A(2) was titrated by physiologic increments of calcium ion (K-d similar to 200 nM). Moreover, ternary complex affinity chromatography with calmodulin-Sepharose demonstrated that inhibition of myocardial phospholipase A(2) activity by calmodulin resulted from the direct interaction of calmodulin with the myocardial phospholipase A(2) catalytic complex, Exposure of cultured A-10 muscle cells to three structurally disparate calmodulin antagonists (W-7, trifluoperazine, and calmidazolium) resulted in the robust release of arachidonic acid, which was entirely ablated by pretreatment of cells with (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2-H-tetrahydropyran-2-one. Collectively, this study identifies a novel mechanism whereby latent phospholipase A(2) activity can be released from tonic inhibition by alterations in the interactions between the phospholipase A(2) catalytic complex, calcium ion, and the intracellular calcium transducer, calmodulin.	WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT MOL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852				ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; BRANDES R, 1993, BIOPHYS J, V65, P1973, DOI 10.1016/S0006-3495(93)81274-8; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COYNE MD, 1985, ARCH BIOCHEM BIOPHYS, V236, P629, DOI 10.1016/0003-9861(85)90667-8; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GIETZEN K, 1983, BIOCHEM J, V216, P611, DOI 10.1042/bj2160611; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; GROSS RW, 1995, J LIPID MEDIAT CELL, V12, P131, DOI 10.1016/0929-7855(95)00014-H; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; KIHARA Y, 1989, CIRC RES, V65, P1029, DOI 10.1161/01.RES.65.4.1029; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEVIN RM, 1979, J PHARMACOL EXP THER, V208, P454; LEVIN RM, 1977, MOL PHARMACOL, V13, P690; MOORE PB, 1982, J BIOL CHEM, V257, P9663; OGANA Y, 1984, J BIOCHEM-TOKYO, V95, P19; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; SHARMA RK, 1990, J BIOL CHEM, V265, P1152; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; TANAKA T, 1980, J BIOL CHEM, V255, P1078; THANDROYEN FT, 1991, CIRC RES, V69, P810, DOI 10.1161/01.RES.69.3.810; VANBELLE H, 1981, CELL CALCIUM, V2, P484; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WOLF RA, 1985, J BIOL CHEM, V260, P7259; XIAO YF, 1995, P NATL ACAD SCI USA, V92, P11000, DOI 10.1073/pnas.92.24.11000	40	83	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20989	20992		10.1074/jbc.271.35.20989	http://dx.doi.org/10.1074/jbc.271.35.20989			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702861	hybrid			2022-12-27	WOS:A1996VE47700005
J	Cao, X; Teitelbaum, SL; Zhu, HJ; Zhang, LM; Feng, X; Ross, FP				Cao, X; Teitelbaum, SL; Zhu, HJ; Zhang, LM; Feng, X; Ross, FP			Competition for a unique response element mediates retinoic acid inhibition of vitamin D-3-stimulated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCALCIN GENE; HORMONE RECEPTOR-BETA; THYROID-HORMONE; BONE-RESORPTION; DNA-BINDING; DIRECT REPEATS; LIGAND SENSITIVITY; NUCLEAR RECEPTORS; CELL-ADHESION; SUBUNIT GENE	We have identified a novel steroid hormone response element in the avian beta(3) integrin promoter. This sequence, comprising three hexameric direct repeat half-sites separated by nine and three nucleotides binds vitamin D receptor (VDR)-retinoid X receptor (RXR) and retinoic acid receptor (RAR)-RXR heterodimers. VDR-RXR binds direct repeats separated by three basepairs, and RAR-RXR recognizes half-sites separated by nine bases, whereas the central half-site interacts with both heterodimers. Retinoic acid and 1,25-dihydroxyvitamin D-3 activate both a genomic fragment including the transcriptional start site and an oligonucleotide containing the three repeats, linked to a heterologous promoter. Co-addition of the steroids produces neither synergy nor an additive effect; rather the result equals that for retinoic acid alone. Scatchard analysis demonstrates that RAR-RXR has greater affinity than VDR-RXR for the composite element. Based on these findings we propose a model in which there is specific, polarity-defined binding of VDR-RXR and RAR-RXR to three half-sites, which form two overlapping steroid response elements, with the central half-site common to both, Our results identify a novel mechanism by which one steroid hormone can modulate the activity of a second, by competing for a shared half-site in a composite response element.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR32788, AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R01AR042404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BALDWIN AS, 1994, CURRENT PROTOCOLS MO; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; CAO X, 1993, J BIOL CHEM, V268, P27371; DRESNERPOLLAK R, 1994, J CELL BIOCHEM, V56, P323, DOI 10.1002/jcb.240560308; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONOWICZ GA, 1994, J BONE MINER RES, V9, P193, DOI 10.1002/jbmr.5650090208; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HORTON MA, 1995, ANN NY ACAD SCI, V760, P190, DOI 10.1111/j.1749-6632.1995.tb44630.x; HOUGH S, 1988, ENDOCRINOLOGY, V122, P2933, DOI 10.1210/endo-122-6-2933; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAJI H, 1995, LIFE SCI, V56, P1903, DOI 10.1016/0024-3205(95)00165-3; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KING KL, 1994, J BONE MINER RES, V9, P381; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIUSI BF, 1991, NATURE, V352, P497; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MIMURA H, 1994, ENDOCRINOLOGY, V134, P1061, DOI 10.1210/en.134.3.1061; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20650	20654		10.1074/jbc.271.34.20650	http://dx.doi.org/10.1074/jbc.271.34.20650			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702813	hybrid			2022-12-27	WOS:A1996VD33700065
J	Cooper, CE; Lynagh, GR; Hoyes, KP; Hider, RC; Cammack, R; Porter, JB				Cooper, CE; Lynagh, GR; Hoyes, KP; Hider, RC; Cammack, R; Porter, JB			The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMALL SUBUNIT; CELL-GROWTH; PROTEIN; ENZYME; DESFERRIOXAMINE; MOSSBAUER; MECHANISM; RESONANCE; OXYGEN	The depletion of cellular iron can lead to the inhibition of ribonucleotide reductase, preventing new DNA synthesis and hence inhibiting cell proliferation. Electron paramagnetic resonance (EPR) spectroscopy has been used to examine simultaneously for the first time the relationship between chelation of intracellular iron and the rate of removal and regeneration of the tyrosyl radical of ribonucleotide reductase within intact human leukemia K562 cells. The different physiochemical characteristics of relatively hydrophobic low molecular weight bidentate hydroxypyridinone chelators and the higher molecular weight hexadentate ferrioxamine have been exploited to elucidate these interactions further. The base-line concentration of EPR detectable mononuclear nonheme iron complexes was 3.15 +/- 1.05 mu M, rising on incubation with chelators more rapidly with hydroxypyridinones than with desferrioxamine. Hydroxypyridinones also removed the tyrosyl radical more rapidly, apparently as a consequence of depletion of the intracellular iron pools necessary to regenerate the active enzyme and compatible with their reportedly greater cell toxicity. The radical decay rate is consistent with previous models, suggesting that iron is spontaneously removed from mammalian ribonucleotide reductase. Upon removal of extracellular chelator the regeneration of the tyrosyl radical was significantly faster for hydroxypyridinones than for desferrioxamine, consistent with their differential effects on cell cycle synchronization.	UCL, SCH MED, DEPT HAEMATOL, LONDON WC1E 6HX, ENGLAND; UNIV LONDON KINGS COLL, DIV LIFE SCI, MET BIOL & MED CTR, LONDON W8 7AH, ENGLAND	University of London; University College London; UCL Medical School; University of London; King's College London	Cooper, CE (corresponding author), UNIV ESSEX, DEPT BIOL & CHEM SCI, CENT CAMPUS, WIVENHOE PK, COLCHESTER CO4 3SQ, ESSEX, ENGLAND.		Cammack, Richard/B-7841-2008; Cooper, Chris/AAK-9729-2020	Cooper, Chris/0000-0003-0381-3990; Porter, John/0000-0003-3000-9359	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BARANKIEWICZ J, 1987, BIOCHEM PHARMACOL, V36, P2343, DOI 10.1016/0006-2952(87)90601-0; BROWN NC, 1969, EUR J BIOCHEM, V9, P512, DOI 10.1111/j.1432-1033.1969.tb00639.x; CAMMACK R, 1988, METHOD ENZYMOL, V167, P427; CAMMACK R, 1993, METHOD ENZYMOL, V227, P353, DOI 10.1016/0076-6879(93)27014-8; CHITAMBAR CR, 1988, BLOOD, V72, P1930; COOPER CE, 1994, FREE RADICAL DAMAGE, P65; DOBBIN PS, 1993, J MED CHEM, V36, P2448, DOI 10.1021/jm00069a002; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HIDER RC, 1994, DEVELOPMENT OF IRON CHELATORS FOR CLINICAL USE, P353; HOYES KP, 1993, BRIT J HAEMATOL, V85, P393, DOI 10.1111/j.1365-2141.1993.tb03184.x; HOYES KP, 1992, CANCER RES, V52, P4591; KONTOGHIORGHES GJ, 1990, CLIN PHARMACOL THER, V48, P255, DOI 10.1038/clpt.1990.147; LAMMERS M, 1983, STRUCT BOND, V54, P27; LEE P, 1993, DRUG METAB DISPOS, V21, P640; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; NOCENTINI G, 1993, CANCER RES, V53, P19; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Porter J. B., 1994, British Journal of Haematology, V87, P114; PORTER JB, 1994, ADV EXP MED BIOL, V356, P361; PORTER JB, 1989, CLIN HAEMATOL, V2, P257; PORTER JB, 1994, BR J HAEMATOL S1, V84, P64; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROBERTS PJ, 1990, BLOOD, V75, P976; SIMPSON RJ, 1992, BIOCHIM BIOPHYS ACTA, V1156, P19, DOI 10.1016/0304-4165(92)90090-H; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; THELANDER L, 1983, J BIOL CHEM, V258, P4063; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WEIR MP, 1985, BIOCHIM BIOPHYS ACTA, V828, P298, DOI 10.1016/0167-4838(85)90311-5	40	169	172	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20291	20299		10.1074/jbc.271.34.20291	http://dx.doi.org/10.1074/jbc.271.34.20291			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702762	hybrid			2022-12-27	WOS:A1996VD33700014
J	Detimary, P; VandenBerghe, G; Henquin, JC				Detimary, P; VandenBerghe, G; Henquin, JC			Concentration dependence and time course of the effects of glucose on adenine and guanine nucleotides in mouse pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; INSULIN-SECRETING CELLS; INTACT RAT ISLETS; BETA-CELLS; K+-CHANNELS; B-CELLS; ENERGY-STATE; HIT CELLS; G-PROTEIN; 2 SITES	Changes in the ATP:ADP ratio in pancreatic B cells may participate in the regulation of insulin secretion by glucose. Here, we have investigated the possible role of guanine nucleotides. Mouse islets were incubated in a control medium (when K+-ATP channels are the major site of regulation) or in a high K+ medium (when glucose modulates the effectiveness of cytosolic Ca2+ on exocytosis). Glucose induced a concentration-dependent (0-20 mM) increase in GTP and a decrease in GDP in both types of medium, thus causing a progressive rise of the GTP:GDP ratio, ATP and ADP levels were 4-5-fold higher but varied in a similar way as those of guanine nucleotides. Insulin secretion was inversely correlated with ADP and GDP levels and positively correlated with the ATP:ADP and GTP:GDP ratios between 6 and 20 mM glucose in control medium and between 0 and 20 mM glucose in high K+ medium, The increases in the GTP:GDP and ATP:ADP ratios induced by a rise of glucose were faster than the decreases induced by a fall in glucose, but the changes of both ratios were again parallel. In conclusion, glucose causes large, concentration-dependent changes in guanine as well as in adenine nucleotides in islet cells. This raises the possibility that both participate in the regulation of nutrient-induced insulin secretion.	UNIV CATHOLIQUE LOUVAIN,FAC MED,UNITE ENDOCRINOL & METAB,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,FAC MED,CHIM PHYSIOL LAB,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Catholique Louvain								ALEYASSINE H, 1970, ENDOCRINOLOGY, V87, P84, DOI 10.1210/endo-87-1-84; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DETIMARY P, 1994, BIOCHEM J, V297, P455, DOI 10.1042/bj2970455; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; DUNNE MJ, 1986, PFLUG ARCH EUR J PHY, V407, P564, DOI 10.1007/BF00657518; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GHOSH A, 1991, J BIOL CHEM, V266, P22887; HAMMPP R, 1986, METHOD ENZYMAT AN, P870; HELLMAN B, 1969, DIABETES, V18, P509, DOI 10.2337/diab.18.8.509; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOENIG M, 1987, METABOLISM, V36, P295, DOI 10.1016/0026-0495(87)90192-2; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; JONAS JC, 1994, BIOCHEM J, V301, P523, DOI 10.1042/bj3010523; JONES PM, 1993, MOL CELL ENDOCRINOL, V94, P97, DOI 10.1016/0303-7207(93)90056-P; KARL DM, 1978, METHOD ENZYMOL, V57, P85; KOCH G, 1992, BIOCHEM BIOPH RES CO, V186, P448, DOI 10.1016/S0006-291X(05)80828-9; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KOWLURU A, 1994, BIOCHEMISTRY-US, V33, P12495, DOI 10.1021/bi00207a017; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3; MEREDITH M, 1995, J CLIN INVEST, V96, P811, DOI 10.1172/JCI118127; METZ SA, 1992, J BIOL CHEM, V267, P12517; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; OHTA M, 1990, J BIOL CHEM, V265, P17525; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; SCHWANSTECHER C, 1994, BRIT J PHARMACOL, V111, P302, DOI 10.1111/j.1476-5381.1994.tb14060.x; SCHWANSTECHER C, 1992, BRIT J PHARMACOL, V107, P87, DOI 10.1111/j.1476-5381.1992.tb14467.x; Sokal R. R., 1969, BIOMETRY PRINCIPLES, P1; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; ZUNKLER BJ, 1986, IRCS MED SCI-BIOCHEM, V14, P354	50	112	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20559	20565		10.1074/jbc.271.34.20559	http://dx.doi.org/10.1074/jbc.271.34.20559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702800	hybrid			2022-12-27	WOS:A1996VD33700052
J	Limbourg, FP; Stadtler, H; Chinnadurai, G; Baeuerle, PA; Schmitz, ML				Limbourg, FP; Stadtler, H; Chinnadurai, G; Baeuerle, PA; Schmitz, ML			A hydrophobic region within the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF-kappa B activated by different stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; 19-KILODALTON PROTEIN; CELL-TRANSFORMATION; TARGETED DISRUPTION; BCL-2 PROTEINS; MICE LACKING; FACTOR-ALPHA; LP+ LOCUS; DNA	The early transcribed adenovirus proteins E1A and E1B display a variety of functions in the transformation of primary rodent cells and the regulation of apoptosis and transcription. We have recently shown recently that the E1B 19 kDa protein from Adenovirus 5 (Ad 5) can functionally antagonize the stimulatory effect of E1A 13S on the human transcription factor NF-kappa B. Here we show that expression of E1B 19 kDa negatively interfered with the activation of NF-kappa B by different stimuli, such as the E1A 13S protein, and treatment with phorbol ester and tumor necrosis factor alpha. This suggests that E1B 19 kDa acts on a common upstream signaling event. Band shift experiments showed that expression of E1B 19 kDa impaired the generation of the nuclear, DNA-binding form of NF-kappa B. Domain mapping experiments employing various E1B 19 kDa mutants revealed the necessity of a hydrophobic Bcl-2 homology region between amino acids 90 and 96 for NF-kappa B inhibition. Cotransfection experiments showed that the inhibitory effect of E1B 19 kDa on E1A 13S-activated NF-kappa B transcription was gradually lost in the course of time. Thus the continuous stimulatory action of E1A 13S can finally override the antagonistic effects of E1B 19 kDa on NF-kappa B activity. In contrast to E1B 19 kDa, expression of the E1B 55 kDa protein did not result in a de novo activation of NF-kappa B, but co-stimulated the transcriptional potential of activated NF-kappa B.	UNIV FREIBURG, INST BIOCHEM & MOL BIOL, D-79104 FREIBURG, GERMANY; ST LOUIS UNIV, HLTH SCI CTR, INST MOL VIROL, ST LOUIS, MO 63110 USA; TULARIK INC, San Francisco, CA 94080 USA	University of Freiburg; Saint Louis University			Limbourg, Florian/AAF-5010-2019; Schmitz, M. Lienhard/D-9328-2017	Limbourg, Florian/0000-0002-8313-7226; Schmitz, M. Lienhard/0000-0002-6984-7192	NCI NIH HHS [R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BERGMAN Y, 1988, J IMMUNOL, V140, P2073; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DERYCKERE F, 1995, IMMUNOBIOLOGY, V193, P186, DOI 10.1016/S0171-2985(11)80542-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eick D, 1996, TRENDS GENET, V12, P4, DOI 10.1016/0168-9525(96)81374-6; EVANS AS, 1958, AM J HYG, V67, P256, DOI 10.1093/oxfordjournals.aje.a119932; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FOX JP, 1977, AM J EPIDEMIOL, V105, P362, DOI 10.1093/oxfordjournals.aje.a112394; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1996, IN PRESS J CELL BIOL; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schmitz ML, 1995, TOXICOL LETT, V82-3, P407, DOI 10.1016/0378-4274(95)03491-9; SCHMITZ ML, 1995, NATO ASI SER H, V92, P279; SCHMITZ ML, 1996, IN PRESS MOL CELL BI; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; TARODI B, 1993, INT J ONCOL, V3, P467; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	65	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20392	20398		10.1074/jbc.271.34.20392	http://dx.doi.org/10.1074/jbc.271.34.20392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702775	hybrid			2022-12-27	WOS:A1996VD33700027
J	Orlowski, J; Kandasamy, RA				Orlowski, J; Kandasamy, RA			Delineation of transmembrane domains of the Na+/H+ exchanger that confer sensitivity to pharmacological antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; MOLECULAR-CLONING; H+ EXCHANGER; FUNCTIONAL EXPRESSION; AMILORIDE INHIBITION; CARDIAC ISCHEMIA; ISOFORM NHE-2; ANTIPORTER; MEMBRANE; CELLS	Plasma membrane Na+/H+ exchanger (NHE) isoforms NNE1 and NHE3 exhibit very different sensitivities to amiloride and its 5-amino-substituted analogues, benzoyl guanidinium derivatives (e.g. (3-methylsulfonyl-4-piperidinobenzoyl)guanidine methanesulfonate (HOE-694)), and cimetidine. To define structural domains that confer differential sensitivity to these antagonists, unique restriction endonuclease sites were engineered into cDNAs for each isoform near the regions that encode the putative membrane-spanning domains. These new sites did not modify their pharmacological properties and allowed several chimeric Na+/H+ exchangers to be constructed by exchanging homologous segments. The modified parental (E1(+) and E3(+)) and chimeric molecules were stably expressed in exchanger-deficient. Chinese hamster ovary AP-1 cells and assayed for their sensitivities to amiloride, ethylisopropylamiloride, HOE694, and cimetidine. Most chimeras showed drug sensitivities corresponding to the dominant parental segment. However, interchanging a 66-amino acid segment containing the putative ninth transmembrane (M9) domain and its adjacent loops caused reciprocal alterations in the sensitivities of E1' and E3' to all antagonists, In addition, substituting the first five putative membrane-spanning domains of E3' with the corresponding region of E1' modestly reduced the transporter's sensitivity to cimetidine but not the other compounds, These data indicate that the protein segment between M8 and M10 mag be a major site of interaction with these antagonists, although other regions modestly influence sensitivity to certain drugs.			Orlowski, J (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL,PQ H3G 1Y6,CANADA.			Orlowski, John/0000-0001-7371-175X				BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; GANAPATHY V, 1986, J PHARMACOL EXP THER, V239, P192; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HARPER IS, 1993, BASIC RES CARDIOL, V88, P430, DOI 10.1007/BF00795410; IVES HE, 1983, J BIOL CHEM, V258, P9710; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MORDUCHOWICZ GA, 1989, KIDNEY INT, V36, P576, DOI 10.1038/ki.1989.233; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PARIS S, 1983, J BIOL CHEM, V258, P3503; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHOLZ W, 1995, CARDIOVASC RES, V29, P260, DOI 10.1016/S0008-6363(96)88579-8; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; WANG Z, 1993, J BIOL CHEM, V268, P11925; WARNOCK DG, 1988, J BIOL CHEM, V263, P7216; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	37	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19922	19927		10.1074/jbc.271.33.19922	http://dx.doi.org/10.1074/jbc.271.33.19922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702706	hybrid			2022-12-27	WOS:A1996VC66900047
J	Pohlschroder, M; Murphy, C; Beckwith, J				Pohlschroder, M; Murphy, C; Beckwith, J			In vivo analyses of interactions between SecE and SecY, core components of the Escherichia coli protein translocation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; SIGNAL-SEQUENCE; PREPROTEIN TRANSLOCASE; EXPORT; RECONSTITUTION; MUTATIONS; GENE; DETERMINANTS; TEMPERATURE; SUFFICIENT	We have carried out structure-function studies on the cytoplasmic membrane protein, SecE, a component of the Escherichia coli secretion machinery. SecE, along with SecY, form a complex in the cytoplasmic membrane essential for protein translocation. By directed mutagenesis, we altered highly conserved residues of the second cytoplasmic domain (CD2) and of the COOH-terminaI periplasmic region (PD2) of SecE. These mutants, as well as previously constructed mutations in the third membrane-spanning segment of SecE (MSS3), were tested for their ability to complement a secE null mutation, for their effects on protein export in vivo, and for their ability to form a stable complex with SecY. Most single mutations at the conserved positions in CD2 caused secretion defects, but had Little effect on growth at 37 degrees C. Double mutations in CD2, or the introduction Or removal of proline residues, affected growth and protein translocation more severely. Co-immunoprecipitations of SecE and SecY revealed that all mutant proteins, except those altered in PD2, destabilized the SecE-SecY complex. These results suggest that several regions contribute to the formation of a stable SecE-SecY complex but the elimination of a single contact point does not necessarily affect the functionality of the complex.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; MYCO PHARMACEUT,CAMBRIDGE,MA 02139	Harvard University; Harvard Medical School			Pohlschroder, Mechy/P-3206-2019					AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; GUZMAN LM, 1992, J BACTERIOL, V174, P7717; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HARTMANN E, 1994, NATURE, V367, P954; INOUYE H, 1977, P NATL ACAD SCI USA, V74, P1440, DOI 10.1073/pnas.74.4.1440; INOUYE S, 1977, P NATL ACAD SCI USA, V74, P1004, DOI 10.1073/pnas.74.3.1004; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MEACOCK PA, 1980, CELL, V20, P529, DOI 10.1016/0092-8674(80)90639-X; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MURPHY C, 1996, COLD SPRING HARB SYM, V60, P277; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; MURPHY CK, 1995, GENE, V155, P1, DOI 10.1016/0378-1119(94)00920-N; NISHIYAMA K, 1992, J BIOL CHEM, V267, P7170; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; STADER J, 1989, GENE DEV, V3, P1045, DOI 10.1101/gad.3.7.1045; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	44	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19908	19914		10.1074/jbc.271.33.19908	http://dx.doi.org/10.1074/jbc.271.33.19908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702704	hybrid			2022-12-27	WOS:A1996VC66900045
J	Dong, F; vonHippel, PH				Dong, F; vonHippel, PH			The ATP-activated hexameric helicase of bacteriophage T4 (gp41) forms a stable primosome with a single subunit of T4-coded primase (gp61)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA PRIMER SYNTHESIS; DNA-REPLICATION SYSTEM; LEADING-STRAND; NUCLEOTIDE-BINDING; EXPRESSED PROTEIN; ASSEMBLY PROTEIN; GENE-41 PROTEIN; PURIFICATION; T4-61-PROTEIN; T4-41-PROTEIN	We have examined the formation of the primosome subassembly of the bacteriophage T4-coded DNA replication (elongation) complex from its helicase, primase, and DNA components, Previously, we had shown that the T4 helicase (gp41) exists in solution in a stable monomer <--> dimer equilibrium at physiological protein (and salt) concentrations and forms a hexamer upon activation by ATP (or GTP) binding (Dong, F., Gogol, E. P., and von Hippel, P. H. (1995) J. Biol. Chem. 270, 7462-7473), Here we report that the T4 primase (gp61) is a monomer in solution under the same conditions, and that the ATP-activated helicase binds to a single gp61 primase molecule on appropriate DNA templates to reconstitute a stable primosome. We show that: (i) the gp41 helicase alone does not form a stable complex with DNA templates, although this helicase by itself can carry out moderately processive ATP-driven translocation along single-stranded DNA (Young, M. C., Schultz, D. E., Ring, D., and von Hippel, P. H. (1994) J. Mel. Biol. 235, 1447-1458); (ii) the primase alone does form a stable complex with DNA; (iii) the helicase can bind to the primase-DNA complex in the presence of ATP or GTP to form a stable ternary complex; (iv) this complex consists of six helicase subunits and one primase subunit; and (v) the reconstituted primosome is stable for at least 10 to 20 min after NTP cleavage and dissociation of the hydrolysis products, These results strongly suggest that the functional T4 DNA replication primosome consists of an integrated 6:1 helicase-primase complex bound to DNA, and that the ATP-activated helicase hexamer remains intact throughout the processive DNA replication process.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, R01GM029158, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1988, CANCER CELL, V6, P1; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HINTON DM, 1985, J BIOL CHEM, V260, P2858; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Nossal Nancy G., 1994, P43; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATEL SS, 1995, BIOPHYS J, V68, pS186; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Weber K., 1975, PROTEINS, VI, P179; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	26	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19625	19631		10.1074/jbc.271.32.19625	http://dx.doi.org/10.1074/jbc.271.32.19625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702659	hybrid			2022-12-27	WOS:A1996VB68400093
J	Tyedmers, J; Brunke, M; Lechte, M; Sandholzer, U; Dierks, T; Schlotterhose, P; Schmidt, B; Zimmermann, R				Tyedmers, J; Brunke, M; Lechte, M; Sandholzer, U; Dierks, T; Schlotterhose, P; Schmidt, B; Zimmermann, R			Efficient folding of firefly luciferase after transport into mammalian microsomes in the absence of luminal chaperones and folding catalysts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; PRESECRETORY PROTEINS; TRANSLOCATION; IMMUNOPHILINS; MEMBRANE; CELL; ATP	Folding of polypeptides emerging from the protein translocase in the membrane of mammalian microsomes was analyzed after synthesis of corresponding precursor proteins in a mammalian translation system. Firefly luciferase was used as a model protein; the corresponding hybrid precursor contained the preprolactin signal peptide. The rates and efficiencies of folding of luciferase in microsomes were compared with those of folding of luciferase in the cytosol. Furthermore, folding of luciferase in microsomes was compared with that in proteoliposomes, i.e. in the absence of luminal molecular chaperones and folding catalysts. Folding in microsomes was less efficient compared with folding in the cytosol. Folding in the absence of luminal proteins was more efficient compared with folding in their presence and identical to folding in the cytosol. Thus, firefly luciferase emerging from translocase can efficiently fold to its native conformation without chaperoning by any luminal proteins. There may be molecular chaperones present in the microsomal membrane that can efficiently substitute for the cytosolic chaperone machinery comprising Hsp40, Hsp60, and Hsp70 with respect to folding of firefly luciferase.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY; UNIV GOTTINGEN,INST BIOCHEM & MOL ZELLBIOL,D-37073 GOTTINGEN,GERMANY	Saarland University; University of Gottingen			Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, TRENDS BIOCHEM SCI, V19, P227; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KRUSE M, 1995, J BIOL CHEM, V270, P2588, DOI 10.1074/jbc.270.6.2588; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904	18	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19509	19513		10.1074/jbc.271.32.19509	http://dx.doi.org/10.1074/jbc.271.32.19509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702642	hybrid			2022-12-27	WOS:A1996VB68400076
J	Bu, GJ; Rennke, S				Bu, GJ; Rennke, S			Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; 39-KDA PROTEIN; INFLUENZA HEMAGGLUTININ; HEYMANN NEPHRITIS; LIGAND-BINDING; CELLS; SYSTEM; SITES; LRP	The 39-kDa receptor-associated protein (RAP) is a receptor antagonist that inhibits ligand interactions with the receptors that belong to the low density lipoprotein receptor gene family. Our previous studies have demonstrated that RAP interacts with the low density Lipoprotein receptor-related protein (LRP) within the endoplasmic reticulum and prevents premature interaction of ligands with the receptor. To analyze whether RAP is also involved in the folding of LRP during receptor biosynthesis, we generated anchor-free, soluble minireceptors that represent each of the four putative ligand-binding domains of LRP (SLRP1, -2, -3, and -4, corresponding to the clusters with 2, 8, 10, and 11 cysteine-rich complement-type repeats, respectively). When these SLRPs were overexpressed by cell transfection, only SLRP1 was secreted. Little or no secretion was observed for SLR92, -3, and -4. However, when RAP cDNA was cotransfected with SLRP2, -3, and -4 cDNAs, each of these SLRP2 was secreted. The cellular retention of SLRPs in the absence of RAP coexpression appeared to be a result of the formation of SDS-resistant, oligomeric aggregates observed under nonreducing conditions. Such oligomers of the SLRPs likely resulted from formation of intermolecular disulfide bonds since they were reduced to monomers when analyzed under reducing conditions. The oligomers were formed not only among molecules of a given SLRP, but also between different SLRPs. The role of RAP in the process of LRP folding was shown by the reduction in aggregated SLRP oligomers upon RAP coexpression. A similar role of RAP in preventing the aggregation of newly synthesized receptor was also observed using- membrane-containing minireceptor of LRP. Coimmunoprecipitation and ligand binding studies demonstrated that RAP binds avidly to SLRP2, -3, and -4, but not to SLRP1. These results suggest that these interactions may be important for proper folding of LRP by ensuring the formation of proper intradomain, but not intermolecular or interdomain, disulfide bonds. Thus, our results strongly suggest that, in addition to the prevention of premature binding of ligands to LRP, RAP also plays an important role in receptor folding.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL)								BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	28	155	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22218	22224		10.1074/jbc.271.36.22218	http://dx.doi.org/10.1074/jbc.271.36.22218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703036	hybrid			2022-12-27	WOS:A1996VF61200078
J	Lee, HW; Smith, L; Pettit, GR; Vinitsky, A; Smith, JB				Lee, HW; Smith, L; Pettit, GR; Vinitsky, A; Smith, JB			Ubiquitination of protein kinase C-alpha and degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TUMOR PROMOTERS; DOWN-REGULATION; PERMISSIVE ACTIVATION; PHORBOL ESTERS; BRYOSTATIN-1; CELLS; INHIBITION; CALPAIN	Bryostatins and phorbol esters acutely activate and subsequently down-regulate protein kinase C (PKC) by inducing its proteolysis via an unknown pathway, Here we show that treatment of renal epithelial cells with bryostatin 1 (Bryo) produced novel PKC-alpha species, which were larger than the native protein (80 kDa). The >80 kDa PKC-alpha species contained Ubi as indicated by immunostaining and accumulated in the presence of lactacystin, a selective inhibitor of proteolysis by the proteasome. In vitro experiments with I-125-ubiquitin and membranes from Bryo-treated cells showed that PKC-alpha became ubiquitinated by a reaction that depended on ATP and a cytosolic fraction. Lactacystin or a peptidyl aldehyde, Bz-Gly-Leu-Ala-leucinal, which inhibits certain proteinase activities of the proteasome, inhibited Bryo-evoked disappearance of PKC-alpha protein from the cells. Lacta preserved Bryo-induced P-32-labeled PKC-alpha indicating that the proteasome inhibitor spared activated enzyme from down-regulation in, vivo. These findings show that Bryo induces the degradation of PKC-alpha by the ubiquitin-proteasome complex.	UNIV ALABAMA,SCH MED,DEPT PHARMACOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT PHARMACOL,BIRMINGHAM,AL 35294; ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287; ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85287; CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL44408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COSTAGNA M, 1982, J BIOL CHEM, V257, P7847; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HUWILER A, 1994, BIOCHEM PHARMACOL, V48, P689, DOI 10.1016/0006-2952(94)90046-9; ISAKOV N, 1993, J IMMUNOL, V150, P1195; JALAVA A, 1993, BIOCHEM BIOPH RES CO, V191, P472, DOI 10.1006/bbrc.1993.1242; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; LYU RM, 1991, J MEMBRANE BIOL, V124, P73, DOI 10.1007/BF01871366; MAHONEY CW, 1994, PROTEIN KINASE C, P16; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; QUEST AFG, 1994, PROTEIN KINASE C, P64; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SAKO T, 1987, CANCER RES, V47, P5445; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Singer WD, 1996, J BIOL CHEM, V271, P4504; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4; TALLANT EA, 1987, BIOCHIM BIOPHYS ACTA, V929, P40, DOI 10.1016/0167-4889(87)90239-4; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	32	136	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					20973	20976		10.1074/jbc.271.35.20973	http://dx.doi.org/10.1074/jbc.271.35.20973			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702857	hybrid			2022-12-27	WOS:A1996VE47700001
J	Musch, MW; Goldstein, L				Musch, MW; Goldstein, L			High affinity binding of ankyrin induced by volume expansion in skate erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGER; CYTOPLASMIC DOMAIN; MEMBRANE-SKELETON; TAURINE EFFLUX; CELL-LINE; BAND 3; ASSOCIATION; PROTEIN; SPECTRIN; TRANSPORT	Volume expansion of little skate (Raja erinacea) erythrocytes increases the affinity of ankyrin binding without altering in the number of binding sites. Potassium iodide-stripped inside-out vesicles (KI-IOV) were used to assess ankyrin binding under volume expanded conditions. Under isoosmotic conditions, ankyrin binds nearly exclusively to a single class of sites (B-max 52 +/- 12 mu g/mg; K-d, 150 +/- 28 nM). KI-IOV from volume-expanded cells (either with one-half osmolarity medium or with inclusion of the permeant solute ethylene glycol) demonstrate two ankyrin-binding populations. A high affinity population occurs transiently under volume-expanded conditions. This population has a B-max of 18 +/- 7 mu g/mg and a K-d of 25 +/- 9 nM. Total binding of high and low affinity sites is 57 +/- 17 mu g/mg. This change in ankyrin affinity is reversible on volume regulatory decrease. A major target protein in the KI-IOV was identified as the skate homolog of the mammalian red cell anion exchanger band 3. Inclusion of the purified cytoplasmic domain of band 3 competes away more than 80% of the ankyrin binding. To determine whether increased ankyrin affinity is due to band 3 tetramer formation that occurs in volume expansion, cells were treated with pyridoxal 5-phosphate or 4,4'-dinitrostilbene-2,2'-disulfonic acid, two agents that increase tetramer formation under isoosmotic conditions. Both treatments altered the binding affinity with a shift toward higher affinity binding without significant alteration in the number of binding sites.	UNIV CHICAGO,DEPT MED,CTR INFLAMMATORY BOWEL DIS,CHICAGO,IL 60637; MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672; BROWN UNIV,DEPT PHYSIOL,PROVIDENCE,RI 02912	University of Chicago; Mount Desert Island Biological Laboratory; Brown University								ALPER SL, 1988, J BIOL CHEM, V263, P17092; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BRILL SR, 1992, J EXP ZOOL, V264, P19, DOI 10.1002/jez.1402640104; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CIANCI CD, 1988, J CELL BIOCHEM, V37, P219; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; Goldstein L, 1996, KIDNEY INT, V49, P1690, DOI 10.1038/ki.1996.249; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENNINGS ML, 1985, ANNU REV PHYSIOL, V47, P519; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MULZER K, 1990, COLLOID POLYM SCI, V268, P60, DOI 10.1007/BF01410424; MUSCH MW, 1994, AM J PHYSIOL, V266, pR65, DOI 10.1152/ajpregu.1994.266.1.R65; MUSCH MW, 1994, J BIOL CHEM, V269, P19683; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SARABIA VE, 1993, J BIOL CHEM, V268, P10676; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SOONG CJ, 1987, ARCH BIOCHEM BIOPHYS, V254, P509, DOI 10.1016/0003-9861(87)90131-7; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21221	21225		10.1074/jbc.271.35.21221	http://dx.doi.org/10.1074/jbc.271.35.21221			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702894	hybrid			2022-12-27	WOS:A1996VE47700040
J	Rolland, V; LeLiepvre, X; Jump, DB; Lavau, M; Dugail, I				Rolland, V; LeLiepvre, X; Jump, DB; Lavau, M; Dugail, I			A GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes - Implication in the overactivity of FAS promoter in obese Zucker rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED ADIPOCYTES; RESPONSIVE REGIONS; ADIPOSE-TISSUE; TRANSCRIPTION; EXPRESSION; INSULIN; CLONING; ACTIVATION; PROTEINS; IDENTIFICATION	We have previously shown that the proximal 2-kb sequence of the fatty acid synthase (FAS) promoter transfected into rat adipocytes was highly sensitive to the cellular context, displaying an overactivity in obese (fa/fa) versus lean Zucker rat adipocytes, Using deletional analysis, we show here that FAS promoter activity mainly depends on a region from -200 to -126. This sequence exerts a strong negative effect on FAS promoter in adipocytes from lean rats but not in those from obese rats, resulting in a marked overtranscriptional activity in the latter cells, This region, fused to a heterologous promoter, the E1b TATA box, induced differential levels of gene reporter activity in lean and obese rat adipocytes, indicating it harbors fa-responsive element(s), Whatever the rat genotype, adipocyte nuclear proteins were shown to footprint the same protected sequence within the fa-responsive region, and supershift analysis demonstrated that Sp1 or Sp1-like proteins were bound to this DNA subregion, Compelling evidence that the Sp1 binding site contained in this sequence was implicated in the differential promoter activity in lean versus obese rats, was provided by the observation that mutations at this Sp1 site induced a 2.5-fold increase in FAS promoter activity in adipocytes from lean rats, whereas they had no effect in adipocytes from obese rats.	MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824	Michigan State University	Rolland, V (corresponding author), INSERM,U177,UNITE RECH PHYSIOPATHOL NUTR,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.		Dugail, Isabelle/L-1567-2017	Dugail, Isabelle/0000-0003-3631-2252	NIDDK NIH HHS [R01 DK043220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; BAZIN R, 1982, J LIPID RES, V23, P839; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONFELLE F, 1992, J BIOL CHEM, V267, P20543; GUICHARD C, 1992, J LIPID RES, V33, P679; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAINAULT I, 1995, BIOCHEM BIOPH RES CO, V209, P1053, DOI 10.1006/bbrc.1995.1604; JUMP DB, 1994, J LIPID RES, V35, P1076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V182, P631, DOI 10.1016/0006-291X(92)91779-P; MAXAM A, 1980, METHOD ENZYMOL, V152, P721; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MURATA Y, 1994, J BIOL CHEM, V269, P20674; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; ROLLAND V, 1995, J BIOL CHEM, V270, P1102, DOI 10.1074/jbc.270.3.1102; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21297	21302		10.1074/jbc.271.35.21297	http://dx.doi.org/10.1074/jbc.271.35.21297			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702907	hybrid			2022-12-27	WOS:A1996VE47700053
J	Sharma, V; Vijayan, M; Surolia, A				Sharma, V; Vijayan, M; Surolia, A			Imparting exquisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its combining site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIS-HYPOGAEA AGGLUTININ; T-ANTIGEN; DIRECTED MUTAGENESIS; LEGUME LECTINS; BINDING; RECOGNITION; PROTEIN; EXPRESSION; SEQUENCE; REVEALS	Lectins from legumes constitute one of the most thoroughly studied families of proteins, yet the absence of a rigorous framework to explain their carbohydrate binding specificities appears to have prevented a rational approach to alter their ligand binding activity. Studies reported here deal with the redesign of the recognition propensity of peanut agglutinin (PNA), an important member of the family. PNA is extensively used as a tool for recognition of the tumor-associated Thomsen-Friedenrich antigen (T-antigen; Gal beta 1-3GalNAc) on the surfaces of malignant cells and immature thymocytes. PNA also recognizes N-acetyllactosamine (LacNAc; Gal beta 1-4GlcNAc), which is present at the termini of several cell-surface glycoproteins. The crystal structure of the PNA-lactose complex revealed, in addition to the expected interactions with the residues constituting the binding site, the presence of leucine 212 at a position close enough to be in steric contact with the acetamido group on LacNAc. We report here two leucine mutants, one to asparagine (L212N) and the other to alanine (L212A), that exhibit distinct preference for T-antigen and N-acetyllactosamine, respectively. Carbohydrate binding studies reveal that mutant L212N does not recognize LacNAc at high concentrations, thus making it an exquisitely specific cell-surface marker compared with its wild-type counterpart.	INDIAN INST SCI,MOL BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore			SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; ARANGO R, 1993, FEBS LETT, V330, P133, DOI 10.1016/0014-5793(93)80258-V; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; Banerjee R, 1996, J MOL BIOL, V259, P281, DOI 10.1006/jmbi.1996.0319; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; CLAUSEN H, 1988, MOL IMMUNOL, V25, P199, DOI 10.1016/0161-5890(88)90068-5; CLING CK, 1989, BRIT J CANCER, V59, P949; GOULUTCHASSAING C, 1992, BIOCHIMIE, V74, P101, DOI 10.1016/0300-9084(92)90189-L; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; IRIMURA T, 1975, CARBOHYD RES, V39, P317, DOI 10.1016/S0008-6215(00)86141-8; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGKLIDE NC, 1995, GLYCOCONJUGATE J, V12, P567; LEINER LE, 1986, LECTINS PROPERTIES F; LOTAN R, 1975, J BIOL CHEM, V250, P8518; OKEEFE D, 1982, CLIN EXP IMMUNOL, V48, P329; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; REISNER Y, 1979, P NATL ACAD SCI USA, V76, P447, DOI 10.1073/pnas.76.1.447; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; RINDERLE SJ, 1989, J BIOL CHEM, V264, P16123; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SALUNKE DM, 1985, J BIOL CHEM, V260, P3576; Sambrook J., 2002, MOL CLONING LAB MANU; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SHARMA V, 1994, GENE, V148, P299, DOI 10.1016/0378-1119(94)90702-1; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x; ZABEL PL, 1983, EUR J NUCL MED, V8, P250, DOI 10.1007/BF00522515; ZEBDA N, 1994, J CELL BIOCHEM, V54, P161, DOI 10.1002/jcb.240540205	35	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21209	21213		10.1074/jbc.271.35.21209	http://dx.doi.org/10.1074/jbc.271.35.21209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702892	hybrid			2022-12-27	WOS:A1996VE47700038
J	Vaughan, RA; Kuhar, MJ				Vaughan, RA; Kuhar, MJ			Dopamine transporter ligand binding domains - Structural and functional properties revealed by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; COCAINE RECEPTORS; CLONING; GLYCOSYLATION; SITES; EXPRESSION; SUBSTRATE; PROGRESS; PROTEINS; COMPLEX	Dopamine transporters (DATs) are members of the Na+- and Cl--dependent neurotransmitter and amino acid transporter family predicted by hydrophobicity analysis to have 12 transmembrane-spanning helices. The structure of DAT was studied using the photoaffinity compounds [I-125]1-[2-(diphenylmethoxy)-ethyl]-4-[2-(4-azido-3- iodophenyl)ethyl]piperazine ([I-125]DEEP), a 1-(2-diphenylmethoxy)-ethyl-4-(3-phenyl propyl)piperazine (GBR analog), and [I-125]-3 beta-(p-chlorophenyl)tropane-2 beta-carboxylic acid, 4'-azido-3'-idophenylethyl ester ([I-125]RTI 82), a cocaine analog, which had been shown in a previous study to become incorporated into different regions of the DAT primary sequence. The proximity of the photolabeled binding sites to integral membrane structures was investigated by subjecting photolabeled membrane suspensions to limited proteolysis with trypsin and separately analyzing the resulting membranes and supernatants for the presence of photolabeled DAT fragments. Trypsin treatment of [I-125] DEEP-labeled membranes generated labeled 45- and 14-kDa DAT fragments that immunoprecipitated with an epitope-specific antiserum generated against amino acids 42-59 near the first putative transmembrane domain, whereas [I-125]RTI 82 was found in 32- and 16-kDa tryptic fragments that precipitated with an antiserum directed against a sequence near transmembrane domain 4 (amino acids 225-238), All of the photolabeled fragments were recovered in the protease-treated membranes, indicating that they possess integral membrane structures that prevent their release from the membrane as soluble forms. The size of the two smallest fragments in conjunction with their retention in the membrane suggests that incorporation of the photoaffinity ligands occurs in or near membrane spanning regions and delineates the maximum possible distance between the transmembrane structures, incorporated photolabel, and antibody epitopes. Carbohydrate analysis of the fragments identified sialic acids and N-linked oligosaccharides exclusively on the 45 kDa [I-125]DEEP-labeled fragment, which, based on size, would be expected to contain four consensus glycosylation sites between putative transmembrane domains 3 and 4. Photoaffinity labeling after trypsin treatment of membranes showed that the larger but not the smaller fragments retain binding capacity, as the 45- and 32-kDa fragments were capable of becoming photolabeled. Binding of photoaffinity ligands at these fragments was displaced with the same pharmacology as that of intact DATs. These results verify numerous aspects of DAT structure and topology heretofore only predicted from theoretical considerations and extend our knowledge of DAT structure function properties.	EMORY UNIV,YERKES REG PRIMATE RES CTR,DIV NEUROSCI,ATLANTA,GA 30322	Emory University	Vaughan, RA (corresponding author), NIDA,NEUROSCI BRANCH,INTRAMURAL RES PROGRAM,POB 5180,BALTIMORE,MD 21224, USA.							AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BERGER P, 1990, EUR J PHARMACOL, V176, P251, DOI 10.1016/0014-2999(90)90540-M; BERGER SP, 1991, MOL PHARMACOL, V39, P429; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; FREED C, 1995, J COMP NEUROL, V359, P340, DOI 10.1002/cne.903590211; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1992, MOL PHARMACOL, V42, P383; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; HERELD D, 1994, J BIOL CHEM, V269, P7036; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LEW R, 1991, BRAIN RES, V539, P239, DOI 10.1016/0006-8993(91)91627-D; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MAURICE T, 1991, NEUROPHARMACOLOGY, V30, P591, DOI 10.1016/0028-3908(91)90078-P; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; PATEL A, 1992, BRAIN RES, V576, P173, DOI 10.1016/0006-8993(92)90627-L; PRISTUPA ZB, 1994, MOL PHARMACOL, V45, P125; REITH MEA, 1992, EUR J PHARM-MOLEC PH, V227, P417, DOI 10.1016/0922-4106(92)90160-W; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SALLEE FR, 1989, FEBS LETT, V256, P219, DOI 10.1016/0014-5793(89)81752-1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TATE CG, 1994, J BIOL CHEM, V269, P26303; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; Wang J.-B., 1993, Society for Neuroscience Abstracts, V19, P745; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	41	61	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21672	21680		10.1074/jbc.271.35.21672	http://dx.doi.org/10.1074/jbc.271.35.21672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702957	hybrid			2022-12-27	WOS:A1996VE47700103
J	Rao, GN; Runge, MS				Rao, GN; Runge, MS			Cyclic AMP inhibition of thrombin-induced growth in vascular smooth muscle cells correlates with decreased JNK1 activity and c-Jun expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; N-TERMINAL KINASE; DEPENDENT ACTIVATION; MOLECULAR-CLONING; PHOSPHORYLATION; RECEPTOR; DOMAIN; FOS; RAF-1	Thrombin is a potent modulator of vascular tone and vascular smooth muscle cell (VSMC) mitogenesis. Early studies from other laboratories demonstrated that cyclic AMP (cAMP) antagonizes the mitogenic effects of platelet-derived growth factor and epidermal growth factor by inhibiting the extracellular signal-regulated protein kinases (ERKs; p42, p44) group of mitogen-activated protein kinases (MAPKs) in several cell types. This report examines the role of ERKs and Jun N-terminal kinase 1 (JNK1) groups of mitogen-activated protein kinases in thrombin-induced DNA synthesis in VSMCs using agents such as forskolin and dibutyrylcyclic AMP that increase intracellular cAMP levels, Both agents significantly inhibited thrombin-stimulated DNA synthesis in VSMCs, These agents, however, had no effect on thrombin induction of ERKs activation and c-Fos expression, suggesting divergence of the latter two events from the growth-signaling events of thrombin that are sensitive to inhibition by cAMP. Thrombin activated JNK1 and induced c-Jun expression in VSMCs in a time-dependent manner, In contrast to ERKs and c-Fos, thrombin-induced JNK1 activation and c-Jun expression were sensitive to inhibition by forskolin, suggesting an association of these events with thrombin-stimulated growth in these cells, Thrombin also increased AP-1 activity, and this response was significantly blunted by forskolin, Together, these results demonstrate a correlation between JNK1 activation and c-Jun expression by thrombin and their association with the mitogenic signaling events of thrombin in VSMCs.			Rao, GN (corresponding author), UNIV TEXAS,MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,301 UNIV BLVD,RT 1064,GALVESTON,TX 77555, USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIVESEY SA, 1982, J BIOL CHEM, V257, P4983; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RYSECK RP, 1991, ONCOGENE, V6, P533; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	45	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20805	20810		10.1074/jbc.271.34.20805	http://dx.doi.org/10.1074/jbc.271.34.20805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702835	hybrid			2022-12-27	WOS:A1996VD33700087
J	Binder, BM; OConnor, TM; Bownds, MD; Arshavsky, VY				Binder, BM; OConnor, TM; Bownds, MD; Arshavsky, VY			Phosphorylation of non-bleached rhodopsin in intact retinas and living frogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PROTEIN-KINASE-C; PHOTORECEPTOR-MEMBRANES; CYCLIC-GMP; PHOSPHODIESTERASE ACTIVATION; VERTEBRATE PHOTORECEPTORS; VISUAL TRANSDUCTION; LIGHT; PHOTOTRANSDUCTION; DEPHOSPHORYLATION	The photoresponse in retinal photoreceptors begins when a molecule of rhodopsin is excited by a photon of light. Photoexcited rhodopsin activates an enzymatic cascade including the G-protein transducin and cyclic GMP phosphodiesterase. As a result, cytoplasmic cyclic GMP concentration is decreased and the photoresponse is initiated. This process is terminated when rhodopsin is phosphorylated by rhodopsin kinase and subsequently blocked by a protein called arrestin. It has been noted by several investigators that light can cause phosphorylation of not only photoexcited but also non-excited rhodopsin in rod photoreceptors. A goal of this study was to determine how much non-bleached rhodopsin is phosphorylated. To determine how the structural integrity of the photoreceptor influences the extent of non-breached rhodopsin phosphorylation, we studied the reaction in electropermeabilized rod outer segments, in rod outer segments still attached to isolated retinas and in living frogs. In the first two preparations, we found that the maximum extent of non-bleached rhodopsin phosphorylation was approximately 1% of the total rhodopsin pool. In living frogs, the maximal amount of non-bleached rhodopsin phosphorylation was similar to 2% of the total rhodopsin pool and occurred after prolonged illumination by the relatively dim light intensity of 20 lux. These data appear to exclude models for light adaptation that postulate high levels of phosphorylation of non-bleached rhodopsin in rod photoreceptors.	HARVARD UNIV, SCH MED, MASSACHUSETTS EYE & EAR INFIRM, HOWE LAB OPHTHALMOL, BOSTON, MA 02114 USA; UNIV WISCONSIN, MOL BIOL LAB, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Binder, Brad/0000-0002-8172-2034	NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10336, EY-00463] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1986, BIOL MEMBRANY, V3, P1197; ATON BR, 1986, BIOCHEMISTRY-US, V25, P677, DOI 10.1021/bi00351a025; ATON BR, 1984, J GEN PHYSIOL, V85, P83; BARBEHENN EK, 1986, EXP EYE RES, V43, P729, DOI 10.1016/S0014-4835(86)80004-5; BAUMANN C, 1970, VISION RES, V10, P627, DOI 10.1016/0042-6989(70)90011-8; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BIERNBAUM MS, 1991, VISUAL NEUROSCI, V7, P499, DOI 10.1017/S0952523800009780; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BOWNDS D, 1974, EXP EYE RES, V18, P253, DOI 10.1016/0014-4835(74)90153-5; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COCOZZA JD, 1987, VISION RES, V27, P1085, DOI 10.1016/0042-6989(87)90023-X; DEAN KR, 1993, EUR J BIOCHEM, V213, P881, DOI 10.1111/j.1432-1033.1993.tb17832.x; DEAZEREDO FAM, 1981, J BIOL CHEM, V256, P2731; DIZHOOR AM, 1985, BIOL MEMBRANY, V2, P272; FONG SL, 1985, VISION RES, V25, P1387, DOI 10.1016/0042-6989(85)90216-0; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; KUHN H, 1977, BIOPHYS STRUCT MECH, V3, P199, DOI 10.1007/BF00535820; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1976, BIOCHIM BIOPHYS ACTA, V428, P13, DOI 10.1016/0304-4165(76)90103-3; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; MAKINO CL, 1990, J GEN PHYSIOL, V96, P1199, DOI 10.1085/jgp.96.6.1199; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MILLER JA, 1975, J BIOL CHEM, V250, P4427; MILLER JA, 1977, BIOCHEMISTRY-US, V16, P2633, DOI 10.1021/bi00631a009; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEPPERBERG DR, 1992, EXP EYE RES, V54, P369, DOI 10.1016/0014-4835(92)90049-X; PERLMAN JI, 1982, J GEN PHYSIOL, V80, P885, DOI 10.1085/jgp.80.6.885; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19826	19830		10.1074/jbc.271.33.19826	http://dx.doi.org/10.1074/jbc.271.33.19826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702691	hybrid			2022-12-27	WOS:A1996VC66900032
J	Cobuzzi, RJ; Burhans, WC; Beerman, TA				Cobuzzi, RJ; Burhans, WC; Beerman, TA			Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOVALENT BINDING SELECTIVITY; ANTITUMOR ANTIBIOTIC CC-1065; SEQUENCE SPECIFICITY; (+)-CC-1065; POLYMERASE; MECHANISM; INVITRO; DAMAGE; AGENT; SITE	Adozelesin is a member of a family of extraordinarily cytotoxic DNA damaging agents that bind to the DNA minor groove in a sequence-specific manner and form covalent adducts with adenines. Previous studies employing purified enzymes and adozelesin-modified template DNAs suggested that adozelesin-DNA adducts inhibit DNA replication at the level of nascent DNA chain elongation. In this study, neutral/neutral two-dimensional agarose gel electrophoresis was employed to analyze simian virus 40 (SV40) DNA replication intermediates recovered from adozelesin-treated SV40 virus-infected cells. SV40 replication intermediates rapidly disappeared from infected cells when they were treated with adozelesin, but not when the cells were also treated with aphidicolin to block maturation of replicating SV40 DNA. We conclude that the disappearance of SV40 replication intermediates induced by adozelesin treatment was a consequence of maturation of these intermediates in the absence of new initiation events. Adozelesin inhibition of nascent chain elongation is first observed at concentrations above those needed to block initiation. Adozelesin treatment inhibits SV40 DNA replication at concentrations that produce adducts on just a small fraction of the intracellular population of SV40 DNA molecules.	ROSWELL PK CANC INST,DEPT EXPT THERAPEUT,BUFFALO,NY 14263; ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute; Roswell Park Cancer Institute					NCI NIH HHS [CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHUYAN BK, 1992, CANCER CHEMOTH PHARM, V30, P348, DOI 10.1007/BF00689961; BHUYAN BK, 1992, CANCER RES, V52, P5687; BOGER DL, 1991, P NATL ACAD SCI USA, V88, P1431, DOI 10.1073/pnas.88.4.1431; BOGER DL, 1991, J AM CHEM SOC, V113, P3980, DOI 10.1021/ja00010a046; BOGER DL, 1991, TETRAHEDRON, V47, P2661, DOI 10.1016/S0040-4020(01)81798-1; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHIDESTER CG, 1981, J AM CHEM SOC, V103, P7629, DOI 10.1021/ja00415a035; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; CLEAVER JE, 1992, RADIAT RES, V131, P338, DOI 10.2307/3578425; COLVIN M, 1990, CANCER CHEMOTHERAPY, P276; COTE S, 1993, ANTI-CANCER DRUG, V4, P327, DOI 10.1097/00001813-199306000-00006; FLEMING GF, 1994, J NATL CANCER I, V86, P368, DOI 10.1093/jnci/86.5.368; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HIGHTOWER RD, 1992, GYNECOL ONCOL, V47, P186, DOI 10.1016/0090-8258(92)90104-Q; HURLEY LH, 1988, BIOCHEMISTRY-US, V27, P3886, DOI 10.1021/bi00410a054; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LEE CS, 1994, BIOCHEMISTRY-US, V33, P6024, DOI 10.1021/bi00185a043; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LI LH, 1991, INVEST NEW DRUG, V9, P137; LI LH, 1982, CANCER RES, V42, P990; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; MCHUGH MM, 1994, BIOCHEMISTRY-US, V33, P9158, DOI 10.1021/bi00197a019; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NGUYEN HN, 1992, CANCER CHEMOTH PHARM, V30, P37, DOI 10.1007/BF00686483; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; REYNOLDS VL, 1985, BIOCHEMISTRY-US, V24, P6228, DOI 10.1021/bi00343a029; SNAPKA RM, 1991, NUCLEIC ACIDS RES, V19, P5065, DOI 10.1093/nar/19.18.5065; SPADARI S, 1984, ADV EXP MED BIOL, V179, P169; SUN D, 1992, BIOCHEMISTRY-US, V31, P2822, DOI 10.1021/bi00125a025; SUN DK, 1992, ANTI-CANCER DRUG DES, V7, P15; SUN DY, 1992, J MED CHEM, V35, P1773, DOI 10.1021/jm00088a012; SWENSON DH, 1982, CANCER RES, V42, P2821; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; WARPEHOSKI MA, 1988, CHEM RES TOXICOL, V1, P315, DOI 10.1021/tx00006a001; WARPEHOSKI MA, 1988, J MED CHEM, V31, P590, DOI 10.1021/jm00398a017; WEILAND KL, 1991, BIOCHEMISTRY-US, V30, P7559, DOI 10.1021/bi00244a027; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189; ZSIDO TJ, 1992, BIOCHEM PHARMACOL, V43, P1817, DOI 10.1016/0006-2952(92)90715-U	41	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19852	19859		10.1074/jbc.271.33.19852	http://dx.doi.org/10.1074/jbc.271.33.19852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702695	hybrid			2022-12-27	WOS:A1996VC66900036
J	Gu, XY; Bennett, RAO; Povirk, LF				Gu, XY; Bennett, RAO; Povirk, LF			End-joining of free radical-mediated DNA double-strand breaks in vitro is blocked by the kinase inhibitor wortmannin at a step preceding removal of damaged 3' termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NONHOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; SHUTTLE VECTOR; REPAIR; GENE; ACTIVATION; EXPRESSION	Both mammalian cells and Xenopus eggs possess activities for the joining of nonhomologous DNA ends, and such activities may play a major role in double-strand break repair. In order to dissect the biochemical processing of breaks with oxidatively modified ends, vectors containing various site-specific double-strand breaks with 3'-phosphoglycolate termini were constructed and treated with Xenopus egg extracts. These vectors were rejoined by the extracts at rates 30-100 times slower than comparable 3'-hydroxyl vectors. Vectors with blunt or cohesive 3'-phosphoglycolate ends yielded single repair products corresponding to simple phosphoglycolate removal followed by ligation, while a vector with mismatched ends was also rejoined but yielded a mixture of products, Addition of the kinase inhibitors wortmannin and dimethylaminopurine not only blocked rejoining, but also suppressed phosphoglycolate removal, implying an early, essential, kinase-dependent restriction point in the pathway. The results suggest that double-strand breaks with oxidatively modified ends are repaired in Xenopus eggs by a highly conservative and stringently regulated end-joining pathway, in which all biochemical processing of the breaks is contingent on both end alignment and a specific phosphorylation event. Several lines of indirect evidence suggest DNA-dependent protein kinase as a likely candidate for effecting this phosphorylation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL CANCER INSTITUTE [R01CA040615] Funding Source: NIH RePORTER; NCI NIH HHS [CA40615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT RAO, 1996, IN PRESS INT J RAD B; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CHOUDHURY GG, 1994, KIDNEY INT, V46, P37, DOI 10.1038/ki.1994.242; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DERBYSHIRE MK, 1994, MOL CELL BIOL, V14, P156, DOI 10.1128/MCB.14.1.156; ENGLUND PT, 1972, J MOL BIOL, V66, P209, DOI 10.1016/0022-2836(72)90474-3; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOEDECKE W, 1992, MOL CELL BIOL, V12, P811, DOI 10.1128/MCB.12.2.811; GOEDECKE W, 1994, NUCLEIC ACIDS RES, V22, P2094, DOI 10.1093/nar/22.11.2094; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEHMAN CW, 1993, MOL CELL BIOL, V13, P6897, DOI 10.1128/MCB.13.11.6897; LOPEZ B, 1987, NUCLEIC ACIDS RES, V17, P6813; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; RESNICK MA, 1979, NUCLEIC ACIDS RES, V6, P3145, DOI 10.1093/nar/6.9.3145; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; SCHAAL H, 1993, GENE, V124, P275, DOI 10.1016/0378-1119(93)90405-R; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WANG P, 1990, CANCER RES, V50, P7527; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; YANO H, 1993, J BIOL CHEM, V268, P25846	35	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19660	19663		10.1074/jbc.271.33.19660	http://dx.doi.org/10.1074/jbc.271.33.19660			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702667	hybrid			2022-12-27	WOS:A1996VC66900008
J	Kon, N; Suhadolnik, RJ				Kon, N; Suhadolnik, RJ			Identification of the ATP binding domain of recombinant human 40-kDa 2',5'-oligoadenylate synthetase by photoaffinity labeling with 8-azido-[alpha-P-32]ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ESCHERICHIA-COLI; 2-5A SYNTHETASE; HUMAN-CELLS; INTERFERON; 2-AZIDOADENOSINE; TRIPHOSPHATE; PURIFICATION; EXPRESSION; PEPTIDES	Three isoforms of the interferon-inducible 2',5'-oligoadenylate (2-5A) synthetase that require double-stranded RNA have been isolated and cloned. However, identification of the amino acid(s) of 2-5A synthetase directly interacting with ATP is crucial to the elucidation of the mechanism of the enzymatic conversion of ATP to 2',5'-oligoadenylates by 2-5A synthetase. Recombinant human 40-kDa 2-5A synthetase has been expressed as a glutathione S-transferase fusion protein in E. coli and purified to near homogeneity in milligram quantities. The azido photoprobe, 8-azido-[alpha-P-32]ATP, has been used to identify the ATP binding domain of the recombinant human 40-kDa 2-5A synthetase. Specific covalent photoincorporation of 8-azido-[alpha-P-32]ATP into the 2-5A synthetase, tryptic digestion of the covalently P-32-labeled enzyme, isolation of the photolabeled phosphopeptide by metal (Al3+) chelate chromatography, and high pressure liquid chromatography identified a P-32-pentapeptide, which has been assigned to the ATP binding domain of 2-5A synthetase. The radioactive pentapeptide has the sequence D(196)FLKQ(200) in which the photoprobe, 8-azido-[alpha-P-32]ATP, chemically modified the amino acid lysine 199. The catalytic importance of Lys(199) was further established by mutation of lysine 199 to arginine 199 and histidine 199 using site directed mutagenesis, The K199R and K199H recombinant human 40-kDa 2-5A synthetase mutants bind 8-azido-ATP and the allosteric activator, poly(I). poly(C) but are enzymatically inactive. These photoaffinity labeling and mutation data strongly suggest that lysine 199 is essential for the formation of a productive 2-5A synthetase-ATP double-stranded RNA complex for the enzymatic conversion of ATP to 2-5A.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034765] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA12227] Funding Source: Medline; NIAID NIH HHS [R01-AI-34765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Chebath J, 1985, Prog Clin Biol Res, V202, P149; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; DOMBROWSKI KE, 1992, BIOCHEMISTRY-US, V31, P3785, DOI 10.1021/bi00130a008; FERBUS D, 1981, BIOCHEM BIOPH RES CO, V100, P847, DOI 10.1016/S0006-291X(81)80251-3; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GRAMMER JC, 1993, BIOCHEMISTRY-US, V32, P5725, DOI 10.1021/bi00073a001; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; IEHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117; JULIN DA, 1987, J BIOL CHEM, V262, P9044; JUSTESEN J, 1980, P NATL ACAD SCI-BIOL, V77, P4618, DOI 10.1073/pnas.77.8.4618; KUNKEL TA, 1991, CURRENT PROTOCOLS MO, V1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LI SW, 1990, J BIOL CHEM, V265, P5470; MARIE I, 1992, J BIOL CHEM, V267, P9933; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; O IS, 1994, J BIOL CHEM, V269, P5009; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; SUHADOLNIK RJ, 1988, BIOCHEMISTRY-US, V27, P8846, DOI 10.1021/bi00424a024; SZUMILO T, 1993, J BIOL CHEM, V268, P17943; TRUVE E, 1993, PROG MOL SUBCELL BIO, V14, P139	30	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19983	19990		10.1074/jbc.271.33.19983	http://dx.doi.org/10.1074/jbc.271.33.19983			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702715	hybrid			2022-12-27	WOS:A1996VC66900056
J	McCoon, PE; Angerer, RC; Angerer, LM				McCoon, PE; Angerer, RC; Angerer, LM			SpFGFR, a new member of the fibroblast growth factor receptor family, is developmentally regulated during early sea urchin development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FGF RECEPTOR; GENE-EXPRESSION; SIGNALING PATHWAY; BASIC-FGF; EMBRYOS; BINDING; DROSOPHILA; PROTEIN; KINASE; DOMAIN	We describe the cloning of a new fibroblast growth factor receptor, SpFGFR1, that is differentially regulated at the level of transcript abundance during sea urchin embryogenesis. Sequence representing the conserved tyrosine kinase domain was obtained by reverse transcription-polymerase chain reaction using degenerate primers, and the entire open reading frame was obtained by standard cDNA library screening methods. SpFGFR contains a series of domains characteristic of FGFRs: three immunoglobulin-like motifs, an acid box, a transmembrane domain, a relatively long juxtamembrane sequence, a split tyrosine kinase domain, and two conserved intracellular tyrosine residues. Alternative splicing of SpFGFR generates two variants (Ig3L and Ig3S), which differ by insertion in the center of the Ig3 domain of 34 extra amino acids, encoded by an additional exon. Transcripts encoding both variants accumulate when morphogenesis beans with mesenchyme cell ingression and gastrulation. SpFGFR transcripts accumulate in all cell types of the embryo, although in situ hybridization shows that they are somewhat enriched in cells of oral ectoderm and endoderm. Transcripts encoding the Ig3S variant, whose structure resembles more closely that of vertebrate receptors, are enriched in endomesoderm, suggesting that the SpFGFR variants could play distinct roles in the sea urchin embryo.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Rochester					NIGMS NIH HHS [GM25553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANGERER LM, 1981, NUCLEIC ACIDS RES, V9, P2819, DOI 10.1093/nar/9.12.2819; ANGERER LM, 1991, IN SITU HYBRIDIZATIO, P15; AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; EISEMANN A, 1991, ONCOGENE, V6, P1195; ETTENSOHN CA, 1988, DEV BIOL, V125, P396, DOI 10.1016/0012-1606(88)90220-5; ETTENSOHN CA, 1990, SCIENCE, V248, P1113; FUKUSHI TSUKASA, 1962, BULL MAR BIOL STA ASAMUSHI, V11, P21; GAGNON ML, 1992, DEVELOPMENT, V114, P457; GALAU GA, 1974, CELL, V2, P9, DOI 10.1016/0092-8674(74)90003-8; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; GRIMWADE JE, 1991, DEV BIOL, V143, P44, DOI 10.1016/0012-1606(91)90053-6; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENRY JJ, 1989, DEV BIOL, V136, P140, DOI 10.1016/0012-1606(89)90137-1; HORSTADIUS S, 1973, EXPT EMBRYOLOGY ECHI, P41; HOU JZ, 1993, PROTEIN SCI, V2, P86; HURLEY DL, 1989, DEVELOPMENT, V106, P567; HYMAN L, 1955, INVERTEBRATES, V4, P691; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KHANER O, 1991, DEVELOPMENT, V112, P881; KHANER O, 1990, DEVELOPMENT, V109, P625; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1987, J MOL BIOL, V196, P497; LIVINGSTON BT, 1989, P NATL ACAD SCI USA, V86, P3669, DOI 10.1073/pnas.86.10.3669; Logan C. Y., 1994, Molecular Biology of the Cell, V5, p106A; MCCLAY DR, 1979, DEV BIOL, V71, P289, DOI 10.1016/0012-1606(79)90170-2; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NEMER M, 1984, DEV BIOL, V102, P471, DOI 10.1016/0012-1606(84)90212-4; NOCENTEMCGRATH C, 1989, DEV BIOL, V136, P264, DOI 10.1016/0012-1606(89)90147-4; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RANSICK A, 1993, SCIENCE, V259, P1134, DOI 10.1126/science.8438164; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONUBISCH L, 1929, W ROUX ARCH ENTWMECH, V117, P81; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; WOLPERT L, 1962, EXP CELL RES, V29, P561; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	58	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20119	20125		10.1074/jbc.271.33.20119	http://dx.doi.org/10.1074/jbc.271.33.20119			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702734	hybrid			2022-12-27	WOS:A1996VC66900075
J	Morrical, SW; Beernink, HTH; Dash, A; Hempstead, K				Morrical, SW; Beernink, HTH; Dash, A; Hempstead, K			The gene 59 protein of bacteriophage T4 - Characterization of protein-protein interactions with gene 32 protein, the T4 single-stranded DNA binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ASSEMBLY PROTEIN; NUCLEIC-ACIDS; REPLICATION; RECOMBINATION; PURIFICATION; MUTATIONS; REQUIRES; PHAGE	The gene 59 protein (gp59) of bacteriophage T4 stimulates the activities of gene 41 protein (gp41), the T4 replicative DNA helicase, by promoting the assembly of gp41 onto single-stranded (ss)-DNA molecules that are covered with cooperatively bound gene 32 protein (gp32). This helicase-ssDNA assembly process, which is important for the reconstitution of the primosome component of the T4 DNA replication fork, appears to require both gp59-gp41 and gp59-gp32 protein-protein interactions. In this study we characterize the physical and functional interactions of gp59 with gp32, the T4 ssDNA-binding protein. Experimental results presented herein indicate: 1) that gp59 binds specifically to both free and ssDNA-bound gp32 molecules; and 2) that in both cases binding involves contacts of gp32 (the so-called ''A-domain''). We further show that single-stranded DNA molecules coated with (gp32-A), a truncated form of gp32 lacking A-domain, are refractory to gp59-dependent helicase assembly. The data indicate that specific contacts between gp59 molecules and the A-domains of gp32 molecules are essential for gp59-dependent assembly of gp41 onto gp32-ssDNA complexes. Our results are consistent with a model in which gp59 binds to gp32 molecules within the gp32-ssDNA complex and therein forms a target site for helicase-ssDNA assembly.	UNIV VERMONT, VERMONT CANC CTR, COLL MED, BURLINGTON, VT 05405 USA; UNIV VERMONT, DEPT BIOCHEM, COLL MED, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont	Morrical, SW (corresponding author), UNIV VERMONT, DEPT MICROBIOL & MOL GENET, COLL MED, BURLINGTON, VT 05405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048847, R56GM048847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; CUNNINGHAM RP, 1978, VIROLOGY, V88, P62, DOI 10.1016/0042-6822(78)90110-1; DOHERTY DH, 1982, MOL GEN GENET, V188, P77, DOI 10.1007/BF00332998; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Kreuzer Kenneth N., 1994, P89; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MOISE H, 1976, NATURE, V259, P455, DOI 10.1038/259455a0; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Mosig Gisela, 1994, P54; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; Williams Kenneth R., 1994, P301; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	30	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20198	20207		10.1074/jbc.271.33.20198	http://dx.doi.org/10.1074/jbc.271.33.20198			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702746	hybrid			2022-12-27	WOS:A1996VC66900088
J	Raufman, JP; Lin, JY; Raffaniello, RD				Raufman, JP; Lin, JY; Raffaniello, RD			Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach - Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; CYCLOSPORINE-A; PHOSPHATASES; PHOSPHORYLATION; INHIBITORS; CALMODULIN; CAMP; YANG; CA2+; YIN	In cholera toxin treated gastric chief cells, incubation with a cholinergic agonist (carbamylcholine), a regulatory peptide (cholecystokinin), or a calcium ionophore (A23187) causes a dose- and time-dependent potentiation of cAMP levels. Because this augmented response is calcium/calmodulin dependent, we hypothesized that it was mediated by calcineurin (protein phosphatase 2B). To test this hypothesis, we examined the actions of calcineurin inhibitors on secretagogue-induced potentiation of cAMP levels in guinea pig chief cells. Preincubation of cells with 0.1 CCM FK-506 completely prevented carbachol-induced augmentation of cAMP levels and pepsinogen secretion from cholera toxin-treated cells. Cyclosporin-A, another calcineurin inhibitor, also prevented the augmented cAMP response, FK-506 and cyclosporin inhibited augmentation of cAMP levels following treatment with cholecystokinin(26-33) and A23187, but not the smaller increase in cAMP following treatment with a phorbol ester that activates protein kinase C. Hence, the actions of calcineurin inhibitors were limited to secretagogues that increase cellular calcium, Rapamycin, an agent that competes with FK-506 for the immunophilin, FK binding protein 12, does not inhibit calcineurin. In the present study, preincubation with rapamycin did not prevent carbachol-induced augmentation of cAMP levels in cholera toxin-treated chief cells, However, a molar excess of rapamycin reversed the inhibitory actions of FK-506. These experiments provide further evidence that the actions of FK-506 on cholera toxin-treated gastric chief cells are caused by its inhibitory actions on calcineurin. FK-506 also inhibited potentiation of cAMP levels when carbachol was added to cells that were preincubated with forskolin, an agent that directly activates adenylyl cyclase. We conclude that, in gastric chief cells, calcineurin mediates crosstalk between the calcium/calmodulin and adenylyl cyclase signaling pathways.	SUNY HLTH SCI CTR,DEPT MED,GASTROINTESTINAL CELL BIOL LAB,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Raufman, JP (corresponding author), UNIV ARKANSAS MED SCI HOSP,DIV GASTROENTEROL,SLOT 567,4301 W MARKHAM ST,LITTLE ROCK,AR 72205, USA.							BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COOPERSTEIN SJ, 1995, BIOCHEM BIOPH RES CO, V2156, P75; GARDNER JD, 1979, BIOCHIM BIOPHYS ACTA, V585, P250, DOI 10.1016/0304-4165(79)90025-4; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MALHOTRA R, 1993, GASTROENTEROLOGY, V104, pA139; MALHOTRA R, 1994, GASTROENTEROLOGY, V106, pA824; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; PAN GZ, 1992, BICOH BIOPHYS ACTA, V720, P338; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; RAUFMAN JP, 1984, AM J PHYSIOL, V247, pG95, DOI 10.1152/ajpgi.1984.247.1.G95; RAUFMAN JP, 1992, GASTROENTEROLOGY, V102, P699, DOI 10.1016/0016-5085(92)90124-H; RAUFMAN JP, 1987, J BIOL CHEM, V262, P5957; RAUFMAN JP, 1986, BIOCHEM BIOPH RES CO, V137, P281, DOI 10.1016/0006-291X(86)91207-6; RAUFMAN JP, 1992, BIOCHIM BIOPHYS ACTA, V1135, P61, DOI 10.1016/0167-4889(92)90166-9; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SUTLIFF VE, 1986, AM J PHYSIOL, V251, pG96, DOI 10.1152/ajpgi.1986.251.1.G96; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	32	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19877	19882		10.1074/jbc.271.33.19877	http://dx.doi.org/10.1074/jbc.271.33.19877			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702699	hybrid			2022-12-27	WOS:A1996VC66900040
J	Smith, BF; Stedman, H; Rajpurohit, Y; Henthorn, PS; Wolfe, JH; Patterson, DF; Giger, U				Smith, BF; Stedman, H; Rajpurohit, Y; Henthorn, PS; Wolfe, JH; Patterson, DF; Giger, U			Molecular basis of canine muscle type phosphofructokinase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; SKELETAL-MUSCLE; GENE; EXPRESSION; ISOZYMES; CDNA; METABOLISM; HEMOLYSIS; MYOBLASTS; SUBUNITS	Muscle type phosphofructokinase (M-PFK) deficiency is a rare inherited glycogen storage disease in humans that causes exertional myopathy and hemolysis. The molecular basis of canine M-PFK deficiency, the only naturally occurring animal homologue, was investigated. Lack of M-PFK enzyme activity was caused by a nonsense mutation in the penultimate exon of the M-PFK gene, leading to rapid degradation of a truncated (40 amino acids) and therefore unstable M-PFK protein, A polymerase chain reaction-based test was devised to identify M-PFK-deficient and carrier animals, This represents one of only a fe rv inborn errors of metabolism where the molecular defect has been identified in a large animal model which can now be used to develop and assess novel therapeutic strategies.	UNIV PENN,SCH VET MED,MED GENET SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,PATHOL LAB,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK037602, R23DK037602, R01DK037602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37602] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07170] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNEREN G, 1988, UPSALA J MED SCI, V93, P33, DOI 10.1517/03009734000000034; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GIGER U, 1987, J AM VET MED ASSOC, V191, P453; GIGER U, 1985, BLOOD, V65, P345; GIGER U, 1986, ANIM GENET, V17, P15, DOI 10.1111/j.1365-2052.1986.tb03184.x; GIGER U, 1988, ENZYME, V40, P25, DOI 10.1159/000469137; GUIXE V, 1988, ARCH BIOCHEM BIOPHYS, V264, P519, DOI 10.1016/0003-9861(88)90317-7; LAU FTK, 1987, BIOCHEMISTRY-US, V26, P4143, DOI 10.1021/bi00387a060; LEBRAS G, 1986, BIOCHEMISTRY-US, V25, P2490, DOI 10.1021/bi00357a031; LEE CP, 1987, J BIOL CHEM, V262, P4195; LEVANON D, 1987, BIOCHEM BIOPH RES CO, V147, P1182, DOI 10.1016/S0006-291X(87)80194-8; MANDARINO LJ, 1987, J CLIN INVEST, V80, P655, DOI 10.1172/JCI113118; MEHTA J, 1987, ANN NUTR METAB, V31, P35, DOI 10.1159/000177246; MNASKAR Y, 1991, ENZYME, V45, P137; MORRISON N, 1992, HUM GENET, V89, P105, DOI 10.1007/BF00207053; NAKAJIMA H, 1987, FEBS LETT, V223, P113, DOI 10.1016/0014-5793(87)80519-7; NAKAJIMA H, 1990, J BIOL CHEM, V265, P9392; NEWTON PA, 1989, BIOCHEM SOC T, V17, P1106, DOI 10.1042/bst0171106; NOBLE NA, 1989, BLOOD, V74, P475; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P2517, DOI 10.1093/nar/19.9.2517; RABEN N, 1995, AM J HUM GENET, V56, P131; ROBERTS SJ, 1987, BIOCHEMISTRY-US, V26, P3437, DOI 10.1021/bi00386a028; ROWLAND LP, 1986, MYOLOGY, P1603; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SHARMA PM, 1989, GENE, V77, P177, DOI 10.1016/0378-1119(89)90372-7; SHERMAN JB, 1994, AM J HUM GENET, V55, P305; SMITH BF, 1990, MOL CELL BIOL, V10, P3268, DOI 10.1128/MCB.10.6.3268; SMITH BF, 1995, GENE AMST, V168, P275; TRIGUN SK, 1987, CELL MOL BIOL, V33, P767; TRIGUN SK, 1988, ARCH GERONTOL GERIAT, V7, P239, DOI 10.1016/0167-4943(88)90007-6; VORA S, 1985, P NATL ACAD SCI USA, V82, P8109, DOI 10.1073/pnas.82.23.8109; WILLS KN, 1990, ARCH BIOCHEM BIOPHYS, V278, P81, DOI 10.1016/0003-9861(90)90234-P	35	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20070	20074		10.1074/jbc.271.33.20070	http://dx.doi.org/10.1074/jbc.271.33.20070			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702726	hybrid			2022-12-27	WOS:A1996VC66900067
J	Turcatti, G; Nemeth, K; Edgerton, MD; Meseth, U; Talabot, F; Peitsch, M; Knowles, J; Vogel, H; Chollet, A				Turcatti, G; Nemeth, K; Edgerton, MD; Meseth, U; Talabot, F; Peitsch, M; Knowles, J; Vogel, H; Chollet, A			Probing the structure and function of the tachykinin neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at specific sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSFER RNAPHE; CONNECTING HELIX-C; TRANSFER-RNAS; NK2 RECEPTOR; XENOPUS OOCYTES; ENERGY-TRANSFER; BINDING; PROTEINS; ANTAGONISTS; NUCLEOTIDES	A general method for understanding the mechanisms of ligand recognition and activation of G protein coupled receptors has been developed, A study of ligand-receptor interactions in the prototypic seven-transmembrane neurokinin-a receptor (NK2) using this fluorescence-based approach is presented, A fluorescent unnatural amino acid was introduced at known sites into NK2 by suppression of UAG nonsense codons with the aid of a chemically misacylated synthetic tRNA specifically designed for the incorporation of unnatural amino acids during heterologous expression in Xenopus oocytes, Fluorescence-labeled NK2 mutants containing an unique 3-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-2,3-diaminopropionic acid (NBD-Dap) residue at either site 103, in the first extracellular loop, or 248, in the third cytoplasmic loop, were functionally active, The fluorescent NK2 mutants were investigated by microspectrofluorimetry in a native membrane environment, Intermolecular distances were determined by measuring the fluorescence resonance energy transfer (FRET) between the fluorescent unnatural amino acid and a fluorescently labeled NK2 heptapeptide antagonist, These distances, calculated by the theory of Forster, permit to fix the ligand in space and define the structure of the receptor in a molecular model for NK2 ligand-receptor interactions, Our data are the first report of the incorporation of a fluorescent unnatural amino acid into a membrane protein in intact cells by the method of nonsense codon suppression, as well as the first measurement of experimental distances between a G protein-coupled receptor and its ligand by FRET, The method presented here can be generally applied to the analysis of spatial relationships in integral membrane proteins such as receptors or channels.	GLAXO WELLCOME, GENEVA BIOMED RES INST, CH-1228 GENEVA, SWITZERLAND; ECOLE POLYTECH FED LAUSANNE, INST CHIM PHYS, CH-1015 LAUSANNE, SWITZERLAND	GlaxoSmithKline; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne			Vogel, Horst/AAJ-5490-2021; Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				AKINSTALL S, 1994, FEBS LETT, V338, P75; BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BRADSHAW CG, 1994, J MED CHEM, V37, P1991, DOI 10.1021/jm00039a012; BRUCE AG, 1982, P NATL ACAD SCI-BIOL, V79, P7127, DOI 10.1073/pnas.79.23.7127; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CHERRY JM, 1991, METHOD CELL BIOL, V36, P675; Chollet Andre, 1996, P177; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FAY SP, 1993, BIOCHEMISTRY-US, V32, P1627, DOI 10.1021/bi00057a029; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GETHER U, 1995, J BIOL CHEM, V270, P28268; HARADA Y, 1987, J NEUROSCI, V7, P3265; Herzyk P, 1995, BIOPHYS J, V69, P2419, DOI 10.1016/S0006-3495(95)80112-8; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAKOWICZ J, 1983, PRINCIPLES FLUORESCE, P131; LAKOWICZ JR, 1990, BIOPHYS CHEM, V36, P99, DOI 10.1016/0301-4622(90)85014-W; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NEMETH K, 1995, J BIOL CHEM, V270, P27601, DOI 10.1074/jbc.270.46.27601; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SMITH PW, 1993, BIOORG MED CHEM LETT, V3, P931, DOI 10.1016/S0960-894X(00)80695-2; SOLARI G, 1977, NUCLEIC ACIDS RES, V4, P1873; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; VOGEL H, 1993, EUR J BIOCHEM, V212, P305, DOI 10.1111/j.1432-1033.1993.tb17663.x; WALKER P, 1994, J BIOL CHEM, V269, P2863; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; WHITE SH, 1994, CURR OPIN STRUC BIOL, V4, P79, DOI 10.1016/S0959-440X(94)90063-9; ZOZYULA SA, 1990, PROTEIN ENG, V3, P453	41	110	167	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19991	19998		10.1074/jbc.271.33.19991	http://dx.doi.org/10.1074/jbc.271.33.19991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702716	hybrid			2022-12-27	WOS:A1996VC66900057
J	Chamberlain, LH; Henry, J; Burgoyne, RD				Chamberlain, LH; Henry, J; Burgoyne, RD			Cysteine string proteins are associated with chromaffin granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM-CHANNEL; SYNAPTIC VESICLES; SUPPRESSION CLONING; ENDOCRINE-CELLS; DROSOPHILA; MUTANTS; NEURONS; CDNA; RAT	In this work, we have examined the subcellular distribution of cysteine string proteins (Csps) in bovine adrenal medullary chromaffin cells. Csps did not, leak from digitonin-permeabilized chromaffin cells, suggesting that there is no cytosolic pool of the protein in these cells. Subcellular fractionation studies confirmed that there was essentially no Csp immunoreactivity in the cytosolic fraction. However, immunoreactivity was detected in the membrane fractions of these cells. Csp immunoreactivity codistributed with dopamine beta-hydroxylase, a granule marker protein, in sucrose gradient-separated granule fractions. Immunofluorescence studies showed that all chromaffin cells in culture were stained with a punctate appearance consistent with a granular localization. These results mere confirmed by immunogold labeling which demonstrated specific labeling of chromaffin granule membranes. In addition to its presence on synaptic vesicles, cysteine. string protein is therefore a bona fide chromaffin granule membrane protein.	UNIV LIVERPOOL, PHYSIOL LAB, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, DEPT VET PRECLIN SCI, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool; University of Liverpool			Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; KOHAN SA, 1995, J NEUROSCI, V15, P6230; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; MASTROGIACOMO A, 1995, MOL BRAIN RES, V28, P12, DOI 10.1016/0169-328X(94)00172-B; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; UMBACH JA, 1991, ANN NY ACAD SCI, V635, P443, DOI 10.1111/j.1749-6632.1991.tb36522.x; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	18	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19514	19517		10.1074/jbc.271.32.19514	http://dx.doi.org/10.1074/jbc.271.32.19514			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702643	hybrid			2022-12-27	WOS:A1996VB68400077
J	Shuttleworth, TJ				Shuttleworth, TJ			Arachidonic acid activates the noncapacitative entry of Ca2+ during [Ca2+](i) oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; AVIAN SALT-GLAND; PHOSPHOLIPASE-C; EXOCRINE CELL; MAST-CELLS; CHOLECYSTOKININ RECEPTOR; BISCOCLAURINE ALKALOIDS; PANCREATIC ACINI	Current models for agonist-activated Ca2+ entry in nonexcitable cells focus on the capacitative mechanism where entry is activated as a downstream result of the sustained depletion of agonist-sensitive stores without any direct requirement for inositol phosphates. This mechanism has been shown to be important for the sustained Ca2+ signals seen in a variety of nonexcitable cells under conditions of maximal stimulation. In contrast, relatively little attention has been given to Ca2+ entry under more physiological levels of agonist where, for example, oscillating Ca2+ responses are common. In recent studies using cells from the exocrine avian nasal gland, we have shown that agonist-activated Ca2+ entry under these conditions demonstrates properties that are inconsistent with current versions of the capacitative model. We now report that activation of this novel noncapacitative Ca2+ entry is via a distinct signaling pathway involving an agonist-induced, phospholipase A(2)-mediated generation of arachidonic acid.	UNIV ROCHESTER,SCH MED & DENT,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14642	University of Rochester					NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIBA S, 1992, BIOCHEM PHARMACOL, V44, P45, DOI 10.1016/0006-2952(92)90036-I; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOMALASKI JS, 1990, J LAB CLIN MED, V116, P814; CHOW SC, 1990, J BIOL CHEM, V265, P902; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIXON JF, 1984, J BIOL CHEM, V259, P4418; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELIX JP, 1992, BIOCHEMISTRY-US, V31, P11793, DOI 10.1021/bi00162a017; HASHIZUME T, 1991, BIOCHEM PHARMACOL, V41, P419, DOI 10.1016/0006-2952(91)90539-H; HILDEBRANDT JP, 1993, J MEMBRANE BIOL, V133, P183; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUNT TW, 1994, J BIOL CHEM, V269, P29565; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; LIGETI E, 1993, EUR J BIOCHEM, V216, P813, DOI 10.1111/j.1432-1033.1993.tb18202.x; MARTIN SC, 1994, FEBS LETT, V352, P32, DOI 10.1016/0014-5793(94)00913-9; MARTIN SC, 1994, PFLUG ARCH EUR J PHY, V426, P231, DOI 10.1007/BF00374776; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; SHUTTLEWORTH TJ, 1990, BIOCHEM J, V269, P417, DOI 10.1042/bj2690417; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; TSUNODA Y, 1993, BIOCHEM BIOPH RES CO, V194, P1194, DOI 10.1006/bbrc.1993.1949; TSUNODA Y, 1995, BIOCHEM BIOPH RES CO, V211, P648, DOI 10.1006/bbrc.1995.1861; TSUNODA Y, 1995, AM J PHYSIOL-GASTR L, V269, pG435, DOI 10.1152/ajpgi.1995.269.3.G435; WU L, 1994, CELL CALCIUM, V15, P228, DOI 10.1016/0143-4160(94)90062-0; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	40	138	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21720	21725		10.1074/jbc.271.36.21720	http://dx.doi.org/10.1074/jbc.271.36.21720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702966	hybrid			2022-12-27	WOS:A1996VF61200008
J	Turko, IV; Haik, TL; McAllisterLucas, LM; Burns, F; Francis, SH; Corbin, JD				Turko, IV; Haik, TL; McAllisterLucas, LM; Burns, F; Francis, SH; Corbin, JD			Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases - A putative NKX(n)D motif for cGMP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE; PREDICTED STRUCTURES; CRYSTAL-STRUCTURE; DOMAINS; CAMP; RAS; DERIVATIVES; RESOLUTION; ANALOGS	cGMP-binding phosphodiesterases contain two kinetically distinct cGMP-binding sites (a and b), and each site contains a conserved N(K/R)X(n)FX(3)DE sequence, N276A, K277A, R277R, D289A, and E290A mutants in the N(276)KX(7)FX(3)DE(290) sequence of site a (higher affinity site) of bovine cGMP-binding, cGMP-specific phosphodiesterase (cGB-PDE or PDE5A) were expressed in High Five cells and purified, The cGMP-binding affinities of three mutants [K277A (K-d approximate to 12 mu M), D289A (K-d approximate to 24 mu M) and N276A (K-d approximate to 60 mu M)] were decreased in comparison with wild-type enzyme (K-d = 1.3 mu M), which suggested an important role for Asn(276), Lys(277), and Asp(289) in cGMP binding, These residues could be presented as a putative NKX(n)D motif, and their functions were predicted based on analogy with the canonical NKXD motifin GTP-binding proteins, No marked differences in catalytic functions such as specific activity, K-m for cGMP, and IC50 for zaprinast or 3-isobutyl-1-methylxanthine were found among wild-type and mutant cGB-PDEs. This suggested that cGMP binding to site a does not influence the catalytic properties of cGB-PDE.			Turko, IV (corresponding author), VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, 221 KIRKLAND HALL, NASHVILLE, TN 37232 USA.				NIGMS NIH HHS [GM41269, GM07347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269, T32GM007347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BELTMAN J, 1995, MOL PHARMACOL, V47, P330; BENATTI L, 1991, GENE, V101, P255, DOI 10.1016/0378-1119(91)90420-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUCHIE D, 1983, EUR J BIOCHEM, V136, P571, DOI 10.1111/j.1432-1033.1983.tb07778.x; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; ERNEUX C, 1984, ADV CYCLIC NUCL PROT, V16, P107; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; Maniatis T, 1989, MOL CLONING; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	25	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22240	22244		10.1074/jbc.271.36.22240	http://dx.doi.org/10.1074/jbc.271.36.22240			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703039	hybrid			2022-12-27	WOS:A1996VF61200081
J	Anafi, M; Rosen, MK; Gish, GD; Kay, LE; Pawson, T				Anafi, M; Rosen, MK; Gish, GD; Kay, LE; Pawson, T			A potential SH3 domain-binding site in the Crk SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; C-13-LABELED PROTEINS; HIGH-AFFINITY; WW DOMAIN; SRC; PEPTIDE; IDENTIFICATION; PHOSPHATASE; SPECIFICITY; SUBSTRATE	The Src homology 2 (SH2) domain of the mammalian adaptor protein Crk-II contains a proline-rich insert, predicted to lie within an extended DE loop, which is dispensable for phosphopeptide binding, Using the yeast two-hybrid system, this region of the Crk-II SH2 domain was found to interact with a subset of SH3 domains, notably the Abl SH3 domain. Furthermore, this proline-rich insert was found to modify the efficiency with which Crk-II was phosphorylated by the p140(c-abl) tyrosine kinase, In vitro, the interaction of full length non-phosphorylated Crk-II with a glutathione S-transferase Abl SH3 domain fusion protein was very weak, However, phosphorylation of Crk-II on Tyr-221 which induces an intramolecular association with the SH2 domain, or addition of a phosphopeptide corresponding to the Crk-II Tyr-221 phosphorylation site, stimulated association of Crk-II with the Abl SH3 domain, NMR spectroscopic analysis showed that binding of the Tyr-221 phosphopeptide to the Crk SH2 domain induced a chemical shift change in Val-71, located in the proline-rich insert, indicative of a change in the structure of the proline-rich loop in response of Crk SH2 pTyr-221 interaction, These results suggest that the proline-rich insert in the Crk SH2 domain constitutes an SH3 domain-binding site that can be regulated by binding of a phosphopeptide ligand to the Crk SH2 domain.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, PROT ENGN NETWORK CTR EXCELLENCE, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT CHEM, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					ANAFI M, 1992, J BIOL CHEM, V267, P4518; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLUBB RT, 1992, J BIOMOL NMR, V2, P203, DOI 10.1007/BF01875531; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FRIEDRICHS MS, 1994, J BIOMOL NMR, V4, P703, DOI 10.1007/BF00404279; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; ODA T, 1994, J BIOL CHEM, V269, P22925; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZONGHAN D, 1995, GENE DEV, V9, P2569	51	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21365	21374		10.1074/jbc.271.35.21365	http://dx.doi.org/10.1074/jbc.271.35.21365			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702917	hybrid			2022-12-27	WOS:A1996VE47700063
J	Chen, CG; Yin, YL; deRiel, JK; DesJarlais, RL; Raveglia, LF; Zhu, JM; LiuChen, LY				Chen, CG; Yin, YL; deRiel, JK; DesJarlais, RL; Raveglia, LF; Zhu, JM; LiuChen, LY			Determination of the amino acid residue involved in [H-13]beta-funaltrexamine covalent binding in the cloned rat mu opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; H-3 BETA-FUNALTREXAMINE; GUINEA-PIG BRAIN; OPIATE RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; IRREVERSIBLE BINDING; EXTRACELLULAR LOOP; MOLECULAR-CLONING; SELECTIVE AGONIST	We previously demonstrated that [H-3]beta-funaltrexamine ([H-3]beta-FNA) labeled the rat mu opioid receptor expressed in Chinese hamster ovary cells with high specificity, and [H-3] beta-FNA-Iabeled receptors migrated as one broad band with a mass of 80 kDa. In this study, we determined the region and then the amino acid residue of the mu receptor involved in the covalent binding of [H-3]beta-FNA. [H-3]beta-FNA-labeled receptors were solubilized and purified to similar to 10% purity by immunoaffinity chromatography with antibodies against a C-terminal domain peptide. The site of covalent bond formation was determined to be within Ala(206)-Met(243) by CNBr cleavage of partially purified labeled mu receptors and determinations of sizes of labeled receptor fragments. The amino acid residue of beta-FNA covalent incorporation was then determined by site-directed mutagenesis studies within this region. Mutation of Lys(233) to Ala, Arg, His, and Leu completely eliminated covalent binding of [H-3]beta-FNA, although these mutants bound beta-FNA with high affinity. Mutations of other amino acid residues did not affect covalent binding of [H-3]beta-FNA. These results indicate that [H-3]beta-FNA binds covalently to Lys(233). Since [H-3]beta-FNA is a rigid molecule, the information will be very useful for molecular modeling of interaction between morphinans and the mu receptor.	TEMPLE UNIV, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST MOL BIOL & CANC RES, PHILADELPHIA, PA 19140 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM SPA, DEPT CHEM, I-20021 BARANZATE, MILAN, ITALY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline; GlaxoSmithKline					NIDA NIH HHS [DA 04745, T32 DA07237] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA004745, R01DA004745, T32DA007237] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLEN G, 1981, SEQUENCING PROTEINS, P62; BARE LA, 1994, FEBS LETT, V354, P213, DOI 10.1016/0014-5793(94)01129-X; Befort K, 1996, MOL PHARMACOL, V49, P216; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUNZOW JR, 1995, J NEUROCHEM, V64, P14; CHEN CG, 1995, J BIOL CHEM, V270, P17866, DOI 10.1074/jbc.270.30.17866; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FRANKLIN TG, 1991, BRIT J PHARMACOL, V102, P718, DOI 10.1111/j.1476-5381.1991.tb12239.x; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; GRIFFIN JF, 1986, J MED CHEM, V29, P778, DOI 10.1021/jm00155a031; Harlow E, 1988, ANTIBODIES LAB MANUA, P104; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; LIUCHEN LY, 1990, MOL PHARMACOL, V37, P243; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; LIUCHEN LY, 1991, BRAIN RES, V544, P235, DOI 10.1016/0006-8993(91)90059-5; LUTHIN GR, 1988, MOL PHARMACOL, V34, P327; MATSUI H, 1989, BIOCHEMISTRY-US, V28, P4125, DOI 10.1021/bi00435a075; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PASTERNAK GW, 1988, OPIATE RECEPTORS; PORTOGHESE PS, 1980, J MED CHEM, V23, P233, DOI 10.1021/jm00177a002; RECHT LD, 1987, EUR J PHARMACOL, V140, P209, DOI 10.1016/0014-2999(87)90807-7; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYRE LM, 1983, J MED CHEM, V26, P1229, DOI 10.1021/jm00363a005; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1985, ANNU REV PHARMACOL, V25, P193; TAM SW, 1986, J PHARMACOL EXP THER, V239, P351; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; XUE JC, 1995, J BIOL CHEM, V270, P12977; XUE JC, 1994, J BIOL CHEM, V269, P30195; Zhu JM, 1996, J BIOL CHEM, V271, P1430, DOI 10.1074/jbc.271.3.1430; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	58	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21422	21429		10.1074/jbc.271.35.21422	http://dx.doi.org/10.1074/jbc.271.35.21422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702924				2022-12-27	WOS:A1996VE47700070
J	Hiasa, H; Marians, KJ				Hiasa, H; Marians, KJ			Two distinct modes of strand unlinking during theta-type DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-IV; PBR322 DNA; IN-VITRO; DEOXYRIBONUCLEIC-ACID; LEADING-STRAND; GENE-PRODUCT; GYRASE; IDENTIFICATION; DECATENATION	DNA gyrase and topoisomerase IV (Topo IV) are type II bacterial DNA topoisomerases that show a high degree of similarity to each other yet appear to have different functions during DNA replication. We show here that the torsional stress generated during theta-type DNA replication in vitro can take the form of either positive supercoils ahead of the replication fork or catenane-like right-handed windings (precatenanes) of the two partially replicated duplexes behind the fork. Gyrase prefers to act on the former, whereas Topo IV prefers the latter. Removal of either form of positive winding can support nascent chain elongation, but only precatenane removal can support the final stages of DNA replication: processing of the late intermediate and daughter chromosome decatenation.			Hiasa, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; Champoux JJ, 1980, MECH STUDIES DNA REP, P809; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; FILUTOWICZ M, 1983, MOL GEN GENET, V191, P282, DOI 10.1007/BF00334827; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1994, J BIOL CHEM, V269, P32655; HIASA H, 1994, J BIOL CHEM, V269, P2093; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KIM RA, 1992, J BIOL CHEM, V267, P17178; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KORNBERG A, 1992, DNA REPLICATION, P379; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; MORRISON A, 1980, J BIOL CHEM, V255, P2211; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; PENG H, 1995, THESIS CORNELL U; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030; YAMAGISHI JI, 1981, J BACTERIOL, V148, P450, DOI 10.1128/JB.148.2.450-458.1981; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	33	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21529	21535		10.1074/jbc.271.35.21529	http://dx.doi.org/10.1074/jbc.271.35.21529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702938	hybrid			2022-12-27	WOS:A1996VE47700084
J	Lau, LF; Mammen, A; Ehlers, MD; Kindler, S; Chung, WJ; Garner, CC; Huganir, RL				Lau, LF; Mammen, A; Ehlers, MD; Kindler, S; Chung, WJ; Garner, CC; Huganir, RL			Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; HETEROMERIC NMDA RECEPTORS; GLUTAMATE-RECEPTOR; RAT-BRAIN; ACETYLCHOLINE-RECEPTOR; POSTSYNAPTIC PROTEIN; GUANYLATE KINASES; DROSOPHILA; PHOSPHORYLATION; SUBUNITS	Ionotropic glutamate receptors are known to cluster at high concentration on the postsynaptic membrane of excitatory synapses, but the mechanism by which this occurs is poorly understood. Studies on the neuromuscular junction and central inhibitory synapses suggest that clustering of neurotransmitter receptors requires its interaction with a cytoplasmic protein. Recently, in vitro studies have shown that members of the N-methyl-D-aspartate (NMDA) class of glutamate receptors interact with a synapse-associated protein, SAP90 (PSD-95). However, evidence for the in vivo interaction of NMDA receptors with SAPs is still lacking. In the present study, we demonstrate the specific interaction between SAP102, a novel synapse-associated protein, and the NMDA receptor complex from the rat cortical synaptic plasma membranes using co-immunoprecipitation techniques. No association was observed between SAP102 and GluR1, a member of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate class of glutamate receptors. To identify the domain on the NMDA receptor responsible for this interaction, we constructed hexahistidine fusion proteins hom different regions of the NR1a and NR2 subunits of the NMDA receptor. Immunoblot overlay experiments showed that while the C-terminal domain of the NR2 subunit displayed strong binding, the NR1a intracellular C-terminal tail did not interact with SAP102. The site of interaction was more precisely located to the last 20 amino acids of the NR2 subunit as indicated by the interaction of the synthetic peptide with SAP102. In summary, we demonstrate here for the first time an in vivo interaction between the native NMDA receptor complex and a synapse-associated protein. These results suggest that SAP102 may play an important role in NMDA receptor clustering and immobilization at excitatory synapses.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV ALABAMA,BIRMINGHAM,AL 35294	Howard Hughes Medical Institute; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham			Mammen, Andrew/AAF-2885-2021	Garner, Craig/0000-0003-1970-5417				APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BROSE N, 1993, J BIOL CHEM, V268, P22663; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Hunt CA, 1996, J NEUROSCI, V16, P1380; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1996, J NEUROSCI, V16, P2157; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WO ZGL, 1995, J BIOL CHEM, V270, P2000, DOI 10.1074/jbc.270.5.2000; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	44	157	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21622	21628		10.1074/jbc.271.35.21622	http://dx.doi.org/10.1074/jbc.271.35.21622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702950	hybrid			2022-12-27	WOS:A1996VE47700096
J	Butcher, BA; Turco, SJ; Hilty, BA; Pimenta, PF; Panunzio, M; Sacks, DL				Butcher, BA; Turco, SJ; Hilty, BA; Pimenta, PF; Panunzio, M; Sacks, DL			Deficiency in beta 1,3-galactosyltransferase of a Leishmania major lipophosphoglycan mutant adversely influences the Leishmania sand fly interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTES; DONOVANI; IDENTIFICATION; EXPRESSION; VIRULENCE	To study the function of side chain oligosaccharides of the cell-surface lipophosphoglycan (LPG), mutagenized Leishmania major defective in side chain biosynthesis were negatively selected by agglutination with the monoclonal antibody WIC79,3, which recognizes the galactose-containing side chains of L, major LPG, One such mutant, called Spock, lacked the ability to bind significantly to midguts of the natural L. major vector, Phlebotomus papatasi, and to maintain infection in the sand fly after excretion of the digested bloodmeal, Biochemical characterization of Spock LPG revealed its structural similarity to the LPG of Leishmania donovani, a species whose inability to bind to and maintain infections in P, papatasi midguts has been strongly correlated with the expression of a surface LPG lacking galactose-terminated oligosaccharide side chains, An in vitro galactosyltransferase assay using wild-type or Spock membranes was used to determine that the defect in Spock LPG biosynthesis is a result of defective beta 1,3-galactosyltransferase activity as opposed to a modification of LPG, which would prevent it from serving as a competent substrate for galactose addition, The results of these experiments show that Speck lacks the beta 1,3-galactosyltransferase for side chain addition and that the LPG side chains are required for L, major to bind to and to produce transmissible infection in P, papatasi.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; NIH,PARASIT DIS LAB,INTRACELLULAR PARASITE BIOL SECT,BETHESDA,MD 20892; UNIV ESTADUAL NORTE FLUMINENSE,PARASITOL LAB,CTR BIOCIENCIAS & BITECNOL,RIO JANEIRO,BRAZIL; UNIV BARI,INST MED MICROBIOL,BARI,ITALY	University of Kentucky; National Institutes of Health (NIH) - USA; Universidade Estadual do Norte Fluminense; Universita degli Studi di Bari Aldo Moro			Pimenta, Paulo/AAH-1502-2020		NIAID NIH HHS [R37 AI20491] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; BERGER EG, 1994, TRENDS CELL BIOL, V2, P103; CAPPAI R, 1994, PARASITOLOGY, V108, P397, DOI 10.1017/S0031182000075946; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KELLEHER M, 1992, P NATL ACAD SCI USA, V66, P187; LOW MG, 1983, BIOCHEM J, V215, P325, DOI 10.1042/bj2150325; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCCONVILLE MJ, 1995, BIOCHEM J, V307, P807; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SACKS DL, 1985, J IMMUNOL, V135, P564; TESH RB, 1987, AM J TROP MED HYG, V33, P41; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; THURNHER M, 1993, J CLIN INVEST, V91, P2103, DOI 10.1172/JCI116434; TOLSON DL, 1994, PARASITOL RES, V80, P537, DOI 10.1007/BF00932704; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433	25	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20573	20579		10.1074/jbc.271.34.20573	http://dx.doi.org/10.1074/jbc.271.34.20573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702802	hybrid			2022-12-27	WOS:A1996VD33700054
J	Roberts, LJ; Moore, KP; Zackert, WE; Oates, JA; Morrow, JD				Roberts, LJ; Moore, KP; Zackert, WE; Oates, JA; Morrow, JD			Identification of the major urinary metabolite of the F-2-isoprostane 8-iso-prostaglandin F-2 alpha in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; PROSTANOIDS F2-ISOPROSTANES; FREE-RADICALS; HUMAN-DISEASE; RAT; PROSTAGLANDIN; NONCYCLOOXYGENASE; THROMBOXANE-B2; MECHANISM; RECEPTORS	F-2-isoprostanes are prostaglandin-like products of nonenzymatic lipid peroxidation, Measurement of levels of endogenous unmetabolized F-2-isoprostanes has proven to be a valuable approach to assess oxidative stress in vivo. However, measurement of levels of urinary metabolites of F-2-isoprostanes in timed urine collections offers an advantage over measuring unmetabolized F-2-isoprostanes, e,g, in a plasma sample, in that it can provide an integrated index of isoprostane production over time. Therefore, we sought to identify the major urinary metabolite in humans of one of the more abundant F-2-isoprostanes produced, 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)). 20 mu Ci of tritiated 8-iso PGF(2 alpha) was infused over 1 h into a male volunteer, 75% of the infused radioactivity was excreted into the urine during the following 4.5 h and was combined with urine collected for 4 h from a rhesus monkey following infusion of 500 mu g of unlabeled 8 iso PGF(2 alpha). Urinary metabolites were isolated and purified by adsorption chromatography and high pressure liquid chromatography. The major urinary metabolite, representing 29% of the total extractable recovered radioactivity in the urine, was structurally identified by gas chromatography and mass spectrometry as 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F-2 alpha. The identification of 2,3 dinor-5,6-dihydro-prostaglandin F-2 alpha as the major urinary metabolite of 8-iso-prostaglandin F-2 alpha provides the basis for the development of methods of assay for its quantification as a means to obtain an integrated assessment of oxidative stress status in humans.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON NW3 2PF,ENGLAND; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Vanderbilt University								AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; GRANSTROM E, 1968, J BIOL CHEM, V243, P4104; GREEN K, 1971, BIOCHIM BIOPHYS ACTA, V231, P419, DOI 10.1016/0005-2760(71)90111-1; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1994, BBA-LIPID LIPID MET, V1210, P244, DOI 10.1016/0005-2760(94)90128-7; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1991, ANAL BIOCHEM, V193, P142, DOI 10.1016/0003-2697(91)90054-W; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; PACEASCIAK CR, 1989, ADV PROSTAGLANDIN TH, V18, P322; ROBERTS LJ, 1977, J BIOL CHEM, V252, P7415; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, P233; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; TAYLOR BM, 1980, J PHARMACOL EXP THER, V214, P24	24	137	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20617	20620		10.1074/jbc.271.34.20617	http://dx.doi.org/10.1074/jbc.271.34.20617			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702808	hybrid			2022-12-27	WOS:A1996VD33700060
J	Saxena, SK; Gravell, M; Wu, YN; Mikulski, SM; Shogen, K; Ardelt, W; Youle, RJ				Saxena, SK; Gravell, M; Wu, YN; Mikulski, SM; Shogen, K; Ardelt, W; Youle, RJ			Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; III REPLICATION INVITRO; ALPHA-A-INTERFERON; CYTOTOXIC RIBONUCLEASES; SYNERGISTIC INHIBITION; MOLECULAR EVOLUTION; P-30 PROTEIN; H9 CELLS; INFECTION; SUPERFAMILY	Ribonucleases appear to have physiologic roles in host defense against cancer, viruses, and other parasites, Previously it was shown that select ribonucleases added to cells concurrently with virions blocked human immunodeficiency virus, type I (HIV-1) infection of H9 cells, We now report that a ribonuclease homologous to RNase A, named onconase, inhibits virus replication in chronically HIV-1-infected human cells without killing the virally infected cell, Examining the mechanism of this inhibition shows that onconase enters the infected cells and degrades HIV-1 RNA without degrading ribosomal RNA or the three different cellular messenger RNAs analyzed, The homologous human pancreatic RNase lacks anti-viral activity, Comparing recombinant forms of onconase and a onconase-human RNase chimera shows that the N-terminal 9 amino acids and the pyroglutamyl residue of onconase are required for full anti-viral activity. Thus extracellular ribonucleases can enter cells, metabolize select RNAs, and inhibit HIV virion production within viable replicating cells.	NINCDS, BIOCHEM SECT, SURG NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; NINCDS, LAB MOL MED & NEUROSCI, BETHESDA, MD 20892 USA; ALFACELL CORP, BLOOMFIELD, NJ 07003 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Saxena, Shailendra K/X-4252-2019; Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARDELT W, 1991, J BIOL CHEM, V266, P245; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BENNER SA, 1988, FEBS LETT, V233, P225, DOI 10.1016/0014-5793(88)80431-9; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; CARTER WA, 1987, LANCET, V1, P1286; CHAKRAVORTY AK, 1974, NATURE, V247, P577, DOI 10.1038/247577b0; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTSHORN KL, 1986, ANTIMICROB AGENTS CH, V30, P189, DOI 10.1128/AAC.30.1.189; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1985, LANCET, V1, P602; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; LIN JJ, 1994, BIOCHEM BIOPH RES CO, V204, P156, DOI 10.1006/bbrc.1994.2439; LORING HUBERT S., 1942, JOUR GEN PHYSIOL, V25, P497, DOI 10.1085/jgp.25.3.497; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NATSOULIS G, 1995, P NATL ACAD SCI USA, V92, P364, DOI 10.1073/pnas.92.2.364; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; PETERS GG, 1980, J VIROL, V33, P708, DOI 10.1128/JVI.33.2.708-716.1980; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; Rybak S.M., 1993, DRUG DELIV, V1, P3; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; Schroder H C, 1994, Prog Mol Subcell Biol, V14, P176; SCHRODER HC, 1989, J BIOL CHEM, V264, P5669; SEN GC, 1992, J BIOL CHEM, V267, P5017; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	42	81	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20783	20788		10.1074/jbc.271.34.20783	http://dx.doi.org/10.1074/jbc.271.34.20783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702832	hybrid			2022-12-27	WOS:A1996VD33700084
J	Titorenko, VI; Eitzen, GA; Rachubinski, RA				Titorenko, VI; Eitzen, GA; Rachubinski, RA			Mutations in the PAY5 gene of the yeast Yarrowia lipolytica cause the accumulation of multiple subpopulations of peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID-SYNTHESIS; BIOGENESIS; PROTEIN; GOLGI; MEMBRANES; MITOCHONDRIA; POPULATIONS; TRANSPORT	We previously reported the cloning of the PAYS gene of the yeast Yarrowia lipolytica by complementation of the peroxisome assembly mutant pay5-1 (Eitzen, G. A., Titorenko, V. I., Smith, J. J., Veenhuis, M., Szilard, R. K., and Rachubinski, R. A. (1996) J Biol. Chem. 271, 20300-20306). The peroxisomal integral membrane protein Pay5p is a homologue of mammalian PAF-1 proteins, which are essential for peroxisome assembly and whose mutation in humans results in peroxisome biogenesis disorders, Mutations in the PAYS gene result in the accumulation of three distinct peroxisomal subpopulations. These subpopulations are characterized by differences in 1) buoyant density, 2) the relative distribution of peroxisomal matrix and membrane proteins, 3) the efficiency of import of several peroxisomal matrix proteins, and 4) the phospholipid levels of peroxisomal membranes. These data, together with the analysis of temporal changes in the relative abundance of individual peroxisomal subpopulations in pay5 mutants, suggest that these subpopulations represent intermediates in a multistep peroxisome assembly pathway normally operating in yeast cells.	UNIV ALBERTA, DEPT ANAT & CELL BIOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta			Eitzen, Gary/D-3682-2009					ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; AIKAWA J, 1991, P NATL ACAD SCI USA, V88, P10084, DOI 10.1073/pnas.88.22.10084; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; DONALDSO.RP, 1972, ARCH BIOCHEM BIOPHYS, V152, P199, DOI 10.1016/0003-9861(72)90208-1; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; FAHIMI HD, 1993, BIOCHIMIE, V75, P201, DOI 10.1016/0300-9084(93)90078-7; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1994, METABOLIC BASIS INHE, P2287; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; THIERINGER R, 1991, MOL CELL BIOL, V11, P510, DOI 10.1128/MCB.11.1.510; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WATERHAM HR, 1992, J BACTERIOL, V174, P4057, DOI 10.1128/jb.174.12.4057-4063.1992; WILCKE M, 1995, J BIOL CHEM, V270, P6949, DOI 10.1074/jbc.270.12.6949; ZAAR K, 1987, BIOCHIM BIOPHYS ACTA, V897, P135, DOI 10.1016/0005-2736(87)90321-X; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	33	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20307	20314		10.1074/jbc.271.34.20307	http://dx.doi.org/10.1074/jbc.271.34.20307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702764	hybrid			2022-12-27	WOS:A1996VD33700016
J	Cancedda, FD; Malpeli, M; Gentili, C; DiMarzo, V; Bet, P; Carlevaro, M; Cermelli, S; Cancedda, R				Cancedda, FD; Malpeli, M; Gentili, C; DiMarzo, V; Bet, P; Carlevaro, M; Cermelli, S; Cancedda, R			The developmentally regulated avian Ch21 lipocalin is an extracellular fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIC CHONDROCYTES UNDERGO; ENDOCHONDRAL BONE-FORMATION; IN-VITRO DIFFERENTIATION; DEVELOPING CHICK-EMBRYO; OSTEOBLAST-LIKE CELLS; HYDROPHOBIC MOLECULES; EPIPHYSEAL CARTILAGE; EXPRESSION; COLLAGEN; IDENTIFICATION	Ch21, a developmentally regulated extracellular protein expressed in chick embryos and in cultured chondrocytes, was expressed in the baculovirus system, and the recombinant protein was purified to homogeneity by gel-filtration chromatography. Separation of two isoforms was achieved on an ion-exchange column. Previous work had shown that Ch21 belongs to the superfamily of lipocalins, which are transport proteins for small hydrophobic molecules. Studies were performed to identify the Ch21 ligand. By analysis of recombinant Ch21 on native polyacrylamide gel electrophoresis and by Lipidex assay, the binding of fatty acid to the protein was shown and a preferential binding of long-chain unsaturated fatty acids was observed. Both isoforms had the same behavior. The binding was saturable. Stoichiometry was about 0.7 mol of ligand/mol of protein. The protein binds the ligand in its monomeric form. Calculated dissociation constants were 2 x 10(-7) M for unsaturated fatty acids and 5 x 10(-7) M for stearic acid. The binding was specific; other hydrophobic molecules, as retinoic acid, progesterone, prostaglandins, and long-chain alcohols and aldehydes did not bind to the protein. Short-chain fatty acids did not bind to the protein. Ch21, also present in chicken serum, represents the first extracellular protein able to selectively bind and transport fatty acid in extracellular fluids and serum. We propose to rename the Ch21 protein as (e) under bar xtracellular (f) under bar atty (a) under bar cid-(b) under bar inding (p) under bar rotein (Ex-FABP).	IST NAZL RIC CANC,CTR BIOTECNOL AVANZATE,I-16132 GENOA,ITALY; UNIV GENOA,IST ONCOL CLIN & SPERIMENTALE,I-16132 GENOA,ITALY; CNR,IST INT GENET & BIOFIS,I-80100 NAPLES,ITALY; CNR,IST CHIM MOL INTERESSE BIOL,I-80100 NAPLES,ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR)			Di Marzo, Vincenzo/AAD-7742-2019; Gentili, Chiara/AAE-8046-2021	Di Marzo, Vincenzo/0000-0002-1490-3070; GENTILI, CHIARA/0000-0001-6745-3782	Telethon [E.0166] Funding Source: Medline	Telethon(Fondazione Telethon)		ASHBROOK JD, 1975, J BIOL CHEM, V250, P2333; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; BOESKEI Z, 1992, NATURE, V360, P186; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BONUCCI E, 1994, BONE, V15, P153, DOI 10.1016/8756-3282(94)90702-1; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CANCEDDA FD, 1990, BIOCHEM BIOPH RES CO, V168, P933, DOI 10.1016/0006-291X(90)91118-C; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CANCEDDA FD, 1995, EUR J CELL BIOL, V66, P60; CANCEDDA FD, 1992, J CELL BIOL, V117, P427, DOI 10.1083/jcb.117.2.427; CAPASSO O, 1984, MOL CELL BIOL, V4, P1163, DOI 10.1128/MCB.4.6.1163; CAPASSO O, 1982, EXP CELL RES, V142, P197, DOI 10.1016/0014-4827(82)90423-2; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DOZIN B, 1992, J BIOL CHEM, V267, P2979; FLORES LD, 1994, ANAT REC, V238, P68; GALOTTO M, 1994, J BONE MINER RES, V9, P1239; GALOTTO M, 1985, EUR J CELL BIOL, V67, P99; GENTILI C, 1994, J CELL BIOL, V124, P579, DOI 10.1083/jcb.124.4.579; GENTILI C, 1993, J CELL BIOL, V122, P703, DOI 10.1083/jcb.122.3.703; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HAYASHI M, 1986, J CELL BIOL, V102, P2302, DOI 10.1083/jcb.102.6.2302; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; KOSHER RA, 1983, CARTILAGE, V1, P59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levi G, 1996, DEVELOPMENT, V122, P113; MANDUCA P, 1989, EUR J CELL BIOL, V50, P154; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; OKIJI T, 1993, ARCH ORAL BIOL, V38, P31, DOI 10.1016/0003-9969(93)90151-B; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; PEARLMAN WH, 1973, J BIOL CHEM, V248, P5736; ROACH HI, 1989, BONE MINER, V6, P289, DOI 10.1016/0169-6009(89)90035-4; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; STRAUSS PG, 1990, J CELL BIOL, V110, P1369, DOI 10.1083/jcb.110.4.1369; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUZUKI M, 1982, J NEUROCHEM, V39, P1756; SWAIN LD, 1992, BONE MINER, V17, P192, DOI 10.1016/0169-6009(92)90735-V; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG CY, 1992, EICOSANOIDS, V5, P109; YOSHIOKA C, 1988, J CRAN GENET DEV BIO, V8, P253	52	39	43	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20163	20169		10.1074/jbc.271.33.20163	http://dx.doi.org/10.1074/jbc.271.33.20163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702740	hybrid			2022-12-27	WOS:A1996VC66900082
J	Kawabe, J; Toya, Y; Schwencke, C; Oka, N; Ebina, T; Ishikawa, Y				Kawabe, J; Toya, Y; Schwencke, C; Oka, N; Ebina, T; Ishikawa, Y			Soluble adenylyl cyclase from Spodoptera frugiperda (Sf9) cells - Purification and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT TESTIS; ACTIVATION; CALMODULIN; PROTEIN; STIMULATION; BINDING; BRAIN; SITE	An insect ovarian cell, Spodoptera frugiperda (Sf9), has been widely used to express recombinant proteins, including adenylyl cyclase, as a host cell in the baculovirus expression system. We report the presence and characterization of a soluble adenylyl cyclase (sAC) distinct from a membrane-bound form of adenylyl cyclase (mAC) that is also present in Sf9 cells. sAC was purified 3,500-fold to near homogeneity; a single band at 25 kDa on SDS-polyacrylamide gel electrophoresis correlated well with adenylyl cyclase catalytic activity. The purified enzyme had a catalytic activity of 0.1 mu mol/min . mg and the K-m of 0.55 mM for the substrate ATP. In contrast to mAC, sAC was heat-stable. Enzymatic activity of sAC was not stimulated by forskolin and was inhibited by salts at high concentrations. sAC utilized both manganese- and magnesium-ATP as substrate. Di- or triphosphate-containing nucleotides, such as GTP and GDP, as well as pyrophosphate, noncompetitively inhibited sAC. Our data suggest that the physical and biochemical characteristics of sAC are different from those of mAC in Sf9 cells as well as from those of other known forms of adenylyl cyclase in animal cells; sAC in Sf9 cells may constitute a new member of adenylyl cyclase found in animals.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38070] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON WB, 1978, J BIOL CHEM, V253, P2921; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; BRAUN T, 1977, BIOCHIM BIOPHYS ACTA, V481, P227, DOI 10.1016/0005-2744(77)90155-3; BRAUN T, 1991, METHOD ENZYMOL, V195, P130; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; GREENBERGER LM, 1994, TRENDS CARDIOVAS MED, V4, P193, DOI 10.1016/1050-1738(94)90057-4; HEIDEMAN W, 1987, J BIOL CHEM, V262, P7087; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KAWABE J, 1994, J BIOL CHEM, V269, P24906; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KORNBLIHTT AR, 1981, BIOCHEMISTRY-US, V20, P1262, DOI 10.1021/bi00508a033; LATHIGRA R, 1986, GENE, V44, P89, DOI 10.1016/0378-1119(86)90046-6; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; MARSHAK DR, 1980, J BIOL CHEM, V255, P4781; Neer E J, 1978, Adv Cyclic Nucleotide Res, V9, P69; NEER EJ, 1978, J BIOL CHEM, V253, P5808; ONODA JM, 1987, BIOCHEM PHARMACOL, V36, P1907, DOI 10.1016/0006-2952(87)90487-4; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; SANO M, 1983, ARCH BIOCHEM BIOPHYS, V220, P333, DOI 10.1016/0003-9861(83)90421-6; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STENGEL D, 1982, J BIOL CHEM, V257, P818; TANG WJ, 1991, J BIOL CHEM, V266, P8595; YANG JK, 1983, J BIOL CHEM, V258, P3750	30	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20132	20137		10.1074/jbc.271.33.20132	http://dx.doi.org/10.1074/jbc.271.33.20132			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702736	hybrid			2022-12-27	WOS:A1996VC66900077
J	Kenner, KA; Anyanwu, E; Olefsky, JM; Kusari, J				Kenner, KA; Anyanwu, E; Olefsky, JM; Kusari, J			Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; RECEPTOR SUBSTRATE-1; XENOPUS OOCYTES; KINASE-ACTIVITY; DEPHOSPHORYLATION; PHOSPHORYLATION; RESISTANCE; ACTIVATION; SUBUNIT; CLONING	To understand the physiological role of protein-tyrosine phosphatase 1B (PTPase 1B) in insulin and insulinlike growth factor-I (IGF-I) signaling we established clonal cell lines overexpressing wild type or inactive mutant (C215S) PTPase 1B in cells overexpressing insulin (Hirc) or IGF-I (CIGFR) receptors. PTPase 1B overexpression in transfected cells was verified by immunoblot analysis with a molloclonal PTPase 1B antibody. Subfractionation of parental cells demonstrated that greater than 90% of PTPase activity was localized in the Triton X-100-soluble particulate (P1) cell fraction. PTPase activity in the P1 fraction of cells overexpressing wild type PTPase 1B was 3-6-fold higher than parental cells but was unaltered in all fractions from C215S PTPase 1B-containing cells. The overexpression of wild type and C215S PTPase 1B had no effects on intrinsic receptor kinase activity growth rate, or general. cell morphology. The effects of PTPase IB overexpression on cellular protein tyrosine phosphorylation were examined by anti-phosphotyrosine immunoblot analysis. No differences were apparent under basal conditions, but hormone-stimulated receptor autophosphorylation and/or insulin receptor substrate tyrosine phosphorylation were inhibited in cells overexpressing wild type PTPase 1B and increased in cells expressing mutant PTPase 1B, in comparison with parental cells. Metalbolic signaling, assessed by ligand-stimulated [C-14]glucose incorporation into glycogen, was also inhibited in cells overexpressing active PTPase 1B and enhanced in cells containing C215S PTPase 1B. These data strongly suggest that PTPase 1B acts as a negative regulator of insulin and IGF-I signaling.	TULANE UNIV,MED CTR,DEPT PHYSIOL,NEW ORLEANS,LA 70112; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL METAB,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161	Tulane University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R29DK046490, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46490-02, DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, BBA-PROTEIN STRUCT M, V1248, P57, DOI 10.1016/0167-4838(95)00003-D; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; DING W, 1994, BIOCHEM BIOPH RES CO, V202, P902, DOI 10.1006/bbrc.1994.2015; FAURE R, 1992, J BIOL CHEM, V267, P11215; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; GUAN K, 1991, J BIOL CHEM, V266, P12964; HASHIMOTO N, 1992, BIOCHEM BIOPH RES CO, V188, P1305, DOI 10.1016/0006-291X(92)91373-X; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OBBERGHEN EV, 1983, P NATL ACAD SCI USA, V80, P945; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; SU J, 1994, J BIOL CHEM, V269, P18731; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; UGI S, 1994, FEBS LETT, V340, P516; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; XIAO S, 1994, J BIOL CHEM, V269, P2124; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YU KT, 1984, J BIOL CHEM, V259, P5277; ZHANG WR, 1991, BIOCHEM BIOPH RES CO, V178, P1291, DOI 10.1016/0006-291X(91)91034-A; ZHU GC, 1993, J BIOL CHEM, V268, P1775	52	366	379	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19810	19816		10.1074/jbc.271.33.19810	http://dx.doi.org/10.1074/jbc.271.33.19810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702689	hybrid			2022-12-27	WOS:A1996VC66900030
J	Parente, JA; Goldenring, JR; Petropoulos, AC; Hellman, U; Chew, CS				Parente, JA; Goldenring, JR; Petropoulos, AC; Hellman, U; Chew, CS			Purification, cloning, and expression of a novel, endogenous, calcium-sensitive, 28-kDa phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; GASTRIC PARIETAL-CELLS; IN-GEL DIGESTION; NUCLEOTIDE-SEQUENCE; SECRETION; CA-2+; PHOSPHORYLATION; IDENTIFICATION; SECRETAGOGUES; GLANDS	In gastric parietal cells, cholinergically induced increases in intracellular free calcium concentrations have been well characterized, bat little is known about the signaling events beyond the initial rise in intracellular calcium. In the present study, we report the isolation of a 28-jDa protein, which is rapidly phosphorylated in intact, enriched parietal cells in response to both the cholinergic agonist, carbachol, and the calcium ionophore, ionomycin. A combination of in situ P-32 labeling and one- and two-dimensiomal gel electrophoresis was used to acquire sufficient quantities of protein to obtain partial amino acid sequence, Cloning of the pp28 cDNA revealed a novel protein which we have named CSPP28 based on its calcium-sensitive phosphorylation. There are three CSPP28 mRNA species (1.7, 2.2, and 3.3 kilobases) that are widely distributed throughout a variety of rabbit tissues, Recombinant CSPP28 was phosphorylated by both crude parietal cell homogenate and purified CaM kinase II in a calcium/calmodulin-dependent manner. We propose that CSPP28 may play an important and ubiquitous role in the calcium signaling pathway.	MED COLL GEORGIA,INST MOL MED & GENET,AUGUSTA,GA 30912; VET ADM MED CTR,AUGUSTA,GA 30912; CURATECK PHARMACEUT,ELK GROVE VILLAGE,IL 60007; LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ludwig Institute for Cancer Research					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031900, R01DK048370, R29DK043405, R01DK031900, R01DK043405] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48370, DK 43405, DK 31900] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGLINDH T, 1976, ACTA PHYSIOL SCAND, V96, P150, DOI 10.1111/j.1748-1716.1976.tb10184.x; BERGLINDH T, 1976, ACTA PHYSIOL SCAND, V97, P401, DOI 10.1111/j.1748-1716.1976.tb10281.x; Berridge MJ, 1995, ANN NY ACAD SCI, V766, P31, DOI 10.1111/j.1749-6632.1995.tb26646.x; BROWN MR, 1989, AM J PHYSIOL, V257, pG99, DOI 10.1152/ajpgi.1989.257.1.G99; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; BYRNE JA, 1995, CANCER RES, V55, P2896; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEW CS, 1991, CELL REGUL, V2, P27, DOI 10.1091/mbc.2.1.27; CHEW CS, 1986, BIOCHIM BIOPHYS ACTA, V888, P116, DOI 10.1016/0167-4889(86)90077-7; CHEW CS, 1990, METHOD ENZYMOL, V191, P640; CHEW CS, 1991, CURR OPIN GASTROEN, V7, P856, DOI 10.1097/00001574-199112000-00004; CHEW CS, 1993, HDB EXPT PHARM, V106, P199; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHN JA, 1989, BIOCHEM BIOPH RES CO, V165, P810; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FRIEDMAN KD, 1990, PCR PROTOCOLS GUIDE, P253; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUNASAKA M, 1992, BIOCHEM INT, V27, P1101; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KEAVENEY M, 1993, J MOL ENDOCRINOL, V10, P43; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; MAYER P, 1994, BIOCHEM J, V297, P157, DOI 10.1042/bj2970157; MICHELANGELI F, 1989, BIOCHIM BIOPHYS ACTA, V983, P82, DOI 10.1016/0005-2736(89)90383-0; MUALLEM S, 1986, J BIOL CHEM, V261, P2660; NAKAMURA K, 1996, IN PRESS AM J PHYSL; NEGULESCU PA, 1989, AM J PHYSIOL, V256, pC241, DOI 10.1152/ajpcell.1989.256.2.C241; PARENTE JA, 1995, GASTROENTEROLOGY, V108, pA187, DOI 10.1016/0016-5085(95)23407-1; PUURUNEN J, 1987, BRIT J PHARMACOL, V90, P479, DOI 10.1111/j.1476-5381.1987.tb11197.x; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 2002, MOL CLONING LAB MANU; SOLL AH, 1981, J CLIN INVEST, V68, P270, DOI 10.1172/JCI110243; TSUNODA Y, 1992, AM J PHYSIOL, V262, pG118, DOI 10.1152/ajpgi.1992.262.1.G118; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	35	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20096	20101		10.1074/jbc.271.33.20096	http://dx.doi.org/10.1074/jbc.271.33.20096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702730	hybrid			2022-12-27	WOS:A1996VC66900071
J	Riese, DJ; Kim, ED; Elenius, K; Buckley, S; Klagsbrun, M; Plowman, GD; Stern, DF				Riese, DJ; Kim, ED; Elenius, K; Buckley, S; Klagsbrun, M; Plowman, GD; Stern, DF			The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; KINASE-ACTIVITY; FAMILY MEMBERS; GENE-PRODUCT; HEREGULIN; PROTEIN	The epidermal growth factor (EGF) family hormones amphiregulin (AR), transforming growth factor-alpha (TGF-alpha), and heparin-binding EGF-like growth factor (HB-EGF) are thought to play significant roles in the genesis or progression of a number of human malignancies. However, the ability of these ligands to activate all four erbB family receptors has not been evaluated. Therefore, we have assessed the stimulation of erbB family receptor tyrosine phosphorylation by these hormones in a panel of mouse Ba/F3 cell lines expressing the four erbB family receptors, singly and in pairwise combinations. We also measured the stimulation of interleukin-3-independent survival or proliferation in this panel of Ba/F3 cell lines to compare the patterns of erbB family receptor coupling to physiologic responses induced by these peptides. EGF, TGF-alpha, AR, and HB-EGF all stimulated qualitatively similar patterns of erbB family receptor tyrosine phosphorylation and coupling to physiologic responses. Therefore, EGF, TGF-alpha, AR, and HB-EGF are functionally identical in this model system and behave differently from the EGF family hormones beta-cellulin and neuregulins.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; CHILDRENS HOSP,DEPT SURG RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; SUGEN INC,REDWOOD CITY,CA 94063	Yale University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Bristol-Myers Squibb			PLOWMAN, Greg D/E-2012-2011; Riese, David/AAF-3581-2020	Elenius, Klaus/0000-0001-5700-0827; Riese, David/0000-0002-8823-5802	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45708] Funding Source: Medline; NICHD NIH HHS [HD-07149] Funding Source: Medline; NIGMS NIH HHS [GM-47397] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZAR JH, 1984, BIOSTAT ANAL, P79; Zhang K, 1996, J BIOL CHEM, V271, P3884	46	153	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20047	20052		10.1074/jbc.271.33.20047	http://dx.doi.org/10.1074/jbc.271.33.20047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702723	hybrid			2022-12-27	WOS:A1996VC66900064
J	Segal, RA; Bhattacharyya, A; Rua, LA; Alberta, JA; Stephens, RM; Kaplan, DR; Stiles, CD				Segal, RA; Bhattacharyya, A; Rua, LA; Alberta, JA; Stephens, RM; Kaplan, DR; Stiles, CD			Differential utilization of Trk autophosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR; PC12 CELLS; MAP KINASE; INSULIN-RECEPTOR; BINDING-SITES; ACTIVATION	Tyrosine autophosphorylation controls the catalytic and signaling activities of the neurotrophin receptors, the Trks. To analyze the regulation of distinct tyrosine sites, we generated a panel of antibodies that report the phosphorylation state of individual tyrosines within the Trk cytoplasmic domain. Using pheochromocytoma-derived cell lines, we show that individual tyrosines within the nerve growth factor receptor TrkA are phosphorylated in a non-coordinate fashion following receptor activation. The non-coordinate response of these tyrosines reflects their separate functions in regulating the catalytic and signaling activities of Trk receptors. The differential utilization of distinct sites on Trk receptor tyrosine kinases suggests that the receptor can specify both the timing and the nature of neurotrophin-stimulated signal transduction pathways. Moreover, we show that these Trk autophosphorylation sites, which have hitherto been mapped and characterized only in non-neuronal cell lines, are activated in normal neurons in response to ligand stimulation.	DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Bhattacharyya, Anita/0000-0002-0360-7145	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GAO WQ, 1995, J NEUROSCI, V15, P2656; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MITRA G, 1991, ONCOGENE, V6, P2237; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SEGAL RA, 1995, J NEUROSCI, V15, P4970; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	41	117	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20175	20181		10.1074/jbc.271.33.20175	http://dx.doi.org/10.1074/jbc.271.33.20175			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702742	hybrid			2022-12-27	WOS:A1996VC66900084
J	Kamiya, K; Huang, P; Plunkett, W				Kamiya, K; Huang, P; Plunkett, W			Inhibition of the 3'->5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE-ARABINOSIDE MONOPHOSPHATE; CHRONIC LYMPHOCYTIC-LEUKEMIA; LOW-GRADE LYMPHOMA; RIBONUCLEOTIDE REDUCTASE; 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE; DELTA; TRIPHOSPHATE; MECHANISM; PRIMASE; CELLS	Incorporation of the anticancer drug fludarabine (9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate; F-ara-AMP) into the 3'-end of DNA during replication causes termination of DNA strand elongation and is strongly correlated with loss of clonogenicity. Because the proofreading mechanisms that remove 3'-Fara-AMP from DNA represent a possible means of resistance to the drug, the present study investigated the excision of incorporated F-ara-AMP from DNA by the 3' -->5'-exonuclease activity of DNA polymerase epsilon from human leukemia CEM cells. Using the drug-containing and normal deoxynucleotide oligomers (21-base) annealed to M13mp18(+) DNA as the excision substrates, we demonstrated eel that DNA polymerase a was unable to effectively remove F-ara-AMP from the 3'-end of the oligomer, However, 3'-terminal dAMP and subsequently other deoxynucleotides were readily excised from DNA in a distributive fashion, Kinetic evaluation demonstrated that although DNA polymerase epsilon has a higher affinity for F-ara-AMP-terminated DNA (K-m=7.1 pM) than for dAMP-terminated DNA of otherwise identical sequence (K-m=265 pM), excision of F-ara-AMP proceeded at a substantially slower rate (V-max=0.053 pmol/min/mg) than for 3'-terminal dAMP (V-max=1.96 pmol/min/mg). When the 3'-5' phosphodiester bond between F-ara-AMP at the 3'-terminus and the adjacent normal deoxynucleotide was cleaved by DNA polymerase epsilon, the reaction products appeared to remain associated with the enzyme but without the formation of a covalent bond. No further excision of the remaining oligomers was observed after the addition of fresh DNA polymerase epsilon to the reaction. Furthermore, the addition of DNA polymerase alpha and deoxynucleoside triphosphates to the excision reaction failed to extend the oligomers. After DNA polymerase epsilon had been incubated with 3'-F-ara-AMP-21-mer for 10 min, the enzyme was no longer able to excise 3'-terminal dAMP from a freshly added normal 21-mer annealed to M13mp18(+) template. We conclude that the 3'-->5' exonuclease of human DNA polymerase epsilon can remove 3'-termimal F-ara-AMP hom DNA with difficulty and that this excision results in a mechanism-mediated formation of ''dead end complex.''	UNIV TEXAS,MD ANDERSON CANCER CTR,SECT CELLULAR & MOL PHARMACOL,DEPT CLIN INVEST,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA028596] Funding Source: NIH RePORTER; NCI NIH HHS [CA28596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BIALEK G, 1993, J BIOL CHEM, V268, P6024; BROCKMAN RW, 1977, BIOCHEM PHARMACOL, V26, P2193, DOI 10.1016/0006-2952(77)90275-1; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CATAPANO CV, 1993, J BIOL CHEM, V268, P7179; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; CHOU J, 1985, DOSE EFFECT ANAL MIC, P5; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; GANDHI V, 1988, CANCER RES, V48, P329; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HOCHSTER HS, 1992, J CLIN ONCOL, V10, P28, DOI 10.1200/JCO.1992.10.1.28; HOLLIS GF, 1981, J BIOL CHEM, V256, P8074; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844; Huang P, 1995, CLIN CANCER RES, V1, P1005; HUANG P, 1989, MUTAT RES, V210, P291, DOI 10.1016/0027-5107(89)90090-0; HUANG P, 1990, J BIOL CHEM, V265, P16617; KEATING MJ, 1993, BLOOD, V81, P2878; KUNKEL TA, 1987, P NATL ACAD SCI USA, V84, P4865, DOI 10.1073/pnas.84.14.4865; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; LU CD, 1992, BIOCHEMISTRY-US, V31, P12403, DOI 10.1021/bi00164a015; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NICKEL W, 1992, J BIOL CHEM, V267, P848; NISHIDA C, 1988, J BIOL CHEM, V263, P501; NOVOTNY L, 1990, NUCL ACID CHEM 4, P337; PARKER WB, 1987, MOL PHARMACOL, V31, P146; PARKER WB, 1988, MOL PHARMACOL, V34, P485; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PLUNKETT W, 1990, SEMIN ONCOL, V17, P3; PLUNKETT W, 1980, CANCER RES, V40, P2349; Reardon J E, 1991, Adv Pharmacol, V22, P1, DOI 10.1016/S1054-3589(08)60031-9; REARDON JE, 1989, J BIOL CHEM, V264, P7405; REDMAN JR, 1992, J CLIN ONCOL, V10, P790, DOI 10.1200/JCO.1992.10.5.790; ROBERTSON LE, 1993, BLOOD, V81, P143; SABATINO RD, 1990, CANCER RES, V50, P5340; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SIMON M, 1991, EMBO J, V10, P2166; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKARNES W, 1986, J BIOL CHEM, V261, P6629; SKERRA A, 1992, NUCLEIC ACIDS RES, V20, P3551, DOI 10.1093/nar/20.14.3551; SPRIGGS D, 1986, BIOCHEM PHARMACOL, V35, P247, DOI 10.1016/0006-2952(86)90521-6; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TSENG WC, 1982, MOL PHARMACOL, V21, P474; VASQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55; WHITE EL, 1982, CANCER RES, V42, P2260; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7534, DOI 10.1021/bi00244a024; YANG SW, 1992, J BIOL CHEM, V267, P2345	59	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19428	19435		10.1074/jbc.271.32.19428	http://dx.doi.org/10.1074/jbc.271.32.19428			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702631	hybrid			2022-12-27	WOS:A1996VB68400065
J	Yu, PY; Eisner, GM; Yamaguchi, I; Mouradian, MM; Felder, RA; Jose, PA				Yu, PY; Eisner, GM; Yamaguchi, I; Mouradian, MM; Felder, RA; Jose, PA			Dopamine D-1A receptor regulation of phospholipase C isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; SPONTANEOUSLY HYPERTENSIVE RATS; ALPHA-SUBUNIT; PHOSPHOINOSITIDE HYDROLYSIS; TYROSINE PHOSPHORYLATION; ADENYLATE-CYCLASE; MUSCLE CELLS; TUBULE CELLS; K+-ATPASE	In LTK(-) cells stably transfected with rat D-1A receptor cDNA, fenoldopam, a D-1 agonist, increased phosphatidylinositol 4,5-bisphosphate hydrolysis in a time-dependent manner. In the cytosol, phospholipase C (PLC) activity increased (50 +/- 7%) in 30 s, returned to basal level at 4 h, and decreased below basal values by 24 h; in the membrane, PLC activity also increased (36 +/- 13%) in 30 s, returned to basal level at 10 min, and decreased below basal value at 4 and 24 h. Fenoldopam also increased PLC-gamma protein in a time-dependent manner. The latter was blocked by the D-1 antagonist SKF83742 and by a D-1A antisense oligodeoxynucleotide, indicating involvement of the D-1A receptor. The fenoldopam-induced increase in PLC-gamma and activity was mediated by protein kinase A (PKA) since it was blocked by the PKA antagonist R(p)-8-CTP-adenosine cyclic 3':5'-monophosphorothioate (R(p)-8-CTP-cAMP-S) and mimicked by direct stimulation of adenylyl cyclase with forskolin or by a PKA agonist, S-p-cAMP-S. Protein kinase C (PKC) was also involved, since the fenoldopam-induced increase in PLC-gamma protein was blocked by two different PKC inhibitors, calphostin C and chelerythrine; calphostin C also blocked the fenoldopam-induced increase in PLC activity. In addition, forskolin and a PKA agonist, S-p-8-CTP-cAMP-S, increased PKC activity, and direct stimulation of PKC with phorbol 12-myristate 13-acetate increased PLC-gamma protein and activity, effects that were blocked by calphostin C. We suggest that the D-1A-mediated stimulation of PLC occurs as a result of PKA activation. PKA then stimulates PLC-gamma in cytosol and membrane via activation of PKC.	GEORGETOWN UNIV, MED CTR, DEPT PEDIAT, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, WASHINGTON, DC 20007 USA; UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; NINCDS, GENET PHARMACOL UNIT, NIH, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044756, R29DK042185, R01DK039308] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39308, DK42185, DK44756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CHEN CJ, 1993, HYPERTENSION, V21, P364, DOI 10.1161/01.HYP.21.3.364; CHEN CJ, 1992, HYPERTENSION, V19, P102, DOI 10.1161/01.HYP.19.1.102; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; DEMCHYSHYN LL, 1995, J BIOL CHEM, V270, P4005, DOI 10.1074/jbc.270.8.4005; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FELDER CC, 1989, J BIOL CHEM, V264, P8739; FELDER CC, 1989, J PHARMACOL EXP THER, V248, P171; FELDER CC, 1993, AM J PHYSIOL, V264, pF1032, DOI 10.1152/ajprenal.1993.264.6.F1032; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FISHER SK, 1992, MOL PHARMACOL, V42, P340; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HORIUCHI A, 1993, MOL PHARMACOL, V43, P281; JOSE PA, 1993, ADV BIOSCI, V88, P51; KANSRA V, 1995, CLIN EXP HYPERTENS, V17, P837, DOI 10.3109/10641969509033638; LAITINEN JT, 1993, J NEUROCHEM, V61, P1461, DOI 10.1111/j.1471-4159.1993.tb13641.x; LAUFER R, 1989, J BIOL CHEM, V264, P2683; LEE CW, 1994, J BIOL CHEM, V269, P25335; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MCMILLIAN MK, 1992, J NEUROCHEM, V58, P1308, DOI 10.1111/j.1471-4159.1992.tb11343.x; MEISTER B, 1989, P NATL ACAD SCI USA, V86, P8068, DOI 10.1073/pnas.86.20.8068; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OCONNELL DP, 1995, AM J PHYSIOL-RENAL, V268, pF1185, DOI 10.1152/ajprenal.1995.268.6.F1185; PIZZI M, 1988, BRAIN RES, V456, P235, DOI 10.1016/0006-8993(88)90222-3; RODRIGUES PD, 1990, P NATL ACAD SCI USA, V87, P9693, DOI 10.1073/pnas.87.24.9693; RUBINSTEIN JE, 1990, BIOCHEM PHARMACOL, V39, P1965, DOI 10.1016/0006-2952(90)90616-S; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUGAMORI KS, 1994, P NATL ACAD SCI USA, V91, P10536, DOI 10.1073/pnas.91.22.10536; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VYAS SJ, 1992, J PHARMACOL EXP THER, V260, P134; WU DQ, 1992, J BIOL CHEM, V267, P25798; Yamaguchi I, 1995, Hypertens Res, V18 Suppl 1, pS19, DOI 10.1291/hypres.18.SupplementI_S19; YU PY, 1995, J CLIN INVEST, V95, P304, DOI 10.1172/JCI117656	52	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19503	19508		10.1074/jbc.271.32.19503	http://dx.doi.org/10.1074/jbc.271.32.19503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702641	hybrid			2022-12-27	WOS:A1996VB68400075
J	Hosseini, G; Liu, J; deAgostini, AI				Hosseini, G; Liu, J; deAgostini, AI			Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; AORTIC ENDOTHELIAL-CELLS; MAMMARY EPITHELIAL-CELLS; ANTITHROMBIN-III; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; INTRACELLULAR DEGRADATION; VASCULAR-PERMEABILITY; CULTURED INVITRO; HIGH-AFFINITY	Anticoagulant heparan sulfate proteoglycans endow the vascular endothelium with antithrombotic properties, but their role outside the vascular bed is unknown. Granulosa cells form an avascular compartment in the ovarian follicle, in which a heparin-like activity has been described. At ovulation extravascular coagulation occurs around ovulatory follicles, and after expulsion of the oocyte, a fibrin clot forms in the antral cavity. Granulosa cells synthesize two major heparan sulfate proteoglycans, whose anticoagulant nature has not been investigated. The purpose of this study was to characterize anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells. Affinity purified S-35-labeled anticoagulant heparan sulfate glycosaminoglycans represent 6.5% of the total heparan sulfate synthesized, and they contain 13% 3-O-sulfated disaccharides that are markers of the antithrombin-binding site of heparin. The biological activity of granulosa cell heparan sulfate proteoglycans was demonstrated by their ability to bind antithrombin and to accelerate the formation of thrombin-antithrombin complexes. The impact of hormonal stimulation on granulosa cell anticoagulant heparan sulfate proteoglycans was studied using I-125-antithrombin binding assays. Follicle-stimulating hormone induced a redistribution of anticoagulant heparan sulfate proteoglycans from the granulosa cell layer to the culture medium, indicating that their distribution could be modulated according to the stage of follicular development. These results suggest that anticoagulant heparan sulfate might be critically located in the follicle to maintain fluidity around the oocyte until its expulsion at ovulation.	UNIV HOSP GENEVA, DEPT OBSTET & GYNAECOL, STERIL & GYNAECOL ENDOCRINOL CLIN, CH-1211 GENEVA 14, SWITZERLAND; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of Geneva; Massachusetts Institute of Technology (MIT)								ADASHI EY, 1986, ENDOCRINOLOGY, V118, P456, DOI 10.1210/endo-118-1-456; AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309; ANDRADEGORDON P, 1992, THROMB RES, V66, P475, DOI 10.1016/0049-3848(92)90302-Q; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BERRY L, 1991, AM J RESP CELL MOL, V4, P338, DOI 10.1165/ajrcmb/4.4.338; CANIPARI R, 1986, ENDOCRINOLOGY, V118, P1652, DOI 10.1210/endo-118-4-1652; CARLSON TH, 1985, BLOOD, V66, P13, DOI 10.1182/blood.V66.1.13.13; CAVENDER JL, 1988, BIOL REPROD, V39, P989, DOI 10.1095/biolreprod39.4.989; COLLIEC S, 1994, PHYTOCHEMISTRY, V35, P697, DOI 10.1016/S0031-9422(00)90590-9; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DEAGOSTINI AI, 1991, ANN NY ACAD SCI, V614, P279; DEAGOSTINI AI, 1994, J CELL BIOCHEM, V54, P174, DOI 10.1002/jcb.240540206; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; ENGLAND BG, 1974, J CLIN ENDOCR METAB, V38, P42, DOI 10.1210/jcem-38-1-42; FAULK WP, 1993, HAEMOSTASIS, V23, P194; GERDES U, 1992, J REPROD FERTIL, V95, P539, DOI 10.1530/jrf.0.0950539; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GRAUFFEL V, 1989, BIOMATERIALS, V10, P363, DOI 10.1016/0142-9612(89)90127-0; GULAMALIMAJID F, 1987, CLIN CHEM, V33, P1185; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HATTON MWC, 1988, BLOOD VESSELS, V25, P12; HELUSOVA S, 1995, GLYCOCONJUGATE J, V12, P484; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JIA XC, 1985, NEUROENDOCRINOLOGY, V41, P445, DOI 10.1159/000124216; KAMAT BR, 1995, AM J PATHOL, V146, P157; KERENTAL I, 1993, MOL CELL ENDOCRINOL, V95, pR1, DOI 10.1016/0303-7207(93)90042-I; KOBAYASHI M, 1992, GERONTOLOGY, V38, P36; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOURTEVA Y, 1995, THROMB RES, V78, P521, DOI 10.1016/0049-3848(95)00085-6; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINHARDT RJ, 1995, THROMB HAEMOSTASIS, V73, P1352; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, EXP CELL RES, V166, P253, DOI 10.1016/0014-4827(86)90525-2; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, ANN NY ACAD SCI, V556, P81; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; ORLY J, 1980, CELL, V20, P817, DOI 10.1016/0092-8674(80)90328-1; PARR EL, 1974, BIOL REPROD, V11, P483, DOI 10.1095/biolreprod11.5.483; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PIEPKORN M, 1988, BIOCHEM BIOPH RES CO, V151, P327, DOI 10.1016/0006-291X(88)90597-9; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SHALGI R, 1973, FERTIL STERIL, V24, P429; SHIMADA K, 1991, JPN CIRC J, V55, P1016, DOI 10.1253/jcj.55.1016; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SKINNER MK, 1987, ENDOCRINOLOGY, V121, P1892, DOI 10.1210/endo-121-5-1892; SUCHANEK E, 1990, INT J GYNECOL OBSTET, V32, P53, DOI 10.1016/0020-7292(90)90982-Q; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1979, J BIOL CHEM, V254, P2355; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANAGISHITA M, 1984, J BIOL CHEM, V259, P260; YANAGISHITA M, 1981, ENDOCRINOLOGY, V109, P1641, DOI 10.1210/endo-109-5-1641	74	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22090	22099		10.1074/jbc.271.36.22090	http://dx.doi.org/10.1074/jbc.271.36.22090			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703018	hybrid			2022-12-27	WOS:A1996VF61200060
J	Iwasaki, T; Yamada, M; Satoh, T; Konaka, S; Ren, Y; Hashimoto, K; Kohga, H; Kato, Y; Mori, M				Iwasaki, T; Yamada, M; Satoh, T; Konaka, S; Ren, Y; Hashimoto, K; Kohga, H; Kato, Y; Mori, M			Genomic organization and promoter function of the human thyrotropin-releasing hormone receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; CELL-SPECIFIC EXPRESSION; RAT PITUITARY-CELLS; TRH RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; 5'-FLANKING REGION; MOLECULAR-CLONING; DOWN-REGULATION; PROLACTIN GENE	We isolated and characterized the gene for the human thyrotropin-releasing hormone receptor, The gene spanned more than 30 kilobases and contained three exons and two introns, Intron 1 exists in the 5'-untranslated region, and intron 2 is more than 25 kilobases in length which interrupts the coding region before the beginning of the putative sixth transmembrane domain. Exon 3 encodes the rest of the coding region and the entire 3'-untranslated region. The 3'-flanking region contains four potential polyadenylation signals, and 3'-rapid amplification of cDNA ends studies showed that only a signal at 2076 base pairs downstream of the stop codon was functional in the anterior pituitary, Primer extension and anchor-polymerase chain reaction studies indicated a transcriptional start site at 344 base pairs upstream of the translational start site, The promoter region does not contain either a TATA box or a CAAT box in the appropriate location, Transient transfection study revealed significant activity of the promoter in GH4C1 cells, and the region between -338 and -933 bp from the transcriptional start site worked as a negative regulator, Knowledge of the genomic organization and the promoter region of thyrotropin-releasing hormone (TRH) receptor gene will allow further studies of possible disorders of the TRH receptor, as well as facilitate elucidation of transcriptional control of the human TRH receptor gene.	GUNMA UNIV, SCH MED, DEPT INTERNAL MED 1, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT NEUROSURG, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, BIOSIGNAL RES CTR, MAEBASHI, GUMMA 371, JAPAN	Gunma University; Gunma University; Gunma University								ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BURT DR, 1982, EXP EYE RES, V35, P173, DOI 10.1016/S0014-4835(82)80064-X; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DUTHIE SM, 1993, MOL CELL ENDOCRINOL, V95, pR11, DOI 10.1016/0303-7207(93)90043-J; DUTHIE SM, 1993, J MOL ENDOCRINOL, V11, P141, DOI 10.1677/jme.0.0110141; FAN NC, 1995, MOL CELL ENDOCRINOL, V107, pR1, DOI 10.1016/0303-7207(94)03460-B; FUKUSUMI S, 1995, REGUL PEPTIDES, V57, P115, DOI 10.1016/0167-0115(95)00026-8; GERSHENGORN MC, 1989, ANN NY ACAD SCI, V553, P191; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HINKLE PM, 1984, P NATL ACAD SCI-BIOL, V81, P6183, DOI 10.1073/pnas.81.19.6183; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; HOSODA K, 1992, J BIOL CHEM, V267, P18797; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACKSON IMD, 1982, NEW ENGL J MED, V306, P145, DOI 10.1056/NEJM198201213060305; KAJI H, 1993, NEUROSCI LETT, V151, P81, DOI 10.1016/0304-3940(93)90051-L; KIMURA N, 1994, ENDOCRINOLOGY, V134, P432, DOI 10.1210/en.134.1.432; LECHAN RM, 1982, ENDOCRINOLOGY, V111, P55, DOI 10.1210/endo-111-1-55; LOTTI VJ, 1986, NEUROSCI LETT, V64, P173, DOI 10.1016/0304-3940(86)90095-9; MANTYH PW, 1985, J NEUROSCI, V5, P551; MONDEN T, 1995, J MOL ENDOCRINOL, V15, P73, DOI 10.1677/jme.0.0150073; MORLEY JE, 1979, LIFE SCI, V25, P1539, DOI 10.1016/0024-3205(79)90435-1; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ORON Y, 1987, SCIENCE, V238, P1406, DOI 10.1126/science.2825350; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; SCHOMBURG L, 1995, ENDOCRINOLOGY, V136, P3480, DOI 10.1210/en.136.8.3480; SEARLES RP, 1995, J BIOL CHEM, V270, P157, DOI 10.1074/jbc.270.1.157; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; WU W, 1992, NEUROSCI LETT, V142, P143, DOI 10.1016/0304-3940(92)90359-F; YAMADA M, 1993, BIOCHEM BIOPH RES CO, V195, P737, DOI 10.1006/bbrc.1993.2107; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551; YAMADA M, 1992, BIOCHEM BIOPH RES CO, V184, P367, DOI 10.1016/0006-291X(92)91202-2; YANG JP, 1993, ENDOCRINOLOGY, V133, P487, DOI 10.1210/en.133.2.487; YANG JP, 1993, MOL ENDOCRINOL, V7, P753, DOI 10.1210/me.7.6.753; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529	43	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22183	22188		10.1074/jbc.271.36.22183	http://dx.doi.org/10.1074/jbc.271.36.22183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703031	hybrid			2022-12-27	WOS:A1996VF61200073
J	Yue, CC; MullerGreven, J; Dailey, P; Lozanski, G; Anderson, V; Macintyre, S				Yue, CC; MullerGreven, J; Dailey, P; Lozanski, G; Anderson, V; Macintyre, S			Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; BETA-GLUCURONIDASE; ACTIVE-SITE; ESTERASE; SEQUENCE; EGASYN; COMPARTMENTALIZATION; ACETYLCHOLINESTERASE; INVOLVEMENT; EXPRESSION	C-reactive protein (CRP) is normally synthesized by hepatocytes at relatively low rates and is retained within the endoplasmic reticulum (ER) via interaction with two carboxylesterases (termed gp60a and gp60b), which themselves are restricted to the ER by their COOH-terminal retention signals (HIEL and HTEL), During the acute phase response, an increase in CRP synthesis is accompanied by a decrease in its ER retention as a result of a decrease in the CRP binding affinity of gp60b, Our previous data indicated that the esterase active site, the CRP binding site, and the ER retention signal are functionally distinct. In the present studies, we have identified CRP-binding peptides produced by proteolytic cleavage of gp60a. The sequence shared by two CRP-binding peptides indicated that the CRP binding site of gp60a is contained within residues 477-499, These results were confirmed by expression of cDNAs coding for gp60a and b as bacterial fusion proteins. Fusion proteins containing the complete esterase COOH terminus bound CRP, whereas those truncated at residue 477 (or the homologous site in gp60b) did not, Based on the known crystal structures of three homologous hydrolases, the putative CRP-binding site of the gp60s is located on the surface and is physically distant from the esterase active site and the COOP-terminal ER retention signal.	CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DEPT MED, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University			Anderson, Vernon/W-2673-2019		NIAMS NIH HHS [AR34313] Funding Source: Medline; NIA NIH HHS [AG2467] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034313, R23AR034313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002467] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CYGLER M, 1993, PROTEIN SCI, V2, P366; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DUCLOS TW, 1990, J IMMUNOL, V145, P3869; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; JEWELL W, 1993, MOL IMMUNOL, V30; KORZA G, 1988, J BIOL CHEM, V263, P3486; KUSHNER I, 1993, PERSPECT BIOL MED, V36, P611; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LI H, 1990, J BIOL CHEM, V265, P14732; MACINTYRE S, 1994, J BIOL CHEM, V269, P24496; MACINTYRE SS, 1992, J CELL BIOL, V118, P253, DOI 10.1083/jcb.118.2.253; MACINTYRE SS, 1985, J BIOL CHEM, V260, P4169; Maniatis T., 1982, MOL CLONING; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; ZHEN LD, 1993, ARCH BIOCHEM BIOPHYS, V304, P402, DOI 10.1006/abbi.1993.1368	29	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22245	22250		10.1074/jbc.271.36.22245	http://dx.doi.org/10.1074/jbc.271.36.22245			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703040	hybrid			2022-12-27	WOS:A1996VF61200082
J	Aleshkov, SB; Fa, M; Karolin, J; Strandberg, L; Johansson, LBA; Wilczynska, M; Ny, T				Aleshkov, SB; Fa, M; Karolin, J; Strandberg, L; Johansson, LBA; Wilczynska, M; Ny, T			Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1 - The distance between P3 and P1' determined by donor-donor fluorescence energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTITHROMBIN-III; ESCHERICHIA-COLI; ALPHA-1-PROTEINASE INHIBITOR; PROTEOLYTIC INACTIVATION; CONFORMATIONAL-CHANGES; PROTEINASE-INHIBITORS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; LATENT FORMS; CENTER LOOP	Plasminogen activator inhibitor type 1 (PAI-1) is a fast acting inhibitor of plasminogen activators (PAs). In accordance with other serpins, PAI-1 is thought to undergo a conformational change upon reactive center cleavage. In this study we have developed methods to produce and purify reactive center cleaved wild-type PAI-1 and characterized this molecular form of PAI-1 by biochemical and biophysical methods. Incubation with Sepharose-bound trypsin caused cleavage only at the P1-P1' bond in the reactive center and resulted in 39- and 4-kDa polypeptides, strongly held together by noncovalent interactions. Circular dichroism measurements suggest that the reactive center cleavage triggers larger conformational changes than the conversion from the active to the latent form. Cleaved PAI-1 did not bind to either PAs or vitronectin but retained the heparin-binding capacity. To study the structure of cleaved PAI-1 by polarized fluorescence spectroscopy and to measure intramolecular distances, we used cysteine substitution mutants to which extrinsic fluorescence probes were attached. These studies revealed increasing orientational freedom of probes in the P3 and P1' positions upon cleavage. Distance measurements based on fluorescence energy transfer between probes in positions P3 and P1' indicate that these residues are separated by at least 68 +/- 10 Angstrom in cleaved PAI-1.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT PHYS CHEM,S-90187 UMEA,SWEDEN	Umea University; Umea University								AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DWIVEDI AM, 1991, BIOCHEM BIOPH RES CO, V175, P437, DOI 10.1016/0006-291X(91)91583-X; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Johansson LBA, 1996, J CHEM SOC FARADAY T, V92, P1563, DOI 10.1039/ft9969201563; KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042; KEILDLOUHA V, 1971, FEBS LETT, V16, P287, DOI 10.1016/0014-5793(71)80372-1; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOBERMANN H, 1984, J MOL BIOL, V177, P731; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; Maniatis T., 1982, MOL CLONING; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SANCHO E, 1995, BIOCHEMISTRY-US, V34, P1064, DOI 10.1021/bi00003a042; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SEETHARAM R, 1992, BIOCHEMISTRY-US, V31, P9877, DOI 10.1021/bi00156a004; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; STRANDBERG L, 1994, THROMB RES, V76, P253, DOI 10.1016/0049-3848(94)90197-X; TRISLER P, 1984, J BACTERIOL, V160, P184, DOI 10.1128/JB.160.1.184-191.1984; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	56	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21231	21238		10.1074/jbc.271.35.21231	http://dx.doi.org/10.1074/jbc.271.35.21231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702896	hybrid			2022-12-27	WOS:A1996VE47700042
J	Gliubich, F; Gazerro, M; Zanotti, G; Delbono, S; Bombieri, G; Berni, R				Gliubich, F; Gazerro, M; Zanotti, G; Delbono, S; Bombieri, G; Berni, R			Active site structural features for chemically modified forms of rhodanese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; CATALYSIS; CLONING; FLUORESCENCE; CYSTEINE-254; REFINEMENT; EXPRESSION; SEQUENCE; COVALENT; ENZYME	In the course of the reaction catalyzed by rhodanese, the enzyme cycles between two catalytic intermediates, the sulfur-free and the sulfur-substituted (persulfide-containing) forms. The crystal structure of sulfur-free rhodanese, which was prepared in solution and then crystallized, is highly similar to that of sulfur-substituted enzyme. The inactivation of sulfur-free rhodanese with a small molar excess of hydrogen peroxide relies essentially on a modification limited to the active site, consisting of the oxidation of the essential sulfhydryl to sulfenyl group (-S-OH). Upon reaction of the sulfur-free enzyme with monoiodoacetate in the crystal, the Cys-247 side chain with the bound carboxymethyl group is forced into a conformation that allows favorable interactions of the carboxylate with the four peptide NH groups that participate in hydrogen bonding interactions with the transferable sulfur atom of the persulfide group in the sulfur-substituted rhodanese. It is concluded that active site-specific chemical modifications of sulfur-free rhodanese do not lead to significant changes of the protein structure, consistent with a high degree of similarity of the structures of the sulfur-free and sulfur-substituted forms of the enzyme both in solution and iu the crystal.	UNIV PADUA,DIPARTIMENTO CHIM ORGAN,I-35131 PADUA,ITALY; CNR,BIOPOLYMER RES CTR,I-35131 PADUA,ITALY; UNIV MILAN,INST PHARMACEUT CHEM,I-20135 MILAN,ITALY; UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Parma				Berni, Rodolfo/0000-0002-1839-0479; Zanotti, Giuseppe/0000-0002-0945-6501				BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CANNELLA C, 1986, BIOCHEMISTRY-US, V25, P7319, DOI 10.1021/bi00371a012; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; CHOW SF, 1985, J BIOL CHEM, V260, P2763; DOOLEY TP, 1995, BIOCHEM BIOPH RES CO, V216, P1101, DOI 10.1006/bbrc.1995.2734; DRENTH J, 1971, BIOCHEM BIOPH RES CO, V45, P1320, DOI 10.1016/0006-291X(71)90163-X; FINAZZIAGRO A, 1972, EUR J BIOCHEM, V28, P89, DOI 10.1111/j.1432-1033.1972.tb01887.x; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ P, 1970, J BIOL CHEM, V245, P984; HOROWITZ P, 1983, BIOCHIM BIOPHYS ACTA, V747, P37, DOI 10.1016/0167-4838(83)90118-8; HOROWITZ P, 1982, BIOCHIM BIOPHYS ACTA, V702, P173, DOI 10.1016/0167-4838(82)90499-X; HOROWITZ PM, 1980, BIOCHEM BIOPH RES CO, V94, P419, DOI 10.1016/0006-291X(80)91247-4; ISLAM TA, 1994, J BIOL CHEM, V269, P7908; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHANSKI RA, 1990, J PROTEIN CHEM, V9, P369, DOI 10.1007/BF01024612; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO GX, 1994, J BIOL CHEM, V269, P8220; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P12414; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; PALLINI R, 1991, BIOCHEM BIOPH RES CO, V180, P887, DOI 10.1016/S0006-291X(05)81148-9; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RUSSELL J, 1978, J BIOL CHEM, V253, P8102; SCHLESINGER P, 1974, J BIOL CHEM, V249, P780; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TORCHINSKY YM, 1981, SULFUR PROTEINS, P48; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLINI M, 1973, J BIOL CHEM, V248, P7392; VOLINI M, 1973, J BIOL CHEM, V248, P7386; WANG SF, 1973, J BIOL CHEM, V248, P7376; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; Westley J., 1977, BIOORG CHEM, V1, P371	36	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21054	21061		10.1074/jbc.271.35.21054	http://dx.doi.org/10.1074/jbc.271.35.21054			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702871	hybrid			2022-12-27	WOS:A1996VE47700017
J	Kawamura, S; Kuwata, O; Yamada, M; Matsuda, S; Hisatomi, O; Tokunaga, F				Kawamura, S; Kuwata, O; Yamada, M; Matsuda, S; Hisatomi, O; Tokunaga, F			Photoreceptor protein s26, a cone homologue of S-modulin in frog retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; CANCER-ASSOCIATED RETINOPATHY; CYCLIC-GMP PHOSPHODIESTERASE; RHODOPSIN PHOSPHORYLATION; RECOVERIN; RODS; CDNA; FAMILY; IDENTIFICATION; GENE	A frog retinal protein named s26 is a 26-kDa protein found during purification of S-modulin in frog retina (Kawamura, S. (1992) Photochem. Photobiol. 56, 1173-1180). To identify its role in frog retina, first s26 was purified to nearly homogeneity with three chromatographical steps, Based on the partial amino acid sequences of the proteolysed fragments of s26, we isolated cDNAs that encode s26. The analysis of its amino acid sequence revealed that s26 is an S-modulin-like protein, while it shows higher homology to visinin. Visinin is a Ca2+-binding protein reported to be present in chicken cones, but its localization in the retina had been a subject in dispute, The present study showed that s26 is present in cone photoreceptors, The study also showed that s26 inhibits phosphorylation of rhodopsin after a light flash at high Ca2+ concentrations as S-modulin does. From these results, we concluded that s26 is a cone homologue of S-modulin, The result is consistent with the idea that each type of photoreceptors expresses each cell-type specific version of phototransduction proteins.	OSAKA UNIV,DEPT EARTH & SPACE SCI,GRAD SCH SCI,TOYONAKA,OSAKA 560,JAPAN; KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINJUKU KU,TOKYO 160,JAPAN	Osaka University; Keio University	Kawamura, S (corresponding author), OSAKA UNIV,DEPT BIOL,GRAD SCH SCI,MACHIKANE YAMA 1-1,TOYONAKA,OSAKA 560,JAPAN.		Kuwata, Osamu/I-3218-2016; Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013	Kuwata, Osamu/0000-0002-5226-9250; 				BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Fein A., 1982, PHOTORECEPTORS THEIR, P33; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HISATOMI O, 1991, BIOCHEM BIOPH RES CO, V174, P1125, DOI 10.1016/0006-291X(91)91537-M; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1992, PHOTOCHEM PHOTOBIOL, V56, P1173, DOI 10.1111/j.1751-1097.1992.tb09742.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KAWAMURA S, 1994, NEUROSCI RES, V20, P293, DOI 10.1016/0168-0102(94)90050-7; Kawamura Satoru, 1995, P105; Kimura M., 1983, NEUTRAL THEORY MOL E; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAGNADO L, 1992, NEURON, V8, P955; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1968, VISION RES, V8, P761, DOI 10.1016/0042-6989(68)90128-4; Maniatis T., 1982, MOL CLONING; MCGINNIS JF, 1992, FEBS LETT, V302, P172, DOI 10.1016/0014-5793(92)80433-H; MILAM AH, 1993, VISUAL NEUROSCI, V10, P1, DOI 10.1017/S0952523800003175; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; NILSSON SEG, 1964, J ULTRA MOL STRUCT R, V10, P390, DOI 10.1016/S0022-5320(64)80018-6; NIR I, 1992, J HISTOCHEM CYTOCHEM, V40, P343, DOI 10.1177/40.3.1372630; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; POLANS AS, 1993, INVEST OPHTH VIS SCI, V34, P81; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; POLANS AS, 1993, METH NEUROSCI, V15, P248; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKAMATSU K, 1994, BIOCHEM BIOPH RES CO, V200, P606, DOI 10.1006/bbrc.1994.1491; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YAMAGATA K, 1990, NEURON, V2, P469	44	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21359	21364		10.1074/jbc.271.35.21359	http://dx.doi.org/10.1074/jbc.271.35.21359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702916	hybrid			2022-12-27	WOS:A1996VE47700062
J	Kimura, K; Nozaki, N; Enomoto, T; Tanaka, M; Kikuchi, A				Kimura, K; Nozaki, N; Enomoto, T; Tanaka, M; Kikuchi, A			Analysis of M phase-specific phosphorylation of DNA topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CYCLE-DEPENDENT PHOSPHORYLATION; C-TERMINAL DOMAIN; MITOTIC CHROMOSOMES; FISSION YEAST; EGG EXTRACTS; GROWTH-STATE; FORMS; CELLS; CONDENSATION	In mammalian cells, two isoforms of DNA topoisomerase II (topo II), topo II alpha and topo II beta, are phosphorylated, The phosphorylation of topo II beta changes its apparent molecular mass determined by SDS-polyacrylamide gel electrophoresis from 180 to 190 kDa in mitotic cells, whereas topo II alpha affects it only slightly (Kimura, K,, Nozaki, N,, Saijo, M,, Kikuchi, A., Ui, M,, and Enomoto, T. (1994) J, Biol, Chem, 269, 24523-24526), Here we examined the stability of the protein and the phosphate moiety of each topo II isoform, as the cells progressed from M to G(1) phase, While its protein moiety remained intact, 75% of the phosphates attached to topo II beta were removed within 4 h after release from mitotic block, On the other hand, 35% of topo II alpha protein and 52% of the attached phosphates disappeared, We verified that M phase-specific phosphorylation had no particular effect on the catalytic activities of both topo II isoforms after extensive phosphatase digestion, We also examined the binding of two isoforms to the nucleus or chromosomes, In logarithmically growing cells, both isoforms were extracted from nuclei at the same concentrations of NaCl, From the mitotic chromosomes, topo II beta was extracted at much lower concentrations of NaCl than topo II alpha.	TOHOKU UNIV,DEPT MOL & CELL BIOL,FAC PHARMACEUT SCI,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University	Kimura, K (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; KIMURA K, 1994, J BIOL CHEM, V269, P1173; KIMURA K, 1994, J BIOL CHEM, V269, P24523; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PETROV P, 1993, EXP CELL RES, V204, P73, DOI 10.1006/excr.1993.1010; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAKANO H, 1991, CANCER RES, V51, P3951; TSUTSUI K, 1993, J BIOL CHEM, V268, P19076; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	40	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21439	21445		10.1074/jbc.271.35.21439	http://dx.doi.org/10.1074/jbc.271.35.21439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702926	hybrid			2022-12-27	WOS:A1996VE47700072
J	Rooney, RD; Tuazon, PT; Meek, WE; Carroll, EJ; Hagen, JJ; Gump, EL; Monnig, CA; Lugo, T; Traugh, JA				Rooney, RD; Tuazon, PT; Meek, WE; Carroll, EJ; Hagen, JJ; Gump, EL; Monnig, CA; Lugo, T; Traugh, JA			Cleavage arrest of early frog embryos by the G protein-activated protein kinase PAK I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; XENOPUS-OOCYTES; MAP KINASE; RABBIT RETICULOCYTES; MOLECULAR-CLONING; ONCOGENE PRODUCT; MAMMALIAN-CELLS; PHOSPHORYLATION; MOS; RAS	PAK I is a member of the PAK (p21-activated protein kinase) family and is activated by Cdc42 (Jakobi, R., Chen, C.-J., Tuazon, P. T., and Traugh, J. A. (1996) J. Biol. Chem. 271, 6206-6211). To examine the effects of PAK I on cleavage arrest, subfemtomole amounts of endogenously active (58 kDa) and inactive (60 kDa) PAK I and a tryptic peptide (37 kDa) containing the active catalytic domain were injected into one blastomere of 2-cell frog embryos. Active PAK I resulted in cleavage arrest in the injected blastomere at mitotic metaphase, whereas the uninjected blastomere progressed through mid- to late cleavage. Injection of other protein kinases at similar concentrations had no effect on cleavage. Endogenous PAK I was highly active in frog oocytes, and antibody to PAK I reacted specifically with protein of 58-60 kDa. PAK I protein was decreased at 60 min post-fertilization, with little or no PAK I protein or activity detectable at 80 min post-fertilization or in 2-cell embryos. At the 4-cell stage PAK I protein increased, but the protein kinase was present primarily as an inactive form. Rac2 and Cdc42, but not Rac 1, were identified in oocytes and throughout early embryo development. Thus, PAK I appears to be a potent cytostatic protein kinase involved in maintaining cells in a non-dividing state. PAK I activity is high in oocytes and appears to be regulated by degradation/synthesis and through autophosphorylation via binding of Cdc42. PAK I may act through regulation of the stress-activated protein kinase signaling pathway and/or by direct regulation of multiple metabolic pathways.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DEPT CHEM, RIVERSIDE, CA 92521 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARROLL EJ, 1991, DEV GROWTH DIFFER, V33, P37; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FU XD, 1988, J BIOL CHEM, V263, P2134; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HACCARD O, 1993, MOL REPROD DEV, V36, P96, DOI 10.1002/mrd.1080360114; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hathaway G M, 1979, Methods Enzymol, V60, P495; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEIS J, 1984, J BIOL CHEM, V259, P7726; MALLER JL, 1993, MOL CELL BIOCHEM, V128, P267, DOI 10.1007/BF01076777; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MASUI Y, 1992, BIOCHEM CELL BIOL, V70, P920, DOI 10.1139/o92-138; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROONEY RD, 1992, FASEB J, V6, pA1852; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1984, J BIOL CHEM, V259, P541; TUAZON PT, 1982, EUR J BIOCHEM, V129, P205, DOI 10.1111/j.1432-1033.1982.tb07041.x; VENEMA RC, 1991, J BIOL CHEM, V266, P5298; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; YAN MH, 1994, NATURE, V372, P798; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21498	21504		10.1074/jbc.271.35.21498	http://dx.doi.org/10.1074/jbc.271.35.21498			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702934	hybrid			2022-12-27	WOS:A1996VE47700080
J	Seufferlein, T; Withers, DJ; Rozengurt, E				Seufferlein, T; Withers, DJ; Rozengurt, E			Reduced requirement of mitogen-activated protein kinase (MAPK) activity for entry into the S phase of the cell cycle in Swiss 3T3 fibroblasts stimulated by bombesin and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; GROWTH-FACTORS; TYROSINE PHOSPHORYLATION; IN-VITRO; PATHWAY; RAF; NEUROPEPTIDES; TRANSDUCTION; RECEPTOR; TRANSFORMATION	Bombesin induced a marked and persistent activation of the mitogen-activated protein kinase kinase-1 (MEK-1), p42(mapk) and p90(rsk) in Swiss 3T3 cells by a pathway that was independent of p74(raf-1) but dependent on the activity of protein kinase C. Pretreatment of the cells with a specific inhibitor of MEK-1, PD 098059, markedly reduced the early and abolished the sustained phase of bombesin-induced p42(mapk) activation. In addition, PD 098059 prevented bombesin-induced DNA synthesis and progression of the cells through the cell cycle, indicating that the mitogenic effect of bombesin is dependent on the activation of p42(mapk) However, in the presence of insulin, which neither stimulated p42(mapk) activation nor DNA synthesis on its own in Swiss 3T3 cells, bombesin potently stimulated DNA synthesis even at concentrations of PD 098059 (15 mu m) that completely abolished the mitogenic effect of bombesin alone. Furthermore, Swiss 3T3 cells stably transfected with interfering mutants of MEK-1 showed a marked decrease in the mitogenic effect of bombesin. In contrast, the combination of bombesin and insulin strongly stimulated DNA synthesis in these cells to levels comparable with that obtained in the wild type cells, Thus, our data demonstrate that insulin dramatically reduced the requirement for the mitogen-activated protein kinase pathway for reinitiation of DNA synthesis in bombesin-treated Swiss 3T3 cells and consequently indicate that the contribution of the mitogen-activated protein kinase cascade to mitogenesis depends on the combination of extracellular signals that are used to stimulate these cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018; Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1993, J BIOL CHEM, V268, P18187; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SETHI T, 1992, CANCER RES, V52, pS2737; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SOZERI O, 1992, ONCOGENE, V7, P2259; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21471	21477		10.1074/jbc.271.35.21471	http://dx.doi.org/10.1074/jbc.271.35.21471			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702930	hybrid			2022-12-27	WOS:A1996VE47700076
J	Stemmer, C; RichaletSecordel, P; vanBruggen, M; Kramers, K; Berden, J; Muller, S				Stemmer, C; RichaletSecordel, P; vanBruggen, M; Kramers, K; Berden, J; Muller, S			Dual reactivity of several monoclonal anti-nucleosome autoantibodies for double-stranded DNA and a short segment of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIHISTONE ANTIBODIES; RESTRICTED ANTIBODIES; SYNTHETIC PEPTIDES; BINDING-SITES; PROTEIN; LPR/LPR; MURINE; KIDNEY; IMMUNOGENICITY	We have shown previously that four IgG monoclonal autoantibodies (mAbs) reacted in ELISA with both double-stranded (ds) DNA and peptide 83-100 of histone H3. The peptide 83-100 contains a cysteine residue at position 96 and readily dimerizes at pH 7-8. We describe here that only the 83-100 dimers, and not the 83-100 monomers, are recognized by the four antibodies and inhibit in ELISA the binding of mAbs to dsDNA. The equilibrium affinity constants (K-a) and kinetic rate constants of two of these mAbs were measured in a biosensor system. K-a values were significantly higher when these mAbs were tested with dsDNA as compared with the 83-100 dimer. Further higher K-a values were measured with mononucleosomes containing DNA and histones. It is proposed that these four mAbs are directed against a topographic determinant formed by DNA and the region 83-100 of H3 present as a dimer at the surface of nucleosome, and that they react, although significantly less well, with DNA and peptide dimer tested separately. This study provides a quantitative and kinetic basis to interaction between several antibodies and distinct antigenic structures and allows us to better understand the structural basis of apparent autoantibody cross-reactivity.	INST BIOL MOL & CELLULAIRE, UPR CNRS 9021, F-67000 STRASBOURG, FRANCE; UNIV HOSP, DIV NEPHROL, NL-6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen			Kramers, C./L-4458-2015; Muller, Sylviane/J-5319-2014					AMOURA Z, 1994, ARTHRITIS RHEUM, V37, P1684, DOI 10.1002/art.1780371118; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; ATANASSOV C, 1991, CLIN EXP IMMUNOL, V86, P124; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; BRINKMAN K, 1989, RES IMMUNOL, V140, P595, DOI 10.1016/0923-2494(89)90104-1; CHABRE H, 1995, ARTHRITIS RHEUM, V38, P1485, DOI 10.1002/art.1780381015; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DIVALERIO R, 1995, J IMMUNOL, V155, P2258; ELOUAAI F, 1994, NEPHROL DIAL TRANSPL, V9, P362; FERRARI N, 1987, CELL BIOPHYS, V10, P1; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KARLSSON R, 1993, J IMMUNOL METHODS, V166, P75, DOI 10.1016/0022-1759(93)90330-A; KOREN E, 1995, J IMMUNOL, V154, P4857; KRAMERS C, 1994, J CLIN INVEST, V94, P568, DOI 10.1172/JCI117371; KRAMERS C, 1995, J AM SOC NEPHROL, V6, P425; LOSMAN JA, 1993, ARTHRITIS RHEUM-US, V36, P552, DOI 10.1002/art.1780360417; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MOHAN C, 1995, CLIN IMMUNOL IMMUNOP, V77, P209, DOI 10.1006/clin.1995.1146; MONESTIER M, 1990, J IMMUNOL METHODS, V127, P289, DOI 10.1016/0022-1759(90)90081-6; MULLER S, 1991, MOL IMMUNOL, V28, P763, DOI 10.1016/0161-5890(91)90119-5; NILSSON P, 1995, ANAL BIOCHEM, V224, P400, DOI 10.1006/abio.1995.1057; PASQUALI JL, 1988, EUR J IMMUNOL, V18, P1127, DOI 10.1002/eji.1830180724; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RAZ E, 1989, J IMMUNOL, V142, P3076; SAUNAL H, 1996, IMMUNOCHEMISTRY, V2; SCHMIEDEKE T, 1992, CLIN EXP IMMUNOL, V90, P453; SMEENK RJT, 1988, J IMMUNOL, V140, P3786; STEMMER C, 1995, CLIN IMMUNOL IMMUNOP, V76, P82, DOI 10.1006/clin.1995.1091; STOCKL F, 1994, CLIN NEPHROL, V41, P10; SUBIZA JL, 1989, ARTHRITIS RHEUM, V32, P406, DOI 10.1002/anr.1780320409; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAX WJM, 1995, KIDNEY INT, V48, P666, DOI 10.1038/ki.1995.336; TUAILLON N, 1992, J AUTOIMMUN, V5, P1, DOI 10.1016/S0896-8411(05)80047-2; WING MG, 1995, CLIN EXP IMMUNOL, V99, P313, DOI 10.1111/j.1365-2249.1995.tb05551.x; ZACK DJ, 1995, J IMMUNOL, V154, P1987	39	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21257	21261		10.1074/jbc.271.35.21257	http://dx.doi.org/10.1074/jbc.271.35.21257			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702900	Green Published			2022-12-27	WOS:A1996VE47700046
J	Xu, L; Murphy, J; Otero, AD				Xu, L; Murphy, J; Otero, AD			Participation of nucleoside-diphosphate kinase in muscarinic K+ channel activation does not involve GTP formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; GUANINE-NUCLEOTIDES; ATRIAL CELLS; GUINEA-PIG; MEMBRANE; BINDING; PHOSPHORYLATION; MECHANISM; AGONIST; COMPLEX	Agonist-bound muscarinic receptors open atrial K+ channels through a GTP-dependent pathway mediated by the G protein G(k). However, nucleotides other than GTP are also able to support channel activity, even in the absence of agonists. This process was proposed to be mediated by nucleoside-diphosphate (NDP) kinase, which would transfer phosphate from nucleotide triphosphates to the GDP bound to G(k), producing G(k)-GTP without the need for receptor-induced GDP-GTP exchange. We examined the effect of antibodies to NDP kinase on the ATP-supported activity of atrial muscarinic K+ channels and the corresponding GIRK1/CIR. channels expressed in HEK 293 cells. Inhibitory antibodies reduced ATP-induced channel openings, but this effect displayed an absolute requirement for agonist and was also seen with antibodies that do not inhibit the enzyme. Both types of antibodies also reduced agonist-dependent channel activity in the presence of GTP, ruling out a role for NDP kinase in GDP rephosphorylation. Channel activity was not affected by the antibodies in preparations where ATP-induced muscarinic channels are not under tight receptor control, namely pertussis toxin-treated atrial patches and membranes from cells expressing K-ACh channel subunits. Thus, participation of NDP kinase in this pathway requires activated receptors and has a function distinct from phosphate transfer between nucleotides.	UNIV VIRGINIA, SCH MED, DEPT MOL PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA	University of Virginia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048726] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; HARNILL OP, 1981, PFLUGERS ARCH, V391, P85; HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808; HEIDBUCHEL H, 1990, PFLUG ARCH EUR J PHY, V416, P213, DOI 10.1007/BF00370246; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; KAIBARA M, 1991, J PHYSIOL-LONDON, V433, P589, DOI 10.1113/jphysiol.1991.sp018445; Khromov A, 1995, BIOPHYS J, V69, P2611, DOI 10.1016/S0006-3495(95)80132-3; KIKKAWA S, 1992, FEBS LETT, V305, P237, DOI 10.1016/0014-5793(92)80676-8; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1988, BIOCHEM BIOPH RES CO, V151, P248, DOI 10.1016/0006-291X(88)90586-4; KIMURA N, 1993, HDB EXPT PHARM, V108, P485; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURACHI Y, 1994, TRENDS CARDIOVAS MED, V4, P64, DOI 10.1016/1050-1738(94)90011-6; LACOMBE ML, 1992, TRENDS PHARMACOL SCI, V13, P45; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; NAKAJIMA T, 1992, J GEN PHYSIOL, V99, P665, DOI 10.1085/jgp.99.5.665; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKABEKADO J, 1995, BBA-MOL CELL RES, V1267, P101, DOI 10.1016/0167-4889(95)00037-S; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; OTERO AD, 1993, MOL PHARMACOL, V44, P595; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; OTERO AS, 1988, J MEMBRANE BIOL, V104, P253, DOI 10.1007/BF01872327; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PHILIPSON LH, 1995, J BIOL CHEM, V270, P14604, DOI 10.1074/jbc.270.24.14604; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; RODBELL M, 1971, J BIOL CHEM, V246, P1877; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SZABO G, 1990, ANNU REV PHYSIOL, V52, P293; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Yi XB, 1996, BBA-MOL CELL RES, V1310, P334, DOI 10.1016/0167-4889(95)00164-6	39	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21120	21125		10.1074/jbc.271.35.21120	http://dx.doi.org/10.1074/jbc.271.35.21120			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702881	hybrid			2022-12-27	WOS:A1996VE47700027
J	Kunicki, TJ; Annis, DS; Deng, YJ; Loftus, JC; Shattil, SJ				Kunicki, TJ; Annis, DS; Deng, YJ; Loftus, JC; Shattil, SJ			A molecular basis for affinity modulation of Fab ligand binding to integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GLY-ASP RGD; PLATELET FIBRINOGEN RECEPTORS; THROMBIN-STIMULATED PLATELETS; OUT SIGNAL-TRANSDUCTION; GPIIB-IIIA; NONACTIVATED PLATELETS; CYTOPLASMIC DOMAINS; ADHESION RECEPTOR; RECOGNITION SITE	The Arg-Gly-Asp (RGD) sequence within the third complementarity-determining region (CDR3) of the heavy chain (H3) is responsible for the binding of the recombinant murine Fab molecules, AP7 and PAC1.1, to the platelet integrin alpha(IIb)beta(3). AP7 binding is minimally influenced by the conformational state of this receptor, whereas PAC1.1 binds preferentially to the activated state of the receptor induced by platelet agonists. To study the molecular basis for this functional difference, we replaced the AP7 H3 loop (HPFYRGDGGN) with all or segments of the analogous sequence from PAC1.1 (RSPSYYRGDGAGP). AP7 Fd (V-H domain + C(gamma)1 domain) segments containing these H3 loop sequences were expressed as active Fab molecules by coinfection of Spo-doptera frugiperda cell lines with recombinant baculoviruses containing Fd and AP7 kappa chain cDNA. Replacement of the entire AP7 H3 loop with that from PAC1.1 generated the mutant AP7.3 Fab molecule, which bound selectively to either activated, gel-filtered platelets or to purified alpha(IIb)beta(3) in a manner identical to that of PAC1.1. Identical results were obtained when solely the sequences flanking the amino side of RGD within the respective H3 loops were exchanged. AP7.3 and PAC1.1 exhibited saturable but submaximal binding to activated gel-filtered platelets. Relative to AP7, the number of AP7.3 or PAC 1.1 Fab molecules bound per platelet was 17% in the presence of 1 mM Ca2+ + 1 mM Mg2+ or 40% in the presence of 10 mu M Mn2+. The ratio of Fab molecules bound after versus before activation (mean +/- S.D,; n = 3) was: for AP7.3, 9.8 +/- 0.6; for PAC1.1, 8.8 +/- 0.3; and for AP7, 1.4 +/- 0.2. In addition, AP7 bound to the stably expressed integrin mutant alpha(IIb)beta(3)(S123A), whereas AP7.3 and PAC1 did not. Because AP7.3 behaves in every respect like PAC1.1, we conclude that the ability of RGD-based ligands to distinguish activated from resting conformations of the integrin alpha(IIb)beta(3) can be regulated by limited amino acid sequences immediately adjacent to the RGD tripeptide. Furthermore, those Fab molecules that exhibit increased selectivity for the activated conformation of alpha(IIb)beta(3) bind to a subpopulation of this integrin on platelets that is modulated by divalent cations.	Scripps Res Inst, DEPT VASC BIOL, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Kunicki, TJ (corresponding author), Scripps Res Inst, DEPT MOL & EXPT MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-40387, HL-54023, R01 HL-46979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL046979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BEER JH, 1992, BLOOD, V79, P117; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DeNichilo MO, 1996, J IMMUNOL, V156, P284; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; FURIHATA K, 1987, J CLIN INVEST, V80, P1624, DOI 10.1172/JCI113250; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; HAUNG M, 1993, J CELL BIOL, V12, P473; HAVERSTICK DM, 1985, BLOOD, V66, P946; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KUNICKI TJ, 1995, J BIOL CHEM, V270, P16660, DOI 10.1074/jbc.270.28.16660; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STENBERG PE, 1984, J CELL BIOL, V98, P748, DOI 10.1083/jcb.98.2.748; TOMIYAMA Y, 1992, BLOOD, V79, P2303; WENCELDRAKE JD, 1984, AM J PATHOL, V115, P156	34	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20315	20321		10.1074/jbc.271.34.20315	http://dx.doi.org/10.1074/jbc.271.34.20315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702765	hybrid			2022-12-27	WOS:A1996VD33700017
J	Lou, KL; Saint, N; Prilipov, A; Rummel, G; Benson, SA; Rosenbusch, JP; Schirmer, T				Lou, KL; Saint, N; Prilipov, A; Rummel, G; Benson, SA; Rosenbusch, JP; Schirmer, T			Structural and functional characterization of OmpF porin mutants selected for larger pore size .1. Crystallographic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; ANGSTROM RESOLUTION; BACTERIAL PORIN; CHANNELS; PH	OmpF porin is a nonspecific pore protein from the outer membrane of Escherichia coli. Previously, a set of mutants was selected that allow the passage of long maltodextrins that do not translocate through the wild-type pore. Here, we describe the crystal structures of four point mutants and one deletion mutant from this set; their functional characterization is reported in the accompanying paper (Saint, N,, Leu, K.-L., Widmer, C,, Luckey, M., Schirmer, T,, Rosenbusch, J, P, (1996) J, Biol. Chem. 271, 20676-20680), All mutations have a local effect on the structure of the pore constriction and result in a larger pore cross-section, Substitution of each of the three closely packed arginine residues at the pore constriction (Arg-42, Arg-82, and Arg-132) by shorter uncharged residues causes rearrangement of the adjacent basic residues, This demonstrates mutual stabilization of these residues in the wild-type porin, Deletion of six residues from the internal loop (Delta 109-114) results in disorder of seven adjacent residues but does not alter the structure of the beta-barrel framework, Thus, the large hollow beta-barrel motif can be regarded as an autonomous structure.	UNIV BASEL,DEPT BIOL STRUCT,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOZENTRUM,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND; UNIV MARYLAND,DEPT MICROBIOL,COLLEGE PK,MD 20740	University of Basel; University of Basel; University System of Maryland; University of Maryland College Park			Saint, Nathalie/S-5286-2016	Saint, Nathalie/0000-0001-5219-9486				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BUEHLER LK, 1991, J BIOL CHEM, V266, P24446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FOUREL D, 1993, J BACTERIOL, V175, P2754, DOI 10.1128/JB.175.9.2754-2757.1993; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; JONES TA, 1990, MANUAL O VERSION 5 6; KARSHIKOFF A, 1994, J MOL BIOL, V240, P372, DOI 10.1006/jmbi.1994.1451; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LESLIE AGW, 1992, JOINT CCP4 ESF EACBM; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; LOU KL, 1996, THESIS U BASEL BASEL; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; Saint N, 1996, J BIOL CHEM, V271, P20676, DOI 10.1074/jbc.271.34.20676; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10479, DOI 10.1021/bi00158a010; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W	28	68	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20669	20675		10.1074/jbc.271.34.20669	http://dx.doi.org/10.1074/jbc.271.34.20669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702816	hybrid			2022-12-27	WOS:A1996VD33700068
J	Mahapatra, S; Adhya, S				Mahapatra, S; Adhya, S			Import of RNA into Leishmania mitochondria occurs through direct interaction with membrane-bound receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; VARIABLE REGION; ORGANIZATION; PROTEINS; DONOVANI; INVIVO; DNA	Cytoplasmic tRNAs are imported into the kinetoplast mitochondrion of Leishmania, but the mechanism of import is unknown, particularly whether RNA is transferred as a ribonucleoprotein complex through the protein import pathway or by a distinct receptor-mediated mechanism. Using isolated mitochondria, it was shown that a small, importable RNA, which is structurally homologous to tRNA, binds rapidly, specifically, and with high affinity to the mitochondrial surface in the absence of soluble protein factors to form an import intermediate, Two classes of binding site of apparent K-d 0.3 and 10 an, respectively, were distinguished. tRNA from Leishmania, but not yeast, competitively inhibited the binding. Northwestern blot analysis revealed the presence of a 15-kDa RNA binding protein on the mitochondrial surface, whereas receptor binding was resistant to heparin and KCl, internalization was sensitive to both reagents, These results are consistent with the presence of a direct mechanism of receptor-mediated RNA import on Leishmania mitochondria.	INDIAN INST CHEM BIOL,GENET ENGN LAB,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								DAS S, 1990, J BIOSCIENCES, V15, P239, DOI 10.1007/BF02702665; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hatefi Y, 1978, Methods Enzymol, V53, P27; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLOOF P, 1992, MOL BIOCHEM PARASIT, V56, P289, DOI 10.1016/0166-6851(92)90178-M; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; SUYAMA Y, 1967, GENETICS BIOGENESIS, P763; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; TARASSOV IA, 1992, NUCLEIC ACIDS RES, V20, P1277, DOI 10.1093/nar/20.6.1277; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	22	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20432	20437		10.1074/jbc.271.34.20432	http://dx.doi.org/10.1074/jbc.271.34.20432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702781	hybrid			2022-12-27	WOS:A1996VD33700033
J	Swartz, DA; Park, EI; Visek, WJ; Kaput, J				Swartz, DA; Park, EI; Visek, WJ; Kaput, J			The e subunit gene of murine F1F0-ATP synthase - Genomic sequence, chromosomal mapping, and diet regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ATP SYNTHASE; FATTY-ACIDS; IDENTIFICATION; EXPRESSION; F1-ATPASE; LIVER	Genomic sequences encoding murine Lfm1, whose predicted protein sequence is 96% and 98% similar to bovine and rat F1F0-ATP synthase e subunits (respectively), have been amplified from BALB/cByJ DNA, cloned, and sequenced. The 1,1-kilobase gene has 3 introns and 4 exons, and its coding sequence differs by two nucleotides compared to the previously published BALB/cHnn Lfm1 cDNA sequence. A PstI restriction site polymorphism in intron 2 between C57BL/6J and Mus spretus was used to map this gene to Chromosome 5 near D5Mit9. Related sequences mere mapped on Chromosomes 8, 11, and 2 unlinked loci on Chromosome 2 using Southern blot analyses with the 1.1-kilobase gene as probe. Previous studies from this laboratory indicated that the Lfm1/e subunit was regulated by the level of dietary fat and carbohydrate. Northern hybridization analyses demonstrated that e subunit mRNA abundance showed statistically significant differences (p < 0.025) between hearts of BALB/c mice fed 3% and those fed 20% corn oil for 2 weeks and in liver (p < 0.05) from the same animals. Significant differences were also observed in hepatic and heart mRNA expression at different times after eating in animals subjected to a fast/refeed regimen. The implications of the high degree of sequence similarity to the e subunit for rat and bovine F1F0-ATP synthase and its regulation by diet are discussed.	UNIV ILLINOIS, COLL MED, DIV NUTR, DEPT INTERNAL MED, URBANA, IL 61801 USA; SAPIENTS INST, DEPT INTERNAL MED, MOL GENET NUTR PROGRAM, DALLAS, TX 75209 USA	University of Illinois System; University of Illinois Urbana-Champaign			Kaput, Jim/GSD-5978-2022; Kaput, Jim/AAJ-1386-2020					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AUWERX J, 1992, HORM RES, V38, P269, DOI 10.1159/000182557; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; ELLIOTT TS, 1993, BIOCHEM BIOPH RES CO, V190, P167, DOI 10.1006/bbrc.1993.1026; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; *JACKS LAB, 1996, BSS BSB BACKCR DAT B; JUMP DB, 1994, J LIPID RES, V35, P1076; KAPUT J, 1994, J NUTR, V124, pS1296, DOI 10.1093/jn/124.suppl_8.1296S; KOELLER DM, 1995, GENOMICS, V28, P508, DOI 10.1006/geno.1995.1182; LEBOEUF RC, 1994, J LIPID RES, V35, P121; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PILZ A, 1992, MAMM GENOME, V3, P633, DOI 10.1007/BF00352480; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; *SAS I INC, 1987, SAS STAT GUID PERS C, P549; SHIS H, 1994, J BIOL CHEM, V269, P9380; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7	26	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20942	20948		10.1074/jbc.271.34.20942	http://dx.doi.org/10.1074/jbc.271.34.20942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702853				2022-12-27	WOS:A1996VD33700105
J	Drummond, JT; Anthoney, A; Brown, R; Modrich, P				Drummond, JT; Anthoney, A; Brown, R; Modrich, P			Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; ANTICANCER DRUG CISPLATIN; MUTATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; NUCLEAR EXTRACTS; DNA DAMAGE; HOMOLOG; MUTATIONS; TOLERANT	In contrast to parental A2780 ovarian tumor cells, extracts of one doxorubicin-resistant and two independent cis-diamminedichloroplatinum(II)-resistant derivatives are defective in strand-specific mismatch repair. The repair defect of the three hypermutable, drug-resistant cell lines is only evident when the strand break that directs the reaction is located 3' to the mismatch, and in each case repair is restored to extracts by addition of purified MutL alpha heterodimer. As judged by immunological assay, drug resistance is associated with the virtual absence of the MutL alpha MLH1 subunit and greatly reduced levels of the PMS2 subunit. These findings implicate a functional mismatch repair system in the cytotoxic effects of these antitumor drugs and may have ramifications for their clinical application.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; CRC, BEATSON LABS, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND	Duke University; Howard Hughes Medical Institute; Duke University; Beatson Institute				Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1995, CANCER RES, V55, P2569; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BEHRENS BC, 1987, CANCER RES, V47, P414; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CUMMINGS J, 1991, EUR J CANCER, V27, P532, DOI 10.1016/0277-5379(91)90209-V; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRAM RJ, 1985, MOL PHARMACOL, V28, P51; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAWN MT, 1995, CANCER RES, V55, P3721; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIPPARD SJ, 1993, R A WELCH FDN 37 C C, P49; LOEB LA, 1994, CANCER RES, V54, P5059; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2279, DOI 10.1016/0006-2952(94)90266-6	40	271	290	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19645	19648		10.1074/jbc.271.33.19645	http://dx.doi.org/10.1074/jbc.271.33.19645			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702663	hybrid			2022-12-27	WOS:A1996VC66900004
J	Kalandadze, A; Galleno, M; Foncerrada, L; Strominger, JL; Wucherpfennig, KW				Kalandadze, A; Galleno, M; Foncerrada, L; Strominger, JL; Wucherpfennig, KW			Expression of recombinant HLA-DR2 molecules - Replacement of the hydrophobic transmembrane region by a leucine zipper dimerization motif allows the assembly and secretion of soluble DR alpha beta heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MYELIN BASIC-PROTEIN; T-CELL CLONES; CLASS-II; MHC MOLECULES; PEPTIDES; ANTIGEN; SEQUENCE; BINDING; REQUIREMENTS	Major histocompatability complex (MHC) class II molecules are membrane-anchored heterodimers that present peptides on the surface of antigen presenting cells to T cells. Soluble HLA-DR2 molecules were expressed for structural and functional characterization of the MHC/peptide/T cell receptor recognition unit. The alpha and beta chains of DR2 (encoded by the DRA, DRB1*1501 genes) did not assemble in mammalian or insect cell lines when the transmembrane regions of one or both chains were truncated. The hydrophobic transmembrane regions of DR alpha and DR beta facilitate assembly of the heterodimer and were therefore replaced by the leucine zipper dimerization motifs from the transcription factors Fos and Jun, which assemble as a soluble, tightly packed coiled coil structure. The DR alpha-Fos and DR beta-Jun constructs were expressed in a methyltrophic yeast, Pichia pastoris, using the alpha-mating factor secretion signal to direct expression to the secretory pathway. DR alpha beta heterodimers were purified from supernatants using an antibody specific for the DR alpha beta heterodimer. Kinetic and quantitative peptide binding experiments demonstrated that recombinant DR2 molecules were efficiently loaded with an antigenic peptide. Soluble DR2 molecules can be used to define structural aspects of the MHC/pepticle/T cell receptor interaction and to study the signals induced by T cell receptor recognition of soluble DR2-peptide complexes.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; INVITROGEN CORP,SAN DIEGO,CA 92121	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Thermo Fisher Scientific					NCI NIH HHS [CA47554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAKE AJ, 1990, METHOD ENZYMOL, V185, P408; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; CREGG JM, 1987, BIO-TECHNOL, V5, P479, DOI 10.1038/nbt0587-479; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MARSH SGE, 1995, TISSUE ANTIGENS, V45, P258; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STROMINGER JL, 1995, JAMA-J AM MED ASSOC, V274, P1074, DOI 10.1001/jama.274.13.1074; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	26	79	81	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20156	20162		10.1074/jbc.271.33.20156	http://dx.doi.org/10.1074/jbc.271.33.20156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702739	hybrid			2022-12-27	WOS:A1996VC66900081
J	RehaKrantz, LJ; Nonay, RL; Day, RS; Wilson, SH				RehaKrantz, LJ; Nonay, RL; Day, RS; Wilson, SH			Replication of O-6-methylguanine-containing DNA by repair and replicative DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNA; MAMMALIAN-CELLS; HUMAN-TUMOR; BACTERIOPHAGE-T4; BETA; STRAINS; THYMINE; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; OLIGONUCLEOTIDE; PURIFICATION	The biological consequences of O-6-methylguanine (m6G) in DNA are well recognized, When template m6G is encountered by DNA polymerases, replication is hindered and trans-lesion replication results in the preferential incorporation of dTMP opposite template m6G. Thus, unrepaired m6G in DNA is both cytotoxic and mutagenic, Yet, cell limes tolerant to m6G in DNA have been isolated, which indicates that some cellular DNA polymerases may replicate m6G-containing DNA with reasonable efficiency, Previous reports suggested that mammalian pol beta could not replicate m6G-containing DNA, but we find that pol beta can catalyze trams-lesion replication; however, the lesion must reside in the optimal context for pol beta activity, single- or short nucleotide gapped substrates. Primed single-stranded DNA templates, with or without template m6G, were poor substrates for pol beta as reported in earlier studies. In contrast, trans-lesion replication by bacteriophage T4 DNA polymerase Nas observed for primed single-stranded DNA templates, Replication of m6G-containing DNA by T4 DNA polymerase required the gp45 accessory protein that clamps the polymerase to the DNA template. The rate-limiting step in replicating m6G-containing DNAs by both DNA polymerases tested was incorporation of dTMP across horn the lesion.	CROSS CANC INST, EDMONTON, AB T6G 1Z2, CANADA; UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA	University of Alberta; University of Texas System; University of Texas Medical Branch Galveston	RehaKrantz, LJ (corresponding author), UNIV ALBERTA, DEPT BIOL SCI, EDMONTON, AB T6G 2E9, CANADA.		Wilson, Samuel H/E-6644-2019; Reha-Krantz, Linda/A-3748-2014	Wilson, Samuel H/0000-0002-1702-5293; Reha-Krantz, Linda/0000-0003-4497-423X				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BOWLING JM, 1991, NUCLEIC ACIDS RES, V19, P3089, DOI 10.1093/nar/19.11.3089; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; SCUDIERO DA, 1984, CANCER RES, V44, P961; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SIBGHATULLAH, 1992, BIOCHEMISTRY-US, V31, P7998, DOI 10.1021/bi00149a034; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SNOW ET, 1984, J BIOL CHEM, V259, P8095; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20088	20095		10.1074/jbc.271.33.20088	http://dx.doi.org/10.1074/jbc.271.33.20088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702729	hybrid			2022-12-27	WOS:A1996VC66900070
J	Parra, KJ; Kane, PM				Parra, KJ; Kane, PM			Wild-type and mutant vacuolar membranes support pH-dependent reassembly of the yeast vacuolar H+-ATPase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; NEUROSPORA-CRASSA; ENZYME COMPLEX; SUBUNIT-A; ACIDIFICATION; INACTIVATION; INHIBITION	Treatment of the yeast vacuolar proton-translocating ATPase (H+-ATPase) with 300 mM RI in tile presence of 5 mM Mg-ATP results ill a 90% inhibition of ATPase activity accompanied by removal of at least five of the peripheral subunits of the enzyme from the membrane. Functional reassembly of the enzyme, as indicated by reattachment of the peripheral subunits and a partial (30-70%) recovery of ATPase activity, could be achieved by dialysis of the stripped wild-type membranes to remove the KI and MgATP, but proved to be strongly pH-dependent, with optimal reassembly and recovery of activity occurring after dialysis at pH 5.5. Vacuolar membranes isolated from vma2 Delta mutants, which lack one of the peripheral subunits of the enzyme, do not contain any of the peripheral subunits but are shown to contain assembled membrane (V-o) complexes. The vma2 Delta mutant vacuoles are demonstrated to be competent for attachment of KI-stripped peripheral subunits and reactivation of ATPase activity, The results indicate that previously assembled V-o complexes are capable of inducing assembly of the peripheral subunits. both with each other and with the membrane subunits, and of activating the ATPase activity that resides in the peripheral subunits in a pH-dependent manner.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01-GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CASPANI G, 1985, FEBS LETT, V186, P75, DOI 10.1016/0014-5793(85)81342-9; CHATTERJEE D, 1993, BIOCHEMISTRY-US, V32, P2808, DOI 10.1021/bi00062a011; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; FENG Y, 1994, J BIOL CHEM, V269, P13224; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PURWIN C, 1986, J BIOL CHEM, V261, P8744; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SUMMER JP, 1995, J BIOL CHEM, V270, P5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WARD JM, 1992, PLANT PHYSIOL, V99, P161, DOI 10.1104/pp.99.1.161; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	47	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19592	19598		10.1074/jbc.271.32.19592	http://dx.doi.org/10.1074/jbc.271.32.19592			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702654	hybrid			2022-12-27	WOS:A1996VB68400088
J	Reardon, JT; Mu, D; Sancar, A				Reardon, JT; Mu, D; Sancar, A			Overproduction, purification, and characterization of the XPC subunit of the human DNA repair excision nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-C; PIGMENTOSUM GROUP-C; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; PROTEIN; RAD23; GENE; COMPLEX; RECONSTITUTION	Xeroderma pigmentosum complementation group C gene (XPC) encodes a protein of 125 kDa which is present in a tight complex with a 58-kDa protein encoded by the human homolog of the yeast RAD23 gene, HHR23B (Masutani, C., Sugasawa, K., Yanagisawa, J., Sonoyama, T., Ui, M., Enomoto, T., Takio, K., Tanaka, K., van der Spek, P. J., Bootsma, D., Hoeijmakers, J. H. J., and Hanaoka, F. (1994) EMBO J. 13, 1831-1843). The XPC-HHR23B complex is required for excision of thymine dimers from DNA in a human excision nuclease system reconstituted from purified proteins. In order to understand the role of the XPC-HHR23B complex in excision repair, we have overexpressed each subunit alone and the heterodimer in heterologous systems, purified them, and characterized their biochemical properties. We find that both XPC and the heterodimer bind DNA with high affinity and UV-damaged DNA with slightly higher preference. Surprisingly, we find that the XPC subunit alone is sufficient for reconstitution of the human excision nuclease and that the HHR23B subunit has no detectable effect on the excision activity of the reconstituted system.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FRIEDBERG EC, 1995, DNA REPAIR; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PEROZZI G, 1986, MOL CELL BIOL, V6, P1497, DOI 10.1128/MCB.6.5.1497; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Verhage RA, 1996, MUTAT RES-DNA REPAIR, V362, P155, DOI 10.1016/0921-8777(95)00045-3; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	33	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19451	19456		10.1074/jbc.271.32.19451	http://dx.doi.org/10.1074/jbc.271.32.19451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702634	Green Published, hybrid			2022-12-27	WOS:A1996VB68400068
J	Suzuki, T; Saga, S; Sasakawa, C				Suzuki, T; Saga, S; Sasakawa, C			Functional analysis of Shigella VirG domains essential for interaction with vinculin and actin-based motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN VINCULIN; F-ACTIN; INTERCELLULAR SPREAD; SURFACE PROTEIN; VIRULENCE GENE; FOCAL ADHESION; BINDING-SITE; INTRAMOLECULAR ASSOCIATION; LISTERIA-MONOCYTOGENES; UNIPOLAR LOCALIZATION	The VirG (IcsA) protein of Shigella is required for recruitment of host actin filament (F-actin) by intracellularly motile bacteria. An N-terminal 80-kDa VirG portion (alpha-domain) is exposed on the bacterial surface, while the following C-terminal 37-kDa portion (beta-core) is embedded in the outer membrane. Here, we report that the surface exposed alpha-domain of VirG possesses two distinct functional domains; one is the N-terminal two-thirds portion of the alpha-domain which is required for eliciting F-actin assembly on the bacteria in infected cells, and the other one is the rest of the C-terminal portion of the VirG alpha-domain, which is essential for the asymmetric distribution of VirG on the bacterial surface, Furthermore, we found that vinculin, an actin-binding cytoskeletal protein, accumulates on the surface of bacteria expressing VirG in infected cells, and that the distribution of vinculin coincided with the distribution of VirG and assembled F-actin. The vinculin accumulation depended on the expression of the alpha-domain VirG portion required for F-actin assembly, but the recruitment of vinculin on Shigella appeared prior to the appearance of F-actin in the infected cells. Analysis of proteins interacting with VirG using Xenopus laevis eggs extracts revealed that vinculin was a protein that bound to the alpha-domain portion. This was further confirmed using purified chicken gizzard vinculin, in that the 95-kDa vinculin head part, but not the 30-kDa tail part, directly bound to the alpha-domain portion. These results suggest a possible role for vinculin in recruitment of F-actin to the VirG moiety exposed on Shigella in infected mammalian cells.	UNIV TOKYO,INST MED SCI,DEPT BACTERIOL,MINATO KU,TOKYO 108,JAPAN; AICHI HUMAN SERV CTR,INST DEV RES,DEPT MORPHOL,KASUGAI,AICHI 48003,JAPAN	University of Tokyo								ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; dHauteville H, 1996, INFECT IMMUN, V64, P511, DOI 10.1128/IAI.64.2.511-517.1996; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKUDA I, 1995, J BACTERIOL, V177, P1719, DOI 10.1128/jb.177.7.1719-1726.1995; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; Gerstel B, 1996, INFECT IMMUN, V64, P1929, DOI 10.1128/IAI.64.6.1929-1936.1996; GILMORE AP, 1995, NATURE, V373, P197, DOI 10.1038/373197a0; GOLDBERG MB, 1995, P NATL ACAD SCI USA, V92, P6572, DOI 10.1073/pnas.92.14.6572; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3463, DOI 10.1128/IAI.59.10.3463-3471.1991; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOEKS C, 1995, MOL MICROBIOL, V18, P413; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; NAKATA N, 1993, MOL MICROBIOL, V9, P459, DOI 10.1111/j.1365-2958.1993.tb01707.x; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; RAJAKUMAR K, 1994, J BACTERIOL, V176, P2362, DOI 10.1128/JB.176.8.2362-2373.1994; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SAGA S, 1985, EXP CELL RES, V156, P45, DOI 10.1016/0014-4827(85)90260-5; SANDLIN RC, 1995, INFECT IMMUN, V63, P229, DOI 10.1128/IAI.63.1.229-237.1995; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; SUZUKI T, 1994, MOL MICROBIOL, V11, P31, DOI 10.1111/j.1365-2958.1994.tb00287.x; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; WOOD CK, 1994, J CELL SCI, V107, P709	43	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					21878	21885		10.1074/jbc.271.36.21878	http://dx.doi.org/10.1074/jbc.271.36.21878			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8702989				2022-12-27	WOS:A1996VF61200031
J	Trautwein, C; Rakemann, T; Pietrangelo, A; Plumpe, J; Montosi, G; Mann, MP				Trautwein, C; Rakemann, T; Pietrangelo, A; Plumpe, J; Montosi, G; Mann, MP			C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER; MESSENGER-RNA; GROWTH-FACTOR; INDUCTION-PATTERNS; ALPHA-FETOPROTEIN; PROMOTER ELEMENTS; MOLECULAR-CLONING; NUCLEAR FACTOR; DNA-BINDING; C-JUN	Expression of the albumin gene in the liver is controlled by several liver-enriched transcription factors. However, the mechanisms which contribute to its regulation during pathophysiological states, such as liver regeneration, are still little understood. In the present study we found that during liver regeneration downregulation of albumin mRNA expression is transcriptionally controlled through a minimal element (nucleotide -170 to +22) of the albumin promoter and is observed mainly during the G(1) phase of the cell cycle, while high levels of albumin expression are preserved at later time points, Decreased albumin mRNA levels correlate with a dramatic increase in nuclear expression of C/EBP-beta/LAP, a protein known to bind to the D site of the albumin promoter and also to be involved in cell cycle control. In contrast, nuclear expression of other factors such as HNF-1 or C/EBP-alpha, which also have been shown to transcriptionally control albumin expression, is either unchanged or slightly decreased. We show that pre- and post-translational mechanisms are involved in the higher nuclear expression of C/EBP-beta/LAP as early as 1 h after hepatectomy, which also leads to ifs increased binding toward the D site of the albumin promoter. Finally, in vitro transcription assays with liver nuclear extracts and recombinant C/EBP-beta/LAP demonstrate that C/EBP-beta/LAP can directly down-regulate transcription mediated by the minimal element of the albumin promoter. Additionally the inhibitory role of C/EBP-beta/LAP on the albumin minimal promoter could be confirmed by transfection experiments in hepatoma cells. These results indicate that C/EBP-beta/LAP, while enhancing transcription of cell cycle-related genes and controlling G(1)/S phase checkpoint, down-regulates a major liver function, i.e. albumin synthesis, to prepare the hepatocyte for entry into the cell cycle.	HANNOVER MED SCH,DEPT GASTROENTEROL & HEPATOL,D-30625 HANNOVER,GERMANY; UNIV MODENA,DEPT INTERNAL MED,I-41100 MODENA,ITALY	Hannover Medical School; Universita di Modena e Reggio Emilia			Pietrangelo, Antonello/K-1517-2016	Pietrangelo, Antonello/0000-0002-7411-935X				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; GRISHAM JW, 1962, CANCER RES, V22, P842; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KREN BT, 1994, HEPATOLOGY, V19, P1214, DOI 10.1002/hep.1840190520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUTZKOWENZ E, 1994, GENE DEV, V8, P2781; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PANDURO A, 1986, BIOCHEMISTRY-US, V25, P1414, DOI 10.1021/bi00354a034; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; PIETRANGELO A, 1994, P NATL ACAD SCI USA, V91, P182, DOI 10.1073/pnas.91.1.182; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; PIETRANGELO A, 1992, J CLIN INVEST, V89, P1755, DOI 10.1172/JCI115778; PIETRANGELO A, 1994, HEPATOLOGY, V19, P714, DOI 10.1002/hep.1840190325; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRAUTWEIN C, 1992, BIOCHEM BIOPH RES CO, V182, P617, DOI 10.1016/0006-291X(92)91777-N; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	1996	271	36					22262	22270		10.1074/jbc.271.36.22262	http://dx.doi.org/10.1074/jbc.271.36.22262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VF612	8703043	hybrid			2022-12-27	WOS:A1996VF61200085
J	Ahn, BC; Grossman, L				Ahn, BC; Grossman, L			RNA polymerase signals UvrAB landing sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI UVRAB; LAMBDA-PL-PROMOTER; DNA-REPAIR; TRANSCRIPTION FACTOR; DAMAGED DNA; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-PROPERTIES; SUPERCOILED DOMAINS; (A)BC EXCINUCLEASE	Transcription when coupled to nucleotide excision repair specifies the location in active genes where preferential DNA repair is to take place, During DNA damage-induced recruitment of RNA polymerase (RNAP), there is a physical association of the beta subunit of Escherichia coli RNAP and the UvrA component of the repair apparatus (G. C, Lin and L, Grossman, submitted for publication). This molecular affinity is reflected in the ability of the RNAP to increase, in a promoter-dependent manner, DNA supercoiling by the UvrAB complex. In the presence of the RNAP, the UvrAB complex is able to bind to promoter regions and to translocate in a 5' to 3' direction along the non-transcribed strand. As a consequence of this helicase-catalyzed translocation, preferential incision of DNA damaged sites occurs downstream on the transcribed strand. Because of the helicase directionality, the initial binding of the UvrAB complex to the transcribed strand would inevitably lead to its collision with the RNAP. These results imply that the RNAP-induced DNA structure in the vicinity of the transcription start site signals a landing or entry site for the UvrAB complex on DNA.	JOHNS HOPKINS UNIV,DEPT BIOCHEM,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022846, R37GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GILADI H, 1992, J MOL BIOL, V224, P937, DOI 10.1016/0022-2836(92)90461-R; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OH EY, 1987, THESIS J HOPKINS U B; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18322; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1994, BIOCHEMISTRY-US, V33, P9881, DOI 10.1021/bi00199a009; WANG JT, 1993, J BIOL CHEM, V268, P5323; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	59	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21453	21461		10.1074/jbc.271.35.21453	http://dx.doi.org/10.1074/jbc.271.35.21453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702928	hybrid			2022-12-27	WOS:A1996VE47700074
J	Kershaw, MH; Darcy, PK; Hulett, MD; Hogarth, PM; Trapani, JA; Smyth, MJ				Kershaw, MH; Darcy, PK; Hulett, MD; Hogarth, PM; Trapani, JA; Smyth, MJ			Redirected cytotoxic effector function - Requirements for expression of chimeric single chain high affinity immunoglobulin E receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; ZETA-CHAIN; MOLECULAR-CLONING; GAMMA-SUBUNIT; ALPHA-SUBUNIT; ETA-CHAIN; SEQUENCE REQUIREMENTS; TRANSFECTED CELLS	The aim of this study was to construct a single chain chimeric Fc epsilon RI alpha receptor capable of effector function in leukocytes, including cytotoxic lymphocytes. To determine the most effective single chain Fc epsilon RI alpha receptor with respect to IgE binding and signaling function, a variety of chimeric gene constructs were transiently transfected into COS-7 cells. The most effective chimera consisted of four parts including: wild-type or mutated extracellular domains (Trp(130) --> Ala(130), W130A) of Fc epsilon RI alpha, membrane proximal and transmembrane regions of Fc gamma RIIa, and intracellular CD3 zeta (epsilon(IIa)IIa zeta). Scatchard analysis indicated that these Fc epsilon RI alpha chimeric receptor bound ligand with an affinity of 0.9 to 2.2 x 10(9) M(-1). Ligand binding capacity was dramatically reduced with the deletion of 11 membrane proximal amino acids of Fc epsilon RI alpha; however, function was restored by substitution with the equivalent region of Fc gamma RIIa, suggesting a crucial requirement for a ''spacer'' segment between the transmembrane and extracellular ligand binding domain. Chimeras that bound IgE effectively also mediated phagocytosis. Chimeric receptors that contained transmembrane zeta were expressed as multimers and consequently did not bind IgE effectively; however, cotransfection of these chimeras with gamma-chain largely reconstituted IgE-mediated phagocytosis. The mouse cytotoxic T lymphocyte cell line, CTLLR8 was stably transfected with epsilon(IIa)IIa zeta, and cloned transfectants were demonstrated to lyse target cells in an anti-Fc epsilon RI alpha or IgE antibody-dependent manlier. Therefore, functional single chain chimeric Fe epsilon RI alpha receptors were expressed in the absence or presence of associated zeta or gamma molecules and were used to redirect killer lymphocytes to target cells.	AUSTIN HOSP,HELEN SCHUTT LAB,HEIDELBERG,VIC 3084,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Kershaw, MH (corresponding author), AUSTIN HOSP,CELLULAR CYTOTOX LAB,HEIDELBERG,VIC 3084,AUSTRALIA.		Hulett, Mark D/C-4160-2012; Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Hulett, Mark/0000-0003-2072-5968; Kershaw, Michael/0000-0002-2697-487X; Trapani, Joseph/0000-0003-0983-1532; Hogarth, Mark/0000-0002-0360-7890; Darcy, Phillip/0000-0002-5303-9561				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BROCKER T, 1995, J EXP MED, V181, P1653, DOI 10.1084/jem.181.5.1653; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CAPRA JD, 1989, J BIOL CHEM, V264, P12745; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HOLOWKA D, 1985, BIOCHEMISTRY-US, V24, P6260, DOI 10.1021/bi00343a033; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3475, DOI 10.1021/bi00283a026; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1995, ADV IMMUNOL, V57, P1; HUTCHINSON MJ, 1995, EUR J IMMUNOL, V25, P481, DOI 10.1002/eji.1830250226; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISAACS JD, 1992, J IMMUNOL, V148, P3062; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LICHTENHELD MG, 1995, J IMMUNOL, V154, P2153; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MORITZ D, 1994, P NATL ACAD SCI USA, V91, P4318, DOI 10.1073/pnas.91.10.4318; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PALLADINO MA, 1983, CANCER RES, V43, P572; PARK JG, 1995, P NATL ACAD SCI USA, V92, P7381, DOI 10.1073/pnas.92.16.7381; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROBERTS MR, 1994, BLOOD, V84, P2878; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SNOW PM, 1983, J BIOL CHEM, V258, P4675; STANCOVSKI I, 1993, J IMMUNOL, V151, P6577; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TRAN AC, 1995, J IMMUNOL, V155, P1000; TUIJNMAN WB, 1992, BLOOD, V79, P1651; VIVIER E, 1991, J IMMUNOL, V147, P4263; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	52	13	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	1996	271	35					21214	21220		10.1074/jbc.271.35.21214	http://dx.doi.org/10.1074/jbc.271.35.21214			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VE477	8702893	hybrid			2022-12-27	WOS:A1996VE47700039
J	Eitzen, GA; Titorenko, VI; Smith, JJ; Veenhuis, M; Szilard, RK; Rachubinski, RA				Eitzen, GA; Titorenko, VI; Smith, JJ; Veenhuis, M; Szilard, RK; Rachubinski, RA			The Yarrowia lipolytica gene PAY5 encodes a peroxisomal integral membrane protein homologous to the mammalian peroxisome assembly factor PAF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HANSENULA-POLYMORPHA; PICHIA-PASTORIS; TARGETING SIGNAL; ZELLWEGER-SYNDROME; MATRIX PROTEIN; VACUOLAR BIOGENESIS; DEFICIENT MUTANTS; REPEAT FAMILY; CELL MUTANT	Pay mutants of the yeast Yarrowia lipolytica fail to assemble functional peroxisomes. One mutant strain, pay5-1, lacks normal peroxisomes and instead contains irregular vesicular structures surrounded by multiple unit membranes. The pay5-1 mutant is not totally deficient in peroxisomal matrix protein targeting, as a subset of matrix proteins continues to localize to a subcellular fraction enriched for peroxisomes. The functionally complementing gene PAYS encodes a protein, Pay5p, of 380 amino acids (41,720 Da). Pay5p is a peroxisomal integral membrane protein homologous to mammalian PAF-1 proteins, which are essential for peroxisome assembly and whose mutation in humans results in Zellweger syndrome. Pay5p is targeted to mammalian peroxisomes, demonstrating the evolutionary conservation of the targeting mechanism for peroxisomal membrane proteins. Our results suggest that in pay5 mutants, normal peroxisome assembly is blocked, which leads to the accumulation of the membranous vesicular structures observed.	UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA; UNIV GRONINGEN,ELECTRON MICROSCOPY LAB,NL-9750 AA HAREN,NETHERLANDS	University of Alberta; University of Groningen			Eitzen, Gary/D-3682-2009					Ausubel FM, 1988, MOL REPROD DEV; BARTH G, 1993, MOL GEN GENET, V241, P422, DOI 10.1007/BF00284696; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERNINGER G, 1993, EUR J BIOCHEM, V216, P607, DOI 10.1111/j.1432-1033.1993.tb18180.x; BERTEAUXLECELLIER V, 1995, CELL, V81, P1043, DOI 10.1016/S0092-8674(05)80009-1; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; EITZEN GA, 1995, J BIOL CHEM, V270, P1429, DOI 10.1074/jbc.270.3.1429; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P2432; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GOODMAN JM, 1990, J CELL SCI, V97, P193; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KALISH JE, 1995, MOL CELL BIOL, V15, P6406; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIU H, 1992, J BACTERIOL, V174, P4943, DOI 10.1128/JB.174.15.4943-4951.1992; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; NUTTLEY WM, 1995, GENE, V160, P33, DOI 10.1016/0378-1119(95)00230-4; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; ROBINSON JS, 1991, MOL CELL BIOL, V12, P5813; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; WOOLFORD CA, 1990, GENETICS, V125, P739; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	51	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20300	20306		10.1074/jbc.271.34.20300	http://dx.doi.org/10.1074/jbc.271.34.20300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702763	hybrid, Green Published			2022-12-27	WOS:A1996VD33700015
J	Gauzzi, MC; Velazquez, L; McKendry, R; Mogensen, KE; Fellous, M; Pellegrini, S				Gauzzi, MC; Velazquez, L; McKendry, R; Mogensen, KE; Fellous, M; Pellegrini, S			Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; SIGNAL-TRANSDUCTION; CATALYTIC DOMAIN; PROTEIN-KINASE; BETA RECEPTOR; SUBUNIT; FAMILY; AUTOPHOSPHORYLATION; EXPRESSION; PATHWAY	Tyk2 and JAK1, members of the Janus kinase (JAK) family of protein tyrosine kinases, are required for interferon-alpha/beta binding and signaling, Both enzymes are associated with the interferon-alpha/beta receptor, and upon ligand binding, they undergo tyrosine phosphorylation and catalytic activation in an interdependent manner. To identify residues involved in Tyk2 regulation and to understand the basis of the interdependence of Tyk2 and JAK1, six mutated versions of Tyk2 bearing single or multiple point mutations in the tyrosine kinase domain were studied in a cell line lacking endogenous Tyk2. The Y1054F/Y1055F substitutions in the putative activation loop prevented ligand-dependent activation of Tyk2, without abolishing its catalytic potential. The K930R mutation in the ATP binding site generated a kinase-negative protein, which however, still became phosphorylated upon interferon-cu treatment, The Y1054F/Y1055F substitutions in this kinase-negative Tyk2 abolished the induced phosphorylation. These results indicate that Tyk2 is activated by phosphorylation on Tyr-1054 and/or Tyr-1055 and that this phosphorylation requires another kinase, most likely JAK1. While the Tyk2 forms mutated on Tyr-1054 and Tyr-1055 or on Lys-930 allowed some inducible gene expression, the combination of the three point mutations totally abolished signaling.	INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE; INST GENET MOL, CNRS, UMR 9942, MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Pellegrini, Sandra -/G-5546-2015; Gauzzi, Maria Cristina/N-7038-2017; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Gauzzi, Maria Cristina/0000-0002-2996-5231; Pellegrini, Sandra/0000-0001-5837-7589				ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; EID P, 1988, EUR J BIOCHEM, V171, P675, DOI 10.1111/j.1432-1033.1988.tb13839.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPUR AG, 1992, ONCOGENE, V7, P1347; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LONGATI P, 1994, ONCOGENE, V9, P49; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20494	20500		10.1074/jbc.271.34.20494	http://dx.doi.org/10.1074/jbc.271.34.20494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702790	Green Published, hybrid			2022-12-27	WOS:A1996VD33700042
J	MarieCardine, A; Fischer, S; Gorvel, JP; MaridonneauParini, I				MarieCardine, A; Fischer, S; Gorvel, JP; MaridonneauParini, I			Recruitment of activated p56(lck) on endosomes of CD2-triggered T cells, colocalization with ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; THROMBIN-STIMULATED PLATELETS; EPIDERMAL GROWTH-FACTOR; HUMAN LYMPHOCYTES-T; HUMAN NEUTROPHILS; INTRACELLULAR-LOCALIZATION; PLASMA-MEMBRANE; FUSION INVITRO; EGF RECEPTOR; JURKAT CELLS	We have previously established that upon CD2 activation of T cells, p56(lck) showed a transient increase in its kinase activity and was partially internalized. Here we studied the possibility that p56(lck) could retain its kinase activity in the endosomes of CD2-triggered cells. T cells were fractionated on a sucrose gradient, and the endosomal fraction was isolated. In CD2-triggered cells, part of Lck was internalized and presented a maximal kinase activity in the endosome-enriched fraction after 5 min, decreasing thereafter. In the endosomal fraction of activated cells, four tyrosine-phosphorylated proteins of apparent molecular masses of 30, 40, 56, and 70 kDa were detected. We demonstrated that the protein tyrosine kinase ZAP-70 was recruited to the endosomal fraction upon CD2 stimulation with kinetics similar to that of p56(lck), suggesting that recruitment of protein tyrosine kinases to endosomal vesicles could promote specific transduction signals at the intracellular level.	INST COCHIN GENET MOL, INSERM, U332, F-75014 PARIS, FRANCE; CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Maridonneau-Parini, Isabelle/F-1985-2011; Gorvel, Jean-Pierre/O-1332-2018	Gorvel, Jean-Pierre/0000-0002-2829-9804; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				ANAND R, 1993, ONCOGENE, V8, P3013; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1991, EUR J IMMUNOL, V21, P1967, DOI 10.1002/eji.1830210828; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DHAR A, 1991, J BIOL CHEM, V266, P18797; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ESCOLA JM, 1995, J CELL SCI, V108, P2337; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FERRELL JE, 1990, ONCOGENE, V5, P1033; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; LECABEC V, 1995, J BIOL CHEM, V270, P2067; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARIECARDINE A, 1992, J IMMUNOL, V148, P3879; MARIECARDINE A, 1994, EUR J IMMUNOL, V24, P1255, DOI 10.1002/eji.1830240603; MARTH JD, 1989, J IMMUNOL, V142, P2430; MOHN H, 1995, BIOCHEM J, V309, P657; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; RENDU F, 1989, BLOOD, V73, P1545; ROSENFELD M, 1984, CELL PHYSL, V121, P236; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SOULA M, 1993, J BIOL CHEM, V268, P27420; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALKER F, 1993, J BIOL CHEM, V268, P19552	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20734	20739		10.1074/jbc.271.34.20734	http://dx.doi.org/10.1074/jbc.271.34.20734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702825	hybrid			2022-12-27	WOS:A1996VD33700077
J	Parekh, BS; Sheridan, SD; Hatfield, GW				Parekh, BS; Sheridan, SD; Hatfield, GW			Effects of integration host factor and DNA supercoiling on transcription from the ilvP(G) promoter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ILVGMEDA OPERON; RNA-POLYMERASE; FACTOR IHF; PROTEIN; MUTATIONS; BINDING; LAMBDA; GROWTH; GENE	Integration host factor (IHF) activates transcription from the ilvP(G) promoter by severely distorting the DNA helix in an upstream region of a supercoiled DNA template in a way that alters the structure of the DNA in the downstream promoter region and facilitates open complex formation. In this report, the in vivo and in vitro influence of DNA supercoiling on transcription from this promoter is examined. In the absence of IHF, promoter activity increases with increased DNA supercoiling. In the presence of IHF, the same increases in superhelical DNA densities result in larger increases in promoter activity until a maximal activation of 5-fold is obtained. However, the relative transcriptional activities of the promoter in the presence and absence of IHF at any given DNA superhelical density remains the same. Thus, IHF and increased DNA supercoiling activate transcription by different mechanisms. Also, IHF binds with equal affinities to its target site on linear and supercoiled DNA templates. Therefore, IHF binding does not activate transcription simply by increasing the local negative supercoiling of the DNA helix in the downstream promoter region or by differential binding to relaxed and supercoiled DNA templates.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOL GENET,COLL MED,IRVINE,CA 92697	University of California System; University of California Irvine					NIGMS NIH HHS [GM49388, GM07311] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUER WR, 1995, J MOL BIOL, V253, P438, DOI 10.1006/jmbi.1995.0565; BAUER WR, 1993, J MOL BIOL, V284, P1184; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; COLE JR, 1986, P NATL ACAD SCI USA, V83, P4129, DOI 10.1073/pnas.83.12.4129; DITTO MD, 1994, J BACTERIOL, V176, P3738, DOI 10.1128/JB.176.12.3738-3748.1994; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1984, J BACTERIOL, V157, P490, DOI 10.1128/JB.157.2.490-497.1984; FRIEDMAN DI, 1984, J BACTERIOL, V157, P484, DOI 10.1128/JB.157.2.484-489.1984; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GELLERT M, 1983, COLD SPRING HARB SYM, V2, P763; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; HAUSER CA, 1985, J BIOL CHEM, V260, P1765; HECK JD, 1988, J BIOL CHEM, V263, P857; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; Hildebrand F. B., 1974, INTRO NUMERICAL ANAL; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LILLEY DMJ, 1986, BIOCHEM SOC T, V14, P489, DOI 10.1042/bst0140489; LUTTINGER A, 1995, MOL MICROBIOL, V15, P601, DOI 10.1111/j.1365-2958.1995.tb02369.x; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MENDELSON I, 1991, J BACTERIOL, V173, P1670, DOI 10.1128/jb.173.5.1670-1676.1991; Miller J.H., 1972, EXPT MOL GENETICS; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PEREIRA RF, 1988, NUCLEIC ACIDS RES, V16, P5973, DOI 10.1093/nar/16.13.5973; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; TSUI P, 1988, J MOL BIOL, V203, P817, DOI 10.1016/0022-2836(88)90212-4; UMBARGER HE, 1987, ESCHERICHIA COLI SAL, V1, P302; VANRIJN PA, 1988, NUCLEIC ACIDS RES, V16, P4595, DOI 10.1093/nar/16.10.4595; WANG JC, 1982, PROMOTERS STRUCTURE; WINKELMAN JW, 1990, J BIOL CHEM, V265, P10055; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	43	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20258	20264		10.1074/jbc.271.34.20258	http://dx.doi.org/10.1074/jbc.271.34.20258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702758	hybrid			2022-12-27	WOS:A1996VD33700010
J	Brown, CY; Lagnado, CA; Vadas, MA; Goodall, GJ				Brown, CY; Lagnado, CA; Vadas, MA; Goodall, GJ			Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MESSENGER-RNA DEGRADATION; IL-10; EXPRESSION; CELLS; COLONY; SEQUENCE; RELEASE	Adenosine-uridine (AU) instability elements, found in the 3'-untranslated regions of numerous mRNAs, target these mRNAs for rapid degradation. In addition, the degradation rate of some mRNAs that contain AU instability elements can change. This modulation of mRNA stability is an important component in the regulation of expression of many of the cytokines that control the production and function of blood cells. However, it has not been clear whether the instabilities of individual cytokine mRNAs that contain AU instability elements are coordinately regulated or whether different mRNAs can be independently regulated. We have investigated the influence of the cytokine synthesis inhibitory factor interleukin (IL)-10 on the turnover of granulocyte-colony stimulating factor (G-CSF), and IL-10 mRNAs in human blood monocytes stimulated with lipopolysaccharide. We find that all three mRNAs are destabilized in response to IL-10 but at different times. The G-CSF and GM-CSF mRNAs respond similarly, being rapidly destabilized, consistent with a direct influence of IL-10 receptor-mediated signals on the stability of these mRNAs. In contrast the IL-10 mRNA became unstable only after several hours of treatment with IL-10, suggesting that the IL-10 mRNA, although it also contains AU instability elements, is not co-regulated with the G-CSF and GM-CSF mRNAs but is regulated by a secondary factor produced in response to IL-10.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia			Vadas, Mathew/R-1378-2019	Goodall, Gregory/0000-0003-1294-0692				AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELIAS JA, 1990, J IMMUNOL, V145, P161; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GUBA SC, 1989, J CLIN INVEST, V84, P1701, DOI 10.1172/JCI114352; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KASAMA T, 1994, J IMMUNOL, V152, P3559; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALEFYT RD, 1991, J EXP MED, V174, P1209; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; WANG P, 1994, J IMMUNOL, V153, P811; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; YANG L, 1994, J BIOL CHEM, V269, P32732; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	25	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20108	20112		10.1074/jbc.271.33.20108	http://dx.doi.org/10.1074/jbc.271.33.20108			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702732	hybrid			2022-12-27	WOS:A1996VC66900073
J	DAngelo, DD; Oliver, BG; Davis, MG; McCluskey, TS; Dorn, GW				DAngelo, DD; Oliver, BG; Davis, MG; McCluskey, TS; Dorn, GW			Novel role for Sp1 in phorbol ester enhancement of human platelet thromboxane receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; RNA POLYMERASE-II; PROTEIN-KINASE-C; TRANSCRIPTION FACTORS; ACTIVATION; PROMOTER; THROMBIN; CELLS; GENERATION; INDUCTION	Expression of platelet thromboxane receptors is transcriptionally increased during megakaryocytic differentiation stimulated by phorbol 12-myristate 13-acetate (PMA). We previously cloned and characterized the promoter region of the human thromboxane receptor gene and localized PMA-responsive elements to a region between 1.84 and 1.95 kilobase pairs (kb) 5' of the transcription initiation site (D'Angelo, D. D., Davis, M. G., Houser, W. A., Eubank, J. J., Ritchie, M. E., and Dorn, G. W., II (1995) Circ. Res. 77, 466-474). Herein we report the localization of the PMA response element to a 14-nucleotide C-rich sequence, flanked by an octanucleotide inverted repeat, located -1.938 to -1.925 kb 5' of the transcription start site of this gene. We further identify the PMA-responsive enhancer factor that binds to this C-rich sequence as Sp1. Heterologous thromboxane receptor gene promoter/thymidilate kinase reporter constructs transfected into K562 cells exhibited PMA responsiveness when the C-rich element was included with additional 3' sequence from -1.924 to -1.84 kb. However, mutations of the C-rich element that disrupted a GC box located on the inverse strand eliminated PMA responsiveness and, in gel mobility shift assays, eliminated binding of Sp1. PMA treatment of K562 cells significantly increased, by 5-fold, Sp1 binding to the C-rich element and increased both phosphorylated and nonphosphorylated Sp1 protein levels by 2-fold. Furthermore, PMA treatment transiently increased Sp1 mRNA levels prior to increasing thromboxane receptor mRNA, suggesting that up-regulation of Sp1 contributes to up-regulation of thromboxane receptors. Finally, we have detected an unidentified K562 nuclear protein that binds specifically to the sense strand of the C-rich sequence overlapping the Sp1 binding site and that, by stabilizing a double stem-loop conformation of this DNA segment, may also play a role in Sp1 regulation of this gene. These studies are the first to describe regulatory and regulated roles for Sp1 in PMA-responsive gene expression and suggest that modulation of Sp1 levels controls thromboxane receptor expression during megakaryocytic differentiation.	UNIV CINCINNATI,CINCINNATI,OH 45267; VET ADM MED CTR,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center					NHLBI NIH HHS [HL49267] Funding Source: Medline; PHS HHS [P50 52318-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DANGELO DD, 1995, CIRC RES, V77, P466, DOI 10.1161/01.RES.77.3.466; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; DORN GW, 1994, AM J PHYSIOL, V266, pC1231, DOI 10.1152/ajpcell.1994.266.5.C1231; DORN GW, 1992, AM J PHYSIOL, V262, pC991, DOI 10.1152/ajpcell.1992.262.4.C991; DORN GW, 1992, AM J PHYSIOL, V263, pC864, DOI 10.1152/ajpcell.1992.263.4.C864; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRANGER CB, 1995, CIRCULATION, V91, P1929, DOI 10.1161/01.CIR.91.7.1929; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HIRSH P D, 1981, New England Journal of Medicine, V304, P685, DOI 10.1056/NEJM198103193041201; *HIT SOFTW ENG, 1993, HIBIO MACDNASIS PRO; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MODESTI PA, 1995, AM HEART J, V129, P873, DOI 10.1016/0002-8703(95)90106-X; NAKAJIMA M, 1989, BIOCHEM BIOPH RES CO, V158, P958, DOI 10.1016/0006-291X(89)92815-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINN JP, 1995, BBA-GENE STRUCT EXPR, V1263, P25, DOI 10.1016/0167-4781(95)00071-N; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SZCZEKLIK A, 1992, ARTERIOSCLER THROMB, V12, P548, DOI 10.1161/01.ATV.12.5.548; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402	32	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19696	19704		10.1074/jbc.271.33.19696	http://dx.doi.org/10.1074/jbc.271.33.19696			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702673	hybrid			2022-12-27	WOS:A1996VC66900014
J	Chen, L; Zhang, H; Powers, RW; Russell, PT; Larsen, WJ				Chen, L; Zhang, H; Powers, RW; Russell, PT; Larsen, WJ			Covalent linkage between proteins of the inter-alpha-inhibitor family and hyaluronic acid is mediated by a factor produced by granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS EXTRACELLULAR-MATRIX; TRYPSIN INHIBITOR; HEAVY-CHAINS; CROSS-LINKS; BINDING; IDENTIFICATION; EXPANSION; MOUSE; SERUM; MASS	The direct interaction of hyaluronic acid (HA) and proteins of the inter-alpha-inhibitor family plays a critical role in organization and stabilization of the expanding cumulus extracellular matrix (cECM) following an ovulatory stimulus, Despite similarities in the morphology of cumulus oocyte complexes (COCs) expanding in vivo and in vitro, we find that the cECM of COCs which expand within intact follicles are more elastic and resistant to shear stress than the cECM of those stabilized in vitro, Western blot analysis shows that only the heavy chains of inter-alpha-inhibitor are incorporated into the cECM and appears to be covalently linked to HA after stabilization in vivo while intact inter-alpha-inhibitor is bound to the HA-enriched cECM by a non-covalent mechanism in in vitro stabilized COCs, However, purified pre-alpha-inhibitor and HA can form covalent linkage in the presence of granulosa cells or with granulosa cell-conditioned medium, In addition, COCs resistance to shear stress is also enhanced by coincubation with granulosa cells, Upon formation of the apparent covalent linkage between heavy chains and HA in culture medium, the light chain (bikunin) is concomitantly released into the medium as a complex with chondroitin sulfate moieties of inter-alpha-inhibitor supporting the possibility that HA may replace the chondroitin sulfate linkage to the heavy chains, We speculate that a factor(s) secreted by granulosa cells within the follicle may catalyze a transesterification reaction resulting in an exchange of chondroitin sulfate with HA at the heavy chain/chondroitin sulfate junction followed by release of chondroitin sulfate-bikunin into the follicular fluid. It is also possible that the consequent further stabilization of the cECM through the covalent interaction of HA and heavy chains of inter-alpha-inhibitor may play an important role in the process of ovulation.	UNIV CINCINNATI,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,CINCINNATI,OH 45267; CHRIST HOSP,FERTIL LAB,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; Christ Hospital - Ohio					NICHD NIH HHS [HD29894] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029894] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BJERSING L, 1974, CELL TISSUE RES, V149, P287, DOI 10.1007/BF00226764; Blandau R. J., 1969, MAMMALIAN OVIDUCT, P129; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; CHEN L, 1995, BIOL REPROD, V52, P195; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; GEBHARD W, 1990, BIOL CHEM H-S, V371, P13; HENDRIX EM, 1992, TISSUE CELL, V24, P61, DOI 10.1016/0040-8166(92)90081-H; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; MALKI N, 1992, BIOL CHEM H-S, V373, P1009, DOI 10.1515/bchm3.1992.373.2.1009; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; POWERS RW, 1995, AM J PHYSIOL-ENDOC M, V269, pE290, DOI 10.1152/ajpendo.1995.269.2.E290; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1990, DEV BIOL, V138, P26, DOI 10.1016/0012-1606(90)90173-G; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	24	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19409	19414		10.1074/jbc.271.32.19409	http://dx.doi.org/10.1074/jbc.271.32.19409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702628	hybrid			2022-12-27	WOS:A1996VB68400062
J	Holvoet, P; Zhao, Z; Deridder, E; Dhoest, A; Collen, D				Holvoet, P; Zhao, Z; Deridder, E; Dhoest, A; Collen, D			Effects of deletion of the carboxyl terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; BINDING; PROTEINS; FIBROBLASTS; ACTIVATION; RECEPTORS; MEMBRANES; LIPIDS	In the present study, the lipoprotein association of apoA-I, an apoA-I (Delta Ala(190)-Gln(243)) deletion mutant and an apoA-I (Asp(1)-Leu(189))/apoA-II (Ser(12)-Gln(77)) chimera were compared. At equilibrium, 80% of the I-125-labeled apolipoproteins associated with lipoproteins in rabbit or human plasma but with very different distribution profiles. High density lipoprotein (HDL),(2,3)-associated fractions were 0.60 for apoA-I, 0.30 for the chimera, and 0.15 for the deletion mutant, and corresponding very high density lipoprotein-associated fractions were 0.20, 0.50, and 0.65. Clearance curves after intravenous bolus injection of I-125-labeled apolipoproteins (3 mu g/kg) in normolipemic rabbits could be adequately fitted with a sum of three exponential terms, yielding overall plasma clearance rates of 0.028 +/- 0.0012 ml . min(-1) for apoA-I (mean +/- S.E.; n = 6), 0.10 +/- 0.008 ml . min(-1) for the chimera (p < 0.001 versus apoA-I) and 0.38 +/- 0.022 ml . min(-1) for the deletion mutant (p < 0.001 versus apoA-I and versus the chimera). Fractions that were initially cleared with a t1/2 of 3 min, most probably representing free apolipoproteins, were 0.30 +/- 0.04, 0.50 +/- 0.06 (p = 0.02 versus apoA-I), and 0.64 +/- 0.07 (p = 0.002 versus apoA-I), respectively. At 20 min after the bolus, the fractions of injected material associated with HDL(2,3) were 0.55 +/- 0.06, 0.25 +/- 0.03 (p = 0.001 versus apoA-I), and 0.09 +/- 0.01 (p < 0.001 versus apoA-I and versus the chimera), respectively, whereas the fractions associated with very high density lipoprotein were 0.15 +/- 0.006, 0.25 +/- 0.03 (p = 0.008 versus apoA-I), and 0.27 +/- 0.03 (p = 0.003 versus apoA-I), respectively. The ability of the different apolipoproteins to bind to HDL, particles and displace apoA-I in vitro were compared, The molar ratios at which 50% of I-125-labeled apoA-I was displaced from the surface of HDL, particles were 1:1 for apoA-I, 3:1 for the chimera and 12:1 for the deletion mutant, indicating 3- and 12-fold reductions of the affinities for HDL, of the chimera and the deletion mutant, respectively. These data suggest that the carboxyl-terminal pair of helices of apoA-I are involved in the initial rapid binding of apoA-I to the lipid surface of HDL. Although the lipid affinity of apoA-II is higher than that of apoA-I, substitution of the carboxyl-terminal helices of apoA-I with those of apoA-II only partially restores its lipoprotein association. Thus, this substitution may affect cooperative interactions with the middle amphipathic helices of apoA-I that are critical for its specific distribution over the different HDL species.			Holvoet, P (corresponding author), UNIV LOUVAIN,CTR MOL & VASC BIOL,CAMPUS GASTHUISBERG,O&N HEREST 49,B-3000 LOUVAIN,BELGIUM.		HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772				ALLAN CM, 1992, J BIOL CHEM, V267, P13257; ASSMANN G, 1974, P NATL ACAD SCI USA, V71, P989, DOI 10.1073/pnas.71.3.989; BOLTON AE, 1973, BIOCHIM BIOPHYS ACTA, V329, P318, DOI 10.1016/0304-4165(73)90296-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; CHEN TC, 1979, BIOCHEMISTRY-US, V18, P1617, DOI 10.1021/bi00575a037; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHRISTIAN JC, 1990, ARTERIOSCLEROSIS, V10, P1020, DOI 10.1161/01.ATV.10.6.1020; DALTON MB, 1993, J BIOL CHEM, V268, P19273; DANIELS RJ, 1981, J BIOL CHEM, V256, P4978; DEBACKER G, 1986, AM HEART J, V112, P478, DOI 10.1016/0002-8703(86)90510-7; DEEB SS, 1991, J BIOL CHEM, V266, P13654; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; GIBALDI M, 1983, PHARMACOKINETICS, P45; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HARA H, 1991, J BIOL CHEM, V266, P3080; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; IKEWAKI K, 1993, J LIPID RES, V34, P2207; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE NA, 1988, METABOLISM, V37, P614, DOI 10.1016/0026-0495(88)90077-7; LOEB J, 1983, MOL CELL BIOCHEM, V52, P161; MAO SJT, 1977, BIOCHEMISTRY-US, V16, P4150, DOI 10.1021/bi00638a003; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; ORAM JF, 1981, J BIOL CHEM, V256, P8348; ORAM JF, 1990, ATHEROSCLER REV, V20, P103; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; POMETTA D, 1979, ATHEROSCLEROSIS, V34, P419, DOI 10.1016/0021-9150(79)90066-2; POWNALL HJ, 1981, J BIOL CHEM, V256, P9849; RADER DJ, 1992, J LIPID RES, V33, P755; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1991, PROTEINS, V9, P79; SEGREST JP, 1992, J LIPID RES, V33, P141; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITELLO LB, 1976, J BIOL CHEM, V251, P1131	47	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19395	19401		10.1074/jbc.271.32.19395	http://dx.doi.org/10.1074/jbc.271.32.19395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702626	hybrid			2022-12-27	WOS:A1996VB68400060
J	Karnieli, E; Werner, H; Rauscher, FJ; Benjamin, LE; LeRoith, D				Karnieli, E; Werner, H; Rauscher, FJ; Benjamin, LE; LeRoith, D			The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma Wilms' tumor 1 fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUND-CELL TUMOR; GROWTH-FACTOR RECEPTOR; ZINC FINGER PROTEIN; CHROMOSOME-TRANSLOCATION; TRANSCRIPTION FACTOR; PERIPHERAL NEUROEPITHELIOMA; CHIMERIC TRANSCRIPTS; SUPPRESSOR WT1; BINDING; PRODUCT	Desmoplastic small round cell tumor (DSRCT) is an abdominal malignancy in children which is characterized by a recurrent chromosomal translocation, t(11; 22)(p13;q12). This rearrangement results in the fusion of the ubiquitously expressed EWS1 gene to the Wilms' tumor suppressor (WT1) gene. The chimeric protein contains the N-terminal domain of EWS1 fused to the DNA-binding domain of WT1, including zinc fingers 2-4, Because WT1 has been shown previously to bind and repress the insulin-like growth factor I (IGF-I-R) promoter, we investigated whether this promoter is, in addition, a target for the aberrant EWS/WT1 transcription factor. EWS/WT1 activated the ICF-I-R. promoter similar to 340%, whereas a fusion protein containing a three-amino acid insert (KTS) between zinc fingers 3 and 4 had no effect. On the other hand, expression vectors encoding either WT1 or EWS1 reduced the activity of the promoter to 46 and 58% of control values, respectively. Results of gel shift assays indicate that the binding affinity of EWS/WT1 to a fragment of the 5'-flanking region of the receptor promoter was higher than the affinity of WT1 itself. Consistent with the results of functional assays, the binding of EWS/WT1(+KTS) was significantly reduced. Due to the central role of the IGF-I-R in tumorigenesis, activation of the receptor promoter by EWS/WT1 may constitute a potential mechanism for the etiology and/or progression of DSRCT.	NIDDK, DIABET BRANCH, SECT MOL & CELLULAR PHYSIOL, NIH, BETHESDA, MD 20892 USA; TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, RAMBAM MED CTR, INST ENDOCRINOL & METAB, IL-31096 HAIFA, ISRAEL; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; The Wistar Institute					NCI NIH HHS [CA52009, CA10815] Funding Source: Medline; NIDDK NIH HHS [DK49210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, P01CA052009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASERGA R, 1992, RECEPTOR, V2, P261; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MORRIS JF, 1991, ONCOGENE, V6, P2339; ORDONEZ NG, 1993, HUM PATHOL, V24, P850, DOI 10.1016/0046-8177(93)90135-4; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHEN WPV, 1992, CANCER GENET CYTOGEN, V64, P189; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; Werner H, 1991, INSULIN LIKE GROWTH, P17; WERNER H, 1996, IN PRESS P NATL ACAD; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	45	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19304	19309		10.1074/jbc.271.32.19304	http://dx.doi.org/10.1074/jbc.271.32.19304			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702614	hybrid			2022-12-27	WOS:A1996VB68400048
J	Nelson, CC; Hendy, SC; Faris, JS; Romaniuk, PJ				Nelson, CC; Hendy, SC; Faris, JS; Romaniuk, PJ			Retinoid X receptor alters the determination of DNA binding specificity by the P-box amino acids of the thyroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; DIRECT REPEATS; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; HALF-SITES; RXR-BETA; GENE; HETERODIMERS; PROMOTER	Nuclear hormone receptors bind to hormone response elements in DNA consisting of two half-sites of 6 base pairs. The P-box amino acids of each receptor determine the identities of the central nucleotides of the half-site, 57 P-box variants of the human thyroid hormone receptor (hT3R beta) were used to demonstrate the relationship between P-box sequence and DNA binding specificity by homodimers and heterodimers formed with the retinoid X receptor (RXR). In general, the formation of heterodimers relieved many of the constraints on the compatibility of hT3R beta P-box sequences with DNA binding. Effects were most dramatic for heterodimers bound to a direct repeat spaced by four base pairs. RXR also overrides the P-box-derived DNA binding specificity of hT3R beta when heterodimers are bound to inverted or everted repeat elements, These effects of RXR are most pronounced on AGGTCA half-sites but are squelched when the RXR partner of the heterodimer is bound to an AGGACA half-site. The influence of RXR on hT3R beta DNA binding specificity varies with the orientation of half-sites in the element, the identity of the fourth base pair of the half-site, and the spacing between the half-sites of direct repeats. These differences suggest that the DNA binding domains of RXR-hT3R beta heterodimers are not positioned equivalently on the various elements, affecting the manner in which the P-box amino acids of hT3R beta interact with base pairs within the half-site.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA	University of Victoria				Romaniuk, Paul/0000-0002-5931-8879				AHLQUIST JAO, 1989, BIOCHIM BIOPHYS ACTA, V1008, P251, DOI 10.1016/0167-4781(80)90017-2; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRENT GA, 1989, J BIOL CHEM, V264, P178; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GEWIRTH DT, 1995, NAT STRUCT BIOL, V2, P386, DOI 10.1038/nsb0595-386; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PREDKI PF, 1995, BIOCHEM J, V305, P805, DOI 10.1042/bj3050805; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOZ ML, 1991, J BIOL CHEM, V266, P13397; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175	52	17	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19464	19474		10.1074/jbc.271.32.19464	http://dx.doi.org/10.1074/jbc.271.32.19464			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702636	hybrid			2022-12-27	WOS:A1996VB68400070
